ANNUAL REPORT
FY 2020 — Annual report
FY 2020PDF · 512 pages2.0 MB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2020
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number: 001-16751
ANTHEM, INC.
(Exact name of registrant as specified in its charter)
Indiana 35-2145715
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer Identification Number)
220 Virginia Avenue
Indianapolis, Indiana 46204
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (800) 331-1476
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading symbol(s) Name of each exchange on which registered
Common Stock, Par Value $0.01 ANTM New York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act: NONE
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes x No ¨
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No x
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the
past 90 days. Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of
Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes
x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an
emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in
Rule 12b-2 of the Exchange Act.
Large accelerated filer ☒ Accelerated filer ☐
Non-accelerated filer ☐ Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control
over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its
audit report. x
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No x
The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant (assuming solely for the purposes of this
calculation that all directors and executive officers of the registrant are “affiliates”) as of June 30, 2020 was approximately $66,230,779,383.
As of February 4, 2021, 244,905,689 shares of the registrant’s common stock were outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Part III of this Annual Report on Form 10-K incorporates by reference information from the registrant’s Definitive Proxy Statement for the Annual Meeting of
Shareholders to be held May 26, 2021.
-- 1 of 512 --
Anthem, Inc.
Annual Report on Form 10-K
For the Year Ended December 31, 2020
Table of Contents
PART I
ITEM 1. BUSINESS 3
ITEM 1A. RISK FACTORS 25
ITEM 1B. UNRESOLVED SEC STAFF COMMENTS 39
ITEM 2. PROPERTIES 40
ITEM 3. LEGAL PROCEEDINGS 40
ITEM 4. MINE SAFETY DISCLOSURES 40
PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER
PURCHASES OF EQUITY SECURITIES 41
ITEM 6. SELECTED FINANCIAL DATA 43
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 44
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 70
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 73
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 145
ITEM 9A. CONTROLS AND PROCEDURES 145
ITEM 9B. OTHER INFORMATION 148
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 148
ITEM 11. EXECUTIVE COMPENSATION 148
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED
STOCKHOLDER MATTERS 148
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 149
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES 149
PART IV
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES 150
ITEM 16. FORM 10-K SUMMARY 154
SIGNATURES 161
-1-
-- 2 of 512 --
References in this Annual Report on Form 10-K to the terms “we,” “our,” “us,” “Anthem” or the “Company” refer to Anthem, Inc., an Indiana corporation,
and, unless the context otherwise requires, its direct and indirect subsidiaries. References to the term “states” include the District of Columbia, unless the context
otherwise requires.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K, including Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains
certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about
future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,”
“intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are
not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future
operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are
difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the
forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also
urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission
from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent otherwise required by federal securities
laws, we do not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof. These risks and
uncertainties include, but are not limited to: the impact of large scale medical emergencies, such as public health epidemics and pandemics, including COVID-19,
and catastrophes; trends in healthcare costs and utilization rates; our ability to secure sufficient premium rates, including regulatory approval for and
implementation of such rates; the impact of federal and state regulation, including ongoing changes in the Patient Protection and Affordable Care Act and the
Health Care and Education Reconciliation Act of 2010, as amended (collectively, the “ACA”), and the ultimate outcome of legal challenges to the ACA; changes
in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; our ability to contract with providers
on cost-effective and competitive terms; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth
opportunities; reduced enrollment; unauthorized disclosure of member or employee sensitive or confidential information, including the impact and outcome of any
investigations, inquiries, claims and litigation related thereto; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-
compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star
ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix;
costs and other liabilities associated with litigation, government investigations, audits or reviews; the ultimate outcome of litigation between Cigna Corporation,
and us related to the merger agreement between the parties and the potential for such litigation to cause us to incur substantial additional costs, including potential
settlement and judgment costs; risks and uncertainties related to our pharmacy benefit management (“PBM”) business, including non-compliance by any party with
the PBM services agreement between us and CaremarkPCS Health, L.L.C.; medical malpractice or professional liability claims or other risks related to healthcare
and PBM services provided by our subsidiaries; general risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of
the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends
from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common
stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding
indebtedness; a downgrade in our financial strength ratings; the effects of any negative publicity related to the health benefits industry in general or us in particular;
failure to effectively maintain and modernize our information systems; events that may negatively affect our licenses with the Blue Cross and Blue Shield
Association; the impact of international laws and regulations; changes in U.S. tax laws; intense competition to attract and retain employees; and various laws and
provisions in our governing documents that may prevent or discourage takeovers and business combinations.
-2-
-- 3 of 512 --
PART I
ITEM 1. BUSINESS.
General
We are one of the largest health benefits companies in the United States in terms of medical membership, serving approximately 43 million medical members
through our affiliated health plans as of December 31, 2020. We deliver a number of leading health benefit solutions through a broad portfolio of integrated health
plans and related services, along with a wide range of specialty products as well as flexible spending accounts. In the second quarter of 2019, we began using our
pharmacy benefits manager called IngenioRx to market and offer pharmacy benefits management (“PBM”) services to our affiliated health plan customers
throughout the country, as well as to customers outside of the health plans we own. In addition, we are expanding our business into integrated health services
through our Diversified Business Group, which includes certain of our subsidiaries such as AIM Specialty Health, Aspire Health, and Beacon Health Options, Inc.
(“Beacon”) and other companies. At the time of its acquisition in 2020, Beacon was the largest independently held behavioral health organization in the country.
Our acquisition of Beacon aligns with our strategy to diversify into health services and deliver both integrated solutions and care delivery models that personalize
care for people with complex and chronic conditions.
We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our
members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana,
Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and
upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do
business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also conduct business through
arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states across the
country as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, Optimum HealthCare, Simply
Healthcare, and/or UniCare. We are licensed to conduct insurance operations in all 50 states and the District of Columbia through our subsidiaries.
For our insurance products, based on the level of risk we assume in the product contract, we categorize principal funding arrangements as fully-insured and
self-funded. Fully-insured products are products in which we indemnify our policyholders against costs for health benefits. Self-funded products are offered to
customers, generally larger employers, who elect to retain most or all of the financial risk associated with their employees’ healthcare costs. Some self-funded
customers choose to purchase stop loss coverage to limit their retained risk. For our fully-insured products, we charge a premium and assume the risk for the cost
of covered healthcare services. Under self-funded products, we charge a fee for services and the employer or plan sponsor funds or reimburses us for the healthcare
costs. In addition, we charge a premium to underwrite stop loss insurance for employers that maintain self-funded health plans. We also generate revenues from
providing PBM services including prescription drug fulfillment.
We offer a broad spectrum of network-based managed care plans to Large Group, Small Group, Individual, Medicaid and Medicare markets. Our managed
care plans include: Preferred Provider Organizations (“PPOs”); Health Maintenance Organizations (“HMOs”); Point-of-Service (“POS”) plans; traditional
indemnity plans and other hybrid plans, including Consumer-Driven Health Plans (“CDHPs”); and hospital only and limited benefit products. In addition, we
provide a broad array of managed care services to self-funded customers, including claims processing, stop loss insurance, actuarial services, provider network
access, medical cost management, disease management, wellness programs and other administrative services. We provide an array of specialty and other insurance
products and services such as PBM services, dental, vision, life and disability insurance benefits, radiology benefit management and analytics-driven personal
healthcare. We also provide services to the federal government in connection with our Federal Health Products & Services business (“FHPS”) which administers
the Federal Employees Health Benefits (“FEHB”) Program.
An ongoing focus on healthcare costs by employers, the government and consumers has continued to drive the growth of alternatives to traditional indemnity
health insurance. HMO, PPO and hybrid plans are among the various forms of managed care products that have been developed. Through these types of products,
insurers attempt to contain the cost of healthcare by
-3-
-- 4 of 512 --
negotiating contracts with hospitals, physicians and other providers to deliver high-quality healthcare to members at favorable rates. These products usually feature
medical management and other quality and cost optimization measures such as pre-admission review and approval for certain non-emergency services, pre-
authorization of outpatient surgical procedures, network credentialing to determine that network physicians and hospitals have the required certifications and
expertise, and various levels of care management programs to help members better understand and navigate the healthcare system. In addition, providers may have
incentives to achieve certain quality measures, may share medical cost risk or may have other incentives to deliver quality medical services in a cost-effective
manner. Also, certain plans offer members incentives for healthy behaviors, such as smoking cessation and weight management. Members are charged periodic,
prepaid premiums and generally pay co-payments, coinsurance and/or deductibles when they receive services. While the distinctions between the various types of
plans have lessened over recent years, PPO, POS and CDHP products generally provide reduced benefits for out-of-network services, while traditional HMO
products generally provide little to no reimbursement for non-emergency out-of-network utilization, but often offer more generous benefit coverage. An HMO plan
may also require members to select one of the network primary care physicians (“PCPs”) to coordinate their care and approve any specialist or other services.
Economic factors, greater consumer and employer sophistication and accountability have resulted in an increased demand for choice in both product/benefit
designs and provider network configurations. As a result, we continue to offer our broad access PPO networks with multiple benefit designs, but are also focused
on leveraging our provider collaboration initiatives with our accountable care organization (“ACO”) partnerships to develop both narrow and tiered network
offerings. This array of network and product configurations allows both the employer and the employee to design and select the combination of benefit designs
(e.g., traditional PPOs, high deductibles, health reimbursement accounts, health savings accounts, PCP based products, tiered copays) and networks (e.g., broad,
narrow, tiered, closed or exclusive provider, and open) that optimize choice, quality and price at the consumer, employer and market level. We believe we are well-
positioned in each of our states to respond to these market preferences.
Our medical membership includes seven different customer types: Local Group, Individual, National Accounts, BlueCard , Medicare, Medicaid and FEHB. In
addition, we also serve customers who purchase one or more of our other products or services that are often ancillary to our health business.
Our products are generally developed and marketed with an emphasis on the differing needs of our customers. In particular, our product development and
marketing efforts take into account the differing characteristics between the various customers served by us, as well as the unique needs of educational and public
entities, labor groups, FEHB program, national employers and state-run programs servicing low-income, high-risk and underserved markets. Overall, we seek to
establish pricing and product designs to provide value for our customers while achieving an appropriate level of profitability for each of our customer categories
balanced with the competitive objective to grow market share. We believe that one of the keys to our success has been our focus on these distinct customer types,
which better enables us to develop benefit plans and services that meet our customers’ unique needs. Further, IngenioRx was built to simplify pharmacy care and
focus on the whole person, and we expect it will make it easier for our customers to achieve better health outcomes at a lower total cost of care.
We market our Individual, Medicare and certain Local Group products through direct marketing activities and an extensive network of independent agents,
brokers and retail partnerships. Products for National Accounts and Local Group customers with a larger employee base are generally sold through independent
brokers or consultants retained by the customer who work with industry specialists from our in-house sales force. In the Individual and Small Group markets, we
offer on-exchange products through state- or federally-facilitated marketplaces, referred to as public exchanges, and off-exchange products. Federal subsidies are
available for certain members, subject to income and family size, who purchase public exchange products.
Being a licensee of the BCBS association of companies, of which there were 36 independent primary licensees including us as of December 31, 2020,
provides significant market value, especially when competing for very large multi-state employer groups. For example, each BCBS member company is able to
utilize other BCBS licensees’ substantial provider networks and discounts when any BCBS member works or travels outside of the state in which their policy is
written. This program is referred to as BlueCard and is a source of revenue when we provide member services in the states where we are the BCBS licensee to
individuals who are customers of BCBS plans not affiliated with us. This program also provides a national provider network for our members when they travel to
other states. See “BCBSA Licenses” herein for additional information on our BCBSA licenses. We refer to members in our service areas licensed by the BCBSA
as our BCBS-branded
®
®
-4-
-- 5 of 512 --
business. Non-BCBS-branded business refers to members in our non-BCBS-branded Amerigroup, Freedom Health, HealthSun, Optimum Health Care and Simply
Healthcare plans, as well as Beacon, HealthLink and UniCare members.
For additional information describing each of our customer types, detailed marketing efforts and changes in medical membership over the last three years, see
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Part II, Item 7 of this Annual Report on Form 10-K.
Our results of operations depend in large part on our ability to accurately predict and effectively manage healthcare costs through effective contracting with
providers of care to our members, product pricing, medical management and health and wellness programs, including service coordination and case management
for addressing complex and specialized healthcare needs, innovative product design and our ability to maintain or achieve improvement in our Centers for
Medicare and Medicaid Services (“CMS”) Star ratings. CMS Star ratings affect Medicare Advantage plan reimbursements as well as our eligibility to earn quality-
based bonus payments for those plans. See “Regulation” herein for additional information on our CMS Star ratings. For additional information on our networks
and provider relations, product pricing and healthcare cost management programs, see “Networks and Provider Relations”, “Pricing and Underwriting of Our
Products”, “Medical Management Programs”, “Care Management Programs” and “Healthcare Quality Initiatives” herein.
Advances in medical technology, increases in specialty drug costs, increases in hospital expenditures and other provider costs, the aging of the population,
other demographic characteristics and the COVID-19 pandemic continue to contribute to rising healthcare costs. Our managed care plans and products are
designed to encourage providers and members to participate in quality, cost-effective health benefit programs by using the full range of our innovative medical
management services, quality initiatives and financial incentives. Our market share and high business retention rates enable us to realize the long-term benefits of
investing in preventive and early detection programs. Our ability to provide cost-effective health benefits products and services is enhanced through a disciplined
approach to internal cost containment, prudent management of our risk exposure and successful integration of acquired businesses. In addition, our ability to
manage selling, general and administrative costs continues to be a driver of our overall profitability.
The future results of our operations will also be impacted by certain external forces and resulting changes in our business model and strategy. The continuing
growth in our government-sponsored business exposes us to increased regulatory oversight. The Patient Protection and Affordable Care Act and the Health Care
and Education Reconciliation Act of 2010, as amended (collectively, the “ACA”), has changed and may continue to make broad-based changes to the U.S.
healthcare system. The ACA presented us with new growth opportunities, but also introduced new risks, regulatory challenges and uncertainties, and required
changes in the way products are designed, underwritten, priced, distributed and administered. We currently offer Individual ACA-compliant products in 103 of the
143 rating regions in which we operate. Our strategy has been, and will continue to be, to only participate in rating regions where we have an appropriate level of
confidence that these markets are on a path toward sustainability, including, but not limited to, factors such as expected financial performance, regulatory
environment, and underlying market characteristics. Changes to our business environment are likely to continue as elected officials at the national and state levels
continue to enact, and both elected officials and candidates for election continue to propose, significant modifications to existing laws and regulations, including
changes to taxes and fees. In addition, the legal challenges regarding the ACA, including a federal district court decision invalidating the ACA, which was argued
before the U.S. Supreme Court in November 2020 and has been stayed pending the U.S. Supreme Court’s decision, continue to contribute to this uncertainty. We
will continue to evaluate the impact of the ACA as additional guidance is made available and any further developments or judicial rulings occur. For additional
discussion, see “Regulation” herein and Part I, Item 1A “Risk Factors” in this Annual Report on Form 10-K.
In addition to the external forces discussed in the preceding paragraph, our results of operations are impacted by levels and mix of membership which can
change as a result of the quality and pricing of our health benefits products and services, aging population, economic conditions, changes in unemployment,
acquisitions, entry into new markets and expansions in or exits from existing markets. These membership trends could be negatively impacted by various factors
that could have a material adverse effect on our future results of operations such as general economic downturns that result in business failures, failure to obtain
new customers or retain existing customers, premium increases, benefit changes or our exit from a specific market. See Part I, Item 1A “Risk Factors” and Part II,
Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in this Annual Report on Form 10-K.
-5-
-- 6 of 512 --
We believe healthcare is local and that we have the strong local presence required to understand and meet local customer needs with regard to any product
they are enrolled in with us. Further, we believe we are well-positioned to deliver what customers want: innovative, choice-based and affordable products;
distinctive service; simplified transactions; and better access to information for quality care. Our local presence, combined with our national expertise, has created
opportunities for collaborative programs that reward physicians and hospitals for clinical quality and excellence. We feel that our commitment to health
improvement and care management provides added value to customers and healthcare professionals. Ultimately, we believe that practical and sustainable
improvements in healthcare must focus on improving healthcare quality while managing costs for total affordability. We have implemented initiatives driving
payment innovation and partnering with providers to lower cost and improve the quality of healthcare for our members, and we continue to develop new and
innovative ways to effectively manage risk and engage our members. Further, we are expanding our financial arrangements with providers to include payment
models that encourage value-based care. We believe focusing on quality of care rather than volume of care is the foundation for improving patient outcomes. Our
value-based payment model supports patient-centered care by improving collaboration between providers and health partners and delivering to our patients the
right care, at the right time, in the right place. In addition, we are focused on achieving efficiencies from our national scale while optimizing service performance
for our customers. Finally, we expect to continue to rationalize our portfolio of businesses and products and align our investments to capitalize on new
opportunities to drive growth in our existing markets and expand into new markets in the future.
We continue to enhance interactions with customers, providers, brokers, agents, employees and other stakeholders through digital technology and improving
internal operations. Our approach includes not only the sales and distribution of health benefits products through digital technology, but also implementing
advanced capabilities that improve services benefiting customers, agents, brokers, and providers while optimizing administrative costs. These enhancements can
also help improve the quality, coordination and safety of healthcare through increased communications between patients and their physicians.
At Anthem, we strive to improve the health of humanity. We believe in working together to achieve our mission of improving lives and communities,
simplifying healthcare and expecting more. As we seek to accomplish these goals through a collaborative focus on execution and delivering for those we serve, our
vision is to be the most innovative, valuable and inclusive health partner. We focus on ensuring quality products and services that give members access to the care
they need. With an unyielding commitment to meeting the needs of our diverse customers, we are guided by the following values:
• Leadership – Redefine what is possible
• Community – Committed, connected, invested
• Integrity – Do the right thing, with a spirit of excellence
• Agility – Delivery today, transform tomorrow
• Diversity – Open your hearts and minds
In pursuing our vision, we intend to transform healthcare by providing trusted and caring solutions and delivering quality products and services that give
customers access to the care they need. At the same time, we will focus on earnings, organic membership growth, improvements in our operating cost structure,
strategic acquisitions and the efficient use of capital.
-6-
-- 7 of 512 --
COVID-19
In March 2020, the World Health Organization declared the outbreak of a novel strain of coronavirus (“COVID-19”) a global health pandemic. The COVID-
19 pandemic continues to evolve, and the virus and mitigation efforts have continued to impact the global economy, cause market instability, increase
unemployment in the United States, and put pressure on the healthcare system, and it has impacted and will continue to impact our membership and benefit
expense. As the COVID-19 pandemic continues, we remain focused on increasing access and coverage for our members, making changes to our membership
benefits and business operations and adapting tools and policies to assist consumers and care providers, including:
• Waiving cost-sharing for COVID-19 diagnostic tests and treatment;
• Providing expanded telehealth coverage for our Medicare and Medicaid plans, where permissible, and waiving cost-sharing for in-network telehealth
visits, including telephonic visits and those for mental health;
• Providing expanded telehealth coverage for our members in fully-insured employer plans and Individual plans (we also waived cost-sharing for in-
network telehealth and phone visits through September 30, 2020);
• Encouraging the use of home delivery services to enable access to necessary medications and relaxing early prescription refill policies for maintenance
and specialty medications for our members in fully-insured employer plans and Individual plans at least through September 30, 2020, and for Medicare
and Medicaid plans in accordance with applicable regulations;
• Providing a one-month premium credit to members enrolled in select individual plans and to fully insured employer group customers ranging from 10 to
15 percent of the monthly premium;
• Providing a one-month premium credit of 50 percent of the monthly premium to individuals in stand-alone and group dental plans;
• Leveraging data and advanced analytics to provide innovative solutions in response to the COVID-19 pandemic, and introducing a suite of digital tools
that serve various functions, including providing member data and updates related to COVID-19, aggregating real-time COVID-19 data to present trends
and predictions for our communities, and providing individuals with resources for mental health and free or reduced-cost programs that provide food,
transportation, childcare and more;
• Providing support to care provider partners of our affiliated health plans to help them continue to focus on caring for patients, including funding and
financial assistance, working with care providers to accelerate claims processing for outstanding accounts receivables, resolve claims where possible and
appropriate, and accelerate payments to support state-specific Medicaid programs;
• Simplifying access to care by temporarily suspending select prior authorization requirements for certain services and equipment critical to COVID-19
treatment;
• Offering in-network dental providers a $10 personal protective equipment credit per patient, per visit, through December 31, 2020;
• Transitioning the majority of our employees to a remote work environment, expanding our employee benefits to provide additional support, imposing
travel limitations and implementing workplace modifications consistent with the Centers for Disease Control and Prevention guidelines and social
distancing protocols;
• Committing to lifting up our local communities through a variety of partnership and relief efforts, contributing $50 million to the Anthem Foundation to
support its COVID-19 response and recovery efforts to help areas of greatest need, including care provider safety, food insecurity, and mental and
behavioral health resources; and
• Sponsoring and participating in collaborative efforts to promote innovative solutions related to COVID-19 and healthcare needs caused by the pandemic.
For additional discussion see Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations–COVID-19” included
in this Annual Report on Form 10-K. For information regarding our risks related to the COVID-19 pandemic and our other risk factors, see Part I, Item 1A, “Risk
Factors,” included in this Annual Report on Form 10-K.
-7-
-- 8 of 512 --
Competition
The managed care industry is highly competitive, both nationally and in our local markets. Competition continues to be intense due to aggressive marketing,
pricing, government-sponsored programs bid activity, business consolidations, new strategic alliances, new competitors in the market, a proliferation of new
products, technological advancements, the impact of legislative reform, increased quality awareness and price sensitivity among customers and changing market
practice such as increased usage of telehealth.
We believe that participants in the managed care industry compete for customers based on quality of service, price, access to provider networks, access to care
management and wellness programs (including health information), innovation, effective use of technology such as electronic data transfer, breadth and flexibility
of products and benefits, expertise and reputation (including National Committee on Quality Assurance (“NCQA”) accreditation status as well as CMS Star
ratings), brand recognition and financial stability. Our ability to attract and retain customers is substantially tied to our ability to distinguish ourselves from our
competitors in these areas.
We believe our exclusive right to market products under the most recognized brand in the industry, BCBS, in our most significant markets provides us with
greater brand recognition over competitive product offerings. Typically, we are the largest participant in each of our BCBS branded markets and, thus, are a
closely-watched target by other insurance competitors.
Product pricing remains competitive and we strive to price our healthcare benefit products and design our Medicare and Medicaid bids consistent with
anticipated underlying medical trends. We believe our pricing and bid strategy, based on predictive modeling, proprietary research and data-driven processes, has
positioned us to benefit from the potential growth opportunities available through entry into new markets, expansions in existing markets and as a result of any
future changes to the current regulatory scheme. We believe that our pricing and bid strategy, brand name and network quality will provide a strong foundation for
membership growth opportunities in the future.
Our provider networks give us a highly competitive unit cost position and provide distinctive service levels which allow us to offer a broad range of affordable
health benefit products to our customers. To build our provider networks, we compete with other health benefits plans for the best contracts with hospitals,
physicians and other providers. We believe that physicians and other providers primarily consider customer volume, reimbursement rates, timeliness of
reimbursement and administrative service capabilities along with the reduction of non-value added administrative tasks when deciding whether to contract with a
health benefits plan.
At the sales and distribution level, we compete for qualified agents and brokers to recommend and distribute our products. Strong competition exists among
insurance companies and health benefits plans for agents and brokers with demonstrated ability to secure new business and maintain existing accounts. We believe
that the quality and price of our products, support services, reputation and prior relationships, along with a reasonable commission structure, are the factors agents
and brokers consider in choosing whether to market our products. We believe that we have good relationships with our agents and brokers, and that our products,
support services and commission structure compare favorably to those of our competitors in all of our markets.
In addition, the PBM industry is highly competitive, and IngenioRx is subject to competition from national, regional and local PBMs, insurers, health plans,
large retail pharmacy chains, large retail stores, supermarkets, other mail order pharmacies, web pharmacies and specialty pharmacies. Strong competition within
the PBM industry has generated greater demand for lower product and service pricing, increased revenue sharing and enhanced product and service offerings.
Reportable Segments
We manage our operations through four reportable segments: Commercial & Specialty Business, Government Business, IngenioRx and Other. We regularly
evaluate the appropriateness of our reportable segments, particularly in light of organizational changes, merger and acquisition activity and changing laws and
regulations.
Our Commercial & Specialty Business and Government Business segments both offer a diversified mix of managed care products, including PPOs, HMOs,
traditional indemnity benefits and POS plans, as well as a variety of hybrid benefit plans including CDHPs, hospital only and limited benefit products.
-8-
-- 9 of 512 --
Our Commercial & Specialty Business segment includes our Local Group, National Accounts, Individual and Specialty businesses. Business units in the
Commercial & Specialty Business segment offer fully-insured health products; provide a broad array of managed care services to self-funded customers including
claims processing, stop loss insurance, provider network access, medical cost management, disease management, wellness programs, underwriting, actuarial
services and other administrative services; and provide an array of specialty and other insurance products and services such as dental, vision, life and disability
insurance benefits.
Our Government Business segment includes our Medicare and Medicaid businesses, National Government Services (“NGS”) and services provided to the
federal government in connection with our FHPS business. Medicaid makes federal matching funds available to all states for the delivery of healthcare benefits to
eligible individuals, principally those with incomes below specified levels who meet other state-specified requirements. Medicaid is structured to allow each state
to establish its own eligibility standards, benefits package, payment rates and program administration under broad federal guidelines. Our Medicare customers are
Medicare-eligible individual members age 65 and over who have enrolled in Medicare Advantage, a managed care alternative for the Medicare program, or who
have purchased Medicare Supplement benefit coverage, some disabled members under age 65, or members of all ages with end stage renal disease. Medicare
Supplement policies are sold to Medicare recipients as supplements to the benefits they receive from the Medicare program. Medicare Supplement policy rates are
filed with, and in some cases approved by, state insurance departments. Most of the premium for Medicare Advantage is based on bids submitted to CMS and paid
directly by the federal government on behalf of the participant who may also be charged a small premium. Additionally, through our alliance partnership
engagements with larger provider groups and BCBS plans, we offer a variety of Medicaid and Medicare services that include joint ventures, administrative service
offerings, and full-risk arrangements. NGS acts as a Medicare contractor for the federal government in several regions across the nation.
Our IngenioRx segment includes our PBM business, which began its operations during the second quarter of 2019. IngenioRx markets and offers PBM
services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. IngenioRx has a comprehensive PBM services
portfolio, which includes services such as formulary management, pharmacy networks, prescription drug database, member services and mail order capabilities. In
2019, IngenioRx was included in our Other reportable segment.
Our Other segment includes our Diversified Business Group (“DBG”), which is our integrated health services business, and certain eliminations and corporate
expenses not allocated to our other reportable segments.
For additional information, see Note 20, “Segment Information”, of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual
Report on Form 10-K.
We experience seasonality in our Commercial & Specialty Business and Government Business segments. While our premium revenues are not seasonal, our
benefit costs typically increase during the year as our fully-insured members pay their annual deductibles and reach their out-of-pocket maximum limits. However,
this seasonality may change in the future as the COVID-19 pandemic continues and COVID-19 vaccines become widely available. Our expenses associated with
COVID-19, including testing and treatment and the actions taken to support our members in response to the pandemic, accelerated in the fourth quarter of 2020
and exceeded the benefit we experienced during the quarter from the lower volume of healthcare claims attributable to decreased utilization of non-COVID-19
health services.
Through our participation in various federal government programs, we generated approximately 20.3%, 20.7% and 19.8% of our total consolidated revenues
from agencies of the U.S. government for the years ended December 31, 2020, 2019 and 2018, respectively. These revenues are contained in the Government
Business segment. An immaterial amount of our total consolidated revenues is derived from activities outside of the U.S.
Product and Service Descriptions
A general description of our products and services is provided below:
Preferred Provider Organization: PPO products offer the member an option to select any healthcare provider, with benefits reimbursed by us at a higher
level when care is received from a participating network provider. Increasingly, customers are choosing our PPO products offered with an exclusive provider
organization, which eliminates coverage out of
-9-
-- 10 of 512 --
network. Coverage is subject to co-payments or deductibles and coinsurance, with member cost sharing usually limited by out-of-pocket maximums.
Consumer-Driven Health Plans: CDHPs provide consumers with increased financial responsibility, choice and control regarding how their healthcare
dollars are spent. Generally, CDHPs combine a high-deductible PPO plan with an employer-funded and/or employee-funded personal care account, which may
result in tax benefits to the employee. Some or all of the dollars remaining in the personal care account at year-end can be rolled over to the next year for future
healthcare needs.
Traditional Indemnity: Indemnity products offer the member an option to select any healthcare provider for covered services. Coverage is subject to
deductibles and coinsurance, with member cost sharing usually limited by out-of-pocket maximums.
Health Maintenance Organization: HMO products include comprehensive managed care benefits, generally through a participating network of physicians,
hospitals and other providers. A member in one of our HMOs must typically select a PCP from our network. PCPs generally are family practitioners, internists or
pediatricians who provide necessary preventive and primary medical care, and are generally responsible for coordinating other necessary healthcare services. We
offer HMO plans with varying levels of co-payments, which result in different levels of premium rates.
Point-of-Service: POS products blend the characteristics of HMO, PPO and indemnity plans. Members can have comprehensive HMO-style benefits
through participating network providers with minimum out-of-pocket expenses (co-payments) and also can go directly, without a referral, to any provider they
choose, subject to, among other things, certain deductibles and coinsurance. Member cost sharing is limited by out-of-pocket maximums.
Public Exchange and Off-Exchange Products: Individual and Small Group products cover essential health benefits as defined in the ACA along with many
other requirements and cost-sharing features. Individual and Small Group products offered on and off the public exchanges meet the definition of the “metal”
product requirements (bronze, silver, gold and platinum) and each metal product must satisfy a specific actuarial value with respect to essential benefits. Health
insurers participating on the public exchanges must offer at least one silver and one gold product.
Administrative Services: In addition to fully-insured products, we provide administrative services to Large Group, Small Group and National Account
employers that maintain self-funded health plans. These administrative services include claims processing, medical cost management, disease management,
wellness programs, underwriting, actuarial services and other administrative services for self-funded employers. Self-funded health plans are also able to use our
provider networks and to realize savings through our negotiated provider arrangements, while allowing employers the ability to design certain health benefit plans
in accordance with their own requirements and objectives. We also underwrite stop loss insurance for self-funded plans.
BlueCard : BlueCard is a national program that links participating healthcare providers and independent BCBS plans. BlueCard host members are
generally members who reside in or travel to a state in which an Anthem subsidiary is the Blue Cross and/or Blue Shield licensee and who are covered under an
employer-sponsored health plan serviced by a non-Anthem controlled BCBS licensee, which is the “home” plan. We perform certain administrative functions for
BlueCard host members, including claims pricing and administration for which we receive administrative fees from the BlueCard members’ home plans. Other
administrative functions, including maintenance of enrollment information and customer service, are performed by the home plan.
Medicare Plans: We offer a wide variety of plans, products and options to individuals age 65 and older such as Medicare Supplement plans; Medicare
Advantage, including Special Needs Plans (“SNPs”), also known as Medicare Advantage SNPs; Medicare Part D Prescription Drug Plans (“Medicare Part D”);
and dual-eligible programs through Medicare-Medicaid Plans (“MMPs”). Medicare Supplement plans typically pay the difference between healthcare costs
incurred by a beneficiary and amounts paid by Medicare. Medicare Advantage plans provide Medicare beneficiaries with a managed care alternative to traditional
Medicare and often include a Medicare Part D benefit. In addition, our Medicare Advantage SNPs provide tailored benefits to special needs individuals who are
institutionalized or have severe or disabling chronic conditions and to dual-eligible customers, who are low-income seniors and persons under age 65 with
disabilities. Medicare Advantage SNPs are coordinated care plans specifically designed to provide targeted care, covering all the healthcare services considered
medically necessary for members and often providing professional care coordination services, with personal guidance and programs that help members maintain
their health. Medicare Advantage membership also
® ® ®
® ®
-10-
-- 11 of 512 --
includes Medicare Advantage members in our Group Retiree Solutions business who are related to National Accounts, retired members of Local Group accounts,
or retired members of groups who are not affiliated with our Commercial accounts who have selected a Medicare Advantage product through us. Medicare Part D
offers a prescription drug plan to Medicare and MMP beneficiaries. MMP is a demonstration program focused on serving members who are dually eligible for
Medicaid and Medicare, which was established as a result of the passage of the ACA.
Individual Plans: We offer a full range of health insurance plans with a variety of options and deductibles for individuals who are not covered by employer-
sponsored coverage and are not eligible for government sponsored plans, such as Medicare and/or Medicaid. Individual policies are generally sold through
independent agents and brokers, retail partnerships, our in-house sales force or via the exchanges. Individual business is sold on a fully-insured basis. We offer on-
exchange products through public exchanges and off-exchange products. Federal premium subsidies are available only for certain public exchange Individual
products. Unsubsidized Individual customers are generally more sensitive to product pricing and, to a lesser extent, the configuration of the network and the
efficiency of administration. Instability in the Individual market has resulted in a targeted approach where we offer products in select geographies.
Medicaid Plans and Other State-Sponsored Programs: We have state contracts to serve members enrolled in publicly funded healthcare programs,
including Medicaid; ACA-related Medicaid expansion programs; Temporary Assistance for Needy Families (“TANF”); programs for seniors and people with
disabilities (“SPD”); Children’s Health Insurance Programs (“CHIP”); and specialty programs such as those focused on long-term services and support (“LTSS”),
HIV/AIDS, children living in foster care, behavioral health and/or substance abuse disorders, and intellectual disabilities and/or developmental disabilities
(“ID/DD programs”). The Medicaid program makes federal matching funds available to all states for the delivery of healthcare benefits for low income and/or high
medical risk individuals. These programs are managed by the individual states based on broad federal guidelines. TANF is a state and federally funded program
designed for a population consisting primarily of low-income children and their guardians. SPD is a federal income supplement program designed for
Supplemental Security Income recipients; however, states can broaden eligibility criteria. This population generally consists of low-income seniors and people with
disabilities. CHIP is a state and federally funded program that provides healthcare coverage to children not otherwise covered by Medicaid or other insurance
programs. LTSS is a state and federally funded program that offers states a broad and flexible set of program design options and covers the delivery of long-term
services and support for our members who receive home and community- or institution-based services for long-term care. Our HIV/AIDS program is a state and
federally sponsored program that provides services to those living with HIV/AIDS. Our foster care program is a state and federally sponsored program serving
children with complex needs within the foster care system. Our behavioral health program is a state and federally sponsored program providing services to those
with mental health and/or substance abuse disorders. ID/DD is a state and federally sponsored program serving those living with limitations in intellectual
functioning and adaptive behavior learning disabilities. Our Medicaid plans also cover certain dual-eligible customers, as previously described above, who also
receive Medicare benefits. We provide Medicaid and other state sponsored services, such as administrative services, in Arkansas, California, Colorado, Florida,
Georgia, Indiana, Iowa, Kentucky, Louisiana, Maryland, Minnesota, Missouri, Nebraska, Nevada, New Jersey, New York, South Carolina, Tennessee, Texas,
Virginia, Washington, West Virginia, and Wisconsin.
Pharmacy Products: In the second quarter of 2019, we began using IngenioRx to market and offer PBM services to our affiliated health plan customers
throughout the country, as well as to customers outside of the health plans we own. Our comprehensive PBM services portfolio includes features such as formulary
management, pharmacy networks, a prescription drug database, member services, and mail order capabilities. IngenioRx delegates certain PBM administrative
functions, such as claims processing and prescription fulfillment, to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation (“CVS
Health”), pursuant to a five-year agreement (the “CVS PBM Agreement”). With IngenioRx, we retain the responsibilities for clinical and formulary strategy and
development, member and employer experiences, operations, sales, marketing, account management and retail network strategy. From December 2009 through
December 2019, we delegated certain PBM functions and administrative services to Express Scripts Inc. (“Express Scripts”). Express Scripts managed the network
of pharmacy providers, operated mail order pharmacies and processed prescription drug claims on our behalf, while we sold and supported the product for our
members, made formulary decisions, sold drug benefit design strategy and provided front line member support. We began transitioning existing members from
Express Scripts to IngenioRx in the second quarter of 2019, and completed the transition by January 1, 2020.
Behavioral Health: We offer managed care and member services for behavioral health and/or substance use disorders under contracts with state publicly
funded healthcare programs, including Medicare and Medicaid, and through private health
-11-
-- 12 of 512 --
plans and ACOs. In addition, we provide management and member benefit services for employee assistance plans to private employers and the federal
government’s Military OneSource support services. Through our subsidiary, Beacon, we also provide direct behavioral health counseling services through licensed
clinicians in convenient and accessible locations, principally within a retail store environment.
Life Insurance: We offer an array of competitive individual and group life insurance benefit products to both Large Group and Small Group customers in
conjunction with our health plans. The life insurance products include term life and accidental death and dismemberment.
Disability: We offer short-term and long-term disability products, usually in conjunction with our health plans.
Dental: Our dental plans include networks in certain states in which we operate. Many of the dental benefits are provided to customers enrolled in our
health plans and are offered on both a fully-insured and self-funded basis. Our members also have access to additional dental providers through our participation in
the National Dental GRID, a national dental network developed by and for BCBS plans. The National Dental GRID includes dentists in all 50 states and the
District of Columbia and provides multi-state customers with a national solution that offers in-network discounts across the country. Additionally, we offer
managed dental services to other healthcare plans to assist those plans in providing dental benefits to their customers.
Vision Services and Products: Our vision plans include networks within the states in which we operate. Many of the vision benefits are provided to
customers enrolled in our health plans and are offered on both a fully-insured and self-funded basis.
Medicare Administrative Operations: Through our subsidiary, NGS, we serve as a fiscal intermediary, carrier and Medicare administrative contractor for the
federal government by providing administrative services for the Medicare program, Parts A and B, which generally provides coverage for persons who are 65 or
older and for persons who are under 65 and disabled or with end-stage renal disease. Part A of the Medicare program provides coverage for services provided by
hospitals, skilled nursing facilities and other healthcare facilities. Part B of the Medicare program provides coverage for services provided by physicians, physical
and occupational therapists and other professional providers, as well as certain durable medical equipment and medical supplies.
Radiology Benefit Management: We offer outpatient diagnostic imaging management services to health plans, which promote the most appropriate use of
clinical services to improve the quality of care delivered to members. These services include utilization management for advanced diagnostic imaging procedures,
network development and optimization, patient safety, claims adjudication and provider payment.
Personal Healthcare Guidance: We offer evidence-based and analytics-driven personal healthcare guidance. These services help improve the quality,
coordination and safety of healthcare, enhance communications between patients and their physicians, and reduce medical costs.
Networks and Provider Relations
Our relationships with physicians, hospitals and professionals that render healthcare services to our members are guided by local, regional and national
standards for network development, reimbursement and contract methodologies. While following industry standards, we are simultaneously seeking to lead
transformation efforts within our healthcare system, moving from a fragmented model premised on episodic intervention to one based on proactive, coordinated
care built around the needs of the patient. A key element of this transformation involves a transition from traditional fee-for-service payment models to models
where providers are paid based on the value, both in quality and affordability, of the care they deliver.
We establish “market-based” hospital reimbursement payments that we believe are fair, but aggressive, and among the most competitive in the market. We
also seek to ensure that physicians in our network are paid in a timely manner at appropriate rates. In many instances, we deploy multi-year contracting strategies,
including case rates or fixed rates, to limit our exposure to medical cost inflation and to increase cost predictability. We maintain both broad and narrow provider
networks to ensure member choice, based on both price and access needs, while implementing programs designed to improve the quality of care our members
receive. Increasingly, we are supplementing our broad-based networks with smaller or more
-12-
-- 13 of 512 --
cost-effective networks that are designed to be attractive to a more price-sensitive customer segment, such as public exchange customers.
Our reimbursement strategies vary across markets and depend on the degree of consolidation and integration of physician groups and hospitals. Under a fee-
for-service reimbursement methodology for physicians, fee schedules are developed at the state level based on an assessment of several factors and conditions,
including the CMS resource-based relative value system (“RBRVS”), medical practice cost inflation and physician supply. We utilize CMS RBRVS fee schedules
as a reference point for fee schedule development and analysis. The RBRVS structure was developed, maintained, and updated by CMS and is used by the
Medicare program and other major payers. In addition, we have implemented and continue to expand physician incentive contracting, or “pay-for-performance,”
which ties physician payment levels to performance on clinical measures.
While we generally do not delegate full financial responsibility to our physician providers in the form of capitation-based reimbursement, we maintain
capitation-based arrangements in certain markets where we determine that market dynamics result in it being a useful method to lower costs and reduce
underwriting risk.
Our hospital contracts provide for a variety of reimbursement arrangements depending on local market dynamics and current hospital utilization efficiency.
Most hospitals are reimbursed a fixed amount per day or reimbursed a per-case amount, per admission, for inpatient covered services. A small percentage of
hospitals, primarily rural, sole community hospitals, are reimbursed on a discount from approved charge basis for covered services. Our “per-case” reimbursement
methods utilize many of the same attributes contained in Medicare’s Diagnosis Related Groups methodology. Hospital outpatient services are reimbursed by fixed
case rates, fee schedules or percent of approved charges. Our hospital contracts recognize unique hospital attributes, such as academic medical centers or
community hospitals, and the volume of care performed for our members. To improve predictability of expected costs, we frequently use a multi-year contracting
approach with providers. In addition, the majority of our hospital contracts include a pay-for-performance component where reimbursement levels are linked to
improved clinical performance, patient safety and medical error reduction.
Our provider engagement and contracting strategies are moving away from “unit price” or volume-based payment models to payment models that align
compensation with the value delivered as measured by healthcare outcomes, quality and cost. Our Enhanced Personal Health Care program augments traditional
fee-for-service with shared savings opportunities for providers when actual healthcare costs are below projected costs and providers meet specific quality
measures. The quality measures are based on nationally accepted, credible standards (e.g., NCQA, the American Diabetes Association and the American Academy
of Pediatrics) and span preventive, acute and chronic care. We understand, however, that payment incentives alone are insufficient to create the large-scale,
system-wide transformation required to achieve meaningful impacts on cost, quality and member experience. Accordingly, we are investing in care delivery
transformation and population health management support structures to help providers succeed under value-based payment models. This support includes our web-
based population health management technology and teams of dedicated practice consultants who work alongside providers, sharing best practices, and helping
them leverage our data to the benefit of their patients. In some of these arrangements, participating physician practices receive a per-member, per-month clinical
coordination fee to compensate them for important care management activities that occur outside of the patient visit (e.g., purchasing an electronic health record or
hiring care management nurses), all of which have been shown to reduce healthcare costs and improve care outcomes. Since the launch of our Enhanced Personal
Health Care program, we now have arrangements with provider organizations covering 52% of our PCPs and have rolled this program out in each of the 14 states
where we operate as a licensee of the BCBSA.
Medical Management Programs
Our medical management programs include a broad array of activities that facilitate improvements in the quality of care provided to our members and promote
cost-effective medical care. These medical management activities and programs are administered and directed by physicians and nurses. The goals of our medical
management strategies are to ensure that the care delivered to our members is supported by appropriate medical and scientific evidence, is received on a timely
basis and occurs in the most appropriate setting. The following is a general description of our medical management programs, which are available to our members
depending on the particular plan or product in which they participate:
Precertification: A traditional medical management program involves assessment of the appropriateness of certain hospitalizations and other medical
services prior to the services being rendered. For example, precertification is used to
-13-
-- 14 of 512 --
determine whether a set of hospital and medical services is being appropriately applied to the member’s clinical condition, in accordance with criteria for medical
necessity as that term is defined in the member’s benefits contract. All of our health plans have implemented precertification programs for selected medical
services including surgeries, major diagnostic procedures, devices, drugs and other services to help members maximize benefits and avoid unnecessary charges or
penalties. Through our American Imaging Management, Inc. subsidiary, doing business as AIM Specialty Health (“AIM”) we promote appropriate, safe and
affordable member care in the areas of imaging, sleep disorders, cardiac testing, oncology drugs and musculoskeletal procedures. These expanded specialty benefit
management solutions leverage clinical expertise and technology to engage our provider communities and members in more effective and efficient use of
outpatient services.
Care coordination: Another traditional medical management strategy we use is care coordination, which is based on nationally recognized criteria developed
by third-party medical specialists. With inpatient care coordination, the requirements and intensity of services during a patient’s hospital stay are reviewed, at times
by an onsite, skilled nurse professional in collaboration with the hospital’s medical and nursing staff, in order to coordinate care and determine the most effective
transition of care from the hospital setting. In addition, continued stay cases are reviewed with physician medical directors to ensure appropriate utilization of
medical services. We also coordinate care for outpatient services to help ensure that patients with chronic conditions who receive care from multiple physicians are
able to manage the exchange of information between physicians and coordinate office visits to their physicians.
Case management: We have implemented a medical management strategy focused on identifying the small percentage of the membership that will require a
high level of intervention and assistance to manage their healthcare needs. Case management identifies members who are likely to be re-admitted to the hospital
through claims analysis using predictive modeling techniques, the use of health risk assessment data, utilization management reports and referrals from a physician
or one of our other programs, such as the 24/7 NurseLine. Registered nurses, medical directors, behavioral health experts, pharmacists and other clinicians focus on
these members and help them coordinate their care through pharmacy compliance, post-hospital care, follow-up visits to see their physician and support in their
home. Increasingly, we collaborate with our providers and key health partners within the member’s provider care team by providing actionable patient data
insights, practice-coaching capabilities, technology and programs and products that help our providers and health partners to successfully deliver the right care, at
the right time, in the right place.
Formulary management: We have developed formularies, which are selections of drugs based on clinical quality and effectiveness. A pharmacy and
therapeutics committee of physicians uses scientific and clinical evidence to ensure that our members have access to the appropriate drug therapies and receive
these therapies through proper settings.
Medical policy: A medical policy committee determines our national policies and guidelines for the application of medical technologies, procedures and
services. This committee is comprised of internal and external physician leaders from various specialties and areas of the country. We also work in cooperation
with academic medical centers, practicing community physicians and medical specialty organizations. All guidelines and policies are reviewed at least once a year
or as new published clinical evidence becomes available.
Quality programs: We are actively engaged with our hospital and physician networks to enable them to improve medical and surgical care and achieve
better outcomes for our members. We endorse, encourage and incentivize hospitals and physicians to support national initiatives to improve the quality of clinical
care and patient outcomes and to reduce medication errors and hospital infections.
External review procedures: We work with outside experts through a process of external review to provide our members scientifically and clinically,
evidence-based medical care. When we receive member concerns, we have formal appeals procedures that ultimately allow coverage disputes related to medical
necessity decisions under the benefits contract to be settled by independent expert physicians.
Provider cost comparison tools: Through Estimate Your Cost, Care & Cost Finder, and other web-based tools, our members can compare cost estimates,
quality accreditation data and patient reviews for common services at contracted providers, with cost estimates for facility, professional and ancillary services.
These cost estimates bundle related services typically performed at the time of the procedure, not just for the procedure itself. Users can review cost data for over
400 common, shop-able medical procedures in all states. Members can also estimate out-of-pocket costs based on a member’s own benefit coverage, deductible,
and out-of-pocket maximum. We also offer information on overall facility
-14-
-- 15 of 512 --
ratings and patient experience using trusted third-party data. We continue to work on enhancing and evolving our tools to assist members in making informed and
value-based healthcare decisions. In addition, we collaborate with an external independent vendor to support employers wanting to purchase a consumer
engagement solution with certain additional functionality.
Anthem Health Guide: Anthem Health Guide integrates the customer service experience with clinical and wellness coaching to provide easier navigation of
healthcare services for our members. Anthem Health Guide provides members with education on benefit options and digital opportunities that fit member
references, and makes recommendations for eligible clinical programs to ensure members are connected to the most appropriate care and clinical resources. By
allowing members to connect with us using voice, click-to-chat, secure email and mobile technology, we enhance our ability to engage with our members.
Anthem Whole Health Connection: Anthem Whole Health Connection is a differentiated approach to whole person health that connects medical, pharmacy,
dental, vision, disability, behavioral health and supplemental health clinical and claims data to proactively identify health issues earlier and engage our members
with their health providers in new ways to support health, lower costs and deliver a better healthcare experience. Anthem Whole Health Connection is included
when Anthem health benefits are combined with one or more of the Anthem pharmacy, dental, vision, life, disability, behavioral health or supplemental health
coverage plans.
Care Management Programs
We continue to expand our 360º Health suite of integrated care management programs and tools. 360º Health offers the following programs, among others,
which are available to our members depending on the particular plan or product in which they participate, and have been proven to increase quality and reduce
medical costs for our members:
ConditionCare and FutureMoms are care management and maternity management programs that serve as adjuncts to physician care. Skilled nurse
professionals, with added support from our team of dietitians, social workers, pharmacists, health educators and other health professionals, help participants
understand their condition, their doctor’s orders and how to become a better self-manager of their condition. We also offer members infertility consultation through
our SpecialOffers@Anthem program, a comprehensive and integrated assembly of discounted health and wellness products and services from a variety of the
nation’s leading retailers.
24/7 NurseLine offers access to qualified, registered nurses anytime. This allows our members to make informed decisions about the appropriate level of care
and avoid unnecessary worry. This program also includes a referral process to the nearest urgent care facility, a robust audio library, accessible by phone, with
more than 600 health and wellness topics, as well as on-line health education topics designed to educate members about symptoms and treatment of many common
health concerns.
MyHealth Advantage utilizes integrated information systems and sophisticated data analytics to help our members improve their compliance with evidence-
based care guidelines, providing personal care notes that alert members to potential gaps in care, enable more prudent healthcare choices, and assist in the
realization of member out-of-pocket cost savings. Key opportunities are also shared with physicians through Availity at the time of membership eligibility
verification. Availity is an electronic data interchange system that allows for the exchange of health information among providers over a secure network.
MyHealth Coach provides our members with a professional guide who helps them navigate the healthcare system and make better decisions about their well-
being. MyHealth Coach proactively reaches out to people who are at risk for potentially serious health issues or have complex healthcare needs. Our health coaches
help participants understand and manage chronic conditions, handle any health and wellness related services they need and make smart lifestyle choices.
HealthyLifestyles helps employees transform unhealthy habits into positive ones by focusing on behaviors that can have a positive effect on their health and
their employer’s financial well-being. HealthyLifestyles programs include smoking cessation, weight management, stress management, physical activity, and diet
and nutrition.
Behavioral Health Case Management is a comprehensive program supporting a wide range of members who are impacted by their behavioral health condition,
including specialty areas such as eating disorders, anxiety, depression and
®
®
-15-
-- 16 of 512 --
substance abuse. The program assists members and their families with obtaining appropriate behavioral health treatment, offering community resources, providing
education and telephonic support, and promoting provider collaboration.
Autism Spectrum Disorder Program is a specialized case management program staffed by a dedicated team of clinicians who have been trained on the unique
challenges and needs of families with a member who has a diagnosis of autism spectrum disorder. These clinicians provide education, information on community
resources to help with care and support, guidance on the appropriate usage of benefits, and assistance in exploring effective treatments, such as medical services,
that may help the member and their families.
Employee Assistance Programs provide 24/7 telephonic support for personal and crisis events. Members also gain access to many resources that allow support
within work and personal life by providing quick and easy access to confidential resources to help meet the challenges of daily life. Examples of services available
include counseling, referral assistance with child care, health and wellness, financial issues, legal issues, adoption and daily living.
Healthcare Quality Initiatives
Increasingly, the healthcare industry is able to define quality healthcare based on preventive health measurements, outcomes of care and optimal care
management for chronic disease. A key to our success has been our ability to work with our network physicians and hospitals to improve the quality and outcomes
of the healthcare services provided to our members. Our ability to promote quality medical care has been recognized by NCQA, the largest and most respected
national accreditation program for managed care health plans.
Several quality healthcare measures, including the Healthcare Effectiveness Data and Information Set (“HEDIS ”), have been incorporated into NCQA’s
accreditation processes. HEDIS measures range from preventive services, such as screening mammography and pediatric immunization, to elements of care,
including decreasing the complications of diabetes and improving treatment for patients with heart disease. In 2020, NCQA announced that it was eliminating its
then-existing status levels for health plans and moving to CMS Star ratings in order to make accreditation ratings more transparent. Accredited plans earn ratings
after they submit HEDIS/CAHPS reporting and can advertise the rating alongside their accreditation seal. Due to the COVID-19 pandemic, NCQA did not release
2020-2021 Health Plan Ratings or Star ratings for any product line. CMS reported Star ratings for Medicare; however, HEDIS/CAHPS utilized the scores from the
2018 measurement year.
Even though the utilization of clinical data for scoring is uncertain, we continued to support our members by promoting health and wellness in a variety of
ways. In an effort to promote the importance of preventive screenings and chronic condition management, we conducted check-in calls to high-risk Medicaid and
Medicare members at the onset of the COVID-19 pandemic to address access to medication, adequate food supply and social isolation. Outreach was also
conducted to remind our members of overdue screenings and appointment scheduling assistance was provided, when requested by the member. Additionally, to
address our members’ concerns over potential exposure to COVID-19, we deployed home lab kits to members enabling them to complete colon cancer screenings
and manage their diabetes in the safety of their own homes.
Our wholly-owned health outcomes research subsidiary, HealthCore, Inc. (“HealthCore”) generates consistent and actionable evidence to support decision
making while helping to guide fresh initiatives for a range of stakeholders in the healthcare industry. By leveraging a rich array of medical and pharmacy
utilization data queried from administrative claims, patient surveys, medical charts and laboratory diagnostics, among other health records, HealthCore’s multi-
disciplinary research teams develop a broad spectrum of safety, clinical research trials, effectiveness, pharmacoepidemiology, and health economics evidence.
HealthCore’s real world evidence and comparative effectiveness research, among other data, have played roles in the product planning and development campaigns
of biotechnology and pharmaceutical companies and today it lists most of the leading biologics and drug manufacturers as clients or alliance partners.
Our AIM subsidiary supports quality by implementing clinical appropriateness and patient safety solutions for advanced imaging procedures, cardiology, sleep
medicine, medical oncology, radiation therapy, rehabilitative, certain outpatient surgical and musculoskeletal services. These programs, based on widely accepted
and evidence-based clinical guidelines, promote the most appropriate use of clinical services to improve the quality of overall healthcare delivered to our members
and members of other health plans that are covered under AIM’s programs. To provide additional impact to its clinical appropriateness program, AIM has also
implemented a provider assessment program, OptiNet , which promotes more
®
®
®
-16-
-- 17 of 512 --
informed selection of diagnostic imaging and testing facilities by providing cost and facility information to physician offices at the point that a procedure is
ordered. We have also leveraged AIM’s provider network assessment information to proactively engage and educate our members about imaging providers and
sleep testing choices based on site capabilities and cost differences. This program is another example of how we facilitate improvements in the quality of care
provided to our members and promote cost-effective medical care.
Pricing and Underwriting of Our Products
We price our products based on our assessment of current healthcare claim costs and emerging healthcare cost trends, combined with charges for
administrative expenses, risk and profit, including charges for the ACA taxes and fees, where applicable. We continually review our product designs and pricing
guidelines on a national and regional basis so that our products remain competitive and consistent with our profitability goals and strategies.
Our revenue on Medicare policies is based on annual bids submitted to CMS. We base the commercial and Medicaid premiums we charge and our Medicare
bids on our estimates of future medical costs over the fixed contract period. In applying our pricing to each employer group and customer, we aim to maintain
consistent, competitive, disciplined underwriting standards. We employ our proprietary accumulated actuarial and financial data to determine underwriting and
pricing parameters for both our fully-insured and self-funded businesses.
In most circumstances, our pricing and underwriting decisions follow a prospective rating process in which a fixed premium is determined at the beginning of
the contract period. For our fully-insured business, any deviation, favorable or unfavorable, from the medical costs assumed in determining the premium is our
responsibility. Some of our larger groups employ retrospective rating reviews, where positive experience is partially refunded to the group, and negative experience
is charged against a rate stabilization fund established from the group’s favorable experience or charged against future favorable experience. In addition, our ACA
and government fully-insured contracts may include minimum medical loss ratio, risk adjustment, or risk corridor arrangements, which also stabilize premiums
based upon claims experience.
Our pharmacy pricing through IngenioRx is presented to market via discounts off the average wholesale price for drugs dispensed through the retail, mail and
specialty channels as well as through rebate projections. We utilize group-specific script data, formulary, network and clinical care program selection combined
with administrative expense, risk and profit guidance to set market competitive pricing discounts and rebate projections. Pharmacy pricing guidelines guide the
underwriting process and undergo an annual external review process to ensure market competitiveness.
BCBSA Licenses
We are a party to license agreements with the BCBSA that entitle us to the exclusive, and in certain areas, non-exclusive use of the Blue Cross and Blue Shield
names and marks in assigned geographic territories. BCBSA is a national trade association of Blue Cross and Blue Shield licensees, the primary function of which
is to promote and preserve the integrity of the BCBS names and marks, as well as provide certain coordination among the member companies. Each BCBSA
licensee is an independent legal organization and is not responsible for obligations of other BCBSA member organizations. Although we have no right to market
products and services using the BCBS names and marks outside of the states in which we are licensed to sell BCBS products, in accordance with the subscriber
settlement agreement and release (“Subscriber Settlement Agreement”) that was agreed to in 2020 by the BCBSA and Blue Cross and/or Blue Shield licensees,
including us (the “Blue plans”), some large national employers with self-funded benefits plans have a right to request a bid for insurance coverage from a second
Blue plan in addition to the local Blue plan. We are required to pay an annual license fee to the BCBSA based on enrollment and also to comply with various
requirements and restrictions regarding our operations and our use of the BCBS names and marks. These requirements and restrictions include, among other things:
minimum capital and liquidity requirements; enrollment and customer service performance requirements; participation in programs that provide portability of
membership between plans; disclosures to the BCBSA relating to enrollment and financial conditions; disclosures as to the structure of the BCBS system in
contracts with third parties and in public statements; plan governance requirements; cybersecurity requirements; a requirement that at least 80% (or, in the case of
Blue Cross of California, substantially all) of a licensee’s annual combined local net revenue, as defined by the BCBSA, attributable to healthcare plans and related
services within its service areas must be sold, marketed, administered or underwritten under the BCBS names and marks; a requirement that at least two-thirds of a
licensee’s annual combined national net revenue, as defined by the BCBSA, attributable to healthcare plans and related services must be sold, marketed,
administered or underwritten under the BCBS names and marks; a requirement that neither a plan nor any of its licensed affiliates may permit an entity other than a
plan or
-17-
-- 18 of 512 --
a licensed affiliate to obtain control of the plan or the licensed affiliate or to acquire a substantial portion of its assets related to licensable services; governance
requirements such as a requirement that we divide our Board of Directors into three classes serving staggered three-year terms; a requirement that we guarantee
certain contractual and financial obligations of our licensed affiliates; and a requirement that we indemnify the BCBSA against any claims asserted against it
resulting from the contractual and financial obligations of any subsidiary that serves as a fiscal intermediary providing administrative services for Medicare Parts A
and B. In addition, a change of control or violation of the BCBSA ownership limitations on our capital stock, impending financial insolvency or the appointment of
a trustee or receiver or the commencement of any action against us seeking our dissolution could cause a termination of our BCBSA license agreements.
We believe that we and our licensed affiliates are currently in compliance with these standards. The standards under the license agreements may be modified
in certain instances by the BCBSA. See Part I, Item 1A “Risk Factors” in this Annual Report on Form 10-K for additional details on the impact if we were not to
comply with these license agreements and Note 14, “Commitments and Contingencies - Litigation and Regulatory Proceedings – Blue Cross Blue Shield Antitrust
Litigation” of the Notes to our Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K for additional information on the
Subscriber Settlement Agreement.
Regulation
General
Our operations are subject to comprehensive and detailed state, federal and international regulation throughout the jurisdictions in which we do business.
These laws and regulations, which can vary significantly from jurisdiction to jurisdiction, restrict how we conduct our businesses and result in additional burdens
and costs to us. Further, federal and state laws and regulations are subject to amendments and changing interpretations in each jurisdiction. The application of these
complex legal and regulatory requirements to the detailed operation of our businesses creates areas of uncertainty. In addition, there are numerous proposed
healthcare laws and regulations at the federal and state levels, including single payer, Medicare for All and public option proposals, some of which could materially
adversely affect our businesses if they were to be enacted.
Supervisory agencies, including federal and state regulators and departments of health, insurance and corporation, have broad authority to:
• grant, suspend and revoke licenses to transact business;
• regulate our products and services in great detail;
• regulate, limit, or suspend our ability to market products, including participation in Medicare and the ACA public exchanges;
• determine through a procurement process our ability to participate in certain programs, including state Medicaid programs;
• retroactively adjust premium rates;
• monitor our solvency and reserve adequacy;
• scrutinize our investment activities on the basis of quality, diversification and other quantitative criteria; and
• impose monetary and criminal sanctions for non-compliance with regulatory requirements.
To carry out these tasks, these government entities periodically examine our operations and accounts.
The health benefits business also may be adversely impacted by court and regulatory decisions that expand or invalidate the interpretations of existing statutes
and regulations. It is uncertain whether we could recoup, through higher premiums or other measures, the increased costs of mandated benefits or other increased
costs caused by potential legislation, regulation or court rulings. See Part I, Item 1A “Risk Factors” in this Annual Report on Form 10-K.
-18-
-- 19 of 512 --
COVID-19
Federal and state legislation has been enacted, and is likely to continue to be enacted, in response to the COVID-19 pandemic that has had, and we expect will
continue to have, a significant impact on all of our lines of business, including mandates to waive cost-sharing on COVID-19 vaccination, testing, treatment and
related services. The federal government enacted the Coronavirus Preparedness and Response Supplemental Appropriations Act, the Families First Coronavirus
Response Act and the Coronavirus Aid, Relief and Economic Security (“CARES”) Act in March 2020, the Paycheck Protection Program and Health Care
Enhancement Act in April 2020, and the Consolidated Appropriations Act of 2021 in December 2020 (the “Appropriations Act”). These acts provide, among other
things, prohibitions on prior authorization and cost-sharing for certain items and services related to COVID-19 tests, reforms including waiving Medicare
originating site restrictions for qualified providers providing telehealth services, financial support to healthcare providers, including expansion of the Medicare
accelerated payment program to all providers receiving Medicare payments, and funding to replenish and administer small business loan programs to help small
businesses keep their workers employed and healthcare benefits covered in the group market.
Regulatory changes have also been enacted, and are likely to continue to be enacted, at the state and federal level in response to the COVID-19 pandemic.
Those changes, which could have a significant impact on health benefits, consumer eligibility for public programs, and our cash flows, include mandated
expansion of premium payment terms including the time period for which claims can be denied for lack of payment, mandates related to prior authorizations and
payment levels to providers, additional consumer enrollment windows, and an increased ability to provide services through telehealth. We are providing extensions
to premium payment terms in certain situations and working closely with state regulators that are mandating or requesting such relief.
The Appropriations Act
The Appropriations Act contains a number of provisions that may have a material effect upon our business, including procedures and coverage requirements
related to surprise medical bills and new mandates for continuity of care for certain patients, price comparison tools, disclosure of broker compensation and
reporting on pharmacy benefits and drug costs. The various health plan-related requirements of the Appropriations Act will go into effect on January 1, 2022, and
our first report on pharmacy benefits and drug costs due on December 27, 2021.
State Regulation of Insurance Companies and HMOs
Our insurance and HMO subsidiaries must obtain a certificate of authority and maintain that license in the jurisdictions in which they conduct business. The
National Association of Insurance Commissioners (“NAIC”) has adopted model regulations that, where adopted by states, require expanded governance practices,
risk and solvency assessment reporting and the filing of periodic financial and operating reports. Most states have adopted these or similar measures to expand the
scope of regulations relating to corporate governance and internal control activities of HMOs and insurance companies. Health insurers and HMOs are subject to
state examination and periodic license renewal.
In addition, we are regulated as an insurance holding company and are subject to the insurance holding company acts of the states in which our insurance
company and HMO subsidiaries are domiciled. These acts contain certain reporting requirements, as well as restrictions on transactions between an insurer or
HMO and its affiliates, and may restrict the ability of our regulated subsidiaries to pay dividends to our holding companies. These holding company laws and
regulations generally require registration with applicable state departments of insurance and the filing of reports describing capital structure, ownership, financial
condition, certain intercompany transactions, enterprise risks, corporate governance and general business operations. In addition, state insurance holding company
laws and regulations require notice or prior regulatory approval of transactions including acquisitions, material intercompany transfers of assets, guarantees and
other transactions between the regulated companies and their affiliates, including parent holding companies. Applicable state insurance holding company acts also
restrict the ability of any person to obtain control of an insurance company or HMO without prior regulatory approval. “Control” is generally defined as the direct
or indirect power to direct or cause the direction of the management and policies of a person and is presumed to exist if a person directly or indirectly owns or
controls 10% or more of the voting securities of another person. Dispositions of control generally are also regulated under the state insurance holding company
acts.
-19-
-- 20 of 512 --
The states of domicile of our regulated subsidiaries have statutory risk-based capital (“RBC”) requirements for health and other insurance companies and
HMOs based on the Risk-Based Capital (RBC) For Health Organizations Model Act. These RBC requirements are intended to assess the capital adequacy of life
and health insurers and HMOs, taking into account the risk characteristics of a company’s investments and products. In general, under these laws, an insurance
company or HMO must submit a report of its RBC level to the insurance department or insurance commissioner of its state of domicile for each calendar year. The
law requires increasing degrees of regulatory oversight and intervention as a company’s RBC declines. As of December 31, 2020, the RBC levels of our insurance
and HMO subsidiaries exceeded all applicable mandatory RBC requirements. For more information on RBC capital and additional liquidity and capital
requirements for a licensee of the BCBSA, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations–Liquidity and Capital
Resources–Risk-Based Capital,” included in Part II, Item 7 of this Annual Report on Form 10-K.
Ongoing Requirements and Changes Stemming from the ACA
The ACA significantly changed the United States healthcare system. While we anticipate continued efforts to invalidate, modify, repeal or replace the ACA,
either through Congress or court challenges, we expect the major portions of the ACA to remain in place and continue to significantly impact our business
operations and results of operations, including pricing, minimum medical loss ratios (“MLRs”) and the geographies in which our products are available.
The ACA prohibits lifetime limits, certain annual limits, member cost-sharing on specified preventive benefits and pre-existing condition exclusions. Further,
the ACA implemented certain requirements for insurers, including changes to Medicare Advantage payments and the minimum MLR provision that requires
insurers to pay rebates to customers when insurers do not meet or exceed the specified MLR thresholds. In addition, the ACA also required a number of other
changes with significant effects on both federal and state health insurance markets, including strict rules on how health insurance is rated, what benefits must be
offered, the assessment of new taxes and fees (including annual fees on health insurance companies), the creation of public exchanges for Individuals and Small
Groups, the availability of premium subsidies for qualified individuals, and expansions in eligibility for Medicaid. Changes to our business environment are likely
to continue as elected officials at the national and state levels continue to enact, and both elected officials and candidates for election continue to propose,
significant modifications to existing laws and regulations, including changes to taxes and fees. In addition, the legal challenges regarding the ACA, including a
federal district court decision invalidating the ACA in its entirety, which was argued before the U.S. Supreme Court in November 2020 and has been stayed
pending the U.S. Supreme Court’s decision, continue to contribute to this uncertainty.
In a separate development, in April 2020, the U.S. Supreme Court ruled that the federal government is required to pay health insurance companies for amounts
owed, as calculated under the risk corridor program of the ACA. In June 2020, the U.S. Court of Federal Claims entered a final judgment stipulating that we are
entitled to reimbursement for risk corridor amounts from 2014, 2015 and 2016. At the end of December 2020, the U.S. Department of Health and Human Services
(“HHS”) issued guidance on how to treat the risk corridor recoveries, which requires us to revise previously filed minimum MLR reports and issue incremental
MLR rebate payments. We recognized the net premium impact of the risk corridor recoveries in the fourth quarter of 2020. We will continue to review and
evaluate the impact of the ACA as any further developments or judicial rulings occur.
In general, the Individual market risk pool that includes public exchange markets has become less healthy since its inception in 2014 and continues to exhibit
risk volatility. Based on our experience in public exchange markets to date, we have made adjustments to our premium rates and participation footprint and
continue to evaluate the performance of our public exchange plans. In addition, insurers have faced uncertainties related to federal government funding for various
ACA programs. These factors may have a material adverse effect on our results of operations if premiums are not adequate or do not appropriately reflect the
acuity of these individuals. Any variation from our expectations regarding acuity, enrollment levels, adverse selection, or other assumptions utilized in setting
premium rates could have a material adverse effect on our results of operations, financial position, and cash flows.
Further, implementation of the ACA brings with it significant oversight responsibilities by health insurers that may result in increased governmental audits,
increased assertions of False Claims Act violations, and an increased risk of other litigation.
-20-
-- 21 of 512 --
Federal regulatory agencies continue to modify regulations and guidance related to the ACA and markets more broadly. Some of the more significant ACA
rules are described below:
• The minimum MLR thresholds by line of business for the Commercial market, as defined by HHS, are as follows:
Line of Business %
Large Group 85
Small Group 80
Individual 80
New York state regulations require us to meet a more restrictive MLR threshold of 82% for both Small Group and Individual lines of business. The
minimum MLR thresholds disclosed above are based on definitions of an MLR calculation provided by HHS, or specific states, as applicable, and differ
from our calculation of “benefit expense ratio” based on premium revenue and benefit expense as reported in accordance with U.S. generally accepted
accounting principles (“GAAP”). Furthermore, the definitions of the lines of business differ under the various federal and state regulations and may not
correspond to our lines of business. Definitions under the MLR regulation also impact insurers differently depending upon their organizational structure
or tax status, which could result in a competitive advantage to some insurance providers that may not be available to us, resulting in an uneven playing
field in the industry.
The ACA also imposed a separate minimum MLR threshold of 85% for Medicare Advantage and Medicare Part D prescription drug plans (“Medicare
Part D plans”). Medicare Advantage or Medicare Part D plans that do not meet this threshold will have to pay a minimum MLR rebate. If a plan’s MLR is
below 85% for three consecutive years, enrollment will be restricted. A Medicare Advantage or Medicare Part D plan contract will be terminated if the
plan’s MLR is below 85% for five consecutive years.
In addition, state Medicaid programs are required to set managed care capitation rates such that a minimum 85% MLR is projected to be achieved;
however, states are not required to collect remittances if the minimum MLR is not achieved.
Approximately 54.8% and 20.2% of our premium revenue and medical membership, respectively, were subject to the minimum MLR regulations as of
and for the year ended December 31, 2020. Approximately 58.9% and 20.8% of our premium revenue and medical membership, respectively, were
subject to the minimum MLR regulations as of and for the year ended December 31, 2019.
• The ACA created an incentive payment program for Medicare Advantage plans. CMS developed the Medicare Advantage Star ratings system, which
awards between 1.0 and 5.0 stars to Medicare Advantage plans based on performance in several categories, including quality of care and customer
service. The Star ratings are used by CMS to award quality-based bonus payments to plans that receive a rating of 4.0 or higher. The methodology and
measures included in the Star ratings system can be modified by CMS annually. As of December 31, 2020, all of our Medicare Advantage plans have
received a rating of 3.0 or higher.
• Regulations require premium rate increases to be reviewed for Small Group and Individual products above specified thresholds, and may be adjusted from
time to time. The regulations provide for state insurance regulators to conduct the reviews, except for cases where a state does not have an “effective” rate
review program or in federal enforcement states, in which cases HHS will conduct the reviews for any rate increase.
• The ACA precludes health insurers from using health status and gender in the determination of the insurance premium.
• The ACA imposed an annual Health Insurance Provider Fee (“HIP Fee”) on health insurers that write certain types of health insurance on U.S. risks,
which has been permanently eliminated effective January 1, 2021. The HIP Fee was allocated to health insurers based on the ratio of the amount of an
insurer’s net premium revenues written during the preceding calendar year to the amount of health insurance premium for all U.S. health risk for those
certain lines of business written during the preceding calendar year. The HIP Fee was non-deductible for federal income tax purposes. Our affected
products were priced to cover the increased selling, general and administrative and income
-21-
-- 22 of 512 --
tax expenses associated with the HIP Fee when it was in effect. The total amount due from allocations to health insurers was $15.5 billion for 2020 and
was suspended for 2019.
• Medicare Advantage reimbursement rates will not increase as much as they would otherwise due to the payment formula promulgated by the ACA that
continues to impact reimbursements. We also expect further and ongoing regulatory guidance on a number of issues related to Medicare, including
evolving methodology for ratings and quality bonus payments. CMS is also proposing changes to its program that audits data submitted under the risk
adjustment programs in a way that would increase financial recoveries from plans.
Drug Benefit and Pharmacy Benefit Manager Regulation
Pharmacy benefit managers are regulated at both the federal and state levels and must comply with federal and state statutes and regulations governing
labeling, packaging, advertising and adulteration of prescription drugs, dispensing of controlled substances, and licensing. In recent years the federal government
has banned certain business practices, including “gag clauses,” which prohibited pharmacists from informing patients when a lower cost drug was available as a
substitute, and “clawbacks,” which occurred when pharmacy benefit managers sought to recoup the difference between the reimbursed cost of the drug and the
patient’s copay and the drug itself was less expensive than the copay paid by the patient. Regulation in the states varies dramatically and ranges from licensure of
PBMs as third-party administrators, licensure specifically as a pharmacy benefit manager, and licensure accompanied by additional disclosures and limitations of
business practices to varying degrees. The NAIC is working on a PBM model law that, if adopted widely, could result in a more standardized approach to PBM
regulation in the states in the future. However, in December 2020, the U.S. Supreme Court let stand an Arkansas law regulating PBMs, which could be a precursor
to greater state regulation of PBMs in the future.
A number of proposals are being considered at the federal and state levels that would increase regulation of drug benefits and pharmacy benefit managers.
Such proposals under consideration include (1) regulation of rebates from drug manufacturers that would require rebate dollars to be applied at the point-of-sale,
(2) federal policy changes to set the prices for a subset of drugs covered under the Medicare program, (3) reforms to the Medicare drug benefit, such as beneficiary
cost-sharing changes that aim to lower consumer costs, (4) attempts at both the federal and state levels to ban the use of spread pricing contracts in both the
Commercial and Medicaid markets, and (5) electronic prior authorizations of drugs. These reforms have the potential to have broad impacts on our PBM business
and could materially adversely affect our business if they are enacted.
Privacy, Confidentiality and Data Standards Regulation
The federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) and the administrative simplification provisions of HIPAA impose a
number of requirements on covered entities (including insurers, HMOs, group health plans, providers and clearinghouses) and their business associates relating to
the use, disclosure and safeguarding of protected health information. These requirements include uniform standards of common electronic healthcare transactions;
privacy and security regulations; and unique identifier rules for employers, health plans and providers.
Also, the Health Information Technology for Economic and Clinical Health (“HITECH”) Act provisions of the American Recovery and Reinvestment Act of
2009 and corresponding implementing regulations have imposed additional requirements on the use and disclosure of protected health information such as
additional breach notification and reporting requirements, contracting requirements for HIPAA business associate agreements, strengthened enforcement
mechanisms and increased penalties for HIPAA violations. Federal consumer protection laws may also apply in some instances to privacy and security practices
related to personally identifiable information.
The federal Gramm-Leach-Bliley Act generally places restrictions on the disclosure of non-public information to non-affiliated third parties, and requires
financial institutions, including insurers, to provide customers with notice regarding how their non-public personal information is used, including an opportunity to
“opt out” of certain disclosures. State departments of insurance and certain federal agencies adopted implementing regulations as required by federal law.
The Cybersecurity Information Sharing Act of 2015 encourages organizations to share cyber threat indicators with the federal government and, among other
things, directed HHS to develop a set of voluntary cybersecurity best practices for organizations in the healthcare industry.
-22-
-- 23 of 512 --
In addition, public exchanges are required to adhere to privacy and security standards with respect to personally identifiable information and to impose privacy
and security standards that are at least as protective as those the public exchange has implemented for itself on insurers offering plans through the public exchanges
and their designated downstream entities, including pharmacy benefit managers and other business associates. These standards may differ from, and be more
stringent than, HIPAA.
Furthermore, states have begun enacting more comprehensive privacy laws and regulations addressing consumer rights to data protection or transparency that
may affect our privacy and security practices, such as state laws like the California Consumer Privacy Act that govern the use, disclosure and protection of member
data and impose additional breach notification requirements. State consumer protection laws may also apply to privacy and security practices related to personally
identifiable information, including information related to consumers and care providers. Complying with conflicting cybersecurity regulations and varying
enforcement philosophies, which may differ from state to state, requires significant resources and may materially and adversely affect our ability to standardize our
products and services across state lines.
Federal regulations have been finalized in the following areas that will materially impact our operations:
• Federal regulations on data interoperability that will require claims data to be made available to third parties unaffiliated with Anthem; and
• Federal regulations requiring hospitals and health insurers to publish negotiated prices for services.
Federal regulations have also been proposed that will expand the final regulation on data interoperability to require health insurers to build new application
programming interfaces to afford patients access to their health information and require electronic prior authorizations for commercial Qualified Health Plans in
the federal exchange as well as Medicaid and CHIP fee-for-service and managed care organizations. These regulations are expected to materially impact our
operations if finalized.
Employee Retirement Income Security Act of 1974
The provision of services to certain employee welfare benefit plans is subject to the Employee Retirement Income Security Act of 1974, as amended
(“ERISA”) a complex set of laws and regulations subject to interpretation and enforcement by the Internal Revenue Service (“IRS”) and the Department of Labor.
ERISA regulates certain aspects of the relationships between us, the employers that maintain employee welfare benefit plans subject to ERISA and participants in
such plans. Some of our administrative services and other activities may also be subject to regulation under ERISA. In addition, certain states require licensure or
registration of companies providing third-party claims administration services for benefit plans. We provide a variety of products and services to employee welfare
benefit plans that are covered by ERISA. Plans subject to ERISA can also be subject to state laws, and the question of whether and to what extent ERISA preempts
a state law has been, and will continue to be, interpreted by many courts.
Guaranty Fund Assessments
Under insolvency or guaranty association laws in most states, insurance companies and HMOs can be assessed for amounts paid by guaranty funds for
policyholder losses incurred when an insurance company or HMO becomes insolvent. Most state insolvency or guaranty association laws currently provide for
assessments based upon the amount of premiums received on insurance underwritten within such state (with a minimum amount payable even if no premium is
received). Under many of these guaranty association laws, assessments are made retrospectively. Some states permit insurers or HMOs to recover assessments paid
through full or partial premium tax offsets or through future policyholder surcharges. The amount and timing of any future assessments cannot be predicted with
certainty; however, future assessments are likely to occur.
Human Capital
At Anthem, it starts with our culture, and our associates are critical to fulfilling our purpose of improving the health of humanity. As of December 31, 2020,
we had approximately 83,400 associates. We are working to build a high performance culture that enhances our ability to deliver on our commitments and guides
us to address the challenges of today. We believe that our culture allows us to attract and retain talented and experienced individuals to support the communities we
serve. Our
-23-
-- 24 of 512 --
associates actively participate through online feedback tools and we leverage these associate feedback tools and engagement surveys to monitor and take action on
responses.
Inclusion & Diversity
The diversity of our associates is central to achieving key strategies and improving performance. We believe a diverse and inclusive workforce enables a
deeper connection with members and drives greater business results. We honor the diversity of our associates—in gender, race/ethnicity, age, gender identity,
sexual orientation, socio-economic status, language, nationality, abilities and life experiences. As of December 31, 2020, our U.S. associate population was
approximately 76% female and 48% ethnically diverse.
Talent Development
Growing and developing our talent internally is key to our succession plans and our ability to lead at our best every day. To inspire a high-performance culture
and promote talent excellence, we offer individual, career and leadership development opportunities, encouraging associates to continually learn and grow. We
offer various instructor-led and virtual instructor-led programs and maintain a vast curriculum of relevant, on-demand learning and development resources.
Health & Wellbeing
We have the privilege of touching the lives of millions of people each day, and for us, this starts with the health of our own associates. To improve the health
and wellbeing of our associates, we offer a comprehensive compensation package, including competitive salaries, a 401(k) plan and medical, dental, vision and
disability coverage. In addition, we offer our associates wellness and behavioral programs and tools to help them get and stay healthy and more easily manage their
work and personal lives.
COVID-19 Response
We moved swiftly in our response to the COVID-19 pandemic to promote the safety of our associates and best serve our members and communities. In March
of 2020, we implemented business continuity plans, transitioning the majority of our associates to remote work environments, while maintaining service
operations. We have provided our associates with additional benefits, support and resources to help them manage the complexities of working from home and
handling caregiver and family needs. In addition to their current benefits, we are providing up to 80 hours of COVID-related additional paid time off for associates
to use when they are unable to work due to quarantine or illness or to provide care to a family member, and we provided a one-month premium holiday and added
an extra paid day off as a “Wellness Holiday” on December 31, 2020. In addition to our associate assistance program, we provide materials and behavioral health
resources to our associates that address important emotional health issues.
Available Information
We are a large accelerated filer (as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) and are required,
pursuant to Item 101 of Regulation S-K, to provide certain information regarding our website and the availability of certain documents filed with or furnished to
the U.S. Securities and Exchange Commission (“SEC”). The SEC maintains a website that contains reports, proxy and information statements and other
information regarding issuers at www.sec.gov. Our website is www.antheminc.com. We have included our website address throughout this Annual Report on Form
10-K as a textual reference only. The information contained on, or accessible through, our website is not incorporated into this Annual Report on Form 10-K. We
make available, free of charge, by mail or through our website, our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K,
and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically
file such material with or furnish it to the SEC. We also include on our website our Corporate Governance Guidelines, our Code of Conduct and the charter of each
standing committee of our Board of Directors. In addition, we intend to disclose on our website any amendments to, or waivers from, our Code of Conduct that are
required to be publicly disclosed pursuant to rules of the SEC and the New York Stock Exchange (“NYSE”). Anthem, Inc. is an Indiana corporation incorporated
on July 17, 2001.
-24-
-- 25 of 512 --
ITEM 1A. RISK FACTORS.
In evaluating our business, the risks described below, as well as the other information contained in this Annual Report on Form 10-K, should be carefully
considered. Any one or more of such risks could materially and adversely affect our business, financial condition, results of operations and stock price and could
cause our actual results of operations and financial condition to vary materially from past or anticipated future results of operations and financial condition.
Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect us.
BUSINESS RISKS
The outbreak of the COVID-19 pandemic and measures taken to prevent its spread are adversely affecting our business in a number of ways, and we are
unable to predict the full extent of those impacts on our business, cash flows, financial condition and results of operations, but the impact could be
material.
The COVID-19 pandemic is evolving, and the impact of COVID-19, and the actions taken to contain its spread or address its impact, could have a material
adverse effect on our operations and financial results in the future. We continue to closely monitor developments related to the COVID-19 pandemic to assess its
ongoing impact on our business. The extent of this impact will depend on future developments, which are highly uncertain and cannot be predicted at this time,
including, but not limited to, the transmission rate, duration and spread of the outbreak, its severity, the extent and effectiveness of the actions taken to contain the
spread of the virus and address its impacts, and how quickly and to what extent normal economic and operating conditions can resume. Factors that could
negatively impact our ability to operate successfully during or following the COVID-19 pandemic, or that could otherwise significantly adversely impact and
disrupt our business, cash flows, financial condition and results of operations include, but are not limited to, the following:
• Continued increases in healthcare costs due to higher utilization rates of medical facilities and services, medical expenses and other increases in associated
hospital and pharmaceutical costs. We continue to offer our members expanded benefit coverage, such as providing full coverage for COVID-19 testing
and treatment and governmental action has required, and may continue to require, us to provide additional coverage.
• Decreased predictability of Medicare and Medicaid rates due to changes in utilization of medical facilities and services, medical expenses, and other costs
as a result of the impact of COVID-19. We experienced rate adjustments from certain state Medicaid regulators in 2020 in response to decreased
utilization of medical facilities and services, and we may experience further adjustments in the future with regard to current and prior year rates.
• Increased estimation uncertainty on our claims liability due to the impact of COVID-19 on healthcare utilization and medical claims submission.
• A reduction in enrollment in our health benefits and PBM products and services, or a continued change in membership mix to less profitable lines of
business, as a result of reductions in workforce by existing customers and other impacts of an economic downturn.
• Cash flow volatility or shortfalls caused by an increase in delayed, delinquent or non-collectable payments from customers and government payers.
• Reductions in our operating effectiveness as our employees work from home or otherwise are impacted by COVID-19. The majority of our workforce
continues to work remotely in an effort to mitigate the spread of COVID-19, which may exacerbate certain risks to our business, including an increased
demand for information technology resources, increased risk of phishing and other cybersecurity attacks, and increased risk of unauthorized dissemination
of sensitive personal information or proprietary or confidential information about us, our members or other third parties.
• Disruptions in our normal business operations due to disruptions in public and private infrastructure, including communications, financial services and
supply chains.
• Loss of functionality due to the disruption of services provided to us by third-party vendors, including as a result of financial difficulties experienced by
such vendors and the impact of vendor employees working from home or otherwise being impacted by COVID-19.
• A decrease in the value of our investments, which may result in losses charged to income.
• Increased cost of capital and limited ability to access the capital markets due to disruption and volatility in global financial markets or a downgrade in our
credit rating.
-25-
-- 26 of 512 --
If we fail to appropriately predict, price for and manage healthcare costs, the profitability of our products could decline, which could materially adversely
affect our business, cash flows, financial condition and results of operations.
Our profitability depends in large part on accurately predicting and pricing healthcare costs and on our ability to manage future healthcare costs through
medical management, product design, negotiation of favorable provider contracts and underwriting criteria. Total healthcare costs are affected by the number of
individual services rendered, the cost of each service and the type of service rendered. Numerous factors affecting the cost of healthcare may adversely affect our
ability to predict and manage healthcare costs, as well as our business, cash flows, financial condition and results of operations. These factors include, among
others, changes in healthcare practices, demographic characteristics including the aging population, medical cost inflation, the introduction of new technologies,
drugs and treatments, increased cost of individual services, increases in the cost and number of prescription drugs, clusters of high cost cases, increased use of
services, including due to natural catastrophes or other large-scale medical emergencies, epidemics or pandemics such as COVID-19, new treatment guidelines,
new mandated benefits (such as the expansion of essential benefits coverage) and changes to other regulations impacting our business, such as the health plan price
transparency regulations issued in October 2020 by the U.S. Departments of Health and Human Services, Labor and Treasury (the “Health Plan Transparency
Rule”) and the Appropriations Act.
Relatively small differences between predicted and actual medical costs or utilization rates as a percentage of premium revenues can result in significant
changes in our results of operations. Generally, our premiums on Commercial policies and Medicaid contracts are fixed for a 12-month period and are determined
several months prior to the commencement of the premium period. Our revenue on Medicare policies is based on bids submitted to CMS six months prior to the
start of the contract year. Accordingly, the costs we incur in excess of our benefit cost projections generally are not recovered in the contract year through higher
premiums. Existing Medicaid contract rates are often established by the applicable state, and our actual costs may exceed those rates. Although we base our
Commercial premiums, our Medicare and Medicaid bids, and our acceptance of state-established Medicaid rates on our estimates of future medical costs over the
fixed contract period, many factors, including those discussed above, may cause actual costs to exceed those estimated and reflected in premiums and bids.
Although federal and state premium and risk adjustment mechanisms could help offset healthcare benefit costs in excess of our projections if our assumptions
utilized in setting our premium rates are significantly different than actual results, our results of operations and financial condition could still be adversely affected.
The reserves that we establish for health insurance policy benefits and other contractual rights and benefits are based upon assumptions concerning a number of
factors, including trends in healthcare costs, expenses, general economic conditions and other factors. To the extent the actual claims experience is unfavorable as
compared to our underlying assumptions, our incurred losses would increase and future earnings could be adversely affected.
In addition to the challenge of managing healthcare costs, we face pressure to contain premium rates. Our customers may renegotiate their contracts to seek to
contain their costs or may move to a competitor to obtain more favorable premiums. Further, federal and state regulatory agencies may restrict or prevent entirely
our ability to implement changes in premium rates. A limitation on our ability to increase or maintain our premium or reimbursement levels or a significant loss of
membership resulting from our need to increase or maintain premium or reimbursement levels could adversely affect our business, cash flows, financial condition
and results of operations.
A significant reduction in the enrollment in our health benefits programs or PBM products or services, particularly in states where we have large
regional concentrations, could have an adverse effect on our business, cash flows, financial condition and results of operations.
A significant reduction in the number of enrollees in our health benefits programs or PBM products or services could adversely affect our business, cash
flows, financial condition and results of operations. Factors that could contribute to a reduction in enrollment include: reductions in workforce by existing
customers; a general economic upturn that results in fewer individuals being eligible for Medicaid programs; a general economic downturn that results in business
failures and high unemployment rates, as has been experienced as a result of the COVID-19 pandemic; employers no longer offering certain healthcare coverage as
an employee benefit or electing to offer coverage on a voluntary, employee-funded basis; participation on public exchanges; federal and state regulatory changes;
failure to obtain new customers or retain existing
-26-
-- 27 of 512 --
customers; premium increases and benefit changes; our exit from a specific market; negative publicity and news coverage; and failure to attain or maintain
nationally recognized accreditations.
The states in which we operate that have the largest concentrations of revenues include California, Florida, Georgia, Indiana, New York, Ohio, Texas and
Virginia. Due to this concentration of business in these states, we are exposed to potential losses resulting from the risk of state-specific or regional economic
downturns impacting these states. If any such negative economic conditions do not improve, we may experience a reduction in existing and new business, which
could have a material adverse effect on our business, cash flows, financial condition and results of operations.
A cyber attack or other privacy or data security incident could result in an unauthorized disclosure of sensitive or confidential information, cause a loss
of data, disrupt a large amount of our operations, give rise to remediation or other expenses, expose us to liability under federal and state laws, and
subject us to litigation and investigations, which could have an adverse effect on our business, cash flows, financial condition and results of operations.
As part of our normal operations, we collect, process and retain certain sensitive and confidential information. We are subject to a variety of continuously
evolving federal, state and international laws and rules regarding the use and disclosure of certain sensitive or confidential information, including HIPAA, the
HITECH Act, the Gramm-Leach-Bliley Act and numerous state laws governing personal information. Our facilities and systems, and those of our third-party
service providers, are regularly the target of, and may be vulnerable to, cyber attacks, security breaches, acts of vandalism, computer viruses, misplaced or lost
data, programming and/or human errors or other threats.
We have been, and may in the future be subject to litigation and governmental investigations related to cyber attacks and security breaches, which could divert
the attention of management from the operation of our business, result in reputational damage and have a material adverse impact on our business, cash flows,
financial condition and results of operations. While we have contingency plans and insurance coverage for potential liabilities of this nature, they may not be
sufficient to cover all claims and liabilities.
We cannot ensure that we will be able to identify, prevent or contain the effects of cyber attacks or other cybersecurity risks that bypass our security measures
or disrupt our information technology systems or business. We have security technologies, processes and procedures in place to protect against cybersecurity risks
and security breaches. However, hardware, software or applications we develop or procure from third parties may contain defects in design, manufacturer defects
or other problems that could unexpectedly compromise information security. In addition, because the techniques used to obtain unauthorized access, disable or
degrade service or sabotage systems change frequently, are becoming increasingly sophisticated, and may not immediately produce signs of intrusion, we may be
unable to anticipate these techniques, timely discover or counter them or implement adequate preventative measures. Viruses, worms or other malicious software
programs may be used to attack our systems or otherwise exploit any security vulnerabilities, and such security attacks may cause system disruptions or shutdowns,
or may cause personal information or proprietary or confidential information to be misappropriated or compromised. As a result, cybersecurity and the continued
development and enhancement of our controls, processes and practices designed to protect our systems, computers, software, data and networks from attack,
damage and unauthorized access remain a priority for us.
Noncompliance with any privacy or security laws and regulations, or any security breach, cyber attack or cybersecurity breach, and any incident involving the
misappropriation, loss or other unauthorized disclosure or use of, or access to, sensitive or confidential information, whether by us or by one of our third-party
service providers, could require us to expend significant resources to continue to modify or enhance our protective measures and to remediate any damage. In
addition, this could negatively affect our operations, cause system disruptions, damage our reputation, cause membership losses and contract breaches, and could
also result in regulatory enforcement actions, material fines and penalties, litigation or other actions that could have a material adverse effect on our business, cash
flows, financial condition and results of operations.
There are various risks associated with participating in Medicaid and Medicare programs, including dependence upon government funding and the
timing of payments, compliance with government contracts and increased regulatory oversight.
We contract with various federal and state agencies, including CMS, to provide managed healthcare services, such as Medicare Advantage, Medicare Part D,
Medicare Supplement, Medicaid, TANF, SPD, LTSS, CHIP, ACA-related Medicaid expansion programs and various specialty programs. We also provide various
administrative services for several other entities
-27-
-- 28 of 512 --
offering medical and/or prescription drug plans to their Medicaid or Medicare eligible members through our affiliated companies, and we offer employer group
waiver plans which provide medical and/or prescription drug coverage to retirees. We are also participating in programs in several states for the care of dual-
eligible members. Regulatory reform initiatives or changes in existing laws or regulations applicable to these programs, or their interpretations, are difficult to
predict and could have a material adverse effect on our business, cash flows, financial condition and results of operations.
Revenues from the Medicare and Medicaid programs are dependent, in whole or in part, upon annual funding from the federal government and/or applicable
state governments, and base premium rates paid by each state or federal agency differ depending upon a combination of factors such as defined upper payment
limits, a member’s health status, age, gender, county or region, benefit mix, member eligibility category and risk scores. Future rates may be affected by continued
government efforts to contain costs as well as federal and state budgetary constraints, and certain state contracts are subject to cancellation in the event of the
unavailability of state funds. Additionally, ongoing CMS system changes related to the data it uses to calculate risk scores in the Medicare Advantage program may
impact our federal funding. If the federal government or any state in which we operate were to decrease rates paid to us, pay us less than the amount necessary to
keep pace with our cost trends, cancel our contracts retroactively or seek an adjustment to previously negotiated rates, it could have a material adverse effect on our
business, cash flows, financial condition and results of operations. In addition, various states’ MMPs are still subject to uncertainty surrounding payment rates and
other requirements, which could affect where we seek to participate in these programs. An unexpected reduction in payments, inadequate government funding or
significantly delayed payments for these programs may adversely affect our business, cash flows, financial condition and results of operations.
Other potential risks associated with Medicare Advantage and Medicare Part D plans include increased medical or pharmaceutical costs, data corrections
identified as a result of ongoing auditing and monitoring activities, potential uncollectability of receivables resulting from processing and/or verifying enrollment,
inadequacy of underwriting assumptions, inability to receive and process correct information (including inability due to systems issues by the federal government,
the applicable state government or us), uncollectability of premiums from members, and limited enrollment periods. Actual results may be materially different than
our assumptions and estimates and could have a material adverse effect on our business, financial condition and results of operations. Finally, there is the
possibility that the Medicare Advantage program could be significantly impacted by any future modification, repeal or replacement of the ACA.
Our contracts with CMS and state governmental agencies contain certain provisions regarding data submission, risk adjustment, provider network
maintenance, quality measures, claims payment, encounter data, continuity of care, call center performance and other requirements specific to federal and state
program regulations. We have been subject in the past, and may again be in the future, to administrative actions, fines, penalties, liquidated damages or
retrospective adjustments in payments made to our health plans as a result of a failure to comply with those requirements, which has impacted and in the future
could impact our profitability. Due to decreased utilization of medical facilities and services as a result of the COVID-19 pandemic, we experienced retroactive
rate adjustments by certain state Medicaid agencies, and rate adjustments may continue in the future. As members have accessed care during the COVID-19
pandemic, we have experienced increased difficulty obtaining provider information required by CMS and state governmental agencies and, as a result, may have
difficulty meeting these quality measures. In addition, we could be required to file a corrective plan of action with additional penalties for noncompliance, which
could have a negative impact on future membership enrollment levels. Further, our existing CMS or state Medicaid contracts have not always been renewed, we
have not always been awarded new contracts as a result of the competitive procurement process, and in some cases we have lost members under existing contracts
as a result of a post-award challenge, each of which could take place again in the future and have a material adverse effect on our business, cash flows, financial
condition and results of operations.
Further, the Star Rating System utilized by CMS to evaluate Medicare Advantage Plans may have a significant effect on our revenue, as higher-rated plans
tend to experience increased enrollment and plans with a Star rating of 4.0 or higher are eligible for quality-based bonus payments and can market to and enroll
members year-round. If we do not maintain or continue to improve our Star ratings, fail to meet or exceed our competitors’ Star ratings, or if quality-based bonus
payments are reduced or eliminated, we may experience a negative impact on our revenues and the benefits that our plans can offer, which could materially and
adversely affect the marketability of our plans, our membership levels, results of operations, financial condition and cash flows. Similarly, if we fail to meet or
exceed any performance standards imposed by state Medicaid programs in which we participate, we may not receive performance-based bonus payments or may
incur penalties.
-28-
-- 29 of 512 --
In addition, our failure to comply with federal and state healthcare laws and regulations applicable to our participation in Medicaid and Medicare programs,
including those directed at preventing fraud, abuse and discrimination in government-funded programs, could result in investigations, litigation, fines, restrictions
on, or exclusions from, program participation, or the imposition of corporate integrity agreements or other agreements with a federal or state governmental agency,
any of which could adversely impact our business, cash flows, financial condition and results of operations.
We are periodically subject to government audits, including CMS Risk Adjustment Data Validation (“RADV”) audits of our Medicare Advantage Plans to
validate diagnostic data, patient claims and financial reporting, and audits of our Medicare Part D plans by the Medicare Part D Recovery Audit Contractor
(“RAC”) as well as state Medicaid RAC programs authorized by the ACA. These audits could result in significant adjustments in payments made to our health
plans, which could adversely affect our financial condition and results of operations. If we fail to report and correct errors discovered through our own auditing
procedures or during a RADV or RAC audit, or otherwise fail to comply with applicable laws and regulations, we could be subject to fines, civil penalties or other
sanctions which could have a material adverse effect on our ability to participate in these programs, and on our financial condition, cash flows and results of
operations.
Our Medicare and Medicaid contracts are also subject to various MLR rules, including minimum MLR thresholds, rebate requirements and audits, which
could adversely affect our membership and revenues if any of our state Medicare or Medicaid plans do not meet an applicable minimum MLR threshold. If a
Medicare Advantage, MMP or Medicare Part D contract pays minimum MLR rebates for three consecutive years, it will become ineligible to participate in open
enrollment. If a Medicare Advantage or Medicare Part D contract pays such rebates for five consecutive years, it will be terminated by CMS.
A change in our healthcare product mix may impact our profitability.
Our healthcare products that involve greater potential risk generally tend to be more profitable than administrative services products and those healthcare
products where the employer groups assume the underwriting risks. Individuals and small employer groups are more likely to purchase our higher-risk healthcare
products because such purchasers are generally unable or unwilling to bear greater liability for healthcare expenditures. Typically, government-sponsored programs
also involve our higher-risk healthcare products. A shift of enrollees from more profitable products to less profitable products could have a material adverse effect
on our cash flows, financial condition and results of operations.
If we fail to develop and maintain satisfactory relationships with hospitals, physicians, PBM service providers and other healthcare providers, our
business, cash flows, financial condition and results of operations may be adversely affected.
Our profitability is dependent in part upon our ability to contract on favorable terms with hospitals, physicians, PBM service providers and supply chain
partners and other healthcare providers. Physicians, hospitals and other healthcare providers may elect not to contract with us, and the failure to secure or maintain
cost-effective healthcare provider contracts on competitive terms may result in a loss of membership or higher medical costs, which could adversely affect our
business. In addition, consolidation among healthcare providers, ACO practice management companies, and other organizational structures that physicians,
hospitals and other care providers choose, as well as the ability of larger employers to contract directly with providers, may change the way that these providers
interact with us and may change the competitive landscape. Such organizations or groups of physicians may compete directly with us, which may impact our
relationship with these providers or affect the way that we price our products and estimate our costs and may require us to incur costs to change our operations,
which could adversely affect our business, cash flows, financial condition and results of operations. In addition, price transparency initiatives, such as the Health
Plan Transparency Rule, may impact our ability to obtain or maintain favorable contract terms. For example, beginning in 2021, hospitals will be required to
publish online payer-specific negotiated charges for each item or services the hospital provides.
Our inability to contract with providers, or if providers attempt to use their market position to negotiate more favorable contracts or place us at a competitive
disadvantage, or the inability of providers to provide adequate care, could adversely affect our business. In addition, we do not have contracts with all providers
that render services to our members and, as a result, may not have a pre-established agreement about the amount of compensation those out-of-network providers
will accept for the services they render, which can result in significant litigation or arbitration proceedings, or provider attempts to obtain payment from our
members for the difference between the amount we have paid and the amount they have charged.
-29-
-- 30 of 512 --
We are dependent on the success of our relationships with third parties for various services and functions.
We contract with various third parties to perform certain functions and services and provide us with certain information technology systems. Certain of these
third parties provide us with significant portions of our business infrastructure and operating requirements. For example, a single vendor provides us with a wide
range of technology infrastructure services, including end user (help desk and field support), data center, mainframe, storage and database services, cloud
infrastructure and multi-cloud management services, and we are subject to the risks of any operational failure, termination or other restraints in this arrangement.
We could become overly dependent on key vendors, which could cause us to lose core competencies. A termination of our agreements with, or disruption in the
performance of, one or more of these service providers could result in service disruptions or unavailability, reduced service quality and effectiveness, increased or
duplicative costs or an inability to meet our obligations to our customers. In addition, we may also have to seek alternative service providers, which may be
unavailable or only available on less favorable contract terms. Any of these outcomes could adversely affect our business, reputation, cash flows, financial
condition and operating results.
Our PBM services business in particular would be adversely affected if we are unable to contract on favorable terms with third-party vendors, including
pharmaceutical manufacturers. We delegate certain PBM administrative functions, such as claims processing and prescription fulfillment, to CVS Health pursuant
to the CVS PBM Agreement. If CVS Health fails to provide PBM services as contractually required, we may not be able to meet the full demands of our
customers, which could have a material adverse effect on our business, reputation and results of operations. For additional information on the CVS PBM
Agreement, see “Business — Product and Service Descriptions,” in Part I, Item 1 of this Annual Report on Form 10-K.
The failure to effectively maintain and upgrade our information systems could adversely affect our business.
Our business depends significantly on effective information systems, and we have many different information systems for our various businesses, including
those that we have acquired as a result of our merger and acquisition activities. Our information systems require an ongoing commitment of significant resources to
maintain and enhance existing systems and develop new systems in order to keep pace with continuing changes in information processing technology, emerging
cybersecurity risks and threats, changing customer preferences, evolving industry and regulatory standards and legal requirements, including as a result of the
ACA, the Health Plan Transparency Rule, the Appropriations Act and proposed federal data interoperability regulations. In addition, we may from time to time
obtain significant portions of our systems-related or other services or facilities from independent third parties, which may make our operations vulnerable if such
third parties fail to perform adequately.
Failure to adequately implement and maintain effective and efficient information systems with sufficiently advanced technological capabilities, or our failure
to efficiently and effectively consolidate our information systems to eliminate redundant or obsolete applications, could result in competitive and cost
disadvantages to us compared to our competitors, and a diversion of management’s time and could have a material adverse effect on our business, financial
condition and results of operations. If the information we rely upon to run our business were found to be inaccurate or unreliable or if we fail to adequately
maintain our information systems and data integrity effectively, we could experience problems in determining medical cost estimates and establishing appropriate
pricing and reserves, have disputes with customers and providers, face regulatory problems, including sanctions and penalties, incur increases in operating
expenses or suffer other adverse consequences, including a decrease in membership.
Large-scale medical emergencies may have a material adverse effect on our business, cash flows, financial condition and results of operations.
Natural disasters, war, terrorism, political events, global climate change and other similar occurrences could create large-scale medical emergencies or
otherwise have a material adverse effect on our business, cash flows, financial condition and results of operations. Large-scale medical emergencies can take many
forms and can cause widespread illness and death and have other far-reaching impact. For example, the ongoing COVID-19 global pandemic has caused illness,
deaths, quarantines, business and school shutdowns, reductions in business activity, travel and financial transactions, unemployment, labor shortages, supply chain
interruptions and overall economic and financial market instability. In addition, federal and state law enforcement officials have issued warnings about potential
terrorist activity involving biological and other weapons, and natural disasters such as hurricanes and the potential for a widespread pandemic of influenza or other
illness coupled with the lack of availability of appropriate preventative medicines could have a significant impact on the health of the population
-30-
-- 31 of 512 --
of widespread areas. If the United States were to experience widespread bioterrorism or other attacks, large-scale natural disasters in our concentrated coverage
areas or an epidemic or pandemic such as the ongoing COVID-19 pandemic, our covered medical expenses could rise, our operations could be interrupted and we
could experience a material adverse effect on our business, cash flows, financial condition and results of operations or, in the event of extreme circumstances, our
viability could be threatened. Furthermore, global climate change could result in certain types of natural disasters occurring more frequently or with more intense
effects, and may have a long-term effect on general economic conditions and the healthcare or pharmacy industry in particular, which could adversely affect our
business and financial results. For additional information, see the risk factor above describing the impact of the COVID-19 pandemic on our business, cash flows,
financial condition and results of operations.
LEGAL, REGULATORY AND PUBLIC POLICY RISKS
We are subject to significant government regulation, and changes or proposed changes in the regulation of our business by federal and state regulators
may adversely affect our business, cash flows, financial condition and results of operations and the market price of our securities.
We are subject to significant state and federal regulation associated with many aspects of our business, including, but not limited to, licensing, premiums,
marketing activities, provider contracting, access and payment standards, and corporate governance and financial reporting matters, as described in greater detail in
Part I, Item 1 “Business—Regulation” in this Annual Report on Form 10-K. Further, the integration into our business of entities that we acquire, or the expansion
of our business into new areas, may affect the way in which existing laws and rules apply to us, including by subjecting us to laws and rules that did not previously
apply to us.
Changes in existing laws, rules and regulatory interpretation or future laws, rules, regulatory interpretations or judgments could force us to change how we
conduct our business, affect the products we offer (and where we offer them), restrict revenue and enrollment growth, increase our costs, including operating,
healthcare technology and administrative costs, restrict our ability to obtain new product approvals and implement changes in premium rates and require
enhancements to our compliance infrastructure and internal controls environment, which could adversely impact our business and results of operations. In addition,
legislative and/or regulatory policies or proposals that seek to manage the healthcare industry or otherwise impact our business may cause the market price of our
securities to decrease, even if such policies or proposals never become effective.
We are required to obtain and maintain insurance and other regulatory approvals to market certain of our products, to increase prices for certain regulated
products and to consummate some of our acquisitions and dispositions. Delays in obtaining or failure to obtain or maintain these approvals, as well as future
regulatory action by state or federal authorities, could have a material adverse effect on the profitability or marketability of our health benefits or managed care
products or on our business, financial condition and results of operations. For example, requirements in the Health Plan Transparency Rule and the Appropriations
Act including the price comparison tool and other requirements have the potential to increase healthcare costs and our operating costs in order to comply, and also
may impact provider negotiations and market pricing. In addition, changes in government regulations or policies that apply to government-sponsored programs
such as Medicare and Medicaid including, among other things, reimbursement levels, eligibility requirements, benefit coverage requirements and additional
governmental participation, could also adversely affect our business, cash flows, financial condition and results of operations. Where states allow certain programs
to expire or have not opted for Medicaid expansion under the ACA, we could experience reduced Medicaid enrollment and reduced growth opportunities. If future
modifications to laws and regulations significantly reduce Medicaid enrollment, our Medicaid business will be negatively impacted.
We have experienced assessments in the past under state or federal insolvency or guaranty association laws applicable to insurance companies, HMOs and
other payers, and may experience assessments in the future if, for example, premiums established by other companies for their health insurance products, including
certain long-term care products, are inadequate to cover their costs. Any such assessment could expose us to the risk of paying a portion of an impaired or insolvent
insurance company’s claims through state guaranty associations. We are not currently able to estimate our potential financial obligations, losses, or the availability
of offsets associated with potential guaranty association assessments; however, any significant increase in guaranty association assessments could have a material
adverse effect on our business, cash flows, financial condition and results of operations.
-31-
-- 32 of 512 --
We expect state legislatures will continue to focus on healthcare delivery and financing issues, including actions to reduce or limit increases to premium
payments, provider billing protections, and broader reforms of their health insurance markets. State ballot initiatives can also be put to voters that would
substantially impair our operating environment. If enacted into law, these state proposals could have a material adverse impact on our business, cash flows,
operations or financial condition.
Additionally, from time to time, Congress has considered, and may consider in the future, various forms of managed care reform legislation which, if adopted,
could fundamentally alter the treatment of coverage decisions under ERISA and could increase our costs, expose us to expanded liability or require us to revise the
ways in which we conduct business. There have been legislative attempts to limit ERISA’s preemptive effect on state laws and litigants’ ability to seek damages
beyond the benefits offered under their plans. If adopted, such limitations could increase our liability exposure, permit greater state regulation of our operations,
and expand the scope of damages, including punitive damages, litigants could be awarded.
The ongoing changes to the ACA and related laws and regulations could adversely affect our business, cash flows, financial condition and results of
operations.
The ongoing changes in federal and state laws and regulations stemming from the ACA, including the steps that have been taken to amend, repeal and limit the
scope and application of the ACA, continue to represent significant challenges to the U.S. healthcare system. We are unable to predict how these events will
ultimately be resolved, what impact the 2020 U.S. Presidential and Senate elections may have, and what the ultimate impact may be on our business, including, but
not limited to, our products, services, processes and technology, and on our relationships with current and future customers and healthcare providers. The legal
challenges regarding the ACA, including a federal district court decision invalidating the ACA in its entirety, which was argued before the U.S. Supreme Court in
November 2020 and has been stayed pending the U.S. Supreme Court’s decision, continue to contribute to this uncertainty. Further regulations and modifications
to the ACA at the federal or state level, including a judicial invalidation of the ACA, could significantly impact the market for our products, the regulations
applicable to us and the fees and taxes payable by us and otherwise have significant effects on our business and future operations, some of which may adversely
affect our results of operations and financial condition.
In general, the risk pool for the Individual market, which includes public exchange markets, has become less healthy since its inception in 2014 and continues
to exhibit risk volatility. In addition, insurers have faced uncertainties related to federal government funding for various ACA programs. Based on our experience
in public exchange markets to date, we have made adjustments to our premium rates and geographic participation, and will continue to evaluate the performance of
our public exchange plans, the future viability of the public exchanges and availability of federal subsidies, and may make further adjustments to our rates and
participation going forward. These factors may have a material adverse effect on our results of operations if premiums are not adequate or do not appropriately
reflect the acuity of these individuals. Any variation from our expectations regarding acuity, enrollment levels, adverse selection, or other assumptions utilized in
setting premium rates could have a material adverse effect on our results of operations, financial position, and cash flows.
For additional information related to the ACA, see Part I, Item 1 “Business” and Part II, Item 7 “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” of this Annual Report on Form 10-K.
We are subject to various risks associated with our international operations.
Certain of our subsidiaries that provide services to some of our health plans operate internationally and are subject to regulation in the jurisdictions in which
they are organized or conduct business related to, among other things, taxation, intellectual property, investment, management control, labor, anti-fraud, anti-
corruption and privacy and data protection regulations. In addition, we are subject to U.S. laws that regulate the conduct and activities of U.S.-based businesses
operating abroad, such as the Foreign Corrupt Practices Act. Violations of these laws and regulations could result in fines, criminal sanctions against us, our
officers or employees, restrictions or outright prohibitions on the conduct of our business and significant reputational harm.
We face risks related to litigation.
We are, and may in the future be, a party to a variety of legal actions that may affect our business, such as administrative charges before government agencies,
employment and employment discrimination-related suits, employee benefit claims, breach of contract actions, tort claims and intellectual property-related
litigation. In addition, because of the nature of our
-32-
-- 33 of 512 --
business, we are subject to a variety of legal actions relating to our business operations, including the design, administration and offering of our products and
services. These could include claims relating to the denial or limitation of healthcare benefits; federal and state false claims act laws; dispensing of drugs associated
with our PBM business; professional liability claims arising out of the delivery of healthcare and related services to the public; development or application of
medical policies and coverage and clinical guidelines; medical malpractice actions; product liability claims; allegations of anti-competitive and unfair business
activities; provider disputes over reimbursement and contracts; provider tiering programs; narrow networks; termination of provider contracts; the recovery of
overpayments from providers; self-funded business; disputes over co-payment calculations; reimbursement of out-of-network claims; the failure to disclose certain
business practices; the failure to comply with various state or federal laws, including but not limited to, ERISA and the Mental Health Parity Act; and customer
audits and contract performance, including government contracts. These actions or proceedings could result in substantial costs to us, require our officers to spend
substantial time focused on the litigation, and result in negative media attention, and may adversely affect our business, reputation, financial condition, results of
operations and cash flows.
We are also involved in, or may in the future be party to, pending or threatened litigation of the character incidental to the business we transact or arising out
of our operations, including, but not limited to, breaches of security and violations of privacy requirements, shareholder actions, compliance with federal and state
laws and regulations (including qui tam or “whistleblower” actions), or sales and acquisitions of businesses or assets (including as a result of the now terminated
Agreement and Plan of Merger between us and Cigna Corporation, or as more fully described under Note 14, “Commitments and Contingencies - Litigation and
Regulatory Proceedings - Cigna Corporation Merger Litigation,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual
Report on Form 10-K). From time to time, we are involved as a party in various governmental investigations, audits, reviews and administrative proceedings,
including challenges relating to the award of government contracts. These investigations, audits and reviews include routine and special investigations by various
state insurance departments, various federal regulators including CMS and the HHS Office of Inspector General, state attorneys general, the Department of Justice,
and various offices of the U.S. Attorney General. Following an investigation, we may be subject to civil or criminal fines, penalties and other sanctions if we are
determined to be in violation of applicable laws or regulations. Liabilities that may result from these actions could have a material adverse effect on our cash flows,
results of operations and financial condition.
Recent court decisions and legislative activity may increase our exposure for any of these types of claims. In some cases, substantial non-economic (including
injunctive relief), treble or punitive damages may be sought. Although we maintain insurance coverage for some of these potential liabilities, some liabilities and
damages may not be covered by insurance, insurers may dispute coverage or the amount of insurance may not be enough to cover the damages awarded. In
addition, insurance coverage for all or certain forms of liability may become unavailable or prohibitively expensive in the future. Any adverse judgment against us
resulting in such damage awards could result in negative publicity and have an adverse effect on our cash flows, results of operations and financial condition.
There are various risks associated with providing healthcare services.
The direct provision of healthcare services by certain of our subsidiaries involves risks of additional litigation arising from medical malpractice actions based
on our treatment decisions or brought against us or our associates for alleged malpractice or professional liability claims arising out of the delivery of healthcare
and related services. In addition, liability may arise from maintaining healthcare premises that serve the public. The defense of any actions may result in significant
expenses, and if we fail to maintain adequate insurance coverage for these liabilities, or if such insurance is not available, the resulting costs could adversely affect
our business, cash flows, financial condition and results of operations.
Additionally, many states in which certain of our subsidiaries operate limit the practice of medicine to licensed individuals or professional organizations
comprised of licensed individuals. Business corporations generally may not exercise control over the medical decisions of physicians, and we are not licensed to
practice medicine. Rules and regulations relating to the practice of medicine, fee-splitting between physicians and referral sources, and similar issues vary from
state to state. Further, certain federal and state laws, including those covering our Medicare and Medicaid plans, prohibit the offer, payment, solicitation or receipt
of any form of remuneration to induce, or in return for, the referral of patient care opportunities and also generally prohibit physicians from making referrals to any
entity providing certain designated health services if the referring physician or related person has an ownership or financial interest in the entity. Any enforcement
-33-
-- 34 of 512 --
actions by governmental officials alleging non-compliance with these rules and regulations could adversely affect our business, cash flows, financial condition and
results of operations.
Our PBM services business and related operations are subject to a number of risks and uncertainties that are in addition to those we face in our core
healthcare business.
We provide PBM services through our IngenioRx business, and we are responsible to regulators and our customers for the delivery of those PBM services that
we contract to provide. Our PBM services business is subject to the risks inherent in the dispensing, packaging, fulfillment and distribution of pharmaceuticals and
other healthcare products, including exposure to liabilities and reputational harm related to purported dispensing and other operational errors by us or our PBM
services suppliers. Any failure by us or one of our PBM services suppliers to adhere to the laws and regulations applicable to the dispensing of pharmaceuticals
could subject our PBM business to civil and criminal penalties.
Our PBM services business is subject to federal and state laws and regulations that govern its relationships with pharmaceutical manufacturers, physicians,
pharmacies and customers, including without limitation, federal and state anti-kickback laws, beneficiary inducement laws, consumer protection laws, ERISA,
HIPAA and laws related to the operation of internet and mail-service pharmacies, as well as an increasing number of licensure, registration and other laws and
accreditation standards that impact the business practices of a PBM services business. In addition, the practice of pharmacy is subject to federal and state laws and
regulation, including those of state boards of pharmacy, individual state-controlled substance authorities, the U.S. Drug Enforcement Agency and the U.S. Food
and Drug Administration. Also, we and our third-party vendors are subject to registration requirements and state and federal laws concerning labeling, packaging,
advertising, handling and adulteration of prescription drugs and dispensing of controlled substances. Noncompliance with applicable laws and regulations by us or
our third-party vendors could have material adverse effects on our business, results of operations, financial condition, liquidity and reputation.
Federal and state legislatures also regularly consider new regulations and changes to existing regulations for the industry that could materially affect current
industry practices and our business, including the regulation implemented by HHS in November 2020 related to rebates and the pricing of pharmaceuticals, the
Appropriations Act, and potential new regulations regarding rebates, fees from pharmaceutical companies, the development and use of formularies and other
utilization management tools, the use of average wholesale prices or other pricing benchmarks, pricing for specialty pharmaceuticals, limited access to networks
and pharmacy network reimbursement methodologies. In December 2020, the U.S. Supreme Court let stand an Arkansas law regulating PBMs that may be a
precursor to greater state regulation of PBMs.
We are a party to license agreements with the BCBSA that entitle us to the exclusive and, in certain areas, non-exclusive use of the BCBS names and
marks in our geographic territories. The termination of these license agreements or changes in the terms and conditions of these license agreements could
adversely affect our business, cash flows, financial condition and results of operations.
Our license agreements with the BCBSA contain certain requirements and restrictions regarding our operations and our use of the BCBS names and marks,
and failure to comply with those requirements could result in a termination of the license agreements. The license agreements may be modified by the BCBSA,
which could have a material adverse effect on our future expansion plans or results of operations. Further, BCBS licensees have certain requirements to perform
administrative services for members of other BCBS licensees. As of December 31, 2020, we provided services to approximately 32 million Blue Cross and/or Blue
Shield enrollees. If we or another BCBS licensee are not in compliance with all legal requirements or are unable to perform administrative services as required, this
could have an adverse effect on our members and our ability to maintain our licenses, which could have a material adverse effect on our business, cash flows,
financial condition and results of operations.
Upon the occurrence of an event causing termination of the license agreements, we would no longer have the right to use the BCBS names and marks or to sell
BCBS health insurance products and services in one or more of our service areas. Furthermore, the BCBSA would be free to issue a license to use the BCBS names
and marks in these service areas to another entity. Our existing BCBS members would be provided with instructions for obtaining alternative products and services
licensed by the BCBSA. We believe that the BCBS names and marks are valuable identifiers of our products and services in the marketplace.
-34-
-- 35 of 512 --
Upon termination of either license agreement, the BCBSA would have the right to impose a “Re-establishment Fee” upon us, which would be used in part to
fund the establishment of a replacement Blue Cross and/or Blue Shield licensee in the vacated service area. The fee is set at $98.33 per licensed enrollee. If the Re-
establishment Fee was applied to our total Blue Cross and/or Blue Shield enrollees of approximately 32 million as of December 31, 2020, we would be assessed
approximately $3 billion by the BCBSA. As a result, termination of the license agreements would have a material adverse effect on our business, cash flows,
financial condition and results of operations.
For more information on the BCBSA license agreements, including requirements, restrictions and termination events set forth in these license agreements, see
Part I, Item 1, “Business — BCBSA Licenses” of this Annual Report on Form 10-K.
Indiana law, other applicable laws, our articles of incorporation and bylaws, and provisions of our BCBSA license agreements may prevent or discourage
takeovers and business combinations that our shareholders might consider to be in their best interest.
Indiana law, other applicable laws and regulations and provisions in our articles of incorporation and bylaws may delay, defer, prevent or render more difficult
a takeover attempt that our shareholders might consider to be in their best interests. For instance, they may prevent our shareholders from receiving the benefit
from any premium to the market price of our common stock offered by a bidder in a takeover context or adversely affect the price that some investors are willing to
pay for our stock.
The insurance holding company acts and certain health statutes of the states in which our insurance company or HMO subsidiaries are regulated restrict the
ability of any person to obtain control of an insurance company or HMO without prior regulatory approval. Further, the Indiana Business Corporation Law
contains business combination provisions that, in general, prohibit for five years any business combination with a beneficial owner of 10% or more of our common
stock unless the holder’s acquisition of the stock was approved in advance by our Board of Directors.
Our articles of incorporation and bylaws contain provisions that could have anti-takeover effects and may delay, defer or prevent a takeover attempt that our
shareholders might consider to be in their best interests. Our articles of incorporation provide that no person may beneficially own shares of voting capital stock in
excess of specified ownership limits, except with the prior approval of a majority of the “continuing directors.” The ownership limits, which may not be exceeded
without the prior approval of the BCBSA, are the following: (1) for any institutional investor (as defined in our articles of incorporation), one share less than 10%
of our outstanding voting securities; (2) for any non-institutional investor (as defined in our articles of incorporation), one share less than 5% of our outstanding
voting securities; and (3) for any person, one share less than the number of shares of our common stock or other equity securities (or a combination thereof)
representing a 20% ownership interest in us.
In addition, our articles of incorporation and bylaws: divide our Board of Directors into three classes serving staggered three-year terms (which is required by
our license agreement with the BCBSA); permit our Board of Directors to determine the terms of and issue one or more series of preferred stock without further
action by shareholders; restrict the maximum number of directors and the ability to increase that number; limit the ability of shareholders to remove directors;
impose restrictions on shareholders’ ability to fill vacancies on our Board of Directors; impose advance notice requirements for shareholder proposals and
nominations of directors to be considered at meetings of shareholders; prohibit shareholders from amending certain provisions of our bylaws; and impose
restrictions on who may call a special meeting of shareholders.
The health benefits industry is subject to negative publicity, which could adversely affect our business, cash flows, financial condition and results of
operations.
The health benefits industry is subject to negative publicity, which can arise from, among other things, increases in premium rates, industry consolidation, cost
of care initiatives and debate around existing or proposed legislation. Negative publicity may result in increased regulation and legislative review of industry
practices, which may further increase our costs of doing business and adversely affect our profitability by limiting our ability to market or provide our products and
services, requiring us to change our products and services, or increasing the regulatory oversight under which we operate. In addition, any negative publicity
concerning the BCBSA or other BCBSA licensees may adversely affect us and the sale of our health benefits products and services. Negative public perception or
publicity of the health benefits industry in general, the BCBSA, other BCBSA licensees, or us or our key vendors in particular, could adversely affect our business,
cash flows, financial condition and results of operations.
-35-
-- 36 of 512 --
STRATEGIC RISKS
We face competition in many of our markets, and if we fail to adequately adapt to changes in our industry and develop and implement strategic growth
opportunities, our ability to compete and grow may be adversely affected.
As a health benefits company, we operate in a highly competitive environment and in an industry that is subject to significant changes from and competition
due to legislative reform, business consolidations, new strategic alliances, new market entrants, aggressive marketing practices, technological advancements and
changing market practices such as increasing usage of telehealth. We also will have to respond to pricing and other actions taken by existing competitors and
potentially disruptive new entrants in the public exchanges and in our other lines of business. These factors have produced and will likely continue to produce
significant pressures on our profitability. Furthermore, decisions to buy our products and services are increasingly made or influenced by consumers, through
means such as direct purchasing (for example, Medicare Advantage plans) and insurance exchanges that allow individual choice, or by large employers that may
increasingly have the ability to contract directly with providers. This creates unique market pressures, and in order to compete effectively in the consumer-driven
marketplace, we will be required to develop and deliver innovative and potentially disruptive products and services to satisfy evolving market demands.
In addition, the PBM industry is highly competitive, and IngenioRx is subject to competition from national, regional and local PBMs, other insurers, health
plans, large retail pharmacy chains, large retail stores, supermarkets, other mail order and web pharmacies, discount cards and specialty pharmacies. Strong
competition within the PBM business has generated greater demand for lower product and service pricing, increased revenue sharing and enhanced product and
service offerings. Our inability to maintain positive trends, contract on favorable terms with pharmaceutical manufacturers for, among other things, rebates,
discounts and administrative fees or a failure to identify and implement new ways to mitigate pricing pressures, could negatively impact our ability to attract or
retain customers, negatively impact our margins and have a material adverse effect on our business and results of operations. In addition, legislative reforms such
as the regulation issued by HHS in November 2020 related to rebates, and the Appropriations Act, which requires reporting of plan spending, the cost of plan
pharmacy benefits, enrollee premiums and any manufacturer rebates received by the plan or issuer, may adversely affect our competitive position, cash flows,
financial condition and results of operations.
In order to profitably grow our business in the future, we need to not only grow our profitable medical membership, but also continue to diversify our sources
of revenue and earnings, including through the increased sale of our specialty products, such as dental, vision and other supplemental products, expansion of
products, expansion of our non-insurance assets and establishment of new cost of care solutions, including innovations in PBM services. If we are unable to
acquire or develop and successfully manage new opportunities that further our strategic objectives and differentiate our products from our competitors, our ability
to profitably grow our business could be adversely affected.
We are currently dependent on the non-exclusive services of independent agents and brokers in the marketing of our healthcare products, particularly with
respect to individuals, seniors and local group customers. We face intense competition for the services and allegiance of these independent agents and brokers, who
may also market the products of our competitors. Our relationship with our brokers and independent agents could be adversely impacted by changes in our
business practices to address legislative changes, including potential reductions in commissions and consulting fees paid to agents and brokers. We cannot ensure
that we will be able to compete successfully against current and future competitors for these services or that competitive pressures faced by us will not materially
and adversely affect our business, cash flows, financial condition and results of operations.
For additional information, see “Business — Competition,” in Part I, Item 1 of this Annual Report on Form 10-K.
We have built a significant portion of our current business through mergers and acquisitions, joint ventures and strategic alliances, and we expect to
pursue such opportunities in the future.
The following are some of the risks associated with mergers, acquisitions, joint ventures and strategic alliances, referred to collectively as business
combinations, that could have a material adverse effect on our business, cash flows, financial condition and results of operations:
• some of the business combinations may not achieve anticipated revenues, earnings or cash flow, business opportunities, synergies, growth prospects and
other anticipated benefits;
-36-
-- 37 of 512 --
• we may assume liabilities that were not disclosed to us or which were underestimated;
• we may experience difficulties in integrating business combinations, be unable to integrate business combinations successfully or as quickly as expected
and be unable to realize anticipated economic, operational and other benefits in a timely manner or at all;
• business combinations, and proposed business combinations that are not completed, could disrupt our ongoing business, lead to the incurrence of
significant fees, distract management, result in the loss of key employees, divert resources, result in tax costs or inefficiencies and make it difficult to
maintain our current business standards, controls, information technology systems, policies and procedures;
• we may finance future business combinations by issuing common stock for some or all of the purchase price, which could dilute the ownership interests
of our shareholders;
• we may compete with other firms, some of which may have greater financial and other resources, to acquire attractive companies;
• we may experience disputes with our partners in our strategic alliances and joint ventures, which could result in litigation or a loss of business; and
• future business combinations may make it difficult to comply with the requirements of the BCBSA and lead to an increased risk that our BCBSA license
agreements may be terminated.
We face intense competition to attract and retain employees. Further, managing key executive transition, succession and retention is critical to our
success.
Our success depends on our ability to attract and retain qualified employees and to integrate employees who have joined us through acquisitions. We face
intense competition for qualified employees, and there can be no assurance that we will be able to attract and retain such employees or that such competition
among potential employers will not result in increasing salaries. An inability to retain existing employees or attract additional employees could have a material
adverse effect on our business, cash flows, financial condition and results of operations.
We would be adversely affected if we fail to adequately plan for the succession of our President and Chief Executive Officer and other senior management or
retain key executives. While we have succession plans in place for members of our senior management, and employment arrangements with certain key executives,
these plans and arrangements do not guarantee that the services of our senior executives will continue to be available to us or that we will be able to attract,
transition and retain suitable successors.
FINANCIAL RISKS
As a holding company, we are dependent on dividends from our subsidiaries. These dividends are necessary to pay our outstanding indebtedness. Our
regulated subsidiaries are subject to state regulations, including restrictions on the payment of dividends, maintenance of minimum levels of capital and
restrictions on investment portfolios.
As a holding company, we are dependent on dividends and administrative expense reimbursements from our subsidiaries. Our regulated subsidiaries are not
obligated to make funds available to us, and creditors of our subsidiaries will have a superior claim to certain of our subsidiaries’ assets. Furthermore, among other
restrictions, state insurance and HMO laws may restrict the ability of our regulated subsidiaries to pay dividends. In some states, we have made special
undertakings that may limit the ability of our regulated subsidiaries to pay dividends. In addition, our subsidiaries’ ability to make any payments to us will also
depend on their earnings, the terms of their indebtedness, business and tax considerations and other legal restrictions. Our ability to repurchase shares or pay
dividends in the future to our shareholders and meet our obligations, including paying operating expenses and debt service on our outstanding and future
indebtedness, will depend upon the receipt of dividends from our subsidiaries. An inability of our subsidiaries to pay dividends in the future in an amount sufficient
for us to meet our financial obligations may materially adversely affect our business, cash flows, financial condition and results of operations.
Most of our regulated subsidiaries are subject to RBC standards or other forms of minimum capital requirements imposed by their states of domicile that
require them to report their results of risk-based capital calculations to the departments of insurance and the NAIC. Failure to maintain the minimum RBC
standards could subject our regulated subsidiaries to corrective action, including state supervision or liquidation. Changes to the existing RBC standards and the
-37-
-- 38 of 512 --
NAIC’s December 2020 adoption of an RBC requirement at the holding company level, which requires submission of the first report in May 2023, could further
restrict our or our regulated subsidiaries’ ability to pay dividends and adversely affect our business. In addition, as discussed in more detail above, we are a party to
license agreements with the BCBSA which contain certain requirements and restrictions regarding our operations, including minimum capital and liquidity
requirements, which could restrict the ability of our regulated subsidiaries to pay dividends.
Our regulated subsidiaries are subject to state laws and regulations that require diversification of their investment portfolios and limit the amount of
investments in certain riskier investment categories, such as below-investment-grade fixed maturity securities, mortgage loans, real estate and equity investments,
which could generate higher returns on their investments. Failure to comply with these laws and regulations might cause investments exceeding regulatory
limitations to be treated as non-admitted assets for purposes of measuring statutory surplus and risk-based capital, and, in some instances, require the sale of those
investments.
We have substantial indebtedness outstanding and may incur additional indebtedness in the future, which could adversely affect our ability to pursue
desirable business opportunities and to react to changes in the economy or our industry, and exposes us to interest rate risk to the extent of our variable
rate indebtedness.
Our debt service obligations require us to use a portion of our cash flow to pay interest and principal on debt instead of for other corporate purposes, including
funding future expansion. If our cash flow and capital resources are insufficient to service our debt obligations, we may be forced to seek extraordinary dividends
from our subsidiaries, sell assets, seek additional equity or debt capital or restructure our debt. However, these measures might be unsuccessful or inadequate to
meet scheduled debt service obligations, or may not be available on commercially reasonable terms.
We may also incur future debt obligations that might subject us to restrictive covenants that could affect our financial and operational flexibility. Our breach or
failure to comply with any of these covenants could result in a default under our credit facilities or other indebtedness. If we default under our credit agreement, the
lenders could cease to make further extensions of credit or cause all of our outstanding debt obligations under our credit agreement to become immediately due and
payable, together with accrued and unpaid interest. If the indebtedness under our notes or our credit agreement or our other indebtedness is accelerated, we may be
unable to repay or finance the amounts due, on commercially reasonable terms, or at all.
A downgrade in our credit ratings could have an adverse effect on our business, cash flows, financial condition and results of operations.
Claims-paying ability as well as financial strength and debt ratings by nationally recognized statistical rating organizations are important factors in
establishing the competitive position of insurance companies and health benefits companies. We believe our strong credit ratings are an important factor in
marketing our products to customers. In addition, if our credit ratings are downgraded or placed under review, our business, cash flows, financial condition and
results of operations could be adversely impacted by limitations on future borrowings and a potential increase in our borrowing costs. Each of the ratings
organizations reviews our ratings periodically, and there can be no assurance that our current ratings will be maintained in the future.
The value of our intangible assets may become impaired.
As of December 31, 2020, we had $31 billion of goodwill and other intangible assets, representing 36% of our total consolidated assets. In accordance with
applicable accounting standards, we periodically evaluate our goodwill and other intangible assets for potential impairment, using assumptions and judgments
regarding the estimated fair value of our reporting units. Estimated fair values might be significantly different if other reasonable assumptions and estimates were
to be used. If estimated fair values are less than the carrying values of goodwill and other intangible assets with indefinite lives in future impairment tests, or if
significant impairment indicators are noted relative to other intangible assets subject to amortization, we may be required to record impairment losses against future
income.
The value we place on intangible assets may be adversely impacted if existing or future business combinations fail to perform in a manner consistent with our
assumptions. In addition, from time to time we divest businesses, and any such divestiture could result in significant asset impairment and disposition charges,
including those related to goodwill and other intangible assets. In addition, the estimated value of our reporting units may be impacted as a result of business
decisions we
-38-
-- 39 of 512 --
make associated with any future changes to laws and regulations, which could unfavorably affect the carrying value of certain goodwill and other intangible assets
and result in impairment charges in future periods. Any future evaluations requiring an impairment of our goodwill and other intangible assets could materially
affect our results of operations and shareholders’ equity which could, in turn, negatively impact our debt ratings or potentially impact our compliance with existing
debt covenants.
The value of our investments is influenced by varying economic and market conditions, and a decrease in value may result in a loss charged to income.
We maintain a significant investment portfolio of cash equivalents and short-term and long-term investments in a variety of securities, which are subject to
general credit, liquidity, market and interest rate risks. As a result, we may experience a reduction in value or loss of our investments, which may have a negative
adverse effect on our results of operations, liquidity and financial condition. Changes in the economic environment, including periods of increased volatility in the
securities markets such as those experienced in 2020 related to the ongoing COVID-19 pandemic, can increase the difficulty of assessing investment impairment
and increase the risk of potential impairment of these assets. There is continuing risk that declines in fair value may occur and material impairments may be
charged to income in future periods, resulting in realized losses.
GENERAL RISKS
Changes in tax laws and regulations could have a material adverse effect on our business, cash flow, financial condition and results of operations. In
addition, we may not be able to realize the value of our deferred tax assets.
Changes in tax laws and regulations , including a potential increase in U.S. corporate tax rates or changes in the deductibility of expenses, or changes in the
interpretation of tax laws and regulations by federal and/or state authorities, could have a material impact on the future value of our deferred tax assets and deferred
tax liabilities, could result in significant one-time charges in the current or future taxable years and could increase our future U.S. tax expense. In addition, we are
regularly audited by federal and other tax authorities. Although we believe our tax positions comply with applicable tax law, the final determination of audits and
any related litigation in the jurisdictions where we are subject to taxation could be materially different from our historical income provisions and accruals. These
changes could have a material adverse effect on our business, cash flow, financial condition and results of operations.
In addition, any future increase in our valuation allowance with regard to our deferred tax assets would result in additional income tax expense and a decrease
in shareholders’ equity, which could materially affect our financial position and results of operations in the period in which the increase occurs. A material
decrease in shareholders’ equity could, in turn, negatively impact our debt ratings or potentially impact our compliance with existing debt covenants.
We also face other risks that could adversely affect our business, financial condition or results of operations, which include:
• adverse securities and credit market conditions, which could impact our ability to meet liquidity needs;
• any requirement to restate financial results in the event of inappropriate application of accounting principles;
• a significant failure of our internal control over financial reporting;
• failure of our prevention and control systems related to employee compliance with internal policies, including data security;
• provider fraud that is not prevented or detected and impacts our medical costs or those of self-insured customers;
• failure to protect our proprietary information; and
• failure of our corporate governance policies or procedures.
ITEM 1B. UNRESOLVED SEC STAFF COMMENTS.
None.
-39-
-- 40 of 512 --
ITEM 2. PROPERTIES.
We lease our principal executive offices located at 220 Virginia Avenue, Indianapolis, Indiana. In addition to this location, we have operating facilities located
in each state where we operate as licensees of the BCBSA, in each state where Amerigroup conducts business and in certain other states and countries where our
other subsidiaries operate. A majority of these locations are also leased properties. Our facilities support our various business segments. We modified certain of our
workforce practices in 2020 in response to the COVID-19 pandemic, including having the majority of our workforce work remotely. In the third quarter of 2020,
our management introduced enterprise-wide initiatives to streamline our operations and optimize our business, including a reduction of our office space footprint.
We believe that our properties are adequate and suitable for our business as presently conducted; however, we are continuing to evaluate our real estate strategy as
it relates to the impact of the COVID-19 pandemic and the changing needs of a more remote workforce.
ITEM 3. LEGAL PROCEEDINGS.
For information regarding our legal proceedings, see Note 14, “Commitments and Contingencies - Litigation and Regulatory Proceedings,” of the Notes to
Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K, which information is incorporated herein by reference.
ITEM 4. MINE SAFETY DISCLOSURES.
Not applicable.
-40-
-- 41 of 512 --
PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY
SECURITIES.
Market Information
Our common stock, par value $0.01 per share, is listed on the NYSE under the symbol “ANTM.”
Holders
As of February 4, 2021, there were 55,764 shareholders of record of our common stock.
Securities Authorized for Issuance under Equity Compensation Plans
The information required by this Item concerning securities authorized for issuance under our equity compensation plans is set forth in Part III, Item 12
“Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” in this Annual Report on Form 10-K.
Issuer Purchases of Equity Securities
The following table presents information related to our repurchases of common stock for the periods indicated (in millions, except share and per share data):
Period
Total Number
of Shares
Purchased
Average
Price Paid
per Share
Total Number
of Shares
Purchased as
Part of
Publicly
Announced
Programs
Approximate
Dollar Value
of Shares that
May Yet Be
Purchased
Under the
Programs
October 1, 2020 to October 31, 2020 1,236,624 $ 288.64 1,234,200 $ 2,093
November 1, 2020 to November 30, 2020 1,483,621 310.05 1,481,675 1,634
December 1, 2020 to December 31, 2020 1,744,143 314.04 1,725,700 1,092
4,464,388 4,441,575
1 Total number of shares purchased includes 22,813 shares delivered to or withheld by us in connection with employee payroll tax withholding upon exercise or
vesting of stock awards. Stock grants to employees and directors and stock issued for stock option plans and stock purchase plans in the consolidated
statements of shareholders’ equity are shown net of these shares purchased.
2 Represents the number of shares repurchased through the common stock repurchase program authorized by our Board of Directors, which the Board evaluates
periodically. During the year ended December 31, 2020, we repurchased 9,429,067 shares at an aggregate cost of $2,700 under the program, including the cost
of options to purchase shares. The Board of Directors has authorized our common stock repurchase program since 2003. On January 26, 2021, our Audit
Committee, pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to our common stock repurchase program. No duration
has been placed on our common stock repurchase program, and we reserve the right to discontinue the program at any time.
1 2
-41-
-- 42 of 512 --
Performance Graph
The following Performance Graph and related information compares the cumulative total return to shareholders of our common stock for the period from
December 31, 2015 through December 31, 2020, with the cumulative total return over such period of (i) the Standard & Poor’s 500 Stock Index (the “S&P 500
Index”) and (ii) the Standard & Poor’s Managed Health Care Index (the “S&P Managed Health Care Index”). The graph assumes an investment of $100 on
December 31, 2015 in each of our common stock, the S&P 500 Index and the S&P Managed Health Care Index (and the reinvestment of all dividends).
The comparisons shown in the graph below are based on historical data, and we caution that the stock price performance shown in the graph below is not
indicative of, and is not intended to forecast, the potential future performance of our common stock. Information used in the graph was obtained from S&P Global
Market Intelligence, a source believed to be reliable, but we are not responsible for any errors or omissions in such information. The following graph and related
information shall not be deemed “soliciting materials” or to be “filed” with the SEC, nor shall such information be incorporated by reference into any future filing
under the Exchange Act, except to the extent that we specifically incorporate it by reference into such filing.
December 31,
2015 2016 2017 2018 2019 2020
Anthem, Inc. $ 100 $ 105 $ 167 $ 197 $ 229 $ 247
S&P 500 Index 100 112 136 130 171 203
S&P Managed Health Care Index 100 120 172 191 229 266
Based upon an initial investment of $100 on December 31, 2015 with dividends reinvested.
-42-
-- 43 of 512 --
ITEM 6. SELECTED FINANCIAL DATA.
The table below provides selected consolidated financial data of Anthem. The information has been derived from our consolidated financial statements for
each of the years in the five-year period ended December 31, 2020. You should read this selected consolidated financial data in conjunction with the audited
consolidated financial statements and notes as of and for the year ended December 31, 2020 included in Part II, Item 8 “Financial Statements and Supplementary
Data,” and Part II, Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in this Annual Report on Form 10-
K.
As of and for the Years Ended December 31
2020 2019 2018 2017 2016
(in millions, except where indicated and except per share data)
Income Statement Data
Total operating revenue $ 120,808 $ 103,141 $ 91,341 $ 89,061 $ 84,194
Total revenues 121,867 104,213 92,105 90,040 84,863
Net income 4,572 4,807 3,750 3,843 2,470
Per Share Data
Basic net income per share $ 18.23 $ 18.81 $ 14.53 $ 14.70 $ 9.39
Diluted net income per share 17.98 18.47 14.19 14.35 9.21
Dividends per share 3.80 3.20 3.00 2.70 2.60
Other Data (unaudited)
Benefit expense ratio 84.6 % 86.8 % 84.2 % 86.4 % 84.8 %
Selling, general and administrative expense ratio 14.4 % 13.0 % 15.3 % 14.2 % 14.9 %
Income before income tax expense as a percentage of total revenues 5.1 % 5.7 % 5.5 % 4.4 % 5.4 %
Net income as a percentage of total revenues 3.8 % 4.6 % 4.1 % 4.3 % 2.9 %
Medical membership (in thousands) 42,925 41,000 39,938 40,299 39,940
Balance Sheet Data
Cash and investments $ 31,295 $ 26,127 $ 22,639 $ 25,179 $ 23,263
Total assets 86,615 77,453 71,571 70,540 65,083
Long-term debt, less current portion 19,335 17,787 17,217 17,382 14,359
Total liabilities 53,416 45,725 43,030 44,037 39,982
Total shareholders’ equity 33,199 31,728 28,541 26,503 25,101
1 The net assets of and results of operations for Beacon, America’s 1st Choice and HealthSun are included from their respective acquisition dates of February 28, 2020, February 15, 2018
and December 21, 2017, respectively.
2 Operating revenue is obtained by adding premiums, product revenue, and administrative fees and other revenue.
3 The benefit expense ratio represents benefit expenses as a percentage of premium revenue.
4 The selling, general and administrative expense ratio represents selling, general and administrative expenses as a percentage of total operating revenue.
5 Cash and investments is obtained by adding cash and cash equivalents, current and long-term fixed maturity securities and equity securities.
1 1 1
2
3
4
5
-43-
-- 44 of 512 --
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
(In Millions, Except Per Share Data or As Otherwise Stated Herein)
This Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”), should be read in conjunction with our audited
consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K. References to the terms “we,” “our,” “us,” “Anthem” or the
“Company” used throughout this MD&A refer to Anthem, Inc., an Indiana corporation, and, unless the context otherwise requires, its direct and indirect
subsidiaries. References to the “states” include the District of Columbia, unless the context otherwise requires.
This section of this Annual Report on Form 10-K generally discusses 2020 and 2019 items and year-over-year comparisons between 2020 and 2019. A
detailed discussion of 2018 items and year-over-year comparisons between 2019 and 2018 that are not included in this Annual Report on Form 10-K can be found
in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of our Annual Report on Form 10-K for the year
ended December 31, 2019.
Overview
We are one of the largest health benefits companies in the United States in terms of medical membership, serving approximately 43 medical members through
our affiliated health plans as of December 31, 2020. We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of
independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for
Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the
New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a
majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue
Cross. In addition, we conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also
serve customers in numerous states across the country as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink,
HealthSun, Optimum HealthCare, Simply Healthcare, and/or UniCare. Also, in the second quarter of 2019, we began providing pharmacy benefits management
(“PBM”) services through our IngenioRx subsidiary. We are licensed to conduct insurance operations in all 50 states and the District of Columbia through our
subsidiaries.
We manage our operations through four reportable segments: Commercial & Specialty Business, Government Business, IngenioRx and Other. In 2019,
IngenioRx was included in our Other reportable segment. Amounts for 2019 have been reclassified to conform to the current year presentation of our reportable
segments for comparability.
Our operating revenue consists of premiums, product revenue, and administrative fees and other revenue. Premium revenue is generated from fully-insured
contracts where we indemnify our policyholders against costs for covered health and life insurance benefits. Product revenue represents services performed by
IngenioRx for unaffiliated PBM customers and includes ingredient costs (net of any rebates or discounts), including co-payments made by or on behalf of the
customer, and administrative fees. Unaffiliated PBM customers include our self-funded groups that contract with IngenioRx for PBM services and external
customers outside of the health plans we own. Administrative fees and other revenue come from fees from our self-funded customers for the processing of
transactions or network discount savings realized, revenues from our Medicare processing business and revenues from other health-related businesses, including
disease management programs and miscellaneous other income.
Our benefit expense primarily includes costs of care for health services consumed by our fully-insured members, such as outpatient care, inpatient hospital
care, professional services (primarily physician care) and pharmacy benefit costs. All four components are affected both by unit costs and utilization rates. Unit
costs include the cost of outpatient medical procedures per visit, inpatient hospital care per admission, physician fees per office visit and prescription drug prices.
Utilization rates represent the volume of consumption of health services and typically vary with the age and health status of our members and their social and
lifestyle choices, along with clinical protocols and medical practice patterns in each of our markets. A portion of benefit expense recognized in each reporting
period consists of actuarial estimates of claims incurred but not yet paid by
-44-
-- 45 of 512 --
us. Any changes in these estimates are recorded in the period the need for such an adjustment arises. While we offer a diversified mix of managed care products
and services through our managed care plans, our aggregate cost of care can fluctuate based on a change in the overall mix of these products and services. Our
managed care plans include: Preferred Provider Organizations; Health Maintenance Organizations (“HMOs”); Point-of-Service plans; traditional indemnity plans
and other hybrid plans, including Consumer-Driven Health Plans; and hospital only and limited benefit products.
We classify certain quality improvement costs as benefit expense. Quality improvement activities are those designed to improve member health outcomes,
prevent hospital readmissions and improve patient safety. They also include expenses for wellness and health promotion provided to our members. These quality
improvement costs may be comprised of expenses incurred for: (i) medical management, including care coordination and case management; (ii) health and
wellness, including disease management services for such conditions as diabetes, high-risk pregnancies, congestive heart failure and asthma management and
wellness initiatives like weight-loss programs and smoking cessation treatments; and (iii) clinical health policy, such as identification and use of best clinical
practices to avoid harm, identifying clinical errors and safety concerns, and identifying potential adverse drug interactions.
Our cost of products sold represents the cost of pharmaceuticals dispensed by IngenioRx for our unaffiliated PBM customers (net of rebates or discounts),
including any co-payments made by or on behalf of the customer, per-claim administrative fees for prescription fulfillment and certain direct costs related to sales
and administration of customer contracts.
Our selling, general and administrative expenses consist of fixed and variable costs. Examples of fixed costs are depreciation, amortization and certain
facilities expenses. Certain variable costs, such as premium taxes, vary directly with premium volume. Commission expense generally varies with premium or
membership volume. Other variable costs, such as salaries and benefits, do not vary directly with changes in premium but are more aligned with changes in
membership. The acquisition or loss of a significant block of business would likely impact staffing levels and thus, associated compensation expense. Other
variable costs include professional and consulting expenses and advertising. Other factors can impact our administrative cost structure, including systems
efficiencies, inflation and changes in productivity.
Our results of operations depend in large part on our ability to accurately predict and effectively manage healthcare costs through effective contracting with
providers of care to our members, product pricing, medical management and health and wellness programs, innovative product design and our ability to maintain
or achieve improvement in our CMS Star ratings. Several economic factors related to healthcare costs, such as regulatory mandates of coverage as well as direct-
to-consumer advertising by providers and pharmaceutical companies, have a direct impact on the volume of care consumed by our members. The potential effect
of escalating healthcare costs, any changes in our ability to negotiate competitive rates with our providers and any regulatory or market-driven restrictions on our
ability to obtain adequate premium rates to offset overall inflation in healthcare costs, including increases in unit costs and utilization resulting from the aging of
the population and other demographics, the impact of epidemics and pandemics, as well as advances in medical technology, may impose further risks to our ability
to profitably underwrite our business, and may have a material adverse impact on our results of operations.
For additional information about our business and reportable segments, see Part I, Item 1, “Business” and Note 20, “Segment Information” of the Notes to
Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.
COVID-19
In March 2020, the World Health Organization declared the outbreak of a novel strain of coronavirus (“COVID-19”) a global health pandemic. At the onset of
the pandemic, to prevent its spread, most states issued shelter-in-place or stay-at-home orders, which generally required the businesses not considered essential to
close their physical offices. While these orders were largely lifted during the second quarter of 2020, many states and local authorities continued to impose certain
restrictions on the conduct of businesses and individuals.
The COVID-19 pandemic continues to evolve, and the virus and mitigation efforts have continued to impact the global economy, cause market instability,
increase unemployment and put pressure on the healthcare system. The COVID-19 pandemic has impacted and will continue to impact our membership and
benefit expense and has influenced and will likely continue to influence member behavior, impacting how members access healthcare services. Although increased
unemployment caused by the COVID-19 pandemic resulted in a decline in our Local Group membership, our Medicaid
-45-
-- 46 of 512 --
membership grew as a result of the temporary suspension of eligibility recertification efforts in response to the COVID-19 pandemic. While reduced or cancelled
utilization of non-COVID-19 health services by our members decreased our claim costs overall in 2020, in the second half of 2020 utilization of such services
began to rebound, and non-COVID-19 claim costs began to normalize as the shelter-in-place, stay-at-home orders and other restrictions on the conduct of
businesses were lifted. Our expenses in 2020 included additional costs to cover COVID-19 related testing, treatment, expanded coverage of insurance benefits,
waivers for cost-sharing and actions to support our providers. Furthermore, our expenses associated with COVID-19, including testing and treatment and the
actions taken to support our members in response to the pandemic, accelerated in the fourth quarter of 2020 and exceeded the benefit we experienced during the
quarter from the lower volume of healthcare claims attributable to decreased utilization of non-COVID-19 health services.
We remain focused on increasing access and coverage for our members and made several changes to our membership benefits and business operations,
adopted tools and policies to assist consumers and care providers and provided support to our associates and our local communities, which were discussed in Part I,
Item 1, “Business — COVID-19,” of this Annual Report on Form 10-K. Further, during 2020 we proactively took several actions to preserve our liquidity and
financial flexibility and minimize the effects of the COVID-19 pandemic, including:
• Borrowing under our senior revolving credit facility in March 2020, which was repaid in April 2020;
• Delaying certain tax payments as permitted by the IRS and the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”); and
• Temporarily suspending our share repurchase activity in March 2020, which was resumed in late June 2020.
The COVID-19 pandemic has created unique and unprecedented challenges, and although it has impacted and will likely continue to impact our membership
and benefit expense, it did not have a material adverse effect on our reported results in 2020. However, this may change in the future as the COVID-19 pandemic is
evolving, and the extent of its impact will depend on future developments, which are highly uncertain and cannot be predicted at this time. We will continue to
monitor the COVID-19 pandemic as well as resulting legislative and regulatory changes that may impact our business. For additional discussion regarding our
risks related to the COVID-19 pandemic and our other risk factors, see Part I, Item 1A, “Risk Factors” in this Annual Report on Form 10-K and “Business Trends”
in this MD&A.
Business Trends
The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended (collectively, the “ACA”), has
changed and may continue to make broad-based changes to the U.S. healthcare system. We expect the ACA will continue to impact our business model and
strategy. Also, the legal challenges regarding the ACA, including a federal district court decision invalidating the ACA, which was argued before the U.S. Supreme
Court in November 2020 and has been stayed pending the U.S. Supreme Court’s decision, could significantly disrupt our business. We currently offer Individual
ACA-compliant products in 103 of the 143 rating regions in which we operate. Our strategy has been, and will continue to be, to only participate in rating regions
where we have an appropriate level of confidence that these markets are on a path toward sustainability, including, but not limited to, factors such as expected
financial performance, regulatory environment, and underlying market characteristics. In addition, the continuing growth in our government-sponsored business
exposes us to increased regulatory oversight.
In the second quarter of 2019, we began using IngenioRx to market and offer PBM services to our affiliated health plan customers throughout the country, as
well as to customers outside of the health plans we own. Our comprehensive PBM services portfolio includes features such as formulary management, pharmacy
networks, a prescription drug database, member services and mail order capabilities. IngenioRx delegates certain PBM administrative functions, such as claims
processing and prescription fulfillment, to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement. With
IngenioRx, we retain the responsibilities for clinical and formulary strategy and development, member and employer experiences, operations, sales, marketing,
account management and retail network strategy. From December 2009 through December 2019, we delegated certain PBM functions and administrative services
to Express Scripts, Inc. (“Express Scripts”). We began transitioning existing members from Express Scripts to IngenioRx in the second quarter of 2019, and
completed the transition of all of our members by January 1, 2020.
Pricing Trends: We strive to price our healthcare benefit products consistent with anticipated underlying medical cost trends. We continue to closely monitor the
COVID-19 pandemic and the impacts it may have on our pricing, such as surges
-46-
-- 47 of 512 --
in COVID-19 hospitalizations, infection rates, and the cost of COVID-19 vaccines. We frequently make adjustments to respond to legislative and regulatory
changes as well as pricing and other actions taken by existing competitors and new market entrants. Product pricing in our Commercial & Specialty Business
segment, including our Individual and Small Group lines of business, remains competitive. Revenues from the Medicare and Medicaid programs are dependent, in
whole or in part, upon annual funding from the federal government and/or applicable state governments. The ACA imposed an annual Health Insurance Provider
Fee (“HIP Fee”) on health insurers that write certain types of health insurance on U.S. risks. We priced our affected products to cover the impact of the HIP Fee
when it was in effect. The HIP Fee was suspended for 2019, was resumed for 2020 and has been permanently repealed beginning in 2021.
Medical Cost Trends: Our medical cost trends are primarily driven by increases in the utilization of services across all provider types and the unit cost increases of
these services. We work to mitigate these trends through various medical management programs such as utilization management, condition management, program
integrity and specialty pharmacy management, as well as benefit design changes. There are many drivers of medical cost trends that can cause variance from our
estimates, such as changes in the level and mix of services utilized, regulatory changes, aging of the population, health status and other demographic characteristics
of our members, epidemics, pandemics, advances in medical technology, new high cost prescription drugs, and healthcare provider or member fraud. Our
underlying Local Group medical cost trends reflect the “allowed amount,” or contractual rate, paid to providers.
The COVID-19 pandemic has caused a decrease in utilization of non-COVID-19 health services, which decreased our claim costs in 2020. While the utilization of
such services began to rebound and claim costs began to normalize in the second half of 2020, further increases in the utilization of such services may increase our
claim costs in the future and affect our medical cost trends. Our expenses in 2020 include additional costs to cover COVID-19 related testing, treatment, expanded
benefits coverage and waivers for cost-sharing. In response to the current crisis, we expanded coverage for certain members in our affiliated health plans for testing
and treatment related to a COVID-19 diagnosis. Governmental action has required us to provide full coverage for COVID-19 testing to our members, and future
governmental action could require us to provide additional coverage, including, for example, vaccines. Increased member demand for care, along with continued
COVID-19 care, testing and vaccination costs, are expected to result in increased future medical costs. The continued cost and volume of covered services related
to the COVID-19 pandemic may have a material adverse effect on our future claim costs. We continue to closely monitor the COVID-19 pandemic and its impacts
on our business, financial condition, results of operations and medical cost trends.
For additional discussion regarding business trends, see Part I, Item 1, “Business” of this Annual Report on Form 10-K.
Regulatory Trends and Uncertainties
Federal and state legislation has been enacted, and is likely to continue to be enacted, in response to the COVID-19 pandemic that has had, and we expect will
continue to have, a significant impact on all of our lines of business, including mandates to waive cost-sharing on COVID-19 testing, treatment and related
services. The federal government enacted the Coronavirus Preparedness and Response Supplemental Appropriations Act, the Families First Coronavirus Response
Act and the CARES Act in March 2020, the Paycheck Protection Program and Health Care Enhancement Act in April 2020 and the Consolidated Appropriations
Act of 2021 in December 2020 (the “Appropriations Act”). These acts provide, among other things, prohibitions on prior authorization and cost-sharing for certain
items and services related to COVID-19 tests, reforms including waiving Medicare originating site restrictions for qualified providers providing telehealth services,
financial support to healthcare providers, including expansion of the Medicare accelerated payment program to all providers receiving Medicare payments, and
funding to replenish and administer small business loan programs to help small businesses keep their workers employed and healthcare benefits covered in the
group market.
The Appropriations Act contains a number of provisions that may have a material effect upon our business, including procedures and coverage requirements
related to surprise medical bills and new mandates for continuity of care for certain patients, price comparison tools, disclosure of broker compensation and
reporting on pharmacy benefits and drug costs. The various health plan-related requirements of the Appropriations Act will go into effect on January 1, 2022, and
our first report on pharmacy benefits and drug costs is due December 27, 2021.
Regulatory changes have also been enacted, and are likely to continue to be enacted, at the state and federal level in response to the COVID-19 pandemic.
Those changes, which could have a significant impact on health benefits, consumer
-47-
-- 48 of 512 --
eligibility for public programs, and our cash flows, include mandated expansion of premium payment terms including the time period for which claims can be
denied for lack of payment, mandates related to prior authorizations and payment levels to providers, additional consumer enrollment windows, and an increased
ability to provide services through telehealth. We are providing extensions to premium payment terms in certain situations and working closely with state
regulators that are mandating or requesting such relief.
The ACA presented us with new growth opportunities, but also introduced new risks, regulatory challenges and uncertainties, and required changes in the way
products are designed, underwritten, priced, distributed and administered. Changes to our business environment are likely to continue as elected officials at the
national and state levels continue to enact, and both elected officials and candidates for election continue to propose, significant modifications to existing laws and
regulations, including changes to taxes and fees. In addition, the legal challenges regarding the ACA, including a federal district court decision invalidating the
ACA in its entirety, which was argued before the U.S. Supreme Court in November 2020 and has been stayed pending the U.S. Supreme Court’s decision, continue
to contribute to this uncertainty. In a separate development, in April 2020, the U.S. Supreme Court ruled that the federal government is required to pay health
insurance companies for amounts owed, as calculated under the risk corridor program of the ACA. In June 2020, the U.S. Court of Federal Claims entered a final
judgment stipulating that we are entitled to reimbursement for risk corridor amounts from 2014, 2015 and 2016. At the end of December 2020, the U.S.
Department of Health and Human Services (“HHS”) issued final guidance on how to treat the risk corridor recoveries that we expect to receive. Based on the
guidance from HHS, we revised previously filed minimum medical loss ratio (“MLR”) reports and recognized the net premium impact of the risk corridor
recoveries in the fourth quarter of 2020. We will continue to evaluate the impact of the ACA as any further developments or judicial rulings occur.
The annual HIP Fee, which has been permanently eliminated beginning in 2021, was allocated to health insurers based on the ratio of the amount of an
insurer’s net premium revenues written during the preceding calendar year to the amount of health insurance premium for all U.S. health risk for those certain lines
of business written during the preceding calendar year. The HIP Fee was non-deductible for federal income tax purposes. Our affected products were priced to
cover the increased selling, general and administrative and income tax expenses associated with the HIP Fee when applicable. The HIP Fee was suspended for
2019. For 2020, the HIP Fee resumed and the total amount due from allocations to health insurers was $15,523. For the year ended December 31, 2020, we
recognized $1,570 as selling, general and administrative expense related to the HIP Fee. There was no corresponding expense for 2019 due to the suspension of the
HIP Fee for 2019. The HIP Fee has been permanently eliminated beginning in 2021.
As a result of the ACA, the HHS issued MLR regulations that require us to meet minimum MLR thresholds of 85% for Large Group and 80% for Small Group
and Individual lines of business. Plans that do not meet the minimum thresholds have to pay a MLR rebate. For purposes of determining MLR rebates, HHS has
defined the types of costs that should be included in the MLR rebate calculation. However, certain components of the MLR calculation as defined by HHS cannot
be classified consistently under U.S. generally accepted accounting principles (“GAAP”). While considered benefit expense or a reduction of premium revenue by
HHS, certain of these costs are classified as other types of expense, such as selling, general and administrative expense or income tax expense, in our GAAP basis
financial statements. Accordingly, the benefit expense ratio determined using our consolidated GAAP operating results is not comparable to the MLR calculated
under HHS regulations.
The ACA also imposed a separate minimum MLR threshold of 85% for Medicare Advantage and Medicare Part D prescription drug plans (“Medicare Part
D”). Medicare Advantage or Medicare Part D plans that do not meet this threshold have to pay an MLR rebate. If a plan’s MLR is below 85% for three consecutive
years, enrollment is restricted. A Medicare Advantage or Medicare Part D plan contract will be terminated if the plan’s MLR is below 85% for five consecutive
years.
For additional discussion regarding regulatory trends and uncertainties, and risk factors that could cause actual results to differ materially from those contained
in forward-looking statements made in this Annual Report on Form 10-K, see Part I, Item 1, “Business — Regulation” and Part I, Item 1A, “Risk Factors.”
-48-
-- 49 of 512 --
Other Significant Items
Business and Operational Matters
On February 2, 2021, we announced our entrance into an agreement with InnovaCare Health, L.P. to acquire its Puerto Rico-based subsidiaries, including
MMM Holdings, LLC (“MMM”) and its Medicare Advantage plan MMM Healthcare, LLC, Medicaid plan and other affiliated companies. MMM is an integrated
healthcare organization and seeks to provide its Medicare Advantage and Medicaid members with a whole health experience through its network of specialized
clinics and wholly owned independent physician associations. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner
by providing care management programs that improve the lives of the people we serve. The acquisition is expected to close by the end of the second quarter of
2021 and is subject to standard closing conditions and customary approvals.
In 2020, we introduced enterprise-wide initiatives to optimize our business and as a result, recorded a charge of $653 in selling, general and administrative
expenses. We believe these initiatives largely represent the next step forward in our progression towards becoming a more agile organization, including process
automation and a reduction in our office space footprint. For additional information, see Note 4, “Business Optimization Initiatives” and Note 18, “Leases,” of the
Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.
On February 28, 2020, we completed our acquisition of Beacon Health Options, Inc. (“Beacon”), the largest independently held behavioral health organization
in the country. At the time of acquisition, Beacon served more than thirty-four million individuals across all fifty states. This acquisition aligned with our strategy
to diversify into health services and deliver both integrated solutions and care delivery models that personalize care for people with complex and chronic
conditions. For additional information, see Note 3, “Business Acquisitions,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this
Annual Report on Form 10-K.
In February 2018, we completed our acquisition of Freedom Health, Inc., Optimum HealthCare, Inc., America’s 1st Choice of South Carolina, Inc. and related
entities. This Medicare Advantage organization offers HMO products, including Chronic Special Needs Plans and Dual-Eligible Special Needs Plans, under its
Freedom Health and Optimum HealthCare brands in Florida and its America’s 1st Choice of South Carolina brand in South Carolina. This acquisition aligned with
our plans for continued growth in the Medicare Advantage and Special Needs populations.
Other significant transactions in recent years that have impacted or will impact our capital structure or that have influenced or will influence how we conduct
our business operations include our Board of Directors’ declarations of dividends on our common stock, repurchases of our common stock, debt repurchases and
new debt issuances (2020 and prior). For additional information regarding these transactions, see Note 13, “Debt” and Note 15, “Capital Stock,” of the Notes to
Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.
Litigation Matters
In the consolidated multi-district proceeding in the United States District Court for the Northern District of Alabama (the “Court”) captioned In re Blue Cross
Blue Shield Antitrust Litigation (“BCBSA Litigation”), the Blue Cross Blue Shield Association (the “BCBSA”), and Blue Cross and/or Blue Shield licensees,
including us (the “Blue plans”) have approved a settlement agreement and release (the “Subscriber Settlement Agreement”) with the plaintiffs representing a
putative nationwide class of health plan subscribers. Generally, the lawsuits in the BCBSA Litigation challenge elements of the licensing agreements between the
BCBSA and the independently owned and operated Blue plans. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers
and providers, and the Subscriber Settlement Agreement applies only to the putative subscriber class. No settlement agreement has been reached with the provider
plaintiffs at this time, and the defendants continue to contest the consolidated cases brought by the provider plaintiffs.
If approved by the Court, the Subscriber Settlement Agreement will require the defendants to make a monetary settlement payment, our portion of which is
estimated to be $594, and will contain certain non-monetary terms including (i) eliminating the “national best efforts” rule in the BCBSA license agreements
(which rule limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers with self-funded benefit
plans to request a bid for insurance coverage from a second Blue plan in addition to the local Blue plan. We recognized our estimated payment obligation of $548,
net of third-party insurance coverage received as of December 31, 2020.
-49-
-- 50 of 512 --
On November 30, 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following which members of the Subscriber
class were provided notice of the Settlement Agreement and an opportunity to opt out of the class. All terms of the Subscriber Settlement Agreement are subject to
final approval by the Court before they become effective. Objections to the settlement as well as the deadline for those that wish to opt-out from the settlement
must be submitted by July 28, 2021. Claims must be filed by November 5, 2021. A final approval hearing has been scheduled for October 20, 2021. If the Court
grants approval of the Subscriber Settlement Agreement, and after all appellate rights have expired or have been exhausted in a manner that affirms the Court’s
final order and judgment, the defendants’ payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective. For additional
information regarding this lawsuit, see Note 14, “Commitments and Contingencies - Litigation and Regulatory Proceedings – Blue Cross Blue Shield Antitrust
Litigation,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.
In August 2020, the Delaware Court of Chancery ruled that neither we nor Cigna Corporation could collect damages in connection with the now terminated
Agreement and Plan of Merger, between us and Cigna Corporation. Cigna filed a notice of appeal in November 2020 challenging the trial court’s opinion that
Anthem did not owe Cigna a termination fee. Cigna filed its appellate brief in December 2020, and we filed a response in January 2021. For additional information,
see Note 14, “Commitments and Contingencies - Litigation and Regulatory Proceedings - Cigna Corporation Merger Litigation,” of the Notes to Consolidated
Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.
In January 2019, we exercised our contractual right to terminate our PBM Agreement with Express Scripts (the “ESI PBM Agreement”) and we completed the
transition of our members from Express Scripts to IngenioRx by January 1, 2020. Notwithstanding our termination of the ESI PBM Agreement, the litigation
between us and Express Scripts regarding the ESI PBM Agreement continues. For additional information regarding this lawsuit, see Note 14, “Commitments and
Contingencies - Litigation and Regulatory Proceedings - Express Scripts, Inc. Pharmacy Benefit Management Litigation,” of the Notes to Consolidated Financial
Statements included in Part II, Item 8 of this Annual Report on Form 10-K.
Selected Operating Performance
During the year ended December 31, 2020, total medical membership increased by 1.9, or 4.7%. Our medical membership grew in both our Government
Business and Commercial & Specialty Business segments. The increase in medical membership in our Government Business segment was driven by organic
growth in our Medicaid business due to the temporary suspension of eligibility recertification efforts in our markets in response to the COVID-19 pandemic, as
well as acquisitions, and growth in our Medicare business. The increase in medical membership in our Commercial & Specialty Business segment was primarily
driven by growth in our self-funded business, partially offset by declines in our fully-insured Local Group membership due to negative in-group changes as a result
of increased unemployment caused by the COVID-19 pandemic.
Operating revenue for the year ended December 31, 2020 was $120,808, an increase of $17,667, or 17.1%, from the year ended December 31, 2019. The
increase in operating revenue was primarily driven by higher premium revenue in our Government Business segment, as well as increased pharmacy product
revenue related to the launch of IngenioRx.
Net income for the year ended December 31, 2020 was $4,572, a decrease of $235, or 4.9%, from the year ended December 31, 2019. The decrease in net
income was a result of lower operating results in our Commercial & Specialty Business segment, which was largely driven by costs associated with actions taken
to support our members and providers in response to the COVID-19 pandemic and costs for COVID-19 related care, as well as our estimated payment obligation
related to the BCBSA Litigation and expenses related to our business optimization initiatives recognized in 2020, higher income tax expense, and a decrease in net
earnings from investment activities. These decreases in net income were largely offset by higher operating results in our IngenioRx and Government Business
segments.
Our fully-diluted earnings per share (“EPS”) for the year ended December 31, 2020 were $17.98, a decrease of $0.49, or 2.7%, from the year ended
December 31, 2019. Our diluted shares for the year ended December 31, 2020 were 254.3, a decrease of 6.0, or 2.3%, compared to the year ended December 31,
2019. The decrease in EPS resulted from the decrease in net income, partially offset by the impact of a lower number of shares outstanding in 2020.
-50-
-- 51 of 512 --
Operating cash flow for the year ended December 31, 2020 was $10,688, or approximately 2.3 times net income. Operating cash flow for the year ended
December 31, 2019 was $6,061, or approximately 1.3 times net income. The increase in operating cash flow was primarily due to the impact of the timing of
working capital changes. The increase was further due to membership growth in our Government Business segment and higher net income in 2020, excluding the
non-cash impact of accrued expenses related to our business optimization initiatives and the BCBSA Litigation.
Our results of operations discussed throughout this MD&A are determined in accordance with GAAP. We also calculate operating gain to further aid investors
in understanding and analyzing our core operating results. We define operating revenue as premium income, product revenue and administrative fees and other
revenue. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and selling, general and administrative expense. We use
these measures as a basis for evaluating segment performance, allocating resources, forecasting future operating periods and setting incentive compensation
targets. This information is not intended to be considered in isolation or as a substitute for income before income tax expense, net income or EPS prepared in
accordance with GAAP, and may not be comparable to similarly titled measures reported by other companies. For additional details on operating gain, see our
“Reportable Segments Results of Operations” discussion included in this MD&A. For a reconciliation of reportable segment operating revenue to the amounts of
total revenue included in the consolidated statements of income and a reconciliation of reportable segment operating gain to income before income tax expense, see
Note 20, “Segment Information,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.
We intend to expand through a combination of organic growth, strategic acquisitions and efficient use of capital in both existing and new markets. Our growth
strategy is designed to enable us to take advantage of additional economies of scale, as well as providing us access to new and evolving technologies and products.
In addition, we believe geographic and product diversity reduces our exposure to local or regional regulatory, economic and competitive pressures and provides us
with increased opportunities for growth. In 2019, we began using IngenioRx to market and offer PBM services, and we expect IngenioRx to improve our ability to
integrate pharmacy benefits within our medical and specialty platform. In 2020, we continued growing our government-sponsored business. In all other markets,
we intend to maintain our position by delivering excellent service, offering competitively priced products, providing access to high-quality provider networks and
effectively capitalizing on the brand strength of the Blue Cross and Blue Shield names and marks.
Membership
Our medical membership includes seven different customer types: Local Group, Individual, National Accounts, BlueCard , Medicare, Medicaid and our
Federal Employees Health Benefits (“FEHB”) Program. BCBS-branded business generally refers to members in our service areas licensed by the BCBSA. Non-
BCBS-branded business refers to members in our non-BCBS-branded Amerigroup, Freedom Health, HealthSun, Optimum HealthCare and Simply Healthcare
plans, as well as Beacon, HealthLink and UniCare members. In addition to the above medical membership, we also serve customers who purchase one or more of
our other products or services that are often ancillary to our health business.
• Local Group consists of those employer customers with less than 5% of eligible employees located outside of the headquarter state, as well as customers
with more than 5% of eligible employees located outside of the headquarter state with up to 5,000 eligible employees. In addition, Local Group includes
Student Health and UniCare members. Local Group accounts are generally sold through brokers or consultants who work with industry specialists from
our in-house sales force and are offered both on and off the public exchanges. Local Group insurance premiums may be based on claims incurred by the
group or sold on a self-insured basis. The customer’s buying decision is typically based upon the size and breadth of our networks, customer service, the
quality of our medical management services, the administrative cost included in our quoted price, our financial stability, our reputation and our ability to
effectively service large complex accounts. Local Group accounted for 36.4%, 38.2% and 39.4% of our medical members at December 31, 2020, 2019
and 2018, respectively.
• Individual consists of individual customers under age 65 and their covered dependents. Individual policies are generally sold through independent agents
and brokers, retail partnerships, our in-house sales force or via the exchanges. Individual business is sold on a fully-insured basis. We offer on-exchange
products through public exchanges and off-exchange products. Federal premium subsidies are available only for certain public exchange Individual
products. Unsubsidized Individual customers are generally more sensitive to product pricing and, to a lesser extent, the configuration of the network and
the efficiency of administration. Customer turnover is generally
®
-51-
-- 52 of 512 --
higher with Individual as compared to Local Group. Individual business accounted for 1.6%, 1.7% and 1.6% of our medical members at December 31,
2020, 2019 and 2018, respectively.
• National Accounts generally consist of multi-state employer groups primarily headquartered in an Anthem service area with at least 5% of the eligible
employees located outside of the headquarter state and with more than 5,000 eligible employees. Some exceptions are allowed based on broker and
consultant relationships. Service area is defined as the geographic area in which we are licensed to sell BCBS products. National Accounts are generally
sold through independent brokers or consultants retained by the customer working with our in-house sales force. We believe we have an advantage when
competing for very large National Accounts due to the size and breadth of our networks and our ability to access the national provider networks of other
BCBS companies at their competitive local market rates. National Accounts represented 18.0%, 18.5% and 19.0% of our medical members at
December 31, 2020, 2019 and 2018, respectively.
• BlueCard host customers represent enrollees of Blue Cross and/or Blue Shield plans not owned by Anthem who receive healthcare services in our
BCBSA licensed markets. BlueCard membership consists of estimated host members using the national BlueCard program. Host members are
generally members who reside in or travel to a state in which an Anthem subsidiary is the Blue Cross and/or Blue Shield licensee and who are covered
under an employer-sponsored health plan issued by a non-Anthem controlled BCBSA licensee (the “home plan”). We perform certain functions including
claims pricing and administration for BlueCard members, for which we receive administrative fees from the BlueCard members’ home plans. Other
administrative functions, including maintenance of enrollment information and customer service, are performed by the home plan. Host members are
computed using, among other things, the average number of BlueCard claims received per month. BlueCard host membership accounted for 14.1%,
14.8% and 14.6% of our medical members at December 31, 2020, 2019 and 2018, respectively.
• Medicare customers are Medicare-eligible individual members age 65 and over who have enrolled in Medicare Supplement plans; Medicare Advantage,
including Special Needs Plans (“SNPs”), also known as Medicare Advantage SNPs; Medicare Part D; and dual-eligible programs through Medicare-
Medicaid Plans (“MMPs”). Medicare Supplement plans typically pay the difference between healthcare costs incurred by a beneficiary and amounts paid
by Medicare. Medicare Advantage plans provide Medicare beneficiaries with a managed care alternative to traditional Medicare and often include a
Medicare Part D benefit. In addition, our Medicare Advantage SNPs provide tailored benefits to special needs individuals who are institutionalized or
have severe or disabling chronic conditions and to dual-eligible customers, who are low-income seniors and persons under age 65 with disabilities.
Medicare Advantage SNPs are coordinated care plans specifically designed to provide targeted care, covering all the healthcare services considered
medically necessary for members and often providing professional care coordination services, with personal guidance and programs that help members
maintain their health. Medicare Advantage membership also includes Medicare Advantage members in our Group Retiree Solutions business who are
related to National Accounts, retired members of Local Group accounts, or retired members of groups who are not affiliated with our Commercial
accounts who have selected a Medicare Advantage product through us. Medicare Part D offers a prescription drug plan to Medicare and MMP
beneficiaries. MMP, which was established as a result of the passage of the ACA, is a demonstration program focused on serving members who are dually
eligible for Medicaid and Medicare. Medicare Supplement and Medicare Advantage products are marketed in the same manner, primarily through
independent agents and brokers. Medicare business accounted for 5.5%, 5.2% and 4.6% of our medical members at December 31, 2020, 2019 and 2018,
respectively.
• Medicaid membership represents eligible members who receive healthcare benefits through publicly funded healthcare programs, including Medicaid,
ACA-related Medicaid expansion programs, Temporary Assistance for Needy Families, programs for seniors and people with disabilities, Children’s
Health Insurance Programs, and specialty programs such as those focused on long-term services and support, HIV/AIDS, foster care, behavioral health
and/or substance abuse disorders, and intellectual disabilities or developmental disabilities, among others. Total Medicaid program business accounted for
20.6%, 17.7% and 16.8% of our medical members at December 31, 2020, 2019 and 2018, respectively.
®
® ®
® ®
® ®
-52-
-- 53 of 512 --
• FEHB members consist of United States government employees and their dependents within our geographic markets through our participation in the
national contract between the BCBSA and the U.S. Office of Personnel Management. FEHB business accounted for 3.8% of our medical members at
December 31, 2020 and 3.9% at both December 31, 2019 and 2018.
In addition to reporting our medical membership by customer type, we report by funding arrangement according to the level of risk that we assume in the
product contract. Our two principal funding arrangement categories are fully-insured and self-funded. Fully-insured products are products in which we indemnify
our policyholders against costs for health benefits. Self-funded products are offered to customers, generally larger employers, who elect to retain most or all of the
financial risk associated with their employees’ healthcare costs. Some self-funded customers choose to purchase stop loss coverage to limit their retained risk.
-53-
-- 54 of 512 --
The following table presents our medical membership by customer type, funding arrangement and reportable segment as of December 31, 2020, 2019 and
2018. Also included below is other membership by product. At this time, the following table does not include membership resulting from our acquisition of
Beacon. The medical membership and other membership presented are unaudited and in certain instances include estimates of the number of members represented
by each contract at the end of the period.
December 31 2020 vs. 2019 2019 vs. 2018
(In thousands) 2020 2019 2018 Change % Change Change % Change
Medical Membership
Customer Type
Local Group 15,614 15,682 15,733 (68) (0.4) % (51) (0.3) %
Individual 680 684 655 (4) (0.6) % 29 4.4 %
National:
National Accounts 7,736 7,596 7,588 140 1.8 % 8 0.1 %
BlueCard 6,059 6,060 5,838 (1) — % 222 3.8 %
Total National 13,795 13,656 13,426 139 1.0 % 230 1.7 %
Medicare:
Medicare Advantage 1,428 1,214 1,006 214 17.6 % 208 20.7 %
Medicare Supplement 933 905 846 28 3.1 % 59 7.0 %
Total Medicare 2,361 2,119 1,852 242 11.4 % 267 14.4 %
Medicaid 8,852 7,265 6,716 1,587 21.8 % 549 8.2 %
FEHB 1,623 1,594 1,556 29 1.8 % 38 2.4 %
Total Medical Membership by Customer Type 42,925 41,000 39,938 1,925 4.7 % 1,062 2.7 %
Funding Arrangement
Self-Funded 25,629 25,418 25,287 211 0.8 % 131 0.5 %
Fully-Insured 17,296 15,582 14,651 1,714 11.0 % 931 6.4 %
Total Medical Membership by Funding Arrangement 42,925 41,000 39,938 1,925 4.7 % 1,062 2.7 %
Reportable Segment
Commercial & Specialty Business 30,089 30,022 29,814 67 0.2 % 208 0.7 %
Government Business 12,836 10,978 10,124 1,858 16.9 % 854 8.4 %
Total Medical Membership by Reportable Segment 42,925 41,000 39,938 1,925 4.7 % 1,062 2.7 %
Other Membership
Life and Disability Members 5,064 5,259 4,795 (195) (3.7) % 464 9.7 %
Dental Members 6,385 6,263 5,807 122 1.9 % 456 7.9 %
Dental Administration Members 1,316 5,516 5,327 (4,200) (76.1) % 189 3.5 %
Vision Members 7,536 7,261 6,946 275 3.8 % 315 4.5 %
Medicare Part D Standalone Members 413 283 309 130 45.9 % (26) (8.4) %
December 31, 2020 Compared to December 31, 2019
Medical Membership
Total medical membership grew in both our Government Business and Commercial & Specialty Business segments as well as by funding arrangement. Fully-
insured membership increased primarily due to growth in our Medicaid and Medicare businesses, partially offset by membership decreases in our fully-insured
Local Group business. Local Group membership decreased due to negative in-group changes as a result of increased unemployment caused by the COVID-19
pandemic,
®
-54-
-- 55 of 512 --
which was partially offset by sales exceeding lapses. Self-funded medical membership increased primarily as a result of membership increases in our National
Accounts business driven by our acquisition of a third-party administrator. Medicaid membership increased primarily due to organic growth in existing markets
due to the temporary suspension of eligibility recertification during the COVID-19 pandemic as well as our acquisition of Medicaid plans
in Missouri and Nebraska in 2020. Medicare membership increased primarily due to higher sales.
Other Membership
Our other membership can be impacted by changes in our medical membership, as our medical members often purchase our other products that are ancillary to
our health business. Life and disability membership decreased due to higher lapses in our fully-insured Local Group business. Dental membership increased
primarily due to new sales and growth in our National Accounts and membership growth in our FEHB program, as well as new sales in our Individual product
offerings. Dental administration membership decreased due to the lapse of a large dental administration services contract. Vision membership increased due to
higher sales in our Medicare and Local Group businesses.
Consolidated Results of Operations
Our consolidated summarized results of operations and other information for the years ended December 31, 2020, 2019 and 2018 are as
follows:
Change
Years Ended December 31 2020 vs. 2019 2019 vs. 2018
2020 2019 2018 $ % $ %
Total operating revenue $ 120,808 $ 103,141 $ 91,341 $ 17,667 17.1 % $ 11,800 12.9 %
Net investment income 877 1,005 970 (128) (12.7)% 35 3.6 %
Net realized gains (losses) on financial instruments 182 67 (206) 115 (171.6)% 273 (132.5)%
Total revenues 121,867 104,213 92,105 17,654 16.9 % 12,108 13.1 %
Benefit expense 88,045 81,786 71,895 6,259 7.7 % 9,891 13.8 %
Cost of products sold 8,953 1,992 — 6,961 349.4 % 1,992 NM
Selling, general and administrative expense 17,450 13,364 14,020 4,086 30.6 % (656) (4.7)%
Other expense 1,181 1,086 1,122 95 8.7 % (36) (3.2)%
Total expenses 115,629 98,228 87,037 17,401 17.7 % 11,191 12.9 %
Income before income tax expense 6,238 5,985 5,068 253 4.2 % 917 18.1 %
Income tax expense 1,666 1,178 1,318 488 41.4 % (140) (10.6)%
Net income $ 4,572 $ 4,807 $ 3,750 $ (235) (4.9)% $ 1,057 28.2 %
Average diluted shares outstanding 254.3 260.3 264.2 (6.0) (2.3)% (3.9) (1.5)%
Diluted net income per share $ 17.98 $ 18.47 $ 14.19 $ (0.49) (2.7)% $ 4.28 30.2 %
Effective tax rate 26.7 % 19.7 % 26.0 % 700bp (630)bp
Benefit expense ratio 84.6 % 86.8 % 84.2 % (220)bp 260bp
Selling, general and administrative expense ratio 14.4 % 13.0 % 15.3 % 140bp (230)bp
Income before income tax expense as a percentage
of total revenues 5.1 % 5.7 % 5.5 % (60)bp 20bp
Net income as a percentage of total revenues 3.8 % 4.6 % 4.1 % (80)bp 50bp
Certain of the following definitions are also applicable to all other results of operations tables in this discussion:
NM Not meaningful.
1 Includes interest expense, amortization of other intangible assets and loss on extinguishment of debt.
2 Benefit expense ratio represents benefit expense as a percentage of premium revenue. Premiums for the years ended December 31, 2020, 2019 and 2018 were $104,109,
$94,173 and $85,421, respectively. Premiums are included in total operating revenue presented above.
1
3 3
2 3 3
4 3 3
3 3
3 3
-55-
-- 56 of 512 --
3 bp = basis point; one hundred basis points = 1%.
4 Selling, general and administrative expense ratio represents selling, general and administrative expense as a percentage of total operating revenue.
Year Ended December 31, 2020 Compared to the Year Ended December 31, 2019
Total operating revenue increased as a result of higher premium revenue due mainly to membership growth in our Government Business segment related to
our Medicaid and Medicare businesses and rate increases designed to cover the impact of the HIP Fee reinstatement for 2020. The increase in operating revenue
was further attributable to an increase in pharmacy product revenue as we completed the transition of all of our unaffiliated PBM customers to IngenioRx between
the second quarter of 2019 and January 1, 2020. The increase in operating revenue was partially offset by a decrease in premiums in our Commercial & Specialty
Business segment related to fully-insured membership declines as a result of increased unemployment caused by the COVID-19 pandemic.
Net investment income decreased primarily due to losses from other invested assets and lower yields on our short term investments. The losses on our other
invested assets were primarily due to losses from energy sector private equity funds recognized in 2020 as a result of a decrease in the worldwide demand for
energy due to the COVID-19 pandemic.
Net realized gains on financial instruments increased primarily due to the changes in the fair values of our investments in equity securities. This increase was
partially offset by a decrease in net realized gains on sales of equity securities.
Benefit expense increased primarily due to increased costs as a result of growth in our Medicaid and Medicare membership and overall cost trends across our
businesses including increased expense to cover COVID-19 related costs such as testing, treatment, expanded coverage of insurance benefits, waivers for cost-
sharing and actions taken to support our members in response to the pandemic. These increases were partially offset by the lower volume of healthcare claims
experienced resulting from decreased utilization of non-COVID-19 health services during the COVID-19 pandemic.
Our benefit expense ratio decreased primarily due to the COVID-19 impact of lower utilization rates of healthcare benefits, and to a lesser extent, the HIP Fee
reinstatement for 2020. These decreases were partially offset by increased benefit costs associated with actions taken to support our members in response to the
pandemic and COVID-19 related care. The decreases were further offset by the impact of retroactive rate adjustments in our Medicaid business and premium
credits provided in response to the COVID-19 pandemic to our members enrolled in select Individual plans and fully-insured employer customers.
Cost of products sold increased as we completed the transition of all of our unaffiliated PBM customers to IngenioRx between the second quarter of 2019,
when it began its operations, and January 1, 2020.
Selling, general and administrative expense increased primarily due to the reinstatement of the HIP Fee for 2020 and increased spend to support growth in our
businesses. The increase was further due to the recognition of expenses related to our business optimization initiatives and the BCBSA Litigation during 2020.
Our selling, general and administrative expense ratio increased as a result of the higher selling, general and administrative expenses discussed above, partially
offset by the growth in operating revenue.
Our effective income tax rate increased primarily due to the reinstatement of the non-tax deductible HIP Fee for 2020.
Our net income as a percentage of total revenue decreased as a result of all factors discussed above.
Reportable Segments Results of Operations
Beginning in 2020, IngenioRx met the quantitative thresholds for a reportable segment and the results of our operations are now described through four
reportable segments: Commercial & Specialty Business, Government Business, IngenioRx and Other. We use operating gain to evaluate the performance of our
reportable segments. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and selling, general and administrative
expense. It does not include net investment income, net realized gains (losses) on financial instruments, interest expense, amortization of other intangible assets,
loss on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of operating
segment management.
-56-
-- 57 of 512 --
The discussion of segment results presented below is based on operating gain, as described above, and operating margin, which is calculated as operating gain
divided by operating revenue. Our definition of operating gain and operating margin may not be comparable to similarly titled measures reported by other
companies. We use these measures as a basis for evaluating segment performance, allocating resources, forecasting future operating periods and setting incentive
compensation targets. This information is not intended to be considered in isolation or as a substitute for income before income tax expense, net income or EPS,
prepared in accordance with GAAP. For our 2019 segment reporting, operating gain generated from IngenioRx activities were allocated and included in our
Commercial & Specialty Business and Government Business based upon their utilization of those services, which aligns with the method by which we assessed the
2019 operating performance of our reportable segments. Beginning January 1, 2020, we are managing the operating performance of each of our segments on a
standalone basis. Prior year 2019 allocations were not restated to conform to the 2020 presentation; however, operating margins for IngenioRx were approximately
8% in 2019. For additional information, see Note 20, “Segment Information,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this
Annual Report on Form 10-K.
The following table presents a summary of our reportable segment financial information for the years ended December 31, 2020, 2019 and 2018:
Change
Years Ended December 31 2020 vs. 2019 2019 vs. 2018
2020 2019 2018 $ % $ %
Operating Revenue
Commercial & Specialty Business $ 36,699 $ 37,421 $ 35,782 $ (722) (1.9)% $ 1,639 4.6 %
Government Business 71,572 62,632 55,348 8,940 14.3 % 7,284 13.2 %
IngenioRx 21,911 5,402 — 16,509 305.6 % 5,402 NM
Other 6,057 2,293 1,519 3,764 164.2 % 774 51.0 %
Eliminations (15,431) (4,607) (1,308) (10,824) 234.9 % (3,299) 252.2 %
Total operating revenue $ 120,808 $ 103,141 $ 91,341 $ 17,667 17.1 % $ 11,800 12.9 %
Operating Gain (Loss)
Commercial & Specialty Business $ 2,681 $ 4,032 $ 3,600 (1,351) (33.5)% 432 12.0 %
Government Business 2,444 2,056 1,928 388 18.9 % 128 6.6 %
IngenioRx 1,361 — — 1,361 NM — NM
Other (126) (89) (102) (37) 41.6 % 13 (12.7)%
Operating Margin
Commercial & Specialty Business 7.3 10.8 % 10.1 % (350)bp 70bp
Government Business 3.4 3.3 % 3.5 % 10bp (20)bp
IngenioRx 6.2 — % NM NM NM
NM Not meaningful.
1 Includes expenses of $524 for the BCBSA Litigation and $311 for business optimization initiatives recognized in 2020.
2 Includes expenses of $205 for business optimization initiatives and $24 for the BCBSA Litigation recognized in 2020.
3 Includes expenses of $4 for business optimization initiatives recognized in 2020.
4 Includes expenses of $133 for business optimization initiatives recognized in 2020.
5 bp = basis point; one hundred basis points = 1%.
Year Ended December 31, 2020 Compared to the Year Ended December 31, 2019
Commercial & Specialty Business
Operating revenue decreased primarily due to fully-insured membership declines as a result of increased unemployment caused by the COVID-19 pandemic.
The decrease in operating revenue was further attributable to the absence of pharmacy
1
2
3
4
5 5
5 5
-57-
-- 58 of 512 --
administrative fee revenue that is now being recognized within the IngenioRx segment and the impact of premium credits provided to certain members in response
to the COVID-19 pandemic. These decreases were partially offset by higher premium revenue resulting from rate increases designed to cover the impact of the HIP
Fee reinstatement for 2020.
The decrease in operating gain was primarily driven by costs associated with actions taken to support our members and providers in response to the pandemic
and COVID-19 related care, as well as expenses for the BCBSA Litigation and business optimization initiatives recognized in 2020. The decrease was further
attributable to the shift of pharmacy earnings to our IngenioRx segment and the impact of premium credits provided to certain members in response to the COVID-
19 pandemic. The decrease was partially offset by the impact of the lower volume of healthcare claims attributable to decreased utilization of non-COVID-19
health services during the COVID-19 pandemic.
Government Business
Operating revenue increased primarily due to higher premium revenue as a result of membership growth in our Medicaid business driven by the temporary
suspension of eligibility recertification efforts during the COVID-19 pandemic, acquisitions and new expansions, as well as membership growth in our Medicare
business. The increase in premium revenue was further attributable to the HIP Fee reinstatement for 2020.
The increase in operating gain was primarily driven by the lower volume of healthcare claims attributable to decreased utilization of non-COVID-19 health
services during the COVID-19 pandemic. The increase was partially offset by costs associated with actions taken to support our members in response to the
pandemic and COVID-19 related care and retroactive rate adjustments and higher experience-rated refunds in our Medicaid business. The increase in operating
gain was further offset by increased spend to support growth and expenses for business optimization initiatives recognized in 2020.
IngenioRx
Operating revenue and operating gain increased as a result of the transition of our existing members to IngenioRx, which commenced its operations during the
second quarter of 2019. Operating revenue represents product revenues from services performed for our fully-insured affiliated health plans and self-funded
customers and external customers outside of the health plans we own. Product revenues and cost of goods sold for our fully-insured affiliated health plan customers
are eliminated in consolidation. Operating gain represents operating revenue less cost of products sold and selling, general and administrative expenses.
Other
Operating revenue increased due to our acquisition of Beacon in February 2020 and higher administrative fees and other revenue from services performed by
DBG in certain markets.
The increase in operating loss was driven by expenses recognized for our business optimization initiatives.
Critical Accounting Policies and Estimates
We prepare our consolidated financial statements in conformity with GAAP. Application of GAAP requires management to make estimates and assumptions
that affect the amounts reported in our consolidated financial statements and accompanying notes and within this MD&A. We consider our most important
accounting policies that require significant estimates and management judgment to be those policies with respect to liabilities for medical claims payable, income
taxes, goodwill and other intangible assets, investments and retirement benefits, which are discussed below. Our other significant accounting policies are
summarized in Note 2, “Basis of Presentation and Significant Accounting Policies,” of the Notes to Consolidated Financial Statements included in Part II, Item 8
of this Annual Report on Form 10-K.
We continually evaluate the accounting policies and estimates used to prepare the consolidated financial statements. In general, our estimates are based on
historical experience, evaluation of current trends, information from third-party professionals and various other assumptions that we believe to be reasonable under
the known facts and circumstances. Estimates can require a significant amount of judgment, and a different set of assumptions could result in material changes to
our reported results.
-58-
-- 59 of 512 --
Medical Claims Payable
The most subjective accounting estimate in our consolidated financial statements is our liability for medical claims payable. At December 31, 2020, this
liability was $11,359 and represented 21% of our total consolidated liabilities. We record this liability and the corresponding benefit expense for incurred but not
paid claims, including the estimated costs of processing such claims. Incurred but not paid claims include (1) an estimate for claims that are incurred but not
reported, as well as claims reported to us but not yet processed through our systems, which approximated 96%, or $10,925, of our total medical claims liability as
of December 31, 2020; and (2) claims reported to us and processed through our systems but not yet paid, which approximated 4%, or $434, of the total medical
claims payable as of December 31, 2020. The level of claims payable processed through our systems but not yet paid may fluctuate from one period-end to the
next, from approximately 1% to 5% of our total medical claims liability, due to timing of when claim payments are made.
Liabilities for both claims incurred but not reported and reported but not yet processed through our systems are determined in the aggregate, employing
actuarial methods that are commonly used by health insurance actuaries and meet Actuarial Standards of Practice. Actuarial Standards of Practice require that the
claim liabilities be appropriate under moderately adverse circumstances. We determine the amount of the liability for incurred but not paid claims by following a
detailed actuarial process that uses both historical claim payment patterns as well as emerging medical cost trends to project our best estimate of claim liabilities.
Under this process, historical paid claims data is formatted into “claim triangles,” which compare claim incurred dates to the dates of claim payments. This
information is analyzed to create “completion factors” that represent the average percentage of total incurred claims that have been paid through a given date after
being incurred. Completion factors are applied to claims paid through the period-end date to estimate the ultimate claim expense incurred for the period. Actuarial
estimates of incurred but not paid claim liabilities are then determined by subtracting the actual paid claims from the estimate of the ultimate incurred claims.
For the most recent incurred months (typically the most recent two months), the percentage of claims paid for claims incurred in those months is generally
low. This makes the completion factor methodology less reliable for such months. Therefore, incurred claims for recent months are not projected from historical
completion and payment patterns; rather, they are projected by estimating the claims expense for those months based on recent claims expense levels and
healthcare trend levels (“trend factors”).
Because the reserve methodology is based upon historical information, it must be adjusted for known or suspected operational and environmental changes.
These adjustments are made by our actuaries based on their knowledge and their estimate of emerging impacts to benefit costs and payment speed. Circumstances
to be considered in developing our best estimate of reserves include changes in utilization levels, unit costs, mix of business, benefit plan designs, provider
reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, claim submission patterns and operational
changes resulting from business combinations. A comparison of prior period liabilities to re-estimated claim liabilities based on subsequent claims development is
also considered in making the liability determination. In our comparison to prior periods, the methods and assumptions are not changed as reserves are
recalculated; rather, the availability of additional paid claims information drives changes in the re-estimate of the unpaid claim liability. To the extent appropriate,
changes in such development are recorded as a change to current period benefit expense. The impact from COVID-19 on healthcare utilization and medical claims
submission patterns has increased estimation uncertainty on our incurred but not reported liability at December 31, 2020. Slowdowns in claims submission patterns
and increases in utilization levels for COVID-19 testing and treatment during the fourth quarter of 2020 are the primary factors that lead to the increased estimation
uncertainty.
We regularly review and set assumptions regarding cost trends and utilization when initially establishing claim liabilities. We continually monitor and adjust
the claims liability and benefit expense based on subsequent paid claims activity. If it is determined that our assumptions regarding cost trends and utilization are
materially different than actual results, our income statement and financial position could be impacted in future periods. Adjustments of prior year estimates may
result in additional benefit expense or a reduction of benefit expense in the period an adjustment is made. Further, due to the considerable variability of healthcare
costs, adjustments to claim liabilities occur each period and are sometimes significant as compared to the net income recorded in that period. Prior period
development is recognized immediately upon the actuary’s judgment that a portion of the prior period liability is no longer needed or that an additional liability
should have been accrued. That determination is made when sufficient information is available to ascertain that the re-estimate of the liability is reasonable.
-59-
-- 60 of 512 --
While there are many factors that are used as a part of the estimation of our medical claims payable liability, the two key assumptions having the most
significant impact on our incurred but not paid claims liability as of December 31, 2020 were the completion and trend factors. As discussed above, these two key
assumptions can be influenced by utilization levels, unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions
and changes, claim inventory levels, claim processing patterns, claim submission patterns and operational changes resulting from business combinations.
There is variation in the reasonable choice of completion factors by duration for durations of three months through twelve months where the completion
factors have the most significant impact. As previously discussed, completion factors tend to be less reliable for the most recent months and therefore are not
specifically utilized for months one and two. In our analysis for the claim liabilities at December 31, 2020, the variability in months three to five was estimated to
be between 40 and 90 basis points, while months six through twelve have much lower estimated variability ranging from 0 to 30 basis points.
The difference in completion factor assumptions, assuming moderately adverse experience, results in variability of 2%, or approximately $204, in the
December 31, 2020 incurred but not paid claims liability, depending on the completion factors chosen. It is important to note that the completion factor
methodology inherently assumes that historical completion rates will be reflective of the current period. However, it is possible that the actual completion rates for
the current period will develop differently from historical patterns and therefore could fall outside the possible variations described herein.
The other major assumption used in the establishment of the December 31, 2020 incurred but not paid claim liability was the trend factors. In our analysis for
the period ended December 31, 2020, there was a 320 basis point differential in the high and low trend factors assuming moderately adverse experience. This range
of trend factors would imply variability of 4%, or approximately $427, in the incurred but not paid claims liability, depending upon the trend factors used. Because
historical trend factors are often not representative of current claim trends, the trend experience for the most recent six to nine months, plus knowledge of recent
events likely affecting current trends, have been taken into consideration in establishing the incurred but not paid claims liability at December 31, 2020. The
COVID-19 pandemic continues to have a significant impact on 2020 dates of service. Our expenses associated with COVID-19 accelerated in the fourth quarter of
2020 and exceeded the benefit from lower volume of healthcare claims attributable to decreased utilization of non-COVID-19 health services. We will continue to
monitor emerging experience in order to better understand the possible implications to our reserves.
See Note 12, “Medical Claims Payable,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K,
for a reconciliation of the beginning and ending balance for medical claims payable for the years ended December 31, 2020, 2019 and 2018. Components of the
total incurred claims for each year include amounts accrued for current year estimated claims expense as well as adjustments to prior year estimated accruals. In
Note 12, “Medical Claims Payable,” the line labeled “Net incurred medical claims: Prior years redundancies” accounts for those adjustments made to prior year
estimates. The impact of any reduction of “Net incurred medical claims: Prior years redundancies” may be offset as we establish the estimate of “Net incurred
medical claims: Current year.” Our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for our claims. When we
recognize a release of the redundancy, we disclose the amount that is not in the ordinary course of business, if material.
The ratio of current year medical claims paid as a percent of current year net medical claims incurred was 87.7% for 2020, 89.3% for 2019 and 90.2% for
2018. This ratio serves as an indicator of claims processing speed whereby 2020 claims were processed at a slower speed than in 2019 and 2018.
We calculate the percentage of prior year redundancies in the current year as a percent of prior year net incurred claims payable less prior year redundancies in
the current year in order to demonstrate the development of the prior year reserves. For the year ended December 31, 2020, this metric was 8.0%, largely driven by
favorable trend factor development at the end of 2019 as well as favorable completion factor development from 2019. For the year ended December 31, 2019, this
metric was 7.4%, largely driven by favorable trend factor development at the end of 2018 as well as favorable completion factor development from 2018. For the
year ended December 31, 2018, this metric was 13.7%, largely driven by favorable trend factor development at the end of 2017 as well as favorable completion
factor development from 2017.
We calculate the percentage of prior year redundancies in the current year as a percent of prior year net incurred medical claims to indicate the percentage of
redundancy included in the preceding year calculation of current year net incurred
-60-
-- 61 of 512 --
medical claims. We believe this calculation supports the reasonableness of our prior year estimate of incurred medical claims and the consistency in our
methodology. For the year ended December 31, 2020, this metric was 0.8%, which was calculated using the redundancy of $637. This metric was 0.7% for 2019
and 1.3% for 2018. We believe these metrics demonstrate an appropriate level of reserve conservatism.
The following table shows the variance between total net incurred medical claims as reported in Note 12, “Medical Claims Payable,” of the Notes to
Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K, for each of 2019 and 2018 and the incurred claims for such
years had it been determined retrospectively (computed as the difference between “net incurred medical claims – current year” for the year shown and “net
incurred medical claims – prior years redundancies” for the immediately following year):
Years Ended December 31
2019 2018
Total net incurred medical claims, as reported $ 78,195 $ 68,651
Retrospective basis, as described above 78,058 69,081
Variance $ 137 $ (430)
Variance to total net incurred medical claims, as reported 0.2 % (0.6)%
Given that our business is primarily short tailed (which means that medical claims are generally paid within twelve months of the member receiving service
from the provider), the variance to total net incurred medical claims, as reported above, is used to assess the reasonableness of our estimate of ultimate incurred
medical claims for a given calendar year with the benefit of one year of experience. We expect that substantially all of the development of the 2020 estimate of
medical claims payable will be known during 2021.
The 2019 variance to total net incurred medical claims, as reported of 0.2% was greater than the 2018 percentage of (0.6)%. This was driven by the fact that
the change in the prior year redundancy reported for 2020 as compared to 2019 was greater than the change in the prior year redundancy reported for 2019 as
compared to 2018.
Income Taxes
We account for income taxes in accordance with the Financial Accounting Standards Board (“FASB”) guidance, which requires, among other things, the
separate recognition of deferred tax assets and deferred tax liabilities. Such deferred tax assets and deferred tax liabilities represent the tax effect of temporary
differences between financial reporting and tax reporting measured at tax rates enacted at the time the deferred tax asset or liability is recorded. A valuation
allowance must be established for deferred tax assets if it is “more likely than not” that all or a portion may be unrealized. Our judgment is required in determining
an appropriate valuation allowance.
At each financial reporting date, we assess the adequacy of the valuation allowance by evaluating each of our deferred tax assets based on the following:
• the types of temporary differences that created the deferred tax asset;
• the amount of taxes paid in prior periods and available for a carry-back claim;
• the tax rate at which the deferred tax assets will likely be utilized in the future;
• the forecasted future taxable income, and therefore, likely future deduction of the deferred tax item; and
• any significant other issues impacting the likely realization of the benefit of the temporary differences.
We, like other companies, frequently face challenges from tax authorities regarding the amount of taxes due. These challenges include questions regarding the
timing and amount of deductions that we have taken on our tax returns. In evaluating any additional tax liability associated with various positions taken in our tax
return filings, we record additional liabilities for potential adverse tax outcomes. Based on our evaluation of our tax positions, we believe we have appropriately
accrued for uncertain tax benefits, as required by the applicable guidance. To the extent we prevail in matters we have accrued for, our future effective tax rate
would be reduced and net income would increase. If we are required to pay more
-61-
-- 62 of 512 --
than accrued, our future effective tax rate would increase and net income would decrease. Our effective tax rate and net income in any given future period could be
materially impacted.
In the ordinary course of business, we are regularly audited by federal and other tax authorities, and from time to time, these audits result in proposed
assessments. We believe our tax positions comply with applicable tax law, and we intend to defend our positions vigorously through the federal, state and local
appeals processes. We believe we have adequately provided for any reasonably foreseeable outcome related to these matters. Accordingly, although their ultimate
resolution may require additional tax payments, we do not anticipate any material impact on our results of operations or financial condition from these matters.
For additional information, see Note 8, “Income Taxes,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on
Form 10-K.
Goodwill and Other Intangible Assets
Our consolidated goodwill at December 31, 2020 was $21,691 and other intangible assets were $9,405. The sum of goodwill and other intangible assets
represented 35.9% of our total consolidated assets and 93.7% of our consolidated shareholders’ equity at December 31, 2020.
We follow FASB guidance for business combinations and goodwill and other intangible assets, which specifies the types of acquired intangible assets that are
required to be recognized and reported separately from goodwill. Under the guidance, goodwill and other intangible assets (with indefinite lives) are not amortized
but are tested for impairment at least annually. Furthermore, goodwill and other intangible assets are allocated to reporting units for purposes of the annual
impairment test. Our impairment tests require us to make assumptions and judgments regarding the estimated fair value of our reporting units, which include
goodwill and other intangible assets. In addition, certain other intangible assets with indefinite lives, such as trademarks, are also tested separately.
We complete our annual impairment tests of existing goodwill and other intangible assets with indefinite lives during the fourth quarter of each year. These
tests involve the use of estimates related to the fair value of goodwill at the reporting unit level and other intangible assets with indefinite lives, and require a
significant degree of management judgment and the use of subjective assumptions. Certain interim impairment tests are also performed when potential impairment
indicators exist or changes in our business or other triggering events occur. We have the option of first performing a qualitative assessment for each reporting unit
to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, which is an indication that our goodwill may
be impaired. These qualitative impairment tests include assessing events and factors that could affect the fair value of the indefinite-lived intangible assets. Our
procedures include assessing our financial performance, macroeconomic conditions, industry and market considerations, various asset specific factors and entity
specific events. If we determine that a reporting unit’s goodwill may be impaired after utilizing these qualitative impairment analysis procedures, we are required
to perform a quantitative impairment test.
Our quantitative impairment test utilizes the projected income and market valuation approaches for goodwill and the projected income approach for our
indefinite lived intangible assets. Use of the projected income and market valuation approaches for our goodwill impairment test reflects our view that both
valuation methodologies provide a reasonable estimate of fair value. The projected income approach is developed using assumptions about future revenue,
expenses and net income derived from our internal planning process. These estimated future cash flows are then discounted. Our assumed discount rate is based on
our industry’s weighted-average cost of capital. Market valuations are based on observed multiples of certain measures including revenue; earnings before interest,
taxes, depreciation and amortization; and book value of invested capital (debt and equity) and include market comparisons to publicly traded companies in our
industry.
We did not incur any impairment losses as a result of our 2020 annual impairment tests, as it was determined that it is more likely than not that the estimated
fair values of our reporting units were substantially in excess of the carrying values as of December 31, 2020. Additionally, we do not believe that the estimated
fair values of our reporting units are at risk of becoming impaired in the next twelve months.
If estimated fair values are less than the carrying values of goodwill and other intangibles with indefinite lives in future annual impairment tests, or if
significant impairment indicators are noted relative to other intangible assets subject to amortization, we may be required to record impairment losses against future
income.
-62-
-- 63 of 512 --
For additional information, see Note 3, “Business Acquisitions” and Note 10, “Goodwill and Other Intangible Assets,” of the Notes to Consolidated Financial
Statements included in Part II, Item 8 of this Annual Report on Form 10-K.
Investments
Current and long-term marketable investment securities were $25,554 at December 31, 2020 and represented 29.5% of our total consolidated assets at
December 31, 2020. We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed
maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual
maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.
Our impairment review is subjective and requires a high degree of judgment. We conduct this review on a quarterly basis, using both qualitative and
quantitative factors. Such factors considered include the extent to which a security’s market value has been less than its cost, the reasons for the decline in value
(i.e., credit event compared to liquidity, general credit spread widening, currency exchange rate or interest rate factors), financial condition and near term prospects
of the issuer, including the credit ratings and changes in the credit ratings of the issuer, recommendations of investment advisors, and forecasts of economic,
market or industry trends.
Prior to 2020, our fixed maturity securities were evaluated for other-than-temporary impairment where credit-related impairments were presented within the
other-than-temporary impairment losses recognized in our consolidated statements of income with an adjustment to the security’s amortized cost basis. Effective
January 1, 2020, if a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not
that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value
and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely
than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the
impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-
credit component of the impairment is recognized in accumulated other comprehensive income. Furthermore, unrealized losses entirely caused by non-credit-
related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other
comprehensive income.
The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost
basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate
implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions
regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and
changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and
estimates regarding timing and amount of recoveries associated with a default.
We have a committee of accounting and investment associates and management that is responsible for managing the impairment review process. We believe
we have adequately reviewed our investment securities for impairment and that our investment securities are carried at fair value. We have established an
allowance for credit loss and recorded credit loss expense as a reflection of our expected impairment losses. Given the inherent uncertainty of changes in market
conditions and the significant judgments involved, there is continuing risk that declines in fair value may occur and additional impairment losses on investments
may be recorded in future periods.
In addition to marketable investment securities, we held additional long-term investments of $4,285, or 4.9% of total consolidated assets, at December 31,
2020. These long-term investments consisted primarily of certain other equity investments, the cash surrender value of corporate-owned life insurance policies and
real estate. Due to their less liquid nature, these investments are classified as long-term.
The COVID-19 pandemic and efforts to prevent its spread have significantly impacted the global economy, causing market instability and declines in the fair
value of our investment holdings in the energy sector and consumer-driven
-63-
-- 64 of 512 --
industries such as travel, entertainment and retail. While the markets have stabilized since the onset of the COVID-19 pandemic, the extent and length of the
recovery remain uncertain. Further, the energy sector and consumer-driven industries remain distressed. Given this market uncertainty, there is a risk that our
investments that have declined may not recover in future periods.
Through our investing activities, we are exposed to financial market risks, including those resulting from changes in interest rates and changes in equity
market valuations. We manage market risks through our investment policy, which establishes credit quality limits and limits on investments in individual issuers.
Ineffective management of these risks could have an impact on our future results of operations and financial condition. Our investment portfolio includes fixed
maturity securities with a fair value of $23,995 at December 31, 2020. The weighted-average credit rating of these securities was “A” as of December 31, 2020.
Included in this balance are investments in fixed maturity securities of states, municipalities and political subdivisions of $1,010 that are guaranteed by third
parties. With the exception of twenty-one securities with a fair value of $34, these securities are all investment-grade and carry a weighted-average credit rating of
“AA” as of December 31, 2020. The securities are guaranteed by a number of different guarantors, and we do not have any material exposure to any single
guarantor, neither indirectly through the guarantees, nor directly through investment in the guarantor. Further, due to the high underlying credit rating of the
issuers, the weighted-average credit rating of the fixed maturity securities without a guarantee, for which such information is available, was “A” as of
December 31, 2020.
Fair values of fixed maturity and equity securities are based on quoted market prices, where available. These fair values are obtained primarily from third-
party pricing services, which generally use Level I or Level II inputs for the determination of fair value in accordance with FASB guidance for fair value
measurements and disclosures. We have controls in place to review the pricing services’ qualifications and procedures used to determine fair values. In addition,
we periodically review the pricing services’ pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable.
We obtain quoted market prices for each security from the pricing services, which are derived through recently reported trades for identical or similar
securities, making adjustments through the reporting date based upon available market observable information. For securities not actively traded, the pricing
services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the
markets for similar securities. Inputs that are often used in these valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit
spreads, default rates and prepayment speeds. As we are responsible for the determination of fair value, we perform analysis on the prices received from the pricing
services to determine whether the prices are reasonable estimates of fair value. Our analysis includes procedures such as a review of month-to-month price
fluctuations and price comparisons to secondary pricing services. There were no adjustments to quoted market prices obtained from the pricing services during the
years ended December 31, 2020 and 2019.
In certain circumstances, it may not be possible to derive pricing model inputs from observable market activity, and therefore, such inputs are estimated
internally. Such securities are designated Level III in accordance with FASB guidance. Securities designated Level III at December 31, 2020 totaled $392 and
represented approximately 1.3% of our total assets measured at fair value on a recurring basis. Our Level III securities primarily consisted of certain corporate
securities and equity securities for which observable inputs were not always available and the fair values of these securities were estimated using inputs including,
but not limited to, prepayment speeds, credit spreads, default rates and benchmark yields.
For additional information, see Part II, Item 7A, “Quantitative and Qualitative Disclosures about Market Risk,” and Note 2, “Basis of Presentation and
Significant Accounting Policies,” Note 5, “Investments,” and Note 7, “Fair Value,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of
this Annual Report on Form 10-K.
Retirement Benefits
Pension Benefits
We sponsor defined benefit pension plans for some of our employees. These plans are accounted for in accordance with FASB guidance for retirement
benefits, which requires that amounts recognized in financial statements be determined on an actuarial basis. As permitted by the guidance, we calculate the value
of plan assets as described below. Further, the difference between our expected rate of return and the actual performance of plan assets, as well as certain changes
in pension liabilities, are amortized over future periods.
-64-
-- 65 of 512 --
An important factor in determining our pension expense is the assumption for expected long-term return on plan assets. As of our December 31, 2020
measurement date, we selected a weighted-average long-term rate of return on plan assets of 6.72%. We use a total portfolio return analysis in the development of
our assumption. Factors such as past market performance, the long-term relationship between fixed maturity and equity securities, interest rates, inflation and asset
allocations are considered in the assumption. The assumption includes an estimate of the additional return expected from active management of the investment
portfolio. Peer data and an average of historical returns are also reviewed for appropriateness of the selected assumption. We believe our assumption of future
returns is reasonable. However, if we lower our expected long-term return on plan assets, future contributions to the pension plan and pension expense would likely
increase.
This assumed long-term rate of return on assets is applied to a calculated value of plan assets, which recognizes changes in the fair value of plan assets in a
systematic manner over three years, producing the expected return on plan assets that is included in the determination of pension expense. We apply a corridor
approach to amortize unrecognized actuarial gains or losses. Under this approach, only accumulated net actuarial gains or losses in excess of 10% of the greater of
the projected benefit obligation or the fair value of plan assets are amortized over the average remaining service or lifetime of the workforce as a component of
pension expense. The net deferral of past asset gains or losses affects the calculated value of plan assets and, ultimately, future pension expense.
The discount rate reflects the current rate at which the pension liabilities could be effectively settled at the end of the year based on our most recent
measurement date. We use the annual spot rate approach for setting our discount rate. Under the spot rate approach, individual spot rates from a full yield curve of
published rates are used to discount each plan’s cash flows to determine the plan’s obligation. At the December 31, 2020 measurement date, the weighted-average
discount rate under the annual spot rate approach was 2.24%, compared to 3.11% at the December 31, 2019 measurement date. The net effect of changes in the
discount rate, as well as the net effect of other changes in actuarial assumptions and experience, have been deferred and amortized as a component of pension
expense in accordance with FASB guidance.
In managing the plan assets, our objective is to be a responsible fiduciary while minimizing financial risk. Plan assets include a diversified mix of equity
securities, investment grade fixed maturity securities and other types of investments across a range of sectors and levels of capitalization to maximize long-term
return for a prudent level of risk. In addition to producing a reasonable return, the investment strategy seeks to minimize the volatility in our expense and cash
flow.
Effective January 1, 2019, we curtailed the benefits under the Anthem Cash Balance Plan B pension plan. All grandfathered participants no longer have pay
credits added to their accounts, but continue to earn interest on existing account balances. Participants continue to earn years of pension service for vesting
purposes.
Other Postretirement Benefits
We provide most associates with certain medical, vision and dental benefits upon retirement. We use various actuarial assumptions, including a discount rate
and the expected trend in healthcare costs, to estimate the costs and benefit obligations for our retiree benefits.
At our December 31, 2020 measurement date, the selected discount rate for all plans was 1.99%, compared to a discount rate of 2.93% at the December 31,
2019 measurement rate. We developed this rate using the annual spot rate approach as described above.
The assumed healthcare cost trend rates used to measure the expected cost of pre-Medicare (those who are not currently eligible for Medicare benefits) other
benefits at our December 31, 2020 measurement date was 7.00% for 2021 with a gradual decline to 4.50% by the year 2033. The assumed healthcare cost trend
rates used to measure the expected cost of post-Medicare (those who are currently eligible for Medicare benefits) other benefits at our December 31, 2020
measurement date was 5.50% for 2021 with a gradual decline to 4.50% by the year 2033. These estimated trend rates are subject to change in the future.
For additional information regarding our retirement benefits, see Note 11, “Retirement Benefits,” of the Notes to Consolidated Financial Statements included
in Part II, Item 8 of this Annual Report on Form 10-K.
-65-
-- 66 of 512 --
New Accounting Pronouncements
For information regarding new accounting pronouncements that were issued or became effective during the year ended December 31, 2020 that had, or are
expected to have, a material impact on our financial position, results of operations or financial statement disclosures, see the “Recently Adopted Accounting
Guidance” and “Recent Accounting Guidance Not Yet Adopted” sections of Note 2, “Basis of Presentation and Significant Accounting Policies,” of the Notes to
Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.
Liquidity and Capital Resources
Introduction
Our cash receipts result primarily from premiums, product revenue, administrative fees and other revenue, investment income, proceeds from the sale or
maturity of our investment securities, proceeds from borrowings, and proceeds from the issuance of common stock under our employee stock plans. Cash
disbursements result mainly from claims payments, administrative expenses, taxes, purchases of investment securities, interest expense, payments on borrowings,
acquisitions, capital expenditures, repurchases of our debt securities and common stock and the payment of cash dividends. Cash outflows fluctuate with the
amount and timing of settlement of these transactions. Any future decline in our profitability would likely have an unfavorable impact on our liquidity.
The COVID-19 pandemic and the related mitigation efforts have significantly impacted the economy, causing market instability and increasing unemployment
in the United States. While the full impact of COVID-19 on our business remains uncertain, it could have a material adverse effect on our claim payments,
collection of our premiums, product or administrative fee revenues, our investments and our ability to access credit. Additional discussion regarding the impact of
COVID-19 can be found elsewhere in this MD&A.
We manage our cash, investments and capital structure so we are able to meet the short-term and long-term obligations of our business while maintaining
financial flexibility and liquidity. We forecast, analyze and monitor our cash flows to enable investment and financing within the overall constraints of our
financial strategy.
To preserve our liquidity and financial flexibility and to minimize the effects of the COVID-19 pandemic, we proactively took several actions during 2020,
including borrowing under our senior revolving credit facility in March 2020, which was repaid in April 2020; delaying certain tax payments as permitted by the
IRS and the CARES Act; and temporarily suspending our share repurchase activity in March 2020, which was resumed in late June 2020. We may take additional
actions going forward to maximize our liquidity, including increasing our borrowings from existing or new Federal Home Loan Bank memberships and other
available borrowings. We will continue to monitor the market conditions and seek to act in a prudent manner.
A substantial portion of the assets held by our regulated subsidiaries are in the form of cash and cash equivalents and investments. After considering expected
cash flows from operating activities, we generally invest cash that exceeds our near term obligations in longer term marketable fixed maturity securities to improve
our overall investment income returns. Our investment strategy is to make investments consistent with insurance statutes and other regulatory requirements, while
preserving our asset base. Our investments are generally available-for-sale to meet liquidity and other needs. Our subsidiaries pay out excess capital annually in the
form of dividends to their respective parent companies for general corporate use, as permitted by applicable regulations.
The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, debt
ratings, contractual restrictions, regulatory requirements and market conditions. The securities and credit markets have in the past experienced higher than normal
volatility, although current market conditions are more stable. During recent years, the federal government and various governmental agencies have taken a number
of steps to strengthen the regulation of the financial services market. In addition, governments around the world have developed their own plans to provide stability
and security in the credit markets and to ensure adequate capital in certain financial institutions. Further, in response to the COVID-19 pandemic, the federal
government has established a number of programs to provide liquidity to the financial system that provides lending to states, municipalities, and eligible
businesses.
-66-
-- 67 of 512 --
A summary of our major sources and uses of cash and cash equivalents for the years ended December 31, 2020, 2019 and 2018 is as follows:
Years Ended December 31 $ Change
2020 2019 2018 2020 vs. 2019 2019 vs. 2018
Sources of Cash:
Net cash provided by operating activities $ 10,688 $ 6,061 $ 3,827 $ 4,627 $ 2,234
Proceeds from sales, maturities, calls and redemptions of investments, net of
purchases — — 1,929 — (1,929)
Issuance of common stock under Equity Units stock purchase contracts — — 1,250 — (1,250)
Issuances of commercial paper and short- and long-term debt, net of repayments — 608 — (608) 608
Issuances of common stock under employee stock plans 176 187 173 (11) 14
Other sources of cash, net 315 — — 315 —
Total sources of cash 11,179 6,856 7,179 4,323 (323)
Uses of Cash:
Purchases of investments, net of proceeds from sales, maturities, calls and
redemptions (3,433) (1,919) — (1,514) (1,919)
Repurchase and retirement of common stock (2,700) (1,701) (1,685) (999) (16)
Purchases of subsidiaries, net of cash acquired (1,976) — (1,760) (1,976) 1,760
Purchases of property and equipment (1,021) (1,077) (1,208) 56 131
Repayments of commercial paper and short- and long-term debt, net of issuances (298) — (1,086) (298) 1,086
Cash dividends (954) (818) (776) (136) (42)
Other uses of cash, net — (338) (337) 338 (1)
Total uses of cash (10,382) (5,853) (6,852) (4,529) 999
Effect of foreign exchange rates on cash and cash equivalents 7 — (2) 7 2
Net increase in cash and cash equivalents $ 804 $ 1,003 $ 325 $ (199) $ 678
Liquidity—Year Ended December 31, 2020 Compared to Year Ended December 31, 2019
The increase in cash provided by operating activities was primarily due to the impact of the timing of working capital changes. The increase was further due to
membership growth in our Government Business segment and higher net income in 2020, excluding the non-cash impact of accrued expenses related to our
business optimization initiatives and the BCBSA Litigation.
Other significant changes in sources and uses of cash year-over-year included increases in cash used for acquisitions, net purchases of investments and cash
used for repurchase and retirement of common stock.
Financial Condition
We maintained a strong financial condition and liquidity position, with consolidated cash, cash equivalents and investments in fixed maturity and equity
securities of $31,295 at December 31, 2020. Since December 31, 2019, total cash, cash equivalents and investments in fixed maturity and equity securities
increased by $5,168, primarily due to cash generated from operations. This increase was partially offset by cash used for common stock repurchases, acquisitions,
purchases of property and equipment and cash dividends paid to shareholders.
Many of our subsidiaries are subject to various government regulations that restrict the timing and amount of dividends and other distributions that may be
paid to their respective parent companies. Certain accounting practices prescribed by insurance regulatory authorities, or statutory accounting practices, differ from
GAAP. Changes that occur in statutory accounting practices, if any, could impact our subsidiaries’ future dividend capacity. In addition, we have agreed to certain
-67-
-- 68 of 512 --
undertakings to regulatory authorities, including the requirement to maintain certain capital levels in certain of our subsidiaries.
At December 31, 2020, we held $1,747 of cash, cash equivalents and investments at the parent company, which are available for general corporate use,
including investment in our businesses, acquisitions, potential future common stock repurchases and dividends to shareholders, repurchases of debt securities and
debt and interest payments.
Debt
Periodically, we access capital markets and issue debt (“Notes”) for long-term borrowing purposes, for example, to refinance debt, to finance acquisitions or
for share repurchases. Certain of these Notes may have a call feature that allows us to redeem the Notes at any time at our option and/or a put feature that allows a
Note holder to redeem the Notes upon the occurrence of both a change in control event and a downgrade of the Notes below an investment grade rating. For more
information on our debt, including redemptions and issuances, see Note 13, “Debt” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of
this Annual Report on Form 10-K.
We calculate our consolidated debt-to-capital ratio, a non-GAAP measure, from the amounts presented on our audited consolidated balance sheets included in
Part II, Item 8 of this Annual Report on Form 10-K. Our debt-to-capital ratio is calculated as total debt divided by total debt plus total shareholders’ equity. Total
debt is the sum of short-term borrowings, current portion of long-term debt, long-term debt, less current portion, and lease liabilities. We believe our debt-to-
capital ratio assists investors and rating agencies in measuring our overall leverage and additional borrowing capacity. In addition, our bank covenants include a
maximum debt-to-capital ratio that we cannot and did not exceed. Our debt-to-capital ratio may not be comparable to similarly titled measures reported by other
companies. Our consolidated debt-to-capital ratio was 38.7% and 39.5% as of December 31, 2020 and 2019, respectively.
Our senior debt is rated “A” by S&P Global, “BBB” by Fitch Ratings, Inc., “Baa2” by Moody’s Investor Service, Inc. and “bbb+” by AM Best Company, Inc.
We intend to maintain our senior debt investment grade ratings. If our credit ratings are downgraded, our business, financial condition and results of operations
could be adversely impacted by limitations on future borrowings and a potential increase in our borrowing costs.
Future Sources and Uses of Liquidity
We have a shelf registration statement on file with the SEC to register an unlimited amount of any combination of debt or equity securities in one or more
offerings. Specific information regarding terms and securities being offered will be provided at the time of an offering. Proceeds from future offerings are expected
to be used for general corporate purposes, including, but not limited to, the repayment of debt, investments in or extensions of credit to our subsidiaries and the
financing of possible acquisitions or business expansions.
We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes. In June 2019, we amended and
restated the credit agreement for the 5-Year Facility to, among other things, extend the maturity date from August 2020 to June 2024 and decrease the amount of
credit available from $3,500 to $2,500. In June 2019, we also entered into a 364-day senior revolving credit facility (the “364-Day Facility”) with a group of
lenders for general corporate purposes, which provides for credit in the amount of $1,000. In May 2020, we amended and extended the 364-Day Facility, which
now matures in June 2021. Our ability to borrow under these credit facilities is subject to compliance with certain covenants. We do not believe the restrictions
contained in these covenants materially affect our financial or operating flexibility. As of December 31, 2020, we were in compliance with all of our debt
covenants. There were no amounts outstanding under the 5-Year Facility or the 364-Day Facility at December 31, 2020.
Through certain subsidiaries, we have entered into multiple 364-day lines of credit (the “Subsidiary Credit Facilities”) with separate lenders for general
corporate purposes. The Subsidiary Credit Facilities provide combined credit up to $300. Our ability to borrow under the Subsidiary Credit Facilities is subject to
compliance with certain covenants. At December 31, 2020, we had no outstanding borrowings under the Subsidiary Credit Facilities.
We have a $3,500 commercial paper program, the proceeds of which may be used for general corporate purposes. Should commercial paper issuance be
unavailable, we have the ability to use a combination of cash on hand and/or our two senior revolving credit facilities, which provide for combined credit in the
amount of $3,500, to redeem any outstanding commercial
-68-
-- 69 of 512 --
paper upon maturity. While there is no assurance in the current economic environment, we believe the lenders participating in our credit facilities, if market
conditions allow, would be willing to provide financing in accordance with their legal obligations. At December 31, 2020, we had $250 outstanding under our
commercial paper program.
We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal
Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York, collectively (the “FHLBs”). As a member, we have the ability to obtain short-term
cash advances, subject to certain minimum collateral requirements. At December 31, 2020, we had no outstanding short-term borrowings from the FHLBs.
As discussed in “Financial Condition” above, many of our subsidiaries are subject to various government regulations that restrict the timing and amount of
dividends and other distributions that may be paid. Based upon these requirements, we currently estimate that approximately $2,505 of dividends will be paid to
the parent company during 2021. During 2020, we received $3,618 of dividends from our subsidiaries.
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The
declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial
condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
On January 26, 2021, our Audit Committee declared a quarterly cash dividend to shareholders of $1.13 per share on the outstanding shares of our common
stock. This quarterly dividend is payable on March 25, 2021 to the shareholders of record as of March 10, 2021.
Under our Board of Directors’ authorization, we maintain a common stock repurchase program. As of December 31, 2020, we had Board authorization of
$1,092 to repurchase our common stock. On January 26, 2021, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a
$5,000 increase to our common stock repurchase program.
For additional information regarding our sources and uses of capital, see Note 5, “Investments,” Note 6, “Derivative Financial Instruments,” Note 13, “Debt”
and Note 15, “Capital Stock–Use of Capital–Dividends and Stock Repurchase Program” of the Notes to Consolidated Financial Statements included in Part II,
Item 8 of this Annual Report on Form 10-K.
Contractual Obligations and Commitments
Our estimated contractual obligations and commitments as of December 31, 2020 are as follows:
Payments Due by Period
Total
Less than
1 Year 1-3 Years 3-5 Years
More than
5 Years
On-Balance Sheet:
Debt $ 31,066 $ 1,679 $ 3,953 $ 17,641 $ 7,793
Operating leases, including imputed interest 982 197 336 213 236
Investment commitments 20 11 7 1 1
Other long-term liabilities 716 9 284 281 142
Off-Balance Sheet:
Purchase obligations 5,761 975 3,143 1,523 120
Operating leases, including imputed interest 139 6 24 24 85
Investment commitments 1,320 270 448 61 541
Total contractual obligations and commitments $ 40,004 $ 3,147 $ 8,195 $ 19,744 $ 8,918
1 Includes estimated interest expense.
2 See Note 18, “Leases,” of the Notes to Consolidated Financial Statements, included in Part II, Item 8 of this Annual Report on Form 10-K.
1
2
3
4
5
2
6
-69-
-- 70 of 512 --
3 Represents low income housing tax credits.
4 Primarily consists of reserves for future policy benefits, projected other postretirement benefits, deferred compensation, supplemental executive retirement plan liabilities
and certain other miscellaneous long-term obligations. Estimated future payments for funded pension benefits have been excluded from this table, as we had no funding
requirements under ERISA at December 31, 2020 as a result of the value of the assets in the plans.
5 Includes estimated payments for future services under contractual arrangements from third-party service contracts.
6 Includes unfunded capital commitments for alternative investments.
The above table does not contain $282 of gross liabilities for uncertain tax positions and interest for which we cannot reasonably estimate the timing of the
resolutions with the respective taxing authorities. For further information, see Note 8, “Income Taxes,” of the Notes to Consolidated Financial Statements included
in Part II, Item 8 of this Annual Report on Form 10-K.
In addition to the contractual obligations and commitments discussed above, we have a variety of other contractual agreements related to acquiring materials
and services used in our operations. However, we do not believe these other agreements contain material noncancelable commitments.
We believe that funds from future operating cash flows, cash and investments and funds available under our senior revolving credit facilities and/or from
public or private financing sources will be sufficient for future operations and commitments, and for capital acquisitions and other strategic transactions.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet derivative instruments, guarantee transactions, agreements or other contractual arrangements or any indemnification
agreements that will require funding in future periods. We have not transferred assets to an unconsolidated entity that serves as credit, liquidity or market risk
support to such entity. We do not hold any variable interest in an unconsolidated entity where such entity provides us with financing, liquidity, market risk or credit
risk support.
Risk-Based Capital
Our regulated subsidiaries’ states of domicile have statutory risk-based capital (“RBC”) requirements for health and other insurance companies and HMOs
largely based on the National Association of Insurance Commissioners (“NAIC”) Risk-Based Capital (RBC) For Health Organizations Model Act (“RBC Model
Act”). These RBC requirements are intended to measure capital adequacy, taking into account the risk characteristics of an insurer’s investments and products. The
NAIC sets forth the formula for calculating the RBC requirements, which are designed to take into account asset risks, insurance risks, interest rate risks and other
relevant risks with respect to an individual insurance company’s business. In general, under the RBC Model Act, an insurance company must submit a report of its
RBC level to the state insurance department or insurance commissioner, as appropriate, at the end of each calendar year. Our regulated subsidiaries’ respective
RBC levels as of December 31, 2020, which was the most recent date for which reporting was required, were in excess of all applicable mandatory RBC
requirements. In addition to exceeding these RBC requirements, we are in compliance with the liquidity and capital requirements for a licensee of the BCBSA and
with the tangible net worth requirements applicable to certain of our California subsidiaries.
For additional information, see Note 22, “Statutory Information,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual
Report on Form 10-K.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
(In Millions, Except As Otherwise Stated Herein)
As a result of our investing and borrowing activities, we are exposed to financial market risks, including those resulting from changes in interest rates and
changes in market valuations. Potential impacts discussed below are based upon sensitivity analyses performed on our financial position as of December 31, 2020.
Actual results could vary from these estimates. Our primary objectives with our investment portfolio are to provide safety and preservation of capital, sufficient
liquidity to meet cash flow requirements, the integration of investment strategy with the business operations and an attainment of a competitive after-tax total
return.
-70-
-- 71 of 512 --
Investments
Our investment portfolio is exposed to three primary sources of risk: credit quality risk, interest rate risk and market valuation risk.
The primary risks associated with our fixed maturity securities, which are classified as available-for-sale, are credit quality risk and interest rate risk. Credit
quality risk is defined as the risk of a credit event, such as a ratings downgrade or default, to an individual fixed maturity security and the potential loss attributable
to that event. Credit quality risk is managed through our investment policy, which establishes credit quality limitations on the overall portfolio as well as
diversification and percentage limits on securities of individual issuers. The result is a well-diversified portfolio of fixed maturity securities, with an average credit
rating of approximately “A.” Interest rate risk is defined as the potential for economic losses on fixed maturity securities due to a change in market interest rates.
Our fixed maturity portfolio is invested primarily in U.S. government securities, corporate bonds, asset-backed bonds, mortgage-related securities and municipal
bonds, all of which have exposure to changes in the level of market interest rates. Interest rate risk is managed by maintaining asset duration within a band based
upon our liabilities, operating performance and liquidity needs. Additionally, we have the capability of holding any security to maturity, which would allow us to
realize full par value.
Investments in fixed maturity securities include corporate securities, which account for 45.4% of our total fixed maturity securities at December 31, 2020 and
are subject to credit/default risk. In a declining economic environment, corporate yields will usually increase, prompted by concern over the ability of corporations
to make interest payments, thus causing a decrease in the price of corporate securities, and the decline in value of the corporate fixed maturity portfolio. We
manage this risk through fundamental credit analysis, diversification of issuers and industries and an average credit rating of our corporate fixed maturity portfolio
of approximately “BBB.”
Market risk for fixed maturity securities is addressed by actively managing the duration, allocation and diversification of our investment portfolio. We have
evaluated the impact on the fixed maturity portfolio’s fair value considering an immediate 100 basis point change in interest rates. A 100 basis point increase in
interest rates would result in an approximate $998 decrease in fair value, whereas a 100 basis point decrease in interest rates would result in an approximate $1,039
increase in fair value. While we classify our fixed maturity securities as “available-for-sale” for accounting purposes, we believe our cash flows and the duration of
our portfolio should allow us to hold securities to maturity, thereby avoiding the recognition of losses should interest rates rise significantly.
Our equity portfolio is comprised of large capitalization and small capitalization domestic equities, foreign equities, exchange-traded funds and index mutual
funds. Our equity portfolio is subject to the volatility inherent in the stock market, driven by concerns over economic conditions, earnings and sales growth,
inflation, and consumer confidence. These systemic risks cannot be managed through diversification alone. However, more routine risks, such as stock/industry
specific risks, are managed by investing in a diversified equity portfolio.
Our other invested assets, reported within our long-term investments, are primarily subject to private market exposures, including private equity, real estate,
and private credit investments. These investments are also indirectly subject to market valuation risk, as public market valuations will form a basis for valuations
for these investments. Given their illiquid nature, we focus on appropriate sizing of these investments relative to our liquidity needs and risk tolerance. Our risk
tolerance is formed by the level of illiquidity and short-term price movements from market valuation risk we are willing to accept relative to the higher long-term
expected returns over the life of these investments.
As of December 31, 2020, 6.1% of our marketable investments were equity securities. An immediate 10% decrease in each equity investment’s value, arising
from market movement, would result in a fair value decrease of $156. Alternatively, an immediate 10% increase in each equity investment’s value, attributable to
the same factor, would result in a fair value increase of $156.
For additional information regarding our investments, see Note 5, “Investments,” of the Notes to Consolidated Financial Statements included in Part II, Item 8
and “Critical Accounting Policies and Estimates - Investments” within Part II, Item 7 “Management’s Discussion and Analysis of Financial Condition and Results
of Operations” included in this Annual Report on Form 10-K.
-71-
-- 72 of 512 --
Long-Term Debt
Our total long-term debt at December 31, 2020 consisted of senior unsecured notes, convertible debentures, commercial paper and subordinated surplus notes
issued by one of our insurance subsidiaries. At December 31, 2020, the carrying value and estimated fair value of our long-term debt was $20,035 and $24,269,
respectively. This debt is subject to interest rate risk, as these instruments have fixed interest rates and the fair value is affected by changes in market interest rates.
Should interest rates increase or decrease in the future, the estimated fair value of our fixed rate debt would decrease or increase accordingly.
For additional information regarding our long-term debt, see Note 7, “Fair Value” and Note 13, “Debt,” of the Notes to Consolidated Financial Statements
included in Part II, Item 8 of this Annual Report on Form 10-K.
Derivatives
We have exposure to economic losses due to interest rate risk arising from changes in the level or volatility of interest rates. We attempt to mitigate our
exposure to interest rate risk through the use of derivative financial instruments. These strategies include the use of interest rate swaps and forward contracts, which
are used to lock-in interest rates or to hedge (on an economic basis) interest rate risks associated with variable rate debt. We have used these types of instruments as
designated hedges against specific liabilities.
Changes in interest rates will affect the estimated fair value of these derivatives. As of December 31, 2020, we recorded a net asset of $37, the estimated fair
value of the swaps at that date. We have evaluated the impact on the interest rate swaps’ fair value considering an immediate 100 basis point change in interest
rates. A 100 basis point increase in interest rates would result in an approximate $18 decrease in fair value, whereas a 100 basis point decrease in interest rates
would result in an approximate $18 increase in fair value.
For additional information regarding our derivatives, see Note 6, “Derivative Financial Instruments” of the Notes to Consolidated Financial Statements
included in Part II, Item 8 of this Annual Report on Form 10-K.
-72-
-- 73 of 512 --
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
ANTHEM, INC.
CONSOLIDATED FINANCIAL STATEMENTS
Years ended December 31, 2020, 2019 and 2018
Contents
Report of Independent Registered Public Accounting Firm 74
Audited Consolidated Financial Statements:
Consolidated Balance Sheets 76
Consolidated Statements of Income 77
Consolidated Statements of Comprehensive Income 78
Consolidated Statements of Cash Flows 79
Consolidated Statements of Shareholders’ Equity 80
Notes to Consolidated Financial Statements 81
-73-
-- 74 of 512 --
Report of Independent Registered
Public Accounting Firm
To the Shareholders and the Board of Directors of Anthem, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Anthem, Inc. (the Company) as of December 31, 2020 and 2019, the related consolidated
statements of income, comprehensive income, shareholders’ equity, and cash flows for each of the three years in the period ended December 31, 2020, and the
related notes and financial statement schedule listed in the Index at Item 15(c) (collectively referred to as the “consolidated financial statements”). In our opinion,
the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results
of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity with U.S. generally accepted accounting
principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal
control over financial reporting as of December 31, 2020, based on criteria established in Internal Control—Integrated Framework issued by the Committee of
Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 18, 2021 expressed an unqualified opinion thereon.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements
based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance
with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to
assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such
procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe
that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be
communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially
challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial
statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the
account or disclosures to which it relates.
-74-
-- 75 of 512 --
Valuation of Incurred but Not Paid Claims
Description of the Matter Medical claims payable was $11,359 million at December 31, 2020, a significant portion of which related to the Company’s
estimate for claims that are incurred but not paid. As discussed in Note 2 to the consolidated financial statements, the
Company’s liability for incurred but not paid claims is determined using actuarial methods that include a number of factors
and assumptions, including completion factors, which represent the average percentage of total incurred claims that have been
paid through a given date after being incurred based on historical paid claims data, and trend factors, which represent an
estimate of claims expense based on recent claims expense levels and healthcare cost levels. There is significant uncertainty
inherent in determining management’s best estimate of completion and trend factors, which are used to calculate actuarial
estimates of incurred but not paid claims.
Auditing management’s estimate of incurred but not paid claims was complex and required the involvement of our actuarial
specialists due to the highly judgmental nature of the completion and trend factor assumptions used in the valuation process.
The significant judgment was primarily due to the sensitivity of management’s best estimate of completion and trend factor
assumptions, which have a significant impact on the valuation of incurred but not paid claims.
How We Addressed the Matter
in Our Audit
We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company’s
actuarial process for estimating the liability for incurred but not paid claims. These audit procedures included among others,
testing management review controls over completion and trend factor assumptions and the review and approval processes that
management has in place for estimating the liability for incurred but not paid claims.
To test the Company’s liability for incurred but not paid claims, our audit procedures included, among others, testing the
completeness and accuracy of the underlying claims and membership data recorded in the source claims processing and
disbursement systems to the data used by management in developing completion and trend factor assumptions and agreeing a
sample of incurred and paid claims to source documentation. With the support of actuarial specialists, we analyzed the
Company’s completion and trend factor assumptions based on historical claim experience and emerging cost trends, and
independently calculated a range of reasonable reserve estimates for comparison to management’s best estimate of the liability
for incurred but not paid claims. Additionally, we performed a review of the prior period liabilities for incurred but not paid
claims to subsequent claims development.
/s/ ERNST & YOUNG LLP
We have served as the Company’s auditor since 1944.
Indianapolis, Indiana
February 18, 2021
-75-
-- 76 of 512 --
Anthem, Inc.
Consolidated Balance Sheets
December 31,
2020
December 31,
2019
(In millions, except share data)
Assets
Current assets:
Cash and cash equivalents $ 5,741 $ 4,937
Fixed maturity securities, current (amortized cost of $22,222 and $19,021; allowance for credit losses of $7 and $0) 23,433 19,676
Equity securities 1,559 1,009
Premium receivables 5,279 5,014
Self-funded receivables 2,849 2,570
Other receivables 2,830 2,807
Other current assets 4,060 3,020
Total current assets 45,751 39,033
Long-term investments:
Fixed maturity securities (amortized cost of $532 and $487; allowance for credit losses of $0 and $0) 562 505
Other invested assets 4,285 4,258
Property and equipment, net 3,483 3,133
Goodwill 21,691 20,500
Other intangible assets 9,405 8,674
Other noncurrent assets 1,438 1,350
Total assets $ 86,615 $ 77,453
Liabilities and shareholders’ equity
Liabilities
Current liabilities:
Medical claims payable $ 11,359 $ 8,842
Other policyholder liabilities 4,590 3,050
Unearned income 1,259 1,017
Accounts payable and accrued expenses 5,493 4,198
Short-term borrowings — 700
Current portion of long-term debt 700 1,598
Other current liabilities 6,052 4,127
Total current liabilities 29,453 23,532
Long-term debt, less current portion 19,335 17,787
Reserves for future policy benefits 794 759
Deferred tax liabilities, net 2,019 2,227
Other noncurrent liabilities 1,815 1,420
Total liabilities 53,416 45,725
Commitments and contingencies—Note 14
Shareholders’ equity
Preferred stock, without par value, shares authorized - 100,000,000; shares issued and outstanding - none — —
Common stock, par value $0.01, shares authorized - 900,000,000; shares issued and outstanding - 245,401,430 and 252,922,161 3 3
Additional paid-in capital 9,244 9,448
Retained earnings 23,802 22,573
Accumulated other comprehensive income (loss) 150 (296)
Total shareholders’ equity 33,199 31,728
Total liabilities and shareholders’ equity $ 86,615 $ 77,453
See accompanying notes.
-- 77 of 512 --
-76-
-- 78 of 512 --
Anthem, Inc.
Consolidated Statements of Income
Years Ended December 31
(In millions, except per share data) 2020 2019 2018
Revenues
Premiums $ 104,109 $ 94,173 $ 85,421
Product revenue 10,384 2,760 —
Administrative fees and other revenue 6,315 6,208 5,920
Total operating revenue 120,808 103,141 91,341
Net investment income 877 1,005 970
Net realized gains (losses) on financial instruments 182 67 (206)
Total revenues 121,867 104,213 92,105
Expenses
Benefit expense 88,045 81,786 71,895
Cost of products sold 8,953 1,992 —
Selling, general and administrative expense 17,450 13,364 14,020
Interest expense 784 746 753
Amortization of other intangible assets 361 338 358
Loss on extinguishment of debt 36 2 11
Total expenses 115,629 98,228 87,037
Income before income tax expense 6,238 5,985 5,068
Income tax expense 1,666 1,178 1,318
Net income $ 4,572 $ 4,807 $ 3,750
Net income per share
Basic $ 18.23 $ 18.81 $ 14.53
Diluted $ 17.98 $ 18.47 $ 14.19
Dividends per share $ 3.80 $ 3.20 $ 3.00
See accompanying notes.
-77-
-- 79 of 512 --
Anthem, Inc.
Consolidated Statements of Comprehensive Income
Years Ended December 31
(In millions) 2020 2019 2018
Net income $ 4,572 $ 4,807 $ 3,750
Other comprehensive income (loss), net of tax:
Change in net unrealized gains/losses on investments 428 680 (418)
Change in non-credit component of impairment losses on investments — — (2)
Change in net unrealized gains/losses on cash flow hedges 12 (16) 37
Change in net periodic pension and postretirement costs (1) 26 (90)
Foreign currency translation adjustments 7 — (1)
Other comprehensive income (loss) 446 690 (474)
Total comprehensive income $ 5,018 $ 5,497 $ 3,276
See accompanying notes.
-78-
-- 80 of 512 --
Anthem, Inc.
Consolidated Statements of Cash Flows
Years Ended December 31
(In millions) 2020 2019 2018
Operating activities
Net income $ 4,572 $ 4,807 $ 3,750
Adjustments to reconcile net income to net cash provided by operating activities:
Net realized (gains) losses on financial instruments (182) (67) 206
Depreciation and amortization 1,154 1,133 1,132
Deferred income taxes (540) 81 91
Impairment of property and equipment 198 — —
Share-based compensation 283 294 226
Changes in operating assets and liabilities:
Receivables, net (256) (1,053) (695)
Other invested assets (32) (48) (1)
Other assets (283) (170) (26)
Policy liabilities 3,528 1,826 (1,059)
Unearned income 202 115 (36)
Accounts payable and other liabilities 1,978 (445) 97
Income taxes 72 (325) 323
Other, net (6) (87) (181)
Net cash provided by operating activities 10,688 6,061 3,827
Investing activities
Purchases of investments (19,492) (22,954) (9,671)
Proceeds from sale of investments 11,318 18,598 9,662
Maturities, calls and redemptions from investments 4,741 2,437 1,938
Changes in securities lending collateral (849) 254 (149)
Purchases of subsidiaries, net of cash acquired (1,976) — (1,760)
Purchases of property and equipment (1,021) (1,077) (1,208)
Other, net (45) (50) (71)
Net cash used in investing activities (7,324) (2,792) (1,259)
Financing activities
Net repayments of commercial paper borrowings (150) (297) (107)
Proceeds from long-term borrowings 2,484 2,473 835
Repayments of long-term borrowings (1,932) (1,123) (1,684)
Proceeds from short-term borrowings 970 7,590 9,120
Repayments of short-term borrowings (1,670) (8,035) (9,250)
Changes in securities lending payable 849 (254) 150
Proceeds from issuance of common stock under Equity Units stock purchase contracts — — 1,250
Repurchase and retirement of common stock (2,700) (1,701) (1,685)
Cash dividends (954) (818) (776)
Proceeds from issuance of common stock under employee stock plans 176 187 173
Taxes paid through withholding of common stock under employee stock plans (128) (84) (81)
Other, net 488 (204) (186)
Net cash used in financing activities (2,567) (2,266) (2,241)
Effect of foreign exchange rates on cash and cash equivalents 7 — (2)
Change in cash and cash equivalents 804 1,003 325
Cash and cash equivalents at beginning of year 4,937 3,934 3,609
Cash and cash equivalents at end of year $ 5,741 $ 4,937 $ 3,934
See accompanying notes.
-- 81 of 512 --
-79-
-- 82 of 512 --
Anthem, Inc.
Consolidated Statements of Shareholders’ Equity
Common Stock Additional
Paid-in
Capital
Accumulated
Other
Comprehensive
Income (Loss)
Total
Shareholders’
Equity (In millions)
Number
of Shares
Par
Value
Retained
Earnings
January 1, 2018 256.1 $ 3 $ 8,547 $ 18,374 $ (421) $ 26,503
Net income — — — 3,750 — 3,750
Other comprehensive loss — — — — (474) (474)
Issuance of common stock under Equity Units stock purchase
contracts 6.0 — 1,250 — — 1,250
Premiums for and settlement of equity options — — 1 — — 1
Repurchase and retirement of common stock (6.8) — (243) (1,442) — (1,685)
Dividends and dividend equivalents — — — (785) — (785)
Issuance of common stock under employee stock plans, net of
related tax benefits 2.1 — 318 — — 318
Convertible debenture conversions — — (337) — — (337)
Adoption of Accounting Standards Update No. 2018-02 — — — 91 (91) —
December 31, 2018 257.4 3 9,536 19,988 (986) 28,541
Adoption of Accounting Standards Update No. 2016-02 — — — 26 — 26
January 1, 2019 257.4 3 9,536 20,014 (986) 28,567
Net income — — — 4,807 — 4,807
Other comprehensive income — — — — 690 690
Repurchase and retirement of common stock (6.3) — (275) (1,426) — (1,701)
Dividends and dividend equivalents — — — (822) — (822)
Issuance of common stock under employee stock plans, net of
related tax benefits 1.8 — 396 — — 396
Convertible debenture conversions — — (209) — — (209)
December 31, 2019 252.9 3 9,448 22,573 (296) 31,728
Adoption of Accounting Standards Update No. 2016-13 (Note
2) — — — (35) — (35)
January 1, 2020 252.9 3 9,448 22,538 (296) 31,693
Net income — — — 4,572 — 4,572
Other comprehensive income — — — — 446 446
Repurchase and retirement of common stock (9.4) — (353) (2,347) — (2,700)
Dividends and dividend equivalents — — — (961) — (961)
Issuance of common stock under employee stock plans, net of
related tax benefits 1.9 — 330 — — 330
Convertible debenture repurchases and conversions — — (181) — — (181)
December 31, 2020 245.4 $ 3 $ 9,244 $ 23,802 $ 150 $ 33,199
See accompanying notes.
-80-
-- 83 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements
December 31, 2020
(In Millions, Except Per Share Data or As Otherwise Stated Herein)
1. Organization
References to the terms “we,” “our,” “us” or “Anthem” used throughout these Notes to Consolidated Financial Statements refer to Anthem, Inc., an Indiana
corporation, and unless the context otherwise requires, its direct and indirect subsidiaries.
We are one of the largest health benefits companies in the United States in terms of medical membership, serving approximately 43 medical members through
our affiliated health plans as of December 31, 2020. We offer a broad spectrum of network-based managed care plans to Large Group, Small Group, Individual,
Medicaid and Medicare markets. Our managed care plans include: Preferred Provider Organizations (“PPOs”); Health Maintenance Organizations (“HMOs”);
Point-of-Service plans; traditional indemnity plans and other hybrid plans, including Consumer-Driven Health Plans; and hospital only and limited benefit
products. In addition, we provide a broad array of managed care services to self-funded customers, including claims processing, stop loss insurance, actuarial
services, provider network access, medical cost management, disease management, wellness programs and other administrative services. We provide an array of
specialty and other insurance products and services such as pharmacy benefits management (“PBM”), dental, vision, life and disability insurance benefits,
radiology benefit management and analytics-driven personal healthcare. We also provide services to the federal government in connection with our Federal Health
Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program.
We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our
members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana,
Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and
upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do
business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also conduct business through
arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states across the
country as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, Optimum HealthCare, Simply
Healthcare, and/or UniCare. Also, in the second quarter of 2019, we began providing PBM services through our IngenioRx subsidiary. We are licensed to conduct
insurance operations in all 50 states and the District of Columbia through our subsidiaries.
2. Basis of Presentation and Significant Accounting Policies
Basis of Presentation: The accompanying consolidated financial statements include the accounts of Anthem and its subsidiaries and have been prepared in
conformity with U.S. generally accepted accounting principles (“GAAP”). All significant intercompany accounts and transactions have been eliminated in
consolidation.
Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and
liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to
USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation
adjustments” in our consolidated statements of comprehensive income.
Reclassifications: Certain prior year amounts have been reclassified to conform to the current year presentation.
-81-
-- 84 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Use of Estimates: The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect
the amounts reported in our consolidated financial statements and accompanying notes. Actual results could differ from those estimates.
Cash and Cash Equivalents: Cash and cash equivalents includes available cash and all highly liquid investments with maturities of three months or less when
purchased. We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits, and we have cash
and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $170 and $215 at December 31, 2020 and 2019, respectively, and
are included in the cash and cash equivalents line on our consolidated balance sheets.
Investments: We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed
maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual
maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.
Prior to 2020, our fixed maturity securities were evaluated for other-than-temporary impairment where credit-related impairments were presented within the
other-than-temporary impairment losses recognized in our consolidated statements of income with an adjustment to the security’s amortized cost basis. Effective
January 1, 2020, if a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not
that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value
and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely
than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the
impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-
credit component of the impairment is recognized in accumulated other comprehensive income. Furthermore, unrealized losses entirely caused by non-credit-
related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other
comprehensive income.
The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost
basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate
implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions
regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and
changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and
estimates regarding timing and amount of recoveries associated with a default.
For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the
estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and
anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since
the purchase date of the securities. Such adjustments are reported within net investment income.
In accordance with the Financial Accounting Standards Board (“FASB”) guidance, the changes in fair value of our marketable equity securities are recognized
in our results of operations within net realized gains and losses on financial instruments.
We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash
surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets.
We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial
decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The
equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets.
-82-
-- 85 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and
losses are determined on the basis of the cost or amortized cost of the specific securities sold.
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in
exchange for cash and securities collateral. Under FASB guidance related to accounting for transfers and servicing of financial assets and extinguishments of
liabilities, we recognize the collateral as an asset, which is reported as securities lending collateral on our consolidated balance sheets, and we record a
corresponding liability for the obligation to return the collateral to the borrower, which is reported as securities lending payable. The securities on loan are reported
in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated
other comprehensive income as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate
in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are
exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the
shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any
shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration
instruments.
Receivables: Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends,
future forecasts and our judgment regarding the ability to collect specific accounts.
Premium receivables include the uncollected amounts from insured groups, individuals and government programs. Premium receivables are reported net of an
allowance for doubtful accounts of $146 and $237 at December 31, 2020 and 2019, respectively.
Self-funded receivables include administrative fees, claims and other amounts due from self-funded customers. Self-funded receivables are reported net of an
allowance for doubtful accounts of $54 and $46 at December 31, 2020 and 2019, respectively.
Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades,
other government receivables and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $374 and
$242 at December 31, 2020 and 2019, respectively.
Income Taxes: We file a consolidated income tax return. Deferred income tax assets and liabilities are recognized for temporary differences between the
financial statement and tax return basis of assets and liabilities based on enacted tax rates and laws. The deferred tax benefits of the deferred tax assets are
recognized to the extent realization of such benefits is more likely than not. Deferred income tax expense or benefit generally represents the net change in deferred
income tax assets and liabilities during the year, excluding the impact from amounts initially recorded for business combinations, if any, and amounts recorded to
accumulated other comprehensive income. Current income tax expense represents the tax consequences of revenues and expenses currently taxable or deductible
on various income tax returns for the year reported.
We account for income tax contingencies in accordance with FASB guidance that contains a model to address uncertainty in tax positions and clarifies the
accounting for income taxes by prescribing a minimum recognition threshold, which all income tax positions must achieve before being recognized in the financial
statements.
Property and Equipment: Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is computed principally by the straight-
line method over estimated useful lives ranging from fifteen to thirty-nine years for buildings and improvements, three to five years for computer equipment and
software, and the lesser of the remaining life of the building lease, if any, or seven years for furniture and other equipment. Leasehold improvements are
depreciated over the term of the related lease. Certain costs related to the development or purchase of internal-use software are capitalized and amortized over
estimated useful lives ranging from five to ten years.
Goodwill and Other Intangible Assets: FASB guidance requires business combinations to be accounted for using the acquisition method of accounting, and it
also specifies the types of acquired intangible assets that are required to be
-83-
-- 86 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
recognized and reported separately from goodwill. Goodwill represents the excess of the cost of acquisition over the fair value of net assets acquired. Other
intangible assets represent the values assigned to customer relationships, provider and hospital networks, Blue Cross and Blue Shield and other trademarks,
licenses and other agreements, such as non-compete. Goodwill and other intangible assets are allocated to reportable segments based on the relative fair value of
the components of the businesses acquired.
Goodwill and other intangible assets with indefinite lives are not amortized but are tested for impairment at least annually. Goodwill and other intangible
assets are allocated to reporting units for purposes of the annual goodwill impairment test. Other intangible assets with indefinite lives, such as trademarks, are
tested for impairment separately. We complete our annual impairment tests of existing goodwill and other intangible assets with indefinite lives during the fourth
quarter of each year. Our impairment tests require us to make assumptions and judgments regarding the estimated fair value of our reporting units, including
goodwill and other intangible assets with indefinite lives. Certain interim impairment tests are also performed when potential impairment indicators exist or
changes in our business or other triggering events occur.
FASB guidance allows for qualitative assessments of whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount for
purposes of a goodwill impairment analysis and whether it is more likely than not that an indefinite-lived intangible asset is impaired for purposes of an indefinite-
lived intangible asset impairment analysis. Estimated fair values developed based on our assumptions and judgments might be different if other reasonable
assumptions and estimates were to be used. Qualitative analysis involves assessing situations and developments that could affect key drivers used to evaluate
whether the fair value of our goodwill and indefinite-lived intangible assets are impaired. Our procedures include assessing our financial performance,
macroeconomic conditions, industry and market considerations, various asset specific factors, and entity specific events.
Quantitative analysis must be performed if qualitative analyses are not conclusive. Entities also have the option to bypass the assessment of qualitative factors
and proceed directly to performing quantitative analyses. Fair value for purposes of a quantitative goodwill impairment test is calculated using a blend of the
projected income and market valuation approaches. The projected income approach is developed using assumptions about future revenue, expenses and net income
derived from our internal planning process. Our assumed discount rate is based on our industry’s weighted-average cost of capital and reflects volatility associated
with the cost of equity capital. Market valuations include market comparisons to publicly traded companies in our industry and are based on observed multiples of
certain measures including revenue; earnings before interest, taxes, depreciation and amortization (“EBITDA”); and book value of invested capital.
A goodwill impairment loss is recognized to the extent that the carrying amount exceeds the asset’s fair value. This determination is made at the reporting unit
level and consists of one step. The fair value of a reporting unit is determined and compared to its carrying amount. If the carrying amount of a reporting unit
exceeds its fair value, an impairment loss is recognized. This goodwill impairment loss is equal to the excess of the reporting unit’s carrying amount over its fair
value.
Fair value for purposes of a quantitative impairment test for indefinite-lived intangible assets is estimated using a projected income approach. We recognize an
impairment loss when the estimated fair value of indefinite-lived intangible assets is less than the carrying value. If significant impairment indicators are noted
relative to other intangible assets subject to amortization, we may be required to record impairment losses against future income.
Derivative Financial Instruments: We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward
contracts, put and call options, swaptions, embedded derivatives and warrants. Derivatives embedded within non-derivative instruments, such as options embedded
in convertible fixed maturity securities, are bifurcated from the host instrument when the embedded derivative is not clearly and closely related to the host
instrument. Our use of derivatives is limited by statutes and regulations promulgated by the various regulatory bodies to which we are subject, and by our own
derivative policy. Our derivative use is generally limited to hedging purposes, on an economic basis, and we generally do not use derivative instruments for
speculative purposes.
We have exposure to economic losses due to interest rate risk arising from changes in the level or volatility of interest rates. We attempt to mitigate our
exposure to interest rate risk through active portfolio management, including rebalancing our existing portfolios of assets and liabilities, as well as changing the
characteristics of investments to be purchased or sold in the future. In addition, derivative financial instruments are used to modify the interest rate exposure of
certain liabilities or forecasted transactions. These strategies include the use of interest rate swaps and forward contracts, which are used to lock-
-84-
-- 87 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
in interest rates or to hedge, on an economic basis, interest rate risks associated with variable rate debt. We have used these types of instruments as designated
hedges against specific liabilities.
All investments in derivatives are recorded as assets or liabilities at fair value. If certain correlation, hedge effectiveness and risk reduction criteria are met, a
derivative may be specifically designated as a hedge of exposure to changes in fair value or cash flow. The accounting for changes in the fair value of a derivative
depends on the intended use of the derivative and the nature of any hedge designation thereon. Amounts excluded from the assessment of hedge effectiveness, if
any, are reported in results of operations immediately. If the derivative is not designated as a hedge, the gain or loss resulting from the change in the fair value of
the derivative is recognized in results of operations in the period of change. Cash flows associated with the settlement of non-designated derivatives are shown on a
net basis in investing activity in our consolidated statements of cash flow.
From time to time, we may also purchase derivatives to hedge, on an economic basis, our exposure to foreign currency exchange fluctuations associated with
the operations of certain of our subsidiaries. We generally use futures or forward contracts for these transactions. We generally do not designate these contracts as
hedges and, accordingly, the changes in fair value of these derivatives are recognized in results of operations immediately.
Credit exposure associated with non-performance by the counterparties to derivative instruments is generally limited to the uncollateralized fair value of the
asset related to instruments recognized in the consolidated balance sheets. We attempt to mitigate the risk of non-performance by selecting counterparties with high
credit ratings and monitoring their creditworthiness and by diversifying derivatives among multiple counterparties. At December 31, 2020, we believe there were
no material concentrations of credit risk with any individual counterparty.
We generally enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. Certain of
our derivative agreements also contain credit support provisions that require us or the counterparty to post collateral if there are declines in the derivative fair value
or our credit rating. The derivative assets and derivative liabilities are reported at their fair values net of collateral and netting by the counterparty.
Retirement Benefits: We recognize the funded status of pension and other postretirement benefit plans on the consolidated balance sheets based on fiscal-
year-end measurements of plan assets and benefit obligations. Prepaid pension benefits represent prepaid costs related to defined benefit pension plans and are
reported with other noncurrent assets. Postretirement benefits represent outstanding obligations for retiree medical, life, vision and dental benefits. Liabilities for
pension and other postretirement benefits are reported with current and noncurrent liabilities based on the amount by which the actuarial present value of benefits
payable in the next twelve months included in the benefit obligation exceeds the fair value of plan assets.
We determine the expected return on plan assets using the calculated value of plan assets, which recognizes changes in the fair value of plan assets in a
systematic manner over three years. We apply a corridor approach to amortize unrecognized actuarial gains or losses. Under this approach, only accumulated net
actuarial gains or losses in excess of 10% of the greater of the projected benefit obligation or the fair value of plan assets are amortized over the average remaining
service or lifetime of the workforce as a component of net periodic benefit cost.
The discount rate reflects the current rate at which the pension liabilities could be effectively settled at the end of the year based on our most recent
measurement date. We use the annual spot rate approach for setting our discount rate. Under the spot rate approach, individual spot rates from a full yield curve of
published rates are used to discount each plan’s cash flows to determine the plan’s obligations.
The assumed healthcare cost trend rates used to measure the expected cost of other postretirement benefits are based on an initial assumed healthcare cost
trend rate declining to an ultimate healthcare cost trend rate over a select number of years.
Medical Claims Payable: Liabilities for medical claims payable include estimated provisions for incurred but not paid claims on an undiscounted basis, as
well as estimated provisions for expenses related to the processing of claims. Incurred but not paid claims include (1) an estimate for claims that are incurred but
not reported, as well as claims reported to us but not yet processed through our systems; and (2) claims reported to us and processed through our systems but not
yet paid.
-85-
-- 88 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Liabilities for both claims incurred but not reported and reported but not yet processed through our systems are determined in the aggregate, employing
actuarial methods that are commonly used by health insurance actuaries and meet Actuarial Standards of Practice. Actuarial Standards of Practice require that the
claim liabilities be appropriate under moderately adverse circumstances. We determine the amount of the liability for incurred but not paid claims by following a
detailed actuarial process that uses both historical claim payment patterns as well as emerging medical cost trends to project our best estimate of claim liabilities.
Under this process, historical paid claims data is formatted into “claim triangles,” which compare claim incurred dates to the dates of claim payments. This
information is analyzed to create “completion factors” that represent the average percentage of total incurred claims that have been paid through a given date after
being incurred. Completion factors are applied to claims paid through the period-end date to estimate the ultimate claim expense incurred for the period. Actuarial
estimates of incurred but not paid claim liabilities are then determined by subtracting the actual paid claims from the estimate of the ultimate incurred claims.
For the most recent incurred months (typically the most recent two months), the percentage of claims paid for claims incurred in those months is generally
low. This makes the completion factor methodology less reliable for such months. Therefore, incurred claims for recent months are not projected from historical
completion and payment patterns; rather, they are projected by estimating the claims expense for those months based on recent claims expense levels and
healthcare trend levels (“trend factors”).
We regularly review and set assumptions regarding cost trends and utilization when initially establishing claim liabilities. We continually monitor and adjust
the claims liability and benefit expense based on subsequent paid claims activity. If it is determined that our assumptions regarding cost trends and utilization are
materially different than actual results, our income statement and financial position could be impacted in future periods.
Premium deficiencies are recognized when it is probable that expected claims and administrative expenses will exceed future premiums on existing medical
insurance contracts without consideration of investment income. Determination of premium deficiencies for longer duration life and disability contracts includes
consideration of investment income. For purposes of premium deficiencies, contracts are deemed to be either short or long duration and are grouped in a manner
consistent with our method of acquiring, servicing and measuring the profitability of such contracts. Once established, premium deficiencies are released
commensurate with actual claims experience over the remaining life of the contract. No premium deficiencies were established at December 31, 2020 or 2019.
Benefit expense includes incurred medical claims as well as quality improvement expenses for our fully-insured members. Quality improvement activities are
those designed to improve member health outcomes, prevent hospital readmissions and improve patient safety. They also include expenses for wellness and health
promotion provided to our members.
Reserves for Future Policy Benefits: Reserves for future policy benefits include liabilities for life and long-term disability insurance policy benefits based
upon interest, mortality and morbidity assumptions from published actuarial tables, modified based upon our experience. Future policy benefits also include
liabilities for insurance policies for which some of the premiums received in earlier years are intended to pay anticipated benefits to be incurred in future years.
Future policy benefits are continually monitored and reviewed, and when reserves are adjusted, differences are reflected in benefit expense.
The current portion of reserves for future policy benefits relates to the portion of such reserves that we expect to pay within one year. We believe that our
liabilities for future policy benefits, along with future premiums received, are adequate to satisfy our ultimate benefit liability; however, these estimates are
inherently subject to a number of variable circumstances. Consequently, the actual results could differ materially from the amounts recorded in our consolidated
financial statements.
Other Policyholder Liabilities: Other policyholder liabilities include rate stabilization reserves associated with retrospectively rated insurance contracts and
certain case-specific reserves. Other policyholder liabilities also include liabilities for premium refunds based upon the minimum medical loss ratio (“MLR”), the
relative health risk of members, and other contractual or regulatory requirements. Rate stabilization reserves represent accumulated premiums that exceed what
customers owe us based on actual claim experience. The timing of payment of these retrospectively rated refunds is based on the contractual terms with our
customers and can vary from period to period based on the specific contractual requirements.
We are required to meet certain minimum MLR thresholds prescribed by the Patient Protection and Affordable Care Act and the Health Care and Education
Reconciliation Act of 2010, as amended (collectively the “ACA”). If we do not meet or
-86-
-- 89 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
exceed the minimum MLR thresholds specified by the ACA, we are required to pay rebates to certain customers. Minimum MLR rebates are calculated by
subsidiary, state and applicable line of business (Large Group, Small Group, Individual and Medicare) in accordance with regulations issued by the Department of
Health and Human Services (“HHS”). Such calculations are made using estimated calendar year medical loss expense and premiums, as defined by HHS.
We follow HHS guidelines for determining the types of expenses that may be included in our minimum MLR rebate calculations, which differ from benefit
expense and premiums as reported in our consolidated financial statements prepared in conformity with GAAP. Certain amounts reported as expense in our
consolidated GAAP financial statements may be reported as a reduction of premiums in accordance with HHS regulations. In addition, profit amounts included in
our payments to third-party administrative service providers are recorded as benefit expense in our consolidated GAAP financial statements, while HHS does not
allow for the inclusion of these expenses within the medical loss expense for purposes of calculating minimum MLR.
Revenue Recognition: Premiums for fully-insured contracts are recognized as revenue over the period insurance coverage is provided, and, if applicable, net
of amounts recognized for MLR rebates, risk adjustment, reinsurance and risk corridor under contractual premium stabilization arrangements, the ACA or other
regulatory requirements. Premium payments from contracted government agencies are based on eligibility lists produced by the government agencies. Premiums
related to the unexpired contractual coverage periods are reflected in the accompanying consolidated balance sheets as unearned income. Premiums include
revenue adjustments for retrospectively rated contracts where revenue is based on the estimated loss experience of the contract. Premium rates for certain lines of
business are subject to approval by the Department of Insurance of each respective state. Additionally, delays in annual premium rate changes from contracted
government agencies require that we defer the recognition of any increases to the period in which the premium rates become final. The value of the impact can be
significant in the period in which it is recognized depending on the magnitude of the premium rate increase, the membership to which it applies and the length of
the delay between the effective date of the rate increase and the final contract date. Premium rate decreases are recognized in the period the change in premium rate
becomes effective and the change in the rate is known, which may be prior to the period when the contract amendment affecting the rate is finalized.
Administrative fees and other revenue include revenue from certain group contracts that provide for the group to be at risk for all, or with supplemental
insurance arrangements, a portion, of their claims experience. We charge these self-funded groups an administrative fee, which is based on the number of members
in a group or the group’s claim experience. In addition, administrative fees and other revenue include amounts received for the administration of Medicare or
certain other government programs. Under our self-funded arrangements, revenue is recognized as administrative services are performed. All benefit payments
under these programs are excluded from benefit expense.
Product revenue includes revenue for services performed by our IngenioRx PBM for unaffiliated PBM customers. Unaffiliated PBM customers include our
self-funded groups that have contracted with IngenioRx for PBM services and, beginning on January 1, 2020, third-party health plans. Product revenues and costs
of goods sold for our affiliated health plans are eliminated in consolidation. Product revenue for PBM services is recognized using the gross method at the
negotiated contract price when IngenioRx has concluded that it is the principal and it controls the services before prescription drugs are transferred to the customer.
IngenioRx determined it is the principal due to its contractual rights to design and develop a listing of prescription drugs offered to the customer (formulary
management); its control over establishing the pharmacy network available to the customer to have its prescription fulfilled (network management); and its
discretion over establishing the pricing for prescription drugs. Overall, control over these activities indicate IngenioRx is primarily responsible for fulfilling the
promise to provide PBM services. Product revenue includes ingredient costs (net of any rebates or discounts), including any co-payments made by or on behalf of
the customer, and administrative fees. IngenioRx recognizes revenue when control of the prescription drugs is transferred to customers, in an amount it expects to
be entitled to in exchange for the products or services provided.
For our non-fully-insured contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance
sheet at December 31, 2020. Revenue recognized in 2020 and 2019 from performance obligations related to prior years, such as due to changes in transaction price,
was not material. For contracts that have an original expected duration of greater than one year, revenue expected to be recognized in future periods related to
unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.
-87-
-- 90 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Cost of Products Sold: IngenioRx’s cost of products sold includes the cost of prescription drugs dispensed to unaffiliated PBM customers (net of rebates or
discounts). This cost includes any co-payments made by or on behalf of the customer. Cost of products sold also includes per-claim administrative fees for
prescription fulfillment by its vendor and certain IngenioRx direct costs related to sales and administration of customer contracts.
Share-Based Compensation: Our current compensation philosophy provides for share-based compensation, including stock options, restricted stock awards
and an employee stock purchase plan. Stock options are granted for a fixed number of shares with an exercise price at least equal to the fair value of the shares at
the date of the grant. Restricted stock awards are issued at the fair value of the stock on the grant date. The employee stock purchase plan allows for a purchase
price per share which is 90% of the fair value of a share of common stock on the lower of the first or last trading day of the plan quarter. The employee stock
purchase plan discount is recognized as compensation expense based on GAAP guidance. All other share-based payments to employees are recognized as
compensation expense in our consolidated statements of income based on their fair values. Additionally, excess tax benefits, which result from actual tax benefits
realized when awards vest or options are exercised exceeding deferred tax benefits previously recognized based on grant date fair value, are recognized as tax
benefits in the income statement. Our share-based employee compensation plans and assumptions are described in Note 15, “Capital Stock.”
Advertising and Marketing Costs: We use print, broadcast and other advertising to promote our products and to develop our corporate image. We market our
products through direct marketing activities and an extensive network of independent agents, brokers and retail partnerships for Individual and Medicare
customers, and for certain Local Group customers with a smaller employee base. Products for National Accounts and Local Group customers with a larger
employee base are generally sold through independent brokers or consultants retained by the customer who work with industry specialists from our in-house sales
force. In the Individual and Small Group markets, we offer products through state or federally facilitated marketplaces, or public exchanges, and off-exchange
products. The cost of advertising and marketing for product promotion is expensed as incurred, while advertising and marketing costs associated with our corporate
image are expensed when first aired. Total advertising and marketing expense was $558, $467 and $385 for the years ended December 31, 2020, 2019 and 2018,
respectively.
Health Insurance Provider Fee: The ACA imposed an annual Health Insurance Provider Fee (“HIP Fee”) on health insurers that write certain types of health
insurance on U.S. risks, which has been permanently repealed effective January 1, 2021. The HIP Fee was allocated to health insurers based on the ratio of the
amount of an insurer’s net premium revenues written during the preceding calendar year to the amount of health insurance premium for all U.S. health risk for
those certain lines of business written during the preceding calendar year. We recorded our estimated liability for the HIP Fee in full at the beginning of the year
with a corresponding deferred asset that was amortized on a straight-line basis to selling, general and administrative expense. The final calculation and payment of
the annual HIP Fee was due by September 30 of each fee year. The HIP Fee was non-deductible for federal income tax purposes. Our affected products were
priced to cover the increased selling, general and administrative and income tax expenses associated with the HIP Fee when it was in effect. The total amount due
from allocations to health insurers was $14,300 for 2018. The HIP Fee was suspended for 2019, resumed and increased to $15,523 for 2020 and has been
permanently eliminated beginning in 2021. For the years ended December 31, 2020 and 2018, we recognized $1,570 and $1,544, respectively, as selling, general
and administrative expense related to the HIP Fee. There was no corresponding expense for 2019 due to the suspension of the HIP Fee for 2019.
Leases: We lease office space and certain computer and related equipment under noncancelable operating leases. We determine whether an arrangement is or
contains a lease at its inception. We recognize lease liabilities based on the present value of the minimum lease payments not yet paid by using the lease term, any
amounts probable of being owed under any residual value guarantees and the discount rate determined at lease commencement. As our leases do not generally
provide an implicit rate, we use our incremental secured borrowing rate commensurate with the underlying lease terms to determine the present value of our lease
payments. Our lease liabilities may include amounts for options to extend or terminate a lease when it is reasonably certain that we will exercise that option. We
recognize operating right-of-use (“ROU”) assets at an amount equal to the lease liability adjusted for prepaid or accrued rent, the remaining balance of any lease
incentives and unamortized initial direct costs.
The operating lease liabilities are reported in other current liabilities and other noncurrent liabilities and the related ROU assets are reported in other
noncurrent assets on our consolidated balance sheets. Lease expense for our operating leases is calculated on a straight-line basis over the lease term and is reported
in selling, general and administrative expense on our
th
-88-
-- 91 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
consolidated statements of income. For our office space leases, we account for the lease and non-lease components (such as common area maintenance) as a single
lease component. We also do not recognize a lease liability or ROU asset for our office space leases whose lease terms, at commencement, are twelve months or
less and that do not include a purchase option or option to extend that we are reasonably certain to exercise.
We assess our ROU assets for impairment when there are indicators and compare the carrying amount of the ROU asset to its estimated undiscounted future
cash flows. If the estimated undiscounted future cash flows are less than the carrying amount of the ROU asset, an impairment calculation is performed. An
impairment loss is recorded for the difference of the ROU asset’s carrying value that exceeds its estimated discounted cash flows. During 2020, we recorded $258
for impairment and abandonment of ROU assets. See Note 18, “Leases” for additional information about the ROU asset impairment and abandonment charges.
Earnings per Share: Earnings per share amounts, on a basic and diluted basis, have been calculated based upon the weighted-average common shares
outstanding for the period.
Basic earnings per share excludes dilution and is computed by dividing income available to common shareholders by the weighted-average number of
common shares outstanding for the period. Diluted earnings per share may include the dilutive effect of stock options, restricted stock, convertible debentures and
Equity Units, using the treasury stock method. See Note 13, “Debt,” for a description of our Equity Units. The treasury stock method assumes exercise of stock
options and vesting of restricted stock, with the assumed proceeds used to purchase common stock at the average market price for the period. The difference
between the number of shares assumed issued and number of shares assumed purchased represents the dilutive shares.
Recently Adopted Accounting Guidance: The FASB issued Accounting Standards Update No. 2021-01, Reference Rate Reform (Topic 848) (“ASU 2021-
01”) in January 2021, and Accounting Standards Update No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on
Financial Reporting (“ASU 2020-04”) in March 2020. ASU 2021-01 and ASU 2020-04 provide optional expedients and exceptions for applying GAAP to contract
modifications and hedging relationships, subject to meeting certain criteria, that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate
expected to be discontinued because of the reference rate reform. The provisions must be applied at a Topic, Subtopic, or Industry Subtopic level for all
transactions other than derivatives, which may be applied at a hedging relationship level. We adopted ASU 2021-01 on January 7, 2021 and ASU 2020-04 on
November 2, 2020, and the adoptions did not have an impact on our consolidated financial position, results of operations or cash flows.
In November 2019, the FASB issued Accounting Standards Update No. 2019-11, Codification Improvements to Topic 326, Financial Instruments—Credit
Losses. In May 2019, the FASB issued Accounting Standards Update No. 2019-05, Financial Instruments—Credit Losses (Topic 326): Targeted Transition Relief.
In April 2019, the FASB issued Accounting Standards Update No. 2019-04, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic
815, Derivatives and Hedging, and Topic 825, Financial Instruments. In November 2018, the FASB issued Accounting Standards Update No. 2018-19,
Codification Improvements to Topic 326, Financial Instruments—Credit Losses. These updates provide an option to irrevocably elect to measure certain individual
financial assets at fair value instead of amortized cost and provide additional clarification and implementation guidance on certain aspects of the previously issued
Accounting Standards Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU
2016-13") and have the same effective date and transition requirements as ASU 2016-13. ASU 2016-13 introduces a current expected credit loss model for
measuring expected credit losses for certain types of financial instruments held at the reporting date based on historical experience, current conditions and
reasonable supportable forecasts. ASU 2016-13 replaces the incurred loss model for measuring expected credit losses, requires expected losses on available-for-
sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities and provides for
additional disclosure requirements. ASU 2016-13 requires a cumulative-effect adjustment to the opening balance of retained earnings on the balance sheet at the
date of adoption and a prospective transition approach for debt securities for which an other-than-temporary impairment had been recognized before the adoption
date. The effect of a prospective transition approach is to maintain the same amortized cost basis before and after the date of adoption. We adopted ASU 2016-13
on January 1, 2020, and recognized a cumulative-effect adjustment of $35 to our opening retained earnings for credit related allowances on receivables. The
adoption did not have an impact on our consolidated statements of income or cash flows.
-89-
-- 92 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
In August 2018, the FASB issued Accounting Standards Update No. 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40):
Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract (“ASU 2018-15”). The amendments in
ASU 2018-15 require implementation costs incurred by customers in cloud computing arrangements to be deferred and recognized over the term of the
arrangement, if those costs would be capitalized by the customer in a software licensing arrangement under the internal-use software guidance. The amendments
also require an entity to disclose the nature of its hosting arrangements and adhere to certain presentation requirements in its balance sheet, income statement and
statement of cash flows. We adopted ASU 2018-15 on January 1, 2020 using a prospective approach for all implementation costs incurred after the date of
adoption, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.
In August 2018, the FASB issued Accounting Standards Update No. 2018-14, Compensation—Retirement Benefits - Defined Benefit Plans—General
(Subtopic 715-20): Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans (“ASU 2018-14”). The amendments in ASU 2018-
14 eliminate, add, and modify certain disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. We adopted the
disclosure requirements of ASU 2018-14 on December 31, 2020, and the adoption did not have an impact on our consolidated financial position, results of
operations or cash flows.
In August 2018, the FASB issued Accounting Standards Update No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the
Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”). The amendments in ASU 2018-13 eliminate, add, and modify certain disclosure
requirements for fair value measurements. The amendments became effective for interim and annual periods beginning after December 15, 2019, with early
adoption permitted for either the entirety of ASU 2018-13 or only the provisions that eliminate or modify disclosure requirements. We early adopted the provisions
that eliminate and modify disclosure requirements, on a retrospective basis, effective in our 2018 Annual Report on Form 10-K. We adopted the new disclosure
requirements on January 1, 2020, on a prospective basis.
In January 2017, the FASB issued Accounting Standards Update No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for
Goodwill Impairment (“ASU 2017-04”). This update removes Step 2 of the goodwill impairment test under the then-existing guidance, which required a
hypothetical purchase price allocation. The new guidance requires an impairment charge to be recognized for the amount by which the carrying amount exceeds
the reporting unit’s fair value. We adopted ASU 2017-04 on January 1, 2020, and the adoption did not have an impact on our consolidated financial position,
results of operations or cash flows.
Recent Accounting Guidance Not Yet Adopted: In November 2020, the FASB issued Accounting Standards Update No. 2020-11, Financial Services—
Insurance (Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 make changes to the effective date and early
application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-
Duration Contracts (“ASU 2018-12”) which was issued in November 2018. The amendments in ASU 2020-11 have extended the original effective date by one
year and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. The amendments in ASU 2018-12
make changes to a variety of areas to simplify or improve the existing recognition, measurement, presentation and disclosure requirements for long-duration
contracts issued by an insurance entity. The amendments require insurers to annually review the assumptions they make about their policyholders and update the
liabilities for future policy benefits if the assumptions change. The amendments also simplify the amortization of deferred contract acquisition costs and add new
disclosure requirements about the assumptions insurers use to measure their liabilities and how they may affect future cash flows. The amendments related to the
liability for future policy benefits for traditional and limited-payment contracts and deferred acquisition costs are to be applied to contracts in force as of the
beginning of the earliest period presented, with an option to apply such amendments retrospectively with a cumulative-effect adjustment to the opening balance of
retained earnings as of the earliest period presented. The amendments for market risk benefits are to be applied retrospectively. We are currently evaluating the
effects the adoption of ASU 2020-11 and ASU 2018-12 will have on our consolidated financial position, results of operations, cash flows, and related disclosures.
In October 2020, the FASB issued Accounting Standards Update No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables—Nonrefundable
Fees and Other Costs (“ASU 2020-08”). The amendments clarify when an entity should assess whether a callable debt security is within the scope of accounting
guidance, which impacts the amortization period for nonrefundable fees and other costs. ASU 2020-08 is effective for interim and annual reporting periods
beginning
-90-
-- 93 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
after December 15, 2020, with early adoption permitted. Upon adoption, the amendments are to be applied on a prospective basis as of the beginning of the period
of adoption for existing or newly purchased callable debt securities. We adopted ASU 2020-08 on January 1, 2021, and the adoption did not have an impact on our
consolidated financial position, results of operations or cash flows.
In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and
Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity
(“ASU 2020-06”). The amendments eliminate two of the three accounting models that require separate accounting for convertible features of debt securities,
simplify the contract settlement assessment for equity classification, require the use of the if-converted method for all convertible instruments in the diluted
earnings per share calculation and expand disclosure requirements. The amendments are effective for our annual and interim reporting periods beginning after
December 15, 2021, with early adoption permitted for reporting periods beginning after December 15, 2020. The guidance can be applied on a full retrospective
basis to all periods presented or a modified retrospective basis with a cumulative effect adjustment to the opening balance of retained earnings during the period of
adoption. We are currently evaluating the effects the adoption of ASU 2020-06 will have on our consolidated financial statements and disclosures.
In December 2019, the FASB issued Accounting Standards Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes
(“ASU 2019-12”). The amendments in ASU 2019-12 remove certain exceptions to the general principles in Accounting Standards Codification Topic 740. The
amendments also clarify and amend existing guidance to improve consistent application. The amendments are effective for our annual reporting periods beginning
after December 15, 2020, with early adoption permitted. The transition method (retrospective, modified retrospective, or prospective basis) related to the
amendments depends on the applicable guidance, and all amendments for which there is no transition guidance specified are to be applied on a prospective basis.
We adopted ASU 2019-12 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.
There were no other new accounting pronouncements that were issued or became effective during the year ended December 31, 2020 that had, or are expected
to have, a material impact on our financial position, results of operations, cash flows or financial statement disclosures.
3. Business Acquisitions
Pending Acquisition of MMM Holdings LLC and Affiliates
On February 2, 2021, we announced our entrance into an agreement with InnovaCare Health, L.P. to acquire its Puerto Rico-based subsidiaries, including
MMM Holdings, LLC (“MMM”) and its Medicare Advantage plan MMM Healthcare, LLC, Medicaid plan and other affiliated companies. MMM is an integrated
healthcare organization and seeks to provide its Medicare Advantage and Medicaid members with a whole health experience through its network of specialized
clinics and wholly owned independent physician associations. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner
by providing care management programs that improve the lives of the people we serve. The acquisition is expected to close by the end of the second quarter of
2021 and is subject to standard closing conditions and customary approvals.
Beacon Health Options, Inc.
On February 28, 2020, we completed our acquisition of Beacon Health Options, Inc. (“Beacon”) the largest independently held behavioral health organization
in the country. At the time of acquisition, Beacon served more than thirty-four million individuals across all fifty states. This acquisition aligned with our strategy
to diversify into health services and deliver both integrated solutions and care delivery models that personalize care for people with complex and chronic
conditions.
In accordance with FASB accounting guidance for business combinations, the consideration transferred was allocated to the preliminary fair value of Beacon’s
assets acquired and liabilities assumed, including identifiable intangible assets. The excess of the consideration transferred over the preliminary fair value of net
assets acquired resulted in preliminary goodwill of $1,072 at December 31, 2020, all of which was allocated to our Other segment. Preliminary goodwill
recognized from the acquisition of Beacon primarily relates to the future economic benefits arising from the assets acquired and is consistent with
-91-
-- 94 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
our stated intentions and strategy. As of December 31, 2020, the initial accounting for the acquisition has not been finalized. Any additional payments or receipts
of cash resulting from contractual purchase price adjustments or any subsequent adjustments made to the assets acquired or liabilities assumed during the
measurement period will continue to be recorded as an adjustment to goodwill.
The preliminary fair value of the net assets acquired from Beacon includes $752 of other intangible assets at December 31, 2020, which primarily consist of
finite-lived customer relationships with amortization periods ranging from 9 to 21 years. The results of operations of Beacon are included in our consolidated
financial statements within our Other segment for the period following February 28, 2020. The pro forma effects of this acquisition for prior periods were not
material to our consolidated results of operations.
4. Business Optimization Initiatives
During 2020, our management introduced enterprise-wide initiatives to optimize our business and, as a result, we recorded a charge of $653 in selling, general
and administrative expenses. This charge includes $258 for impairment and abandonment of operating-lease related right-of-use assets, $198 for impairment and
abandonment of property and equipment and $197 for future payments for employee termination costs in connection with the repositioning and reskilling of our
workforce. The charges recognized in the Commercial & Specialty Business, Government Business, IngenioRx and Other segments in 2020, were $311, $205, $4
and $133, respectively. See also Note 20, “Segment Information”. We expect most of the employee termination costs to be paid by the end of 2021. We believe
these initiatives largely represent the next step forward in our progression towards becoming a more agile organization, including process automation and a
reduction in our office space footprint.
A summary of the employee termination costs activity for the year ended December 31, 2020 and ending balance at December 31, 2020 is as follows:
Commercial &
Specialty Business
Government
Business IngenioRx Other Total
2020 Business Optimization Initiatives
Employee termination costs:
Costs incurred in 2020 $ 96 $ 92 $ 1 $ 8 $ 197
Payments made in 2020 (4) (4) — (2) (10)
Total liabilities for employee termination costs ending balance at
December 31, 2020 $ 92 $ 88 $ 1 $ 6 $ 187
-92-
-- 95 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
5. Investments
A summary of current and long-term fixed maturity securities, available-for-sale, at December 31, 2020 and 2019 is as follows:
Non-Credit
Component of
Impairment
Recognized in
Accumulated
Other
Comprehensive
Loss
Cost or
Amortized
Cost
Gross
Unrealized
Gains
Gross Unrealized Losses
Allowance For
Credit Losses
Estimated
Fair Value
Less than
12 Months
12 Months
or Greater
December 31, 2020:
Fixed maturity securities:
United States Government securities $ 765 $ 11 $ (2) $ — $ — $ 774 $ —
Government sponsored securities 63 6 — — — 69 —
Foreign government securities 290 17 (2) — — 305 —
States, municipalities and political
subdivisions, tax-exempt 5,185 395 (1) — — 5,579 —
Corporate securities 10,233 697 (20) (11) (7) 10,892 (1)
Residential mortgage-backed securities 4,208 154 (8) (9) — 4,345 (2)
Commercial mortgage-backed securities 73 3 (1) (3) — 72 —
Other securities 1,937 33 (5) (6) — 1,959 —
Total fixed maturity securities $ 22,754 $ 1,316 $ (39) $ (29) $ (7) $ 23,995 $ (3)
December 31, 2019
Fixed maturity securities:
United States Government securities $ 524 $ 4 $ (3) $ — $ — $ 525 $ —
Government sponsored securities 136 5 — — — 141 —
States, municipalities and political
subdivisions, tax-exempt 4,592 262 (3) — — 4,851 —
Corporate securities 8,870 339 (9) (15) — 9,185 (3)
Residential mortgage-backed securities 3,654 87 (6) (3) — 3,732 —
Commercial mortgage-backed securities 84 2 — — — 86 —
Other securities 1,648 21 (3) (5) — 1,661 —
Total fixed maturity securities $ 19,508 $ 720 $ (24) $ (23) $ — $ 20,181 $ (3)
-93-
-- 96 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
For fixed maturity securities in an unrealized loss position at December 31, 2020 and 2019, the following table summarizes the aggregate fair values and gross
unrealized losses by length of time those securities have continuously been in an unrealized loss position.
Less than 12 Months 12 Months or Greater
Number of
Securities Estimated
Fair Value
Gross
Unrealized
Loss Number of
Securities Estimated
Fair Value
Gross
Unrealized
Loss
(Securities are whole amounts)
December 31, 2020:
Fixed maturity securities:
United States Government securities 27 $ 301 $ (2) — $ — $ —
Government sponsored securities — — — 1 — —
Foreign government securities 55 35 (2) 9 4 —
States, municipalities and political subdivisions, tax-
exempt 36 57 (1) 1 3 —
Corporate securities 646 765 (20) 150 169 (11)
Residential mortgage-backed securities 224 442 (8) 90 110 (9)
Commercial mortgage-backed securities 6 16 (1) 3 4 (3)
Other securities 207 509 (5) 79 179 (6)
Total fixed maturity securities 1,201 $ 2,125 $ (39) 333 $ 469 $ (29)
December 31, 2019
Fixed maturity securities:
United States Government securities 27 $ 250 $ (3) 2 $ 1 $ —
Government sponsored securities 14 12 — 3 1 —
States, municipalities and political subdivisions, tax-
exempt 114 306 (3) 14 11 —
Corporate securities 386 558 (9) 224 286 (15)
Residential mortgage-backed securities 321 635 (6) 189 237 (3)
Commercial mortgage-backed securities 1 3 — 4 8 —
Other securities 166 415 (3) 113 358 (5)
Total fixed maturity securities 1,029 $ 2,179 $ (24) 549 $ 902 $ (23)
Below are discussions by security type for unrealized losses and credit losses as of December 31, 2020:
Corporate securities: An allowance for credit losses on certain retail, travel and entertainment, energy, and basic materials sector fixed maturity corporate
securities has been determined based on qualitative and quantitative factors including credit rating, decline in fair value and industry condition along with other
available market data. With multiple risk factors present, these securities were reviewed for expected future cash flow to determine the portion of unrealized losses
that were credit related and to record an allowance for credit losses. Unrealized losses on our other corporate securities were largely due to market conditions
relating to the COVID-19 pandemic; however, qualitative factors did not indicate a credit loss as of December 31, 2020. We do not intend to sell these investments
and it is likely we will not have to sell these investments prior to maturity or recovery of amortized cost.
As for the remaining securities shown in the table above, unrealized losses on these securities have not been recognized into income because we do not intend
to sell these investments and it is likely that we will not be required to sell these investments prior to their anticipated recovery. The decline in fair value is largely
due to changes in interest rates and other market conditions. We have evaluated these securities for any change in credit rating and have determined that no
allowance is necessary. The fair value is expected to recover as the securities approach maturity.
-94-
-- 97 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
The table below presents a roll-forward by major security type of the allowance for credit losses on fixed maturity securities available-for-sale held at period
end for the year ended December 31, 2020:
Year Ended December 31, 2020 Corporate
Securities
Foreign
Government
Securities Total
Allowance for credit losses:
Beginning balance $ — $ — $ —
Additions for securities for which no previous expected credit losses were recognized 64 1 65
Securities sold during the period (17) (1) (18)
Decreases to the allowance for credit losses on securities (40) — (40)
Total allowance for credit losses $ 7 $ — $ 7
The amortized cost and fair value of fixed maturity securities at December 31, 2020, by contractual maturity, are shown below. Expected maturities may differ
from contractual maturities because the issuers of the securities may have the right to prepay obligations.
Amortized
Cost
Estimated
Fair Value
Due in one year or less $ 592 $ 595
Due after one year through five years 5,981 6,261
Due after five years through ten years 6,874 7,296
Due after ten years 5,026 5,426
Mortgage-backed securities 4,281 4,417
Total fixed maturity securities $ 22,754 $ 23,995
Equity Securities
A summary of current equity securities at December 31, 2020 and 2019 is as follows:
December 31, 2020 December 31, 2019
Equity Securities:
Exchange traded funds $ 1,154 $ 44
Fixed maturity mutual funds 144 643
Common equity securities 201 237
Private equity securities 60 85
Total $ 1,559 $ 1,009
-95-
-- 98 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Investment Income
The major categories of net investment income for the years ended December 31, 2020, 2019 and 2018 are as follows:
2020 2019 2018
Fixed maturity securities $ 725 $ 721 $ 681
Equity securities 71 100 86
Cash equivalents 28 64 51
Other 91 149 193
Investment income 915 1,034 1,011
Investment expense (38) (29) (41)
Net investment income $ 877 $ 1,005 $ 970
Investment Gains
Net realized investment gains/losses and the net change in unrealized appreciation/depreciation on investments for the years ended December 31, 2020, 2019
and 2018 are as follows:
2020 2019 2018
Net realized gains (losses):
Fixed maturity securities:
Gross realized gains from sales $ 175 $ 125 $ 85
Gross realized losses from sales (105) (59) (116)
Impairment losses recognized in income (7) (13) (9)
Net realized gains (losses) from sales of fixed maturity securities 63 53 (40)
Equity securities:
Gross realized gains 269 147 77
Gross realized losses (75) (84) (276)
Net realized gains (losses) on equity securities 194 63 (199)
Other investments:
Gross realized gains from sales 18 3 27
Gross realized losses from sales — (1) —
Impairment losses recognized in income (91) (34) (17)
Net realized gains (losses) from sales of other investments (73) (32) 10
Net realized gains (losses) on investments 184 84 (229)
Change in net unrealized gains (losses) on investments:
Fixed maturity securities 575 874 (529)
Equity securities — — —
Other investments (5) — 5
Total change in net unrealized gains (losses) on investments 570 874 (524)
Deferred income tax (expense) benefit (142) (194) 106
Change in net unrealized gains (losses) on investments 428 680 (418)
Net realized gains (losses) on investments and change in net unrealized gains (losses) on
investments $ 612 $ 764 $ (647)
-96-
-- 99 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
The gains and losses related to equity securities for the years ended December 31, 2020 and 2019 are as follows:
2020 2019 2018
Net realized gains (losses) recognized on equity securities $ 194 $ 63 $ (199)
Less: Net realized (gains) losses recognized on equity securities sold during the period (61) (39) 57
Unrealized gains (losses) recognized in income on equity securities still held at December 31 $ 133 $ 24 $ (142)
A primary objective in the management of our fixed maturity and equity portfolios is to maximize total return relative to underlying liabilities and respective
liquidity needs. In achieving this goal, assets may be sold to take advantage of market conditions or other investment opportunities as well as tax considerations.
Sales will generally produce realized gains and losses. In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but
not limited to: (i) changes in the investment environment; (ii) expectations that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or
an industry; (iv) changes in credit quality; or (v) changes in expected cash flow.
Proceeds from sales, maturities, calls or redemptions of fixed maturity securities and the related gross realized gains and gross realized losses for the years
ended December 31 are as follows:
2020 2019 2018
Proceeds $ 11,122 $ 8,351 $ 8,380
Gross realized gains 175 125 85
Gross realized losses (105) (59) (116)
A significant judgment in the valuation of investments is the determination of when a credit loss has occurred. We follow a consistent and systematic process
for recognizing impairments on securities that sustain credit declines in value. We have established a committee responsible for the impairment review process.
The decision to impair a security incorporates both quantitative criteria and qualitative information. The impairment review process considers a number of factors
including, but not limited to: (i) the extent to which the fair value is less than book value, (ii) the financial condition and near term prospects of the issuer, (iii) our
intent and ability to retain impaired investments for a period of time sufficient to allow for any anticipated recovery in fair value, (iv) our intent to sell or the
likelihood that we will need to sell a fixed maturity security before recovery of its amortized cost basis, (v) whether the debtor is current on interest and principal
payments, (vi) the reasons for the decline in value (i.e., credit event compared to liquidity, general credit spread widening, currency exchange rate or interest rate
factors) and (vii) general market conditions and industry or sector specific factors. For securities that are deemed to be credit impaired, an allowance is created.
Investment securities are exposed to various risks, such as interest rate, market and credit. Due to the level of risk associated with certain investment securities
and the level of uncertainty related to changes in the value of investment securities, it is possible that changes in these risk factors in the near term could have a
material adverse impact on our results of operations or shareholders’ equity.
At December 31, 2020 and 2019, there were no individual investments that exceeded 10% of shareholders’ equity.
At December 31, 2020 and 2019, there were three and zero, respectively, fixed maturity investments that did not produce income during the years then ended.
As of December 31, 2020 and 2019, we had committed approximately $1,320 and $999, respectively, to future capital calls from various third-party
investments in exchange for an ownership interest in the related entities.
At December 31, 2020 and 2019, securities with carrying values of approximately $562 and $505, respectively, were deposited by our insurance subsidiaries
under requirements of regulatory authorities.
-97-
-- 100 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Securities Lending Programs
The fair value of the collateral received at the time of the securities lending transactions amounted to $1,199 and $351 at December 31, 2020 and 2019,
respectively. The value of the collateral represented 102% and 103% of the market value of the securities on loan at December 31, 2020 and 2019, respectively.
The remaining contractual maturities of our securities lending transactions at December 31, 2020 is as follows:
Overnight and
Continuous
Securities lending transactions
Cash $ 1,056
United States Government securities 143
Total $ 1,199
-98-
-- 101 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
6. Derivative Financial Instruments
We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, swaptions,
embedded derivatives and warrants. We also enter into master netting agreements which reduce credit risk by permitting net settlement of transactions. At
December 31, 2020 and 2019, we had received collateral of $37 and $22, respectively, related to our derivative financial instruments.
A summary of the aggregate contractual or notional amounts and estimated fair values related to derivative financial instruments at December 31, 2020 and
2019 is as follows:
Contractual/
Notional
Amount Balance Sheet Location
Estimated Fair Value
Asset (Liability)
December 31, 2020
Hedging instruments
Interest rate swaps - fixed to floating $ 575 Other assets/other liabilities $ 37 $ —
Non-hedging instruments
Interest rate swaps 27 Equity securities — —
Futures 183 Equity securities 6 (5)
Subtotal non-hedging 210 Subtotal non-hedging 6 (5)
Total derivatives $ 785 Total derivatives 43 (5)
Amounts netted — —
Net derivatives $ 43 $ (5)
December 31, 2019
Hedging instruments
Interest rate swaps - fixed to floating $ 1,200 Other assets/other liabilities $ 22 $ (1)
Non-hedging instruments
Interest rate swaps 1 Equity securities — —
Futures 134 Equity securities 1 —
Subtotal non-hedging 135 Subtotal non-hedging 1 —
Total derivatives $ 1,335 Total derivatives 23 (1)
Amounts netted (1) 1
Net derivatives $ 22 $ —
-99-
-- 102 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Fair Value Hedges
We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-term debt from fixed rates to floating
rates. The floating rates payable on all of our fair value hedges are benchmarked to the LIBOR. A summary of our outstanding fair value hedges at December 31,
2020 and 2019 is as follows:
Type of Fair Value Hedges
Year
Entered
Into
Outstanding Notional Amount Interest Rate
Received Expiration Date 2020 2019
Interest rate swap 2020 $ 75 $ — 4.101 % September 1, 2027
Interest rate swap 2018 50 50 4.101 September 1, 2027
Interest rate swap 2018 450 450 3.300 January 15, 2023
Interest rate swap 2018 — 90 4.350 August 15, 2020
Interest rate swap 2017 — 50 4.350 August 15, 2020
Interest rate swap 2015 — 200 4.350 August 15, 2020
Interest rate swap 2014 — 150 4.350 August 15, 2020
Interest rate swap 2013 — 10 4.350 August 15, 2020
Interest rate swap 2012 — 200 4.350 August 15, 2020
Total notional amount outstanding $ 575 $ 1,200
The following amounts were recorded on our consolidated balance sheets related to cumulative basis adjustments for fair value hedges at December 31, 2020
and 2019:
Balance Sheet Classification in Which Hedged Item is
Included
Carrying Amount of Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment
Included in the Carrying Amount of the Hedged Liability
2020 2019 2020 2019
Current portion of long term-debt $ 700 $ 1,598 $ 37 $ 22
Long-term debt 19,335 17,787 — (1)
Cash Flow Hedges
We have entered into a series of forward starting pay fixed interest rate swaps with the objective of eliminating the variability of cash flows in the interest
payments on future financings that were anticipated at the time of entering into the swaps. During 2020, swaps in the notional amount of $725 were terminated. All
swaps have expired or were terminated as of December 31, 2020.
The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other comprehensive income (loss), net of tax, was $250 and
$262 at December 31, 2020 and 2019, respectively. As of December 31, 2020, the total amount of amortization over the next twelve months for all cash flow
hedges is estimated to increase interest expense by approximately $14. No amounts were excluded from effectiveness testing.
-100-
-- 103 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
A summary of the effect of cash flow hedges in accumulated other comprehensive income (loss) for the years ended December 31, 2020, 2019 and 2018 is as
follows:
Hedge
Loss
Recognized
in Other
Comprehensive
Income (Loss)
Income Statement
Location of
Loss
Reclassification
from Accumulated
Other Comprehensive
Income (Loss)
Hedge Loss
Reclassified from
Accumulated
Other
Comprehensive
Income (Loss) Type of Cash Flow Hedge
Year ended December 31, 2020
Forward starting pay fixed swaps $ — Interest expense $ (15)
Year ended December 31, 2019
Forward starting pay fixed swaps (35) Interest expense (15)
Year ended December 31, 2018
Forward starting pay fixed swaps (33) Interest expense (14)
Income Statement Relationship of Fair Value and Cash Flow Hedging
A summary of the relationship between the effects of fair value and cash flow hedges on the total amount of income and expense presented in our consolidated
statements of income for the years ended December 31, 2020, 2019 and 2018 is as follows:
Classification and Amount of Gain (Loss) Recognized in Income on Fair Value and Cash Flow Hedging
Relationships
2020 2019 2018
Net Realized
Gains (Losses) on
Financial
Instruments
Interest
Expense
Net Realized
Gains (Losses) on
Financial
Instruments
Interest
Expense
Net Realized
Gains (Losses) on
Financial
Instruments
Interest
Expense
Total amount of income or expense in the income statement in
which the effects of fair value or cash flow hedges are recorded $ 182 $ (784) $ 67 $ (746) $ (206) $ (753)
Gain (loss) on fair value hedging relationships:
Interest rate swaps:
Hedged items — (15) — 2 — —
Derivatives designated as hedging instruments — 15 — (2) — —
Loss on cash flow hedging relationships:
Forward starting pay fixed swaps:
Amount of loss reclassified from accumulated other
comprehensive loss into net income — (15) — (15) — (14)
-101-
-- 104 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Non-Hedging Derivatives
A summary of the effect of non-hedging derivatives on our consolidated statements of income for the years ended December 31, 2020, 2019 and 2018 is as
follows:
Type of Non-hedging Derivatives Income Statement Location of
Gain (Loss) Recognized
Derivative
Gain (Loss)
Recognized
Year ended December 31, 2020
Interest rate swaps Net realized gains (losses) on financial instruments $ (1)
Options Net realized gains (losses) on financial instruments (5)
Futures Net realized gains (losses) on financial instruments 4
Total $ (2)
Year ended December 31, 2019
Interest rate swaps Net realized gains (losses) on financial instruments $ 1
Options Net realized gains (losses) on financial instruments (8)
Futures Net realized gains (losses) on financial instruments (10)
Total $ (17)
Year ended December 31, 2018
Interest rate swaps Net realized gains (losses) on financial instruments $ 14
Options Net realized gains (losses) on financial instruments 1
Futures Net realized gains (losses) on financial instruments 8
Total $ 23
7. Fair Value
Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used
to measure their fair value. Level inputs, as defined by FASB guidance for fair value measurements and disclosures, are as follows:
Level Input: Input Definition:
Level I Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level II Inputs other than quoted prices included in Level I that are observable for the asset or liability through corroboration with market data
at the measurement date.
Level III Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at
the measurement date.
The following methods, assumptions and inputs were used to determine the fair value of each class of the following assets and liabilities recorded at fair value
in the consolidated balance sheets:
Cash equivalents: Cash equivalents primarily consist of highly rated money market funds with maturities of three months or less, and are purchased daily at
par value with specified yield rates. Due to the high ratings and short-term nature of the funds, we designate all cash equivalents as Level I.
Fixed maturity securities, available-for-sale: Fair values of available-for-sale fixed maturity securities are based on quoted market prices, where available.
These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value to
facilitate fair value measurements and disclosures. Level II securities primarily include corporate securities, securities from states, municipalities and political
subdivisions, mortgage-backed securities, United States Government securities, foreign government securities, and certain other asset-backed securities. For
securities not actively traded, the pricing services may use quoted market prices of
-102-
-- 105 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. We have controls
in place to review the pricing services’ qualifications and procedures used to determine fair values. In addition, we periodically review the pricing services’ pricing
methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable. Inputs that are often used in the valuation methodologies include,
but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. We also have certain fixed maturity securities,
primarily corporate debt securities, that are designated Level III securities. For these securities, the valuation methodologies may incorporate broker quotes or
discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds
that are not observable in the markets.
Equity securities: Fair values of equity securities are generally designated as Level I and are based on quoted market prices. For certain equity securities,
quoted market prices for the identical security are not always available, and the fair value is estimated by reference to similar securities for which quoted prices are
available. These securities are designated Level II. We also have certain equity securities, including private equity securities, for which the fair value is estimated
based on each security’s current condition and future cash flow projections. Such securities are designated Level III. The fair values of these private equity
securities are generally based on either broker quotes or discounted cash flow projections using assumptions for inputs such as the weighted-average cost of capital,
long-term revenue growth rates and earnings before interest, taxes, depreciation and amortization, and/or revenue multiples that are not observable in the markets.
Securities lending collateral: Fair values of securities lending collateral are based on quoted market prices, where available. These fair values are obtained
primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value, to facilitate fair value measurements
and disclosures.
Derivatives: Fair values are based on the quoted market prices by the financial institution that is the counterparty to the derivative transaction. We
independently verify prices provided by the counterparties using valuation models that incorporate market observable inputs for similar derivative transactions.
Derivatives are designated as Level II securities. Derivatives presented within the fair value hierarchy table below are presented on a gross basis and not on a
master netting basis by counterparty.
In addition, the following methods and assumptions were used to determine the fair value of each class of pension benefit plan assets and other benefit plan
assets not defined above (see Note 11, “Retirement Benefits,” for fair values of benefit plan assets):
Mutual funds: Fair values are based on quoted market prices, which represent the net asset value (“NAV”) of the shares held.
Partnership investments: Fair values are estimated based on the plan’s proportionate share of the undistributed partners’ capital as reported in audited financial
statements of the partnership. In accordance with FASB guidance, certain investments that are measured at fair value using the NAV per share as a practical
expedient have been classified in the fair value hierarchy. The fair value amounts presented are intended to permit reconciliation of the fair value hierarchy to the
total investments of the master trust.
Commingled fund: Fair value is based on NAV per fund share, primarily derived from the quoted prices in active markets on the underlying equity securities.
Contract with insurance company: Fair value of the contract in the insurance company general investment account is determined by the insurance company
based on the fair value of the underlying investments of the account.
Investment in DOL 103-12 trust: Fair value is based on the plan’s proportionate share of the fair value of investments held by the trust, qualified as a
Department of Labor Regulation 2520.103-12 entity (“DOL 103-12 trust”) as reported in the audited financial statements of the trust, where the trustee applies fair
value measurements to the underlying investments of the trust.
Life insurance contracts: Fair value is based on the cash surrender value of the policies as reported by the insurer.
-103-
-- 106 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at December 31, 2020 and 2019 is as
follows:
Level I Level II Level III Total
December 31, 2020
Assets:
Cash equivalents $ 3,163 $ — $ — $ 3,163
Fixed maturity securities, available-for-sale:
United States Government securities — 774 — 774
Government sponsored securities — 69 — 69
Foreign government securities — 305 — 305
States, municipalities and political subdivisions, tax-exempt — 5,579 — 5,579
Corporate securities — 10,567 325 10,892
Residential mortgage-backed securities — 4,343 2 4,345
Commercial mortgage-backed securities — 72 — 72
Other securities — 1,954 5 1,959
Total fixed maturity securities, available-for-sale — 23,663 332 23,995
Equity securities:
Exchange traded funds 1,154 — — 1,154
Fixed maturity mutual funds — 144 — 144
Common equity securities 171 30 — 201
Private equity securities — — 60 60
Total equity securities 1,325 174 60 1,559
Securities lending collateral — 1,199 — 1,199
Derivatives — 43 — 43
Total assets $ 4,488 $ 25,079 $ 392 $ 29,959
Liabilities:
Derivatives $ — $ (5) $ — $ (5)
Total liabilities $ — $ (5) $ — $ (5)
December 31, 2019
Assets:
Cash equivalents $ 2,015 $ — $ — $ 2,015
Fixed maturity securities, available-for-sale:
United States Government securities — 525 — 525
Government sponsored securities — 141 — 141
States, municipalities and political subdivisions, tax-exempt — 4,851 — 4,851
Corporate securities — 8,882 303 9,185
Residential mortgage-backed securities — 3,730 2 3,732
Commercial mortgage-backed securities — 86 — 86
Other securities — 1,654 7 1,661
Total fixed maturity securities, available-for-sale — 19,869 312 20,181
Equity securities:
Exchange traded funds 44 — — 44
Fixed maturity mutual funds — 643 — 643
Common equity securities 206 31 — 237
Private equity securities — — 85 85
Total equity securities 250 674 85 1,009
Securities lending collateral — 353 — 353
Derivatives — 23 — 23
Total assets $ 2,265 $ 20,919 $ 397 $ 23,581
Liabilities:
Derivatives $ — $ (1) $ — $ (1)
Total liabilities $ — $ (1) $ — $ (1)
-104-
-- 107 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the years ended
December 31, 2020, 2019 and 2018 is as follows:
Corporate
Securities
Residential
Mortgage-
backed
Securities Other
Securities Equity
Securities Total
Year ended December 31, 2020
Beginning balance at January 1, 2020 $ 303 $ 2 $ 7 $ 85 $ 397
Total gains (losses):
Recognized in net income (3) — — (19) (22)
Recognized in accumulated other comprehensive income (5) — — — (5)
Purchases 85 — — 16 101
Sales (19) — — (22) (41)
Settlements (44) — (2) — (46)
Transfers into Level III 10 — — — 10
Transfers out of Level III (2) — — — (2)
Ending balance at December 31, 2020 $ 325 $ 2 $ 5 $ 60 $ 392
Change in unrealized gains or losses included in net income related to assets still held at
December 31, 2020 $ — $ — $ — $ (19) $ (19)
Year ended December 31, 2019
Beginning balance at January 1, 2019 $ 287 $ 6 $ 17 $ 313 $ 623
Total gains (losses):
Recognized in net income (7) — — (6) (13)
Recognized in accumulated other comprehensive loss 3 — — — 3
Purchases 122 — 2 65 189
Sales (22) — — (79) (101)
Settlements (71) (2) (6) — (79)
Transfers into Level III — — 3 2 5
Transfers out of Level III (9) (2) (9) (210) (230)
Ending balance at December 31, 2019 $ 303 $ 2 $ 7 $ 85 $ 397
Change in unrealized gains or losses included in net income related to assets still held at
December 31, 2019 $ — $ — $ — $ 6 $ 6
Year ended December 31, 2018
Beginning balance at January 1, 2018 $ 229 $ 5 $ 16 $ 287 $ 537
Total gains (losses):
Recognized in net income 1 — — (229) (228)
Recognized in accumulated other comprehensive loss (5) — — — (5)
Purchases 120 2 18 290 430
Sales (33) — (1) (35) (69)
Settlements (88) (1) (10) — (99)
Transfers into Level III 65 — 9 — 74
Transfers out of Level III (2) — (15) — (17)
Ending balance at December 31, 2018 $ 287 $ 6 $ 17 $ 313 $ 623
Change in unrealized gains or losses included in net income related to assets still held at
December 31, 2018 $ — $ — $ — $ 30 $ 30
There were no individually material transfers into or out of Level III during the years ended December 31, 2020, 2019 or 2018.
Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but
are subject to fair value adjustments only in certain circumstances. As disclosed in Note 3, “Business Acquisitions,” we completed our acquisition of Beacon
on February 28, 2020. The preliminary values of net assets acquired in our acquisition of Beacon and resulting goodwill and other intangible assets were recorded
at fair
-105-
-- 108 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
value primarily using Level III inputs. The majority of Beacon’s assets acquired and liabilities assumed were recorded at their carrying values as of
the respective date of acquisition, as their carrying values approximated their fair values due to their short-term nature. The preliminary fair values of goodwill and
other intangible assets acquired in our acquisition of Beacon were internally estimated based on the income approach. The income approach estimates fair value
based on the present value of the cash flows that the assets could be expected to generate in the future. We developed internal estimates for the expected cash flows
and discount rate in the present value calculation. Other than the assets acquired and liabilities assumed in our acquisition of Beacon described above, there were
no material assets or liabilities measured at fair value on a nonrecurring basis during the years ended December 31, 2020 or 2019.
Our valuation policy is determined by members of our treasury and accounting departments. Whenever possible, our policy is to obtain quoted market prices
in active markets to estimate fair values for recognition and disclosure purposes. Where quoted market prices in active markets are not available, fair values are
estimated using discounted cash flow analyses, broker quotes, unobservable inputs or other valuation techniques. These techniques are significantly affected by our
assumptions, including discount rates and estimates of future cash flows. The use of assumptions for unobservable inputs for the determination of fair value
involves a level of judgment and uncertainty. Changes in assumptions that reasonably could have been different at the reporting date may result in a higher or
lower determination of fair value. Changes in fair value measurements, if significant, may affect performance of cash flows.
Potential taxes and other transaction costs are not considered in estimating fair values. Our valuation policy is generally to obtain quoted prices for each
security from third-party pricing services, which are derived through recently reported trades for identical or similar securities making adjustments through the
reporting date based upon available market observable information. As we are responsible for the determination of fair value, we perform analysis on the prices
received from the pricing services to determine whether the prices are reasonable estimates of fair value. This analysis is performed by our internal treasury
personnel who are familiar with our investment portfolios, the pricing services engaged and the valuation techniques and inputs used. Our analysis includes
procedures such as a review of month-to-month price fluctuations and price comparisons to secondary pricing services. There were no adjustments to quoted
market prices obtained from the pricing services during the years ended December 31, 2020, 2019 or 2018.
In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB guidance also requires the disclosure of fair
values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in the consolidated balance
sheets.
Non-financial instruments such as real estate, property and equipment, other current assets, deferred income taxes, intangible assets and certain financial
instruments, such as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our
underlying economic value.
The carrying amounts reported in the consolidated balance sheets for cash, accrued investment income, premium receivables, self-funded receivables, other
receivables, income taxes receivable, unearned income, accounts payable and accrued expenses, security trades pending payable, securities lending payable and
certain other current liabilities approximate fair value because of the short-term nature of these items. These assets and liabilities are not listed in the table below.
The following methods and assumptions were used to estimate the fair value of each class of financial instrument that is recorded at its carrying value on the
consolidated balance sheets:
Other invested assets: Other invested asset primarily include our investments in limited partnerships, joint ventures and other non-controlled corporations, as
well as the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled
corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. The carrying value of corporate-owned life insurance
policies represents the cash surrender value as reported by the respective insurer, which approximates fair value.
Short-term borrowings: The fair value of our short-term borrowings is based on quoted market prices for the same or similar debt, or if no quoted market
prices were available, on the current market interest rates estimated to be available to us for debt of similar terms and remaining maturities.
Long-term debt—commercial paper: The carrying amount for commercial paper approximates fair value, as the underlying instruments have variable interest
rates at market value.
-106-
-- 109 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Long-term debt—senior unsecured notes and surplus notes: The fair values of our notes are based on quoted market prices in active markets for the same or
similar debt, or, if no quoted market prices are available, on the current market observable rates estimated to be available to us for debt of similar terms and
remaining maturities.
Long-term debt—convertible debentures: The fair value of our convertible debentures is based on the quoted market price in the active private market in which
the convertible debentures trade.
A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at
December 31, 2020 and 2019 is as follows:
Carrying
Value
Estimated Fair Value
Level I Level II Level III Total
December 31, 2020
Assets:
Other invested assets $ 4,285 $ — $ — $ 4,285 $ 4,285
Liabilities:
Debt:
Commercial paper 250 — 250 — 250
Notes 19,677 — 23,307 — 23,307
Convertible debentures 108 — 712 — 712
December 31, 2019
Assets:
Other invested assets $ 4,258 $ — $ — $ 4,258 $ 4,258
Liabilities:
Debt:
Short-term borrowings 700 — 700 — 700
Commercial paper 400 — 400 — 400
Notes 18,840 — 20,470 — 20,470
Convertible debentures 145 — 904 — 904
-107-
-- 110 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
8. Income Taxes
The components of deferred income taxes at December 31, 2020 and 2019 are as follows:
2020 2019
Deferred income tax assets:
Accrued expenses $ 588 $ 331
Bad debt reserves 143 89
Insurance reserves 187 139
Lease liabilities 204 180
Retirement liabilities 205 216
Deferred compensation 31 28
Federal and state operating loss carryforwards 274 124
Other 113 71
Subtotal 1,745 1,178
Less: valuation allowance (84) (45)
Total deferred income tax assets 1,661 1,133
Deferred income tax liabilities:
Federal and state intangible assets 2,073 1,999
Capitalized software 670 554
Depreciation and amortization 37 62
Investment basis 407 230
Retirement assets 260 249
Lease right-of-use asset 131 164
Prepaid expenses 102 102
Total deferred income tax liabilities 3,680 3,360
Net deferred income tax liabilities $ 2,019 $ 2,227
In the table above, certain amounts for the year ended December 31, 2019 have been reclassified from a net to gross presentation to more fully reflect the
federal and state tax effects by type of temporary difference. This reclassification does not impact amounts presented in the financial statements.
As of December 31, 2020, the Company’s undistributed earnings from non-U.S. subsidiaries are intended to be indefinitely reinvested in non-U.S. operations,
and therefore no U.S. deferred taxes have been recorded.
Significant components of the provision for income taxes for the years ended December 31, 2020, 2019 and 2018 consist of the following:
2020 2019 2018
Current tax expense:
Federal $ 1,731 $ 1,019 $ 1,128
State and local 461 84 78
Total current tax expense 2,192 1,103 1,206
Deferred tax (benefit) expense (526) 75 112
Total income tax expense $ 1,666 $ 1,178 $ 1,318
-108-
-- 111 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
State and local current tax expense is reported gross of federal benefit, and includes amounts related to audit settlements, uncertain tax positions, state tax
credits and true up of prior years’ tax. Such items are included in multiple lines in the following rate reconciliation table on a net of federal tax basis.
A reconciliation of income tax expense recorded in the consolidated statements of income and amounts computed at the statutory federal income tax rate for
the years ended December 31, 2020, 2019 and 2018 is as follows:
2020 2019 2018
Amount Percent Amount Percent Amount Percent
Amount at statutory rate $ 1,310 21.0 % $ 1,257 21.0 % $ 1,064 21.0 %
State and local income taxes net of federal tax expense/benefit 235 3.8 138 2.3 63 1.2
Tax exempt interest and dividends received deduction (22) (0.4) (24) (0.4) (27) (0.5)
HIP fee 330 5.3 — — 324 6.4
Basis adjustments from recent acquisitions (110) (1.8) — — (28) (0.6)
Tax Cuts and Jobs Act — — — — (28) (0.6)
Other, net (77) (1.2) (193) (3.2) (50) (0.9)
Total income tax expense $ 1,666 26.7 % $ 1,178 19.7 % $ 1,318 26.0 %
During the year ended December 31, 2020, we recognized income tax expense of $1,666, or $6.55 per diluted share, which included income tax expense of
$330, or $1.30 per diluted share as a result of the non-tax deductibility of the HIP Fee payment, which was reinstated for 2020.
During the year ended December 31, 2019, we recognized income tax expense of $1,178, or $4.53 per diluted share. The HIP Fee payment was suspended for
2019.
During the year ended December 31, 2018, we recognized income tax expense of $324, or $1.23 per diluted share, as a result of the non-tax deductibility of
the HIP Fee payment.
On December 22, 2017, the federal government enacted the Tax Cuts and Jobs Act, which contains significant changes to corporate taxation, including, but
not limited to, reducing the U.S. federal corporate income tax rate from 35% to 21% and modifying or limiting many business deductions. At December 31, 2018,
we completed our accounting for the tax effects of enactment of the Tax Cuts and Jobs Act and there was no material change to our 2017 provisional amount. In
addition we reclassified, for our interim and annual reporting periods beginning on January 1, 2018, $91 of stranded tax effects from accumulated other
comprehensive loss to retained earnings on our consolidated balance sheets.
The change in the carrying amount of gross unrecognized tax benefits from uncertain tax positions for the years ended December 31, 2020 and 2019 is as
follows:
2020 2019
Balance at January 1 $ 146 $ 241
Additions based on:
Tax positions related to current year 76 1
Tax positions related to prior years 40 —
Reductions based on:
Tax positions related to prior years (13) (63)
Settlements with taxing authorities — (33)
Balance at December 31 $ 249 $ 146
The table above excludes interest, net of related tax benefits, which is treated as income tax expense (benefit) under our accounting policy. The interest is
included in the amounts described in the following paragraph.
-109-
-- 112 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
The amount of unrecognized tax benefits that would impact our effective tax rate in future periods, if recognized, was $227 and $140 at December 31, 2020
and 2019, respectively. Also included in the table above, at December 31, 2020, is $2 that would be recognized as an adjustment to additional paid-in capital,
which would not affect our effective tax rate. In addition to the contingent liabilities included in the table above, during 2017 we filed protective state income tax
refund claims of approximately $310. There were no equivalent protective state income tax refund claims filed in 2020, 2019, or 2018.
For the year ended December 31, 2020, we recognized a net interest expense of $7. For the years ended December 31, 2019 and 2018, we recognized a net
interest (benefit) expense of $(11) and $15, respectively. We had accrued approximately $33 and $26 for the payment of interest at December 31, 2020 and 2019,
respectively.
As of December 31, 2020, as further described below, certain tax years remain open to examination by the Internal Revenue Service (“IRS”) and various state
and local authorities. As a result of these examinations and discussions with taxing agencies, we have recorded amounts for uncertain tax positions. It is anticipated
that the amount of unrecognized tax benefits will change in the next twelve months due to possible settlements of audits and changes in temporary items. However,
the ultimate resolution of these items is dependent on the completion of negotiations with various taxing authorities. While it is difficult to determine when other
tax settlements will actually occur, it is reasonably possible that one could occur in the next twelve months and our unrecognized tax benefits could change within
a range of approximately ($15) to ($147).
We are a member of the IRS Compliance Assurance Process (“CAP”). The objective of CAP is to reduce taxpayer burden and uncertainty while assuring the
IRS of the accuracy of tax returns prior to filing, thereby reducing or eliminating the need for post-filing examinations.
As of December 31, 2020, the IRS examination of our 2020 and 2019 tax years continues to be in process.
In certain states, we pay premium taxes in lieu of state income taxes. Premium taxes are reported in selling, general and administrative expense.
At December 31, 2020, we had federal net operating loss carryforwards of $40 that will expire beginning 2033 through 2037 and $7 that have an indefinite
carryforward period; state net operating loss carryforwards expire beginning 2022 through 2040, with some having an indefinite carryforward period.
During 2020, 2019 and 2018, federal income taxes paid totaled $1,790, $1,403 and $738, respectively.
9. Property and Equipment
A summary of property and equipment at December 31, 2020 and 2019 is as follows:
2020 2019
Computer software, purchased and internally developed $ 5,247 $ 4,314
Computer equipment, furniture and other equipment 1,218 1,264
Leasehold improvements 671 715
Building and improvements 174 169
Land and improvements 17 17
Property and equipment, gross 7,327 6,479
Accumulated depreciation and amortization (3,844) (3,346)
Property and equipment, net $ 3,483 $ 3,133
Depreciation expense for 2020, 2019 and 2018 was $176, $147 and $124, respectively. Amortization expense on computer software and leasehold
improvements for 2020, 2019 and 2018 was $462, $528 and $528, respectively, which includes amortization expense on computer software, both purchased and
internally developed, for 2020, 2019 and 2018 of $412, $450 and $465, respectively. Capitalized costs related to the internal development of software of $4,783
and $3,939 at December 31, 2020 and 2019, respectively, are reported with computer software.
-110-
-- 113 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Our activities as disclosed in Note 4, “Business Optimization Initiatives”, include impairment of property and equipment. We recorded an impairment charge
of $198 for property and equipment in 2020 which is in selling, general and administrative expenses.
10. Goodwill and Other Intangible Assets
A summary of the change in the carrying amount of goodwill for our segments (see Note 20, “Segment Information”) for 2020 and 2019 is as follows:
Commercial
and Specialty
Business
Government
Business IngenioRx Other Total
Balance as of January 1, 2019 $ 11,551 $ 8,953 $ — $ — $ 20,504
Adjustments — (674) — 670 (4)
Balance as of December 31, 2019 11,551 8,279 — 670 20,500
Acquisitions and adjustments 42 52 48 1,049 1,191
Balance as of December 31, 2020 $ 11,593 $ 8,331 $ 48 $ 1,719 $ 21,691
Accumulated impairment as of December 31, 2020 $ (41) $ — $ — $ — $ (41)
Goodwill adjustments in 2019 include certain reclassifications made for changes in segment reporting. For additional information, see Note 20, “Segment
Information”.
As required by FASB guidance, we completed annual impairment tests of existing goodwill and other intangible assets with indefinite lives during 2020, 2019
and 2018. We perform these annual impairment tests during the fourth quarter. FASB guidance also requires interim impairment testing to be performed when
potential impairment indicators exist. These tests involve the use of estimates related to the fair value of goodwill and intangible assets with indefinite lives and
require a significant degree of management judgment and the use of subjective assumptions. Qualitative testing procedures include assessing our financial
performance, macroeconomic conditions, industry and market considerations, various asset specific factors and entity specific events. For quantitative testing, the
fair values are estimated using the projected income and market valuation approaches, incorporating Level III internal estimates for inputs, including, but not
limited to, revenue projections, income projections, cash flows and discount rates. We did not incur any impairment losses in 2020, 2019 or 2018, as the estimated
fair values of our reporting units were substantially in excess of their carrying values.
The components of other intangible assets as of December 31, 2020 and 2019 are as follows:
2020 2019
Gross
Carrying
Amount
Accumulated
Amortization
Net
Carrying
Amount
Gross
Carrying
Amount
Accumulated
Amortization
Net
Carrying
Amount
Intangible assets with finite lives:
Customer relationships $ 5,180 $ (3,766) $ 1,414 $ 4,500 $ (3,469) $ 1,031
Provider and hospital relationships 323 (114) 209 228 (98) 130
Other 444 (177) 267 352 (129) 223
Total 5,947 (4,057) 1,890 5,080 (3,696) 1,384
Intangible assets with indefinite lives:
Blue Cross and Blue Shield and other trademarks 6,299 — 6,299 6,299 — 6,299
State Medicaid licenses 1,216 — 1,216 991 — 991
Total 7,515 — 7,515 7,290 — 7,290
Other intangible assets $ 13,462 $ (4,057) $ 9,405 $ 12,370 $ (3,696) $ 8,674
-111-
-- 114 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
As of December 31, 2020, the estimated amortization expense for each of the five succeeding years is as follows: 2021, $324; 2022, $271; 2023, $233; 2024,
$196; and 2025, $159.
11. Retirement Benefits
We sponsor various non-contributory employee defined benefit plans through certain subsidiaries.
The Anthem Cash Balance Plan A and the Anthem Cash Balance Plan B are cash balance pension plans covering certain eligible employees of the affiliated
companies that participate in these plans. Effective January 1, 2006, benefits were curtailed, with the result that most participants stopped accruing benefits but
continue to earn interest on benefits accrued prior to the curtailment. Certain participants subject to collective bargaining and certain other participants who met
grandfathering rules continued to accrue benefits. Participants who did not receive credits and/or benefit accruals were included in the Anthem Cash Balance Plan
A, while employees who were still receiving credits and/or benefits participated in the Anthem Cash Balance Plan B. Effective January 1, 2019, benefits under the
Anthem Cash Balance Plan B were curtailed. All grandfathered participants no longer have pay credits added to their accounts but continue to earn interest on
existing account balances. Participants continue to earn years of pension service for vesting purposes. Several pension plans acquired through various corporate
mergers and acquisitions were merged into these plans in prior years.
The Employees’ Retirement Plan of Blue Cross of California (the “BCC Plan”) is a defined benefit pension plan that covers eligible employees of Blue Cross
of California who are covered by a collective bargaining agreement. Effective January 1, 2007, benefits were curtailed under the BCC Plan with the result that no
Blue Cross of California employees hired or rehired after December 31, 2006 are eligible to participate in the BCC Plan.
All of the plans’ assets consist primarily of equity securities, fixed maturity securities, investment funds and cash. The funding policies for all plans are to
contribute amounts at least sufficient to meet the minimum funding requirements set forth in the Employee Retirement Income Security Act of 1974, as amended
(“ERISA”), as further amended by the Pension Protection Act of 2006, and in accordance with income tax regulations, plus such additional amounts as are
necessary to provide assets sufficient to meet the benefits to be paid to plan participants.
The following tables disclose consolidated “pension benefits,” which include the defined benefit pension plans described above, and consolidated “other
benefits,” which include postretirement health and welfare benefits including medical, vision and dental benefits offered to certain employees. Calculations were
computed using assumptions at the December 31 measurement dates.
The reconciliation of the benefit obligation is as follows:
Pension Benefits Other Benefits
2020 2019 2020 2019
Benefit obligation at beginning of year $ 1,880 $ 1,743 $ 423 $ 431
Service cost — — 1 1
Interest cost 47 62 10 15
Plan participant contributions — — 18 17
Actuarial loss (gain) 219 200 (15) 5
Settlements (80) (35) — —
Benefits paid (57) (90) (38) (46)
Benefit obligation at end of year $ 2,009 $ 1,880 $ 399 $ 423
-112-
-- 115 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
The changes in the fair value of plan assets are as follows:
Pension Benefits Other Benefits
2020 2019 2020 2019
Fair value of plan assets at beginning of year $ 2,026 $ 1,818 $ 367 $ 336
Actual return on plan assets 290 329 33 55
Employer contributions 7 4 11 5
Plan participant contributions — — 18 17
Settlements (80) (35) — —
Benefits paid (57) (90) (38) (46)
Fair value of plan assets at end of year $ 2,186 $ 2,026 $ 391 $ 367
The net amount included in the consolidated balance sheets is as follows:
Pension Benefits Other Benefits
2020 2019 2020 2019
Noncurrent assets $ 248 $ 212 $ — $ —
Current liabilities (6) (6) — —
Noncurrent liabilities (65) (60) (8) (56)
Net amount at December 31 $ 177 $ 146 $ (8) $ (56)
The net amounts included in accumulated other comprehensive income (loss) that have not been recognized as components of net periodic benefit costs are as
follows:
Pension Benefits Other Benefits
2020 2019 2020 2019
Net actuarial loss $ 749 $ 734 $ 3 $ 25
Prior service cost (credit) — 1 (12) (19)
Net amount before tax at December 31 $ 749 $ 735 $ (9) $ 6
The accumulated benefit obligation for the defined benefit pension plans was $2,007 and $1,878 at December 31, 2020 and 2019, respectively.
As of December 31, 2020, certain pension plans had accumulated benefit obligations in excess of plan assets. Such plans had accumulated benefit obligation
and fair value of plan assets of $111 and $42, respectively. For those same plans, the projected benefit obligation was also in excess of plan assets. Such plans had
projected benefit obligation and fair value of plan assets of $113 and $42, respectively.
The weighted-average assumptions used in calculating the benefit obligations for all plans are as follows:
Pension Benefits Other Benefits
2020 2019 2020 2019
Discount rate 2.24 % 3.11 % 1.99 % 2.93 %
Rate of compensation increase 3.00 % 3.00 % 3.00 % 3.00 %
Expected rate of return on plan assets 6.72 % 7.33 % 6.60 % 7.00 %
Interest crediting rate 3.82 % 3.82 % 0.87 % 1.81 %
-113-
-- 116 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
The components of net periodic benefit credit included in the consolidated statements of income are as follows:
2020 2019 2018
Pension Benefits
Service cost $ — $ — $ 8
Interest cost 47 62 55
Expected return on assets (138) (138) (147)
Recognized actuarial loss 24 17 22
Settlement loss 29 9 5
Net periodic benefit credit $ (38) $ (50) $ (57)
Other Benefits
Service cost $ 1 $ 1 $ 1
Interest cost 10 15 15
Expected return on assets (25) (22) (24)
Recognized actuarial loss — 2 3
Amortization of prior service credit (7) (12) (12)
Net periodic benefit credit $ (21) $ (16) $ (17)
During the years ended December 31, 2020, 2019 and 2018, we incurred total settlement losses of $29, $9 and $5, respectively, as lump-sum payments
exceeded the service cost and interest cost components of net periodic benefit cost for certain of our plans.
The weighted-average assumptions used in calculating the net periodic benefit cost for all plans are as follows:
2020 2019 2018
Pension Benefits
Discount rate 3.11 % 4.15 % 3.44 %
Rate of compensation increase 3.00 % 3.00 % 3.00 %
Expected rate of return on plan assets 7.33 % 7.44 % 7.83 %
Interest crediting rate 3.82 % 3.83 % 3.82 %
Other Benefits
Discount rate 2.93 % 4.04 % 3.42 %
Rate of compensation increase 3.00 % 3.00 % 3.00 %
Expected rate of return on plan assets 7.00 % 7.00 % 7.00 %
Interest crediting rate 1.81 % 3.12 % 2.35 %
The assumed healthcare cost trend rates used to measure the expected cost of pre-Medicare (those who are not currently eligible for Medicare benefits) other
benefits at our December 31, 2020 measurement date was 7.00% for 2021 with a gradual decline to 4.50% by the year 2033. The assumed healthcare cost trend
rates used to measure the expected cost of post-Medicare (those who are currently eligible for Medicare benefits) other benefits at our December 31, 2020
measurement date was 5.50% for 2021 with a gradual decline to 4.50% by the year 2033. These estimated trend rates are subject to change in the future.
Plan assets include a diversified mix of equity securities, investment grade fixed maturity securities and other types of investments across a range of sectors
and levels of capitalization to maximize long-term return for a prudent level of risk. The weighted-average target allocation for pension benefit plan assets is 44%
equity securities, 48% fixed maturity securities, and 8% to all other types of investments. Equity securities primarily include a mix of domestic securities, foreign
securities and
-114-
-- 117 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
mutual funds invested in equities. Fixed maturity securities primarily include treasury securities, corporate bonds and asset-backed investments issued by
corporations and the U.S. government. Other types of investments primarily include insurance contracts designed specifically for employee benefit plans and a
commingled fund comprised primarily of equity securities. As of December 31, 2020, there were no significant concentrations of investments in the pension
benefit assets or other benefit assets. No plan assets were invested in Anthem common stock.
The partnerships hold various types of underlying assets such as real estate and investments in oil and gas companies. Generally, the partnership interests are
not redeemable and are transferable only with the consent of the general partner. Unfunded commitments related to all partnership interests totaled approximately
$3 and $29 at December 31, 2020 and 2019, respectively.
Pension benefit assets and other benefit assets recorded at fair value are categorized based upon the level of judgment associated with the inputs used to
measure their fair value.
-115-
-- 118 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
The fair values of our pension benefit assets and other benefit assets by asset category and level inputs at December 31, 2020, excluding cash, investment
income receivable and amounts due to/from brokers, resulting in a net asset of $64, are as follows (see Note 7, “Fair Value,” for additional information regarding
the definition of level inputs):
Level I Level II Level III Total
December 31, 2020
Pension Benefit Assets:
Equity securities:
U.S. securities $ 710 $ — $ — $ 710
Foreign securities 238 — — 238
Mutual funds 42 — — 42
Fixed maturity securities:
Government securities — 237 — 237
Corporate securities — 394 — 394
Asset-backed securities — 137 — 137
Other types of investments:
Commingled fund — 112 — 112
Insurance company contracts — — 189 189
Total pension benefit assets at fair value $ 990 $ 880 $ 189 2,059
Partnership investments 74
Total pension benefit assets $ 2,133
Other Benefit Assets:
Equity securities:
U.S. securities $ 9 $ — $ — $ 9
Foreign securities 3 — — 3
Mutual funds 23 — — 23
Fixed maturity securities:
Government securities — 2 — 2
Corporate securities — 4 — 4
Asset-backed securities — 3 — 3
Other types of investments:
Commingled fund — 2 — 2
Life insurance contracts — — 323 323
Investment in DOL 103-12 trust — 11 — 11
Total other benefit assets $ 35 $ 22 $ 323 $ 380
-116-
-- 119 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
The fair values of our pension benefit assets and other benefit assets by asset category and level inputs at December 31, 2019, excluding cash, investment
income receivable and amounts due to/from brokers, resulting in a net asset of $64, are as follows:
Level I Level II Level III Total
December 31, 2019
Pension Benefit Assets:
Equity securities:
U.S. securities $ 626 $ — $ — $ 626
Foreign securities 197 — — 197
Mutual funds 38 — — 38
Fixed maturity securities:
Government securities — 252 — 252
Corporate securities — 339 — 339
Asset-backed securities — 163 — 163
Other types of investments:
Insurance company contracts — — 175 175
Commingled fund — 136 — 136
Total pension benefit assets at fair value $ 861 $ 890 $ 175 1,926
Partnership investments 52
Total pension benefit assets $ 1,978
Other Benefit Assets:
Equity securities:
U.S. securities $ 8 $ — $ — $ 8
Foreign securities 2 — — 2
Mutual funds 25 — — 25
Fixed maturity securities:
Government securities — 2 — 2
Corporate securities — 4 — 4
Asset-backed securities — 3 — 3
Other types of investments:
Life insurance contracts — — 294 294
Investment in DOL 103-12 trust — 12 — 12
Commingled fund — 1 — 1
Total other benefit assets at fair value $ 35 $ 22 $ 294 $ 351
-117-
-- 120 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
A reconciliation of the beginning and ending balances of plan assets measured at fair value using Level III inputs for the years ended December 31, 2020,
2019 and 2018 is as follows:
Insurance
Company
Contracts
Life
Insurance
Contracts Total
Year ended December 31, 2020
Beginning balance at January 1, 2020 $ 175 $ 294 $ 469
Actual return on plan assets relating to assets still held at the reporting date 7 29 36
Purchases 15 — 15
Sales (8) — (8)
Ending balance at December 31, 2020 $ 189 $ 323 $ 512
Year ended December 31, 2019
Beginning balance at January 1, 2019 $ 166 $ 249 $ 415
Actual return on plan assets relating to assets still held at the reporting date 12 45 57
Purchases 6 — 6
Sales (9) — (9)
Ending balance at December 31, 2019 $ 175 $ 294 $ 469
Year ended December 31, 2018
Beginning balance at January 1, 2018 $ 173 $ 269 $ 442
Actual return on plan assets relating to assets still held at the reporting date (7) (15) (22)
Purchases 8 — 8
Sales (8) (5) (13)
Ending balance at December 31, 2018 $ 166 $ 249 $ 415
There were no other transfers into or out of Level III during the years ended December 31, 2020, 2019 or 2018.
Our current funding strategy is to fund an amount at least equal to the minimum required funding as determined under ERISA with consideration of maximum
tax deductible amounts. We may elect to make discretionary contributions up to the maximum amount deductible for income tax purposes. For the years ended
December 31, 2020, 2019 and 2018, no material contributions were necessary to meet ERISA required funding levels. However, during each of the years ended
December 31, 2020, 2019 and 2018, we made tax deductible discretionary contributions to the pension benefit plans of $7, $4, and $4. Employer contributions to
other benefit plans represent discretionary contributions and do not include payments to retirees for current benefits.
Our estimated future payments for pension benefits and postretirement benefits, which reflect expected future service, as appropriate, are as follows:
Pension
Benefits
Other
Benefits
2021 $ 131 $ 35
2022 128 34
2023 126 32
2024 121 31
2025 119 30
2026 - 2030 552 125
-118-
-- 121 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
In addition to the defined benefit plans, we maintain the Anthem 401(k) Plan, which is a qualified defined contribution plan covering substantially all
employees. Voluntary employee contributions are matched by us subject to certain limitations. Contributions made by us totaled $221, $201 and $211 during 2020,
2019 and 2018, respectively. Contributions in 2018 include approximately $58 for a one time contribution made to employees following the enactment of the Tax
Cuts and Jobs Act.
12. Medical Claims Payable
A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 20, “Segment Information”), for the year ended
December 31, 2020 is as follows:
Commercial
& Specialty
Business Government
Business Other Total
Gross medical claims payable, beginning of year $ 3,039 $ 5,608 $ — $ 8,647
Ceded medical claims payable, beginning of year (14) (19) — (33)
Net medical claims payable, beginning of year 3,025 5,589 — 8,614
Business combinations and purchase adjustments — 141 198 339
Net incurred medical claims:
Current year 24,894 58,912 1,288 85,094
Prior years redundancies (375) (262) — (637)
Total net incurred medical claims 24,519 58,650 1,288 84,457
Net payments attributable to:
Current year medical claims 21,736 51,602 1,291 74,629
Prior years medical claims 2,527 5,165 — 7,692
Total net payments 24,263 56,767 1,291 82,321
Net medical claims payable, end of year 3,281 7,613 195 11,089
Ceded medical claims payable, end of year 13 33 — 46
Gross medical claims payable, end of year $ 3,294 $ 7,646 $ 195 $ 11,135
Activity in our Other segment resulted from our acquisition of Beacon.
-119-
-- 122 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
A reconciliation of the beginning and ending balances for medical claims payable, by segment, for the year ended December 31, 2019 is as follows:
Commercial
& Specialty
Business
Government
Business Total
Gross medical claims payable, beginning of year $ 2,586 $ 4,680 $ 7,266
Ceded medical claims payable, beginning of year (10) (24) (34)
Net medical claims payable, beginning of year 2,576 4,656 7,232
Net incurred medical claims:
Current year 25,942 52,753 78,695
Prior years redundancies (190) (310) (500)
Total net incurred medical claims 25,752 52,443 78,195
Net payments attributable to:
Current year medical claims 23,026 47,268 70,294
Prior years medical claims 2,277 4,242 6,519
Total net payments 25,303 51,510 76,813
Net medical claims payable, end of year 3,025 5,589 8,614
Ceded medical claims payable, end of year 14 19 33
Gross medical claims payable, end of year $ 3,039 $ 5,608 $ 8,647
A reconciliation of the beginning and ending balances for medical claims payable, by segment, for the year ended December 31, 2018 is as follows:
Commercial
& Specialty
Business Government
Business Total
Gross medical claims payable, beginning of year $ 3,383 $ 4,431 $ 7,814
Ceded medical claims payable, beginning of year (78) (27) (105)
Net medical claims payable, beginning of year 3,305 4,404 7,709
Business combinations and purchase adjustments — 199 199
Net incurred medical claims:
Current year 24,094 45,487 69,581
Prior years redundancies (456) (474) (930)
Total net incurred medical claims 23,638 45,013 68,651
Net payments attributable to:
Current year medical claims 21,633 41,115 62,748
Prior years medical claims 2,734 3,845 6,579
Total net payments 24,367 44,960 69,327
Net medical claims payable, end of year 2,576 4,656 7,232
Ceded medical claims payable, end of year 10 24 34
Gross medical claims payable, end of year $ 2,586 $ 4,680 $ 7,266
Amounts incurred related to prior years vary from previously estimated liabilities as the claims are ultimately settled. Liabilities at any period-end are
continually reviewed and re-estimated as information regarding actual claims payments, or runout, becomes known. This information is compared to the
originally established year end liability. Negative amounts reported for incurred medical claims related to prior years result from claims being settled for amounts
less than originally estimated. The prior year redundancy of $637 shown above for the year ended December 31, 2020 represents an estimate
-120-
-- 123 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
based on paid claim activity from January 1, 2020 to December 31, 2020. Medical claim liabilities are usually described as having a “short tail,” which means that
they are generally paid within twelve months of the member receiving service from the provider. Accordingly, the majority of the $637 redundancy relates to
claims incurred in calendar year 2019.
The following table provides a summary of the two key assumptions having the most significant impact on our incurred but not paid liability estimates for the
years ended December 31, 2020, 2019 and 2018, which are the completion and trend factors. These two key assumptions can be influenced by utilization levels,
unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim
processing patterns, claim submission patterns and operational changes resulting from business combinations. The impact from COVID-19 on healthcare
utilization and medical claims submission patterns has increased estimation uncertainty on our incurred but not reported liability at December 31, 2020.
Slowdowns in claims submission patterns and increases in utilization levels for COVID-19 testing and treatment during the fourth quarter of 2020 are the primary
factors that lead to the increased estimation uncertainty.
Favorable Developments
by Changes in Key Assumptions
2020 2019 2018
Assumed trend factors $ (599) $ (325) $ (515)
Assumed completion factors (38) (175) (415)
Total $ (637) $ (500) $ (930)
The favorable development recognized in 2020 resulted primarily from trend factors in late 2019 developing more favorably than originally expected as well
as a smaller contribution from completion factor development.
The favorable development recognized in 2019 resulted primarily from trend in late 2018 developing more favorably than originally expected as well as a
smaller but significant contribution from completion factor development.
The favorable development recognized in 2018 resulted from trend and completion factors developing more favorably than originally expected.
The reconciliation of net incurred medical claims to benefit expense included in the consolidated statements of income is as follows:
Years Ended December 31
2020 2019 2018
Net incurred medical claims:
Commercial & Specialty Business $ 24,519 $ 25,752 $ 23,638
Government Business 58,650 52,443 45,013
Other 1,288 — —
Total net incurred medical claims 84,457 78,195 68,651
Quality improvement and other claims expense 3,588 3,591 3,244
Benefit expense $ 88,045 $ 81,786 $ 71,895
-121-
-- 124 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Incurred claims development, net of reinsurance, for the Commercial & Specialty Business for the years ended December 31, 2020, 2019 and 2018 is as
follows:
Commercial & Specialty Business Cumulative Incurred Claims and Allocated Claim
Adjustment Expenses, Net of Reinsurance
2018 2019
Claim Years (Unaudited) (Unaudited) 2020
2018 & Prior $ 26,943 $ 26,753 $ 26,747
2019 25,942 25,572
2020 24,894
Total $ 77,213
Paid claims development, net of reinsurance, for the Commercial & Specialty Business for the years ended December 31, 2020, 2019 and 2018 is as follows:
Commercial & Specialty Business Cumulative Paid Claims and Allocated Claim Adjustment
Expenses, Net of Reinsurance
2018 2019
Claim Years (Unaudited) (Unaudited) 2020
2018 & Prior $ 24,367 $ 26,643 $ 26,721
2019 23,026 25,475
2020 21,736
Total $ 73,932
At December 31, 2020, the total of incurred but not reported liabilities plus expected development on reported claims for the Commercial & Specialty
Business was $26, $97 and $3,158 for the claim years 2018 and prior, 2019 and 2020, respectively.
At December 31, 2020, the cumulative number of reported claims for the Commercial & Specialty Business was 93, 87 and 74 for the claim years 2018 and
prior, 2019 and 2020, respectively.
Incurred claims development, net of reinsurance, for the Government Business as of and for the years ended December 31, 2020, 2019 and 2018 is as follows:
Government Business Cumulative Incurred Claims and Allocated Claim
Adjustment Expenses, Net of Reinsurance
2018 2019
Claim Years (Unaudited) (Unaudited) 2020
2018 & Prior $ 49,616 $ 49,306 $ 49,278
2019 52,753 52,518
2020 59,053
Total $ 160,849
-122-
-- 125 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Paid claims development, net of reinsurance, for the Government Business as of and for the years ended December 31, 2020, 2019 and 2018 is as follows:
Government Business Cumulative Paid Claims and Allocated Claim Adjustment
Expenses, Net of Reinsurance
2018 2019
Claim Years (Unaudited) (Unaudited) 2020
2018 & Prior $ 44,959 $ 49,201 $ 49,231
2019 47,269 52,403
2020 51,602
Total $ 153,236
At December 31, 2020, the total of incurred but not reported liabilities plus expected development on reported claims for the Government Business was $47,
$115 and $7,451 for the claim years 2018 and prior, 2019 and 2020, respectively.
At December 31, 2020, the cumulative number of reported claims for the Government Business was 225, 241 and 236 for the claim years 2018 and prior, 2019
and 2020, respectively.
Incurred claims development, net of reinsurance, for Other as of and for the years ended December 31, 2020, 2019 and 2018 is as follows:
Other Cumulative Incurred Claims and Allocated Claim Adjustment
Expenses, Net of Reinsurance
2018 2019
Claim Years (Unaudited) (Unaudited) 2020
2018 & Prior $ — $ — $ —
2019 — —
2020 1,486
Total $ 1,486
Paid claims development, net of reinsurance, for Other as of and for the years ended December 31, 2020, 2019 and 2018 is as follows:
Other Cumulative Paid Claims and Allocated Claim Adjustment
Expenses, Net of Reinsurance
2018 2019
Claim Years (Unaudited) (Unaudited) 2020
2018 & Prior $ — $ — $ —
2019 — —
2020 1,291
Total $ 1,291
At December 31, 2020, the total of incurred but not reported liabilities plus expected development on reported claims for Other was $0, $0 and $195 for the
claim years 2018 and prior, 2019 and 2020, respectively.
At December 31, 2020, the cumulative number of reported claims for Other was $0, $0, and $27 for the claim years 2018 and prior, 2019 and 2020,
respectively.
The information about incurred claims development, paid claims development and cumulative number of reported claims for the years ended December 31,
2018 and 2019 for our Commercial & Specialty Business, Government Business and Other, is unaudited and presented as supplementary information.
The cumulative number of reported claims for each claim year for our Commercial & Specialty Business, Government Business and Other have been
developed using historical data captured by our claim payment systems. The provided claim
-123-
-- 126 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
amounts are not a precise tool for understanding utilization of medical services. They could be impacted by a variety of factors including changes in provider
billing practices, provider reimbursement arrangements, mix of services, benefit design or processing systems. The cumulative number of reported claims has been
provided to comply with FASB accounting standards and is not used by management in its claims analysis. Our cumulative number of reported claims may not be
comparable to similar measures reported by other health benefits companies.
The reconciliation of the Commercial & Specialty Business, Government Business and Other incurred and paid claims development information for the three
years ended December 31, 2020, reflected in the tables above, to the consolidated ending balance for medical claims payable included in the consolidated balance
sheet, as of December 31, 2020, is as follows:
Commercial
& Specialty
Business
Government
Business Other Total
Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance $ 77,213 $ 160,849 $ 1,486 $ 239,548
Less: Cumulative paid claims and allocated claim adjustment expenses, net of
reinsurance 73,932 153,236 1,291 228,459
Net medical claims payable, end of year 3,281 7,613 195 11,089
Ceded medical claims payable, end of year 13 33 — 46
Insurance lines other than short duration — 224 — 224
Gross medical claims payable, end of year $ 3,294 $ 7,870 $ 195 $ 11,359
13. Debt
Short-term Borrowings
We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal
Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York, (collectively, the “FHLBs”). As a member we have the ability to obtain short-term
cash advances, subject to certain minimum collateral requirements. At December 31, 2020 and 2019, $0 and $650, respectively, were outstanding under our short-
term FHLB borrowings. Outstanding short-term FHLB borrowings at December 31, 2019 had fixed interest rates of 1.664%.
Through certain subsidiaries, we have entered into multiple 364-day lines of credit (the “Subsidiary Credit Facilities”) with separate lenders for general
corporate purposes. The Subsidiary Credit Facilities provide combined credit of up to $300. The interest rate on each line of credit is based on the LIBOR rate plus
a predetermined rate. Our ability to borrow under the lines of credit is subject to compliance with certain covenants. At December 31, 2020 and 2019, $0 and $50,
respectively, were outstanding under our Subsidiary Credit Facilities.
-124-
-- 127 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Long-term Debt
The carrying value of long-term debt at December 31, 2020 and 2019 consists of the following:
2020 2019
Senior unsecured notes:
2.500%, due 2020 $ — $ 899
4.350%, due 2020 — 699
3.700%, due 2021 700 699
2.950%, due 2022 749 747
3.125%, due 2022 848 847
3.300%, due 2023 1,027 1,013
3.350%, due 2024 847 846
3.500%, due 2024 796 795
2.375%, due 2025 1,253 845
3.650%, due 2027 1,591 1,590
4.101%, due 2028 1,257 1,253
2.875%, due 2029 819 819
2.250%, due 2030 1,089 —
5.950%, due 2034 334 334
5.850%, due 2036 396 396
6.375%, due 2037 366 366
5.800%, due 2040 114 124
4.625%, due 2042 873 888
4.650%, due 2043 978 987
4.650%, due 2044 779 792
5.100%, due 2044 565 594
4.375%, due 2047 1,387 1,386
4.550%, due 2048 839 838
3.700%, due 2049 811 811
3.125%, due 2050 987 —
4.850%, due 2054 247 247
Surplus note:
9.000%, due 2027 25 25
Senior convertible debentures:
2.750%, due 2042 108 145
Variable rate debt:
Commercial paper program 250 400
Total long-term debt 20,035 19,385
Current portion of long-term debt (700) (1,598)
Long-term debt, less current portion $ 19,335 $ 17,787
All debt is a direct obligation of Anthem, Inc., except for the surplus note, the FHLB borrowings and the Subsidiary Credit Facilities.
-125-
-- 128 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
We generally issue senior unsecured notes (“Notes”) for long-term borrowing purposes. Certain of these Notes may have a call feature that allows us to
redeem the Notes at any time at our option and/or a put feature that allows a Note holder to redeem the Notes upon the occurrence of both a change in control event
and a downgrade of the Notes below an investment grade rating.
On November 23, 2020, we repaid, at maturity, the $900 outstanding balance of our 2.500% senior unsecured notes. On August 17, 2020, we repaid, at
maturity, the $700 outstanding balance of our 4.350% senior unsecured notes.
Additionally, during the year ended December 31, 2020, we repurchased $79 of outstanding principal amount of certain other senior unsecured notes, plus
applicable premium for early redemption plus accrued and unpaid interest, for cash totaling $109. We recognized a loss on extinguishment of debt of $30 for the
repurchase of these notes.
On May 5, 2020, we issued $400 aggregate principal amount of additional senior notes pursuant to a reopening of our existing 2.375% Notes due 2025 (the
“2025 Notes”), $1,100 aggregate principal amount of 2.250% Notes due 2030 (the “2030 Notes”), and $1,000 aggregate principal amount of 3.125% Notes due
2050 (the “2050 Notes”) under our shelf registration statement. The 2025 Notes constitute an additional issuance of our 2.375% notes due 2025, of which $850
aggregate principal amount was issued on September 9, 2019. Interest on the 2025 Notes is deemed to have accrued from January 15, 2020 and is payable semi-
annually in arrears on January 15 and July 15 of each year, commencing July 15, 2020. Interest on the 2030 Notes and 2050 Notes is payable semi-annually in
arrears on May 15 and November 15 of each year, commencing November 15, 2020. The proceeds were used for working capital and general corporate purposes,
including, but not limited to, repayment of short-term and long-term debt, repurchase of our common stock pursuant to our share repurchase program and to fund
acquisitions.
On September 9, 2019, we issued $850 aggregate principal amount of the 2025 Notes, $825 aggregate principal amount of 2.875% Notes due 2029 (the “2029
Notes”), and $825 aggregate principal amount of 3.700% Notes due 2049 (the “2049 Notes”) under our shelf registration statement. Interest on the 2025 Notes is
payable semi-annually in arrears on January 15 and July 15 of each year, commencing January 15, 2020. Interest on the 2029 Notes and the 2049 Notes is payable
semi-annually in arrears on March 15 and September 15 each year, commencing March 15, 2020. The proceeds were used for working capital and general
corporate purposes, including, but not limited to, the repurchase of our common stock pursuant to our share repurchase program, repayment of short-term and long-
term debt and to fund acquisitions.
On August 15, 2019, we repaid, at maturity, the $850 outstanding balance of our 2.250% senior unsecured notes.
On July 16, 2018, we repaid, at maturity, the $650 outstanding balance of our 2.300% senior unsecured notes. On January 15, 2018, we repaid, at maturity, the
$625 outstanding balance of our 1.875% senior unsecured notes.
On May 1, 2018, we settled our Equity Units stock purchase contracts at a settlement rate of 0.2412 shares of our common stock, using a market value formula
set forth in the Equity Units purchase contracts. This resulted in the issuance of approximately 6 shares. We had issued 25 Equity Units on May 12, 2015, pursuant
to an underwriting agreement dated May 6, 2015, in an aggregate principal amount of $1,250. Each Equity Unit had a stated amount of $50 (whole dollars) and
consisted of a purchase contract obligating the holder to purchase a certain number of shares of our common stock on May 1, 2018, subject to earlier termination or
settlement, for a price in cash of $50 (whole dollars); and a 5% undivided beneficial ownership interest in $1,000 (whole dollars) principal amount of our 1.900%
remarketable subordinated notes (“RSNs”), due 2028. On March 2, 2018, we remarketed the RSNs and used the proceeds to purchase U.S. Treasury securities that
were pledged to secure the stock purchase obligations of the holders of the Equity Units. The purchasers of the RSNs transferred the RSNs to us in exchange for
$1,250 principal amount of our 4.101% senior notes due 2028 (the “2028 Notes”), and a cash payment of $4. We canceled the RSNs upon receipt and recognized a
loss on extinguishment of debt of $18. At the remarketing, we also issued $850 aggregate principal amount of 4.550% notes due 2048 (the “2048 Notes”) under
our shelf registration statement. We used the proceeds from the 2048 Notes for working capital and general corporate purposes. Interest on the 2028 Notes and the
2048 Notes is payable semi-annually in arrears on March 1 and September 1 of each year, commencing on September 1, 2018.
The surplus note is an unsecured obligation of Anthem Insurance Companies, Inc. (“Anthem Insurance”), a wholly owned subsidiary, and is subordinate in
right of payment to all of Anthem Insurance’s existing and future indebtedness. Any payment of interest or principal on the surplus note may be made only with the
prior approval of the Indiana Department of
-126-
-- 129 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Insurance (“IDOI”) and only out of capital and surplus funds of Anthem Insurance that the IDOI determines to be available for the payment under Indiana
insurance laws.
We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes. The 5-Year Facility provides credit
up to $2,500 and matures in June 2024. We also have a 364-day senior revolving credit facility (the “364-Day Facility”) with a group of lenders for general
corporate purposes, which provides for credit in the amount of $1,000. In May 2020, we amended and extended the 364-Day Facility, which now matures in June
2021. Our ability to borrow under these credit facilities is subject to compliance with certain covenants, including covenants requiring us to maintain a defined
debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the applicable credit agreement. As of December 31, 2020, our
debt-to-capital ratio, as defined and calculated under the credit facilities, was 37.6%. We do not believe the restrictions contained in any of our credit facility
covenants materially affect our financial or operating flexibility. As of December 31, 2020, we were in compliance with all of the debt covenants under these credit
facilities. There were no amounts outstanding under the 364-Day Facility at any time during the years ended December 31, 2020 or the year ended December 31,
2019. At December 31, 2020 and December 31, 2019, there were no amounts outstanding under our 5-Year Facility.
We have an authorized commercial paper program of up to $3,500, the proceeds of which may be used for general corporate purposes. At December 31, 2020,
we had $250 outstanding under our commercial paper program with a weighted-average interest rate of 0.1600%. At December 31, 2019, we had $400 outstanding
under our commercial paper program with a weighted-average interest rate of 1.8528%. Commercial paper borrowings have been classified as long-term debt at
December 31, 2020 and 2019, as our general practice and intent is to replace short-term commercial paper outstanding at expiration with additional short-term
commercial paper for an uninterrupted period extending for more than one year, and we have the ability to redeem our commercial paper with borrowings under
the senior revolving credit facilities described above.
Convertible Debentures
On October 9, 2012, we issued $1,500 of senior convertible debentures (the “Debentures”) in a private offering to qualified institutional buyers pursuant to
Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The Debentures are governed by an indenture dated as of October 9, 2012 between
us and The Bank of New York Mellon Trust Company, N.A., as trustee (the “Indenture”). The Debentures bear interest at a rate of 2.750% per year, payable semi-
annually in arrears in cash on April 15 and October 15 of each year, and mature on October 15, 2042, unless earlier redeemed, repurchased or converted into shares
of common stock at the applicable conversion rate. The Debentures also have a contingent interest feature that will require us to pay additional interest based on
certain thresholds and for certain events, as defined in the Indenture, beginning on October 15, 2022.
Holders may convert their Debentures at their option prior to the close of business on the business day immediately preceding April 15, 2042, only under the
following circumstances: (1) during any fiscal quarter if the last reported sale price of our common stock for at least 20 trading days during a period of 30
consecutive trading days ending on the last trading day of the preceding fiscal quarter is greater than or equal to 130% of the applicable conversion price on each
applicable trading day; (2) during the five business day period after any 10 consecutive trading day period (the “measurement period”) in which the trading price
per $1,000 (whole dollars) principal amount of Debentures for each trading day of that measurement period was less than 98% of the product of the last reported
sale price of our common stock and the applicable conversion rate on each such day; (3) if we call any or all of the Debentures for redemption, at any time prior to
the close of business on the third scheduled trading day prior to the redemption date; or (4) upon the occurrence of specified corporate events, as defined in the
Indenture. On and after April 15, 2042 and until the close of business on the third scheduled trading day immediately preceding the Debentures’ maturity date of
October 15, 2042, holders may convert their Debentures into common stock at any time irrespective of the preceding circumstances. The Debentures are
redeemable at our option at any time on or after October 20, 2022, upon the occurrence of certain events, as defined in the Indenture.
Upon conversion of the Debentures, we will deliver cash up to the aggregate principal amount of the Debentures converted. With respect to any conversion
obligation in excess of the aggregate principal amount of the Debentures converted, we have the option to settle the excess with cash, shares of our common stock
or a combination thereof based on a daily conversion value, determined in accordance with the Indenture. The initial conversion rate for the Debentures was
13.2319 shares of our common stock per Debenture, which represented a 25% conversion premium based on the closing price of $60.46 per share of our common
stock on October 2, 2012 (the date the Debentures’ terms were finalized) and is equivalent to an initial conversion price of $75.575 per share of our common stock.
-127-
-- 130 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
During the year ended December 31, 2020, $56 aggregate principal amount of the Debentures was surrendered for conversion by certain holders in accordance
with the terms and provisions of the Indenture. We elected to settle the excess of the principal amount of the conversions with cash for total payments of $222. We
recognized a loss on the extinguishment of debt related to the Debentures of $6, based on the fair values of the debt on the conversion settlement dates. During the
year ended December 31, 2019, we repurchased $15 of the aggregate principal balance of the Debentures. In addition, $57 aggregate principal amount of the
Debentures was surrendered for conversion by certain holders in accordance with the terms and provisions of the Indenture. We elected to settle the excess of the
principal amount of the repurchases and conversions with cash for total payments of $273. We recognized a loss on the extinguishment of debt related to the
Debentures of $2. During the year ended December 31, 2018, $109 aggregate principal amount of the Debentures was surrendered for conversion. We elected to
settle the excess of the principal amount of the conversions with cash for total payments of $402. We recognized a gain on the extinguishment of debt related to the
Debentures of $7.
As of December 31, 2020, our common stock was last traded at a price of $321.09 per share. If the remaining Debentures had been converted or matured at
December 31, 2020, we would have been obligated to pay the principal of the Debentures plus an amount in cash or shares equal to $560. The Debentures and
underlying shares of our common stock have not been and will not be registered under the Securities Act, or any state securities laws, and may not be offered or
sold in the United States absent registration or an applicable exemption from registration requirements.
We have accounted for the Debentures in accordance with the cash conversion guidance in FASB guidance for debt with conversion and other options. As a
result, the value of the embedded conversion option, net of deferred taxes and equity issuance costs, has been bifurcated from its debt host and recorded as a
component of additional paid-in capital in our consolidated balance sheets.
The following table summarizes, at December 31, 2020, the related balances, conversion rate and conversion price of the Debentures:
Outstanding principal amount $ 159
Unamortized debt discount $ 49
Net debt carrying amount $ 108
Equity component carrying amount $ 58
Conversion rate (shares of common stock per $1,000 of principal amount) 14.0808
Effective conversion price (per $1,000 of principal amount) $ 71.0187
The remaining amortization period of the unamortized debt discount as of December 31, 2020 is approximately 22 years. The unamortized discount will be
amortized into interest expense using the effective interest method based on an effective interest rate of 5.130%, which represents the market interest rate for a
comparable debt instrument that does not have a conversion feature. During the years ended December 31, 2020, 2019 and 2018, we recognized $6, $9 and $12,
respectively, of interest expense related to the Debentures, of which $5, $7 and $10, respectively, represented interest expense recognized at the stated interest rate
of 2.750% and $1, $2 and $2, respectively, represented interest expense resulting from amortization of the debt discount.
Total interest paid during 2020, 2019 and 2018 was $794, $755, and $728, respectively.
We were in compliance with all applicable covenants under all of our outstanding debt agreements at December 31, 2020 and 2019.
Future maturities of all long-term debt outstanding at December 31, 2020 are as follows: 2021, $950; 2022, $1,597; 2023, $1,027; 2024, $1,643; 2025, $1,253
and thereafter, $13,565.
14. Commitments and Contingencies
Litigation and Regulatory Proceedings
In the ordinary course of business, we are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff
or plaintiffs in the following cases have specified in their complaint or in other court
-128-
-- 131 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
filings the amount of damages being sought, we have noted those alleged damages in the descriptions below. With respect to the cases described below, we contest
liability and/or the amount of damages in each matter and believe we have meritorious defenses.
Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can
reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to income. In many proceedings, however, it is difficult to determine whether
any loss is probable or reasonably possible. In addition, even where loss is possible or an exposure to loss exists in excess of the liability already accrued with
respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible loss or range of loss.
With respect to many of the proceedings to which we are a party, we cannot provide an estimate of the possible losses, or the range of possible losses in
excess of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal issues
presented, (ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and
scope of the class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in
many cases, the plaintiffs have not specified damages in their complaint or in court filings. For those legal proceedings where a loss is probable, or reasonably
possible, and for which it is possible to reasonably estimate the amount of the possible loss or range of losses, we currently believe that the range of possible
losses, in excess of established reserves is, in the aggregate, from $0 to approximately $250 at December 31, 2020. This estimated aggregate range of reasonably
possible losses is based upon currently available information taking into account our best estimate of such losses for which such an estimate can be made.
Blue Cross Blue Shield Antitrust Litigation
We are a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees (the “Blue plans”)
across the country. Cases filed in twenty-eight states were consolidated into a single, multi-district proceeding captioned In re Blue Cross Blue Shield Antitrust
Litigation that is pending in the United States District Court for the Northern District of Alabama (the “Court”). Generally, the suits allege that the BCBSA and the
Blue plans have conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue
of each plan, restrictions on acquisitions, rules governing the BlueCard and National Accounts programs and other arrangements in violation of the Sherman
Antitrust Act (“Sherman Act”) and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and
providers.
In response to cross motions for partial summary judgment by plaintiffs and defendants, the Court issued an order in April 2018 determining that the
defendants’ aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard program
and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. The Court also found that there remain genuine
issues of material fact as to whether the defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks. In April
2019, plaintiffs filed their motions for class certification in conjunction with their supporting expert reports, and the defendants filed their motions to exclude
plaintiffs’ experts, as well as their opposition to plaintiffs’ motions for class certification, in July 2019.
The BCBSA and Blue plans have approved a settlement agreement and release (the “Subscriber Settlement Agreement”) with the subscriber plaintiffs. If
approved by the Court, the Subscriber Settlement Agreement will require the defendants to make a monetary settlement payment, our portion of which is estimated
to be $594, and will contain certain non-monetary terms including (i) eliminating the “national best efforts” rule in the BCBSA license agreements (which rule
limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers with self-funded benefit plans to
request a bid for insurance coverage from a second Blue plan in addition to the local Blue plan. We recognized our estimated payment obligation of $548, net of
third party insurance coverage received as of December 31, 2020.
On November 30, 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following which members of the Subscriber
class were provided notice of the Settlement Agreement and an opportunity to opt out of the class. All terms of the Subscriber Settlement Agreement are subject to
final approval by the Court before they
®
®
-129-
-- 132 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
become effective. Objections to the settlement as well as the deadline for those that wish to opt-out from the settlement must be submitted by July 28, 2021. Claims
must be filed by November 5, 2021. A final approval hearing has been scheduled for October 20, 2021. If the Court grants approval of the Subscriber Settlement
Agreement, and after all appellate rights have expired or have been exhausted in a manner that affirms the Court’s final order and judgment, the defendants’
payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective.
In October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for class certification, and defendants
filed an opposition to that motion. We intend to continue to vigorously defend the provider suit; however, its ultimate outcome cannot be presently determined.
Blue Cross of California Taxation Litigation
In July 2013, our California affiliate Blue Cross of California (doing business as Anthem Blue Cross) (“BCC”) was named as a defendant in a California
taxpayer action filed in Los Angeles County Superior Court (the “Superior Court”) captioned Michael D. Myers v. State Board of Equalization, et al. This action
was brought under a California statute that permits an individual taxpayer to sue a governmental agency when the taxpayer believes the agency has failed to
enforce governing law. Plaintiff contends that BCC, a licensed Health Care Service Plan, is an “insurer” for purposes of taxation despite acknowledging it is not
an “insurer” under regulatory law. At the time, under California law, “insurers” were required to pay a gross premiums tax (“GPT”) calculated as 2.35% on gross
premiums. As a licensed Health Care Service Plan, BCC has paid the California Corporate Franchise Tax (“CFT”), the tax paid by California businesses
generally. Plaintiff contends that BCC must pay the GPT rather than the CFT, and seeks a writ of mandate directing the taxing agencies to collect the GPT and an
order requiring BCC to pay GPT back taxes, interest, and penalties for the eight-year period prior to the filing of the complaint.
Because the GPT is constitutionally imposed in lieu of certain other taxes, BCC has filed protective tax refund claims with the City of Los Angeles, the
California Department of Health Care Services and the Franchise Tax Board to protect its rights to recover certain taxes previously paid should BCC eventually
be determined to be subject to the GPT for the tax periods at issue in the litigation.
In March 2018, the Superior Court denied BCC's motion for judgment on the pleadings and similar motions brought by other entities. BCC filed a motion for
summary judgment with the Superior Court, which was heard in October 2020. In December 2020, the Superior Court granted BCC's motion for summary
judgment, dismissing the plaintiff's lawsuit. We intend to vigorously defend any appeal of this lawsuit.
Express Scripts, Inc. Pharmacy Benefit Management Litigation
In March 2016, we filed a lawsuit against Express Scripts, Inc. (“Express Scripts”), our vendor at the time for PBM services, captioned Anthem, Inc. v.
Express Scripts, Inc., in the U.S. District Court for the Southern District of New York. The lawsuit seeks to recover over $14,800 in damages for pharmacy pricing
that is higher than competitive benchmark pricing under the agreement between the parties (the “ESI PBM Agreement”), over $158 in damages related to
operational breaches, as well as various declarations under the ESI PBM Agreement, including that Express Scripts: (i) breached its obligation to negotiate in good
faith and to agree in writing to new pricing terms; (ii) was required to provide competitive benchmark pricing to us through the term of the ESI PBM Agreement;
(iii) has breached the ESI PBM Agreement; and (iv) is required under the ESI PBM Agreement to provide post-termination services, at competitive benchmark
pricing, for one year following any termination.
Express Scripts has disputed our contractual claims and is seeking declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI
PBM Agreement, and (ii) that it has no obligation to ensure that we receive any specific level of pricing, that we have no contractual right to any change in pricing
under the ESI PBM Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claims that we
have been unjustly enriched by its payment of $4,675 at the time we entered into the ESI PBM Agreement. In March 2017, the court granted our motion to dismiss
Express Scripts’ counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. The only remaining
claims are for breach of contract and declaratory relief. Rebuttal expert reports were submitted in October 2020, discovery must be completed in April 2021, and
motions for summary judgment must be filed in May 2021. We intend to vigorously pursue our claims and defend against any counterclaims, which we believe are
without merit; however, the ultimate outcome cannot be presently determined.
-130-
-- 133 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
In re Express Scripts/Anthem ERISA Litigation
We are a defendant in a class action lawsuit that was initially filed in June 2016 against Anthem, Inc. and Express Scripts, which has been consolidated into a
single multi-district lawsuit captioned In Re Express Scripts/Anthem ERISA Litigation, in the U.S. District Court for the Southern District of New York. The
consolidated complaint was filed by plaintiffs against Express Scripts and us on behalf of all persons who are participants in or beneficiaries of any ERISA or non-
ERISA healthcare plan from December 1, 2009 to December 31, 2019 in which we provided prescription drug benefits through the ESI PBM Agreement and paid
a percentage based co-insurance payment in the course of using that prescription drug benefit. The plaintiffs allege that we breached our duties, either under
ERISA or with respect to the implied covenant of good faith and fair dealing implied in the health plans, (i) by failing to adequately monitor Express Scripts’
pricing under the ESI PBM Agreement, (ii) by placing our own pecuniary interest above the best interests of our insureds by allegedly agreeing to higher pricing in
the ESI PBM Agreement in exchange for the purchase price for our NextRx PBM business, and (iii) with respect to the non-ERISA members, by negotiating and
entering into the ESI PBM Agreement that was allegedly detrimental to the interests of such non-ERISA members. Plaintiffs seek to hold us and Express Scripts
jointly and severally liable and to recover all losses suffered by the proposed class, equitable relief, disgorgement of alleged ill-gotten gains, injunctive relief,
attorney’s fees and costs and interest.
In April 2017, we filed a motion to dismiss the claims brought against us, and it was granted, without prejudice, in January 2018. Plaintiffs filed a notice of
appeal with the United States Court of Appeals for the Second Circuit (the “Second Circuit”), which was heard in October 2018. In December 2020, the Second
Circuit affirmed the trial court's decision dismissing the ERISA complaint. Plaintiffs have filed a Petition for Rehearing and Rehearing En Banc. We intend to
vigorously defend this suit; however, its ultimate outcome cannot be presently determined.
Cigna Corporation Merger Litigation
In July 2015, we and Cigna Corporation (“Cigna”) announced that we entered into the Cigna Agreement and Plan of Merger (“Cigna Merger Agreement”)
pursuant to which we would acquire all outstanding shares of Cigna. In July 2016, the U.S. Department of Justice (“DOJ”) along with certain state attorneys
general, filed a civil antitrust lawsuit in the U.S. District Court for the District of Columbia (“District Court”) seeking to block the merger. In February 2017, Cigna
purported to terminate the Cigna Merger Agreement and commenced litigation against us in the Delaware Court of Chancery (“Delaware Court”) seeking damages,
including the $1,850 termination fee pursuant to the terms of the Cigna Merger Agreement, and a declaratory judgment that its purported termination of the Cigna
Merger Agreement was lawful, among other claims, which is captioned Cigna Corp. v. Anthem Inc.
Also in February 2017, we initiated our own litigation against Cigna in the Delaware Court seeking a temporary restraining order to enjoin Cigna from
terminating the Cigna Merger Agreement, specific performance compelling Cigna to comply with the Cigna Merger Agreement and damages, which is captioned
Anthem Inc. v. Cigna Corp. In April 2017, the U.S. Circuit Court of Appeals for the District of Columbia affirmed the ruling of the District Court, which blocked
the merger. In May 2017, after the Delaware Court denied our motion to enjoin Cigna from terminating the Cigna Merger Agreement, we delivered to Cigna a
notice terminating the Cigna Merger Agreement.
In the Delaware Court litigation, trial commenced in late February 2019 and concluded in March 2019. The Delaware Court held closing arguments in
November 2019 and took the matter under consideration. In August 2020, the Delaware Court issued an opinion finding that neither party was owed damages and
that we did not owe Cigna the $1,850 termination fee. The Delaware Court issued an order implementing its opinion in October 2020. Cigna filed its notice of
appeal in November 2020 challenging the Court's decision that Anthem did not owe Cigna a termination fee. Cigna filed its appellate brief in December 2020, and
we filed our response in January 2021. We believe Cigna’s allegations are without merit and we intend to vigorously defend against Cigna’s allegations; however,
the ultimate outcome of the appeal of this litigation with Cigna cannot be presently determined.
In October 2018, a shareholder filed a derivative lawsuit in the State of Indiana Marion County Superior Court, captioned Henry Bittmann, Derivatively, et al.
v. Joseph R Swedish, et al., purportedly on behalf of us and our shareholders against certain current and former directors and officers alleging breaches of fiduciary
duties, unjust enrichment and corporate waste associated with the Cigna Merger Agreement. This case has been stayed at the request of the parties pending
-131-
-- 134 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
the outcome of our litigation with Cigna in the Delaware Court. This lawsuit’s ultimate outcome cannot be presently determined.
Medicare Risk Adjustment Litigation
In March 2020, the DOJ filed a civil lawsuit against Anthem, Inc. in the U.S. District Court for the Southern District of New York in a case captioned United
States v. Anthem, Inc. The DOJ’s suit alleges, among other things, that we falsely certified the accuracy of the diagnosis data we submitted to the Centers for
Medicare and Medicaid Services (“CMS”) for risk-adjustment purposes under Medicare Part C and knowingly failed to delete inaccurate diagnosis codes. The DOJ
further alleges that, as a result of these purported acts, we caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which
enabled us to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended complaint in July 2020,
alleging the same causes of action but revising some of its allegations. In September 2020, we filed a motion to transfer the lawsuit to the Southern District of
Ohio, a motion to dismiss part of the lawsuit, and a motion to strike certain allegations in the amended complaint. The motions are fully briefed and no decision has
been rendered. We intend to continue to vigorously defend this suit; however, the ultimate outcome cannot be presently determined.
Investigations of CareMore and HealthSun
With the assistance of outside counsel, we are conducting investigations of risk-adjustment practices involving data submitted to CMS (unrelated to our
retrospective chart review program) at CareMore Health Plans, Inc. (“CareMore”), one of our California subsidiaries, and HealthSun Health Plans, Inc.
(“HealthSun”), one of our Florida subsidiaries. Our CareMore investigation has resulted in the termination of CareMore’s relationship with one contracted provider
in California. Our HealthSun investigation focuses on risk adjustment practices initiated prior to our acquisition of HealthSun in December 2017 that continued
after the acquisition. We have voluntarily self-disclosed the existence of both of our investigations to CMS and the Criminal Division of the DOJ, which then
initiated an investigation. We are cooperating with the government's investigation. We are in the process of analyzing the scope of potential data corrections to be
submitted to CMS. We have also asserted indemnity claims for escrowed funds under the HealthSun purchase agreement for, among other things, breach of
healthcare and financial representation provisions, based on the conduct discovered during our investigation. We are in active litigation with two groups of sellers
regarding part of the escrowed funds in cases captioned Shareholder Representative Services, LLC v. ATH Holding Company, LLC and Highland Acquisition
Holdings, LLC and LPPAS Representative, LLC v. ATH Holding Company, LLC, both pending in the Delaware Court.
Cyber Attack Regulatory Proceedings and Litigation
In February 2015, we reported that we were the target of a sophisticated external cyber attack during which the attackers gained unauthorized access to certain
of our information technology systems and obtained personal information related to many individuals and employees. To date, there is no evidence that credit card
or medical information was accessed or obtained. Upon discovery of the cyber attack, we took immediate action to remediate the security vulnerability and have
continued to implement security enhancements since this incident.
Federal and state agencies have investigated events related to the cyber attack, including how it occurred, its consequences and our responses. In September
2020, we entered into a settlement to resolve the investigation by a multi-state group of attorneys general, which was the final outstanding matter related to the
2015 cyber attack. We have undertaken commitments that align with our ongoing and consistent focus to protect information in addition to a monetary payment of
$39, which was fully accrued in a prior period.
We have contingency plans and insurance coverage for certain expenses and potential liabilities of this nature and will pursue coverage for all applicable
losses; however, the ultimate outcome of our pursuit of insurance coverage cannot be presently determined.
Other Contingencies
From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the
ordinary course of business. We, like HMOs and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, PPO and
other plans. We are, in the ordinary course of
-132-
-- 135 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if
it results in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability under punitive damage
theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims.
In addition to the lawsuits described above, we are also involved in other pending and threatened litigation of the character incidental to our business, and are
from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits, reviews
and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and
subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines,
penalties, other sanctions and additional rules, regulations or other restrictions on our business operations. Any liability that may result from any one of these
actions, or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations.
Contractual Obligations and Commitments
In March 2020, we entered into an agreement with a vendor for information technology infrastructure and related management and support services through
June 2025. The new agreement supersedes certain prior agreements for such services and includes provisions for additional services not provided under those
agreements. Our remaining commitment under this agreement at December 31, 2020 is approximately $1,426. We will have the ability to terminate the agreement
upon the occurrence of certain events, subject to early termination fees.
Beginning in the second quarter of 2019, we began using our pharmacy benefits manager IngenioRx, Inc. (“IngenioRx”) to market and offer PBM services to
our fully-insured and self-funded affiliated health plan customers, as well as to external customers outside of the health plans we own. The comprehensive
prescription benefits management services portfolio includes, but is not limited to, formulary management, pharmacy networks, prescription drug database,
member services and mail order capabilities. Also in the second quarter of 2019, IngenioRx began delegating certain PBM administrative functions, such as claims
processing and prescription fulfillment, to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement. With
IngenioRx, we retain the responsibilities for clinical and formulary strategy and development, member and employer experiences, operations, sales, marketing,
account management and retail network strategy.
Vulnerability from Concentrations
Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents, investment securities, premium
receivables and instruments held through hedging activities. All investment securities are managed by professional investment managers within policies authorized
by our Board of Directors. Such policies limit the amounts that may be invested in any one issuer and prescribe certain investee company criteria. Concentrations
of credit risk with respect to premium receivables are limited due to the large number of employer groups that constitute our customer base in the states in which
we conduct business. As of December 31, 2020, there were no significant concentrations of financial instruments in a single investee, industry or geographic
location.
15. Capital Stock
Stock Incentive Plans
Our Board of Directors has adopted the 2017 Anthem Incentive Compensation Plan (“2017 Incentive Plan”) which has been approved by our shareholders.
The term of the 2017 Incentive Plan is such that no awards may be granted on or after May 18, 2027. The 2017 Incentive Plan gives authority to the Compensation
Committee of the Board of Directors to make incentive awards to our non-employee directors, employees and consultants, consisting of stock options, stock,
restricted stock, restricted stock units, cash-based awards, stock appreciation rights, performance shares and performance units. The 2017 Incentive Plan limits the
number of available shares for issuance to 37.5 shares, subject to adjustment as set forth in the 2017 Incentive Plan.
-133-
-- 136 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Stock options are granted for a fixed number of shares with an exercise price at least equal to the fair value of the shares at the grant date. Stock options vest
over three years in equal annual installments and generally have a term of ten years from the grant date.
Certain option grants contain provisions whereby the employee continues to vest in the award subsequent to termination due to retirement. Our attribution
method for newly granted awards considers all vesting and other provisions, including retirement eligibility, in determining the requisite service period over which
the fair value of the awards will be recognized.
Awards of restricted stock or restricted stock units are issued at the fair value of the stock on the grant date and may also include one or more performance
measures that must be met for the award to vest. For restricted stock or restricted stock units without performance measures, the restrictions lapse in three equal
annual installments. Restricted stock or restricted stock units with performance measures vest in three year installments. Performance units issued in 2020 will vest
in 2023, based on certain revenue and earnings targets over the three year period of 2020 to 2022. Performance units issued in 2019 will vest in 2022, based on
certain revenue and earnings targets over the three year period of 2019 to 2021. Performance units issued in 2018 will vest in 2021, based on certain revenue and
earnings targets over the three year period of 2018 to 2020.
For the years ended December 31, 2020, 2019 and 2018, we recognized share-based compensation expense of $283, $294 and $226, respectively, as well as
related tax benefits of $74, $78 and $61, respectively.
A summary of stock option activity for the year ended December 31, 2020 is as follows:
Number of
Shares
Weighted-Average
Option Price per
Share
Weighted-Average
Remaining
Contractual Life
(Years)
Aggregate
Intrinsic
Value
Outstanding at January 1, 2020 3.1 $ 190.28
Granted 1.0 271.61
Exercised (0.9) 136.89
Forfeited or expired (0.1) 273.91
Outstanding at December 31, 2020 3.1 230.00 6.75 $ 280
Exercisable at December 31, 2020 1.6 185.08 5.37 $ 217
The intrinsic value of options exercised during the years ended December 31, 2020, 2019 and 2018 amounted to $147, $188 and $172, respectively. We
recognized tax benefits of $40, $52 and $47 during the years ended December 31, 2020, 2019 and 2018, respectively, from option exercises and disqualifying
dispositions. During the years ended December 31, 2020, 2019 and 2018, we received cash of $129, $143 and $141, respectively, from exercises of stock options.
The total fair value of restricted stock awards that vested during the years ended December 31, 2020, 2019 and 2018 was $335, $245 and $237, respectively.
A summary of the status of nonvested restricted stock activity, including restricted stock units, for the year ended December 31, 2020 is as follows:
Restricted
Stock Shares
and Units
Weighted-Average
Grant Date
Fair Value
per Share
Nonvested at January 1, 2020 1.4 $ 242.54
Granted 1.3 272.37
Vested (1.3) 196.25
Forfeited (0.1) 272.50
Nonvested at December 31, 2020 1.3 272.51
-134-
-- 137 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
During the year ended December 31, 2020, we granted approximately 0.3 restricted stock units that are contingent upon us achieving certain revenue and
earning targets over the three year period of 2020 to 2022. These grants have been included in the activity shown above, but will be subject to adjustment at the end
of 2022, based on results in the three year period.
As of December 31, 2020, the total remaining unrecognized compensation expense related to nonvested stock options and restricted stock, including restricted
stock units, amounted to $30 and $154, respectively, which will be amortized over the weighted-average remaining requisite service periods of 11 months and 13
months, respectively.
As of December 31, 2020, there were approximately 19.5 shares of common stock available for future grants under the 2017 Incentive Plan.
Fair Value
We use a binomial lattice valuation model to estimate the fair value of all stock options granted. Expected volatility assumptions used in the binomial lattice
model are based on an analysis of implied volatilities of publicly traded options on our stock and historical volatility of our stock price. The risk-free interest rate is
derived from the U.S. Treasury strip rates at the time of the grant. The expected term of the options was derived from the outputs of the binomial lattice model,
which incorporates post-vesting forfeiture assumptions based on an analysis of historical data. The dividend yield was based on our estimate of future dividend
yields. Similar groups of employees that have dissimilar exercise behavior are considered separately for valuation purposes. We utilize the multiple-grant approach
for recognizing compensation expense associated with each separately vesting portion of the share-based award.
The following weighted-average assumptions were used to estimate the fair values of options granted during the years ended December 31, 2020, 2019 and
2018:
2020 2019 2018
Risk-free interest rate 1.30 % 2.69 % 2.90 %
Volatility factor 26.00 % 25.00 % 30.00 %
Dividend yield (annual) 1.40 % 1.00 % 1.30 %
Weighted-average expected life (years) 4.30 4.40 3.70
The following weighted-average fair values were determined for the years ending December 31, 2020, 2019 and 2018:
2020 2019 2018
Options granted during the year $ 54.05 $ 68.66 $ 55.48
Restricted stock awards granted during the year 272.37 305.88 233.73
The binomial lattice option-pricing model requires the input of highly subjective assumptions including the expected stock price volatility. Because our stock
option grants have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect
the fair value estimate, in our opinion, existing models do not necessarily provide a reliable single measure of the fair value of our stock option grants.
Employee Stock Purchase Plan
We have registered 14.0 shares of common stock for the Employee Stock Purchase Plan (the “Stock Purchase Plan”) which is intended to provide a means to
encourage and assist employees in acquiring a stock ownership interest in Anthem. Pursuant to the terms of the Stock Purchase Plan, an eligible employee is
permitted to purchase no more than $25,000 (actual dollars) worth of stock in any calendar year, based on the fair value of the stock at the end of each plan quarter.
Employees become participants by electing payroll deductions from 1% to 15% of gross compensation. Once purchased, the stock is accumulated in the
employee’s investment account. The Stock Purchase Plan allows participants to purchase shares of our common stock at a discounted price per share of 90% of the
fair value of a share of common stock on the lower of the first or last trading day of the plan quarter purchase period. The Stock Purchase Plan discount was
recognized as compensation expense for the year ended December 31, 2020, based on GAAP guidance. There were 0.2 shares issued during the year ended
December 31, 2020. As of December 31, 2020, 4.6 shares were available for issuance under the Stock Purchase Plan.
-135-
-- 138 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Use of Capital and Stock Repurchase Program
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The
declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial
condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
A summary of the cash dividend activity for the years ended December 31, 2020 and 2019 is as follows:
Declaration Date Record Date Payment Date Cash Dividend per
Share Total
Year ended December 31, 2020
January 28, 2020 March 16, 2020 March 27, 2020 $ 0.95 $ 240
April 28, 2020 June 10, 2020 June 25, 2020 0.95 242
July 28, 2020 September 10, 2020 September 25, 2020 0.95 238
October 27, 2020 December 7, 2020 December 22, 2020 0.95 234
Year ended December 31, 2019
January 29, 2019 March 18, 2019 March 29, 2019 $ 0.80 $ 206
April 23, 2019 June 10, 2019 June 25, 2019 0.80 206
July 23, 2019 September 10, 2019 September 25, 2019 0.80 204
October 22, 2019 December 5, 2019 December 20, 2019 0.80 202
On January 26, 2021, our Audit Committee declared a quarterly cash dividend to shareholders of $1.13 per share on the outstanding shares of our common
stock. This quarterly dividend is payable on March 25, 2021 to the shareholders of record as of March 10, 2021.
Under our Board of Directors’ authorization, we maintain a common stock repurchase program. On January 26, 2021, our Audit Committee, pursuant to
authorization granted by the Board of Directors, authorized a $5,000 increase to our common stock repurchase program. Repurchases may be made from time to
time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are effected from time to time in the open market,
through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities
Exchange Act of 1934, as amended. Our stock repurchase program is discretionary, as we are under no obligation to repurchase shares. We repurchase shares
under the program when we believe it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to
additional paid-in capital and retained earnings. We temporarily suspended our share repurchase program in March 2020 as a precautionary measure in light of the
COVID-19 pandemic, but resumed the program in late June 2020 after market conditions improved.
A summary of common stock repurchases for the years ended December 31, 2020 and 2019 is as follows:
Years Ended December 31
2020 2019
Shares repurchased 9.4 6.3
Average price per share $ 286.35 $ 268.65
Aggregate cost $ 2,700 $ 1,701
Authorization remaining at end of year $ 1,092 $ 3,792
We expect to utilize the remaining authorized amount over a multi-year period, subject to market and industry conditions.
For additional information regarding the use of capital for debt security repurchases, see Note 13, “Debt.”
-136-
-- 139 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
16. Accumulated Other Comprehensive Income
A reconciliation of the components of accumulated other comprehensive income (loss) at December 31, 2020 and 2019 is as follows:
2020 2019
Investments:
Gross unrealized gains $ 1,316 $ 720
Gross unrealized losses (65) (44)
Net pretax unrealized gains 1,251 676
Deferred tax liability (302) (155)
Net unrealized gains on investments 949 521
Non-credit components of impairments on investments:
Gross unrealized losses (3) (3)
Deferred tax asset 1 1
Net unrealized non-credit component of impairments on investments (2) (2)
Cash flow hedges:
Gross unrealized losses (316) (331)
Deferred tax asset 66 69
Net unrealized losses on cash flow hedges (250) (262)
Defined benefit pension plans:
Deferred net actuarial loss (749) (734)
Deferred prior service cost — (1)
Deferred tax asset 190 188
Net unrecognized periodic benefit costs for defined benefit pension plans (559) (547)
Postretirement benefit plans:
Deferred net actuarial loss (3) (25)
Deferred prior service credits 12 19
Deferred tax (liability) asset (2) 2
Net unrecognized periodic benefit credit (costs) for postretirement benefit plans 7 (4)
Foreign currency translation adjustments:
Gross unrealized gains (losses) 6 (3)
Deferred tax (liability) asset (1) 1
Net unrealized gains (losses) on foreign currency translation adjustments 5 (2)
Accumulated other comprehensive income (loss) $ 150 $ (296)
-137-
-- 140 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Other comprehensive income (loss) reclassification adjustments for the years ended December 31, 2020, 2019 and 2018 are as follows:
2020 2019 2018
Investments:
Net holding gain (loss) on investment securities arising during the period, net of tax (expense) benefit of
$(160), $(198), and $133, respectively $ 478 $ 695 $ (465)
Reclassification adjustment for net realized (gain) loss on investment securities, net of tax expense
(benefit) of $13, $4, and $(13), respectively (50) (15) 47
Total reclassification adjustment on investments 428 680 (418)
Non-credit component of impairments on investments:
Non-credit component of impairments on investments, net of tax benefit of $0, $0, and $1, respectively — — (2)
Cash flow hedges:
Holding gain (loss), net of tax (expense) benefit of $(3), $4, and $(10), respectively 12 (16) 37
Other:
Net change in unrecognized periodic benefit costs for defined benefit pension and postretirement benefit
plans, net of tax (expense) benefit of $(2), $(9), and $29, respectively (1) 26 (90)
Foreign currency translation adjustment, net of tax expense of $2, $0, and $0, respectively 7 — (1)
Net gain (loss) recognized in other comprehensive income (loss), net of tax (expense) benefit of $(154),
$(199), and $140, respectively $ 446 $ 690 $ (474)
17. Reinsurance
We reinsure certain risks with other companies and assume risk from other companies. We remain primarily liable to policyholders under ceded insurance
contracts and are contingently liable for amounts recoverable from reinsurers in the event that such reinsurers do not meet their contractual obligations.
A summary of direct, assumed and ceded premiums written and earned for the years ended December 31, 2020, 2019 and 2018 is as follows:
2020 2019 2018
Written Earned Written Earned Written Earned
Direct $ 102,479 $ 100,832 $ 91,579 $ 91,131 $ 83,652 $ 84,030
Assumed 3,326 3,356 3,196 3,087 1,447 1,442
Ceded (79) (79) (45) (45) (51) (51)
Net premiums $ 105,726 $ 104,109 $ 94,730 $ 94,173 $ 85,048 $ 85,421
Percentage—assumed to net premiums 3.1 % 3.2 % 3.4 % 3.3 % 1.7 % 1.7 %
The table above includes certain reclassifications between direct and assumed premiums for 2019 and 2018. These reclassifications did not impact any
amounts presented in the consolidated financial statements.
-138-
-- 141 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
A summary of net premiums written and earned by segment (see Note 20, “Segment Information”) for the years ended December 31, 2020, 2019 and 2018 is
as follows:
2020 2019 2018
Written Earned Written Earned Written Earned
Reportable segments:
Commercial & Specialty Business $ 31,745 $ 31,471 $ 32,113 $ 31,944 $ 30,661 $ 30,532
Government Business 72,308 71,188 62,617 62,229 54,387 54,889
Other 1,673 1,450 — — — —
Net premiums $ 105,726 $ 104,109 $ 94,730 $ 94,173 $ 85,048 $ 85,421
The effect of reinsurance on benefit expense for the years ended December 31, 2020, 2019 and 2018 is as follows:
2020 2019 2018
Direct $ 85,168 $ 79,110 $ 70,789
Assumed 2,967 2,733 1,179
Ceded (90) (57) (73)
Net benefit expense $ 88,045 $ 81,786 $ 71,895
The effect of reinsurance on certain assets and liabilities at December 31, 2020 and 2019 is as follows:
2020 2019
Policy liabilities, assumed $ 490 $ 471
Unearned income, assumed 85 114
Premiums payable, ceded 12 11
Premiums receivable, assumed 347 324
18. Leases
We lease office space and certain computer and related equipment using noncancelable operating leases. Our leases have remaining lease terms of 1 year to 14
years.
The information related to our leases is as follows:
Balance Sheet Location December 31, 2020 December 31, 2019
Operating Leases
Right-of-use assets Other noncurrent assets $ 646 $ 575
Lease liabilities, current Other current liabilities 110 158
Lease liabilities, noncurrent Other noncurrent liabilities 847 482
Years Ended December 31
2020 2019
Lease Expense
Operating lease expense $ 438 $ 198
Short-term lease expense 50 46
Sublease income (9) (16)
Total lease expense $ 479 $ 228
Lease expense for 2018 was $207.
-139-
-- 142 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
Our activities as disclosed in Note 4, “Business Optimization Initiatives”, include reducing our office space footprint. As a result, we performed an interim
impairment test and recorded an impairment charge of $258 for affected right-of-use assets in 2020 which is included in the operating lease expense shown above.
Years Ended December 31
2020 2019
Other information
Operating cash paid for amounts included in the measurement of lease liabilities, operating leases $ 207 $ 176
Right-of-use assets obtained in exchange for new lease liabilities, operating leases $ 384 $ 112
Weighted average remaining lease term in years, operating leases 7 6
Weighted average discount rate, operating leases 3.21 % 4.09 %
At December 31, 2020, future lease payments for noncancelable operating leases with initial or remaining terms of one year or more are as follows:
2021 $ 197
2022 180
2023 156
2024 125
2025 88
Thereafter 236
Total future minimum payments $ 982
Less imputed interest (25)
Total lease liabilities $ 957
As of December 31, 2020, we have additional operating leases for building spaces that have not yet commenced, and some building spaces are being
constructed by the lessors and their agents. These leases have terms of up to 12 years and are expected to commence on various dates during 2021 when the
construction is complete and we take possession of the buildings. The undiscounted lease payments for these leases, which are not included in the tables above,
aggregate $139.
19. Earnings per Share
The denominator for basic and diluted earnings per share at December 31, 2020, 2019 and 2018 is as follows:
2020 2019 2018
Denominator for basic earnings per share—weighted-average shares 250.8 255.5 258.1
Effect of dilutive securities—employee stock options, non-vested restricted stock awards, convertible debentures
and equity units 3.5 4.8 6.1
Denominator for diluted earnings per share 254.3 260.3 264.2
During the years ended December 31, 2020, 2019 and 2018, weighted-average shares related to certain stock options of 1.2, 0.6 and 0.3, respectively, were
excluded from the denominator for diluted earnings per share because the stock options were anti-dilutive. The Equity Unit purchase contracts were settled in May
2018, and approximately 6.0 shares of our common stock were issued and included in the basic earnings per share calculation.
During the years ended December 31, 2020, 2019 and 2018, we issued approximately 0.3, 0.2 and 0.3 restricted stock units, respectively, of which vesting was
contingent upon us meeting certain earnings targets. Contingent restricted stock units are excluded from the denominator for diluted earnings per share and are
included only if and when the contingency is met. The 2020 contingent restricted stock units are being measured over the three year period of 2020 through 2022,
the 2019 contingent restricted stock units are being measured over the three year period of 2019 through 2021 and the 2018 contingent restricted stock units are
being measured over the three year period of 2018 through 2020. Contingent restricted stock units generally vest in March of the year following each measurement
period.
-140-
-- 143 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
20. Segment Information
Beginning in 2020, IngenioRx meets the quantitative threshold for a reportable segment based on the FASB guidance. The results of our operations are now
described through four reportable segments: Commercial & Specialty Business, Government Business, IngenioRx and Other.
Our Commercial & Specialty Business segment includes our Local Group, National Accounts, Individual and Specialty businesses. Business units in the
Commercial & Specialty Business segment offer fully-insured health products; provide a broad array of managed care services to self-funded customers including
claims processing, stop loss insurance, provider network access, medical cost management, disease management, wellness programs, underwriting, actuarial
services and other administrative services; and provide an array of specialty and other insurance products and services such as dental, vision, life and disability
insurance benefits.
Our Government Business segment includes our Medicare and Medicaid businesses, National Government Services (“NGS”) and services provided to the
federal government in connection with the FEHB program. Our Medicare business includes services such as Medicare Supplement plans; Medicare Advantage,
including Special Needs Plans; Medicare Part D; and dual-eligible programs through Medicare-Medicaid Plans. Medicare Advantage membership also includes
Medicare Advantage members in our Group Retiree Solutions business who are related to National Accounts, retired members of Local Group accounts, or retired
members of groups who are not affiliated with our Commercial accounts who have selected a Medicare Advantage product through us. Our Medicaid business
includes our managed care alternatives through publicly funded healthcare programs, including Medicaid, ACA-related Medicaid expansion programs, Temporary
Assistance for Needy Families programs, programs for seniors and people with disabilities, Children’s Health Insurance Programs, and specialty programs such as
those focused on long-term services and support, HIV/AIDS, foster care, behavioral health and/or substance abuse disorders, and intellectual disabilities or
developmental disabilities. NGS acts as a Medicare contractor for the federal government in several regions across the nation.
Our IngenioRx segment includes our PBM business, which began its operations during the second quarter of 2019. IngenioRx markets and offers PBM
services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. IngenioRx has a comprehensive PBM services
portfolio, which includes services such as formulary management, pharmacy networks, prescription drug database, member services and mail order capabilities. In
2019, IngenioRx was included in our Other reportable segment. Amounts for 2019 have been reclassified to conform to the current year presentation for
comparability.
Our Other segment includes our Diversified Business Group (“DBG”), which is our integrated health services business, and certain eliminations and corporate
expenses not allocated to our other reportable segments. Also, beginning on February 28, 2020, our Other segment includes Beacon.
We define operating revenues to include premium income, product revenue and administrative fees and other revenues. Operating revenues are derived from
premiums and fees received, primarily from the sale and administration of health benefit products. Operating gain is calculated as total operating revenue less
benefit expense, cost of products sold and selling, general and administrative expense.
Through our participation in various federal government programs, we generated approximately 20.3%, 20.7% and 19.8% of our total consolidated revenues
from agencies of the U.S. government for the years ended December 31, 2020, 2019, and 2018, respectively. These revenues are contained in the Government
Business segment.
The accounting policies of the segments are consistent with those described in the summary of significant accounting policies in Note 2, “Basis of Presentation
and Significant Accounting Policies,” except that certain shared administrative expenses for each segment are recognized on a pro rata allocated basis, which in the
aggregate approximates the consolidated expense. Any difference between the allocated expenses and actual consolidated expense is included in other expenses not
allocated to reportable segments. Affiliated revenues represent revenues or cost for services provided by IngenioRx and DBG to our subsidiaries, are recorded at
cost or management’s estimate of fair market value, and are eliminated in consolidation. We evaluate performance of the reportable segments based on operating
gain or loss as defined above. We evaluate net investment income, net realized gains (losses) on financial instruments, interest expense, amortization expense, gain
or loss on extinguishment of debt, income taxes and assets and liabilities on a consolidated basis, as these items are managed in a corporate shared service
environment and are not the responsibility of segment operating management.
-141-
-- 144 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
For our 2019 segment reporting, operating gain generated from IngenioRx activities were allocated and included in our Commercial & Specialty Business and
Government Business based upon their utilization of those services, which aligns with the method by which we assessed the 2019 operating performance of our
reportable segments. Beginning January 1, 2020, we are managing the operating performance of each of our segments on a standalone basis. Prior year 2019
allocations were not restated to conform to the 2020 presentation; however, operating margins for IngenioRx were approximately 8% in 2019.
Financial data by reportable segment for the years ended December 31, 2020, 2019 and 2018 is as follows:
Commercial &
Specialty
Business
Government
Business IngenioRx Other Eliminations Total
Year ended December 31, 2020
Operating revenue - unaffiliated $ 36,699 $ 71,572 10,384 $ 2,153 $ — $ 120,808
Operating revenue - affiliated — — 11,527 3,904 (15,431) —
Operating gain (loss) 2,681 2,444 1,361 (126) — 6,360
Depreciation and amortization of property and equipment — — — 638 — 638
Year ended December 31, 2019
Operating revenue - unaffiliated $ 37,421 $ 62,632 2,007 $ 1,081 $ — $ 103,141
Operating revenue - affiliated — — 3,395 1,212 (4,607) —
Operating gain (loss) 4,032 2,056 — (89) — 5,999
Depreciation and amortization of property and equipment — — — 675 — 675
Year ended December 31, 2018
Operating revenue - unaffiliated $ 35,782 $ 55,348 — $ 211 $ — $ 91,341
Operating revenue - affiliated — — — 1,308 (1,308) —
Operating gain (loss) 3,600 1,928 — (102) — 5,426
Depreciation and amortization of property and equipment — — — 652 — 652
-142-
-- 145 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
The major product revenues for each of the reportable segments for the years ended December 31, 2020, 2019 and 2018 are as follows:
2020 2019 2018
Commercial & Specialty Business
Managed care products $ 29,815 $ 30,311 $ 29,012
Managed care services 5,296 5,451 5,218
Dental/Vision products and services 1,231 1,302 1,220
Other 357 357 332
Total Commercial & Specialty Business 36,699 37,421 35,782
Government Business
Managed care products 71,188 62,229 54,889
Managed care services 384 403 459
Total Government Business 71,572 62,632 55,348
IngenioRx
Pharmacy products and services 21,911 5,402 —
Other
Integrated health services 5,787 2,149 1,489
Other 270 144 30
Total Other Business 6,057 2,293 1,519
Eliminations
Eliminations (15,431) (4,607) (1,308)
Total product revenues $ 120,808 $ 103,141 $ 91,341
The classification between managed care products and managed care services in the above table primarily distinguishes between the levels of risk assumed.
Managed care products represent insurance products where we bear the insurance risk, whereas managed care services represent product offerings where we
provide claims adjudication and other administrative services to the customer, but the customer principally bears the insurance risk.
Asset, liability and equity details by reportable segment have not been disclosed, as we do not internally report such information.
A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the years
ended December 31, 2020, 2019 and 2018 is as follows:
2020 2019 2018
Reportable segments operating revenues $ 120,808 $ 103,141 $ 91,341
Net investment income 877 1,005 970
Net realized gains (losses) on financial instruments 182 67 (206)
Total revenues $ 121,867 $ 104,213 $ 92,105
-143-
-- 146 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
A reconciliation of reportable segments’ operating gain to income before income tax expense included in our consolidated statements of income for the years
ended December 31, 2020, 2019 and 2018 is as follows:
2020 2019 2018
Reportable segments operating gain $ 6,360 $ 5,999 $ 5,426
Net investment income 877 1,005 970
Net realized gains (losses) on financial instruments 182 67 (206)
Interest expense (784) (746) (753)
Amortization of other intangible assets (361) (338) (358)
Loss on extinguishment of debt (36) (2) (11)
Income before income tax expense $ 6,238 $ 5,985 $ 5,068
21. Related Party Transactions
We have a 19.50% equity investment in National Accounts Service Company, LLC (“NASCO”) which processes National Accounts claims and provides other
administrative services for us and certain other BCBS plans. Administrative expenses incurred related to NASCO services totaled $58, $78 and $79, for the years
ended December 31, 2020, 2019 and 2018, respectively. Amounts due to NASCO were $5 and $4 at December 31, 2020 and 2019, respectively.
We have an equity investment in APC Passe, LLC, which offers Medicaid products in Arkansas. During the years ended December 31, 2020 and 2019, in the
normal course of business, we assumed premiums of $446 and $408, respectively, from APC Passe, LLC, which is included in our total assumed premiums (see
Note 17, “Reinsurance”). Amounts due to APC Passe, LLC were $115 and $162 at December 31, 2020 and 2019, respectively.
22. Statutory Information
The majority of our insurance and HMO subsidiaries report their accounts in conformity with accounting practices prescribed or permitted by state insurance
regulatory authorities, commonly referred to as statutory accounting, which vary in certain respects from GAAP. However, certain of our insurance and HMO
subsidiaries, including BCC, Blue Cross of California Partnership Plan, Inc., Golden West Health Plan, Inc., Beacon Health Options of California, Inc. and
CareMore Health Plan are regulated by the California Department of Managed Health Care (“DMHC”) and report their accounts in conformity with GAAP (these
entities are collectively referred to as the “DMHC regulated entities”). Typical differences of GAAP reporting as compared to statutory reporting are the
recognition of all assets including those that are non-admitted for statutory purposes and recognition of all deferred tax assets without regard to statutory limits.
The National Association of Insurance Commissioners (“NAIC”) developed a codified version of the statutory accounting principles, designed to foster more
consistency among the states for accounting guidelines and reporting. Prescribed statutory accounting practices are set forth in a variety of publications of the
NAIC as well as state laws, regulations and general administrative rules.
Our ability to pay dividends and credit obligations is significantly dependent on receipt of dividends from our subsidiaries. The payment of dividends to us by
our insurance and HMO subsidiaries without prior approval of the insurance departments of each subsidiary’s domiciliary jurisdiction is limited by formula.
Dividends in excess of these amounts are subject to prior approval by the respective state insurance departments or the DMHC.
Our statutory basis insurance and HMO subsidiaries are subject to risk-based capital (“RBC”) requirements. RBC is a method developed by the NAIC to
determine the minimum amount of statutory capital appropriate for an insurance company or HMO to support its overall business operations in consideration of its
size and risk profile. The formula for determining the amount of RBC specifies various factors, weighted based on the perceived degree of risk, which are applied
to certain financial balances and financial activity. Below minimum RBC requirements are classified within certain levels, each of which requires specified
corrective action. Additionally, the DMHC regulated entities are subject to capital and solvency requirements as prescribed by the DMHC. As of December 31,
2020 and 2019, all of our regulated subsidiaries exceeded the minimum applicable mandatory RBC requirements and/or capital and solvency requirements of their
applicable governmental regulator. The statutory RBC necessary to satisfy regulatory requirements of our statutory basis insurance and HMO subsidiaries was
approximately $5,800 and $5,500 as of December 31, 2020 and 2019, respectively. The tangible net
-144-
-- 147 of 512 --
Anthem, Inc.
Notes to Consolidated Financial Statements (continued)
equity required for the DMHC regulated entities was approximately $600 and $610 as of December 31, 2020 and 2019, respectively.
Statutory-basis capital and surplus of our insurance and HMO subsidiaries and capital and surplus of our other regulated subsidiaries, excluding the DMHC
regulated entities, was $13,717 and $13,044 at December 31, 2020 and 2019, respectively. Statutory-basis net income of our insurance and HMO subsidiaries and
net income of our other regulated subsidiaries, excluding the DMHC regulated entities, was $3,170, $3,840 and $3,412 for 2020, 2019 and 2018, respectively.
GAAP equity of the DMHC regulated entities was $3,851 and $3,359 at December 31, 2020 and 2019, respectively. GAAP net income of the DMHC regulated
entities was $753, $878 and $789 for the years ended December 31, 2020, 2019 and 2018, respectively.
23. Selected Quarterly Financial Data (Unaudited)
Selected quarterly financial data is as follows:
For the Quarter Ended
March 31 June 30 September 30 December 31
2020
Total revenues $ 29,621 $ 29,264 $ 31,158 $ 31,824
Income before income tax expense 2,089 3,149 389 611
Net income 1,523 2,276 222 551
Basic net income per share $ 6.03 $ 9.02 $ 0.88 $ 2.23
Diluted net income per share 5.94 8.91 0.87 2.19
2019
Total revenues $ 24,666 $ 25,466 $ 26,674 $ 27,407
Income before income tax expense 1,945 1,453 1,489 1,098
Net income 1,551 1,139 1,183 934
Basic net income per share $ 6.03 $ 4.44 $ 4.64 $ 3.69
Diluted net income per share 5.91 4.36 4.55 3.62
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.
There have been no changes in or disagreements with our independent registered public accounting firm on accounting or financial disclosures.
ITEM 9A. CONTROLS AND PROCEDURES.
Evaluation of Disclosure Controls and Procedures
We carried out an evaluation as of December 31, 2020, under the supervision and with the participation of our management, including our Chief Executive
Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15(e) of the
Exchange Act. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are
effective in timely alerting them to material information relating to us (including our consolidated subsidiaries) required to be disclosed in our reports under the
Exchange Act. In addition, based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures
were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and
communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required
disclosures.
-145-
-- 148 of 512 --
Management’s Report on Internal Control over Financial Reporting
Management, under the supervision and with the participation of the principal executive officer and principal financial officer, of Anthem, Inc. (the
“Company”) is responsible for establishing and maintaining effective internal control over financial reporting (“Internal Control”), as such term is defined in the
Exchange Act. The Company’s Internal Control is designed to provide reasonable assurance regarding the reliability of the Company’s financial reporting and the
preparation of financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles (“GAAP”). The Company’s
Internal Control includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the
transactions and dispositions of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of
financial statements in accordance with GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of
management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or
disposition of the Company’s assets that could have a material effect on the financial statements.
Because of inherent limitations in any Internal Control, no matter how well designed, misstatements due to error or fraud may occur and not be detected.
Accordingly, even effective Internal Control can provide only reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with GAAP.
Management, under the supervision and with the participation of the principal executive officer and principal financial officer, assessed the effectiveness of
the Company’s Internal Control as of December 31, 2020. Management’s assessment was based on criteria established in Internal Control—Integrated Framework
(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
The Company completed its acquisition of Beacon Health Options, Inc. on February 28, 2020. As permitted by the U.S. Securities and Exchange Commission,
management's assessment as of December 31, 2020 did not include the Internal Control of Beacon Health Options, Inc., which is included in the Company's
consolidated financial statements as of December 31, 2020. Such operations of Beacon Health Options, Inc. constituted 3% and 6% of the Company's total assets
and net assets, respectively, as of December 31, 2020, and 2% and 0% of the Company's total revenues and net income for the year then ended.
Based on management’s assessment, which excluded an assessment of Internal Control of Beacon Health Options, Inc., management has concluded that the
Company’s Internal Control was effective as of December 31, 2020 to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external reporting purposes in accordance with GAAP.
Ernst & Young LLP, the Company’s independent registered public accounting firm, has audited the consolidated financial statements of the Company for the
year ended December 31, 2020, and has also issued an audit report dated February 18, 2021, on the effectiveness of the Company’s Internal Control as of
December 31, 2020, which is included in this Annual Report on Form 10-K.
/S/ GAIL K. BOUDREAUX /S/ JOHN E. GALLINA
President and Chief Executive Officer Executive Vice President and Chief Financial Officer
Changes in Internal Control Over Financial Reporting
There have been no changes in our internal control over financial reporting that occurred during the three months ended December 31, 2020 that have
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
-146-
-- 149 of 512 --
Report of Independent Registered Public Accounting Firm
To the Shareholders and the Board of Directors of Anthem, Inc.
Opinion on Internal Control Over Financial Reporting
We have audited Anthem, Inc.’s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control–Integrated
Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Anthem,
Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on the COSO criteria.
As indicated in the accompanying Management’s Report on Internal Control Over Financial Reporting, management’s assessment of and conclusion on the
effectiveness of internal control over financial reporting did not include the internal controls of Beacon Health Options, Inc., which is included in the 2020
consolidated financial statements of the Company and constituted 3% and 6% of total and net assets, respectively, as of December 31, 2020 and 2% and 0% of
revenues and net income, respectively, for the year then ended. Our audit of internal control over financial reporting of the Company also did not include an
evaluation of the internal control over financial reporting of Beacon Health Options, Inc.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance
sheets of Anthem, Inc. as of December 31, 2020 and 2019, the related consolidated statements of income, comprehensive income, shareholders’ equity and cash
flows for each of the three years in the period ended December 31, 2020, and the related notes and financial statement schedule listed in the Index at Item 15(c) and
our report dated February 18, 2021 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal
control over financial reporting included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express
an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the
Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating
the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the
circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial
reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the
transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of
financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in
accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of
effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with
the policies or procedures may deteriorate.
/s/ ERNST & YOUNG LLP
Indianapolis, Indiana
February 18, 2021
-147-
-- 150 of 512 --
ITEM 9B. OTHER INFORMATION.
None.
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.
The information required by this Item concerning our Executive Officers, Directors and nominees for Director, Audit Committee members and financial
expert(s) and concerning disclosure of any delinquent filers under Section 16(a) of the Exchange Act and our Code of Conduct is incorporated herein by reference
from our definitive Proxy Statement for our 2021 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation 14A within 120 days
after the end of our last fiscal year.
ITEM 11. EXECUTIVE COMPENSATION.
The information required by this Item concerning remuneration of our Executive Officers and Directors, material transactions involving such Executive
Officers and Directors and Compensation Committee interlocks, as well as the Compensation and Talent Committee Report and CEO Pay Ratio disclosure are
incorporated herein by reference from our definitive Proxy Statement for our 2021 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to
Regulation 14A within 120 days after the end of our last fiscal year.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.
Securities Authorized for Issuance under Equity Compensation Plans
Securities authorized for issuance under our equity compensation plans as of December 31, 2020 are as follows:
Plan
Category
Number of securities to be
issued upon exercise of
outstanding options, warrants and rights
(a)
Weighted-average
exercise price of
outstanding options, warrants and
rights
(b)
Number of securities
remaining available for
future issuance under equity
compensation plans (excluding securities
reflected in column (a))
(c)
Equity compensation plans approved by shareholders as of
December 31, 2020 5,367,044 $230.00 24,139,655
1 We have no equity compensation plans pursuant to which awards may be granted in the future that have not been approved by shareholders.
2 Includes shares that may be issued under the Anthem Incentive Compensation Plan and the Anthem 2017 Incentive Compensation Plan pursuant to the following
outstanding awards: 3,071,776 stock options, 625,254 unvested restricted stock units, and 1,670,014 performance stock units (assuming that the outstanding performance
stock units are earned at the maximum award level).
3 Represents the weighted average exercise price of outstanding stock options. Does not take into consideration outstanding restricted stock units or performance stock units,
which, once vested, may be converted into shares of our common stock on a one-for-one basis upon distribution at no additional cost.
4 Excludes securities reflected in the first column, “Number of securities to be issued upon exercise of outstanding options, warrants and rights”. Includes 19,498,782 shares
of common stock available for issuance as stock options, restricted stock awards, performance stock awards, performance awards and stock appreciation rights under the
Anthem 2017 Incentive Compensation Plan at December 31, 2020. Includes 4,640,873 shares of common stock available for issuance under the Stock Purchase Plan at
December 31, 2020.
The information required by this Item concerning the stock ownership of management and five percent beneficial owners is incorporated herein by reference
from our definitive Proxy Statement for our 2021 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation 14A within 120 days
after the end of our last fiscal year.
1
2 3 4
-148-
-- 151 of 512 --
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.
The information required by this Item concerning certain relationships and related person transactions and director independence is incorporated herein by
reference from our definitive Proxy Statement for our 2021 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation 14A within
120 days after the end of our last fiscal year.
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.
The information required by this Item concerning principal accountant fees and services is incorporated herein by reference from our definitive Proxy
Statement for our 2021 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation 14A within 120 days after the end of our last
fiscal year.
-149-
-- 152 of 512 --
PART IV
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.
(a) 1. Financial Statements:
The following consolidated financial statements of the Company are set forth in Part II, Item 8:
Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets as of December 31, 2020 and 2019
Consolidated Statements of Income for the years ended December 31, 2020, 2019, and 2018
Consolidated Statements of Comprehensive Income for the years ended December 31, 2020, 2019, and 2018
Consolidated Statements of Shareholders’ Equity for the years ended December 31, 2020, 2019 and 2018
Consolidated Statements of Cash Flows for the years ended December 31, 2020, 2019 and 2018
Notes to Consolidated Financial Statements
2. Financial Statement Schedule:
The following financial statement schedule of the Company is included in Item 15(c):
Schedule II—Condensed Financial Information of Registrant (Parent Company Only).
All other schedules for which provision is made in the applicable accounting regulations of the SEC are not required under the related instructions,
are inapplicable, or the required information is included in the consolidated financial statements, and therefore, have been omitted.
3. Exhibits required to be filed as part of this report:
Exhibit
Number Exhibit
3.1 Amended and Restated Articles of Incorporation of the Company, as amended and restated effective May 15, 2019, incorporated by reference to
Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on May 15, 2019.
3.2 Bylaws of the Company, as amended effective September 30, 2020, incorporated by reference to Exhibit 3.1 to the Company’s Current Report
on Form 8-K filed on October 6, 2020
4.1 Form of Specimen Certificate of the Company’s common stock, $0.01 par value per share, incorporated by reference to Exhibit 4.3 to the
Company’s Post-Effective Amendment No.1 to Form S-8 Registration Statement filed on May 23, 2017.
4.2 Indenture, dated as of December 9, 2004, between the Company and The Bank of New York Trust Company, N.A., as trustee, including the
Form of the Company’s 5.950% Notes due 2034, incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed
on December 15, 2004.
4.3 Indenture, dated as of January 10, 2006, between the Company and The Bank of New York Mellon Trust Company, N.A. (formerly known as
The Bank of New York Trust Company, N.A.), as trustee, incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form
8-K filed on January 11, 2006.
(a) Form of 5.85% Notes due 2036, incorporated by reference to Exhibit 4.4 to the Company’s Current Report on Form 8-K filed on
January 11, 2006.
(b) Form of 6.375% Notes due 2037, incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on
June 8, 2007.
(c) Form of 5.800% Notes due 2040, incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on
August 12, 2010.
(d) Form of 3.700% Notes due 2021, incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on
August 15, 2011.
-150-
-- 153 of 512 --
Exhibit
Number Exhibit
(e) Form of 3.125% Notes due 2022, incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on
May 7, 2012.
(f) Form of 4.625% Notes due 2042, incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on
May 7, 2012.
(g) Form of 3.300% Notes due 2023, incorporated by reference to Exhibit 4.4 to the Company’s Current Report on Form 8-K filed on
September 10, 2012.
(h) Form of 4.650% Notes due 2043, incorporated by reference to Exhibit 4.5 to the Company’s Current Report on Form 8-K filed on
September 10, 2012.
(i) Form of 5.100% Notes due 2044, incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on July
31, 2013.
(j) Form of 3.500% Notes due 2024, incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on
August 12, 2014.
(k) Form of 4.650% Notes due 2044, incorporated by reference to Exhibit 4.4 to the Company’s Current Report on Form 8-K filed on
August 12, 2014.
(l) Form of 4.850% Notes due 2054, incorporated by reference to Exhibit 4.5 to the Company’s Current Report on Form 8-K filed on
August 12, 2014.
4.4 Indenture dated as of October 9, 2012 between the Company and The Bank of New York Mellon Trust Company, N.A. as trustee, including the
Form of the 2.750% Senior Convertible Debentures due 2042, incorporated by reference to Exhibit 4.1 to the Company’s Current Report on
Form 8-K filed on October 9, 2012.
4.5 Subordinated Indenture, dated as of May 12, 2015, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee,
incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on May 12, 2015.
4.6 Indenture dated as of November 21, 2017 between the Company and The Bank of New York Mellon Trust Company, N.A. as trustee,
incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on November 21, 2017.
(a) Form of 2.950% Notes due 2022, incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on
November 21, 2017.
(b) Form of 3.350% Notes due 2024, incorporated by reference to Exhibit 4.4 to the Company’s Current Report on Form 8-K filed on
November 21, 2017.
(c) Form of 3.650% Notes due 2027, incorporated by reference to Exhibit 4.5 to the Company’s Current Report on Form 8-K filed on
November 21, 2017.
(d) Form of 4.375% Notes due 2047, incorporated by reference to Exhibit 4.6 to the Company’s Current Report on Form 8-K filed on
November 21, 2017.
(e) Form of 4.101% Notes due 2028, incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on
March 2, 2018.
(f) Form of 4.550% Notes due 2048, incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on
March 2, 2018.
(g) Form of 2.375% Notes due 2025, incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on
September 9, 2019.
(h) Form of 2.875% Notes due 2029, incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on
September 9, 2019.
(i) Form of 3.700% Notes due 2049, incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on
September 9, 2019.
-151-
-- 154 of 512 --
Exhibit
Number Exhibit
(j) Form of the 2.250% Notes due 2030, incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on
May 5, 2020.
(k) Form of the 3.125% Notes due 2050, incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on
May 5, 2020.
4.7 Upon the request of the Securities and Exchange Commission, the Company will furnish copies of any other instruments defining the rights of
holders of long-term debt of the Company or its subsidiaries.
4.8 Description of the Company’s Securities Registered Pursuant to Section 12 of the Exchange Act.
10.1 * Anthem Incentive Compensation Plan, as amended and restated effective December 2, 2014, incorporated by reference to Exhibit 10.2 to the
Company’s Current Report on Form 8-K filed on December 2, 2014.
(a) Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2014, incorporated by reference to Exhibit
10.2(p) to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.
(b) Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2015, incorporated by reference to Exhibit
10.2(n) to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.
(c) Form of Amendment, dated March 9, 2016, to Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2014,
incorporated by reference to Exhibit 10.2(m) to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016.
(d) Form of Amendment, dated March 9, 2016, to Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2015,
incorporated by reference to Exhibit 10.2(p) to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016.
(e) Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2016 and 2017, incorporated by reference to
Exhibit 10.2(s) to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016.
(f) Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement for 2017, incorporated by reference to Exhibit 10.2(t) to
the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016.
10.2 * 2017 Anthem Incentive Compensation Plan, as amended and restated effective October 1, 2019, incorporated by reference to Exhibit 10.2 to the
Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019.
(a) Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2018, incorporated by reference to Exhibit
10.2(d) to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.
(b) Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement for 2018, incorporated by reference to Exhibit 10.2(e) to
the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.
(c) Form of Incentive Compensation Plan Performance Stock Unit Award Agreement for 2018, incorporated by reference to Exhibit 10.2(f)
to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.
(d) Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement commencing July 2018, incorporated by reference
to Exhibit 10.2(h) to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018.
(e) Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement commencing July 2018, incorporated by reference to
Exhibit 10.2(i) to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018.
-152-
-- 155 of 512 --
Exhibit
Number Exhibit
(f) Form of Incentive Compensation Plan Performance Stock Unit Award Agreement commencing July 2018, incorporated by reference to
Exhibit 10.2(j) to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018.
(g) Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2019, incorporated by reference to Exhibit
10.2(l) to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019.
(h) Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement for 2019, incorporated by reference to Exhibit 10.2(m) to
the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019.
(i) Form of Incentive Compensation Plan Performance Stock Unit Award Agreement for 2019, incorporated by reference to Exhibit 10.2(n)
to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019.
(j) Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2020, incorporated by reference to Exhibit
10.2(l) to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.
(k) Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement for 2020, incorporated by reference to Exhibit 10.2(m) to
the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.
(l) Form of Incentive Compensation Plan Performance Stock Unit Award Agreement for 2020, incorporated by reference to Exhibit 10.2(n)
to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.
10.3 * Anthem, Inc. Comprehensive Nonqualified Deferred Compensation Plan, as amended and restated effective October 1, 2019, incorporated by
reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019.
10.4 * Anthem, Inc. Executive Agreement Plan, as amended and restated effective December 2, 2014, incorporated by reference to Exhibit 10.4 to the
Company’s Annual Report on Form 10-K for the year ended December 31, 2014.
(a) First Amendment, dated March 9, 2016, to Executive Agreement Plan, incorporated by reference to Exhibit 10.4(a) to the Company’s
Quarterly Report on Form 10-Q for the quarter ended March 31, 2016.
(b) Second Amendment, dated January 6, 2017, to Executive Agreement Plan, incorporated by reference to Exhibit 10.3(b) to the
Company’s Annual Report on Form 10-K for the year ended December 31, 2016.
(c) Third Amendment, dated August 27, 2018, to Executive Agreement Plan, incorporated by reference to Exhibit 10.4(c) to the
Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018.
10.5 * Anthem, Inc. Executive Salary Continuation Plan, as amended and restated effective December 2, 2014, incorporated by reference to Exhibit
10.5 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.
10.6 * Anthem, Inc. Directed Executive Compensation Plan amended effective January 1, 2020.
10.7 * Anthem, Inc. Board of Directors Compensation Program, as amended effective May 15, 2019, incorporated by reference to Exhibit 10.7 to the
Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019.
10.8 * Anthem Board of Directors’ Deferred Compensation Plan, as amended and restated effective December 2, 2014, incorporated by reference to
Exhibit 10.8 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.
10.9 * (a) Form of Employment Agreement between the Company and each of the following: John E. Gallina, Peter D. Haytaian, and Gloria
McCarthy, incorporated by reference to Exhibit A to Exhibit 10.41 to the Company’s Quarterly Report on Form 10-Q for the quarter
ended September 30, 2007.
-153-
-- 156 of 512 --
Exhibit
Number Exhibit
(b) Form of Employment Agreement between the Company and Gail Boudreaux, incorporated by reference to Exhibit A to Exhibit 10.1 to
the Company’s Current Report on Form 8-K filed on November 6, 2017.
(c) Form of Employment Agreement between the Company and each of the following: Felicia F. Norwood, Prakash Patel, Leah Stark,
Jeffrey D. Alter, and Blair W. Todt incorporated by reference to Exhibit 10.9(d) to the Company’s Quarterly Report on Form 10-Q for
the quarter ended June 30, 2018.
10.10 * Offer Letter, by and between the Company and Gail Boudreaux, dated as of November 5, 2017, incorporated by reference to Exhibit 10.1 to the
Company’s Current Report on Form 8-K filed on November 6, 2017.
10.11 Blue Cross License Agreement by and between Blue Cross Blue Shield Association and the Company, including revisions, if any, adopted by
the Member Plans through September 17, 2020.
10.12 Blue Shield License Agreement by and between Blue Cross Blue Shield Association and the Company, including revisions, if any, adopted by
the Member Plans through September 17, 2020.
21 Subsidiaries of the Company.
23 Consent of Independent Registered Public Accounting Firm.
31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act Rules, as adopted pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act Rules, as adopted pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
32.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
101 The following materials from Anthem, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2020, formatted in Inline XBRL
(Inline Extensible Business Reporting Language): (i) the Consolidated Balance Sheets; (ii) the Consolidated Statements of Income; (iii) the
Consolidated Statements of Comprehensive Income; (iv) the Consolidated Statements of Cash Flows; (v) the Consolidated Statements of
Shareholders’ Equity; (vi) the Notes to Consolidated Financial Statements and (vii) Financial Statement Schedule II. The instance document
does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
104 Cover Page Interactive Data File formatted in Inline XBRL and contained in Exhibit 101.
* Indicates management contracts or compensatory plans or arrangements.
(b) Exhibits
The response to this portion of Item 15 is set forth in paragraph (a) 3 above.
(c) Financial Statement Schedule
Schedule II—Condensed Financial Information of Registrant (Parent Company Only).
ITEM 16. FORM 10-K SUMMARY.
None.
-154-
-- 157 of 512 --
Schedule II—Condensed Financial Information of Registrant
Anthem, Inc. (Parent Company Only)
Balance Sheets
(In millions, except share data)
December 31,
2020
December 31,
2019
Assets
Current assets:
Cash and cash equivalents $ 700 $ 1,818
Fixed maturity securities, current (amortized cost of $594 and $592;
allowance for credit losses of $0 and $0) 608 602
Equity securities 439 253
Other receivables 41 92
Net due from subsidiaries — 602
Other current assets 800 653
Total current assets 2,588 4,020
Other invested assets 664 657
Property and equipment, net 209 170
Deferred tax assets, net 391 216
Investments in subsidiaries 51,739 47,423
Other noncurrent assets 211 263
Total assets $ 55,802 $ 52,749
Liabilities and shareholders’ equity
Liabilities
Current liabilities:
Accounts payable and accrued expenses $ 429 $ 887
Net due to subsidiaries 1,239 —
Current portion of long-term debt 700 1,598
Other current liabilities 494 263
Total current liabilities 2,862 2,748
Long-term debt, less current portion 19,310 17,762
Other noncurrent liabilities 431 511
Total liabilities 22,603 21,021
Commitments and contingencies—Note 5
Shareholders’ equity
Preferred stock, without par value, shares authorized - 100,000,000; shares issued and outstanding - none — —
Common stock, par value $0.01, shares authorized - 900,000,000; shares issued and outstanding - 245,401,430 and 252,922,161 3 3
Additional paid-in capital 9,244 9,448
Retained earnings 23,802 22,573
Accumulated other comprehensive income (loss) 150 (296)
Total shareholders’ equity 33,199 31,728
Total liabilities and shareholders’ equity $ 55,802 $ 52,749
See accompanying notes.
-155-
-- 158 of 512 --
Anthem, Inc. (Parent Company Only)
Statements of Income
Years ended December 31
(In millions) 2020 2019 2018
Revenues
Net investment income $ 65 $ 81 $ 39
Net realized gains (losses) on financial instruments 28 (85) (61)
Administrative fees and other revenue 22 22 2
Total revenues (losses) 115 18 (20)
Expenses
General and administrative expense 169 88 86
Interest expense 779 723 723
Loss on extinguishment of debt 36 2 11
Total expenses 984 813 820
Loss before income tax credits and equity in net income of subsidiaries (869) (795) (840)
Income tax credits (386) (251) (238)
Equity in net income of subsidiaries 5,055 5,351 4,352
Net income $ 4,572 $ 4,807 $ 3,750
See accompanying notes.
-- 159 of 512 --
-156-
-- 160 of 512 --
Anthem, Inc. (Parent Company Only)
Statements of Comprehensive Income
Years ended December 31
(in millions) 2020 2019 2018
Net income $ 4,572 $ 4,807 $ 3,750
Other comprehensive income, net of tax:
Change in net unrealized gains/losses on investments 428 680 (418)
Change in non-credit component of impairment losses on investments — — (2)
Change in net unrealized gains/losses on cash flow hedges 12 (16) 37
Change in net periodic pension and postretirement costs (1) 26 (90)
Foreign currency translation adjustments 7 — (1)
Other comprehensive income (loss) 446 690 (474)
Total comprehensive income $ 5,018 $ 5,497 $ 3,276
See accompanying notes.
-157-
-- 161 of 512 --
Anthem, Inc. (Parent Company Only)
Statements of Cash Flows
Years ended December 31
(In millions) 2020 2019 2018
Operating activities
Net income $ 4,572 $ 4,807 $ 3,750
Adjustments to reconcile net income to net cash provided by operating activities:
Undistributed earnings of subsidiaries (1,418) (1,561) (744)
Net realized (gains) losses on financial instruments (28) 85 61
Deferred income taxes (178) 2 (43)
Impairment of property and equipment 10 — —
Depreciation and amortization 96 106 113
Share-based compensation 283 294 226
Changes in operating assets and liabilities:
Receivables, net 53 41 (73)
Other invested assets (27) 6 (5)
Other assets 33 (235) (225)
Amounts due to/(from) subsidiaries 1,841 (432) 2,259
Accounts payable and other liabilities (554) (422) 457
Income taxes 87 (282) 187
Other, net 40 2 12
Net cash provided by operating activities 4,810 2,411 5,975
Investing activities
Purchases of investments (2,729) (9,682) (800)
Proceeds from sales, maturities, calls and redemptions of investments 2,593 9,457 1,865
Capitalization of subsidiaries (2,460) (232) (4,379)
Changes in securities lending collateral (234) 18 (21)
Purchases of property and equipment, net of sales (107) (54) (137)
Other, net 11 — 4
Net cash used in investing activities (2,926) (493) (3,468)
Financing activities
Net repayments of commercial paper borrowings (150) (297) (107)
Proceeds from long-term borrowings 2,484 2,473 835
Repayments of long-term borrowings (1,932) (1,123) (1,684)
Changes in securities lending payable 234 (18) 21
Proceeds from issuance of common stock under Equity Units stock purchase contracts — — 1,250
Repurchase and retirement of common stock (2,700) (1,701) (1,685)
Cash dividends (1,000) (856) (812)
Proceeds from issuance of common stock under employee stock plans 176 187 173
Taxes paid through withholding of common stock under employee stock plans (128) (84) (81)
Other, net 14 29 (83)
Net cash used in financing activities (3,002) (1,390) (2,173)
Change in cash and cash equivalents (1,118) 528 334
Cash and cash equivalents at beginning of year 1,818 1,290 956
Cash and cash equivalents at end of year $ 700 $ 1,818 $ 1,290
See accompanying notes.
-158-
-- 162 of 512 --
Anthem, Inc.
(Parent Company Only)
Notes to Condensed Financial Statements
December 31, 2020
(In Millions, Except Per Share Data)
1. Basis of Presentation and Significant Accounting Policies
In the parent company only financial statements of Anthem, Inc. (“Anthem”) Anthem’s investment in subsidiaries is stated at cost plus equity in undistributed
earnings of the subsidiaries. Anthem’s share of net income of its unconsolidated subsidiaries is included in income using the equity method of accounting.
Certain amounts presented in the parent company only financial statements are eliminated in the consolidated financial statements of Anthem.
Anthem’s parent company only financial statements should be read in conjunction with Anthem’s audited consolidated financial statements and the
accompanying notes included in Part II, Item 8 of this Annual Report on Form 10-K.
2. Subsidiary Transactions
Dividends from Subsidiaries
Anthem received cash dividends from subsidiaries of $3,618, $3,790 and $3,606 during 2020, 2019 and 2018, respectively.
Dividends to Subsidiaries
Certain subsidiaries of Anthem own shares of Anthem common stock. Anthem paid cash dividends to subsidiaries related to these shares of common stock in
the amount of $46, $38 and $36 during 2020, 2019 and 2018, respectively.
Investments in Subsidiaries
Capital contributions to subsidiaries were $2,460, $232 and $4,379 during 2020, 2019 and 2018, respectively.
Amounts Due to and From Subsidiaries
At December 31, 2020 and 2019, Anthem reported amounts due to and from subsidiaries of $1,239 and $602, respectively. The amounts due from subsidiaries
primarily include amounts for allocated administrative expenses or daily cash management activities. These items are routinely settled, and as such, are classified
as current assets or liabilities.
Guarantees on Behalf of Subsidiaries
Anthem guarantees contractual or financial obligations or solvency requirements for certain of its subsidiaries. These guarantees approximated $538 at
December 31, 2020. There were no payments made on these guarantees in 2020.
3. Derivative Financial Instruments
The information regarding derivative financial instruments contained in Note 6, “Derivative Financial Instruments,” of the Notes to Consolidated Financial
Statements of Anthem and its subsidiaries, included in Part II, Item 8 of this Annual Report on Form 10-K, is incorporated herein by reference.
4. Long-Term Debt
The information regarding long-term debt contained in Note 13, “Debt,” of the Notes to Consolidated Financial Statements of Anthem and its subsidiaries,
included in Part II, Item 8 of this Annual Report on Form 10-K, is incorporated herein by reference.
-159-
-- 163 of 512 --
5. Commitments and Contingencies
The information regarding commitments and contingencies contained in Note 14, “Commitments and Contingencies,” of the Notes to Consolidated Financial
Statements of Anthem and its subsidiaries, included in Part II, Item 8 of this Annual Report on Form 10-K, is incorporated herein by reference.
6. Capital Stock
The information regarding capital stock contained in Note 15, “Capital Stock,” of the Notes to Consolidated Financial Statements of Anthem and its
subsidiaries, included in Part II, Item 8 of this Annual Report on Form 10-K, is incorporated herein by reference.
7. Leases
Beginning in 2019, certain of our leases, including the lease for our principal executive offices located at 220 Virginia Avenue, Indianapolis, Indiana, are
obligations of Anthem, Inc. (Parent Company). At December 31, 2020, these leases had an aggregate right-of-use asset of $95, a lease liability balance of $98,
operating lease expense of $15 and future lease payments as follows: 2021, $21; 2022, $19; 2023, $16; 2024, $13; 2025, $11; and thereafter $59. At December 31,
2019, the aggregate right-of-use asset balance was $39, the lease liability balance was $40, and the operating lease expense recognized in 2019 was $7. All other
information regarding leases is contained in Note 18, “Leases,” of the Notes to Consolidated Financial Statements of Anthem and its subsidiaries, included in Part
II, Item 8 of this Annual Report on Form 10-K. Our activities as disclosed in Note 4, “Business Optimization Initiatives” of the Notes to Consolidated Financial
Statements of Anthem and its subsidiaries, included in Part II, Item 8 of this Annual Report on Form 10-K, include reducing our office space footprint. As a result,
we performed an interim impairment test and recorded an impairment charge of $1 for affected right-of-use assets in 2020 which is included in the operating lease
expense shown above.
8. Property and Equipment
The information regarding property and equipment contained in Note 9, “Property and Equipment,” of the Notes to Consolidated Financial Statements of
Anthem and its subsidiaries, included in Part II, Item 8 of this Annual Report on Form 10-K, is incorporated herein by reference. Our activities as disclosed in Note
4, “Business Optimization Initiatives” of the Notes to Consolidated Financial Statements of Anthem and its subsidiaries, included in Part II, Item 8 of this Annual
Report on Form 10-K, include impairment and abandonment of property and equipment. We recorded an impairment charge of $10 for property and equipment
which is included in general and administrative expenses.
-160-
-- 164 of 512 --
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
ANTHEM, INC.
By: /s/ GAIL K. BOUDREAUX
Gail K. Boudreaux
President and Chief Executive Officer
Dated: February 18, 2021
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant
and in the capacities and on the dates indicated.
Signature Title Date
/s/ GAIL K. BOUDREAUX President and Chief Executive Officer, Director
(Principal Executive Officer) February 18, 2021
Gail K. Boudreaux
/s/ JOHN E. GALLINA
Executive Vice President and Chief Financial Officer (Principal
Financial Officer)
February 18, 2021
John E. Gallina
/s/ RONALD W. PENCZEK
Senior Vice President and Chief Accounting Officer (Principal
Accounting Officer)
February 18, 2021
Ronald W. Penczek
/s/ ELIZABETH E. TALLETT Chair of the Board February 18, 2021
Elizabeth E. Tallett
/s/ R. KERRY CLARK Director February 18, 2021
R. Kerry Clark
/s/ ROBERT L. DIXON, JR. Director February 18, 2021
Robert L. Dixon, Jr.
/s/ LEWIS HAY III Director February 18, 2021
Lewis Hay III
/s/ JULIE A. HILL Director February 18, 2021
Julie A. Hill
/s/ BAHIJA JALLAL Director February 18, 2021
Bahija Jallal
/s/ ANTONIO F. NERI Director February 18, 2021
Antonio F. Neri
/s/ RAMIRO G. PERU Director February 18, 2021
Ramiro G. Peru
/s/ RYAN M. SCHNEIDER Director February 18, 2021
Ryan M. Schneider
-161-
-- 165 of 512 --
EXHIBIT 4.8
DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF
1934
The common stock of Anthem, Inc. (“Anthem,” “we,” “our,” or “us”) is the only class of securities registered under Section 12 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”).
The following is a summary of the general terms and provisions of our common stock. This summary does not purport to be complete and is subject to and
qualified by reference to our amended and restated articles of incorporation, as amended (our “articles of incorporation”) and our bylaws, as amended (our
“bylaws”), both of which are filed as exhibits to our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”).
For additional information, please read our articles of incorporation, our bylaws and the applicable provisions of the Indiana Business Corporation Law, as
amended (the “IBCL”).
General
We are authorized to issue up to 900,000,000 shares of common stock, par value $0.01 per share, as well as up to 100,000,000 shares of preferred stock,
without par value. We have no shares of preferred stock issued or outstanding.
Each holder of our common stock is entitled to one vote per share of record on all matters to be voted upon by the shareholders. Holders do not have
cumulative voting rights in the election of directors or any other matter. Subject to the preferential rights of the holders of any preferred stock that may at the time
be outstanding, each share of common stock will entitle the holder of that share to an equal and ratable right to receive dividends or other distributions (other than
purchases, redemptions or other acquisitions of shares by us) if declared from time to time by our board of directors and if there are sufficient funds to legally pay a
dividend.
In the event of our liquidation, dissolution or winding up, whether voluntary or involuntary, the holders of common stock will be entitled to share ratably in
all assets remaining after payments to creditors and after satisfaction of the liquidation preference, if any, of the holders of any preferred stock that may at the time
be outstanding. Holders of common stock have no preemptive or redemption rights and will not be subject to further calls or assessments by us.
Our common stock trades on the New York Stock Exchange under the symbol “ANTM.” Computershare Trust Company, N.A. is the registrar, transfer
agent, conversion agent and dividend disbursing agent for the common stock.
Authorized But Unissued Shares
Indiana law does not require shareholder approval for any issuance of authorized shares. Authorized but unissued shares may be used for a variety of
corporate purposes, including future public or private offerings to raise additional capital or to facilitate corporate acquisitions. One of the effects of the existence
of authorized but unissued shares may be to enable our board of directors to issue shares to persons friendly to current management, which issuance could render
more difficult or discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise, and thereby protect the continuity of
current management and possibly deprive the shareholders of opportunities to sell their shares of common stock at prices higher than prevailing market prices. In
addition, depending on the rights prescribed for any series of preferred stock that may be issued, the issuance of preferred stock could have an adverse effect on the
voting power of the holders of common stock or could impose restrictions upon the payment of dividends and other distributions to the holders of common stock.
Limitations on Ownership of Our Common Stock in Articles of Incorporation
As required under our licenses with the Blue Cross and Blue Shield Association (“BCBSA”), our articles of incorporation contain certain limitations on the
ownership of our common stock. Our articles of incorporation provide that no person may beneficially own shares of voting capital stock in excess of specified
ownership limits,
1
US.131016551.01
-- 166 of 512 --
EXHIBIT 4.8
except with the prior approval of a majority of the “continuing directors.” The ownership limits, which may not be exceeded without the prior approval of the
BCBSA, are the following:
• for any institutional investor (as defined in our articles of incorporation), one share less than 10% of our outstanding voting securities;
• for any non-institutional investor (as defined in our articles of incorporation), one share less than 5% of our outstanding voting securities; and
• for any person, one share less than the number of shares of our common stock or other equity securities (or a combination thereof) representing a 20%
ownership interest in us.
Any transfer of stock that would result in any person beneficially owning shares of capital stock in excess of any ownership limit will result in the intended
transferee acquiring no rights in the shares exceeding such ownership limit (with certain exceptions) and the person’s excess shares will be deemed transferred to
an escrow agent to be held until the shares are transferred to a person whose ownership of the shares will not violate the ownership limit.
Certain Other Provisions of Our Articles of Incorporation and Bylaws
Certain other provisions of our articles of incorporation and bylaws may delay or make more difficult unsolicited acquisitions or changes of control of us.
These provisions could have the effect of discouraging third parties from making proposals involving an unsolicited acquisition or change in control of us, although
these proposals, if made, might be considered desirable by a majority of our shareholders. These provisions may also have the effect of making it more difficult for
third parties to cause the replacement of the current management without the concurrence of the board of directors. These provisions include:
• the division of the board of directors into three classes serving staggered terms of office of three years;
• provisions limiting the maximum number of directors to 19 and requiring that any increase in the number of directors then in effect must be approved by
a majority of continuing directors;
• provisions requiring that, except in certain limited circumstances, the filling of any vacancy on the board of directors must be approved by a majority of
continuing directors;
• permitting a special meeting of shareholders to be called only by the board of directors, the Chair of the Board, the Lead Director, the Chief Executive
Officer, the President, or upon the written demand of any one or more shareholders owning at least 20% of our outstanding common stock; and
• requirements for advance notice for raising business or making nominations at shareholders’ meetings.
Our bylaws provide that if the requirement for a classified board structure set forth in our licenses with the BCBSA is eliminated or otherwise no longer
applicable to the Company, the board of directors will take all necessary actions to implement the elimination of the classified board structure and the annual
election of all directors, which shall be phased in over a three-year period commencing with the first annual meeting of shareholders occurring at least 90 days after
the board of directors determines that such requirement is eliminated or is otherwise no longer applicable to the Company.
Our bylaws establish an advance notice procedure with regard to business to be brought before an annual or special meeting of shareholders and advance
notice and proxy access procedures with regard to the nomination of candidates for election as directors, other than by or at the direction of the board of directors.
Although our bylaws do not give the board of directors any power to approve or disapprove shareholder nominations for the election of directors or proposals for
action, they may have the effect of precluding a contest for the election of directors or the consideration of shareholder proposals if the established procedures are
not followed, and of discouraging or deterring a third party from conducting a solicitation of proxies to elect its own slate of directors or to approve its proposal
without regard to whether consideration of those nominees or proposals might be harmful or beneficial to us and our shareholders.
2
US.131016551.01
-- 167 of 512 --
EXHIBIT 4.8
In addition, our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum for (a) any derivative
action or proceeding brought on our behalf, (b) any action asserting a claim for breach of a fiduciary duty owed by any of our directors, officers, employees or
agents to us or certain specified constituents of ours, (c) any action asserting a claim arising pursuant to any provision of the IBCL or our articles of incorporation
or bylaws, or (d) any action asserting a claim governed by the internal affairs doctrine, will be, to the fullest extent permitted by law, the Marion Superior Court in
Marion County, Indiana or, if the Marion Superior Court lacks jurisdiction, the United States District Court for the Southern District of Indiana.
Amendment and Repeal of Bylaws
Our articles of incorporation and bylaws provide that the bylaws may be altered, amended or repealed by either (1) the affirmative vote of a majority of the
entire number of directors, or (2) except for certain provisions of the bylaws, the affirmative vote, at a shareholder meeting, of at least a majority of the votes
entitled to be cast by the holders of the outstanding shares of all classes of our stock entitled to vote generally in the election of directors, considered for this
purpose as a single voting group.
Certain Provisions of the Indiana Business Corporation Law
As an Indiana corporation, we are governed by the IBCL. The following are some of the more significant provisions of the IBCL that may delay, prevent or
make more difficult certain unsolicited acquisitions or changes of control of us. These provisions also may have the effect of preventing changes in our
management. It is possible that these provisions could make it more difficult to accomplish transactions which shareholders may otherwise deem to be in their best
interest.
Control Share Acquisitions. Under Chapter 42 of the IBCL, an acquiring person or group who acquires, directly or indirectly, ownership of, or the power to
direct the exercise of voting power with respect to, issued and outstanding “control shares” in an “issuing public corporation” may not exercise voting rights on any
control shares unless these voting rights are conferred by a majority vote of the disinterested shareholders of the issuing public corporation at a special meeting of
those shareholders held upon the request and at the expense of the acquiring person. If the acquiring person has acquired control shares with a majority or more of
the voting power, and the control shares are accorded full voting rights by the disinterested shareholders, all shareholders of the issuing public corporation have
dissenters’ rights to receive the fair value of their shares pursuant to Chapter 44 of the IBCL. We are an “issuing public corporation” as defined under Chapter 42.
Under Chapter 42, “control shares” means shares acquired by a person that, when added to all other shares of the issuing public corporation owned by that
person or in respect to which that person may exercise or direct the exercise of voting power, would otherwise entitle that person to exercise voting power of the
issuing public corporation in the election of directors within any of the following ranges: (i) one-fifth or more but less than one-third; (ii) one-third or more but less
than a majority; or (iii) a majority or more.
Chapter 42 does not apply if, before a control share acquisition is made, the corporation’s articles of incorporation or bylaws, including a bylaw adopted by
the corporation’s board of directors, provide that they do not apply. Our bylaws provide that we are not subject to Chapter 42; however, our board of directors
could amend our bylaws to rescind our election to opt out of Chapter 42.
Certain Business Combinations. Chapter 43 of the IBCL restricts the ability of an Indiana corporation that has 100 or more shareholders to engage in any
business combinations with an “interested shareholder” for five years after the date the shareholder became an “interested shareholder” (such date, the “share
acquisition date”), unless the business combination or the purchase of shares by the interested shareholder on the interested shareholder’s share acquisition date is
approved by the board of directors of the corporation before the share acquisition date. If such prior approval is not obtained, the interested shareholder may effect
a business combination after the five-year period only if that shareholder receives approval from a majority of the disinterested shareholders or the offer meets
specified fair price criteria.
3
US.131016551.01
-- 168 of 512 --
EXHIBIT 4.8
For purposes of Chapter 43, “interested shareholder” means any person, other than the corporation or its subsidiaries, who is (1) the beneficial owner,
directly or indirectly, of 10% or more of the voting power of the outstanding voting shares of the corporation or (2) an affiliate or associate of the corporation,
which at any time within the five-year period immediately before the date in question, was the beneficial owner, directly or indirectly, of 10% or more of the voting
power of the then outstanding shares of the corporation.
Chapter 43 does not apply to corporations that elect not to be subject to Chapter 43 in an amendment to their articles of incorporation approved by a majority
of the disinterested shareholders. That amendment, however, cannot become effective until 18 months after its passage and would apply only to share acquisitions
occurring after its effective date. Our articles of incorporation do not exclude us from Chapter 43.
Mandatory Classified Board of Directors. Under Chapter 33 of the IBCL, a corporation with a class of voting shares registered with the SEC under
Section 12 of the Exchange Act must have a classified board of directors unless the corporation adopts a bylaw expressly electing not to be governed by this
provision. Although our articles of incorporation and bylaws provide for a classified board of directors so long as we are required to do so under our licenses with
the BCBSA, we adopted an amendment to our bylaws electing not to be subject to this mandatory requirement effective July 29, 2009.
Unanimous Written Consent of Shareholders. Under Chapter 29 of the IBCL, as well as our articles of incorporation and our bylaws, any action required or
permitted to be taken by the holders of common stock may be effected only at an annual meeting or special meeting of such holders, and shareholders may act in
lieu of such meetings only by unanimous written consent.
4
US.131016551.01
-- 169 of 512 --
Summary of the Anthem, Inc. Directed Executive Compensation (DEC) Program (effective January 1, 2020)
Directed Executive Compensation (DEC) is an executive perquisite plan that provides officers of Anthem, Inc. (the “Company”) with
flexibility to tailor certain benefits to meet their needs with a combination of cash (Cash Credits) and reimbursement of allowable expenses
(Core Credits).
Cash Credits are paid directly to the executive and may be used to pay for a variety of expenses that may be incurred in his or her role with
the Company. Core Credits are available as a reimbursement for allowable expenses related to the executive's financial health. The amount of
Cash Credits and Core Credits the executive receives is based upon their position. The CEO receives Core Credits of $27,000 and Cash
Credits of $27,000. Other Named Executive officers receive Core Credits of $15,000 and Cash Credits of $15,000.
Executives newly hired or promoted into an executive position will participate in the program at the beginning of the month following the
date of hire or promotion. New participants receive a prorated portion of both the Cash and Core Credits based on full calendar months of
service in the position.
Cash Credits
Cash Credits are paid to the executive monthly on the first paycheck of the month and may be used for his or her choice of benefits. The
executive does not need to document how these credits are utilized.
Core Credits
Core Credits are available to reimburse executives for costs associated with allowable expenses related to their financial health. An executive
can use his or her Core Credits to be reimbursed for:
• Investment Advisor Fees
• Investment Management Fees
• Financial Counseling Fees
• Retirement Planning and Advice
• Tax Preparation and Advice Fees
• Estate Planning Fees
• Legal Fees or legal software associated with:
◦ Anthem compensation and/or benefits program review
◦ Tax Preparation issues
◦ Estate Planning issues
◦ Financial Counseling issues
• Tax and Investment Software
• Tax, Investment and Financial Subscriptions
-- 170 of 512 --
BLUE CROSS LICENSE AGREEMENT
(Includes revisions, if any, adopted by Member Plans through their September 17, 2020 meeting)
This agreement by and between Blue Cross and Blue Shield Association ("BCBSA") and The
Blue Cross Plan, known as (the "Plan").
Preamble
WHEREAS, the Plan and/or its predecessor(s) in interest (collectively the "Plan") had the
right to use the BLUE CROSS and BLUE CROSS Design service marks (collectively the
"Licensed Marks") for health care plans in its service area, which was essentially local in nature;
WHEREAS, the Plan was desirous of assuring nationwide protection of the Licensed Marks,
maintaining uniform quality controls among Plans, facilitating the provision of cost effective health
care services to the public and otherwise benefiting the public;
WHEREAS, to better attain such ends, the Plan and the predecessor of BCBSA in 1972
simultaneously executed the BCA License Agreement (s) and the Ownership Agreement; and
WHEREAS, BCBSA and the Plan desire to supercede said Agreement(s) and to revise certain
provisions of the Ownership Agreement to reflect their current practices and to assure the continued
integrity of the Licensed Marks and of the BLUE CROSS system;
NOW, THEREFORE, in consideration of the foregoing and the mutual agreements
hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the parties agree as follows:
-- 171 of 512 --
Agreement
1. BCBSA hereby grants to the Plan, upon the terms and conditions of this License
Agreement (“Agreement” or “Primary License Agreement”), the right to use BLUE CROSS in its trade
and/or corporate name (the "Licensed Name"), and the right to use the Licensed Marks, in the sale,
marketing and administration of health care plans and related services in the Service Area set forth
and defined in paragraph 5 below. As used herein, health care plans and related services shall
include acting as a nonprofit health care plan, a for-profit health care plan, or mutual health insurer
operating on a not-for-profit or for-profit basis, under state law; financing access to health care
services; when working with a bank that holds the relevant license to use the Licensed Name and
Marks, offering: (i) tax- favored savings accounts for medical expenses and means for accessing such
accounts, such as debit cards or checks, that are provided solely to support access to such tax-
favored savings accounts, all pursuant to such license, or (ii) prepaid rewards cards that are provided
for completion of a wellness program, all pursuant to such license; providing health care management
and administration; administering, but not underwriting, non- health portions of Workers’
Compensation Insurance; delivering health care services, except hospital services (as defined in the
Guidelines to Membership Standards Applicable to Regular Members); and performing the Eligibility
and Enrollment functions of HR administration for all benefit plans offered by a group account to its
members, including benefit plans not provided by the Plan, provided that the Plan has contracted to
provide Health Coverage under the Licensed Marks to the account (as the terms “Health Coverage,”
“Eligibility” and “Enrollment” are defined in Exhibit 4, Paragraph 2.t.).
2. The Plan may use the Licensed Marks and Name in connection with the offering of: i)
health care plans and related services in the Service Area through Controlled Affiliates, provided that
each such Controlled Affiliate is separately licensed to use the Licensed Marks and Name under the
terms and conditions contained in the Agreement attached as Exhibit 1 hereto (the "Controlled
Affiliate License Agreement"); and ii) insurance coverages offered by life insurers under the
applicable law in the Service Area, other than those which the Plan may offer in its own name,
provided through Controlled Affiliates, provided that each such Controlled Affiliate is separately
licensed to use the Licensed Marks and Name under the terms and conditions contained in the
Agreement attached as Exhibit 1A hereto (the "Controlled Affiliate License Agreement Applicable to
Life Insurance Companies") or the Agreement attached as Exhibit 1A1 hereto (the “Controlled Affiliate
Trademark License Agreement for Life and Disability Insurance Products”) and further provided that
the offering of such services does not and will not dilute or tarnish the unique value of the Licensed
Marks and Name; and iii) administration and underwriting of Workers’ Compensation Insurance
Controlled Affiliates, provided that each such Controlled Affiliate is separately licensed to use the
Licensed Marks and Name under the terms and conditions contained in the Agreement attached as
Exhibit 1 hereto (the “Controlled Affiliate License”); and iv) regional Medicare Advantage PPO
products in cooperation with one or more other Plans through jointly-held Controlled Affiliates,
provided that each such Controlled Affiliate is separately licensed to use the Licensed Marks and
Name under the terms and conditions contained in the Agreement attached as Exhibit 1B hereto (the
“Controlled Affiliate License Agreement Applicable to Regional Medicare Advantage PPO Products”);
and v) regional Medicare Part D Prescription Drug Plan products in cooperation with one or more
other Plans through jointly-held Controlled Affiliates, provided that each such Controlled Affiliate is
separately licensed to use the Licensed Marks and Name under the terms and conditions contained
in the Agreement attached as Exhibit 1C hereto (the “Controlled Affiliate License Agreement
Applicable to Regional Medicare Part D Prescription Drug Plan Products”). As used herein, a
Controlled Affiliate is defined as an entity organized and operated in such a manner that it is subject
to the bona fide control of a Plan or Plans and, if the entity meets the standards of Paragraph 2a.B
but not Paragraph2a.A, the entity, its owners, and persons
Amended as of September 19, 2014
-- 172 of 512 --
with authority to select or appoint members or board members, other than a Plan or Plans, have
received written approval of BCBSA. Absent written approval by BCBSA of an alternative method of
control, bona fide control shall have the meaning set forth in Paragraphs 2a. and 2b.
2a. With respect to the Controlled Affiliate Licenses authorized in clauses i) through
iii) of Paragraph 2, bona fide control shall mean that a Plan (the “Sponsoring Plan”)
authorized to use the Licensed Marks in the Service Area of the Controlled Affiliate pursuant
to this Primary License Agreement with BCBSA must have:
A. The legal authority, directly or indirectly through wholly-owned subsidiaries:
(a) to select members of the Controlled Affiliate's governing body having more
than 50% voting control thereof; (b) to exercise control over the policy and operations
of the Controlled Affiliate; (c) to prevent any change in the articles of incorporation,
bylaws or other establishing or governing documents of the Controlled Affiliate with
which the Sponsoring Plan does not concur. In addition, the Sponsoring Plan directly
or indirectly through wholly-owned subsidiaries shall own more than 50% of any for-
profit Controlled Affiliate, provided that in instances where the Sponsoring Plan
formed a publicly traded Controlled Affiliate Licensee and such publicly traded
Controlled Affiliate Licensee owns and controls other Controlled Affiliate Licensees,
the Sponsoring Plan directly or indirectly shall own and control more than 50% of any
Controlled Affiliate that is indirectly owned and controlled by the publicly traded
Controlled Affiliate Licensee; or
B. The legal authority directly or indirectly through wholly-owned subsidiaries
(b) to select members of the Controlled Affiliate's governing body having not less than
50% voting control thereof; (b) to prevent any change in the articles of incorporation,
bylaws or other establishing or governing documents of the Controlled Affiliate with
which the Sponsoring Plan does not concur; (c) to exercise control over the policy and
operations of the Controlled Affiliate at least equal to that exercised by persons or
entities (jointly or individually) other than the Sponsoring Plan. Notwithstanding anything
to the contrary in
(a) through (c) hereof, the Controlled Affiliate’s establishing or governing documents
must also require written approval by the Sponsoring Plan before the Controlled
Affiliate can:
1. Change its legal and/or trade name;
2. Change the geographic area in which it operates;
3. Change any of the types of businesses in which it engages;
4. Create, or become liable for by way of guarantee, any indebtedness,
other than indebtedness arising in the ordinary course of business;
5. Sell any assets, except for sales in the ordinary course of business or sales
of equipment no longer useful or being replaced;
6. Make any loans or advances except in the ordinary course of business;
Amended as of March 26, 2015
-2-
-- 173 of 512 --
7. Enter into any arrangement or agreement with any party directly or
indirectly affiliated with any of the owners of the Controlled Affiliate or
persons or entities with the authority to select or appoint members or
board members of the Controlled
Affiliate, other than the Sponsoring Plan or other Plans (excluding owners of
stock holdings of under 5% in a publicly traded Controlled Affiliate);
8. Conduct any business other than under the Licensed Marks and Name;
9. Take any action that the Sponsoring Plan or BCBSA reasonably believes
will adversely affect the Licensed Marks or Names.
In addition, the Sponsoring Plan directly or indirectly through wholly owned subsidiaries shall
own at least 50% of any for-profit Controlled Affiliate, provided that in instances where the
Sponsoring Plan formed a publicly traded Controlled Affiliate Licensee and such publicly traded
Controlled Affiliate Licensee owns and controls other Controlled Affiliate Licensees, the
Sponsoring Plan directly or indirectly shall own and control at least 50% of any Controlled
Affiliate that is indirectly owned and controlled by the publicly traded Controlled Affiliate
Licensee; or
C. With respect to a Controlled Affiliate that is 100% controlled by Plans including the
Sponsoring Plan and which offers solely Medicaid, Medicare Advantage PPO, Medicare
Advantage HMO and/or Special Need Plans products and services, the legal authority by
the Sponsoring Plan together with such other Plans (a) to select all members of the
Controlled Affiliate’s governing body; (b) to prevent any change in the articles of
incorporation, bylaws or other establishing or governing documents of the Controlled
Affiliate; (c) to exercise control over the policy and operations of the Controlled Affiliate.
In addition, the Sponsoring Plan and such other Plans shall own 100% of any for-profit
Controlled Affiliate, with the Sponsoring Plan and such other Plans each having an
ownership interest. Such 100% control and ownership by Plans shall be direct or, if
indirect, solely through affiliates that are licensed to use marks owned by BCBSA.
Further, the Sponsoring Plan and such other Plans shall execute the “Addendum to
Controlled Affiliate License” attached as Exhibit B-1 to Exhibit 1 attached hereto; or
Amended as of June 20, 2019
-- 174 of 512 --
D. With respect to a Controlled Affiliate that is 100% controlled by a Sponsoring Plan which
on a Blue-branded basis offers solely a Basic Medicare Part D Prescription Drug product,
the legal authority by the Sponsoring Plan: (a) to select all members of the Controlled
Affiliate’s governing body; (b) to prevent any change in the articles of incorporation,
bylaws or other establishing or governing documents of the Controlled Affiliate; (c) to
exercise control over the policy and operations of the Controlled Affiliate. In addition, the
Sponsoring Plan shall own 100% of any for-profit Controlled Affiliate. Such 100% control
and ownership by the Plan shall be direct or, if indirect, solely through affiliates that are
licensed to use marks owned by BCBSA. Further, the Sponsoring Plan and Participating
Plan as defined on the Controlled Affiliate License Agreement shall execute the
“Addendum to Controlled Affiliate License” attached as Exhibit B-2 to Exhibit 1 attached
hereto.
E. With respect to a Controlled Affiliate that operates as a clinic, the legal authority by the
Sponsoring Plan to exercise control over the policy and operations of the Controlled
Affiliate as defined in Exhibit 1, Standard 1(E) and the Guidelines to Administer Standard
1(E). In addition, if the clinic is for- profit, the Sponsoring Plan shall own at least 50% of
the Controlled Affiliate and prevent any change in the articles of incorporation, bylaws or
other establishing documents of the Controlled Affiliate with which the Sponsoring Plan
does not concur.
2b. With respect to the Controlled Affiliate License Agreements authorized in clauses iv)
and v) of Paragraph 2, bona fide control shall mean that the Controlled Affiliate is organized and
operated in such a manner that it meets the following requirements:
A. The Controlled Affiliate is owned or controlled by two or more Plans authorized to use the
Licensed Marks pursuant to this License Agreement with BCBSA (for purposes of this
subparagraph A. through subparagraph C., the “Controlling Plans”); and
Amended as of June 20, 2019
-2a-
-- 175 of 512 --
B. Each Controlling Plan is authorized pursuant to this Agreement to use the Licensed
Marks in a geographic area in the Region (as that term is defined in such Controlled
Affiliate License Agreements) and every geographic area in the Region is so licensed to
at least one of the Controlling Plans; and
C. The Controlling Plans must have the legal authority directly or indirectly through wholly-
owned subsidiaries (a) to select members of the Controlled Affiliate’s governing body
having not less than 100% voting control thereof; (b) to prevent any change in the articles
of incorporation, bylaws or other establishing or governing documents of the Controlled
Affiliate with which the Controlling Plans do not concur; and (c) to exercise control over
the policy and operations of the Controlled Affiliate. Notwithstanding anything to the
contrary in (a) through (c) of this subparagraph E., the Controlled Affiliate’s establishing
or governing documents must also require written approval by each of the Controlling
Plans before the Controlled Affiliate can:
1. Change its legal and/or trade names;
2. Change the geographic area in which it operates (except such approval
shall not be required with respect to business of the Controlled Affiliate
conducted under the Licensed Marks within the Service Area of one of
the Controlling Plans pursuant to a separate controlled affiliate license
agreement with BCBSA sponsored by such Controlling Plan);
3. Change any of the type(s) of businesses in which it engages (except such
approval shall not be required with respect to business of the Controlled
Affiliate conducted under the Licensed Marks within the Service Area of one
of the Controlling Plans pursuant to a separate controlled affiliate license
agreement with BCBSA sponsored by such Controlling Plan);
4. Take any action that any Controlling Plan or BCBSA reasonably believes
will adversely affect the Licensed Marks and Name.
In addition, the Controlling Plans directly or indirectly through wholly-owned
subsidiaries shall own 100% of any for-profit Controlled Affiliate.
Amended as of June 19, 2014
(The next page is page 3)
-2b-
-- 176 of 512 --
3. With respect to a Controlled Affiliate that is not licensed to use the Licensed Marks and
Name, the Plan may, in communications that contain the Licensed Marks or Name, indicate its
corporate relationship to the Affiliate and permit such Affiliate to indicate its corporate relationship to
the Plan, solely in the circumstances, style and manner specified by BCBSA from time-to-time in
regulations of general application consistent with the avoidance of confusion or mistake or the
dilution or tarnishment of the Licensed Marks and Name. No rights are hereby created in any
Controlled Affiliate to use the Licensed Marks or Name in its own name or otherwise.
4. The Plan recognizes the importance of a comprehensive national network of independent
BCBSA licensees which are committed to strengthening the Licensed Marks and Name. The Plan
further recognizes that its actions within its Service Area may affect the value of the Licensed Marks
and Name nationwide. The Plan agrees (a) to maintain in good standing its membership in BCBSA;
(b) promptly to pay its dues to BCBSA, said dues to represent the royalties for this License
Agreement; (c) materially to comply with all applicable laws; (d) to comply with the Membership
Standards Applicable to Regular Members of BCBSA, a current copy of which is attached as Exhibit 2
hereto; and (e) reasonably to permit BCBSA, upon a written, good faith request and during
reasonable business hours, to inspect the Plan's books and records necessary to ascertain
compliance herewith. As to other Plans and third parties, BCBSA shall maintain the confidentiality of
all documents and information furnished by the Plan pursuant hereto, or pursuant to the Membership
Standards, and clearly designated by the Plan as containing proprietary information of the Plan.
5. The rights hereby granted are exclusive to the Plan within the geographical area(s) served
by the Plan on June 30, 1972, and/or as to which the Plan has been granted a subsequent license,
which is hereby defined as the "Service Area," except that BCBSA reserves the right to use the
Licensed Marks in said Service Area, and except to the extent that said Service Area may overlap
areas served by one or more other licensed Blue Cross Plans as of said date or subsequent license,
as to which overlapping areas the rights hereby granted are nonexclusive as to such other Plan or
Plans only.
Amended as of June 19, 2014
-3-
-- 177 of 512 --
6. Except as expressly provided by BCBSA with respect to National Accounts, Government
Programs and certain other necessary and collateral uses, the current rules and regulations governing
which are attached as Exhibit 3 and Exhibit 4 hereto, and are contained in other documents
referenced herein, or as expressly provided herein, the Plan may not use the Licensed Marks and
Name outside the Service Area or in connection with other goods and services, nor may the Plan use
the Licensed Marks or Name in a manner which is intended to transfer in the Service Area the
goodwill associated therewith to another mark or name. Nothing herein shall be construed to prevent
the Plan from engaging in lawful activity anywhere under other marks and names not confusingly
similar to the Licensed Marks and Name, provided that engaging in such activity does and will not
dilute or tarnish the unique value of the Licensed Marks and Name. In addition to any and all
remedies available hereunder, BCBSA may impose monetary fines on the Plan for the Plan’s use of
the Licensed Marks and Names outside the Service Area, and provided that the procedure used in
imposing a fine is consistent with procedures specifically prescribed by BCBSA from time to time in
regulations of general application. In the case of regional Medicare Advantage PPO and regional
Medicare Part D Prescription Drug Plan products offered by consenting and participating Plans in a
region that includes the Service Areas, or portions thereof, of more than one Plan, such fine may be
imposed jointly on the consenting and participating Plans for use of the Licensed Marks and Name in
any geographic area of the region in which a Plan having exclusive rights to the Licensed Marks and
Name does not consent to and participate in such offering, provided that the basis for imposition of
such fine is consistent with rules specifically prescribed by BCBSA from time to time in regulations of
general application.
7. The Plan agrees that it will display the Licensed Marks and Name only in such form,
style and manner as shall be specifically prescribed by BCBSA from
time-to-time in regulations of general application in order to prevent impairment of the distinctiveness
of the Licensed Marks and Name and the goodwill pertaining thereto. The Plan shall cause to appear
on all materials on or in connection with which the Licensed Marks or Name are used such legends,
markings and notices as BCBSA may reasonably request in order to give appropriate notice of service
mark or other proprietary rights therein or pertaining thereto.
8. BCBSA agrees that: (a) it will not grant any other license effective during the term of this
License Agreement for the use of the Licensed Marks or Name which is inconsistent with the rights
granted to the Plan hereunder; and (b) it will not itself use the Licensed Marks in derogation of the
rights of the Plan or in a manner to deprive the Plan of the full benefits of this License Agreement,
provided that BCBSA shall have the right to use the Licensed Marks in conjunction with any national
offering under the Federal Employees Health Benefits Program in the manner set forth in Exhibit 4,
Paragraph 4 (including subparagraphs) to this License Agreement. The Plan agrees that it will not
attack the title of BCBSA in and to the Licensed Marks or Name or attack the validity of the Licensed
Marks or of this License Agreement. The Plan further agrees that all use by it of the Licensed Marks
and Name or any similar mark or name shall inure to the benefit of BCBSA, and the Plan shall
cooperate with BCBSA in effectuating the assignment to BCBSA of any service mark or trademark
registrations of the Licensed Marks or any similar mark or name held by the Plan or a Controlled
Affiliate of the Plan, all or any portion of which registration consists of the Licensed Marks.
Amended as of November 16, 2006
-3a-
-- 178 of 512 --
9. (a). Should the Plan fail to comply with the provisions of paragraphs 2-4, 6, 7 and/or 12,
and not cure such failure within thirty (30) days of receiving written notice thereof (or commence
curing such failure within such thirty day period and continue diligent efforts to complete the curing of
such failure if such curing cannot reasonably be completed within such thirty day period), BCBSA
shall have the right to issue a notice that the Plan is in a state of noncompliance. Except as to the
termination of a Plan's License Agreement or the merger of two or more Plans, disputes as to
noncompliance, and all other disputes between or among BCBSA, the Plan, other Plans and/or
Controlled Affiliates, shall be submitted promptly to mediation and mandatory dispute resolution
pursuant to the rules and regulations of BCBSA, a current copy of which is attached as Exhibit 5
hereto, and shall be timely presented and resolved. The mandatory dispute resolution panel shall
have authority to issue orders for specific performance and assess monetary penalties. If a state of
noncompliance as aforesaid is undisputed by the Plan or is found to exist by a mandatory dispute
resolution panel and is uncured as provided above, BCBSA shall have the right to seek judicial
enforcement of the License Agreement. Except, however, as provided in paragraphs 9(d)(iii), 15(a)(i)-
(viii), and 15(a)(x) below, no Plan's license to use the Licensed Marks and Name may be finally
terminated for any reason without the affirmative vote of three-fourths of the Plans and three-fourths
of the total then current weighted vote of all the Plans.
(b). Notwithstanding any other provision of this License Agreement, a Plan's
license to use the Licensed Marks and Name may be forthwith terminated by the affirmative vote of
three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans at a
special meeting expressly called by BCBSA for the purpose on ten (10) days written notice to the
Plan advising of the specific matters at issue and granting the Plan an opportunity to be heard and to
present its response to Member Plans for: (i) failure to comply with any minimum capital or liquidity
requirement under the Membership Standard on Financial Responsibility; or (ii) impending financial
insolvency; or
(iii) the pendency of any action instituted against the Plan seeking its dissolution or liquidation or its
assets or seeking appointment of a trustee, interim trustee, receiver or other custodian for any of its
property or business or seeking the declaration or establishment of a trust for any of its property of
business, unless this License Agreement has been earlier terminated under paragraph 15(a); or (iv)
such other reason as is determined in good faith immediately and irreparably to threaten the
integrity and reputation of BCBSA, the Plans and/or the Licensed Marks.
Amended as of March 16, 2006
-4-
-- 179 of 512 --
(c). To the extent not otherwise provided therein, neither: (i) the Membership
Standards Applicable to Regular Members of BCBSA; nor (ii) the rules and regulations governing
Government Programs and certain other uses; nor (iii) the rules and regulations governing mediation
and mandatory dispute resolution, may be amended unless and until each such amendment is first
adopted by the affirmative vote of three-fourths of the Plans and of three-fourths of the total then
current weighted vote of all the Plans. The rules and regulations governing National Accounts and
other national programs required by the Membership Standards Applicable to Regular Members of
BCBSA (Exhibit 2) are contained, in addition to those set forth in Exhibit 3, in the following documents,
as amended from time to time: (1) the Inter-Plan Programs Policies and Provisions; (2) Inter- Plan
Medicare Advantage Program Policies and Provisions. The voting requirements specified in rules and
regulations governing such national programs may not be amended unless and until each such
amendment is first adopted by the affirmative vote of three- fourths of the Plans and of three-fourths of
the total then current weighted vote of all the Plans.
Amended as of November 21, 2014
-4a-
-- 180 of 512 --
(d). The Plan may operate as a for-profit company on the following conditions:
(i) The Plan shall discharge all responsibilities which it has to the Association and to
other Plans by virtue of this Agreement and the Plan's membership in BCBSA.
(ii) The Plan shall not use the licensed Marks and Name, or any derivative thereof, as
part of its legal name or any symbol used to identify the Plan in any securities market. The Plan
shall use the licensed Marks and Name as part of its trade name within its service area for the sale,
marketing and administration of health care and related services in the service area.
(iii) Plan's license to use the Licensed Marks and Name shall automatically terminate
effective: (a) thirty days after the Plan knows, or there is an SEC filing indicating that, any Institutional
Investor, has become the Beneficial Owner of securities representing 10% or more of the voting
power of the Plan (“Excess Institutional Voter”), unless such Excess Institutional Voter shall cease to
be an Excess Institutional Voter prior to such automatic termination becoming effective; (b) thirty days
after the Plan knows, or there is an SEC filing indicating that, any Noninstitutional Investor has
become the Beneficial Owner of securities representing 5% or more of the voting power of the Plan
(“Excess Noninstitutional Voter”) unless such Excess Noninstitutional Voter shall cease to be an
Excess Noninstitutional Voter prior to such automatic termination becoming effective; (c) thirty days
after the Plan knows, or there is an SEC filing indicating that, any Person has become the Beneficial
Owner of 20% or more of the Plan’s then outstanding common stock or other equity securities which
(either by themselves or in combination) represent an ownership interest of 20% or more pursuant to
determinations made under paragraph 9(d)(iv) below (“Excess Owner”), unless such Excess Owner
shall cease to be an Excess Owner prior to such automatic termination becoming effective; (d) ten
business days after individuals who at the time the Plan went public constituted the Board of Directors
of the Plan (together with any new directors whose election to the Board was approved by a vote of
2/3 of the directors then still in office who were directors at the time the Plan went public or whose
election or nomination was previously so approved) (the "Continuing Directors") cease for any reason
to constitute a majority of the Board of Directors; or (e) ten business days after the Plan consolidates
with or merges with or into any person or conveys, assigns, transfers or sells all or substantially all of
its assets to any person other than a merger in which the Plan is the surviving entity and immediately
after which merger, no person is an Excess Institutional Voter, an Excess Noninstitutional Voter or an
Excess Owner: provided that, if requested by the affected Plan in a writing received by BCBSA prior
to such automatic termination becoming effective, the provisions of this paragraph 9(d)(iii) may be
waived, in whole or in part,
Amended as of September 17, 1997
-5-
-- 181 of 512 --
upon the affirmative vote of a majority of the disinterested Plans and a majority of the total then
current weighted vote of the disinterested Plans. Any waiver so granted may be conditioned upon
such additional requirements (including but not limited to imposing new and independent grounds for
termination of this License) as shall be approved by the affirmative vote of a majority of the
disinterested Plans and a majority of the total then current weighted vote of the disinterested Plans. If
a timely waiver request is received, no automatic termination shall become effective until the later of:
(1) the conclusion of the applicable time period specified in paragraphs 9(d)(iii)(a)-(d) above, or (2)
the conclusion of the first Member Plan meeting after receipt of such a waiver request.
In the event that the Plan's license to use the Licensed Marks and Name is terminated pursuant to
this Paragraph 9(d)(iii), the license may be reinstated in BCBSA’s sole discretion if, within 30 days of
the date of such termination, the Plan demonstrates that the Person referred to in clause (a), (b) or
(c) of the preceding paragraph is no longer an Excess Institutional Voter, an Excess Noninstitutional
Voter or an Excess Owner.
(iv) The Plan shall not issue any class or series of security other than (i) shares of
common stock having identical terms or options or derivatives of such common stock, (ii) non-
voting, non-convertible debt securities or (iii) such other securities as the Plan may approve,
provided that BCBSA receives notice at least thirty days prior to the issuance of such securities,
including a description of the terms for such securities, and BCBSA shall have the authority to
determine how such other securities will be counted in determining whether any Person is an
Excess Institutional Voter, Excess Noninstitutional Voter or an Excess Owner.
(v) For purposes of paragraph 9(d)(iii), the following definitions shall apply:
(a) "Affiliate" and "Associate" shall have the respective meanings ascribed to
such terms in Rule 12b-2 of the General Rules and Regulations under the Securities
Exchange Act of 1934, as amended and in effect on November 17, 1993 (the "Exchange
Act").
(b) A Person shall be deemed the "Beneficial Owner" of and shall be
deemed to "beneficially own" any securities:
(i) which such Person or any of such Person's Affiliates or Associates
beneficially owns, directly or indirectly;
Amended as of September 17, 1997
-5a-
-- 182 of 512 --
(ii) which such Person or any of such Person's Affiliates or Associates has (A)
the right to acquire (whether such right is exercisable immediately or only after the passage of
time) pursuant to any agreement, arrangement or understanding, or upon the exercise of
conversion rights, exchange rights, warrants or options, or otherwise; or (B) the right to vote
pursuant to any agreement, arrangement or understanding; provided, however, that a Person
shall not be deemed the Beneficial Owner of, or to beneficially own, any security if the
agreement, arrangement or understanding to vote such security (1) arises solely from a
revocable proxy or consent given to such Person in response to a public proxy or consent
solicitation made pursuant to, and in accordance with, the applicable rules and regulations
promulgated under the Exchange Act and (2) is not also then reportable on Schedule 13D
under the Exchange Act (or any comparable or successor report); or
(iii) which are beneficially owned, directly or indirectly, by any other Person (or
any Affiliate or Associate thereof) with which such Person (or any of such Person's Affiliates or
Associates) has any agreement, arrangement or understanding (other than customary
agreements with and between underwriters and selling group members with respect to a bona
fide public offering of securities) relating to the acquisition, holding, voting (except to the extent
contemplated by the proviso to (b)(ii)(B) above) or disposing of any securities of the Plan.
Notwithstanding anything in this definition of Beneficial Ownership to the contrary, the phrase
"then outstanding," when used with reference to a Person's Beneficial Ownership of securities
of the Plan, shall mean the number of such securities then issued and outstanding together
with the number of such securities not then actually issued and outstanding which such Person
would be deemed to own beneficially hereunder.
(c) A Person shall be deemed an “Institutional Investor” if (but only if) such Person (i) is
an entity or group identified in the SEC’s Rule 13d-1(b)(1)(ii) as constituted on June 1, 1997,
and (ii) every filing made by such Person with the SEC under Regulation 13D-G (or any
successor Regulation) with respect to such Person’s Beneficial Ownership of Plan securities
shall have contained a certification identical to the one required by item 10 of SEC Schedule
13G as constituted on June 1, 1997.
(d) “Noninstitutional Investor” means any Person who is not an Institutional
Investor.
(e) "Person" shall mean any individual, firm, partnership, corporation, trust, association,
joint venture or other entity, and shall include any successor (by merger or otherwise) of such
entity.
Amended as of September 17, 1997
-5b- (The next page is page 6)
-- 183 of 512 --
10. This License Agreement shall remain in effect: (a) until terminated as provided herein; or
(b) until this and all such other License Agreements are terminated by the affirmative vote of three-
fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans; or (c)
until termination of aforesaid Ownership Agreement; or
(d) until terminated by the Plan upon eighteen (18) months written notice to BCBSA or upon a
shorter notice period approved by BCBSA in writing at its sole discretion.
11. Except as otherwise provided in paragraph 15 below or by the affirmative vote of three-
fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans, or unless
this and all such other License Agreements are simultaneously terminated by force of law, the
termination of this License Agreement for any reason whatsoever shall cause the reversion to BCBSA
of all rights in and to the Licensed Marks and Name, and the Plan agrees that it will promptly
discontinue all use of the Licensed Marks and Name, will not use them thereafter, and will promptly,
upon written notice from BCBSA, change its corporate name so as to eliminate the Licensed Name
therefrom.
12. The license hereby granted to Plan to use the Licensed Marks and Name is and shall be
personal to the Plan so licensed and shall not be assignable by any act of the Plan, directly or
indirectly, without the written consent of BCBSA. Said license shall not be assignable by operation of
law, nor shall Plan mortgage or part with possession or control of this license or any right hereunder,
and the Plan shall have no right to grant any sublicense to use the Licensed Marks and Name.
13. BCBSA shall maintain appropriate service mark registrations of the Licensed Marks and
BCBSA shall take such lawful steps and proceedings as may be necessary or proper to prevent use of
the Licensed Marks by any person who is not authorized to use the same. Any actions or proceedings
undertaken by BCBSA under the provisions of this paragraph shall be at BCBSA's sole cost and
expense. BCBSA shall have the sole right to determine whether or not any legal action shall be taken
on account of unauthorized use of the Licensed Marks, such right not to be unreasonably exercised.
The Plan shall report any unlawful usage of the Licensed Marks to BCBSA in writing and agrees, free
of charge, to cooperate fully with BCBSA's program of enforcing and protecting the service mark
rights, trade name rights and other rights in the Licensed Marks.
14. The Plan hereby agrees to save, defend, indemnify and hold BCBSA and any other
Plan(s) harmless from and against all claims, damages, liabilities and costs of every kind, nature and
description which may arise as a result of the activities of the Plan or of any hospital, medical group,
clinic or other provider of health services that is owned or controlled directly or indirectly by Plan.
BCBSA hereby agrees to save, defend, indemnify and hold the Plan and any other Plan(s) harmless
from and against all claims, damages, liabilities And costs of every kind, nature and description which
may arise exclusively and directly as a result of the activities of BCBSA.
Amended as of June 21, 2012
-6-
-- 184 of 512 --
15. (a). This Agreement shall automatically terminate upon the occurrence of any of the
following events: (i) a voluntary petition shall be filed by the Plan or by BCBSA seeking bankruptcy,
reorganization, arrangement with creditors or other relief under the bankruptcy laws of the United
States or any other law governing insolvency or debtor relief, or (ii) an involuntary petition or proceeding
shall be filed against the Plan or BCBSA seeking bankruptcy, reorganization, arrangement with
creditors or other relief under the bankruptcy laws of the United States or any other law governing
insolvency or debtor relief and such petition or proceeding is consented to or acquiesced in by the Plan
or BCBSA or is not dismissed within sixty (60) days of the date upon which the petition or other
document commencing the proceeding is served upon the Plan or BCBSA respectively, or (iii) an order
for relief is entered against the Plan or BCBSA in any case under the bankruptcy laws of the United
States, or the Plan or BCBSA is adjudged bankrupt or insolvent (as that term is defined in the Uniform
Commercial Code as enacted in the state of Illinois) by any court of competent jurisdiction, or (iv) the
Plan or BCBSA makes a general assignment of its assets for the benefit of creditors, or (v) any
government or any government official, office, agency, branch, or unit assumes control of the Plan or
delinquency proceedings (voluntary or involuntary) are instituted, or (vi) an action is brought by the Plan
or BCBSA seeking its dissolution or liquidation of its assets or seeking the appointment of a trustee,
interim trustee, receiver or other custodian for any of its property or business, or (vii) an action is
instituted by any governmental entity or officer against the Plan or BCBSA seeking its dissolution or
liquidation of its assets or seeking appointment of a trustee, interim trustee, receiver or other custodian
for any of its property or business and such action is consented to or acquiesced in by the Plan or
BCBSA or is not dismissed within one hundred thirty (130) days of the date upon which the pleading or
other document commencing the action is served upon the Plan or BCBSA respectively, provided that if
the action is stayed or its prosecution is enjoined, the one hundred thirty (130) day period is tolled for
the duration of the stay or injunction, and provided further, that the Association’s Board of Directors
may toll or extend the 130 day period at any time prior to its expiration, or (viii) a trustee, interim trustee,
receiver or other custodian for any of the Plan's or BCBSA's property or business is appointed, or the
Plan or BCBSA is ordered dissolved or liquidated, or (ix) the Plan shall fail to pay its dues and shall not
cure such failure within thirty (30) days of receiving written notice thereof, or (x) if, due to regulatory
action, the Plan together with any applicable Controlled Affiliate becomes unable to do business using
the Names and Marks in any State or portion thereof included in its Service Area, provided that: (i)
automatic termination shall not occur prior to the exhaustion by any such Plan of its rights to appeal or
challenge such regulatory action; and (ii) in the event the Plan is licensed to do business using the
Names and Marks in multiple States or portions of States, the termination of its License Agreement
shall be solely limited to the State(s) or portions thereof in which the regulatory action applies. By not
appealing or challenging such regulatory action within the time prescribed by law or regulation, and in
any event no later than 120 days after such action is taken, a Plan shall be deemed to have exhausted
its rights to appeal or challenge, and automatic termination shall proceed.
-7-
-- 185 of 512 --
Notwithstanding any other provision of this Agreement, a declaration or a request for declaration of the
existence of a trust over any of the Plan’s or BCBSA’s property or business shall not in itself be
deemed to constitute or seek appointment of a trustee, interim trustee, receiver or other custodian for
purposes of subparagraphs 15(a)(vii) and (viii) of this Agreement.
Amended as of March 26, 2015
-7a-
-- 186 of 512 --
(b). BCBSA, or the Plans (as provided and in addition to the rights conferred in
Paragraph 10(b) above), may terminate this Agreement immediately upon written notice upon
the occurrence of either of the following events: (a) the Plan or BCBSA becomes insolvent (as
that term is defined in the Uniform Commercial Code enacted in the state of Illinois), or (b) any
final judgment against the Plan or BCBSA remains unsatisfied or unbonded of record for a
period of sixty (60) days or longer.
(c). If this License Agreement is terminated as to BCBSA for any reason stated in
subparagraphs 15(a) and (b) above, the ownership of the Licensed Marks shall revert to each
of the Plans as provided in the Ownership Agreement.
(d). Upon termination of this License Agreement or any Controlled Affiliate License
Agreement of a Larger Controlled Affiliate, as defined in Exhibit 1 to this License Agreement,
the following conditions shall apply, except that, in the event of a partial termination of this
Agreement pursuant to Paragraph 15 (a)(x)(ii) of this Agreement, the notices, national
account listing, payment and audit right listed below shall be applicable solely with respect to
the geographic area for which the Plan’s license to use the Licensed Names and Marks is
terminated:
(i) The terminated entity shall send a notice through the U.S. mails, with
first class postage affixed, to all individual and group customers,
providers, brokers and agents of products or services sold, marketed,
underwritten or administered by the terminated entity or its Controlled
Affiliates under the Licensed Marks and Name. The form and content
of the notice shall be specified by BCBSA and shall, at a minimum,
notify the recipient of the termination of the license, the consequences
thereof, and instructions for obtaining alternate products or services
licensed by BCBSA, subject to any conflicting state law and state
regulatory requirements. This notice shall be mailed within 15 days
after termination or, if termination is pursuant to paragraph 10(d) of this
Agreement, within 15 days after the written notice to BCBSA described
in paragraph 10(d).
(ii) The terminated entity shall deliver to BCBSA within five days of a
request by BCBSA a listing of national accounts in which the
terminated entity is involved (in a Control, Participating or Servicing
capacity), identifying the national account and the terminated entity's
role therein. For those accounts where the terminated entity is the
Control Plan, the Plan must also indicate the Participating and
Servicing Plans in the national account syndicate.
Amended as of June 16, 2005
-8-
-- 187 of 512 --
(iii) Unless the cause of termination is an event stated in paragraph 15(a)
or (b) above respecting BCBSA, the Plan and its Licensed Controlled
Affiliates shall be jointly liable for payment to BCBSA of an amount
equal to the Re-Establishment Fee (described below) multiplied by the
number of Licensed Enrollees of the terminated entity and its Licensed
Controlled Affiliates; provided that if any other Plan is permitted by
BCBSA to use marks or names licensed by BCBSA in the Service Area
established by this Agreement, the Re-Establishment Fee shall be
multiplied by a fraction, the numerator of which is the number of
Licensed Enrollees of the terminated entity and its Licensed Controlled
Affiliates and the denominator of which is the total number of Licensed
Enrollees in the Service Area. The Re-Establishment Fee shall be
indexed to a base fee of $80. The Re-Establishment Fee through
December 31, 2005 shall be $80. The Re-Establishment Fee for
calendar years after December 31, 2005 shall be adjusted on January
1 of each calendar year up to and including January 1, 2010 and shall
be the base fee multiplied by 100% plus the cumulative percentage
increase or decrease in the Plans’ gross administrative expense
(standard BCBSA definition) per Licensed Enrollee since December
31, 2004. The adjustment shall end on January 1, 2011, at which time
the Re-Establishment Fee shall be fixed at the then-current amount
and no longer automatically adjusted. For example, if the Plans’ gross
administrative expense per Licensed Enrollee was $278.60, $285.00
and $290.00 for calendar year end 2004, 2005 and 2006, respectively,
the January 1, 2007 Re-Establishment Fee would be $83.27 (100% of
the base fee plus $1.84 for calendar year 2005 and $1.43 for calendar
year 2006). Licensed Enrollee means each and every person and
covered dependent who is enrolled as an individual or member of a
group receiving products or services sold, marketed or administered
under marks or names licensed by BCBSA as determined at the earlier
of (a) the end of the last fiscal year of the terminated entity which
ended prior to termination or (b) the fiscal year which ended before any
transactions causing the termination began. Notwithstanding the
foregoing, the amount payable pursuant to this subparagraph (d)(iii)
shall be due only to the extent that, in BCBSA's opinion, it does not
cause the net worth of the Plan to fall below 100% of the Health Risk-
Based Capital formula or its equivalent under any successor formula,
as set forth in the applicable financial responsibility standards
established by BCBSA (provided such equivalent is approved for
purposes of this sub paragraph by the affirmative vote of three-fourths
of the Plans and
Amended as of June 16, 2005
-8a-
-- 188 of 512 --
three-fourths of the total then current weighted vote of all the Plans),
measured as of the date of termination and adjusted for the value of
any transactions not made in the ordinary course of business. This
payment shall not be due in connection with transactions exclusively
by or among Plan or their affiliates, including reorganizations,
combinations or mergers, where the BCBSA Board of Directors
determines that the license termination does not result in a material
diminution in the number of Licensed Enrollees or the extent of their
coverage. At least 50% of the Re Establishment Fee shall be awarded
to the Plan (or Plans) that receive the new license(s) for the service
area(s) at issue; provided, however, that such award shall not become
due or payable until all disputes, if any, regarding the amount of and
BCBSA’s right to such Re-Establishment Fee have been finally
resolved; and provided further that the award shall be based on the
final amount actually received by BCBSA. The Board of Directors shall
adopt a resolution which it may amend from time to time that shall
govern BCBSA’s use of its portion of the award. In the event that the
terminated entity’s license is reinstated by BCBSA or is deemed to
have remained in effect without interruption by a court of competent
jurisdiction, BCBSA shall reimburse the Plan (and/or its Licensed
Controlled Affiliates, as the case may be) for payments made under
this subparagraph only to the extent that such payments exceed the
amounts due to BCBSA pursuant to subparagraph 15(d)(vi) and any
costs associated with reestablishing the Service Area, including any
payments made by BCBSA to a Plan or Plans (or their Licensed
Controlled Affiliates) for purposes of replacing the terminated entity.
(iv). The terminated entity shall comply with all financial settlement procedures
set forth in BCBSA’s License Termination Contingency Plan, as amended
from time to time and shall work diligently and in good faith with BCBSA, any
Alternative Control Licensee or Replacement Licensee and any existing or
potential
Amended as of June 16, 2005
-8b-
-- 189 of 512 --
new account for Blue-branded products and services to minimize the
disruption of termination, and honor, to the fullest extent possible, the desire
of accounts to continue to receive or obtain Blue-branded products and
services through a new Licensee (“Transition”). Such diligence and good
faith on the part of the terminated entity shall include, but not be limited to:
(a) working cooperatively with BCBSA to protect the Names and Marks from
potential harm; (b) cooperating with BCBSA’s use of the Names and Marks
in the terminated entity’s former service area during the termination and
Transition; (c) transmitting, upon the request of an existing Blue account or
of BCBSA with consent and on behalf of an existing Blue account, all
member and account-data relating to the Federal Employee Program to
BCBSA, and all member and account data relating to other programs to an
Alternative Control Licensee or Replacement Licensee; (d) working with
BCBSA and the Alternative Control or Replacement Licensee with respect to
potential new Blue accounts headquartered in the terminated entity’s former
service area; (e) continuing to service Blue accounts during the Transition;
(f) continuing to comply with National Programs, Federal Employee Program
and NASCO policies and procedures and all voluntary BCBSA programs,
policies and performance standards, such as Away From Home Care,
including being responsible for payment of all penalties for non-compliance
duly levied in conformity with the License Agreements, Membership
Standards, or the Federal Employee Program agreements, that may arise
during the Transition; (g) maintaining and providing access to its provider
networks, as defined by Federal Employee Program agreements and
National Account Program Policies and Provisions, and Inter-Plan Programs
Policies and Provisions, and making those networks and discounts available
to members and providers who participate in National Programs and the
Federal Employee Program during the Transition; (h) maintaining its
technical connections and processing capabilities during the Transition; and
(i) working diligently to conclude all financial settlements and account
reconciliations as negotiated in the termination transition agreement.
Amended as of November 16, 2006
-8c-
-- 190 of 512 --
(v) Notwithstanding any other provision in this Agreement, BCBSA shall
have the right, with the approval of its Board of Directors, to assess
additional fines against the terminated entity during the Transition in
the event it fails to maintain and provide access to provider networks
as defined by Federal Employee Program agreements, National
Account Program Policies and Provisions, and Inter-Plan Programs
Policies and Provisions, and/or pass on applicable discounts. Such
fines shall be in addition to any other assessments, fees or liquidated
damages payable herein, or under existing policies and programs and
shall be imposed to make whole BCBSA and/or the Plans. Terminated
entity shall pay any such fines to BCBSA no later than 30 days after
they are approved by the Board of Directors.
(vi) BCBSA shall have the right to examine and audit and/or hire at
terminated entity’s expense a third-party auditor to examine and
audit the books and records of the terminated entity and its Licensed
Controlled Affiliates to verify compliance with the terms and
requirements this paragraph 15(d).
(vii) Subsequent to termination of this Agreement, the terminated entity
and its affiliates, agents, and employees shall have an ongoing and
continuing obligation to protect all BCBSA and Blue Licensee data that
was acquired or accessed during the period this Agreement was in
force, including but not limited to all confidential processes, pricing,
provider, discount and other strategic and competitively sensitive
information (“Blue Information”) from disclosure, and shall not, either
alone or with another entity, disclose such Blue Information or use it in
any manner to compete without the express written permission of
BCBSA.
(viii) As to a breach of 15 (d) (i), (ii), (iii), (iv), (vi), or (vii) the parties agree
that the obligations are immediately enforceable in a court of
competent jurisdiction. As to a breach of 15 (d) (i), (ii), (iv), (vi), or (vii)
by the Plan, the parties agree there is no adequate remedy at law and
BCBSA is entitled to obtain specific performance.
Amended as of November 16, 2006
-8d-
-- 191 of 512 --
(ix) In the event that the terminated entity’s license is reinstated by
BCBSA or is deemed to have remained in effect without interruption
by a court of competent jurisdiction, the Plan and its Licensed
Controlled Affiliates shall be jointly liable for reimbursing BCBSA the
reasonable costs incurred by BCBSA in connection with the
termination and the reinstatement or court action, and any associated
legal proceedings, including but not limited to: outside legal fees,
consulting fees, public relations fees, advertising costs, and costs
incurred to develop, lease or establish an interim provider network.
Any amount due to BCBSA under this subparagraph may be waived
in whole or in part by the BCBSA Board of Directors in its sole
discretion.
(e).BCBSA shall be entitled to enjoin the Plan or any related party in a court of
competent jurisdiction from entry into any transaction which would result in a termination of
this License Agreement unless the License Agreement has been terminated pursuant to
paragraph 10 (d) of this Agreement upon the required six (6) month written notice.
(f). BCBSA acknowledges that it is not the owner of assets of the Plan.
Amended as of June 16, 2006
-8e-
-- 192 of 512 --
16. This Agreement supersedes any and all other agreements between the parties with
respect to the subject matter herein, and contains all of the covenants and agreements of the parties
as to the licensing of the Licensed Marks and Name. This Agreement may be amended only by the
affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote
of all the Plans as officially recorded by the BCBSA Corporate Secretary.
17. If any provision or any part of any provision of this Agreement is judicially declared
unlawful, each and every other provision, or any part of any provision, shall continue in full force
and effect notwithstanding such judicial declaration.
18. No waiver by BCBSA or the Plan of any breach or default in performance on the part of
BCBSA or the Plan or any other licensee of any of the terms, covenants or conditions of this
Agreement shall constitute a waiver of any subsequent breach or default in performance of said terms,
covenants or conditions.
19a. All notices provided for hereunder shall be in writing and shall be sent in duplicate by
regular mail to BCBSA or the Plan at the address currently published for each by BCBSA and shall be
marked respectively to the attention of the President and, if any, the General Counsel, of BCBSA or
the Plan.
19b. Except as provided in paragraphs 9(b), 9(d)(iii), 15(a), and 15(b) above, this Agreement
may be terminated for a breach only upon at least 30 days’ written notice to the Plan advising of the
specific matters at issue and granting the Plan an opportunity to be heard and to present its response
to the Member Plans.
19c. For all provisions of this Agreement referring to voting, the term ‘Plans’ shall mean all
entities licensed under the Blue Cross License Agreement and/or the Blue Shield License Agreement,
and in all votes of the Plans under this Agreement the Plans shall vote together. For weighted votes of
the Plans, the Plan shall have a number of votes equal to the number of weighted votes (if any) that it
holds as a Blue Cross Plan plus the number of weighted votes (if any) that it holds as a Blue Shield
Plan. For all other votes of the Plans, the Plan shall have one vote. For all questions requiring an
affirmative three-fourths weighted vote of the Plans, the requirement shall be deemed satisfied with a
lesser weighted vote unless the greater of: (i) 6/52 or more of the Plans (rounded to the nearest whole
number, with 0.5 or multiples thereof being rounded to the next higher whole number) fail to cast
weighted votes in favor of the question; or (ii) three (3) of the Plans fail to cast weighted votes in favor
of the question. Notwithstanding the foregoing provision, if there are thirty- six (36) Plans, the
requirement of an affirmative three-fourths weighted vote shall be deemed satisfied with a lesser
weighted vote unless four (4) or more Plans fail to cast weighted votes in favor of the question.
-8f-
Amended as of June 16, 2006
(The next page is page 9)
-- 193 of 512 --
20. Nothing herein contained shall be construed to constitute the parties hereto as partners or
joint venturers, or either as the agent of the other, and Plan shall have no right to bind or obligate
BCBSA in any way, nor shall it represent that it has any right to do so. BCBSA shall have no liability to
third parties with respect to any aspect of the business, activities, operations, products, or services of
the Plan.
21. This Agreement shall be governed, construed and interpreted in accordance with the
laws of the State of Illinois.
IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed, effective
as of the date of last signature written below.
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By
Title
Date
PLAN:
By
Title
Date
-9-
-- 194 of 512 --
EXHIBIT 1
BLUE CROSS
CONTROLLED AFFILIATE LICENSE AGREEMENT
(Includes revisions adopted by Member Plans through their September 17, 2020 meeting)
This Agreement by and among Blue Cross and Blue Shield Association ("BCBSA") and
(“Controlled Affiliate"), a Controlled Affiliate of the Blue Cross Plan, known as
("Plan" or “Sponsoring Plan”), which is also a Party signatory hereto.
WHEREAS, BCBSA is the owner of the BLUE CROSS and BLUE CROSS Design service
marks;
WHEREAS, Plan and Controlled Affiliate desire that the latter be entitled to use the BLUE
CROSS and BLUE CROSS Design service marks (collectively the "Licensed Marks") as service marks
and be entitled to use the term BLUE CROSS in a trade name ("Licensed Name");
NOW THEREFORE, in consideration of the foregoing and the mutual agreements
hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the parties hereby agree as follows:
1. GRANT OF LICENSE
Subject to the terms and conditions of this Agreement, BCBSA hereby grants to Controlled
Affiliate the right to use the Licensed Marks and Name in connection with, and only in connection with:
(i) health care plans and related services, as defined in BCBSA's License Agreement with Plan, and
administering the non-health portion of workers’ compensation insurance, and (ii) underwriting the
indemnity portion of workers’ compensation insurance, provided that Controlled Affiliate’s total premium
revenue comprises less than 15 percent of the Sponsoring Plan’s net subscription revenue.
This grant of rights is non-exclusive and is limited to the Service Area served by the Plan Subject to
paragraph 3A(3) of this Agreement, Controlled Affiliate may use the Licensed Marks and Name in its
legal name on the following conditions: (i) the legal name must be approved in advance, in writing, by
BCBSA; (ii) Controlled Affiliate shall not do business outside the Service Area under any name or mark;
and (iii) Controlled Affiliate shall not use the Licensed Marks and Name, or any derivative thereof, as
part of any name or symbol used to identify itself in any securities market, unless such Controlled
Affiliate is a not-for-profit company which may use the Licensed Marks and Name, or an approved
derivative therefor, to identify itself in debt securities markets. Controlled Affiliate may use the Licensed
Marks and Name in its Trade Name only with the prior, written, consent of BCBSA.
Amended as of March 26, 2015
1
-- 195 of 512 --
2. QUALITY CONTROL
A. Controlled Affiliate agrees to use the Licensed Marks and Name only in connection
with the licensed services and further agrees to be bound by the conditions regarding quality control
shown in attached Exhibit A as they may be amended by BCBSA from time-to-time.
B. Controlled Affiliate agrees to comply with all applicable federal, state and local
laws.
C. Controlled Affiliate agrees that it will provide on an annual basis (or more often
if reasonably required by Plan or by BCBSA) a report or reports to Plan and BCBSA demonstrating
Controlled Affiliate's compliance with the requirements of this Agreement including but not limited to
the quality control provisions of this paragraph and the attached Exhibit A.
D. Controlled Affiliate agrees that Plan and/or BCBSA may, from time-to-time, upon
reasonable notice, review and inspect the manner and method of Controlled Affiliate's rendering of
service and use of the Licensed Marks and Name.
E. As used herein, a Controlled Affiliate is defined as an entity organized and operated
in such a manner, that the Sponsoring Plan has:
(1) The legal authority directly or indirectly through wholly-owned subsidiaries:
(a) to select members of the Controlled Affiliate’s governing body having not less than 50%
voting control thereof; and
(b) to prevent any change in the articles of incorporation, bylaws or other establishing or
governing documents of the Controlled Affiliate with which the Sponsoring Plan does not concur;
and
(c) to exercise control over the policy and operations of the Controlled Affiliate at least
equal to that exercised by persons or entities (jointly or individually) other than the Sponsoring Plan;
and
Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate’s
establishing or governing documents must also require written approval by the Sponsoring Plan
before the Controlled Affiliate can:
(i) change its legal and/or trade names;
(ii) change the geographic area in which it operates;
(iii) change any of the type(s) of businesses in which it engages;
Amended as of September 19, 2014
2
-- 196 of 512 --
(iv) create, or become liable for by way of guarantee, any indebtedness,
other than indebtedness arising in the ordinary course of business;
(v) sell any assets, except for sales in the ordinary
course of business or sales of equipment no longer useful or being
replaced;
(vi) make any loans or advances except in the ordinary course of business;
(vii) enter into any arrangement or agreement with any
party directly or indirectly affiliated with any of the owners or persons or
entities with the authority to select or appoint members or board members of
the Controlled Affiliate, other than the Sponsoring Plan or other Plans
(excluding owners of stock holdings of under 5% in a publicly traded
Controlled Affiliate);
(viii) conduct any business other than under the Licensed Marks and Name;
(ix) take any action that the Sponsoring Plan or BCBSA reasonably believes
will adversely affect the Licensed Marks and Name.
In addition, the Sponsoring Plan directly or indirectly through wholly owned subsidiaries shall own at
least 50% of any for-profit Controlled Affiliate, provided that in instances where the Sponsoring Plan
formed a publicly traded Controlled Affiliate Licensee and such publicly traded Controlled Affiliate
Licensee owns and controls other Controlled Affiliate Licensees, the Sponsoring Plan directly or
indirectly shall own and control at least 50% of any Controlled Affiliate that is indirectly owned and
controlled by the publicly traded Controlled Affiliate Licensee.
Or
(2) the legal authority directly or indirectly through wholly-owned subsidiaries:
(a) to select members of the Controlled Affiliate’s governing body having more than 50% voting
control thereof and;
(b) to prevent any change in the articles of incorporation, bylaws or other establishing or governing
documents of the Controlled Affiliate with which the Sponsoring Plan does not concur; and
(c) to exercise control over the policy and operations of the Controlled Affiliate.
Amended as of March 26, 2015
3
-- 197 of 512 --
In addition, the Sponsoring Plan directly or indirectly through wholly-owned subsidiaries shall own more
than 50% of any for-profit Controlled Affiliate, provided that in instances where the Sponsoring Plan
formed a publicly traded Controlled Affiliate Licensee and such publicly traded Controlled Affiliate
Licensee owns and controls other Controlled Affiliate Licensees, the Sponsoring Plan directly or
indirectly shall own and control more than 50% of any Controlled Affiliate that is indirectly owned and
controlled by the publicly traded Controlled Affiliate Licensee.
Or
(3) With respect to a Controlled Affiliate that is 100% controlled by Plans including the Sponsoring
Plan and which offers solely Medicaid, Medicare Advantage PPO, Medicare Advantage HMO and/or
Special Need Plans products and services, the Sponsoring Plan has the legal authority together with
such other Plans:
(a) to select all members of the Controlled Affiliate’s governing body; and
(b) to prevent any change in the articles of incorporation, bylaws or other
establishing or governing documents of the Controlled Affiliate; and
(c) to exercise control over the policy and operations of the Controlled Affiliate. In
addition, the Sponsoring Plan and such other Plans shall own 100% of any for-profit
Controlled Affiliate with the Sponsoring Plan and such other Plans each having an ownership interest.
Such control and ownership by Plans must be direct or, if indirect, solely through affiliates that are
licensed to use marks owned by BCBSA. Further, the Sponsoring Plan and such other Plans shall
execute a separate Addendum to Controlled Affiliate License Agreement attached hereto as Exhibit B-1
for each product noted in Paragraph 2E(3) that is licensed to use the Marks.
Or
(4) With respect to a Controlled Affiliate that is 100% controlled by a Sponsoring Plan which on a
Blue-branded basis, only offers a Basic Medicare Part D Prescription Drug Plan product, the
Sponsoring Plan has the legal authority:
(a) to select all members of the Controlled Affiliate’s governing body; and
(b) to prevent any change in the articles of incorporation, bylaws or other
establishing or governing documents of the Controlled Affiliate; and
(c) to exercise control over the policy and operations of the Controlled Affiliate.
Amended June 20, 2019
4
-- 198 of 512 --
In addition, the Sponsoring Plan shall own 100% of any for-profit Controlled Affiliate. Such 100% control
and ownership by Sponsoring Plan must be direct or, if indirect, solely through affiliates that are licensed
to use marks owned by BCBSA. Further, the Participating Plan as defined in Exhibit B-2 and the
Sponsoring Plan shall execute the Addendum to Controlled Affiliate License Agreement attached hereto
as Exhibit B-2.
Or
(5) With respect to a Controlled Affiliate that operates as a clinic, absent an alternative method of
control approved in writing by BCBSA, the Sponsoring Plan shall have bona fide operational control
over the Controlled Affiliate as specified in Exhibit A, Standard 1(E) and the Guidelines to Administer
Standard 1(E). In addition, if the clinic is for-profit, the Sponsoring Plan shall own at least 50% of the
Controlled Affiliate and prevent any change in the articles of incorporation, bylaws or other establishing
documents of the Controlled Affiliate with which the Sponsoring Plan does not concur.
3. FOR-PROFIT, PUBLICLY TRADED LICENSEES
A. The Controlled Affiliate may operate as a for-profit publicly traded company on the following
conditions:
(1) The Controlled Affiliate shall discharge all responsibilities which it has to the
Association and to other Plans by virtue of this Agreement.
(2) The Controlled Affiliate shall provide 90 days advance written notice to BCBSA prior to
the initial filing with the SEC.
(3) The Controlled Affiliate shall not use the Licensed Marks and Name, or any derivative
thereof, as part of its legal name or any symbol used to identify the Controlled Affiliate in any
securities market. The Controlled Affiliate shall use the Licensed Marks and Name as part of its
trade name within its service area for the sale, marketing and administration of health care and
related services in the service area.
(4) The Controlled Affiliate’s license to use the Licensed Marks and Name shall automatically
terminate effective: (a) thirty days after the Controlled Affiliate knows, or there is an SEC filing
indicating that, any Institutional Investor, has become the Beneficial Owner of securities
representing 10% or more of the voting power of the Controlled Affiliate (“Excess Institutional
Voter”), unless such Excess Institutional Voter shall cease to be an Excess Institutional Voter
prior to such automatic termination becoming effective; (b) thirty days after the Controlled Affiliate
knows, or there is an SEC filing indicating that, any Noninstitutional Investor, other than a Plan or
Plans or Controlled Affiliate Licensee or Licensees has become the Beneficial Owner of
securities representing 5% or more of the voting power of the Controlled Affiliate (“Excess
Noninstitutional Voter”) unless such Excess Noninstitutional Voter shall cease to be an Excess
Noninstitutional Voter prior to such automatic termination becoming effective; (c) thirty days after
the Controlled Affiliate knows, or there is an SEC filing indicating that, any Person has become
the Beneficial Owner, other than a
Amended as of June 20, 2019
5
-- 199 of 512 --
Plan or Plans or Controlled Affiliate Licensee or Licensees, of 20% or more of the Controlled
Affiliate’s then outstanding common stock or other equity securities which (either by themselves
or in combination) represent an ownership interest of 20% or more pursuant to determinations
made under paragraph 3A(4) below (“Excess Owner”), unless such Excess Owner shall cease to
be an Excess Owner prior to such automatic termination becoming effective; (d) ten business
days after individuals who at the time the Controlled Affiliate went public constituted the Board of
Directors of the Controlled Affiliate (together with any new directors whose election to the Board
was approved by a vote of 2/3 of the directors then still in office who were directors at the time
the Controlled Affiliate went public or whose election or nomination was previously so approved)
(the “Continuing Directors”) cease for any reason to constitute a majority of the Board of
Directors; or (e) ten business days after the Controlled Affiliate consolidates with or merges with
or into any person or conveys, assigns, transfers or sells all or substantially all of its assets to any
person other than a merger
in which the Sponsoring Plan is the surviving entity and immediately after which merger, no
person is an Excess Institutional Voter, an Excess Noninstitutional Voter or an Excess Owner:
provided that, if requested by the affected Controlled Affiliate in a writing received by BCBSA
prior to such automatic termination becoming effective, the provisions of this paragraph 3A(4)
may be waived, in whole or in part, upon the affirmative vote of a majority of the disinterested
Plans and majority of the total then current weighted vote of the disinterested Plans. Any waiver
so granted may be conditioned upon such additional requirements (including but not limited to
imposing new and independent grounds for termination of this License) as shall be approved by
the affirmative vote of a majority of the disinterested Plans and a majority of the total then current
weighted vote of the disinterested Plans. If a timely waiver request is received, no automatic
termination shall become effective until the later of: (1) the conclusion of the applicable time
period specified in paragraphs 3A(4) (a)-(d) above, or (2) the conclusion of the first Member Plan
meeting after receipt of such a waiver request.
In the event that the Controlled Affiliate’s license, or any other license, to use the Licensed Marks
and Name is terminated pursuant to Paragraph 3A(4), the license may be reinstated in BCBSA’s
sole discretion if, within 30 days of the date of such termination, the Controlled Affiliate
demonstrates that the Person referred to in clause (a), (b), or (c) of the preceding paragraph is no
longer an Excess Institutional Voter, an Excess Noninstitutional Voter or an Excess Owner.
(5) The Controlled Affiliate shall not issue any class or series of security other than
(i) shares of common stock having identical terms or options or derivatives of such common
stock, (ii) non-voting, non-convertible debt securities or (iii) such other securities as the
Controlled Affiliate may approve, provided that BCBSA receives notice at least thirty days
prior to the issuance of such securities, including a description of the terms for such
securities, and BCBSA shall have the authority to determine how such other securities will be
counted in determining whether any Person is an Excess Institutional Voter, Excess
Noninstitutional Voter or an Excess Owner.
Amended as of March 26, 2015
6
-- 200 of 512 --
(6) For purposes of paragraph 3A(4) above, the following definitions shall apply:
(i) “Affiliate” and “Associate” shall have the respective meanings ascribed to such terms in
Rule 12b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934,
as amended and in effect on November 17, 1993 (the “Exchange Act”).
(ii) A Person shall be deemed the “Beneficial Owner” of and shall be deemed to
“beneficially own” any securities:
(1) which such Person or any of such Person’s Affiliates or Associates
beneficially owns, directly or indirectly;
(2) which such Person or any of such Person’s Affiliates or Associates has
(A) the right to acquire (whether such right is exercisable immediately or only after the
passage of time) pursuant to any agreement, arrangement or understanding, or upon the
exercise of conversion rights, exchange rights, warrants or options, or otherwise; or (B) the right to
vote pursuant to any agreement, arrangement or understanding; provided, however, that a Person shall
not be deemed the Beneficial Owner of, or to beneficially own, any security if the agreement,
arrangement or understanding to vote such security (1) arises solely from a revocable proxy or consent
given to such Person in response to a public proxy or consent solicitation made pursuant to, and in
accordance with, the applicable rules and regulations promulgated under the Exchange Act and (2) is
not also then reportable on Schedule 13D under the Exchange Act (or any comparable or successor
report); or
3. which are beneficially owned, directly or indirectly, by any other Person (or any
Affiliate or Associate thereof) with which such Person (or any of such Person’s Affiliates or
Associates) has any agreement, arrangement or understanding (other than customary
agreements with and between underwriters and selling group members with respect to a bona
fide public offering of securities) relating to the acquisition, holding, voting (except to the extent
contemplated by the proviso to (ii)2(B) above) or disposing of any securities of the Controlled
Affiliate.
Notwithstanding anything in this definition of Beneficial Ownership to the contrary, the phrase
“then outstanding,” when used with reference to a Person’s Beneficial Ownership of securities of
the Controlled Affiliate, shall mean the number of such securities then issued and outstanding
together with the number of such securities not then actually issued and outstanding which such
Person would be deemed to own beneficially hereunder.
Amended as of March 26, 2015
7
-- 201 of 512 --
(iii) A Person shall be deemed an “Institutional Investor” if (but only if) such Person (i)
is an entity or group identified in the SEC’s Rule 13d-1(b)(1)(ii) as constituted on June 1, 1997,
and (ii) every filing made by such Person with the SEC under Regulation 13D-G (or any
successor Regulation) with respect to such Person’s Beneficial Ownership of Plan securities
shall have contained a certification identical to the one required by item 10 of SEC Schedule
13G as constituted on June 1, 1997.
(iv) “Noninstitutional Investor” means any Person who is not an Institutional Investor.
(v) “Person” shall mean any individual, firm, partnership, corporation, trust, association,
joint venture or other entity, and shall include any successor (by merger or otherwise) of such
entity.
4. SERVICE MARK USE
A. Controlled Affiliate recognizes the importance of a comprehensive national network of
independent BCBSA licensees which are committed to strengthening the Licensed
Marks and Name. The Controlled Affiliate further recognizes that its actions within its Service Area may
affect the value of the Licensed Marks and Name nationwide.
B. Controlled Affiliate shall at all times make proper service mark use of the Licensed
Marks and Name, including but not limited to use of such symbols or words as BCBSA shall specify
to protect the Licensed Marks and Name and shall comply with such rules (generally applicable to
Controlled Affiliates licensed to use the Licensed Marks and Name) relative to service mark use, as
are issued from time-to-time by BCBSA. Controlled Affiliate recognizes and agrees that all use of the
Licensed Marks and Name by Controlled Affiliate shall inure to the benefit of BCBSA.
C. Controlled Affiliate may not directly or indirectly use the Licensed Marks and Name in a
manner that transfers or is intended to transfer in the Service Area the goodwill associated therewith to
another mark or name, nor may Controlled Affiliate engage in activity that may dilute or tarnish the
unique value of the Licensed Marks and Name.
D. If Controlled Affiliate meets the standards of 2E(1) but not 2E(2) above and any of
Controlled Affiliate's advertising or promotional material is reasonably determined by BCBSA and/or the
Plan to be in contravention of rules and regulations governing the use of the Licensed Marks and Name,
Controlled Affiliate shall for ninety (90) days thereafter obtain prior approval from BCBSA of advertising
and promotional efforts using the Licensed Marks and Name, approval or disapproval thereof to be
forthcoming within five (5) business days of receipt of same by BCBSA or its designee. In all advertising
and promotional efforts, Controlled Affiliate shall observe the Service Area limitations applicable to Plan.
Amended as of March 26, 2015
8
-- 202 of 512 --
E. Notwithstanding any other provision in the Plan’s License Agreement with BCBSA or
in this Agreement, Controlled Affiliate shall use its best efforts to promote and build the value of the
Licensed Marks and Name.
5. SUBLICENSING AND ASSIGNMENT
Controlled Affiliate shall not, directly or indirectly, sublicense, transfer, hypothecate, sell,
encumber or mortgage, by operation of law or otherwise, the rights granted hereunder and any such act
shall be voidable at the sole option of Plan or BCBSA. This Agreement and all rights and duties
hereunder are personal to Controlled Affiliate.
6. INFRINGEMENT
Controlled Affiliate shall promptly notify Plan and Plan shall promptly notify BCBSA of any
suspected acts of infringement, unfair competition or passing off that may occur in relation to the
Licensed Marks and Name. Controlled Affiliate shall not be
entitled to require Plan or BCBSA to take any actions or institute any proceedings to prevent
infringement, unfair competition or passing off by third parties. Controlled Affiliate agrees to render to
Plan and BCBSA, without charge, all reasonable assistance in connection with any matter pertaining to
the protection of the Licensed Marks and Name by BCBSA.
7. LIABILITY INDEMNIFICATION
Controlled Affiliate and Plan hereby agree to save, defend, indemnify and hold BCBSA harmless
from and against all claims, damages, liabilities and costs of every kind, nature and description (except
those arising solely as a result of BCBSA's negligence) that may arise as a result of or related to: (i)
Controlled Affiliate's rendering of services under the Licensed Marks and Name; or (ii) the activities of
any hospital, medical group, clinic or other provider of health services that is owned or controlled directly
or indirectly by Plan or Controlled Affiliate.
8. LICENSE TERM
A. Except as otherwise provided herein, the license granted by this Agreement shall
remain in effect for a period of one (1) year and shall be automatically extended for additional one
(1) year periods unless terminated pursuant to the provisions herein.
B. This Agreement and all of Controlled Affiliate's rights hereunder shall immediately
terminate without any further action by any party or entity in the event that: (i) the Plan ceases to be
authorized to use the Licensed Marks and Name; or (ii) pursuant to Paragraph 15(a)(x) of the Blue
Cross License Agreement the Plan ceases to be authorized to use the Licensed Names and Marks in
the geographic area served by the Controlled Affiliate provided, however, that if the Controlled Affiliate is
serving more than one State or portions thereof, the termination of this Agreement shall be limited to the
State(s) or portions thereof in
Amended as of March 26, 2015
9
-- 203 of 512 --
which the Plan’s license to use the Licensed Marks and Names is terminated. By not appealing or
challenging such regulatory action within the time prescribed by law or regulation, and in any event no
later than 120 days after such action is taken, a Plan shall be deemed to have exhausted its rights to
appeal or challenge, and automatic termination shall proceed.
C. Notwithstanding any other provision of this Agreement, this license to use the Licensed
Marks and Name may be forthwith terminated by the Plan or the affirmative vote of the majority of the
Board of Directors of BCBSA present and voting at a special meeting expressly called by BCBSA for
the purpose on ten (10) days written notice to the Plan advising of the specific matters at issue and
granting the Plan an opportunity to be heard and to present its response to the Board for: (1) failure to
comply with any applicable minimum capital or liquidity requirement under the quality control standards
of this Agreement; or (2) failure to comply with the "Organization and Governance" quality control
standard of thisAgreement; or (3) impending financial insolvency; or (4) for a Smaller Controlled Affiliate (as
defined in Exhibit A), failure to comply with any of the applicable requirements of Standards 2, 3, 4, 5 or 7 of
attached Exhibit A; or (5) the pendency of any action instituted against the Controlled Affiliate seeking its
dissolution or liquidation of its assets or seeking appointment of a trustee, interim trustee, receiver or other
custodian for any of its property or business or seeking the declaration or establishment of a trust for any of its
property or business, unless this Controlled Affiliate License Agreement has been earlier terminated under
paragraph 8(E); or (6) failure by a Controlled Affiliate that meets the standards of 2E(1) but not 2E(2) above to
obtain BCBSA's written consent to a change in the identity of any owner, in the extent of ownership, or in the
identity of any person or entity with the authority to select or appoint members or board members, provided
that as to publicly traded Controlled Affiliates this provision shall apply only if the change affects a person or
entity that owns at least 5% of the Controlled Affiliate's stock before or after the change; or (7) such other
reason as is determined in good faith immediately and irreparably to threaten the integrity and reputation of
BCBSA, the Plans, any other licensee including Controlled Affiliate and/or the Licensed Marks and Name.
D. Except as otherwise provided in Paragraphs 8(B), 8(C) or 8(E) herein, should Controlled
Affiliate fail to comply with the provisions of this Agreement and not cure such failure within thirty (30)
days of receiving written notice thereof (or commence a cure within such thirty day period and continue
diligent efforts to complete the cure if such curing cannot reasonably be completed within such thirty day
period) BCBSA or the Plan shall have the right to issue a notice that the Controlled Affiliate is in a state
of noncompliance. If a state of noncompliance as aforesaid is undisputed by the Controlled Affiliate or is
found to exist by a mandatory dispute resolution panel and is uncured as provided above, BCBSA shall
have the right to seek judicial enforcement of the Agreement or to issue a notice of termination thereof.
Notwithstanding any other provisions of this Agreement, any disputes as to the termination of this
License pursuant to Paragraphs 8(B), 8(C) or 8(E) of this Agreement shall not be subject to mediation
and mandatory dispute resolution. All other disputes between BCBSA, the Plan and/or Controlled
Affiliate shall be submitted promptly to mediation and mandatory dispute resolution. The mandatory
dispute resolution panel shall have authority to issue orders for
Amended as of March 26, 2015
10
-- 204 of 512 --
specific performance and assess monetary penalties. Except, however, as provided in Paragraphs 8(B)
and 8(E) of this Agreement, this license to use the Licensed
Marks and Name may not be finally terminated for any reason without the affirmative vote of a majority
of the present and voting members of the Board of Directors of BCBSA.
E. This Agreement and all of Controlled Affiliate’s rights hereunder shall immediately
terminate without any further action by any party or entity in the event that:
(1) Controlled Affiliate shall no longer comply with item 2(E) above;
(2) Appropriate dues, royalties and other payments for Controlled
Affiliate pursuant to paragraph 10 hereof, which are the royalties for this License Agreement, are more
than sixty (60) days in arrears to BCBSA; or
(3) Any of the following events occur: (i) a voluntary petition shall be filed by Controlled Affiliate
seeking bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy
laws of the United States or any other law governing insolvency or debtor relief, or (ii) an involuntary
petition or proceeding shall be filed against Controlled Affiliate seeking bankruptcy, reorganization,
arrangement with creditors or other relief under the bankruptcy laws of the United States or any other
law governing insolvency or debtor relief and such petition or proceeding is consented to or acquiesced
in by Controlled Affiliate or is not dismissed within sixty (60) days of the date upon which the petition or
other document commencing the proceeding is served upon the Controlled Affiliate, or (iii) an order for
relief is entered against Controlled Affiliate in any case under the bankruptcy laws of the United States,
or Controlled Affiliate is adjudged bankrupt or insolvent as those terms are defined in the Uniform
Commercial Code as enacted in the State of Illinois by any court of competent jurisdiction, or (iv)
Controlled Affiliate makes a general assignment of its assets for the benefit of creditors, or (v) any
government or any government official, office, agency, branch, or unit assumes control of Controlled
Affiliate or delinquency proceedings (voluntary or involuntary) are instituted, or (vi) an action is brought
by Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking the appointment of a
trustee, interim trustee, receiver or other custodian for any of its property or business, or (vii) an action
is instituted by any governmental entity or officer against Controlled Affiliate seeking its dissolution or
liquidation of its assets or seeking the appointment of a trustee, interim trustee, receiver or other
custodian for any of its property or business and such action is consented to or acquiesced in by
Controlled Affiliate or is not dismissed within one hundred thirty (130) days of the date upon which the
pleading or other document commencing the action is served upon the Controlled Affiliate, provided
that if the action is stayed or its prosecution is enjoined, the one hundred thirty (130) day period is
tolled for the duration of the stay or injunction, and provided further, that the Association’s Board of
Directors may toll or extend the 130 day period at any time prior to its expiration, or (viii) a trustee,
interim trustee, receiver or other custodian for any of Controlled Affiliate's property or business is
appointed or the Controlled Affiliate is ordered dissolved or liquidated. Notwithstanding any other
provision of this Agreement, a declaration or a request for declaration of the existence of a trust over
any of the Controlled Affiliate’s property or business shall not in itself be
Amended as of March 26, 2015
11
-- 205 of 512 --
deemed to constitute or seek appointment of a trustee, interim trustee, receiver or other custodian for
purposes of subparagraphs 8(E)(3)(vii) and (viii) of this Agreement.
(4) The for-profit, publicly traded Controlled Affiliate is terminated pursuant to Paragraph 3A(4)
of this Agreement. In which case, the licenses of any Controlled Affiliates directly or indirectly
owned by the terminated for-profit, publicly traded Controlled Affiliate also shall immediately
terminate as provided for in paragraph 3A(4) of this Agreement.
F. Upon termination of this Agreement for cause or otherwise, Controlled Affiliate agrees
that it shall immediately discontinue all use of the Licensed Marks and Name, including any use in its
trade name.
G. Upon termination of this Agreement, Controlled Affiliate shall immediately notify all of its
customers that it is no longer a licensee of BCBSA and, if directed by the Association’s Board of
Directors, shall provide instruction on how the customer can contact BCBSA or a designated licensee
to obtain further information on securing coverage. The notification required by this paragraph shall be
in writing and in a form approved by BCBSA. The BCBSA shall have the right to audit the terminated
entity's books and records to verify compliance with this paragraph.
H. In the event this Agreement terminates pursuant to 8(B) hereof, or in the event the
Controlled Affiliate is a Larger Controlled Affiliate (as defined in Exhibit A), upon termination of this
Agreement, the provisions of Paragraph 8.G. shall not apply and the following provisions shall apply,
except that, in the event of a partial termination of this Agreement pursuant to Paragraph 8(B)(ii) of this
Agreement, the notices, national account listing, payment, and audit right listed below shall be
applicable solely with respect to the geographic area for which the Plan’s license to use the Licensed
Names and Marks is terminated.
(1) The Controlled Affiliate shall send a notice through the U.S. mails, with first class postage
affixed, to all individual and group customers, providers, brokers and agents of products or services
sold, marketed, underwritten or administered by the Controlled Affiliate under the Licensed Marks and
Name. The form and content of the notice shall be specified by BCBSA and shall, at a minimum, notify
the recipient of the termination of the license, the consequences thereof, and instructions for obtaining
alternate products or services licensed by BCBSA, subject to any conflicting state law and state
regulatory requirements. This notice shall be mailed within 15 days after termination.
(2) The Controlled Affiliate shall deliver to BCBSA within five days of a request by BCBSA a
listing of national accounts in which the Controlled Affiliate is involved (in a control, participating or
servicing capacity), identifying the national account and the Controlled Affiliate’s role therein.
Amended as of March 26, 2015
12
-- 206 of 512 --
(3) Unless the cause of termination is an event respecting BCBSA stated in paragraph 15(a)
or (b) of the Plan’s license agreement with BCBSA to use the Licensed Marks and Name, the Controlled
Affiliate, the Plan, and any other Licensed Controlled Affiliates of the Plan shall be jointly liable for
payment to BCBSA of an amount equal to the Re-Establishment Fee (described below) multiplied by
the number of Licensed Enrollees of the Controlled Affiliate; provided that if any other Plan is permitted
by BCBSA to use marks or names licensed by BCBSA in the Service Area established by this
Agreement, the Re- Establishment Fee shall be multiplied by a fraction, the numerator of which is the
number of Licensed Enrollees of the Controlled Affiliate, the Plan, and any other Licensed Controlled
Affiliates and the denominator of which is the total number of Licensed Enrollees in the Service Area.
The Re-Establishment Fee shall be indexed to a base fee of $80. The Re-Establishment Fee through
December 31, 2005 shall be $80. The Re-establishment Fee for calendar years after December 31,
2005 shall be adjusted on January 1 of each calendar year up to and including January 1, 2010 and
shall be the base fee multiplied by 100% plus the cumulative percentage increase or decrease in the
Plans’ gross administrative expense (standard BCBSA definition) per Licensed Enrollee since
December 31, 2004. The adjustment shall end on January 1, 2011, at which time the Re-Establishment
Fee shall be fixed at the then- current amount and no longer automatically adjusted. For example, if the
Plans’ gross administrative expense per Licensed Enrollee was $278.60, $285.00 and $290.00 for
calendar year end 2004, 2005 and 2006, respectively, the January 1, 2007 Re-Establishment Fee would
be $83.27 (100% of base fee plus $1.84 for calendar year 2005 and $1.43 for calendar year 2006).
Licensed Enrollee means each and every person and covered dependent who is enrolled as an
individual or member of a group receiving products or services sold, marketed or administered under
marks or names licensed by BCBSA as determined at the earlier of (i) the end of the last fiscal year of
the terminated entity which ended prior to termination or (ii) the fiscal year which ended before any
transactions causing the termination began. Notwithstanding the foregoing, the amount payable
pursuant to this subparagraph H. (3) shall be due only to the extent that, in BCBSA’s opinion, it does not
cause the net worth of the Controlled Affiliate, the Plan or any other Licensed Controlled Affiliates of the
Plan to fall below 100% of the Health Risk-Based Capital formula, or its equivalent under any successor
formula, as set forth in the applicable financial responsibility standards established by BCBSA (provided
such equivalent is approved for purposes of this sub paragraph by the affirmative vote of three-fourths
of the Plans and three-fourths of the total then current weighted vote of all the Plans); measured as of
the date of termination, and adjusted for the value of any transactions not made in the ordinary course
of business. This payment shall not be due in connection with transactions exclusively by or among
Plans or their affiliates, including reorganizations, combinations or mergers, where the BCBSA Board of
Directors determines that the license termination does not result in a material diminution in the number
of Licensed Enrollees or the extent of their coverage. At least 50% of the Re- Establishment Fee shall
be awarded to the Plan (or Plans) that receive the new license(s) for the service area(s) at issue;
provided, however, that such award shall not become due or payable until all disputes, if any, regarding
the amount of and BCBSA’s right to such Re- Establishment Fee have been finally resolved; and
provided further that the award shall be
Amended as of March 26, 2015
13
-- 207 of 512 --
based on the final amount actually received by BCBSA. The Board of Directors shall adopt a resolution
which it may amend from time to time that shall govern BCBSA’s use of its portion of the award. In the
event that the Controlled Affiliate’s license is reinstated by BCBSA or is deemed to have remained in
effect without interruption by a court of competent jurisdiction, BCBSA shall reimburse the Controlled
Affiliate (and/or the Plan or its other Licensed Controlled Affiliates, as the case may be) for payments
made under this subparagraph 8.H.(3) only to the extent that such payments exceed the amounts due
to BCBSA pursuant to paragraph 8.M. and any costs associated with reestablishing the Service Area,
including payments made by BCBSA to a Plan or Plans (or their Licensed Controlled Affiliates) for
purposes of replacing the Controlled Affiliate.
(4) BCBSA shall have the right to examine and audit and/or hire at
terminated entity’s expense a third party auditor to examine and audit the books and records of the
Controlled Affiliate, the Plan, and any other Licensed Controlled Affiliates of the Plan to verify
compliance with this paragraph 8.H.
(5) Subsequent to termination of this Agreement, the terminated entity
and its affiliates, agents, and employees shall have an ongoing and continuing obligation to protect all
BCBSA and Blue Licensee data that was acquired or accessed during the period this Agreement was in
force, including but not limited to all confidential processes, pricing, provider, discount and other
strategic and competitively sensitive information (“Blue Information”) from disclosure, and shall not,
either alone or with another entity, disclose such Blue Information or use it in any manner to compete
without the express written permission of BCBSA.
(6) As to a breach of 8.H.(1), (2), (3), (4) or (5) the parties agree that
the obligations are immediately enforceable in a court of competent jurisdiction. As to a breach of 8.H.
(1), (2) or (4) by the Controlled Affiliate, the parties agree there is no adequate remedy at law and
BCBSA is entitled to obtain specific performance.
I. This Agreement shall remain in effect until terminated by the Controlled Affiliate or the Plan
upon not less than eighteen (18) months written notice to the Association or upon a shorter notice period
approved by BCBSA in writing at its sole discretion, or until terminated as otherwise provided herein.
The Plan’s right to terminate without cause upon such notice is unfettered and may be exercised in the
Plan’s sole discretion.
J. In the event the Controlled Affiliate is a Smaller Controlled Affiliate (as defined in Exhibit
A), the Controlled Affiliate agrees to be jointly liable for the amount described in
H.3. and M. hereof upon termination of the BCBSA license agreement of any Larger Controlled
Affiliate of the Plan.
K. BCBSA shall be entitled to enjoin the Controlled Affiliate or any related party in a court of
competent jurisdiction from entry into any transaction which would result in a termination of this
Agreement unless the Plan’s license from BCBSA to use the Licensed Marks and Names has been
terminated pursuant to 10(d) of the Plan’s license agreement upon the required 18 months written
notice.
Amended as of March 26, 2015
14
-- 208 of 512 --
L. BCBSA acknowledges that it is not the owner of assets of the Controlled Affiliate.
M. In the event that the Plan has more than 50 percent voting control of the Controlled
Affiliate under Paragraph 2(E)(2) above and is a Larger Controlled Affiliate (as defined in Exhibit A),
then the vote called for in Paragraphs 8(C) and 8(D) above shall require the affirmative vote of three-
fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans.
N. In the event this Agreement terminates and is subsequently reinstated by BCBSA or is
deemed to have remained in effect without interruption by a court of competent jurisdiction, the
Controlled Affiliate, the Plan, and any other Licensed Controlled Affiliates of the Plan shall be jointly
liable for reimbursing BCBSA the reasonable costs incurred by BCBSA in connection with the
termination and the reinstatement or court action, and any associated legal proceedings, including but
not limited to: outside legal fees, consulting fees, public relations fees, advertising costs, and costs
incurred to develop, lease or establish an interim provider network. Any amount due to BCBSA under
this subparagraph may be waived in whole or in part by the BCBSA Board of Directors in its sole
discretion.
9. DISPUTE RESOLUTION
The parties agree that any disputes between them or between or among either of them and one
or more Plans or Controlled Affiliates of Plans that use in any manner the Blue Cross and Blue Cross
Marks and Name are subject to the Mediation and Mandatory Dispute Resolution process attached to
and made a part of Plan's License from BCBSA to use the Licensed Marks and Name as Exhibit 5 as
amended from time-to-time, which documents are incorporated herein by reference as though fully set
forth herein.
10. LICENSE FEE
Controlled Affiliate will pay to BCBSA a fee for this License determined pursuant to the formula(s)
set forth in Exhibit C.
11. JOINT VENTURE
Nothing contained in the Agreement shall be construed as creating a joint venture,
partnership, agency or employment relationship between Plan and Controlled Affiliate or between
either and BCBSA.
12. NOTICES AND CORRESPONDENCE
Notices regarding the subject matter of this Agreement or breach or termination thereof shall be
in writing and shall be addressed in duplicate to the last known address of each other party, marked
respectively to the attention of its President and, if any, its General Counsel.
Amended as of March 26, 2015
15
-- 209 of 512 --
13. COMPLETE AGREEMENT
This Agreement contains the complete understandings of the parties in relation to the subject
matter hereof. This Agreement may only be amended by the affirmative vote of three-fourths of the
Plans and three-fourths of the total then current weighted vote of all the Plans as officially recorded by
the BCBSA Corporate Secretary.
14. SEVERABILITY
If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such
findings shall in no way affect the remaining obligations of the parties hereunder and the court may
substitute a lawful term or condition for any unlawful term or condition so long as the effect of such
substitution is to provide the parties with the benefits of this Agreement.
15. NONWAIVER
No waiver by BCBSA of any breach or default in performance on the part of Controlled Affiliate or
any other licensee of any of the terms, covenants or conditions of
this Agreement shall constitute a waiver of any subsequent breach or default in performance of said
terms, covenants or conditions.
15A. VOTING
For all provisions of this Agreement referring to voting, the term ‘Plans’ shall mean all entities licensed
under the Blue Cross License Agreement and/or the Blue Shield License Agreement, and in all votes of
the Plans under this Agreement the Plans shall vote together. For weighted votes of the Plans, the Plan
shall have a number of votes equal to the number of weighted votes (if any) that it holds as a Blue
Cross Plan plus the number of weighted votes (if any) that it holds as a Blue Shield Plan. For all other
votes of the Plans, the Plan shall have one vote. For all questions requiring an affirmative three-fourths
weighted vote of the Plans, the requirement shall be deemed satisfied with a lesser weighted vote
unless the greater of: (i) 6/52 or more of the Plans (rounded to the nearest whole number, with 0.5 or
multiples thereof being rounded to the next higher whole number) fail to cast weighted votes in favor of
the question; or (ii) three (3) of the Plans fail to cast weighted votes in favor of the question.
Notwithstanding the foregoing provision, if there are thirty-six (36) Plans, the requirement of an
affirmative three-fourths weighted vote shall be deemed satisfied with a lesser weighted vote unless
four (4) or more Plans fail to cast weighted votes in favor of the question.
Amended as of March 26, 2015
16
-- 210 of 512 --
THIS PAGE IS INTENTIONALLY BLANK.
-- 211 of 512 --
16. GOVERNING LAW
This Agreement shall be governed by, and construed and interpreted in accordance with, the
laws of the State of Illinois.
17. HEADINGS
The headings inserted in this agreement are for convenience only and shall have no bearing
on the interpretation hereof.
IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed
and effective as of the date of last signature written below.
Controlled Affiliate:
By:
Date:
Plan:
By:
Date:
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By:
Date:
Amended as of March 26, 2015
17
-- 212 of 512 --
EXHIBIT A
CONTROLLED AFFILIATE LICENSE STANDARDS
September 2020
PREAMBLE
For purposes of definition:
• A "smaller Controlled Affiliate:" (1) comprises less than fifteen percent (15%) of Sponsoring
Plan's and its licensed Controlled Affiliates' total member enrollment (as reported on the BCBSA
Quarterly Enrollment Report, excluding rider and freestanding coverage, and treating an entity
seeking licensure as licensed);* or (2) underwrites the indemnity portion of workers’
compensation insurance and has total premium revenue less than 15 percent of the Sponsoring
Plan’s net subscription revenue.
• A "larger Controlled Affiliate" comprises fifteen percent (15%) or more of Sponsoring Plan's and its
licensed Controlled Affiliates' total member enrollment (as reported on the BCBSA Quarterly
Enrollment Report, excluding rider and freestanding coverage, and treating an entity seeking
licensure as licensed.)*
Changes in Controlled Affiliate status:
If any Controlled Affiliate's status changes regarding: its Plan ownership level, its risk acceptance
or direct delivery of medical care, the Controlled Affiliate shall notify BCBSA within thirty (30) days
of such occurrence in writing and come into compliance with the applicable standards within six (6)
months.
If a smaller Controlled Affiliate’s health and workers’ compensation administration business reaches or
surpasses fifteen percent (15%) of the total member enrollment of the Sponsoring Plan and licensed
Controlled Affiliates, the Controlled Affiliate shall:
Amended as of September 19, 2014
18
-- 213 of 512 --
EXHIBIT A (continued)
1. Within thirty (30) days, notify BCBSA of this fact in writing, including evidence that the Controlled
Affiliate meets the minimum liquidity and capital (BCBSA “Health Risk-Based Capital (HRBC)” as
defined by the NAIC and state-established minimum reserve) requirements of the larger
Controlled Affiliate Financial Responsibility standard; and
2. Within six (6) months after reaching or surpassing the fifteen percent (15%) threshold,
demonstrate compliance with all license requirements for a larger Controlled Affiliate.
If a Controlled Affiliate that underwrites the indemnity portion of workers’ compensation insurance
receives a change in rating or proposed change in rating, the Controlled Affiliate shall notify BCBSA
within 30 days of notification by the external rating agency.
*For purposes of this calculation, The
numerator equals:
Applicant Controlled Affiliate's member enrollment, as defined in BCBSA's Quarterly
Enrollment Report (excluding rider and freestanding coverage).
The denominator equals:
Numerator PLUS Sponsoring Plan and all other licensed Controlled Affiliates' member
enrollment, as reported in BCBSA's Quarterly Enrollment Report (excluding rider and
freestanding coverage).
Amended as of September 19, 2014
19
-- 214 of 512 --
EXHIBIT A (continued)
STANDARDS FOR LICENSED CONTROLLED AFFILIATES
Each licensed controlled affiliate shall be subject to certain standards as determined below:
1. What percent of the licensed controlled affiliate is controlled by the Sponsoring Plan and other Plans?
More than 50% by
Sponsoring Plan
ò
Standard 1A, 4
50% by Sponsoring
Plan
ò
Standard 1B, 4
100% Plan control
but less than 50%
Sponsoring Plan
Control and it offers
solely Medicaid,
Medicare Advantage
PPO, Medicare
Advantage HMO
and/or Special Need
Plans products and
services
ò
100% Sponsoring
Plan control and on a
Blue- branded basis,
it only offers a Basic
Medicare Part D
Prescription Drug
Plan product
ò
Standard 1D, 4
At least 50% by
Sponsoring Plan or
operational Control
by Sponsoring Plan
and it solely operates
as a Clinic as defined
in Standard 1E.
ò
Standard 1E, 4
IN ADDITION,
2. Is risk being assumed?
Yes
ò ø ÷
No
ò
Controlled
Affiliate
underwrites any
indemnity portion
of workers’
compensation
insurance
ò
Standards 7A-7E,
11
Controlled
Affiliate
comprises <
15% of total
member
enrollment of
Sponsoring Plan
and its licensed
affiliates, and
does not
underwrite the
indemnity portion
of workers’
compensation
insurance
ò
Standard 2
(Guidelines
1.1,1.2)
and Standard 11
Controlled
Affiliate
comprises > 15%
of total member
enrollment of
Sponsoring Plan
and its licensed
affiliates, and
does not
underwrite the
indemnity portion
of workers’
compensation
insurance
ò
Standard 6H
Controlled Affiliate
comprises < 15% of
total member
enrollment of
Sponsoring Plan
and its licensed
affiliates
ò
Standard 2
(Guidelines 1.1,1.3)
and Standard 11
Controlled
Affiliate
comprises >
15% of total
member
enrollment of
Sponsoring
Plan and its
licensed
affiliates
ò
Standard 6H
IN ADDITION,
3. Is medical care being directly provided as a staff model HMO?
Yes
ò
Standard
3A
No
ò
Standard
3B
Amended June 20, 2019
20
-- 215 of 512 --
EXHIBIT A (continued)
STANDARDS FOR LICENSED CONTROLLED AFFILIATES
Each licensed controlled affiliate shall be subject to certain standards as determined below:
IN ADDITION,
4. Is the licensed controlled affiliate operating as a Clinic as defined in Standard 1(E
Yes
ò
Standard 3C and Standard 2, 1.4 (if organized as a health plan that also operates as a Clinic)
5. If the controlled affiliate has health or workers’ compensation administration business, does such business comprise 15% or more
of the total member enrollment of Plan and its licensed Controlled Affiliates?
Yes
ò ÷ ÷
No
ø
Standards 6A-
6J
Controlled
Affiliate is not a
former
primary licensee and
is not subject to
Standard 1(C)
Standards
5,8,9B,10,11
Controlled Affiliate is a former
primary licensee
ò
Standards 5,8,9A,10,11
Controlled
Affiliate is not a
former primary
licensee and is
subject to
Standard 1(C)
ò
Standards
5,8,9B,11
Amended June 20, 2019
21
-- 216 of 512 --
EXHIBIT A (continued)
Standard 1 - Organization and Governance
1A.) The Standard for more than 50% Plan control is:
A Controlled Affiliate shall be organized and operated in such a manner that a Plan authorized to
use the Licensed Marks in the Service Area of the Controlled Affiliate pursuant to the separate
Primary License Agreement with BCBSA , has the legal authority, directly or indirectly through
wholly-owned subsidiaries: 1) to select members of the Controlled Affiliate’s governing body
having more than 50% voting control thereof; and 2) to prevent any change in the articles of
incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate
with which the Sponsoring Plan does not concur; and 3) to exercise control over the policy and
operations of the Controlled Affiliate. In addition, the Sponsoring Plan directly or indirectly
through wholly-owned subsidiaries shall own more than 50% of any for-profit Controlled Affiliate.
1B.) The Standard for 50% Plan control is:
A Controlled Affiliate shall be organized and operated in such a manner that a Plan
authorized to use the Licensed Marks in the Service Area of the Controlled Affiliate pursuant
to the separate Primary License Agreement with BCBSA has the legal authority, directly or
indirectly through wholly-owned subsidiaries:
1) to select members of the Controlled Affiliate’s governing body having not less than 50%
voting control thereof; and
2) to prevent any change in the articles of incorporation, bylaws or other establishing or
governing documents of the Controlled Affiliate with which the Sponsoring Plan does
not concur; and
3) to exercise control over the policy and operations of the Controlled Affiliate at least equal
to that exercised by persons or entities (jointly or individually) other than the Sponsoring
Plan.
Amended as of September 19, 2014
22
-- 217 of 512 --
EXHIBIT A (continued)
Notwithstanding anything to the contrary in 1) through 3) hereof, the Controlled Affiliate’s
establishing or governing documents must also require written approval by Sponsoring Plan
before the Controlled Affiliate can:
◦ change the geographic area in which it operates
◦ change its legal and/or trade names
◦ change any of the types of businesses in which it engages
◦ create, or become liable for by way of guarantee, any indebtedness, other than
indebtedness arising in the ordinary course of business
◦ sell any assets, except for sales in the ordinary course of business or sales of
equipment no longer useful or being replaced
◦ make any loans or advances except in the ordinary course of business
◦ enter into any arrangement or agreement with any party directly or indirectly
affiliated with any of the owners or persons or entities with the authority to select
or appoint members or board members of the Controlled Affiliate, other than the
Sponsoring Plan or other Plans (excluding owners of stock holdings of under 5%
in a publicly traded Controlled Affiliate)
◦ conduct any business other than under the Licensed Marks and Name
◦ take any action that the Sponsoring Plan or BCBSA reasonably believes will
adversely affect the Licensed Marks and Name.
In addition, the Sponsoring Plan directly or indirectly through wholly-owned
subsidiaries shall own at least 50% of any for-profit Controlled Affiliate.
Amended September 19, 2014
23
-- 218 of 512 --
1C.) The Standard for a Controlled Affiliate that offers solely Medicaid, Medicare Advantage
PPO, Medicare Advantage HMO and/or Special Need Plans products and service and has
100% Plan control but less than 50% Sponsoring Plan Control is:
A Controlled Affiliate shall be organized and operated in such a manner that (i) it offers solely
Medicaid, Medicare Advantage PPO, Medicare Advantage HMO and/or Special Need Plans
products and services; and (ii) a Plan authorized to use the Licensed Marks in the Service Area
of the Controlled Affiliate pursuant to the separate Primary License Agreement with BCBSA has
the legal authority together with Other Plans:
1) to select all members of the Controlled Affiliate’s governing body; and
2) to prevent any change in the articles of incorporation, bylaws, or other
establishing or governing documents of the Controlled Affiliate; and
3) to exercise control over the policy and operations of the Controlled Affiliate. In
addition, the Sponsoring Plan and such other Plans shall own 100% of any for-
profit Controlled Affiliate, with the Sponsoring Plan and such other Plans each having
an ownership interest. Such 100% control and ownership by Plans shall be direct or, if indirect,
solely through affiliates that are licensed to use marks owned by BCBSA. Further, the
Sponsoring Plan and such other Plans shall execute the Addendum to Controlled Affiliate
License.
1D.) The Standard for a Controlled Affiliate that on a Blue-branded basis only offers a Basic
Medicare Part D Prescription Drug Plan product and has 100% Plan control is:
A Controlled Affiliate shall be organized and operated in such a manner that (i) on a Blue-
branded basis, it only offers a Basic Medicare Part D Prescription Drug Plan product; and (ii)
the Sponsoring Plan has the legal authority:
1) to select all members of the Controlled Affiliate's governing body; and
2) to prevent any change in the articles of incorporation, bylaws or other
establishing or governing documents of the Controlled Affiliate; and
3) to exercise control over the policy and operations of the Controlled Affiliate.
In addition, the Sponsoring Plan shall own 100% of any for-profit Controlled Affiliate. Such
100% control and ownership by Sponsoring Plan must be direct or, if indirect, solely through
affiliates that are licensed to use marks owned by BCBSA.
Further, the Sponsoring Plan and Participating Plan shall execute the Addendum to
Controlled Affiliate License.
24
-- 219 of 512 --
1E.) The Standard for a Controlled Affiliate that operates as a Clinic and the
Sponsoring Plan has control of the Clinic is:
A Controlled Affiliate shall be organized in such a manner that it operates as a Clinic and the
Sponsoring Plan exercises operation control over the Controlled Affiliate.
In addition, if the Clinic is for-profit, the Sponsoring Plan shall own at least 50% of the Controlled
Affiliate and prevent any change in the articles of incorporation, bylaws or other establishing or
governing documents of the Controlled Affiliate.
Amended June 20, 2019
25
-- 220 of 512 --
EXHIBIT A (continued)
Standard 2 – Financial Responsibility
A Controlled Affiliate shall be operated in a manner that provides reasonable financial
assurance that it can fulfill all of its contractual obligations to its customers. If a risk- assuming
Controlled Affiliate ceases operations for any reason, Blue Cross and/or Blue Cross Plan
coverage will be offered to all Controlled Affiliate subscribers without exclusions, limitations or
conditions based on health status. If a nonrisk-assuming Controlled Affiliate ceases operations
for any reason, Sponsoring Plan will provide for services to its customers. The requirements of
the preceding two sentences shall apply to all lines of business unless a line of business is
specially exempted from the requirement(s) by the BCBSA Board of Directors.
Standard 3 – State Licensure/Certification
3A.) The Standard for a Controlled Affiliate that employs, owns or contracts on a
substantially exclusive basis for medical services is:
A Controlled Affiliate shall maintain unimpaired licensure or certification for its medical care
providers to operate under applicable state laws.
3B.) The Standard for a Controlled Affiliate that does not employ, own or contract on a
substantially exclusive basis for medical services is:
A Controlled Affiliate shall maintain unimpaired licensure or certification to operate under
applicable state laws.
3C.) The Standard for a Controlled Affiliate that operates as a Clinic as defined in Standard
1(E) is:
A Controlled Affiliate shall maintain appropriate and unimpaired licensure and
certifications.
Standard 4 – Certain Disclosures
A Controlled Affiliate shall make adequate disclosure in contracting with third parties and in
disseminating public statements of 1) the structure of the Blue Cross and Blue Shield System;
and 2) the independent nature of every licensee; and 3) the Controlled Affiliate's financial
condition.
Amended as of June 20, 2019
26
-- 221 of 512 --
EXHIBIT A (continued)
Standard 5 – Reports and Records for Certain Smaller Controlled Affiliates
For a smaller Controlled Affiliate that does not underwrite the indemnity portion of workers’
compensation insurance, the Standard is:
A Controlled Affiliate and/or its Sponsoring licensed Plan shall furnish, on a timely and accurate
basis, reports and records relating to these Standards and the License Agreements between
BCBSA and Controlled Affiliate.
Standard 6 – Other Standards for Larger Controlled Affiliates Standards
6(A) – (I) that follow apply to larger Controlled Affiliates. Standard 6(A):
Board of Directors
A Controlled Affiliate Governing Board shall act in the interest of its Corporation in providing
cost-effective health care services to its customers. A Controlled Affiliate shall maintain a
governing Board, which shall control the Controlled Affiliate, composed of a majority of persons
other than providers of health care services, who shall be known as public members. A public
member shall not be an employee of or have a financial interest in a health care provider, nor be
a member of a profession which provides health care services.
Standard 6(B): Responsiveness to Customers
A Controlled Affiliate shall be operated in a manner responsive to customer needs and
requirements.
Standard 6(C): Participation in National Programs
A Controlled Affiliate shall effectively and efficiently participate in each national program as from
time to time may be adopted by the Member Plans for the purposes of providing portability of
membership between the licensees and ease of claims processing for customers receiving
benefits outside of the Controlled Affiliate's Service Area.
Amended as of September 19, 2014
27
-- 222 of 512 --
EXHIBIT A (continued)
Standard 6(C): Participation in National Programs (continued)
Such programs are applicable to licensees, and include:
1. BlueCard Program;
2. Inter-Plan Teleprocessing System (ITS);
3. National Account Programs
4. Business Associate Agreement for Blue Cross and Blue Shield Licensees, effective
April 14, 2003; and
5. Inter-Plan Medicare Advantage Program.
Standard 6(D): Financial Performance Requirements
In addition to requirements under the national programs listed in
Standard 6C: Participation in National Programs, a Controlled Affiliate shall take such action as
required to ensure its financial performance in programs and contracts of an inter-licensee
nature or where BCBSA is a party.
Standard 6(E): Cooperation with Plan Performance Response Process
A Controlled Affiliate shall cooperate with BCBSA's Board of Directors and its Brand
Enhancement & Protection Committee in the administration of the Plan Performance Response
Process and in addressing Controlled Affiliate performance problems identified thereunder.
Standard 6(F): Independent Financial Rating
A Controlled Affiliate shall obtain a rating of its financial strength from an independent rating
agency approved by BCBSA's Board of Directors for such purpose.
Standard 6(G): Local and National Best Efforts
Notwithstanding any other provision in the Plan’s License Agreement with BCBSA or in this
License Agreement, during each year, a Controlled Affiliate shall use its best efforts to promote
and build the value of the Blue Cross Mark.
Amended as of November 21, 2014
28
-- 223 of 512 --
EXHIBIT A (continued)
Standard 6(H): Financial Responsibility
A Controlled Affiliate shall be operated in a manner that provides reasonable financial
assurance that it can fulfill all of its contractual obligations to its customers.
Standard 6(I): Reports and Records
A Controlled Affiliate shall furnish to BCBSA on a timely and accurate basis reports and records
relating to compliance with these Standards and the License Agreements between BCBSA and
Controlled Affiliate. Such reports and records are the following:
A) BCBSA Controlled Affiliate Licensure Information Request; and
B) Triennial trade name and service mark usage material, including
disclosure material; and
C) Changes in the ownership and governance of the Controlled Affiliate, including
changes in its charter, articles of incorporation, or bylaws, changes in a Controlled
Affiliate's Board composition, or changes in the identity of the Controlled Affiliate's
Principal Officers, and changes in risk acceptance, contract growth, or direct
delivery of medical care; and
D) Semi-annual “Health Risk-Based Capital (HRBC) Report” as defined by the NAIC,
Annual Certified Audit Report, Insurance Department Examination Report, Annual
Statement filed with State Insurance Department (with all attachments), and
Amended as of November 17, 2011
29
-- 224 of 512 --
EXHIBIT A (continued)
Standard 6(J): Control by Unlicensed Entities Prohibited
No Controlled Affiliate shall cause or permit an entity other than a Plan or a Licensed
Controlled Affiliate thereof to obtain control of the Controlled Affiliate or to acquire a
substantial portion of its assets related to licensable services.
Standard 7 - Other Standards for Risk-Assuming Workers’ Compensation
Controlled Affiliates
Standards 7(A) - (E) that follow apply to Controlled Affiliates that underwrite the indemnity
portion of workers’ compensation insurance.
Standard 7 (A): Financial Responsibility
A Controlled Affiliate shall be operated in a manner that provides reasonable financial
assurance that it can fulfill all of its contractual obligations to its customers.
Standard 7(B): Reports and Records
A Controlled Affiliate shall furnish, on a timely and accurate basis, reports and records
relating to compliance with these Standards and the License Agreements between
BCBSA and the Controlled Affiliate. Such reports and records are the following:
A. BCBSA Controlled Affiliate Licensure Information Request; and
B. Triennial trade name and service mark usage materials, including disclosure
materials; and
C. Annual Certified Audit Report, Annual Statement as filed with the State Insurance
Department (with all attachments), Annual NAIC’s Risk-Based Capital Worksheets for
Property and Casualty Insurers; and
D. Quarterly Estimated Risk-Based Capital for Property and Casualty Insurers,
Insurance Department Examination Report; and
Amended as of November 17, 2011
30
-- 225 of 512 --
EXHIBIT A (continued)
Standard 7(B): Reports and Records, continued
E. Notification of all changes and proposed changes to independent ratings within 30
days of receipt and submission of a copy of all rating reports; and
F. Changes in the ownership and governance of the Controlled Affiliate including
changes in its charter, articles of incorporation, or bylaws, changes in a Controlled
Affiliate’s Board composition, Plan control, state license status, operating area, the
Controlled Affiliate’s Principal Officers or direct delivery of medical care.
Standard 7(C): Loss Prevention
A Controlled Affiliate shall apply loss prevention protocol to both new and existing
business.
Standard 7(D): Claims Administration
A Controlled Affiliate shall maintain an effective claims administration process that
includes all the necessary functions to assure prompt and proper resolution of medical
and indemnity claims.
Standard 7(E): Disability and Provider Management
A Controlled Affiliate shall arrange for the provision of appropriate and necessary
medical and rehabilitative services to facilitate early intervention by medical
professionals and timely and appropriate return to work.
Amended as of November 16, 2000
31
-- 226 of 512 --
EXHIBIT A (continued)
Standard 8 - Cooperation with Controlled Affiliate License Performance
Response Process Protocol
A Controlled Affiliate and its Sponsoring Plan shall cooperate with BCBSA’s Board of
Directors and its Brand Enhancement & Protection Committee in the administration of
the Controlled Affiliate License Performance Response Process Protocol (ALPRPP) and
in addressing Controlled Affiliate compliance problems identified thereunder.
Standard 9(A) - Participation in National Programs by Smaller Controlled Affiliates
that were former Primary Licensees
A smaller controlled affiliate that formerly was a Primary Licensee shall effectively and efficiently
participate in certain national programs from time to time as may be adopted by Member Plans
for the purposes of providing ease of claims processing for customers receiving benefits outside
of the Controlled Affiliate’s service area and be subject to certain relevant financial and reporting
requirements.
A. National program requirements include:
• BlueCard Program;
• Inter-Plan Teleprocessing System (ITS);
• National Account Programs.
B. Financial Requirements include:
• Standard 6(D): Financial Performance Requirements and Standard 6(H):
Financial Responsibility; or
• A financial guarantee covering the Controlled Affiliate’s Inter-Plan Programs
obligations in a form, and from a guarantor, acceptable to BCBSA.
Amended as of November 21, 2014
32
-- 227 of 512 --
EXHIBIT A (continued)
Standard 9(A) - Participation in National Programs by Smaller Controlled Affiliates
that were former Primary Licensees
C. Reporting requirements include:
• The Semi-annual Health Risk-Based Capital (HRBC) Report.
Amended as of June 13, 2002
33
-- 228 of 512 --
EXHIBIT A (continued)
Standard 9(B) - Participation in National Programs by Smaller Controlled Affiliates
A smaller controlled affiliate shall participate in national programs in accordance with
BlueCard and other relevant Policies and Provisions shall effectively and efficiently
participate in national programs from time to time as may be adopted by Member Plans for
the purposes of providing ease of claims processing for customers receiving benefits
outside of the controlled affiliate’s service area and be subject to certain relevant financial
and reporting requirements.
A. National program requirements include:
• BlueCard Program;
• Inter-Plan Teleprocessing System (ITS);
• National Account Programs.
B. Financial Requirements include:
• Standard 6(D): Financial Performance Requirements and Standard 6(H):
Financial Responsibility; or
• A financial guarantee covering the Controlled Affiliate’s Inter-Plan Programs
obligations in a form, and from a guarantor, acceptable to BCBSA.
Amended as of June 20, 2013
34
-- 229 of 512 --
EXHIBIT A (continued)
Standard 10 - Participation in Inter-Plan Medicare Advantage Program
A smaller controlled affiliate for which this standard applies pursuant to the Preamble section of
Exhibit A of the Controlled Affiliate License Agreement shall effectively and efficiently participate
in certain national programs from time to time as may be adopted by Member Plans for the
purposes of providing ease of claims processing for customers receiving benefits outside of the
controlled affiliate’s service area.
National program requirements include:
A. Inter-Plan Medicare Advantage Program.
Standard 11: Participation in Master Business Associate Agreement by Smaller
Controlled Affiliate Licensees
Effective April 14, 2003, all smaller controlled affiliates shall comply with the terms of the
Business Associate Agreement for Blue Cross and Blue Shield Licensees to the extent they
perform the functions of a business associate or subcontractor to a business associate, as
defined by the Business Associate Agreement.
Amended as of September 19, 2014
35
-- 230 of 512 --
EXHIBIT B-1
ADDENDUM TO CONTROLLED AFFILIATE LICENSE TO BE EXECUTED BY
CONTROLLED AFFILIATES LICENSED UNDER CONTROLLED AFFILIATE LICENSE
STANDARD 1C.
ADDENDUM TO CONTROLLED AFFILIATE LICENSE
This Addendum is made to that certain Blue Cross Controlled Affiliate License Agreement
executed by and among Blue Cross and Blue Shield Association (“Licensor”), (“Controlled
Affiliate Licensee”) and
(“Sponsoring Plan”) dated the
day of , (“Agreement”). The parties to this Addendum are Licensor, Controlled Affiliate
Licensee, Sponsoring Plan, and the undersigned other Plans (‘Other Plans”). This Addendum
is made and shall be deemed effective as of the date of the Agreement.
WHEREAS, the Sponsoring Plan asserts that it can serve the Medicaid, Medicare Advantage
PPO, Medicare Advantage HMO and/or Special Need Plans market in its Service Area more
efficiently and with less risk through an enterprise jointly owned and controlled with other Plans
than through a wholly owned and Controlled Affiliate Licensee.
WHEREAS, in such circumstance Controlled Affiliate License Standard 1C permits the
licensing of a Controlled Affiliate that is less than 50% owned and controlled by the Sponsoring
Plan but which is 100% owned and controlled by Plans including the Sponsoring Plan, subject
to certain conditions;
WHEREAS, one such condition is that the Sponsoring Plan and all such other owning and
controlling Plans enter into this Addendum;
NOW THEREFORE, for good and valuable consideration, including the promises and
covenants set forth herein, the parties agree as follows:
1. This Addendum is limited to [identify product name].
2. The Sponsoring Plan shall participate operationally in Controlled Affiliate’s business that
is conducted under the Licensed Marks. The parties understand that participation may
take many forms, one of which should be providing a network of providers in the Service
Area of the Controlled Affiliate for the Medicaid, Medicare Advantage PPO, Medicare
Advantage HMO and/or Special Need Plans services being offered under the
Agreement and being involved in network development and provider engagement
functions.
3. Each of the Other Plans agrees that (i) it will cooperate fully with the Sponsoring
Plan and BCBSA as needed to enable Sponsoring Plan and
36
-- 231 of 512 --
Controlled Affiliate Licensee to meet their obligations to Licensor under the Agreement
and all associated rules and regulations of Licensor, including the Brand Regulations, (ii)
it will not take any action, either individually or jointly with any of the Other Plans, that
would cause Sponsoring Plan or Controlled Affiliate Licensee to violate the Agreement,
and (iii) it will not fail to take any action, either individually or jointly with any of the Other
Plans, where such failure would cause Sponsoring Plan or Controlled Affiliate Licensee
to violate the Agreement.
4. Each of the Other Plans acknowledges that it has reviewed the Agreement and
understands that Sponsoring Plan has the right to terminate the Agreement without cause
upon notice as provided in Paragraph 8 of the Agreement, and that such right is
unfettered and may be exercised by Sponsoring Plan in its sole discretion.
WHEREFORE, by signing below the parties agree to be bound to the terms stated herein.
BLUE CROSS BLUE SHIELD ASSOCIATION
By:
[Controlled Affiliate Licensee]
By:
[Sponsoring Plan]
By:
[Other Plan 1]
By:
[Other Plan 2]
By:
Amended September 27, 2018
37
-- 232 of 512 --
EXHIBIT B-2
ADDENDUM TO CONTROLLED AFFILIATE LICENSE TO BE EXECUTED BY
CONTROLLED AFFILIATES LICENSED UNDER CONTROLLED AFFILIATE LICENSE
STANDARD 1D.
ADDENDUM TO CONTROLLED AFFILIATE LICENSE
This Addendum is made to that certain Blue Cross Controlled Affiliate License
Agreement executed by and among Blue Cross and Blue Shield Association
(“Licensor”), (“Controlled Affiliate Licensee”),
(“Sponsoring Plan”) and
(“Participating Plan”) dated the day of , (“Agreement”).
WHEREAS, the Participating Plan is defined as the Plan that holds the Primary License
with BCBSA to use the Service Marks in the Service Area where the Controlled Affiliate
will use the Service Marks;
WHEREAS, the Participating Plan asserts that it can offer a lower cost Basic Medicare Part D
Prescription Drug Plan product more efficiently in the Participating Plan’s Service Area
through the Controlled Affiliate Licensee;
WHEREAS, the Controlled Affiliate shall only use the Service Marks inside of the
Participating Plan(s) Service Area subject to each Participating Plan signing a separate
Addendum;
WHEREAS, in such circumstance Controlled Affiliate License Standard 1D permits the
licensing of a Controlled Affiliate that is 100% owned and controlled by a Sponsoring Plan,
subject to certain conditions;
WHEREAS, one such condition is that the Sponsoring Plan, Controlled Affiliate and the
Participating Plan enter into this Addendum;
NOW THEREFORE, for good and valuable consideration, including the promises and
covenants set forth herein, the parties agree as follows:
1. The Participating Plan shall participate in Controlled Affiliate’s business that is
conducted under the Licensed Marks. The parties understand that the Participating Plan
shall conduct sales support and marketing of the Controlled Affiliate’s Basic Medicare
Part D Prescription Drug Plan product offered in the Participating Plan’s Service Area.
Any other form of participation shall require BCBSA’s written approval.
2. Participating Plan agrees that (i) it will cooperate fully with the Sponsoring Plan and
BCBSA as needed to enable Sponsoring Plan and
38
-- 233 of 512 --
Controlled Affiliate Licensee to meet their obligations to Licensor under the Agreement
and all associated rules and regulations of Licensor, including the Brand Regulations, (ii)
it will not take any action that would cause Sponsoring Plan or Controlled Affiliate
Licensee to violate the Agreement, and (iii) it will not fail to take any action, either
individually or jointly with the Sponsoring Plan or Controlled Affiliate Licensee, where
such failure would cause Sponsoring Plan or Controlled Affiliate Licensee to violate the
Agreement.
3. The Controlled Affiliate Licensee shall only use the Licensed Marks authorized by the
Participating Plan in connection with the Basic Medicare Part D Prescription Drug Plan
product offered in the Participating Plan’s Service Area.
4. The Sponsoring Plan and Controlled Affiliate acknowledge that it has reviewed the
Agreement and understands that Participating Plan has the right to terminate this
Agreement: (i) immediately upon the expiration or termination of the Plan Participation
Agreement by and between Participating Plan and Controlled Affiliate upon written notice
to the Sponsoring Plan, Controlled Affiliate Licensee and Licensor, or (ii) without cause
upon 18 months written notice to the Sponsoring Plan, Controlled Affiliate Licensee and
Licensor, and that such right is unfettered and may be exercised by Participating Plan in
its sole discretion. In the event that Participating Plan and Controlled Affiliate fail to
execute the Plan Participation Agreement by (Date), Participating Plan may terminate
this Agreement immediately upon notice to Sponsoring Plan, Controlled Affiliate
Licensee and Licensor.
5. This Agreement and all of Controlled Affiliate Licensee's rights hereunder shall
immediately terminate without any further action by any party or entity in the event that
the Sponsoring Plan or Participating Plan ceases to be authorized to use the Licensed
Marks and Name.
WHEREFORE, by signing below the parties agree to be bound to the terms stated herein.
BLUE CROSS BLUE SHIELD ASSOCIATION
By:
[Controlled Affiliate Licensee]
By:
[Sponsoring Plan]
By:
[Participating Plan]
By:
Amended September 27, 2018
39
-- 234 of 512 --
EXHIBIT C
ROYALTY FORMULA FOR SECTION 9 OF THE
CONTROLLED AFFILIATE LICENSE AGREEMENT
Controlled Affiliate will pay BCBSA a fee for this license in accordance with the following
formula:
FOR RISK PRODUCTS:
For Controlled Affiliates not underwriting the indemnity portion of workers’ compensation
insurance:
An amount equal to its pro rata share of Sponsoring Plan's dues payable to BCBSA
computed with the addition of the Controlled Affiliate's members using the Marks on health
care plans and related services as reported on the Quarterly Enrollment Report with
BCBSA. The payment by Sponsoring Plan of its dues to BCBSA, including that portion
described in this paragraph, will satisfy the requirement of this paragraph, and no separate
payment will be necessary.
For Controlled Affiliates underwriting the indemnity portion of workers’
compensation insurance:
An amount equal to 0.35 percent of the gross revenue per annum of Controlled Affiliate
arising from products using the marks; plus, an annual fee of $5,000 per license for a
Controlled Affiliate subject to Standard 7.
Amended as of September 19, 2014
40
-- 235 of 512 --
EXHIBIT C (continued)
FOR NONRISK PRODUCTS:
For third-party administrative business, an amount equal to its pro rata share of
Sponsoring Plan’s dues payable to BCBSA computed with the addition of the Controlled
Affiliate’s members using the Marks on health care plans and related services as reported
on the Quarterly Enrollment Report with BCBSA. The payment by Sponsoring Plan of its
dues to BCBSA, including that portion described in this paragraph, will satisfy the
requirement of this paragraph, and no separate payment will be necessary.
For non-third party administrative business (e.g., case management, provider networks,
etc.), an amount equal to 0.24 percent of the gross revenue per annum of Controlled
Affiliate arising from products using the marks; plus:
1) An annual fee of $5,000 per license for a Controlled Affiliate subject to Standard
6 D.
2) An annual fee of $2,000 per license for all other Controlled Affiliates.
The foregoing shall be reduced by one-half where both a BLUE CROSS® and BLUE SHIELD®
License are issued to the same Controlled Affiliate. In the event that any license period is greater
or less than one (1) year, any amounts due shall be prorated. Royalties under this formula will be
calculated, billed and paid in arrears.
Amended as of September 19, 2014
41
-- 236 of 512 --
EXHIBIT 1A
CONTROLLED AFFILIATE LICENSE AGREEMENT APPLICABLE TO LIFE
INSURANCE COMPANIES
(Includes revisions adopted by Member Plans through their September 17, 2020 meeting)
This agreement by and among Blue Cross and Blue Shield Association ("BCBSA")
("Controlled Affiliate"), a Controlled Affiliate of the Blue Cross Plan(s), known as ("Plan").
WHEREAS, BCBSA is the owner of the BLUE CROSS and BLUE CROSS Design service marks;
WHEREAS, the Plan and the Controlled Affiliate desire that the latter be entitled to use the BLUE
CROSS and BLUE CROSS Design service marks (collectively the "Licensed Marks") as service
marks and be entitled to use the term BLUE CROSS in a trade name ("Licensed Name");
NOW, THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter
set forth and for other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties hereby agree as follows:
1. GRANT OF LICENSE
Subject to the terms and conditions of this Agreement, BCBSA hereby grants to the Controlled
Affiliate the exclusive right to use the licensed Marks and Names in connection with and only in
connection with those life insurance and related services authorized by applicable state law, other than
health care plans and related services (as defined in the Plan's License Agreements with BCBSA)
which services are not separately licensed to Controlled Affiliate by BCBSA, in the Service Area served
by the Plan, except that BCBSA reserves the right to use the Licensed Marks and Name in said Service
Area, and except to the extent that said Service Area may overlap the area or areas served by one or
more other licensed Blue Cross Plans as of the date of this License as to which overlapping areas the
rights hereby granted are non-exclusive as to such other Plan or Plans and their respective Licensed
Controlled Affiliates only. Controlled Affiliate cannot use the Licensed Marks or Name outside the
Service Area or in its legal or trade name; provided, however, that if and only for so long as Controlled
Affiliate also holds a Blue Cross Controlled Affiliate License Agreement applicable to health care plans
and related services, Controlled Affiliate may use the Licensed Marks and Name in its legal and trade
name according to the terms of such license agreement.
Amended as of June 12, 2003
-1-
-- 237 of 512 --
2. QUALITY CONTROL
A. Controlled Affiliate agrees to use the Licensed Marks and Name only in relation to the
sale, marketing and rendering of authorized products and further agrees to be bound by the conditions
regarding quality control shown in Exhibit A as it may be amended by BCBSA from time-to-time.
B. Controlled Affiliate agrees that Plan and/or BCBSA may, from time-to-time, upon
reasonable notice, review and inspect the manner and method of Controlled Affiliate's rendering of
service and use of the Licensed Marks and Name.
C. Controlled Affiliate agrees that it will provide on an annual basis (or more often if
reasonably required by Plan or by BCBSA) a report to Plan and BCBSA demonstrating Controlled
Affiliate's compliance with the requirements of this Agreement including but not limited to the quality
control provisions of Exhibit A.
D. As used herein, a Controlled Affiliate is defined as an entity organized and operated in
such a manner that it is subject to the bona fide control of a Plan or Plans. Absent written approval by
BCBSA of an alternative method of control, bona fide control shall mean the legal authority, directly or
indirectly through wholly-owned subsidiaries: (a) to select members of the Controlled Affiliate's
governing body having not less than 51% voting control thereof; (b) to exercise operational control with
respect to the governance thereof; and (c) to prevent any change in its articles of incorporation, bylaws
or other governing documents deemed inappropriate. In addition, a Plan or Plans shall own at least
51% of any for-profit Controlled Affiliate. If the Controlled Affiliate is a mutual company, the Plan or its
designee(s) shall have and maintain, in lieu of the requirements of items (a) and (c) above, proxies
representing 51% of the votes at any meeting of the policyholders and shall demonstrate that there is
no reason to believe this such proxies shall be revoked by sufficient policyholders to reduce such
percentage below 51%.
3. SERVICE MARK USE
Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks,
including but not limited to use of such symbols or words as BCBSA shall specify to protect the
Licensed Marks, and shall comply with such rules (applicable to all Controlled Affiliates licensed to use
the Marks) relative to service mark use, as are issued from
time-to-time by BCBSA. If there is any public reference to the affiliation between the Plan and the
Controlled Affiliate, all of the Controlled Affiliate's licensed services in the Service Area of the Plan shall
be rendered under the Licensed Marks. Controlled Affiliate recognizes and agrees that all use of the
Licensed Marks by Controlled Affiliate shall inure to the benefit of BCBSA.
-2-
-- 238 of 512 --
4. SUBLICENSING AND ASSIGNMENT
Controlled Affiliate shall not sublicense, transfer, hypothecate, sell, encumber or mortgage,
by operation of law or otherwise, the rights granted
hereunder and any such act shall be voidable at the option of Plan or BCBSA.
This Agreement and all rights and duties hereunder are personal to Controlled Affiliate.
5. INFRINGEMENTS
Controlled Affiliate shall promptly notify Plan and BCBSA of any suspected acts of
infringement, unfair competition or passing off which may occur in relation to the Licensed Marks.
Controlled Affiliate shall not be entitled to require Plan or BCBSA to take any actions or institute any
proceedings to prevent infringement, unfair competition or passing off by third parties. Controlled
Affiliate agrees to render to Plan and BCBSA, free of charge, all reasonable assistance in connection
with any matter pertaining to the protection of the Licensed Marks by BCBSA.
6. LIABILITY INDEMNIFICATION
Controlled Affiliate hereby agrees to save, defend, indemnify and hold Plan and BCBSA
harmless from and against all claims, damages, liabilities and costs of every kind, nature and
description which may arise as a result of Controlled Affiliate's rendering of health care services
under the Licensed Marks.
7. LICENSE TERM
The license granted by this Agreement shall remain in effect for a period of one (1) year and
shall be automatically extended for additional one (1) year periods upon evidence satisfactory to the
Plan and BCBSA that Controlled Affiliate meets the then applicable quality control standards, unless
one of the parties hereto notifies the other party of the termination hereof at least sixty (60) days prior to
expiration of any license period.
This Agreement may be terminated by the Plan or by BCBSA for cause at any time provided
that Controlled Affiliate has been given a reasonable opportunity to cure and shall not effect such a
cure within thirty (30) days of receiving written notice of the intent to terminate (or commence a cure
within such thirty day period and continue diligent efforts to complete the cure if such curing cannot
reasonably be completed within such thirty day period). By way of example and not for purposes of
limitation, Controlled Affiliate's failure to abide by the quality control provisions of Paragraph 2, above,
shall be considered a proper ground for cancellation of this Agreement.
-3-
-- 239 of 512 --
This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate
without any further action by any party or entity in the event that:
A. Controlled Affiliate shall no longer comply with Standard No. 1 (Organization
and Governance) of Exhibit A or, following an opportunity to cure, with the remaining
quality control provisions of Exhibit A, as it may be amended from time-to-time; or
B. Plan ceases to be authorized to use the Licensed Marks; or
C. Appropriate dues for Controlled Affiliate pursuant to item 8 hereof, which are
the royalties for this License Agreement are more than sixty (60) days in arrears to
BCBSA.
Upon termination of this Agreement for cause or otherwise, Controlled Affiliate
agrees that it shall immediately discontinue all use of the Licensed Marks including any
use in its trade name.
In the event of any disagreement between Plan and BCBSA as to whether
grounds exist for termination or as to any other term or condition hereof, the decision of
BCBSA shall control, subject to provisions for mediation or mandatory dispute resolution
in effect between the parties.
Upon termination of this Agreement, Licensed Controlled Affiliate shall immediately
notify all of its customers that it is no longer a licensee of the Blue Cross and Blue Shield
Association and provide instruction on how the customer can contact the Blue Cross and
Blue Shield Association or a designated licensee to obtain further information on securing
coverage. The written notification required by this paragraph shall be in writing and in a
form approved by the Association. The Association shall have the right to audit the
terminated entity's books and records to verify compliance with this paragraph.
8. DUES
Controlled Affiliate will pay to BCBSA a fee for this license in accordance with the
following formula:
• An annual fee of five thousand dollars ($5,000) per license, plus
•.05% of gross revenue per year from branded group products, plus
•.5% of gross revenue per year from branded individual products plus
• .14% of gross revenue per year from branded individual annuity
products.
Amended as of November 20, 1997
-4-
-- 240 of 512 --
The foregoing percentages shall be reduced by one-half where both a BLUE
CROSS® and BLUE SHIELD® license are issued to the same entity. In the event that any
License period is greater or less than one (1) year, any amounts due shall be prorated.
Royalties under this formula will be calculated, billed and paid in arrears.
Plan will promptly and timely transmit to BCBSA all dues owed by Controlled
Affiliate as determined by the above formula and if Plan shall fail to do so, Controlled
Affiliate shall pay such dues directly.
9. JOINT VENTURE
Nothing contained in this Agreement shall be construed as creating a joint venture,
partnership, agency or employment relationship between Plan and Controlled Affiliate or
between either and BCBSA.
9A. VOTING
For all provisions of this Agreement referring to voting, the term ‘Plans’ shall
mean all entities licensed under the Blue Cross License Agreement and/or the Blue Shield
License Agreement, and in all votes of the Plans under this Agreement the Plans shall
vote together. For weighted votes of the Plans, the Plan shall have a number of votes
equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the
number of weighted votes (if any) that it holds as a Blue Shield Plan. For all other votes of
the Plans, the Plan shall have one vote. For all questions requiring an affirmative three-
fourths weighted vote of the Plans, the requirement shall be deemed satisfied with a lesser
weighted vote unless the greater of: (i) 6/52 or more of the Plans (rounded to the nearest
whole number, with 0.5 or multiples thereof being rounded to the next higher whole
number) fail to cast weighted votes in favor of the question; or (ii) three (3) of the Plans fail
to cast weighted votes in favor of the question. Notwithstanding the foregoing provision, if
there are thirty-six
(36) Plans, the requirement of an affirmative three-fourths weighted vote shall be
deemed satisfied with a lesser weighted vote unless four (4) or more Plans fail to cast
weighted votes in favor of the question.
10. NOTICES AND CORRESPONDENCE
Notices regarding the subject matter of this Agreement or breach or termination
thereof shall be in writing and shall be addressed in duplicate to the last known address of
each other party, marked respectively to the attention of its President and, if any, its
General Counsel.
Amended as of November 20, 1997
-5-
-- 241 of 512 --
11. COMPLETE AGREEMENT
This Agreement contains the complete understandings of the parties in relation to
the subject matter hereof. This Agreement may only be amended by a writing executed
by all parties.
12. SEVERABILITY
If any term of this Agreement is held to be unlawful by a court of competent
jurisdiction, such finding shall in no way effect the remaining obligations of the parties
hereunder and the court may substitute a lawful term or condition for any unlawful term
or condition so long as the effect of such substitution is to provide the parties with the
benefits of this Agreement.
13. NONWAIVER
No waiver by BCBSA of any breach or default in performance on the part of the
Controlled Affiliate or any other licensee of any of the terms, covenants or conditions of
this Agreement shall constitute a waiver of any subsequent breach or default in
performance of said terms, covenants or conditions.
14. GOVERNING LAW
This Agreement shall be governed by, and construed and interpreted in
accordance with, the laws of the State of Illinois.
Amended as of June 16, 2005
-6-
-- 242 of 512 --
IN WITNESS WHEREOF, the parties have caused this License Agreement to be
executed, effective as of the date of last signature written below.
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By: _ Date: _
Controlled Affiliate:
By: _ Date: _
Plan:
By: _ Date: _
-7-
-- 243 of 512 --
EXHIBIT A
CONTROLLED AFFILIATE LICENSE STANDARDS LIFE
INSURANCE COMPANIES
Page 1 of 2
PREAMBLE
The standards for licensing Life Insurance Companies (Life and Health Insurance
companies, as defined by state statute) are established by BCBSA and are subject to
change from time-to-time upon the affirmative vote of three- fourths (3/4) of the Plans and
three-fourths (3/4) of the total weighted vote of all Plans. Each Licensed Plan is required
to use a standard controlled affiliate license form provided by BCBSA and to cooperate
fully in assuring that the licensed Life Insurance Company maintains compliance with the
license standards.
An organization meeting the following standards shall be eligible for a license to use the
Licensed Marks within the service area of its sponsoring Licensed Plan to the extent and
the manner authorized under the Controlled Affiliate License applicable to Life Insurance
Companies and the principal license to the Plan.
Standard 1 - Organization and Governance
The LIC shall be organized and operated in such a manner that it is controlled by a
licensed Plan or Plans which have, directly or indirectly: 1) not less than 51% of the voting
control of the LIC; and 2) the legal ability to prevent any change in the articles of
incorporation, bylaws or other establishing or governing documents of the LIC with which it
does not concur; and 3) operational control of the LIC.
If the LIC is a mutual company, the Plan or its designee(s) shall have and maintain, in lieu
of the requirements of items 1 and 2 above, proxies representing at least 51% of the votes
at any policyholder meeting and shall demonstrate that there is no reason to believe such
proxies shall be revoked by sufficient policyholders to reduce such percentage below
51%.
Standard 2 - State Licensure
The LIC must maintain unimpaired licensure or certificate of authority to operate under
applicable state laws as a life and health insurance company in each state in which the
LIC does business.
-1-
-- 244 of 512 --
EXHIBIT A
CONTROLLED AFFILIATE LICENSE STANDARDS LIFE
INSURANCE COMPANIES
Page 2 of 2
Standard 3 - Records and Examination
The LIC and its sponsoring licensed Plan(s) shall maintain and furnish, on a timely and
accurate basis, such records and reports regarding the LIC as may be required in order
to establish compliance with the license agreement. The LIC and its sponsoring licensed
Plan(s) shall permit BCBSA to examine the affairs of the LIC and shall agree that
BCBSA's board may submit a written report to the chief executive officer(s) and the
board(s) of directors of the sponsoring Plan(s).
Standard 4 - Mediation
The LIC and its sponsoring Plan(s) shall agree to use the then-current BCBSA mediation
and mandatory dispute resolution processes, in lieu of a legal action between or among
another licensed controlled affiliate, a licensed Plan or BCBSA.
Standard 5 - Financial Responsibility
The LIC shall maintain adequate financial resources to protect its customers and meet its
business obligations.
Standard 6 - Cooperation with Affiliate License Performance Response Process
Protocol
The LIC and its Sponsoring Plan(s) shall cooperate with BCBSA’s Board of Directors
and its Brand Enhancement & Protection Committee in the administration of the
Affiliate License Performance Response Process Protocol (ALPRPP) and in
addressing LIC compliance problems identified thereunder.
-2-
-- 245 of 512 --
Exhibit 1A1
CONTROLLED AFFILIATE TRADEMARK
LICENSE AGREEMENT
FOR LIFE AND DISABILTY INSURANCE PRODUCTS
This Agreement by and among Blue Cross and Blue Shield Association
("BCBSA") and , (“Life and Disability Controlled Affiliate”) which is a company offering
life and disability insurance products owned and controlled by , ,
( individually, “Sponsoring Plan” and when referred to collectively,
“Sponsoring Plans”).
Whereas, BCBSA is the owner of the BLUE CROSS and BLUE SHIELD word and
design service marks and any derivatives thereof (“Licensed Marks”);
Whereas, each Sponsoring Plan is licensed separately by BCBSA to use one or more of
the Licensed Marks in a particular Service Area;
Whereas, the Sponsoring Plans and the Life and Disability Controlled Affiliate desire that
the latter be entitled to use the appropriate Licensed Marks in connection with life and
disability insurance products in some or all of such Sponsoring Plans’ Service Areas and in
the Service Areas of other Regular Member Plans, as defined in the BCBSA By-laws,
(“Blue Plans”) consistent with the terms of this Agreement.
NOW, THEREFORE, in consideration of the foregoing and the mutual agreements
hereinafter set forth and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereby agree as follows:
1. GRANT OF LICENSE
A. Subject to the terms and conditions of this Agreement, BCBSA hereby
grants to the Life and Disability Controlled Affiliate the limited right to use the Licensed
Marks in connection with and only in connection with the following life and disability
insurance products authorized by state law: (1) Group: Term Life, Long Term Disability,
Whole Life, Benefit Life, Universal Life; (2)
Individual: Term Life, Whole Life, Dependent Life, Spouse Life; (3)
Other: Disability Income, Short Term Disability, Long Term Disability, Income
Replacement; and (4) such other life and disability products approved by BCBSA in writing
(“Licensed Products”) in the Service Areas served by the Sponsoring Plans or in the
Service Area or Areas of one or more other licensed Blue Plans, provided that such Blue
Plans have consented to such use as authorized by this Agreement. Life and Disability
Controlled Affiliate may not use the Licensed Marks in its legal or trade name.
1
-- 246 of 512 --
B. Notwithstanding that the license granted to Life and Disability Controlled
Affiliate is a license to use all of the Licensed Marks, Life and Disability Controlled
Affiliate may only use those of the Licensed Marks in the Service Area of a Sponsoring Plan
or other consenting Blue Plan as described below that such Plan is authorized to use as a Blue
Plan pursuant to its separate license agreements with BCBSA.
C. Life and Disability Controlled Affiliate may use the Licensed Marks in the
Service Areas of Sponsoring Plans or in the Service Area of a Blue Plan that is not a
signatory to this Agreement only after such Sponsoring Plan(s) or non-signatory Blue Plan
consents to such use by executing a written consent in substantially the same form as the
Consent Agreement attached as Exhibit B.
D. The following provisions apply with respect to Consent Agreements
once such agreements have been fully and properly executed:
(1) All sales, marketing and advertising materials developed by and
proposed for use by Life and Disability Controlled Affiliate in the Service Area of
Sponsoring Plan or consenting Blue Plan (hereinafter, such consenting Sponsoring
Plan or consenting Blue Plan collectively referred to “Consenting Plan(s)”) must
clearly identify the Consenting Plan (for example, a statement on such materials that
reads “This product is offered with the cooperation of Blue Cross and/or Blue Shield
of [Geography]”);
(2) To the extent the Consenting Plan has separate divisions or other
Affiliates that use the Licensed Marks in distinct geographic areas within its Service
Area, consent obtained under this Agreement may be limited to one or more of such
specific geographic areas as specified by the Consenting Plan in its signed Consent
Agreement. For purposes of this entire Agreement, all references to the Service Area
of a Sponsoring Plan, Blue Plan or Consenting Plan may include the entire Service
Area or a distinct geographic area within such Service Area as specified in this
Section 1 D (2);
(3) Where BCBSA has licensed two or more Blue Plans to use the same
Licensed Marks in the same Service Area, in addition to the requirements set forth in
Section D (1) above, the sales, marketing and advertising materials referenced in
such section above must be communicated to the Consenting Plan’s existing and
prospective accounts through or with the approval of such Consenting Plan, and the
personnel of such Consenting Plan must actively participate in all sales and
marketing activities conducted by Life and Disability Controlled Affiliate in the same
Service Area, including participating in meetings (whether in- person or via
telephone, video or internet conference) with both existing and prospective accounts
of the Consenting Plan;
2
-- 247 of 512 --
(4) Life and Disability Controlled Affiliate shall be entitled to use in a
Service Area only those Licensed Marks that the Consenting Plan has been granted
by BCBSA the license to use under its Blue Plan license
(5) agreements (for example, if a Consenting Plan is licensed to use only
the Blue Cross Marks in its Service Area, the materials used by Life and Disability
Controlled Affiliate in that Service Area may only contain or reference the Blue Cross
Marks and not the Blue Shield Marks).
(6) If a Consent Agreement is terminated, Life and Disability Controlled
Affiliate shall, unless BCBSA and the Consenting Plan agree in their sole discretion
to a phase out in writing, immediately (i) cease all use of the Licensed Marks,
including in connection with any and all sales and marketing of the Licensed
Products in the Service Area where consent has been terminated, and (ii) notify its
customers that it is no longer a licensee and provide instruction on how the
customer can contact BCBSA or a designated licensee to obtain further information
on securing coverage. The notification required by this paragraph shall be in writing
and in form approved by BCBSA.
2. QUALITY CONTROL
A. Life and Disability Controlled Affiliate agrees to use the Licensed Marks
only in relation to the sale, marketing and administration of the Licensed Products and
further agrees to be bound by the conditions regarding quality control shown in Exhibit A
and the Guidelines to Administer the Standards for Trademark License Agreement for
Life and Disability Insurance Products attached thereto.
B. Life and Disability Controlled Affiliate agrees that BCBSA may, from time-
to-time, upon reasonable notice, review and inspect the manner and method of Life and
Disability Controlled Affiliate's rendering of service and use of the Licensed Marks.
C. Life and Disability Controlled Affiliate agrees that it will provide on an annual
basis (or more often if reasonably required by BCBSA) a report to BCBSA demonstrating
Life and Disability Controlled Affiliate's compliance with the requirements of this Agreement
including but not limited to the quality control provisions of Exhibit A.
D. As used herein, a Life and Disability Controlled Affiliate is defined as: An
entity organized and operated in such a manner that it is 100% owned and controlled by
Sponsoring Plans. Absent written approval by BCBSA of an alternative method of control,
control shall mean the legal authority, directly or indirectly through wholly-owned
subsidiaries: (a) to select members of the Life and Disability Controlled Affiliate's
governing body having not less than 100% voting control thereof; (b) to exercise
operational control with respect to the governance thereof; and (c) to prevent any change
in its articles of
-- 248 of 512 --
3
incorporation, bylaws or other governing documents deemed inappropriate. In addition, a
Sponsoring Plan or Plans shall own at least 100% of any for profit Life and Disability
Controlled Affiliate.
3. SERVICE MARK USE
Life and Disability Controlled Affiliate shall at all times make proper service mark
use of the Licensed Marks and shall ensure all uses of the Licensed Marks comply with
the BCBSA Brand Regulations, as amended by BCBSA from time to time. Life and
Disability Controlled Affiliate recognizes and agrees that all use of the Licensed Marks by
Life and Disability Controlled Affiliate shall inure to the benefit of BCBSA.
4. SUBLICENSING AND ASSIGNMENT
The license hereby granted to Life and Disability Controlled Affiliate to use the
Licensed Marks is and shall be personal to Life and Disability Controlled Affiliate and
shall not be assignable by any act of the Life and
Disability Controlled Affiliate, directly or indirectly, without the written consent of BCBSA.
Said license shall not be assignable by operation of law, nor shall Life and Disability
Controlled Affiliate mortgage or part with possession or control of this license or any right
hereunder, and the Life and Disability Controlled Affiliate shall have no right to grant any
sublicense to use the Licensed Marks.
5. INFRINGEMENTS
Life and Disability Controlled Affiliate shall promptly notify BCBSA of any suspected
acts of infringement, unfair competition or passing off which may occur in relation to the
Licensed Marks. Life and Disability Controlled Affiliate shall not be entitled to require
BCBSA to take any actions or institute any proceedings to prevent infringement, unfair
competition or passing off by third parties. Life and Disability Controlled Affiliate agrees to
render to BCBSA, free of charge, all reasonable assistance in connection with any matter
pertaining to the protection of the Licensed Marks by BCBSA. BCBSA shall have sole
control of the defense and resolution of any claim of infringement brought or threatened by
others.
6. LIABILITY INDEMNIFICATION
Life and Disability Controlled Affiliate hereby agrees to save, defend, indemnify
and hold BCBSA harmless from and against all claims, damages, liabilities and costs of
every kind, nature and description which may arise as a result of Life and Disability
Controlled Affiliate's conduct.
4
-- 249 of 512 --
7. LICENSE TERM
A. The license granted by this Agreement shall remain in effect for a period of
one (1) year and shall be automatically extended for additional one (1) year periods, unless
either BCBSA or Life and Disability Controlled Affiliate notifies the other party in writing of
the termination hereof at least sixty (60) days prior to expiration of any license period.
B. This Agreement may be terminated by BCBSA for cause at any time
provided that Life and Disability Controlled Affiliate has been given a reasonable
opportunity to cure and shall not effect such a cure within thirty (30) days of receiving
written notice of the intent to terminate (or commence a cure within such thirty day period
and continue diligent efforts to complete the cure if such curing cannot reasonably be
completed within such thirty day period). By way of example and not for purposes of
limitation, Life and Disability Controlled Affiliate's failure to abide by the conditions
regarding use of the Licensed Marks set forth in Section 1 of this Agreement or the quality
control provisions of Section 2 (other than with respect to Section 2 D which is subject to
immediate termination as stated in Section 7 C (1) below) shall be considered proper
grounds for termination of this Agreement.
C. This Agreement and all of Life and Disability Controlled Affiliate's rights
hereunder shall immediately terminate without any further action by any party or entity in
the event that:
(1) Life and Disability Controlled Affiliate shall no longer comply
with Section 2 D (or Standard No. 1 (Organization and Governance) of
Exhibit A); or
(2) Any Sponsoring Plan ceases to be authorized to use the Licensed
Marks; or
(3) Appropriate fees for Life and Disability Controlled Affiliate pursuant
to Section 8 of this Agreement are more than sixty (60) days in arrears to BCBSA.
Upon termination of this Agreement for cause or otherwise, Life and Disability
Controlled Affiliate agrees that it shall immediately discontinue all use of the
Licensed Marks.
In the event of any disagreement between Life and Disability Controlled
Affiliate and BCBSA as to whether grounds exist for termination or as to any
other term or condition hereof, the decision of BCBSA shall control, subject to
provisions for mediation or mandatory dispute resolution in effect between the
parties.
5
-- 250 of 512 --
Upon termination of this Agreement, Licensed Life and Disability Controlled Affiliate
shall immediately notify all of its customers that it is no longer a licensee of BCBSA
and provide instruction on how the customer can contact BCBSA or a designated
licensee to obtain further information on securing coverage. The notification required
by this paragraph shall be in writing and in a form approved by BCBSA. BCBSA
shall have the right to audit the terminated entity's books and records to verify
compliance with this paragraph.
8. ROYALTIES
Life and Disability Controlled Affiliate will pay to BCBSA a fee for this license in
accordance with the following formula:
• An annual fee of five thousand dollars ($5,000) per license, plus
• .05% of gross revenue per year from group products sold under the
Licensed Marks, plus
• .5% of gross revenue per year from individual products sold under the
Licensed Marks
In the event that any license period is greater or less than one (1) year, any
amounts due shall be prorated. Royalties under this formula will be calculated, billed and
paid in arrears.
Life and Disability Controlled Affiliate will promptly and timely transmit to BCBSA all
fees owed by Life and Disability Controlled Affiliate as determined by the above formula.
9. JOINT VENTURE
Nothing contained in this Agreement shall be construed as creating a joint
venture, partnership, agency or employment relationship between any Sponsoring Plan
and Life and Disability Controlled Affiliate or between among them and/or BCBSA.
10. VOTING
For all provisions of this Agreement referring to voting, the term ‘Plans’ shall
mean all entities licensed under the Blue Cross License Agreement and/or the Blue Shield
License Agreement, and in all votes of the Plans under this Agreement the Plans shall
vote together. For weighted votes of the Plans, the Plan shall have a number of votes
equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the
number of weighted votes (if any) that it holds as a Blue Shield Plan. For all other votes of
the Plans, the
6
-- 251 of 512 --
Plan shall have one vote. For all questions requiring an affirmative three-fourths weighted
vote of the Plans, the requirement shall be deemed satisfied with a lesser weighted vote
unless the greater of: (i) 6/52 or more of the Plans (rounded to the nearest whole number,
with 0.5 or multiples thereof being rounded to the next higher whole number) fail to cast
weighted votes in favor of the question; or (ii) three (3) of the Plans fail to cast weighted
votes in favor of the question. Notwithstanding the foregoing provision, if there are thirty-
six
(36) Plans, the requirement of an affirmative three-fourths weighted vote shall be
deemed satisfied with a lesser weighted vote unless four (4) or more Plans fail to cast
weighted votes in favor of the question.
11. NOTICES AND CORRESPONDENCE
Notices regarding the subject matter of this Agreement or breach or termination
thereof shall be in writing and shall be addressed in duplicate to the last known address of
each other party, marked respectively to the attention of its President and, if any, its
General Counsel.
12. COMPLETE AGREEMENT
This Agreement contains the complete understandings of the parties in relation to
the subject matter hereof. This Agreement may only be amended by:
(a) a writing signed by all parties; or (b) a writing approved by the affirmative vote of three-
fourths of the Blue Plans and three-fourths of the total then current weighted vote of all the
Blue Plans as officially recorded by the BCBSA Corporate Secretary. Upon such adoption
by the Blue Plans, this Agreement and all other Trademark License Agreements for Life
and Disability Insurance Products then in effect shall simultaneously be amended.
13. SEVERABILITY
If any term of this Agreement is held to be unlawful by a court of competent
jurisdiction, such finding shall in no way affect the remaining obligations of the parties
hereunder and the court may substitute a lawful term or condition for any unlawful term
or condition so long as the effect of such substitution is to provide the parties with the
benefits of this Agreement.
14. NONWAIVER
No waiver by BCBSA of any breach or default in performance on the part of the
Life and Disability Controlled Affiliate or any other licensee of any of the terms, covenants
or conditions of this Agreement shall constitute a waiver of any subsequent breach or
default in performance of said terms, covenants or conditions.
15. GOVERNING LAW
This Agreement shall be governed by, and construed and interpreted in
accordance with, the laws of the State of Illinois.
7
-- 252 of 512 --
IN WITNESS WHEREOF, the parties have caused this License Agreement to be
executed, effective as of the date of last signature written below.
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By: _ Date: _
Life and Disability Controlled Affiliate:
By: _ Date: _
Sponsoring Plan:
By: _ Date: _ Name: Sponsoring Plan:
By: _ Date: _ Name: [Add other Sponsoring Plans
as necessary]
8
-- 253 of 512 --
EXHIBIT A
LICENSE STANDARDS APPLICABLE TO TRADEMARK LICENSE
AGREEMENT FOR LIFE AND DISABILITY INSURANCE PRODUCTS
Page 1 of 2
Standard 1 - Organization and Governance
Any Life and Disability Controlled Affiliate licensed under the Trademark License
Agreement for Life and Disability Insurance Products (“licensee”) shall be organized and
operated in such a manner that it is an entity organized and operated in such a manner
that it is 100% owned and controlled by Sponsoring Plans. Absent written approval by
BCBSA of an alternative method of control, control shall mean the legal authority, directly
or indirectly through wholly-owned subsidiaries: (a) to select members of the Life and
Disability Controlled Affiliate's governing body having not less than 100% voting control
thereof; (b) to exercise operational control with respect to the governance thereof; and (c)
to prevent any change in its articles of incorporation, bylaws or other governing documents
deemed inappropriate. In addition, a Sponsoring Plan or Plans shall own at least 100% of
any for profit Life and Disability Controlled Affiliate.
Standard 2 - State Licensure
The licensee must maintain unimpaired licensure or certificate of authority to operate
under applicable state laws as a life company in each state in which the licensee does
business.
Standard 3 - Records and Examination
The licensee shall maintain and furnish, on a timely and accurate basis, such records and
reports regarding the licensee as may be required in order to establish compliance with the
Agreement. The licensee shall permit BCBSA to examine the affairs of the licensee and
shall agree that BCBSA's board may submit a written report to the chief executive officer(s)
and the board(s) of directors of the Sponsoring Plan(s).
Standard 4 - Mediation
The licensee, its Sponsoring Plan(s) and all consenting Blue Plans shall agree to use the
then-current BCBSA mediation and mandatory dispute resolution processes, in lieu of a
legal action between or among another licensed Life and Disability Controlled Affiliate, a
Sponsoring Plan and or consenting Blue Plan or BCBSA.
1
-- 254 of 512 --
EXHIBIT A
LICENSE STANDARDS APPLICABLE TO TRADEMARK LICENSE
AGREEMENT FOR LIFE AND DISABILITY INSURANCE PRODUCTS
Page 2 of 2
Standard 5 - Financial Responsibility
The licensee shall maintain adequate financial resources to protect its
customers and meet its business obligations.
Standard 6 - Cooperation with BCBSA Governance
The licensee shall cooperate with BCBSA’s Board of Directors and its Brand
Enhancement & Protection Committee in the administration of and in addressing
licensee compliance problems that may be identified in connection with the operation
or administration of the Trademark License Agreement for Life and Disability
Insurance Products.
2
-- 255 of 512 --
EXHIBIT B
CONSENT AGREEMENT
This Consent Agreement is made and entered into by and among the undersigned Blue
Plan, and (“Life and Disability Controlled Affiliate”), and the Blue Cross and Blue Shield
Association (“BCBSA”) and shall be deemed effective on (“Effective Date”).
Whereas, BCBSA owns the Blue Cross and Blue Shield word and design service marks and
any derivative mark thereof (the “Brands”);
Whereas, the undersigned Blue Plan is licensed to use one or more of the Brands within a
specific geographic area (“Service Area”);
Whereas Life and Disability Controlled Affiliate is licensed by BCBSA to use one or more of
the Brands to offer life and disability insurance products (“Products”) as defined and
authorized in the Trademark License Agreement for Life and Disability Insurance Products
(“Life and Disability License Agreement”);
Whereas neither the Blue Plan nor its affiliates offer the Products under any of the Brands in
such Blue Plan’s Service Area or portion thereof where Blue Plan has consented to sale of
the Products by Life and Disability Controlled Affiliate; and
Whereas BCBSA and the undersigned Blue Plan desire to consent to Life and Disability
Controlled Affiliate’s use of the Brands in Blue Plan’s Service Area consistent with the
terms of the Life and Disability License Agreement and this Consent Agreement.
Now, therefore, in consideration of the obligations and conditions stated in this Agreement,
Blue Plan, Life and Disability Controlled Affiliate and BCBSA agree as follows:
1. Life and Disability Controlled Affiliate may market, sell, administer and underwrite the
Products in Blue Plan’s Service Area under the Brands licensed to Blue Plan in such
Service Area subject to the terms of this Consent Agreement, the Life and Disability
License Agreement and Blue Plan’s license agreement(s) with BCBSA. Life and
Disability Controlled Affiliate’s rights under the Brands to offer the Products under the
Brands are limited to offering the Products only under the Brand(s) licensed to the
consenting Blue Plan.
2. Life and Disability Controlled Affiliate shall work with the undersigned Blue Plan to
develop a written sales and marketing agreement that identifies the relationship
between it and Blue Plan for the sales, marketing and customer service for the
Products. The term of the sales and marketing agreement shall be the same as the
term of this Consent Agreement.
1
-- 256 of 512 --
3. All sales, marketing and advertising materials developed by and proposed for use by
Life and Disability Controlled Affiliate in a consenting Blue Plan’s Service Area must
clearly identify the consenting Blue Plan (for example, a statement on such materials
that reads “This product is offered with the cooperation of Blue Cross and/or Blue
Shield of [Geography]”);
4. Life and Disability Controlled Affiliate may use the Brands to sell the Products in the
following Service Area or portion thereof as designated by Blue Plan:
5. If two or more Blue Plans to use the same Licensed Marks in the same Service Area,
Life and Disability Controlled Affiliate shall work with the consenting Blue Plan in the
following manner: (a) the sales, marketing and advertising materials must be
communicated to the consenting Blue Plan’s existing and prospective accounts
through or with the approval of such Blue Plan, and (b) the personnel of such Blue
Plan must actively participate in all sales and marketing activities conducted by Life
and Disability Controlled Affiliate in the same Service Area, including participating in
meetings (whether in-person or via telephone, video or internet conference) with both
existing and prospective accounts of the consenting Blue Plan;
6. Life and Disability Controlled Affiliate shall be entitled to use in a Service Area only
those Licensed Marks that the consenting Blue Plan has been granted by BCBSA
the license to use under its license agreement (for example, if a consenting Blue
Plan is licensed to use only the Blue Cross Marks in its Service Area, the materials
used by Life and Disability Controlled Affiliate in that Service Area may only contain
or reference the Blue Cross Marks and not the Blue Shield Marks).
7. If this Consent Agreement is terminated, Life and Disability Controlled Affiliate shall,
unless each BCBSA and the Blue Plan agree in their sole discretion to a phase out in
writing, immediately (i) cease all use of the Licensed Marks, including in connection
with any and all sales and marketing of the Licensed Products in the Service Area
where consent has been terminated, and (ii) notify its customers that it is no longer a
licensee of BCBSA and provide instruction on how the customer can contact BCBSA
or a designated licensee to obtain further information on securing coverage. The
notification required by this paragraph shall be in writing and in form approved by
BCBSA.
2
-- 257 of 512 --
8. The term of this Consent Agreement shall be one year from the Effective Date.
Unless either Blue Plan or Life and Disability Controlled Affiliate provides the other
party with written notice of its desire not to renew this Consent Agreement at least 60
days prior to expiration of the term or any extended term or unless terminated as
provided in Paragraph 9 below, this Consent Agreement shall automatically renew for
subsequent one year periods.
9. This Consent Agreement may be terminated as follows:
a. Upon mutual written consent of Life and Disability Controlled Affiliate and Blue
Plan;
b. By Blue Plan or Life and Disability Controlled Affiliate upon 60 days advance
written notice to the non-terminating party and BCBSA; or
c. By Blue Plan immediately if Life and Disability Controlled Affiliate does not
comply with this Consent Agreement or the sales protocol agreement.
10. This Consent Agreement shall automatically terminate if Blue Plan’s primary
licensee agreement terminates for any reason or if the Life and Disability License
Agreement terminates for any reason.
Agreed and Accepted by: [Blue
Plan]:
By:
Title:
BLUE CROSS AND BLUE SHIELD ASSOCIATION:
By:
Title:
LIFE AND DISABILITY CONTROLLED AFFILIATE:
By:
Title:
3
-- 258 of 512 --
Exhibit 1B
BLUE CROSS
CONTROLLED AFFILIATE LICENSE AGREEMENT APPLICABLE TO
REGIONAL MEDICARE ADVANTAGE PPO PRODUCTS
(Adopted by Member Plans at their September 17, 2020 meeting)
This Agreement by and among Blue Cross and Blue Shield Association ("BCBSA")
and (“Controlled Affiliate"), a Controlled Affiliate of the Blue
WHEREAS, BCBSA is the owner of the BLUE CROSS and BLUE CROSS Design
service marks;
WHEREAS, under the Medicare Modernization Act, companies may apply to and be
awarded a contract by the Centers for Medicare and Medicaid Services (“CMS”) to offer
Medicare Advantage PPO products in geographic regions designated by CMS (hereafter
“regional MAPPO products”).
WHEREAS, some of the CMS-designated regions include the Service Areas, or
portions thereof, of more than one Plan.
WHEREAS, the Controlling Plans and Controlled Affiliate desire that the latter be
entitled to use the BLUE CROSS and BLUE CROSS Design service marks (collectively the
"Licensed Marks") as service marks and be entitled to use the term BLUE CROSS in a trade
name ("Licensed Name") to offer regional MAPPO products in a region that includes the
Service Areas, or portions thereof, of more than one Controlling Plan;
NOW THEREFORE, in consideration of the foregoing and the mutual agreements
hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereby agree as follows:
1. GRANT OF LICENSE
Subject to the terms and conditions of this Agreement, BCBSA hereby grants to
Controlled Affiliate the right to use the Licensed Marks and Name in connection with, and only
in connection with the sale, marketing and administration of regional MAPPO products and
related services.
This grant of rights is non-exclusive and is limited to the following states:
(the “Region”). Controlled Affiliate may use the Licensed
-1-
-- 259 of 512 --
Marks and Name in its legal name on the following conditions: (i) the legal name must be
approved in advance, in writing, by BCBSA; (ii) Controlled Affiliate shall not do business outside
the Region under any name or mark except business conducted in the Service Area of a
Controlling Plan provided that Controlled Affiliate is separately licensed by BCBSA to use the
Licensed Marks and Name in connection with health care plans and related services in the
Service Area of such Controlling Plan; and (iii) Controlled Affiliate shall not use the Licensed
Marks and Name, or any derivative thereof, as part of any name or symbol used to identify itself
in any securities market. Controlled Affiliate may use the Licensed Marks and Name in its
Trade Name only with the prior, written, consent of BCBSA.
2. QUALITY CONTROL
A. Controlled Affiliate agrees to use the Licensed Marks and Name only in connection
with the licensed services and further agrees to be bound by the conditions regarding quality
control shown in attached Exhibit A as they may be amended by BCBSA from time-to-time.
B. Controlled Affiliate agrees to comply with all applicable federal, state and local
laws.
C. Controlled Affiliate agrees that it will provide on an annual basis (or more often if
reasonably required by the Controlling Plans or by BCBSA) a report or reports to the
Controlling Plans and BCBSA demonstrating Controlled Affiliate's compliance with the
requirements of this Agreement including but not limited to the quality control provisions of this
paragraph and the attached Exhibit A.
D. Controlled Affiliate agrees that the Controlling Plans and/or BCBSA may, from time-
to-time, upon reasonable notice, review and inspect the manner and method of Controlled
Affiliate's rendering of service and use of the Licensed Marks and Name.
E. As used herein, a Controlled Affiliate is defined as an entity organized and
operated in such a manner, that it meets the following requirements:
(1) Controlled Affiliate is owned or controlled by two or more Controlling
Plans;
(2) Each Controlling Plan is authorized pursuant to a separate Blue Cross License
Agreement to use the Licensed Marks in a geographic area in the
Region and every geographic area in the Region is so licensed to at least one of the
Controlling Plans; and
-2-
-- 260 of 512 --
(3) The Controlling Plans must have the legal authority directly or indirectly
through wholly-owned subsidiaries:
(a) to select members of the Controlled Affiliate’s governing body having not less than
100% voting control thereof;
(b) to prevent any change in the articles of incorporation, bylaws or other establishing
or governing documents of the Controlled Affiliate with which the Controlling Plans do not
concur;
(c) to exercise control over the policy and operations of the Controlled Affiliate; and
Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate’s
establishing or governing documents must also require written approval by each of the
Controlling Plans before the Controlled Affiliate can:
(i) change its legal and/or trade names;
(ii) change the geographic area in which it operates (except
such approval shall not be required with respect to
business of the Controlled Affiliate conducted under the
Licensed Marks within the Service Area of one of the
Controlling Plans pursuant to a separate controlled affiliate
license agreement with BCBSA sponsored by such
Controlling Plan);
(iii) change any of the type(s) of businesses in which it engages
(except such approval shall not be required with respect to
business of the Controlled Affiliate conducted under the
Licensed Marks within the Service Area of one of the
Controlling Plans pursuant to a separate controlled affiliate
license agreement with BCBSA sponsored by such
Controlling Plan);
(iv) take any action that any Controlling Plan or BCBSA
reasonably believes will adversely affect the Licensed
Marks and Name.
In addition, the Controlling Plans directly or indirectly through wholly owned
subsidiaries shall own 100% of any for-profit Controlled Affiliate.
-3-
-- 261 of 512 --
3. SERVICE MARK USE
A. Controlled Affiliate recognizes the importance of a comprehensive national
network of independent BCBSA licensees which are committed to strengthening the
Licensed Marks and Name. The Controlled Affiliate further recognizes that its actions within
the Region may affect the value of the Licensed Marks and Name nationwide.
B. Controlled Affiliate shall at all times make proper service mark use of the Licensed
Marks and Name, including but not limited to use of such symbols or words as BCBSA shall
specify to protect the Licensed Marks and Name and shall comply with such rules (generally
applicable to Controlled Affiliates licensed to use the Licensed Marks and Name) relative to
service mark use, as are issued from time-to-time by BCBSA. Controlled Affiliate recognizes
and agrees that all use of the Licensed Marks and Name by Controlled Affiliate shall inure to
the benefit of BCBSA.
C. Controlled Affiliate may not directly or indirectly use the Licensed Marks and Name
in a manner that transfers or is intended to transfer in the Region the goodwill associated
therewith to another mark or name, nor may Controlled Affiliate engage in activity that may
dilute or tarnish the unique value of the Licensed Marks and Name.
D. Controlled Affiliate shall use its best efforts to promote and build the value of the
Licensed Marks and Name in connection with the sale, marketing and administration of
regional MAPPO products and related services.
4. SUBLICENSING AND ASSIGNMENT
Controlled Affiliate shall not, directly or indirectly, sublicense, transfer, hypothecate, sell,
encumber or mortgage, by operation of law or otherwise, the rights granted hereunder and any
such act shall be voidable at the sole option of any Controlling Plan or BCBSA. This Agreement
and all rights and duties hereunder are personal to Controlled Affiliate.
-4-
-- 262 of 512 --
5. INFRINGEMENT
Controlled Affiliate shall promptly notify the Controlling Plans and the Controlling Plans
shall promptly notify BCBSA of any suspected acts of infringement, unfair competition or
passing off that may occur in relation to the Licensed Marks and Name. Controlled Affiliate
shall not be entitled to require the Controlling Plans or BCBSA to take any actions or institute
any proceedings to prevent infringement, unfair competition or passing off by third parties.
Controlled Affiliate agrees to render to the Controlling Plans and BCBSA, without charge, all
reasonable assistance in connection with any matter pertaining to the protection of the
Licensed Marks and Name by BCBSA.
6. LIABILITY INDEMNIFICATION
Controlled Affiliate and the Controlling Plans hereby agree to save, defend, indemnify
and hold BCBSA harmless from and against all claims, damages, liabilities and costs of every
kind, nature and description (except those arising solely as a result of BCBSA's negligence)
that may arise as a result of or related to Controlled Affiliate's rendering of services under the
Licensed Marks and Name.
7. LICENSE TERM
A. Except as otherwise provided herein, the license granted by this Agreement
shall remain in effect for a period of one (1) year and shall be automatically extended for
additional one (1) year periods unless terminated pursuant to the provisions herein.
B. This Agreement and all of Controlled Affiliate's rights hereunder shall immediately
terminate without any further action by any party or entity in the event that: (i) any one of the
Controlling Plans ceases to be authorized to use the Licensed Marks and Name; or (ii)
pursuant to Paragraph 15(a)(x) of the Blue Cross License Agreement any one of the
Controlling Plans ceases to be authorized to use the Licensed Names and Marks in the
Region.
C. Notwithstanding any other provision of this Agreement, this license to use the
Licensed Marks and Name may be forthwith terminated by the Controlling Plans or the
affirmative vote of the majority of the Board of Directors of BCBSA present and voting at a
special meeting expressly called by BCBSA for the purpose on ten (10) days written notice to
the Controlling Plans advising of the specific matters at issue and granting the Controlling
Plans an opportunity to be heard and to present their response to the Board for: (1) failure to
comply with any applicable minimum capital or liquidity requirement under the quality control
standards of this
-5-
-- 263 of 512 --
Agreement; or (2) failure to comply with the "Organization and Governance" quality control
standard of this Agreement; or (3) impending financial insolvency; or
1. failure to comply with any of the applicable requirements of Standards 2, 3, 4, or 5 of
attached Exhibit A; or (5) the pendency of any action instituted against the Controlled Affiliate
seeking its dissolution or liquidation of its assets or seeking appointment of a trustee, interim
trustee, receiver or other custodian for any of its property or business or seeking the
declaration or establishment of a trust for any of its property or business, unless this Controlled
Affiliate License Agreement has been earlier terminated under paragraph 7(E); or (6) such
other reason as is determined in good faith immediately and irreparably to threaten the integrity
and reputation of BCBSA, the Plans (including the Controlling Plans), any other licensee
including Controlled Affiliate and/or the Licensed Marks and Name.
D. Except as otherwise provided in Paragraphs 7(B), 7(C) or 7(E) herein, should
Controlled Affiliate fail to comply with the provisions of this Agreement and not cure such failure
within thirty (30) days of receiving written notice thereof (or commence a cure within such thirty
day period and continue diligent efforts to complete the cure if such curing cannot reasonably
be completed within such thirty day period) BCBSA or the Controlling Plans shall have the right
to issue a notice that the Controlled Affiliate is in a state of noncompliance. If a state of
noncompliance as aforesaid is undisputed by the Controlled Affiliate or is found to exist by a
mandatory dispute resolution panel and is uncured as provided above, BCBSA shall have the
right to seek judicial enforcement of the Agreement or to issue a notice of termination thereof.
Notwithstanding any other provisions of this Agreement, any disputes as to the termination of
this License pursuant to Paragraphs 7(B), 7(C) or 7(E) of this Agreement shall not be subject to
mediation and mandatory dispute resolution. All other disputes between or among BCBSA, any
of the Controlling Plans and/or Controlled Affiliate shall be submitted promptly to mediation and
mandatory dispute resolution. The mandatory dispute resolution panel shall have authority to
issue orders for specific performance and assess monetary penalties. Except, however, as
provided in Paragraphs 7(B) and 7(E) of this Agreement, this license to use the Licensed Marks
and Name may not be finally terminated for any reason without the affirmative vote of a
majority of the present and voting members of the Board of Directors of BCBSA.
E. This Agreement and all of Controlled Affiliate's rights hereunder shall immediately
terminate without any further action by any party or entity in the event that:
(1) Controlled Affiliate shall no longer comply with item 2(E) above;
(2) Appropriate dues, royalties and other payments for Controlled Affiliate
pursuant to paragraph 9 hereof, which are the royalties for this License Agreement, are
more than sixty (60) days in arrears to BCBSA; or
-6-
-- 264 of 512 --
(3) Any of the following events occur: (i) a voluntary petition shall be filed by Controlled
Affiliate seeking bankruptcy, reorganization, arrangement with creditors or other relief under the
bankruptcy laws of the United States or any other law governing insolvency or debtor relief, or
(ii) an involuntary petition or proceeding shall be filed against Controlled Affiliate seeking
bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy
laws of the United States or any other law governing insolvency or debtor relief and such
petition or proceeding is consented to or acquiesced in by Controlled Affiliate or is not
dismissed within sixty (60) days of the date upon which the petition or other document
commencing the proceeding is served upon the Controlled Affiliate, or (iii) an order for relief is
entered against Controlled Affiliate in any case under the bankruptcy laws of the United States,
or Controlled Affiliate is adjudged bankrupt or insolvent as those terms are defined in the
Uniform Commercial Code as enacted in the State of Illinois by any court of competent
jurisdiction, or (iv) Controlled Affiliate makes a general assignment of its assets for the benefit
of creditors, or (v) any government or any government official, office, agency, branch, or unit
assumes control of Controlled Affiliate or delinquency proceedings (voluntary or involuntary)
are instituted, or (vi) an action is brought by Controlled Affiliate seeking its dissolution or
liquidation of its assets or seeking the appointment of a trustee, interim trustee, receiver or
other custodian for any of its property or business, or (vii) an action is instituted by any
governmental entity or officer against Controlled Affiliate seeking its dissolution or liquidation of
its assets or seeking the appointment of a trustee, interim trustee, receiver or other custodian
for any of its property or business and such action is consented to or acquiesced in by
Controlled Affiliate or is not dismissed within one hundred thirty (130) days of the date upon
which the pleading or other document commencing the action is served upon the Controlled
Affiliate, provided that if the action is stayed or its prosecution is enjoined, the one hundred
thirty (130) day period is tolled for the duration of the stay or injunction, and provided further,
that the Association’s Board of Directors may toll or extend the 130 day period at any time prior
to its expiration, or (viii) a trustee, interim trustee, receiver or other custodian for any of
Controlled Affiliate's property or business is appointed or the Controlled Affiliate is ordered
dissolved or liquidated. Notwithstanding any other provision of this Agreement, a declaration or
a request for declaration of the existence of a trust over any of the Controlled Affiliate’s
property or business shall not in itself be deemed to constitute or seek appointment of a
trustee, interim trustee, receiver or other custodian for purposes of subparagraphs 7(E)(3)(vii)
and
(viii) of this Agreement.
F. Upon termination of this Agreement for cause or otherwise, Controlled Affiliate
agrees that it shall immediately discontinue all use of the Licensed Marks and Name, including
any use in its trade name, except to the extent that it continues to be authorized to use the
Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate
controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan.
7
-- 265 of 512 --
G. Upon termination of this Agreement, Controlled Affiliate shall immediately notify all
of its customers to whom it provides products or services under the Licensed Marks pursuant
to this Agreement that it is no longer a licensee of BCBSA and, if directed by the Association’s
Board of Directors, shall provide instruction on how the customer can contact BCBSA or a
designated licensee to obtain further information on securing coverage. The notification
required by this paragraph shall be in writing and in a form approved by BCBSA. The BCBSA
shall have the right to audit the terminated entity's books and records to verify compliance with
this paragraph.
H. In the event this Agreement terminates pursuant to 7(B) hereof, upon termination of
this Agreement the provisions of Paragraph 7(G) shall not apply and the following provisions
shall apply, except that, in the event that Controlled Affiliate is separately licensed by BCBSA
to use the Licensed Marks in the Service Area of a Controlling Plan and termination of this
Agreement is due to a partial termination of such Controlling Plan’s license pursuant to
Paragraph 15(a)(x)(ii) of the Blue Cross License Agreement, the notices, national account
listing, payment, and audit right listed below shall be applicable solely with respect to the
Region and the geographic area for which the Controlling Plan’s license to use the Licensed
Names and Marks is terminated:
(1) The Controlled Affiliate shall send a notice through the U.S. mails, with first
class postage affixed, to all individual and group customers,
providers, brokers and agents of products or services sold, marketed, underwritten or
administered by the Controlled Affiliate under the Licensed Marks and Name.
The form and content of the notice shall be specified by BCBSA and shall, at a minimum,
notify the recipient of the termination of the license, the consequences thereof, and
instructions for obtaining alternate products or services licensed by BCBSA. This notice
shall be mailed within 15 days after termination.
(2) The Controlled Affiliate shall deliver to BCBSA within five days
of a request by BCBSA a listing of national accounts in which the Controlled Affiliate is
involved (in a control, participating or servicing capacity), identifying the national account and
the Controlled Affiliate’s role therein.
(3) Unless the cause of termination is an event respecting BCBSA
stated in paragraph 15(a) or (b) of the Plan’s license agreement with BCBSA to use the
Licensed Marks and Name, the Controlled Affiliate, the Controlling Plans, and any other
Licensed Controlled Affiliates of the Controlling Plans shall be jointly liable for payment to
BCBSA of an amount equal to $25 multiplied by the number of Licensed Enrollees of the
Controlled Affiliate; provided that if any Plan other than a Controlling Plan is permitted by
BCBSA to use marks or names licensed by BCBSA in a geographic area in the Region, the
payment for Licensed Enrollees in such geographic area shall be multiplied by a fraction, the
numerator of which is the number of Licensed Enrollees of the Controlled Affiliate, the
Controlling Plans, and
8
-- 266 of 512 --
any other Licensed Controlled Affiliates of the Controlling Plans in such geographic area and
the denominator of which is the total number of Licensed Enrollees in such geographic area.
Licensed Enrollee means each and every person and covered dependent who is enrolled as
an individual or member of a group receiving products or services sold, marketed or
administered under marks or names licensed by BCBSA as determined at the earlier of (i) the
end of the last fiscal year of the terminated entity which ended prior to termination or (ii) the
fiscal year which ended before any transactions causing the termination began.
Notwithstanding the foregoing, the amount payable pursuant to this subparagraph H. (3) shall
be due only to the extent that, in BCBSA’s opinion, it does not cause the net worth of the
Controlled Affiliate, the Controlling Plans or any other Licensed Controlled Affiliates of the
Controlling Plans to fall below 100% of the Health Risk-Based Capital formula, or its equivalent
under any successor formula, as set forth in the applicable financial responsibility standards
established by BCBSA (provided such equivalent is approved for purposes of this
subparagraph by the affirmative vote of three-fourths of the Plans and three-fourths of the total
then current weighted vote of all the Plans); measured as of the date of termination, and
adjusted for the value of any transactions not made in the ordinary course of business. This
payment shall not be due in connection with transactions exclusively by or among Plans
(including the Controlling Plans) or their affiliates, including reorganizations, combinations or
mergers, where the BCBSA Board of Directors determines that the license termination does
not result in a material diminution in the number of Licensed Enrollees or the extent of their
coverage. In the event that the Controlled Affiliate’s license is reinstated by BCBSA or is
deemed to have remained in effect without interruption by a court of competent jurisdiction,
BCBSA shall reimburse the Controlled Affiliate (and/or the Controlling Plans or their other
Licensed Controlled Affiliates, as the case may be) for payments made under this
subparagraph 7.H.(3) only to the extent that such payments exceed the amounts due to
BCBSA pursuant to paragraph 7.K. and any costs associated with reestablishing the
terminated Controlling Plan’s Service Area or the Region, including any payments made by
BCBSA to a Plan or Plans (including the other Controlling Plans), or their Licensed Controlled
Affiliates, for purposes of replacing the Controlled Affiliate.
(4) BCBSA shall have the right to audit the books and records of
the Controlled Affiliate, the Controlling Plans, and any other Licensed Controlled Affiliates
of the Controlling Plans to verify compliance with this paragraph 7.H.
(5) As to a breach of 7.H.(1), (2), (3) or (4), the parties agree that
the obligations are immediately enforceable in a court of competent jurisdiction. As to a
breach of 7.H.(1), (2) or (4) by the Controlled Affiliate, the parties agree there is no adequate
remedy at law and BCBSA is entitled to obtain specific performance.
-9-
-- 267 of 512 --
I. BCBSA shall be entitled to enjoin the Controlled Affiliate or any related party in a
court of competent jurisdiction from entry into any transaction which would result in a
termination of this Agreement unless a Controlling Plan’s license from BCBSA to use the
Licensed Marks and Names has been terminated pursuant to 10(d) of such Controlling Plan’s
license agreement upon the required 6 month written notice.
J. BCBSA acknowledges that it is not the owner of assets of the Controlled
Affiliate.
K. In the event this Agreement terminates and is subsequently reinstated by BCBSA or
is deemed to have remained in effect without interruption by a court of competent jurisdiction,
the Controlled Affiliate, the Controlling Plans, and any other Licensed Controlled Affiliates of
the Controlling Plans shall be jointly liable for reimbursing BCBSA the reasonable costs
incurred by BCBSA in connection with the termination and the reinstatement or court action,
and any associated legal proceedings, including but not limited to: outside legal fees,
consulting fees, public relations fees, advertising costs, and costs incurred to develop, lease or
establish an interim provider network. Any amount due to BCBSA under this subparagraph
may be waived in whole or in part by the BCBSA Board of Directors in its sole discretion.
8. DISPUTE RESOLUTION
The parties agree that any disputes between or among them or between or among any
of them and one or more Plans or Controlled Affiliates of Plans that use in any manner the
Blue Cross and Blue Cross Marks and Name are subject to the Mediation and Mandatory
Dispute Resolution process attached to and made a part of each Controlling Plan’s License
from BCBSA to use the Licensed Marks and Name as Exhibit 5 as amended from time-to-
time, which documents are incorporated herein by reference as though fully set forth herein.
9. LICENSE FEE
Controlled Affiliate will pay to BCBSA a fee for this License determined pursuant
to the formula(s) set forth in Exhibit B.
10. JOINT VENTURE
Nothing contained in this Agreement shall be construed as creating a joint venture,
partnership, agency or employment relationship between the Controlling Plans and
Controlled Affiliate or between either and BCBSA.
11. NOTICES AND CORRESPONDENCE
Notices regarding the subject matter of this Agreement or breach or termination thereof
shall be in writing and shall be addressed in duplicate to the last
10
-- 268 of 512 --
known address of each other party, marked respectively to the attention of its President
and, if any, its General Counsel.
12. COMPLETE AGREEMENT
This Agreement contains the complete understandings of the parties in relation to the
subject matter hereof. This Agreement may only be amended by the affirmative vote of three-
fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans as
officially recorded by the BCBSA Corporate Secretary.
13. SEVERABILITY
If any term of this Agreement is held to be unlawful by a court of competent jurisdiction,
such findings shall in no way affect the remaining obligations of the parties hereunder and the
court may substitute a lawful term or condition for any unlawful term or condition so long as
the effect of such substitution is to provide the parties with the benefits of this Agreement.
14. NONWAIVER
No waiver by BCBSA of any breach or default in performance on the part of Controlled
Affiliate or any other licensee of any of the terms, covenants or conditions of this Agreement
shall constitute a waiver of any subsequent breach or default in performance of said terms,
covenants or conditions.
14A. VOTING
For all provisions of this Agreement referring to voting, the term ‘Plans’ shall mean all
entities licensed under the Blue Cross License Agreement and/or the Blue Shield License
Agreement, and in all votes of the Plans under this Agreement the Plans shall vote together.
For weighted votes of the Plans, the Plan shall have a number of votes equal to the number of
weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes
(if any) that it holds as a Blue Shield Plan. For all other votes of the Plans, the Plan shall have
one vote. For all questions requiring an affirmative three-fourths weighted vote of the Plans,
the requirement shall be deemed satisfied with a lesser weighted vote unless the greater of:
(i) 6/52 or more of the Plans (rounded to the nearest whole number, with
0.5 or multiples thereof being rounded to the next higher whole number) fail to cast weighted
votes in favor of the question; or (ii) three (3) of the Plans fail to cast weighted votes in favor
of the question. Notwithstanding the foregoing provision, if there are thirty-six (36) Plans, the
requirement of an affirmative three-fourths weighted vote shall be deemed satisfied with a
lesser weighted vote unless four (4) or more Plans fail to cast weighted votes in favor of the
question.
11
-- 269 of 512 --
15. GOVERNING LAW
This Agreement shall be governed by, and construed and interpreted in
accordance with, the laws of the State of Illinois.
16. HEADINGS
The headings inserted in this agreement are for convenience only and shall have no
bearing on the interpretation hereof.
12
-- 270 of 512 --
IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed
and effective as of the date of last signature written below.
Controlled Affiliate:
By:
Date:
Controlling Plan:
By:
Date:
Controlling Plan:
By:
Date:
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By:
Date:
13
-- 271 of 512 --
EXHIBIT A
CONTROLLED AFFILIATE LICENSE STANDARDS
APPLICABLE TO REGIONAL MEDICARE ADVANTAGE PPO
PRODUCTS
September 2020
PREAMBLE
The standards for licensing Controlled Affiliates for Medicare Advantage PPO Products are
established by BCBSA and are subject to change from time-to-time upon the affirmative vote of
three-fourths (3/4) of the Plans and three-fourths (3/4) of the total weighted vote. Each
Controlling Plan is required to use a standard Controlled Affiliate license form provided by
BCBSA and to cooperate fully in assuring that the licensed Controlled Affiliate maintains
compliance with the license standards.
Standard 1 - Organization and Governance
A Controlled Affiliate is defined as an entity organized and operated in such a manner,
that it meets the following requirements:
(1) Controlled Affiliate is owned or controlled by two or more Controlling
Plans;
(2) Each Controlling Plan is authorized pursuant to a separate Blue Cross License
Agreement to use the Licensed Marks in a geographic area in the Region and every
geographic area in the Region is so licensed to at least one of the Controlling Plans; and
(3) The Controlling Plans must have the legal authority directly or indirectly through
wholly-owned subsidiaries:
(a) to select members of the Controlled Affiliate’s governing body having
not less than 100% voting control thereof;
(b) prevent any change in the articles of incorporation, bylaws or other
establishing or governing documents of the Controlled Affiliate with
which the Controlling Plans do not concur;
(c) exercise control over the policy and operations of the Controlled Affiliate;
and
1
-- 272 of 512 --
EXHIBIT A (continued)
Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate’s
establishing or governing documents must also require written approval by each of the
Controlling Plans before the Controlled Affiliate can:
(i) change its legal and/or trade names;
(ii) change the geographic area in which it operates (except such
approval shall not be required with respect to business of the
Controlled Affiliate conducted under the Licensed Marks within the
Service Area of one of the Controlling Plans pursuant to a
separate controlled affiliate license agreement with BCBSA
sponsored by such Controlling Plan);
(iii) change any of the type(s) of businesses in which it engages (except
such approval shall not be required with respect to business of the
Controlled Affiliate conducted under the Licensed Marks within the
Service Area of one of the Controlling Plans pursuant to a separate
controlled affiliate license agreement with BCBSA sponsored by
such Controlling Plan);
(iv) take any action that any Controlling Plan or BCBSA reasonably
believes will adversely affect the Licensed Marks and Name.
In addition, the Controlling Plans directly or indirectly through wholly owned
subsidiaries shall own 100% of any for-profit Controlled Affiliate.
Standard 2 - Financial Responsibility
A Controlled Affiliate shall be operated in a manner that provides reasonable financial
assurance that it can fulfill all of its contractual obligations to its customers.
Standard 3 - State Licensure/Certification
A Controlled Affiliate shall maintain appropriate and unimpaired licensure and
certifications.
2
-- 273 of 512 --
EXHIBIT A (continued)
Standard 4 - Certain Disclosures
A Controlled Affiliate shall make adequate disclosure in contracting with third parties
and in disseminating public statements of:
a. the structure of the Blue Cross and Blue Shield System; and
b. the independent nature of every licensee.
Standard 5 - Reports and Records for Controlled Affiliates
A Controlled Affiliate and/or its Controlling Plans shall furnish, on a timely and accurate
basis, reports and records relating to these Standards and the License Agreements between
BCBSA and Controlled Affiliate.
Standard 6 - Best Efforts
During each year, a Controlled Affiliate shall use its best efforts to promote and build
the value of the Blue Cross Marks.
Standard 7 - Participation in Certain National Programs
A Controlled Affiliate shall effectively and efficiently participate in certain national
programs from time to time as may be adopted by Member Plans for the purposes of
providing ease of claims processing for customers receiving benefits outside of the
Controlled Affiliate’s service area.
National program requirements include:
a. Inter-Plan Teleprocessing System (ITS); and
b. Inter-Plan Medicare Advantage Program.
Standard 8 - Participation in Master Business Associate Agreement
Controlled Affiliates shall comply with the terms of the Business Associate Agreement
for Blue Cross and Blue Shield Licensees to the extent they perform the functions of a
business associate or subcontractor to a business associate, as defined by the Business
Associate Agreement.
Amended as of November 15, 2007
3
-- 274 of 512 --
EXHIBIT B
ROYALTY FORMULA FOR SECTION 9 OF THE CONTROLLED
AFFILIATE LICENSE AGREEMENTS
APPLICABLE TO REGIONAL MEDICARE ADVANTAGE PPO PRODUCTS
Controlled Affiliate will pay BCBSA a fee for this license in accordance with the following
formula:
An amount equal to its pro rata share of each Controlling Plan dues payable to BCBSA
computed with the addition of the Controlled Affiliate's members using the Marks on
regional MAPPO products and related services as reported on the Quarterly Enrollment
Report with BCBSA. The payment by each Controlling Plan of its dues to BCBSA,
including that portion described in this paragraph, will satisfy the requirement of this
paragraph, and no separate payment will be necessary.
Amended as of June 14, 2007
4
-- 275 of 512 --
Exhibit 1C
BLUE CROSS
CONTROLLED AFFILIATE LICENSE AGREEMENT
APPLICABLE TO REGIONAL MEDICARE PART D PRESCRIPTION DRUG PLAN
PRODUCTS
(Adopted by Member Plans at their September 17, 2020 meeting)
This Agreement by and among Blue Cross and Blue Shield Association ("BCBSA")
and (“Controlled Affiliate"), a Controlled Affiliate of the Blue Cross Plan(s), known as
_______ ("Controlling Plans"), each of which is also a Party signatory hereto.
WHEREAS, BCBSA is the owner of the BLUE CROSS and BLUE CROSS Design
service marks;
WHEREAS, under the Medicare Modernization Act, companies may apply to and be
awarded a contract by the Centers for Medicare and Medicaid Services (“CMS”) to offer
Medicare Part D Prescription Drug Plan products in geographic regions designated by CMS
(hereafter “regional PDP products).”
WHEREAS, some of the CMS-designated regions include the Service Areas, or
portions thereof, of more than one Plan.
WHEREAS, the Controlling Plans and Controlled Affiliate desire that the latter be
entitled to use the BLUE CROSS and BLUE CROSS Design service marks (collectively the
"Licensed Marks") as service marks and be entitled to use the term BLUE CROSS in a trade
name ("Licensed Name") to offer regional PDP products in a region that includes the Service
Areas, or portions thereof, of more than one Controlling Plan;
NOW THEREFORE, in consideration of the foregoing and the mutual agreements
hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereby agree as follows:
1. GRANT OF LICENSE
Subject to the terms and conditions of this Agreement, BCBSA hereby grants to
Controlled Affiliate the right to use the Licensed Marks and Name in connection with, and only
in connection with the sale, marketing and administration of regional PDP products and related
services.
This grant of rights is non-exclusive and is limited to the following states:
(the “Region”). Controlled Affiliate may use the Licensed
-1-
-- 276 of 512 --
Marks and Name in its legal name on the following conditions: (i) the legal name must be
approved in advance, in writing, by BCBSA; (ii) Controlled Affiliate shall not do business
outside the Region under any name or mark except business conducted in the Service
Area of a Controlling Plan provided that Controlled Affiliate is separately licensed by
BCBSA to use the Licensed Marks and Name in connection with health care plans and
related services in the Service Area of such Controlling Plan; and (iii) Controlled Affiliate
shall not use the Licensed Marks and Name, or any derivative thereof, as part of any
name or symbol used to identify itself in any securities market. Controlled Affiliate may
use the Licensed Marks and Name in its Trade Name only with the prior, written,
consent of BCBSA.
2. QUALITY CONTROL
A. Controlled Affiliate agrees to use the Licensed Marks and Name only in connection
with the licensed services and further agrees to be bound by the conditions regarding quality
control shown in attached Exhibit A as they may be amended by BCBSA from time-to-time.
B. Controlled Affiliate agrees to comply with all applicable federal, state and local
laws.
C. Controlled Affiliate agrees that it will provide on an annual basis (or more often if
reasonably required by the Controlling Plans or by BCBSA) a report or reports to the
Controlling Plans and BCBSA demonstrating Controlled Affiliate's compliance with the
requirements of this Agreement including but not limited to the quality control provisions of this
paragraph and the attached Exhibit A.
D. Controlled Affiliate agrees that the Controlling Plans and/or BCBSA may, from time-
to-time, upon reasonable notice, review and inspect the manner and method of Controlled
Affiliate's rendering of service and use of the Licensed Marks and Name.
E. As used herein, a Controlled Affiliate is defined as an entity organized and
operated in such a manner, that it meets the following requirements:
(1) Controlled Affiliate is owned or controlled by two or more Controlling
Plans;
(2) Each Controlling Plan is authorized pursuant to a separate Blue Cross License
Agreement to use the Licensed Marks in a geographic area in the
Region and every geographic area in the Region is so licensed to at least one of the
Controlling Plans; and
-2-
-- 277 of 512 --
(3) The Controlling Plans must have the legal authority directly or indirectly through
wholly-owned subsidiaries:
(a) to select members of the Controlled Affiliate’s governing Body having
not less than 100% voting control thereof;
(b) to prevent any change in the articles of incorporation,
bylaws or other establishing or governing documents of the Controlled Affiliate with which the
Controlling Plans do not concur;
(c) to exercise control over the policy and operations of the
Controlled Affiliate; and
Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate’s
establishing or governing documents must also require written approval by each of the
Controlling Plans before the Controlled Affiliate can:
(i)change its legal and/or trade names;
(ii)change the geographic area in which it operates
(except such approval shall not be required with respect to business of the Controlled
Affiliate conducted under the Licensed Marks within the Service Area of one of the
Controlling Plans pursuant to a separate controlled affiliate license agreement with
BCBSA sponsored by such Controlling Plan);
(iii) change any of the type(s) of businesses in which it engages (except
such approval shall not be required with respect to business of the Controlled Affiliate
conducted under the Licensed Marks within the Service Area of one of the Controlling
Plans pursuant to a separate controlled affiliate license agreement with BCBSA
sponsored by such Controlling Plan);
(iv) take any action that any Controlling Plan or BCBSA reasonably
believes will adversely affect the Licensed Marks and Name.
In addition, the Controlling Plans directly or indirectly through wholly-owned
subsidiaries shall own 100% of any for-profit Controlled Affiliate.
-3-
-- 278 of 512 --
3. SERVICE MARK USE
A. Controlled Affiliate recognizes the importance of a comprehensive national
network of independent BCBSA licensees which are committed to strengthening the
Licensed Marks and Name. The Controlled Affiliate further recognizes that its actions within
the Region may affect the value of the Licensed Marks and Name nationwide.
B. Controlled Affiliate shall at all times make proper service mark use of the Licensed
Marks and Name, including but not limited to use of such symbols or words as BCBSA shall
specify to protect the Licensed Marks and Name and shall comply with such rules (generally
applicable to Controlled Affiliates licensed to use the Licensed Marks and Name) relative to
service mark use, as are issued from time-to-time by BCBSA. Controlled Affiliate recognizes
and agrees that all use of the Licensed Marks and Name by Controlled Affiliate shall inure to
the benefit of BCBSA.
C. Controlled Affiliate may not directly or indirectly use the Licensed Marks and Name
in a manner that transfers or is intended to transfer in the Region the goodwill associated
therewith to another mark or name, nor may Controlled Affiliate engage in activity that may
dilute or tarnish the unique value of the Licensed Marks and Name.
D. Controlled Affiliate shall use its best efforts to promote and build the value of the
Licensed Marks and Name in connection with the sale, marketing and administration of
regional PDP products and related services.
4. SUBLICENSING AND ASSIGNMENT
Controlled Affiliate shall not, directly or indirectly, sublicense, transfer, hypothecate, sell,
encumber or mortgage, by operation of law or otherwise, the rights granted hereunder and any
such act shall be voidable at the sole option of any Controlling Plan or BCBSA. This Agreement
and all rights and duties hereunder are personal to Controlled Affiliate.
5. INFRINGEMENT
Controlled Affiliate shall promptly notify the Controlling Plans and the Controlling Plans
shall promptly notify BCBSA of any suspected acts of infringement, unfair competition or
passing off that may occur in relation to the Licensed Marks and Name. Controlled Affiliate
shall not be entitled to require the Controlling Plans or BCBSA to take any actions or institute
any proceedings to prevent infringement, unfair competition or passing off by third parties.
Controlled Affiliate agrees to render to the Controlling Plans and BCBSA, without charge, all
reasonable assistance in connection with any matter pertaining to the protection of the
Licensed Marks and Name by BCBSA.
-4-
-- 279 of 512 --
6. LIABILITY INDEMNIFICATION
Controlled Affiliate and the Controlling Plans hereby agree to save, defend, indemnify
and hold BCBSA harmless from and against all claims, damages, liabilities and costs of every
kind, nature and description (except those arising solely
as a result of BCBSA's negligence) that may arise as a result of or related to Controlled
Affiliate's rendering of services under the Licensed Marks and Name.
7. LICENSE TERM
A. Except as otherwise provided herein, the license granted by this Agreement shall
remain in effect for a period of one (1) year and shall be automatically extended for additional
one (1) year periods unless terminated pursuant to the provisions herein.
B. This Agreement and all of Controlled Affiliate's rights hereunder shall immediately
terminate without any further action by any party or entity in the event that: (i) any one of the
Controlling Plans ceases to be authorized to use the Licensed Marks and Name; or (ii)
pursuant to Paragraph 15(a)(x) of the Blue Cross License Agreement any one of the
Controlling Plans ceases to be authorized to use the Licensed Names and Marks in the
Region.
C. Notwithstanding any other provision of this Agreement, this license to use the
Licensed Marks and Name may be forthwith terminated by the Controlling Plans or the
affirmative vote of the majority of the Board of Directors of BCBSA present and voting at a
special meeting expressly called by BCBSA for the purpose on ten (10) days written notice to
the Controlling Plans advising of the specific matters at issue and granting the Controlling
Plans an opportunity to be heard and to present their response to the Board for: (1) failure to
comply with any applicable minimum capital or liquidity requirement under the quality control
standards of this Agreement; or (2) failure to comply with the "Organization and Governance"
quality control standard of this Agreement; or (3) impending financial insolvency; or
1. failure to comply with any of the applicable requirements of Standards 2, 3, 4, or 5 of
attached Exhibit A; or (5) the pendency of any action instituted against the Controlled Affiliate
seeking its dissolution or liquidation of its assets or seeking appointment of a trustee, interim
trustee, receiver or other custodian for any of its property or business or seeking the
declaration or establishment of a trust for any of its property or business, unless this Controlled
Affiliate License Agreement has been earlier terminated under paragraph 7(E); or (6) such
other reason as is determined in good faith immediately and irreparably to threaten the integrity
and reputation of BCBSA, the Plans (including the Controlling Plans), any other licensee
including Controlled Affiliate and/or the Licensed Marks and Name.
D. Except as otherwise provided in Paragraphs 7(B), 7(C) or 7(E) herein, should
Controlled Affiliate fail to comply with the provisions of this Agreement and not cure such failure
within thirty (30) days of receiving written notice thereof (or commence a cure within such thirty
day period and continue diligent efforts to
-5-
-- 280 of 512 --
complete the cure if such curing cannot reasonably be completed within such thirty day period)
BCBSA or the Controlling Plans shall have the right to issue a notice that the Controlled Affiliate
is in a state of noncompliance. If a state of noncompliance as aforesaid is undisputed by the
Controlled Affiliate or is found to exist by a mandatory dispute resolution panel and is uncured
as provided above, BCBSA shall have the right to seek judicial enforcement of the Agreement
or to issue a notice of termination thereof. Notwithstanding any other provisions of this
Agreement, any disputes as to the termination of this License pursuant to Paragraphs 7(B),
7(C) or 7(E) of this Agreement shall not be subject to mediation and mandatory dispute
resolution. All other disputes between or among BCBSA, any of the Controlling Plans and/or
Controlled Affiliate shall be submitted promptly to mediation and mandatory dispute resolution.
The mandatory dispute resolution panel shall have authority to issue orders for specific
performance and assess monetary penalties.
Except, however, as provided in Paragraphs 7(B) and 7(E) of this Agreement, this license to
use the Licensed Marks and Name may not be finally terminated for any reason without the
affirmative vote of a majority of the present and voting members of the Board of Directors of
BCBSA.
E. This Agreement and all of Controlled Affiliate's rights hereunder shall immediately
terminate without any further action by any party or entity in the event that:
(1) Controlled Affiliate shall no longer comply with item 2(E) above;
(2) Appropriate dues, royalties and other payments for Controlled Affiliate
pursuant to paragraph 9 hereof, which are the royalties for this License Agreement, are
more than sixty (60) days in arrears to BCBSA; or
(3) Any of the following events occur: (i) a voluntary petition shall
be filed by Controlled Affiliate seeking bankruptcy, reorganization, arrangement with creditors
or other relief under the bankruptcy laws of the United States or any other law governing
insolvency or debtor relief, or (ii) an involuntary petition or proceeding shall be filed against
Controlled Affiliate seeking bankruptcy, reorganization, arrangement with creditors or other
relief under the bankruptcy laws of the United States or any other law governing insolvency or
debtor relief and such petition or proceeding is consented to or acquiesced in by Controlled
Affiliate or is not dismissed within sixty (60) days of the date upon which the petition or other
document commencing the proceeding is served upon the Controlled Affiliate, or (iii) an order
for relief is entered against Controlled Affiliate in any case under the bankruptcy laws of the
United States, or Controlled Affiliate is adjudged bankrupt or insolvent as those terms are
defined in the Uniform Commercial Code as enacted in the State of Illinois by any court of
competent jurisdiction, or (iv) Controlled Affiliate makes a general assignment of its assets for
the benefit of creditors, or (v) any government or any government official, office, agency,
branch, or unit assumes control of Controlled Affiliate or delinquency proceedings (voluntary or
involuntary) are instituted, or (vi) an action is brought by Controlled Affiliate seeking its
-6-
-- 281 of 512 --
dissolution or liquidation of its assets or seeking the appointment of a trustee, interim trustee,
receiver or other custodian for any of its property or business, or (vii) an action is instituted by
any governmental entity or officer against Controlled Affiliate seeking its dissolution or
liquidation of its assets or seeking the appointment of a trustee, interim trustee, receiver or
other custodian for any of its property or business and such action is consented to or
acquiesced in by Controlled Affiliate or is not dismissed within one hundred thirty (130) days of
the date upon which the pleading or other document commencing the action is served upon the
Controlled Affiliate, provided that if the action is stayed or its prosecution is enjoined, the one
hundred thirty (130) day period is tolled for the duration of the stay or injunction, and provided
further, that the Association’s Board of Directors may toll or extend the 130 day period at any
time prior to its expiration, or (viii) a trustee, interim trustee, receiver or other custodian for any
of Controlled Affiliate's property or business is appointed or the Controlled Affiliate is ordered
dissolved or liquidated. Notwithstanding any other provision of this Agreement, a declaration or
a request for declaration of the existence of a trust over any of the Controlled Affiliate’s property
or business shall not in itself be deemed to constitute or seek appointment of a trustee, interim
trustee, receiver or other custodian for purposes of subparagraphs 7(E)(3)(vii) and
(viii) of this Agreement.
F. Upon termination of this Agreement for cause or otherwise, Controlled Affiliate
agrees that it shall immediately discontinue all use of the Licensed Marks and Name, including
any use in its trade name, except to the extent that it continues to be authorized to use the
Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate
controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan.
G. Upon termination of this Agreement, Controlled Affiliate shall immediately notify all
of its customers to whom it provides products or services under the Licensed Marks pursuant
to this Agreement that it is no longer a licensee of BCBSA and, if directed by the Association’s
Board of Directors, shall provide instruction on how the customer can contact BCBSA or a
designated licensee to obtain further information on securing coverage. The notification
required by this paragraph shall be in writing and in a form approved by BCBSA. The BCBSA
shall have the right to audit the terminated entity's books and records to verify compliance with
this paragraph.
H. In the event this Agreement terminates pursuant to 7(B) hereof, upon termination of
this Agreement the provisions of Paragraph 7(G) shall not apply and the following provisions
shall apply, except that, in the event that Controlled Affiliate is separately licensed by BCBSA
to use the Licensed Marks in the Service Area of a Controlling Plan and termination of this
Agreement is due to a partial termination of such Controlling Plan’s license pursuant to
Paragraph 15(a)(x)(ii) of the Blue Cross
-7-
-- 282 of 512 --
License Agreement, the notices, national account listing, payment, and audit right listed below
shall be applicable solely with respect to the Region and the geographic area for which the
Controlling Plan’s license to use the Licensed Names and Marks is terminated:
(1) The Controlled Affiliate shall send a notice through the U.S. mails, with first
class postage affixed, to all individual and group customers,
providers, brokers and agents of products or services sold, marketed, underwritten or
administered by the Controlled Affiliate under the Licensed Marks and Name.
The form and content of the notice shall be specified by BCBSA and shall, at a minimum,
notify the recipient of the termination of the license, the consequences thereof, and
instructions for obtaining alternate products or services licensed by BCBSA. This notice
shall be mailed within 15 days after termination.
(2) The Controlled Affiliate shall deliver to BCBSA within five days
of a request by BCBSA a listing of national accounts in which the Controlled Affiliate is
involved (in a control, participating or servicing capacity), identifying the national account and
the Controlled Affiliate’s role therein.
(3) Unless the cause of termination is an event respecting BCBSA
stated in paragraph 15(a) or (b) of the Plan’s license agreement with BCBSA to use the
Licensed Marks and Name, the Controlled Affiliate, the Controlling Plans, and any other
Licensed Controlled Affiliates of the Controlling Plans shall be jointly liable for payment to
BCBSA of an amount equal to $25 multiplied by the number of Licensed Enrollees of the
Controlled Affiliate; provided that if any Plan other than a Controlling Plan is permitted by
BCBSA to use marks or names licensed by BCBSA in a geographic area in the Region, the
payment for Licensed Enrollees in such geographic area shall be multiplied by a fraction, the
numerator of which is the number of Licensed Enrollees of the Controlled Affiliate, the
Controlling Plans, and any other Licensed Controlled Affiliates of the Controlling Plans in such
geographic area and the denominator of which is the total number of Licensed Enrollees in
such geographic area. Licensed Enrollee means each and every person and covered
dependent who is enrolled as an individual or member of a group receiving products or
services sold, marketed or administered under marks or names licensed by BCBSA as
determined at the earlier of (i) the end of the last fiscal year of the terminated entity which
ended prior to termination or (ii) the fiscal year which ended before any transactions causing
the termination began. Notwithstanding the foregoing, the amount payable pursuant to this
subparagraph H. (3) shall be due only to the extent that, in BCBSA’s opinion, it does not cause
the net worth of the Controlled Affiliate, the Controlling Plans or any other Licensed Controlled
Affiliates of the Controlling Plans to fall below 100% of the Health Risk-Based Capital formula,
or its equivalent under any successor formula, as set forth in the applicable financial
responsibility standards established by BCBSA (provided such equivalent is approved for
purposes of this subparagraph by the affirmative vote of three-fourths
-8-
-- 283 of 512 --
of the Plans and three-fourths of the total then current weighted vote of all the Plans);
measured as of the date of termination, and adjusted for the value of any transactions not
made in the ordinary course of business. This payment shall not be due in connection with
transactions exclusively by or among Plans (including the Controlling Plans) or their affiliates,
including reorganizations, combinations or mergers, where the BCBSA Board of Directors
determines that the license termination does not result in a material diminution in the number
of Licensed Enrollees or the extent of their coverage. In the event that the Controlled Affiliate’s
license is reinstated by BCBSA or is deemed to have remained in effect without interruption by
a court of competent jurisdiction, BCBSA shall reimburse the Controlled Affiliate (and/or the
Controlling Plans or their other Licensed Controlled Affiliates, as the case may be) for
payments made under this subparagraph 7.H.(3) only to the extent that such payments exceed
the amounts due to BCBSA pursuant to paragraph 7.K. and any costs associated with
reestablishing the terminated Controlling Plan’s Service Area or the Region, including any
payments made by BCBSA to a Plan or Plans (including the other Controlling Plans), or their
Licensed Controlled Affiliates, for purposes of replacing the Controlled Affiliate.
(4) BCBSA shall have the right to audit the books and records of
the Controlled Affiliate, the Controlling Plans, and any other Licensed Controlled Affiliates
of the Controlling Plans to verify compliance with this paragraph 7.H.
(5) As to a breach of 7.H.(1), (2), (3) or (4), the parties agree that
the obligations are immediately enforceable in a court of competent jurisdiction. As to a
breach of 7.H.(1), (2) or (4) by the Controlled Affiliate, the parties agree there is no adequate
remedy at law and BCBSA is entitled to obtain specific performance.
I. BCBSA shall be entitled to enjoin the Controlled Affiliate or any related party in a
court of competent jurisdiction from entry into any transaction which would result in a
termination of this Agreement unless a Controlling Plan’s license from BCBSA to use the
Licensed Marks and Names has been terminated pursuant to 10(d) of such Controlling Plan’s
license agreement upon the required 6 month written notice.
J. BCBSA acknowledges that it is not the owner of assets of the Controlled
Affiliate.
K. In the event this Agreement terminates and is subsequently reinstated by BCBSA or
is deemed to have remained in effect without interruption by a court of competent jurisdiction,
the Controlled Affiliate, the Controlling Plans, and any other Licensed Controlled Affiliates of
the Controlling Plans shall be jointly liable for reimbursing BCBSA the reasonable costs
incurred by BCBSA in connection with the
termination and the reinstatement or court action, and any associated legal proceedings,
including but not limited to: outside legal fees, consulting fees, public relations fees, advertising
costs, and costs incurred to develop, lease or establish an interim provider network. Any
amount due to BCBSA under this subparagraph may be waived in whole or in part by the
BCBSA Board of Directors in its sole discretion.
-9-
-- 284 of 512 --
8. DISPUTE RESOLUTION
The parties agree that any disputes between or among them or between or among any
of them and one or more Plans or Controlled Affiliates of Plans that use in any manner the
Blue Cross and Blue Cross Marks and Name are subject to the Mediation and Mandatory
Dispute Resolution process attached to and made a part of each Controlling Plan’s License
from BCBSA to use the Licensed Marks and Name as Exhibit 5 as amended from time-to-
time, which documents are incorporated herein by reference as though fully set forth herein.
9. LICENSE FEE
Controlled Affiliate will pay to BCBSA a fee for this License determined pursuant
to the formula(s) set forth in Exhibit B.
10. JOINT VENTURE
Nothing contained in this Agreement shall be construed as creating a joint venture,
partnership, agency or employment relationship between the Controlling Plans and
Controlled Affiliate or between either and BCBSA.
11. NOTICES AND CORRESPONDENCE
Notices regarding the subject matter of this Agreement or breach or termination thereof
shall be in writing and shall be addressed in duplicate to the last known address of each other
party, marked respectively to the attention of its President and, if any, its General Counsel.
12. COMPLETE AGREEMENT
This Agreement contains the complete understandings of the parties in relation to the
subject matter hereof. This Agreement may only be amended by the affirmative vote of three-
fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans as
officially recorded by the BCBSA Corporate Secretary.
-10-
-- 285 of 512 --
13. SEVERABILITY
If any term of this Agreement is held to be unlawful by a court of competent jurisdiction,
such findings shall in no way affect the remaining obligations of the parties hereunder and the
court may substitute a lawful term or condition for any unlawful term or condition so long as
the effect of such substitution is to provide the parties with the benefits of this Agreement.
14. NONWAIVER
No waiver by BCBSA of any breach or default in performance on the part of Controlled
Affiliate or any other licensee of any of the terms, covenants or conditions of this Agreement
shall constitute a waiver of any subsequent breach or default in performance of said terms,
covenants or conditions.
14A. VOTING
For all provisions of this Agreement referring to voting, the term ‘Plans’ shall mean all
entities licensed under the Blue Cross License Agreement and/or the Blue Shield License
Agreement, and in all votes of the Plans under this Agreement the Plans shall vote together.
For weighted votes of the Plans, the Plan shall have a number of votes equal to the number of
weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes
(if any) that it holds as a Blue Shield Plan. For all other votes of the Plans, the Plan shall have
one vote. For all questions requiring an affirmative three-fourths weighted vote of the Plans,
the requirement shall be deemed satisfied with a lesser weighted vote unless the greater of:
(i) 6/52 or more of the Plans (rounded to the nearest whole number, with
0.5 or multiples thereof being rounded to the next higher whole number) fail to cast weighted
votes in favor of the question; or (ii) three (3) of the Plans fail to cast weighted votes in favor
of the question. Notwithstanding the foregoing provision, if there are thirty-six (36) Plans, the
requirement of an affirmative three-fourths weighted vote shall be deemed satisfied with a
lesser weighted vote unless four (4) or more Plans fail to cast weighted votes in favor of the
question.
15. GOVERNING LAW
This Agreement shall be governed by, and construed and interpreted in
accordance with, the laws of the State of Illinois.
16. HEADINGS
The headings inserted in this agreement are for convenience only and shall have no
bearing on the interpretation hereof.
-11-
-- 286 of 512 --
IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed
and effective as of the date of last signature written below.
Controlled Affiliate:
By:
Date:
Controlling Plan:
By:
Date:
Controlling Plan:
By:
Date:
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By:
Date:
-12-
-- 287 of 512 --
EXHIBIT A
CONTROLLED AFFILIATE LICENSE STANDARDS
APPLICABLE TO REGIONAL MEDICARE
PART D PRESCRIPTION DRUG PLAN PRODUCTS
September 2020
PREAMBLE
The standards for licensing Controlled Affiliates for Medicare Part D Prescription Drug Plan
Products are established by BCBSA and are subject to change from time- to-time upon the
affirmative vote of three-fourths (3/4) of the Plans and three-fourths (3/4) of the total weighted
vote. Each Controlling Plan is required to use a standard Controlled Affiliate license form
provided by BCBSA and to cooperate fully in assuring that the licensed Controlled Affiliate
maintains compliance with the license standards.
Standard 1 - Organization and Governance
A Controlled Affiliate is defined as an entity organized and operated in such a
manner, that it meets the following requirements:
(1) Controlled Affiliate is owned or controlled by two or more
Controlling Plans;
(2) Each Controlling Plan is authorized pursuant to a separate Blue Cross
License Agreement to use the Licensed Marks in a geographic area in the Region and
every geographic area in the Region is so licensed to at least one of the Controlling Plans;
and
(3) The Controlling Plans must have the legal authority directly or indirectly
through wholly-owned subsidiaries:
(a) to select members of the Controlled Affiliate’s governing body
having not less than 100% voting control thereof;
(b) prevent any change in the articles of incorporation, bylaws or other
establishing or governing documents of the Controlled Affiliate with which the Controlling
Plans do not concur;
(c) exercise control over the policy and operations of the
Controlled Affiliate; and
-13-
-- 288 of 512 --
EXHIBIT A (continued)
Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate’s
establishing or governing documents must also require written approval by each of the
Controlling Plans before the Controlled Affiliate can:
(i) change its legal and/or trade names;
(ii) change the geographic area in which it operates (except such
approval shall not be required with respect to business of the
Controlled Affiliate conducted under the Licensed Marks within
the Service Area of one of the Controlling Plans pursuant to a
separate controlled affiliate license agreement with BCBSA
sponsored by such Controlling Plan);
(iii) change any of the type(s) of businesses in which it engages
(except such approval shall not be required with respect to
business of the Controlled Affiliate conducted under the
Licensed Marks within the Service Area of one of the
Controlling Plans pursuant to a separate controlled affiliate
license agreement with BCBSA sponsored by such Controlling
Plan);
(iv) take any action that any Controlling Plan or BCBSA reasonably
believes will adversely affect the Licensed Marks and Name.
In addition, the Controlling Plans directly or indirectly through wholly-owned
subsidiaries shall own 100% of any for-profit Controlled Affiliate.
Standard 2 - Financial Responsibility
A Controlled Affiliate shall be operated in a manner that provides reasonable
financial assurance that it can fulfill all of its contractual obligations to its customers.
Standard 3 - State Licensure/Certification
A Controlled Affiliate shall maintain appropriate and unimpaired licensure and
certifications.
-14-
-- 289 of 512 --
EXHIBIT A (continued)
Standard 4 - Certain Disclosures
A Controlled Affiliate shall make adequate disclosure in contracting with third
parties and in disseminating public statements of:
a. the structure of the Blue Cross and Blue Shield System; and
b. the independent nature of every licensee.
Standard 5 - Reports and Records for Controlled Affiliates
A Controlled Affiliate and/or its Controlling Plans shall furnish, on a timely and
accurate basis, reports and records relating to these Standards and the License
Agreements between BCBSA and Controlled Affiliate.
Standard 6 - Best Efforts
During each year, a Controlled Affiliate shall use its best efforts to promote and build
the value of the Blue Cross Marks.
Standard 7 - Participation in Master Business Associate Agreement
Controlled Affiliates shall comply with the terms of the Business Associate
Agreement for Blue Cross and Blue Shield Licensees to the extent they perform the
functions of a business associate or subcontractor to a business associate, as defined by
the Business Associate Agreement.
-15-
-- 290 of 512 --
EXHIBIT B
ROYALTY FORMULA FOR SECTION 9 OF THE
CONTROLLED AFFILIATE LICENSE AGREEMENTS
APPLICABLE TO REGIONAL MEDICARE PART D PRESCRIPTION DRUG PLAN
PRODUCTS
Controlled Affiliate will pay BCBSA a fee for this license in accordance with the
following formula:
An amount equal to its pro rata share of each Controlling Plan dues payable to BCBSA
computed with the addition of the Controlled Affiliate's members using the Marks on
regional PDP products and related services as reported on the Quarterly Enrollment
Report with BCBSA. The payment by each Controlling Plan of its dues to BCBSA,
including that portion described in this paragraph, will satisfy the requirement of this
paragraph, and no separate payment will be necessary.
Amended as of June 14, 2007
-16-
-- 291 of 512 --
EXHIBIT 2
Membership Standards
Page 1 of 5
Preamble
The Membership Standards apply to all organizations seeking to become or to continue
as Regular Members of the Blue Cross and Blue Shield Association. Any organization
seeking to become a Regular Member must be found to be in substantial compliance with
all Membership Standards at the time membership is granted and the organization must
be found to be in substantial compliance with all Membership Standards for a period of
two (2) years preceding the date of its application. If Membership is sought by an entity
which controls or is controlled by one or more Plans, such compliance shall be
determined on the basis of compliance by such Plan or Plans.
The Regular Member Plans shall have authority to interpret these Standards.
A Regular Member Plan that operates as a “Shell Holding Company” is defined as an entity
that assumes no underwriting risk and has less than 1% of the consolidated enterprise
assets (excludes investments in subsidiaries) and less than 5% of the consolidated
enterprise net general and administrative expenses.
A Regular Member Plan that operates as a “Hybrid Holding Company” is defined as an
entity that assumes no underwriting risk and has either more than 1% of the consolidated
enterprise assets (excludes investments in subsidiaries) or more than 5% of the
consolidated enterprise net general and administrative expenses.
Standard 1: A Plan shall maintain a governing Board, which shall control the Plan and
ensure that the Plan follows appropriate practices of corporate
governance. A Plan's Board shall not be controlled by any special
interest group, shall make an annual determination that a majority of its
directors are independent, and shall act in the best interest of its
Corporation and its customers. The Board shall be composed of a
majority of persons other than providers of health care services, who
shall be known as public members. A public member shall not be an
employee of or have a financial interest in a health care provider, nor be
a member of a profession which provides health care services.
Amended as of March 15, 2007
-- 292 of 512 --
EXHIBIT 2
Membership Standards
Page 2 of 5
Standard 2: A Plan shall furnish to the Association on a timely and accurate basis
reports and records relating to compliance with these Standards and
the License Agreements between the Association and the Plans. Such
reports and records are the following:
A. BCBSA Membership Information Request;
B. Triennial trade name and service mark usage material, including
disclosure material under Standard 7;
C. Changes in the governance of the Plan, including changes in a
Plan's Charter, Articles of Incorporation, or Bylaws, changes in a
Plan's Board composition, or changes in the identity of the Plan's
Principal Officers;
D. Quarterly Financial Report, Semi-annual “Health Risk- Based
Capital (HRBC) Report” as defined by the NAIC, Annual Budget,
Annual Certified Audit Report, Insurance Department Examination
Report, Annual Statement filed with State Insurance Department
(with all attachments), Plan, Subsidiary and Affiliate Report; and
• Plans that are a Shell Holding Company as defined in the
Preamble hereto are required to furnish only a calendar year-
end “Health Risk-Based Capital (HRBC) Report” as defined by
the NAIC.
Amended as of November 17, 2011
-- 293 of 512 --
EXHIBIT 2
Membership Standards
Page 3 of 5
E. Quarterly Enrollment Report, Quarterly Member Touchpoint
Measures Index (MTM) through 12/31/2011, and Semi-annual
MTM Index starting 1/1/2012 and thereafter.
• For purposes of MTM reporting only, a Plan shall file a
separate MTM report for each Geographic Market.
Standard 3: A Plan shall be operated in a manner that provides reasonable
financial assurance that it can fulfill its contractual obligations
to its customers.
Standard 4: A Plan shall be operated in a manner responsive to customer needs
and requirements.
Standard 5: A Plan shall effectively and efficiently participate in each national program
as from time to time may be adopted by the Member Plans for the
purposes of providing portability of membership between the Plans
and ease of claims processing for customers receiving benefits
outside of the Plan's Service Area.
Such programs are applicable to Blue Cross and Blue Shield
Plans, and include:
A. Inter-Plan Teleprocessing System (ITS);
B. BlueCard Program;
C. National Account Programs;
D. Business Associate Agreement for Blue Cross and Blue
Shield Licensees, effective April 14, 2003; and
E. Inter-Plan Medicare Advantage Program.
Amended as of November 21, 2014
-- 294 of 512 --
EXHIBIT 2
Membership Standards
Page 4 of 5
Standard 6: In addition to requirements under the national programs listed in Standard
5: Participation in National Programs, a Plan shall take such action
as required to ensure its financial performance in programs and
contracts of an inter-Plan nature or where the Association is a party.
Standard 7: A Plan shall make adequate disclosure in contracting with third parties and
in disseminating public statements of (i) the structure of the Blue
Cross and Blue Shield System,
(ii) the independent nature of every Plan, and (iii) the Plan's
financial condition.
Standard 8: A Plan shall cooperate with the Association's Board of Directors and its
Brand Enhancement & Protection Committee in the administration
of the Plan Performance Response Process and in addressing Plan
performance problems identified thereunder.
Standard 9: A Plan shall obtain a rating of its financial strength from an independent
rating agency approved by the Association's Board of Directors for
such purpose.
Standard 10: Notwithstanding any other provision in this License Agreement, during
each year, a Plan and its Controlled Affiliate(s) engaged in
providing licensable services (excluding Life Insurance and
Charitable Foundation Services) shall use their best efforts to
promote and build the value of the Blue Cross Marks.
Standard 11: Neither a Plan nor any Larger Controlled Affiliate shall cause or permit an
entity other than a Plan or a Licensed Controlled Affiliate thereof to
obtain control of the Plan or Larger Controlled Affiliate or to acquire
a substantial portion of its assets related to licensable services.
Amended as of June 16, 2005
-- 295 of 512 --
EXHIBIT 2
Membership Standards
Page 5 of 5
Standard 12: No provider network, or portion thereof, shall be rented or otherwise made
available to a National Competitor if the Licensed Marks or Names
are used in any way with such network.
A provider network may be rented or otherwise made available,
provided there is no use of the Licensed Marks or Names with
respect to the network being rented.
Standard 13: Each Plan shall operate in a manner to reasonably: 1) protect the security
and confidentiality of Personally Identifiable Information (PII) and
Protected Health Information (PHI); 2) protect the Brands from
reputational damage; and 3) cooperate with BCBSA and other Plans
if a data security incident or data breach occurs.
Amended as of June 18, 2015
-- 296 of 512 --
EXHIBIT 3
GUIDELINES WITH RESPECT TO USE OF
LICENSED NAME AND MARKS IN CONNECTION WITH NATIONAL ACCOUNTS
Page 1 of 3
1. The strength of the Blue Cross/Blue Cross National Accounts mechanism, and the
continued provision of cost effective, quality health care benefits to National Accounts, are
predicated on locally managed provider networks coordinated on a national scale in a
manner consistent with effective service to National Account customers and consistent
with the preservation of the integrity of the Blue Cross/Blue Shield system and the
Licensed Marks. These guidelines shall be interpreted in keeping with such ends.
2. A National Account is an entity with employee and/or retiree locations in more than
one Plan's Service Area. Unless otherwise agreed, a National Account is deemed located
in the Service Area in which the corporate headquarters of the National Account is located.
A local plant, office or division headquarters of an entity may be deemed a separate
National Account when that local plant, office or division headquarters 1) has employee
locations in more than one Service Area, and 2) has independent health benefit decision-
making authority for the employees working at such local plant, office or division
headquarters and for employees working at other locations outside the Service Area. In
such a case, the local plant, office or division headquarters is a National Account that is
deemed located in the Service Area in which such local plant, office or division
headquarters is located. The Control Plan of a National Account is the Plan in whose
Service Area the National Account is located. A participating ("Par") Plan is a Plan in
whose Service Area the National Account has employee and/or retiree locations, but in
which the National Account is not located. In the event that a National Account parent
company consolidates health benefit-decision making for itself and its wholly-owned
subsidiary companies, the parent company and the subsidiary companies shall be
considered one National Account. The Control Plan for such a National Account shall be
the Plan in whose Service Area the parent company headquarters is located.
3. The National Account Guidelines enunciated herein below shall be applicable only
with respect to the business of new National Accounts acquired after January 1, 1991.
4. Control Plans shall utilize National Account identification cards complying with
then currently effective BCBSA graphic standards in connection with all National
Accounts business to facilitate administration thereof, to minimize subscriber and
provider confusion, and to reflect a commitment to cooperation among Plans.
Amended as of June 12, 2003
-- 297 of 512 --
EXHIBIT 3
Page 2 of 3
5. Disputes among Plans and/or BCBSA as to the interpretation or implementation of
these Guidelines or as to other National Accounts issues shall be submitted to mediation
and mandatory dispute resolution as provided in the License Agreement. For two years
from the effective date of the License Agreement, however, such disputes shall be subject
to mediation only, with the results of such mediation to be collected and reported in order to
establish more definitive operating parameters for National Accounts business and to serve
as ground rules for future binding dispute resolution.
6. The Control Plan may use the BlueCard Program (as defined by IPPC) to deliver
benefits to employees and non-Medicare eligible retirees in a Participating Plan’s service
area if an alternative arrangement with the Participating Plan cannot be negotiated. The
Participating Plan’s minimum servicing requirement for those employees and non-
Medicare retirees in its service area is to deliver benefits using the BlueCard Program.
Account delivery is subject to the policies, provisions and procedures of the BlueCard
Program.
7. For provider payments in a Participating Plan’s area (on non-BlueCard claims),
payment to the provider may be made by the Participating Plan or the Control Plan at the
Participating Plan's option. If the Participating Plan elects to pay the provider, it may not
withhold payment of a claim verified by the Control Plan or its designated processor, and
payment must be in conformity with service criteria established by the Board of Directors
of BCBSA (or an authorized committee thereof) to assure prompt payment, good service
and minimum confusion with providers and subscribers. The Control Plan, at the
Participating Plan's request, will also assure that measures are taken to protect the
confidentiality of the data pertaining to provider reimbursement levels and profiles.
Amended as of June 14, 1996
-- 298 of 512 --
EXHIBIT 3
Page 3 of 3
8. The Control Plan, in its financial agreements with a National Account, is
expected to reasonably reflect the aggregate amount of differentials passed along to
the Control Plan by all Participating Plans in a National Account.
9. Other than in contracting with health care providers or soliciting such contracts in
areas contiguous to a Plan's Service Area in order to serve its subscribers or those of its
licensed Controlled Affiliate residing or working in its Service Area, a Control Plan may
not use the Licensed Marks and/or Name, as a tag line or otherwise, to negotiate directly
with providers outside its Service Area.
Amended as of March 13, 2003
-- 299 of 512 --
EXHIBIT 4
GOVERNMENT PROGRAMS AND CERTAIN OTHER USES
Page 1 of 14
1. A Plan and its licensed Controlled Affiliate may use the Licensed Marks and Name
in bidding on and executing a contract to serve a Government Program, and in thereafter
communicating with the Government concerning the Program. With respect, however, to
such contracts entered into after the 1st day of January, 1991, the Licensed Marks and
Name will not be used in communications or transactions with beneficiaries or providers in
the Government Program located outside a Plan's Service Area, unless the Plan can
demonstrate to the satisfaction of BCBSA's governing body that such a restriction on use
of the Licensed Marks and Name will jeopardize its ability to procure the contract for the
Government Program. As to both existing and future contracts for Government Programs,
Plans will discontinue use of the Licensed Marks and Name as to beneficiaries and
Providers outside their Service Area as expeditiously as circumstances reasonably permit.
Effective January 1, 1995, except as provided in the first sentence above, all use by a Plan
of the Licensed Marks and Name in Government Programs outside of the Plan's Service
Area shall be discontinued. Incidental communications outside a Plan's Service Area with
resident or former resident beneficiaries of the Plan, and other categories of necessary
incidental communications approved by BCBSA, are not prohibited. For purposes of this
Paragraph 1, the term “Government Programs” shall mean Medicare Part A, Medicare Part
B and other non-risk government programs.
2. In connection with activity otherwise in furtherance of the License Agreement, a
Plan and its Controlled Affiliates that are licensed to use the Licensed Marks and Name in
its Service Area pursuant to the Controlled Affiliate License Agreements authorized in
clauses a) through c) of Paragraph 2 of the Plan’s License Agreement with BCBSA may
use the Licensed Marks and Name outside the Plan’s Service Area in the following
circumstances which are deemed legitimate and necessary and not likely to cause
consumer confusion:
2.1 Common Business Communications
a. sending letterhead, envelopes, and similar items solely for administrative
purposes (e.g., not for purposes of marketing, advertising, promoting,
selling or soliciting the sale of health care plans and related services);
b. distributing business cards other than in marketing and selling;
c. advertising in publications or electronic media solely to persons for
employment;
Amended as of June 19, 2014
-- 300 of 512 --
EXHIBIT 4
Page 2 of 14
2.2 Marketing Spillover
a. advertising in print, electronic or other media which serve, as a substantial
market, the Service Area of the Plan or licensed Controlled Affiliate,
provided that no Plan or Controlled Affiliate may advertise outside its
Service Area on the national broadcast and cable networks and that
advertisements in national print media are limited to the smallest regional
edition encompassing the Service Area;
b. advertising by direct mail where the addressee's zip code plus 4 includes,
at least in part, the Plan's Service Area or that of a licensed Controlled
Affiliate;
2.3 Provider Contracting
a. contracting with health care providers or soliciting such contracts in areas
contiguous to the Plan's Service Area in order to serve its subscribers or
those of such licensed Controlled Affiliates residing or working in its service
area;
b. issuing a small sign containing the legal name or trade name of the Plan or
such licensed Controlled Affiliates for display by a provider to identify the
latter as a participating provider of the Plan or Controlled Affiliate;
c. negotiating case-specific reimbursement rates with a provider that does not
have a contract applicable to a specific member’s services rendered or to be
rendered with the Licensee (or any of the Licensees in the case of
overlapping Service Areas) in whose Service Area the health care provider
is located, so long as
(1) the Licensee engaging in the negotiations complies with all applicable Inter-
Plan Programs Policies and Provisions and Brand Regulations related to
case-specific rate negotiations, and
(2) the Licensee (or all Licensees in the case of overlapping Service Areas) in
whose Service Area the health care provider is located provides consent
before negotiations commence.
Amended as of January 22, 2019
-- 301 of 512 --
EXHIBIT 4
Page 3 of 14
d. contracting with a pharmacy management organization (“Pharmacy
Intermediary”) to gain access to a national or regional pharmacy network to
provide self-administered prescription drugs to deliver a pharmacy benefit for
all of the Plan’s or licensed Controlled Affiliate’s members nationwide,
provided, however, that the Pharmacy Intermediary may not use the
Licensed Marks or Name in contracting with the pharmacy providers in such
network;
Amended as of January 22, 2019
-- 302 of 512 --
EXHIBIT 4
Page 4 of 14
e. contracting with the corporate owner of a national or regional retail pharmacy
chain to gain access to the pharmacies in the chain to provide self-
administered prescription drugs to deliver a pharmacy benefit for all of the
Plan’s or licensed Controlled Affiliate’s members nationwide, provided that
(1) the Plan and the Controlled Affiliate may not contract directly with
pharmacists or pharmacy stores outside the Plan’s Service Area, and (2)
neither the Plan’s or the Controlled Affiliate’s name nor the Licensed Marks
or Name may be posted or otherwise displayed at or by any pharmacy store
outside the Plan’s Service Area;
f. contracting with a dental management organization (“Dental Intermediary”)
to gain access to a national or regional dental network to deliver a routine
dental benefit for all of the Plan’s or licensed Controlled Affiliate’s
members nationwide, provided, however, that the Dental Intermediary may
not use the Licensed Marks or Name in contracting with the dental
providers in such network;
g. contracting with a vision management organization (“Vision Intermediary”)
to gain access to a national or regional vision network to deliver a routine
vision benefit for all of the Plan’s or licensed Controlled Affiliate’s
members nationwide, provided, however, that the Vision Intermediary may
not use the Licensed Marks or Name in contracting with the vision
providers in such network;
h. contracting with an independent clinical laboratory for analysis and clinical
assessment of specimens that are collected within the Plan’s Service Area;
i. contracting with a durable medical equipment or home medical equipment
company for durable medical equipment and supplies and home medical
equipment and supplies that are shipped to a location within the Plan’s
Service Area;
j. contracting with a specialty pharmaceutical company for non- routine
biological therapeutics that are ordered by a health care professional
located within the Plan’s Service Area;
k. contracting with a company that operates provider sites in the Plan’s Service
Area, provided that the contract is solely for services rendered at a site (e.g.,
hospital, mobile van) that is within the Plan’s Service Area;
-- 303 of 512 --
EXHIBIT 4
Page 5 of 14
l. contracting with a company that makes health care professionals available in
the Plans’ Service Area (e.g., traveling home health nurse), provided that the
contract is solely for services rendered by health care professionals who are
located within the Plan’s Service Area.
m. permitting Control/Home Plans’ ability to resolve members’ service issues
requiring outreach to out-of-area providers as set forth in the Inter-Plan
Programs and Inter-Plan Medicare Advantage Program Policies.
2.4 Services to National Accounts
a. in conjunction with contracting with a National Account as Control Licensee or
Alternate Control Licensee (as those terms are defined in the Inter-Plan
Programs Policies and Provisions (“IP Policies”)) to offer Blue-branded Health
Coverage to the National Account, offering Blue-branded Health and Wellness
Programs to all members of the National Account, including members who
have not enrolled in the Blue-branded Health Coverage (“non-Blue Health
Coverage members”), provided that:
(i) the Plan and/or licensed Controlled Affiliate has no contact or
interaction with providers outside of the Plan’s Service Area, except as
specifically provided in the IP Policies and in
2.4 (b); and
(ii) if in accordance with IP Policies another Licensee is soliciting or
servicing under the Brands a local plant, office or division of the
account that is outside of the Plan’s Service Area, the Plan and/or
licensed Controlled Affiliate may not offer Blue-branded Health and
Wellness Programs to any employees working at such local plant,
office or division without the consent of such other Licensee; and
(iii) if the Plan and/or licensed Controlled Affiliate provides an information
card to the non-Blue Health Coverage members, the card may not
display the Symbols in the masthead, must contain a prominent
disclosure conveying that it is not a health insurance card, and
otherwise must be designed so that it is dissimilar to a Blue member
identification card.
Amended as of September 17, 2020
-- 304 of 512 --
EXHIBIT 4
Page 6 of 14
2.4 Services to National Accounts (continued)
For purposes of this subparagraph a, the following definitions apply:
“Health and Wellness Program” shall mean a program that includes at least
one of the following elements or a related element:
– Health Risk Assessment and/or Preventive Screenings
– Exercise and Fitness Programs
– Health and Wellness Events (e.g., attendance at a health fair, a 5K walk)
– Nutrition and Weight Management
– Health Education (e.g., smoking cessation classes)
– Prenatal and Parenting Education
– Disease or Chronic Condition Management
The above listing is intended to represent examples of the types of programs
that may be offered, and other programs, including those offered through
different media such as the internet or telephonically, may also be deemed
Health and Wellness programs.
“Health Coverage” shall mean providing or administering medical, surgical,
hospital, major medical, or catastrophic coverage, or any HMO, PPO, POS or
other managed care plan for the foregoing services.
b. as part of a Health and Wellness Program that is otherwise compliant with
Brand Regulation 4.11.4(a), contracting with a health and wellness
organization to gain access to providers to deliver a discrete health and
wellness event (“Event”) held at a National Account’s worksite outside of the
Licensee’s Service Area, provided that:
(i) the services delivered at the Event are limited to fingerstick screenings
for cholesterol and glucose, seasonal flu immunizations, blood pressure
measurements, body mass index measurements, and other routine
screenings, immunizations and measurements; and
(ii) neither such services nor their costs are applied as claims against
any benefit plan; and
(iii) the Event is presented during one or more limited periods during a
benefit year and is available to all employees at the worksite.
Amended as of March 26, 2015
-- 305 of 512 --
EXHIBIT 4
Page 7 of 14
c. in conjunction with contracting with a National Account as Control Licensee
or Alternate Control Licensee to offer Blue-branded Health Coverage to the
National Account, performing the Eligibility and Enrollment functions of HR
administration for all benefit plans offered by the National Account to its
members, including benefit plans that are not underwritten or administered
by the Plan, provided that:
(i) in performing such functions, the Plan and/or licensed Controlled
Affiliate does not use the Brands in any communications with health
care providers outside of the Plan’s Service Area, and otherwise limits
its use of the Brands outside of the Service Area to communications
with the account’s members, the other benefit plan providers with
which the account has contracted and other reasonably necessary
communications to perform such functions; and
(ii) if in accordance with IP Policies another Licensee is soliciting or
servicing under the Brands a local plant, office or division of the
account that is outside of the Plan’s Service Area, the Plan and/or
licensed Controlled Affiliate may not perform Eligibility and Enrollment
functions for employees working at such local plant, office or division
without the consent of such other Licensee;
d. in conjunction with contracting with a National Account as Control Licensee or
Alternate Control Licensee to perform or investigate fraud, waste and abuse
investigation activities for a non- participating provider in a Par/Host Plan’s
service area, as long as the Control/Home Plan is given permission to do so
by the Par/Host Plan and specific conditions are met in accordance with Inter-
Plan Programs and Inter-Plan Medicare Advantage Program policies.
For purposes of this subparagraph b, the following definitions apply: “Health
Coverage” has the meaning set forth in subparagraph 2.4.a.
Amended September 27, 2018
-- 306 of 512 --
EXHIBIT 4
Page 8 of 14
“Eligibility” means services that manage the account’s eligibility data and determine or
process determinations relating to eligibility for benefit plans offered by the account to its
employees, including such services as:
• monitoring and auditing data to ensure that only entitled individuals are enrolled
in each such benefit plan;
• review of eligibility documentation (e.g. marriage licenses, birth certificates,
student status verification letters, employment records);
• identification of key member segments such as over-age dependents, part-time
employees, employees reaching certain milestones (e.g. Medicare-eligible,
retirees);
• termination of coverage for those individuals found to be ineligible for coverage
under a benefit plan, and, if applicable, generation of a COBRA event; and
• management of “hour-banking” for union environments in which union members
can bank hours to remain eligible for benefits.
“Enrollment” means services that enroll eligible individuals and their spouses/dependents
or terminate or change their enrollment in the account’s benefit plans on an ongoing basis
and during open enrollment periods, including such services as:
• the coordination of each step in open enrollment process from project planning and
system set-up to the generation of confirmation statements;
• ongoing enrollment support for new hires and changes due to life events and work
status adjustments;
• evidence of insurability (EOI) administration for life and disability coverage;
• transmission of eligibility/enrollment information to the account’s benefit plan
providers;
• review and reconciliation of error reports received from the account’s benefit
plan providers; and
• transmission of information to the account’s payroll system (e.g., benefit
deductions, employee demographic data).
Amended as of March 26, 2015
-- 307 of 512 --
EXHIBIT 4
Page 9 of 14
2.5 Knowledge Sharing
a. submitting scholarly articles authored or co-authored by the Plan or
Controlled Affiliate or its respective employees for publication in peer-
reviewed journals;
b. permitting an internal representative of the Licensee (e.g., officer, employee)
to speak or present at a conference or symposium outside of the Licensee’s
Service Area regarding either (i) healthcare financing, administration, delivery
or policy, or (ii) topics within the representative’s functional discipline or
expertise at the Licensee, for which the event sponsor will issue
communications to promote, administer, and/or recap the event that will
identify the Licensee’s representative as a participant. The communications
outside of the Licensee’s Service Area that mention the Licensee’s
representative shall be limited to materials and digital media provided to
attendees, on-site signage, advertising in relevant trade publications, direct
mail and email to attendees and prospective attendees, and the sponsor’s
website. Participation in any conference or symposium outside of the
Licensee’s Service Area may not be for the purpose of marketing or selling
products or services.
If the Licensee’s representative wishes to use the Brands in any manner,
including use in his/her title, when participating as a speaker or presenter
outside of the Licensee’s Service Area about a topic that is not related to
healthcare financing, administration, delivery, or policy, or to topics within the
representative’s functional discipline or expertise at the Licensee, the
Licensee must notify BCBSA and receive prior approval from BCBSA before
participating;
Amended as of March 26, 2015
-- 308 of 512 --
EXHIBIT 4
Page 10 of 14
2.6 Other Uses
a. entering into a license agreement between and among BCBSA, the Plan and
a debit card issuer located outside the Plan’s Service Area, and entering into
a corresponding operating agreement or agreements, in order to offer a debit
card bearing the Licensed Marks and Name to eligible persons as defined by
the aforementioned license agreement;
b. appearing in communications issued by an independent third party to
recognize outstanding performance of the Plan or Controlled Affiliate or a
member of the Plan’s or Controlled Affiliate’s senior management as part of an
established program of the third party for which the Plan has provided
information to be considered for the recognition, provided that such use
complies with regulations of general application specifically prescribed by
BCBSA from time to time;
c. to identify itself as being a joint sponsor of an event, program or activity
along with other Plans or such Plans’ licensed Controlled Affiliates, provided
that such use complies with regulations of general application specifically
prescribed by BCBSA from time to time;
d. hosting meetings or events (collectively, “events”) in Washington,
D.C. or a Plan’s State Capitol related to policy and business issues in the
Licensee’s Service Area, or hosting events in conjunction with the assemblies
or conventions of national political parties. Such events may not involve
marketing or selling products or services. Use of the Brands outside the
Licensee’s Service Area in connection with such events shall be limited to
materials and digital media provided to attendees and prospective attendees
and onsite signage. For any such events in Washington, D.C. that are open to
attendees other than government officials or their staffs, or are briefings open
to all Congressional staff, or are otherwise likely to receive media coverage,
the Licensee is required to provide advance notice to BCBSA. For events
hosted outside of Washington, D.C. in conjunction with the assemblies or
conventions of national political parties, the Licensee is required to provide
advance notice to BCBSA and to the local Plan(s);
Amended as of March 26, 2015
-- 309 of 512 --
EXHIBIT 4
Page 11 of 14
e. permitting an affiliate that is not licensed to use the Licensed Marks to
identify its corporate relationship with the Plan, provided that such use
complies with regulations of general application specifically prescribed by
BCBSA from time to time.
3. In connection with activity otherwise in furtherance of the License Agreement, a
Controlled Affiliate that is licensed to use the Licensed Marks and Name pursuant to a
Controlled Affiliate License Agreement authorized in clauses d) or e) of Paragraph 2 of the
Plan’s License Agreement with BCBSA may use the Licensed Marks and Name outside
the Region (as that term is defined in such respective Controlled Affiliate License
Agreements) in the following circumstances which are deemed legitimate and necessary
and not likely to cause consumer confusion:
a. sending letterhead, envelopes, and similar items solely for administrative
purposes (e.g., not for purposes of marketing, advertising, promoting,
selling or soliciting the sale of health care plans and related services);
b. distributing business cards other than in marketing and selling;
c. contracting with health care providers or soliciting such contracts in areas
contiguous to the Region in order to serve its subscribers residing in the
Region, provided that the Controlled Affiliate may not use the names of any of
its Controlling Plans in connection with such contracting unless the provider is
located in a geographic area that is also contiguous to such Controlling Plan’s
Service Area;
d. issuing a small sign containing the legal name or trade name of the
Controlled Affiliate for display by a provider to identify the latter as a
participating provider of the Controlled Affiliate, provided that the Controlled
Affiliate may not use the names of any of its Controlling Plans on such signs
unless the provider is located in a geographic area that is also contiguous to
such Controlling Plan’s Service Area;
e. advertising in publications or electronic media solely to persons for
employment;
Amended as of March 26, 2015
-- 310 of 512 --
EXHIBIT 4
Page 12 of 14
f. advertising in print, electronic or other media which serve, as a substantial
market, the Region, provided that the Controlled Affiliate may not advertise
outside its Region on the national broadcast and cable networks and that
advertisements in national print media are limited to the smallest regional
edition encompassing the Region, and provided further that any such
advertising by the Controlled Affiliate may not reference the name of any of
its Controlling Plans unless the respective Controlling Plan is authorized
under paragraph 2 of this Exhibit 4 to advertise in such media;
g. advertising by direct mail where the addressee's zip code plus 4 includes, at
least in part, the Region, provided that such advertising by the Controlled
Affiliate may not reference the name of any of its Controlling Plans unless
the respective Controlling Plan is authorized under paragraph 2 of this
Exhibit 4 to send direct mail to such zip code plus 4.
h. [Intentionally left blank, pending review by the Inter-Plan Programs
Committee of the applicability of the case management rule to such
Controlled Affiliates.]
i. contracting with a pharmacy management organization (“Pharmacy
Intermediary”) to gain access to a national or regional pharmacy network to
provide self-administered prescription drugs to deliver a pharmacy benefit for
the Controlled Affiliate’s regional Medicare Advantage PPO or regional
Medicare Part D Prescription Drug members enrolled under the Licensed
Marks pursuant to such respective Controlled Affiliate License Agreements,
provided, however, that the Pharmacy Intermediary may not use the Licensed
Marks or Name in contracting with the pharmacy providers in such network;
j. contracting with the corporate owner of a national or regional retail pharmacy
chain to gain access to the pharmacies in the chain to provide self-
administered prescription drugs to deliver a pharmacy benefit to the
Controlled Affiliate’s regional Medicare Advantage PPO or regional Medicare
Part D Prescription Drug members enrolled under the Licensed Marks
pursuant to such respective
-- 311 of 512 --
EXHIBIT 4
Page 13 of 14
Controlled Affiliate License Agreements, provided that (1) the Controlled
Affiliate may not contract directly with pharmacists or pharmacy stores
outside the Region, and (2) neither the Controlled Affiliate’s name nor the
Licensed Marks or Name may be posted or otherwise displayed at or by any
pharmacy store outside the Region;
k. contracting with a dental management organization (“Dental
Intermediary”) to gain access to a national or regional dental network to
deliver a routine dental benefit for the Controlled Affiliate’s regional
Medicare Advantage PPO members enrolled under the Licensed Marks
pursuant to such Controlled Affiliate License Agreement, provided,
however, that the Dental Intermediary may not use the Licensed Marks or
Name in contracting with the dental providers in such network;
l. contracting with a vision management organization (“Vision Intermediary”) to
gain access to a national or regional vision network to deliver a routine
vision benefit for the Controlled Affiliate’s regional Medicare Advantage
members enrolled under the Licensed Marks pursuant to such Controlled
Affiliate License Agreement, provided, however, that the Vision Intermediary
may not use the Licensed Marks or Name in contracting with the vision
providers in such network;
m. contracting with an independent clinical laboratory for analysis and clinical
assessment of specimens that are collected within the Controlled Affiliate’s
Region;
n. contracting with a durable medical equipment or home medical equipment
company for durable medical equipment and supplies and home medical
equipment and supplies that are shipped to a location within the Controlled
Affiliate’s Region;
o. contracting with a specialty pharmaceutical company for non- routine
biological therapeutics that are ordered by a health care professional
located within the Region;
p. contracting with a company that operates provider sites in the Region,
provided that the contract is solely for services rendered at a site (e.g.,
hospital, mobile van) that is within the Region;
-- 312 of 512 --
EXHIBIT 4
Page 14 of 14
q. contracting with a company that makes health care professionals available
in the Region (e.g., traveling home health nurse), provided that the contract
is solely for services rendered by health care professionals who are located
within the Region.
4. BCBSA shall retain the right to use the Licensed Marks in conjunction with the
Federal Employee Program and with any other national offering made to federal
employees pursuant to the Federal Employees Health Benefits Program (FEHBP),
including the right to license such use to its vendors, but only in the following
manner.
a. the Licensed Marks may only be used by BCBSA with the term “Federal
Employee Program”, “Federal”, “FEP”, or similar language identifying the
program as a benefit program for federal employees;
b. the Licensed Marks may not be used by BCBSA with the name(s) of a
specific Plan or Plans and;
c. any use by BCBSA in conjunction with a new national FEHBP program
proposed after the enactment of this amendment will require the
approval of the BCBSA Board of Directors.
5. Where required by applicable state or local law or regulation, a Plan or its licensed
Controlled Affiliate may submit documents that contain the Brands to, and file forms
that contain the Brands with, state or local regulators in a state not included in its
Service Area, provided that it gives reasonable advance notice to the local Plan of its
intent to submit such documents or file such forms. Notwithstanding, in no event may a
Plan or its licensed Controlled Affiliate use the Brands to register, or to obtain or
maintain a license, a certificate of authority, or an equivalent document authorizing it to
act as a risk-bearing entity or third party administrator in a state not included in its
Service Area. If the local Plan advises BCBSA that it believes its License Agreement
has been or would be violated by any submission or filing, BCBSA shall determine
whether such submission or filing is required by state or local law or regulation and
violates the License Agreement, subject to the Plan’s or licensed Controlled Affiliate’s
rights to obtain an independent review of such determination under Paragraph 9(a)
and Exhibit 5 of its License Agreement or Paragraph 8 of the Controlled Affiliate
License. For purposes of this paragraph, “local Plan” is defined as each Plan whose
Service Area includes all or part of the state in which the foregoing applicable state or
local law or regulation has been enacted.
Amended as of March 26, 2015
-- 313 of 512 --
EXHIBIT 5
Page 1 of 23
MEDIATION AND MANDATORY DISPUTE RESOLUTION (MMDR) RULES
The Blue Cross and Blue Shield Plans ("Plans") and the Blue Cross Blue Shield
Association ("BCBSA") recognize and acknowledge that the Blue Cross and Blue Shield
system is a unique nonprofit and for-profit system offering cost effective health care
financing and services. The Plans and BCBSA desire to utilize Mediation and Mandatory
Dispute Resolution (“MMDR”) to avoid expensive and time-consuming litigation that may
otherwise occur in the federal and state judicial systems. Even MMDR should be viewed,
however, as methods of last resort, all other procedures for dispute resolution having failed.
Except as otherwise provided in the License Agreements, the Plans, their Controlled
Affiliates and BCBSA agree to submit all disputes to MMDR pursuant to these Rules and in
lieu of litigation.
1. Initiation of Proceedings
A. Pre-MMDR Efforts
Before filing a Complaint to invoke the MMDR process, the CEO of a complaining
party, or his/her designated representative, shall undertake good faith efforts with the
other side(s) to try to resolve any dispute.
B. Complaint
To commence a proceeding, the complaining party (or parties) shall provide by
certified mail, return receipt requested, a written Complaint to the BCBSA Corporate
Secretary (which shall also constitute service on BCBSA if it is a respondent) and to any
Plan(s) and/or Controlled Affiliate(s) named therein.
The Complaint shall contain:
i. identification of the complaining party (or parties) requesting the
proceeding;
ii. identification of the respondent(s);
iii. identification of any other persons or entities who are interested in a
resolution of the dispute;
iv. a full statement describing the nature of the dispute;
v. identification of all of the issues that are being submitted for
resolution;
Amended as of November 21, 1996
-- 314 of 512 --
EXHIBIT 5
Page 2 of 23
vi. the remedy sought;
vii. a statement as to whether the complaining party (or parties) elect(s) first
to pursue Mediation;
viii. any request, if applicable, that the matter be handled on an expedited
basis and the reasons there for;
ix. a statement signed by the CEO of the complaining party affirming that
the CEO has undertaken efforts, or has directed efforts to be
undertaken, to resolve the dispute before resorting to the MMDR
process;
The complaining party (or parties) shall file and serve with the Complaint copies of all
documents which the party (or parties) intend(s) to offer at the Arbitration Hearing and a
statement identifying the witnesses the party (or parties) intend(s) to present at the
Hearing, along with a summary of each witness' expected testimony.
C. Answer
Within twenty (20) days after receipt of the Complaint, each respondent shall
serve on BCBSA and on the complaining party (or parties);
i. a full Answer to the aforesaid Complaint;
ii. a statement of any Counterclaims against the complaining party (or
parties), providing with respect thereto the information specified in
Paragraph 1.B., above;
iii. a statement as to whether the respondent elects to first pursue
Mediation; and
iv. any request, if applicable, that the matter be handled on an expedited
basis and the reasons therefor.
The respondent(s) shall file and serve with the Answer or by the date of the Initial
Conference set forth in Paragraph 3.C., below, copies of all documents which the
respondent(s) intend(s) to offer at the Arbitration Hearing and a statement identifying the
witnesses the party (or parties) intend(s) to present at the Hearing, along with a summary of
each witness' expected testimony.
Amended as of September 20, 2007
-- 315 of 512 --
EXHIBIT 5
Page 3 of 23
D. Reply To Counterclaim
Within ten (10) days after receipt of any Counterclaim, the complaining party (or
parties) shall serve on BCBSA and on the responding party (or parties), a Reply to the
Counterclaim. Such Reply must provide the same information required by Paragraph 1.C.,
above.
2. Mediation
To facilitate the mediation of disputes between or among BCBSA, the Plans and/or
their Controlled Affiliates, the BCBSA Board has provided for Mediation under these Rules.
Mediation may be pursued in lieu of or in an effort to obviate the Mandatory Dispute
Resolution process, and all parties are strongly urged, but not required, to exhaust the
mediation procedure provided for herein. In the event any party refuses to proceed with
Mediation, the parties shall proceed immediately to Mandatory Dispute Resolution, as
provided in Section 3.
A. Selection of Mediators
If all parties agree to pursue Mediation, they shall promptly attempt to agree upon:
(i) the number of mediators desired, not to exceed three mediators; and (ii) the selection of
experienced mediator(s) from an independent entity to mediate all disputes set forth in the
Complaint and Answer (and Counterclaim and Reply, if any). In the event the parties are
unable to agree upon the selection or number of mediators, both within five (5) days of the
service of the Answer or Reply to Counterclaim, whichever is later, the BCBSA Corporate
Secretary shall immediately refer the matter to a nationally recognized professional ADR
organization (such as CPR or JAMS) for mediation by a single mediator to be selected by
the ADR organization.
B. Binding Decision
Before the Mediation Hearing described below, the BCBSA Corporate Secretary
shall contact the parties to determine whether they wish to be bound by any
recommendation of the selected mediator(s) for resolution of the disputes. If all wish to be
bound, the Corporate Secretary will send appropriate documentation to them for their
signatures before the Mediation Hearing begins.
Amended as of September 20, 2007
-- 316 of 512 --
EXHIBIT 5
Page 4 of 23
C. Mediation Procedure
The Mediator(s) shall apply the mediation procedures and processes provided for
herein (not the rules of the ADR organization with which they are affiliated) and shall
promptly advise the parties of a scheduled Mediation Hearing date. Unless a party requests
an expedited procedure, or unless all parties to the proceeding agree to one or more
extensions of time, the Mediation Hearing set forth below shall be completed within forty
(40) days of BCBSA's receipt of the Complaint. The selected mediator(s), unless the
parties otherwise agree, shall adhere to the following procedure:
i. Each party must be represented by its CEO or other representative who
has been delegated full authority to resolve the dispute. However, parties
may send additional representatives as they see fit.
ii. Each party will be given one-half hour to present its case, beginning with
the complaining party (or parties), followed by the other party or parties.
The parties are free to structure their presentations as they see fit, using
oral statements or direct examination of witnesses. However, neither
cross-examination nor questioning of opposing representatives will be
permitted. At the close of each presentation, the selected mediator(s) will
be given an opportunity to ask questions of the presenters and witnesses.
All parties must be present throughout the Mediation Hearing. The
selected mediator(s) may extend the time allowed for each party's
presentation at the Mediation Hearing. The selected mediator(s) may meet
in executive session, outside the
presence of the parties, or may meet with the parties separately, to discuss
the controversy.
iii. After the close of the presentations, the parties will attempt to negotiate
a settlement of the dispute. If the parties desire, the selected
mediator(s), or any one or more of the selected mediators, will sit in on
the negotiations.
Amended as of September 20, 2007
-- 317 of 512 --
EXHIBIT 5
Page 5 of 23
iv. After the close of the presentations, the selected mediator(s) may meet
privately to agree upon a recommendation for resolution of the dispute
which would be submitted to the parties for their consideration and
approval. If the parties have previously agreed to be bound by the results
of this procedure, this recommendation shall be binding upon the parties.
v. The purpose of the Mediation Hearing is to assist the parties to settle their
grievances short of mandatory dispute resolution. As a result, the
Mediation Hearing has been designed to be as informal as possible. Rules
of evidence shall not apply. There will be no transcript of the proceedings,
and no party may make a tape recording of the Mediation Hearing.
vi. In order to facilitate a free and open discussion, the Mediation proceeding
shall remain confidential. A "Stipulation to Confidentiality" which prohibits
future use of settlement offers, all position papers or other statements
furnished to the selected mediator(s), and decisions or recommendations
in any Mediation proceeding shall be executed by each party.
vii. Upon request of the selected mediator(s), or one of the parties, BCBSA
staff may also submit documentation at any time during the proceedings.
D. Notice of Termination of Mediation
If the Mediation cannot be completed within the prescribed or agreed time period
due to the lack of cooperation of any party, as determined by the selected mediator(s), or if
the Mediation does not result in a final resolution of all disputes at the Mediation Hearing or
within ten (10) days after the Mediation Hearing, any party or any one of the selected
mediators shall so notify the BCBSA Corporate Secretary, who shall promptly issue a
Notice of Termination of Mediation to all parties, to the selected mediator(s), and to the
MDR Administrator. Such notice shall serve to bring the Mediation to an end and to initiate
Mandatory Dispute Resolution. Upon agreement of all parties and the mediator(s), the
Mediation process may continue at the same time the MDR process is invoked. In such
case, the Notice of Termination of Mediation described above serves to initiate the MDR
proceeding, but does not terminate mediation proceedings, which may proceed
simultaneous with the MDR proceeding.
Amended as of September 20, 2007
-- 318 of 512 --
EXHIBIT 5
Page 6 of 23
3. Mandatory Dispute Resolution (MDR)
If any party elects not to first pursue Mediation, or if a Notice of Termination of
Mediation is issued as set forth in Paragraph 2.D., above, then the unresolved disputes set
forth in any Complaint and Answer (and Counterclaim and Reply, if any) shall be subject to
mandatory binding arbitration (herein referred to as “MDR”).
A. MDR Administrator
The Administrator for purposes of Mandatory Arbitration shall be an independent
nationally recognized entity such as CPR or JAMS, specializing in alternative dispute
resolution. In the event the parties pursued Mediation with CPR, JAMS or a similar
organization, that organization also shall serve as the MDR Administrator, unless all parties
notify the BCBSA Corporate Secretary in writing within two (2) days of receiving the Notice
of Termination of Mediation that they wish to pursue MDR with another nationally
recognized organization serving as MDR Administrator.
In the event the parties (i) did not pursue Mediation, (ii) pursued mediation with a
Mediator not affiliated with an ADR organization that offers a panel of arbitrators, or (iii) all
parties that pursued Mediation notified the BCBSA Corporate Secretary that they wish to
have an MDR Administrator that is different from the organization with which their mediator
was affiliated, they shall promptly attempt to agree on a nationally recognized ADR entity
that supplies a panel of arbitrators. If they reach such agreement within five (5) days of the
Notice of Termination of Mediation or receipt of the Answer or Reply to Counterclaim
(whichever is later), the parties shall promptly inform the BCBSA Corporate Secretary of
their agreed upon ADR organization. In the event the parties are unable to reach agreement
on an MDR Administrator within that timeframe, the BCBSA Corporate Secretary shall
immediately refer the matter to CPR, JAMS or a similar organization for MDR.
Any person who served as a Mediator shall not serve as an arbitrator for the same
or similar dispute for purposes of MDR.
B. Rules for MDR
The rules controlling all aspects of MDR shall be exclusively those provided for
herein. The rules promulgated or otherwise used by the MDR Administrator organization
shall not apply.
Amended as of September 20, 2007
-- 319 of 512 --
EXHIBIT 5
Page 7 of 23
C. Initial Conference
Within seven (7) days after a Notice of Termination has issued or the matter has
otherwise been referred to an MDR Administrator, or within five (5) days after the time for
filing and serving the Answer or Reply to any Counterclaim (whichever is later) if the parties
elect first not to mediate, the parties shall confer with the Administrator to discuss selecting
a dispute resolution panel ("the Panel"). This conference (the “Initial Conference”) may be
by telephone. The parties are encouraged to agree to the composition of the Panel and to
present that agreement to the Administrator at the Initial Conference. If the parties do not
agree on the composition of the Panel by the time of the Initial Conference, or by any
extension thereof agreed to by all parties and the Administrator, then the Panel Selection
Process set forth in subparagraph D, below, shall be followed.
D. Panel Selection Process
The Administrator shall designate, prior to the Initial Conference, at least seven
potential arbitrators. Each party shall be permitted to strike any designee for cause and the
Administrator shall determine the sufficiency thereof in its sole discretion. The Administrator
will designate a replacement for any designee so stricken. Each party shall then be
permitted one peremptory strike from the list of designees. The Administrator shall set the
dates for exercising all strikes, which shall be set to encourage the prompt selection of
arbitrators.
After the parties exercise any designee strikes for cause and their peremptory strike
against any designee of their choice, the parties shall each rank the remaining panel
members in order of preference and provide the Administrator, without serving on any other
party, their ranked list. The Administrator shall not disclose any party’s ranked list to
members of the panel or to other parties.
From the remaining designees, and after considering opportunities to maximize, so
far as possible, the collectively stated arbitrator preferences provided by the parties on their
ranked lists, the Administrator shall select a three member Panel. The Panel Selection
Process shall be completed no later than ten (10) days after the Initial Conference.
Each Arbitrator shall be compensated at his or her normal hourly rate or, in the
absence of an established rate, at a reasonable hourly rate to be promptly fixed by the
Administrator for all time spent in connection with the proceedings and shall be reimbursed
for any travel and other reasonable expenses.
Amended as of September 20, 2007
-- 320 of 512 --
EXHIBIT 5
Page 8 of 23
E. Duties Of The Arbitrators
The Panel shall promptly designate a Presiding Arbitrator for the purposes reflected
below, but shall retain the power to review and modify any ruling or other action of said
Presiding Arbitrator. Each Arbitrator shall be an independent Arbitrator, shall be governed
by the Code of Ethics for Arbitrators in Commercial Disputes and shall at or prior to the
commencement of any Arbitration Hearing take an oath to that effect. Each Arbitrator shall
promptly disclose in writing to the Panel and to the parties any circumstances, whenever
arising, that might cause doubt as to such Arbitrator's compliance, or ability to comply, with
said Code of Ethics, and, absent resignation by such Arbitrator, the remaining Arbitrators
shall determine in their sole discretion whether the circumstances so disclosed constitute
grounds for disqualification and for replacement. With respect to such circumstances
arising or coming to the attention of a party after an Arbitrator's selection, a party may
likewise request the Arbitrator's resignation or a determination as to disqualification by the
remaining Arbitrators. With respect to a sole Arbitrator, the determination as to
disqualification shall be made by the Administrator.
There shall be no ex parte communication between the parties or their counsel
and any member of the Panel.
F. Panel's Jurisdiction And Authority
The Panel's jurisdiction and authority shall extend to all disputes between or among
the Plans, their Controlled Affiliates, and/or BCBSA, except for those disputes excepted
from these MMDR procedures as set forth in the License Agreements.
With the exception of punitive or treble damages, the Panel shall have full authority to
award the relief it deems appropriate to resolve the parties' disputes, including monetary
awards and injunctions, mandatory or prohibitory. The Panel has no authority to award
punitive or treble damages except that the Panel may allocate or assess responsibility for
punitive or treble damages assessed by another tribunal. Subject to the above limitations,
the Panel may, by way of example, but not of limitation:
Amended as of September 20, 2007
-- 321 of 512 --
EXHIBIT 5
Page 9 of 23
i. interpret or construe the meaning of any terms, phrase or provision in
any license between BCBSA and a Plan or a Controlled Affiliate relating
to the use of the BLUE CROSS® or BLUE SHIELD® service marks.
ii. determine whether BCBSA, a Plan or a Controlled Affiliate has violated
the terms or conditions of any license between the BCBSA and a Plan or
a Controlled Affiliate relating to the use of the BLUE CROSS® or BLUE
SHIELD® service marks.
iii. decide challenges as to its own jurisdiction.
iv. issue such orders for interim relief as it deems appropriate pending
Hearing and Award in any Arbitration.
It is understood that the Panel is expected to resolve issues based on governing
principles of law, preserving to the maximum extent legally possible the continued integrity
of the Licensed Marks and the BLUE CROSS/BLUE SHIELD system. The Panel shall apply
federal law to all issues which, if asserted in the United States District Court, would give
rise to federal question jurisdiction, 28 U.S.C. § 1331. The Panel shall apply Illinois law to
all issues involving interpretation, performance or construction of any License Agreement or
Controlled Affiliate License Agreement unless the agreement otherwise provides. As to
other issues, the Panel shall choose the applicable law based on conflicts of law principles
of the State of Illinois.
G. Administrative Conference
Within five (5) days of the Panel being selected, the Presiding Arbitrator shall confer
with the parties and the other members of the Panel and shall schedule, in writing, a
conference in which the parties and the Panel shall participate (the “Administrative
Conference”). The Administrative Conference shall take place no later than fifteen (15) days
after the Panel is selected. At the Administrative Conference the parties and the Panel shall
discuss the scheduling of the Arbitration Hearing and any other matter appropriate to be
considered, including but not limited to: any written discovery in the form of requests for
production of documents or requests to admit facts; the identity of any witness whose
deposition a party may desire and a showing of exceptional good cause for the taking of
any such deposition; the desirability of bifurcation or other separation of the issues; the
need for and the type of record of conferences and hearings, including the need for
transcripts; the need for expert witnesses and
Amended as of September 20, 2007
-- 322 of 512 --
EXHIBIT 5
Page 10 of 23
how expert testimony should be presented; the appropriateness of motions to dismiss
and/or for full or partial summary judgment; consideration of stipulations; the desirability of
presenting any direct testimony in writing; and the necessity for any on-site inspection by
the Panel. If the parties agree, the Administrative Conference may be by telephone.
H. Discovery
i. Requests for Production of Documents: All requests for the production
of documents must be served no later than five (5) days after the date of
the Initial Conference. Within twenty (20) days after receipt of a request
for production of documents, a party shall (a) serve responses and
objections to the request,
(b) produce all responsive, non-privileged documents to the requesting
party, and (c) to the extent any responsive documents are withheld on the
grounds of attorney-client privilege or work product, produce a log
identifying such documents in the manner specified in Fed. R. Civ. P.
26(b)(5). If, after reviewing a privilege log, the requesting party believes
attorney-client privilege or work product protection was improperly claimed
by the producing party with respect to any document, the requesting party
may ask the Presiding Arbitrator to conduct an in-camera inspection of the
same. With respect to documentary and other discovery produced in any
MDR proceeding by BCBSA, the fact that a party’s CEO or other senior
officers may serve on the BCBSA Board of Directors, BCBSA Board
Committees or other BCBSA work groups, task forces and the like, shall
not be a basis for defeating an otherwise valid claim of attorney-client
privilege or work product protection over such documentary or other
discovery materials by BCBSA.
ii. Requests for Admissions: Requests for Admissions may be served up to
twenty-one (21) days prior to the discovery cut-off set by the Presiding
Arbitrator. A party served with Requests For Admissions must respond
within twenty (20) days of receipt of said request. The good faith use of
and response to Requests for Admissions is encouraged, and the Panel
shall have full discretion, with reference to the Federal Rules of Civil
Procedure, in awarding appropriate sanctions with respect to abuse of the
procedure.
Amended as of September 20, 2007
-- 323 of 512 --
EXHIBIT 5
Page 11 of 23
iii. Depositions: As a general rule, the parties will not be permitted to take
party or non-party deposition testimony for discovery purposes. The
Presiding Arbitrator, in his or her sole discretion, shall have the authority to
permit a party to take such deposition testimony upon a showing of
exceptional good cause. The parties will be permitted to take de bene esse
deposition1 testimony to the fullest extent permitted by law of any witness
who cannot be compelled to testify at the Arbitration Hearing. No
deposition, for discovery purposes or otherwise, shall exceed three (3)
hours, excluding objections and colloquy of counsel. Depositions may be
recorded in any manner recognized by the Federal Rules of Civil
Procedure and the parties shall specify in each notice of deposition or
request for permission to take deposition testimony the manner in which
such deposition shall be recorded.
iv. Expert witness(es): If a party intends to present the testimony of an
expert witness during the oral hearing, it shall provide all other parties
with a written statement setting forth the information required to be
provided by Fed. R. Civ. P. 26(a)(2)
A. ten (10) days prior to the discovery cut-off set by the Presiding
Arbitrator. If a party intends to present the testimony of a rebuttal expert
witness during the Arbitration Hearing, it shall provide all other parties with
a written statement setting forth the information required to be provided by
Fed. R. Civ. P. 26(a)(2)(B) within twenty (20) days after the date on which
the written statement of the expert witness whose testimony is to be
rebutted was produced.
v. Discovery cut-off: The Presiding Arbitrator shall determine the date on
which the discovery period will end, but the discovery period shall not
exceed thirty (30) days from the date of the Administrative Conference
without the agreement of all parties.
Amended as of September 20, 2007
––––––––––––––––––––––––
1 As used in these Rules, "de bene esse deposition" means a deposition that is not taken for discovery purposes,
but is taken for the purpose of reading part or all of the deposition transcript into the record at the Arbitration
Hearing, to the extent permitted by the Panel, because the witness cannot be compelled to testify at the
Arbitration Hearing or has exercised a right provided under these Rules to provide deposition testimony in lieu of
testimony at the Arbitration Hearing.
-- 324 of 512 --
EXHIBIT 5
Page 12 of 23
vi. Additional discovery: Any additional discovery will be at the discretion
of the Presiding Arbitrator.
vii. Discovery Disputes: Any discovery disputes shall be raised by motion to
the Presiding Arbitrator, who is authorized to resolve all such disputes, and
whose resolution will be binding on the parties unless modified by the
Arbitration Panel. Prior to raising any discovery dispute with the Presiding
Arbitrator, the parties shall meet and confer, telephonically or in person, in
an attempt to resolve or narrow the dispute. If a party refuses to comply
with a decision resolving a discovery dispute, the Panel, in keeping with
Fed. R. Civ. P. 37, may refuse to allow that party to support or oppose
designated claims or defenses, prohibit that party from introducing
designated matters into evidence or, in extreme cases, decide an issue
submitted for resolution adversely to that party.
viii.Extensions: The time for responding to discovery requests may be
extended by the Presiding Arbitrator for good and sufficient cause shown.
Any request for such an extension shall be made in writing.
I. Panel Suggested Settlement/Mediation
At any point during the proceedings, the Panel at the request of any party or on its
own initiative, may suggest that the parties explore settlement and that they do so at or
before the conclusion of the Arbitration Hearing, and the Panel shall give such assistance in
settlement negotiations as the parties may request and the Panel may deem appropriate.
Alternatively, the Panel may direct the parties to endeavor to mediate their disputes as
provided above, or to explore a mini-trial proceeding, or to have an independent party
render a neutral evaluation of the parties’ respective positions. The Panel shall enter such
sanctions as it deems appropriate with respect to any party failing to pursue in good faith
such Mediation or other alternate dispute resolution methods.
Amended as of September 20, 2007
-- 325 of 512 --
EXHIBIT 5
Page 13 of 23
J. Subpoenas on Third Parties
Pursuant to, and consistent with, the Federal Arbitration Act, 9 U.S.C. § 9 et seq.,
and subject to Paragraph 3.G(iii) above, a party may request the issuance of a subpoena
on any third party, including but not limited to any third party Blue Plan or any officer,
employee or director of a third party Blue Plan, to compel deposition testimony or the
production of documents, and, if good and sufficient cause is shown, the Panel shall issue
such a subpoena.
K. Arbitration Hearing
An Arbitration Hearing will be held within thirty (30) days after the Administrative
Conference if no discovery is taken, or within thirty (30) days after the close of discovery,
unless all parties and the Panel agree to extend the Arbitration Hearing date, or unless the
parties agree in writing to waive the Arbitration Hearing. The parties may mutually agree on
the location of the Arbitration Hearing. If the parties fail to agree, the Arbitration Hearing
shall be held in Chicago, Illinois, or at such other location determined by the Presiding
Arbitrator to be most convenient to the participants. The Panel will determine the date(s)
and time(s) of the Arbitration Hearing(s) after consultation with all parties and shall provide
reasonable notice thereof to all parties or their representatives.
L. Arbitration Hearing Memoranda
Twenty (20) days prior to the Arbitration Hearing, each party shall submit to the other
party (or parties) and to the Panel an Arbitration Hearing Memorandum which sets forth the
applicable law and any argument as to any relevant issue. The Arbitration Hearing
Memorandum will supplement, and not repeat, the allegations, information and documents
contained in or with the Complaint, Answer, Counterclaim and Reply, if any. Ten (10) days
prior to the Arbitration Hearing, each party shall submit to each other party a list of all expert
and fact witnesses (but not including rebuttal fact witness) that such party intends to have
testify at the Arbitration Hearing and a brief summary of the testimony each such witness is
expected to give. In addition, no later than five (5) days prior to the Arbitration, each party
may submit to each other party and to the Panel a Response Arbitration Hearing
Memorandum which sets forth any response to another party's Arbitration Hearing
Memorandum.
Amended as of September 20, 2007
-- 326 of 512 --
EXHIBIT 5
Page 14 of 23
M. Notice For Testimony
Ten (10) days prior to the Arbitration Hearing, any party may serve a Notice on any
other party (or parties) requesting the attendance at the Arbitration Hearing of any officer,
employee or director of the other party (or parties) for the purpose of providing
noncumulative testimony. If a party fails to produce one of its officers, employees or
directors whose noncumulative testimony during the Arbitration Hearing is reasonably
requested by an adverse party, the Panel may refuse to allow that party to support or
oppose designated claims or defenses, prohibit that party from introducing designated
matters into evidence or, in extreme cases, decide an issue submitted for mandatory
dispute resolution adversely to that party; provided, however, that a party may refuse to
produce a director to testify if, within two (2) days of receiving a notice requesting the
attendance of such director at the Arbitration Hearing, the party agrees to make the director
available for a de bene esse deposition at a mutually convenient time at any location within
fifty (50) miles of the director’s primary residence chosen by the party requesting the
director’s testimony. This Rule may not be used for the purpose of burdening or harassing
any party, and the Presiding Arbitrator may impose such orders as are appropriate so as to
prevent or remedy any such burden or harassment.
Pursuant to, and consistent with, the Federal Arbitration Act, 9 U.S.C. § 9 et seq.,
twenty (20) days or more prior to the Arbitration Hearing, a party may request the issuance
of a subpoena on any third party, including but not limited to any third party Blue Plan,
BCBSA or any officer, employee or director of a third party Blue Plan or BCBSA for the
purpose of providing noncummulative testimony at the Arbitration Hearing, and, if good and
sufficient cause is shown, the Panel shall issue such a subpoena; provided however, that a
director of a third party Blue Plan or BCBSA may refuse to testify if, within two (2) days of
receiving a subpoena requesting the attendance of such director at the Arbitration Hearing,
the director agrees to make him/herself available for a de bene esse deposition at a
mutually convenient time at any location within fifty
(50) miles of the director’s primary residence chosen by the party requesting the director’s
testimony. Each Blue Plan agrees to waive, on its own behalf and on behalf of its directors
and officers, any objection it otherwise might have to any such subpoena based on
service, venue or extraterritoriality.
Amended as of September 20, 2007
-- 327 of 512 --
EXHIBIT 5
Page 15 of 23
N. Arbitration Hearing Procedures
i. Attendance at Arbitration Hearing: Any person having a direct interest
in the proceeding is entitled to attend the Arbitration Hearing. The
Presiding Arbitrator shall otherwise have the power to require the
exclusion of any witness, other than a party or other essential person,
during the testimony of any other witness. It shall be discretionary with
the Presiding Arbitrator to determine the propriety of the attendance of
any other person.
ii. Confidentiality: The Panel and all parties shall maintain the privacy of the
Arbitration Proceeding. The parties and the Panel shall treat the Arbitration
Hearing and any discovery or other proceedings or events related thereto,
including any award resulting therefrom, as confidential except as
otherwise necessary in connection with a judicial challenge to or
enforcement of an award or unless otherwise required by law.
iii. Stenographic Record: Any party, or if the parties do not object, the
Panel, may request that a stenographic or other record be made of any
Arbitration Hearing or portion thereof. The costs of the recording and/or
of preparing the transcript shall be borne by the requesting party and by
any party who receives a copy thereof. If the Panel requests a recording
and/or a transcript, the costs thereof shall be borne equally by the
parties.
iv. Oaths: The Panel may require witnesses to testify under oath or
affirmation administered by any duly qualified person and, if requested
by any party, shall do so.
v. Order of Arbitration Hearing: An Arbitration Hearing shall be opened by
the recording of the date, time, and place of the Arbitration Hearing, and
the presence of the Panel, the parties, and their representatives, if any.
The Panel may, at the beginning of the Arbitration Hearing, ask for
statements clarifying the issues involved.
Amended as of September 20, 2007
-- 328 of 512 --
EXHIBIT 5
Page 16 of 23
Unless otherwise agreed, the complaining party (or parties) shall then
present evidence to support their claim(s). The respondent(s) shall then
present evidence supporting their defenses and Counterclaims, if any.
The complaining party (or parties) shall then present evidence supporting
defenses to the Counterclaims, if any, and rebuttal.
Witnesses for each party shall submit to questions by adverse parties
and/or the Panel.
The Panel has the discretion to vary these procedures, but shall afford a
full and equal opportunity to all parties for the presentation of any material
and relevant evidence.
vi. Evidence: The parties may offer such evidence as is relevant and material
to the dispute and shall produce such evidence as the Panel may deem
necessary to an understanding and resolution of the dispute. Unless good
cause is shown, as determined by the Panel or agreed to by all other
parties, no party shall be permitted to offer evidence at the Arbitration
Hearing which was not disclosed prior to the Arbitration Hearing by that
party. The Panel may receive and consider the evidence of witnesses by
affidavit upon such terms as the Panel deems appropriate.
The Panel shall be the judge of the relevance and materiality of the
evidence offered, and conformity to legal rules of evidence, other than
enforcement of the attorney-client privilege and the work product
protection, shall not be necessary. The Federal Rules of Evidence shall be
considered by the Panel in conducting the Arbitration Hearing but those
rules shall not be controlling. All evidence shall be taken in the presence
of the Panel and all of the parties, except where any party is in default or
has waived the right to be present.
Settlement offers by any party in connection with Mediation or MDR
proceedings, decisions or recommendations of the selected mediators,
and a party's position papers or statements furnished to the selected
mediators shall not be admissible evidence or considered by the Panel
without the consent of all parties.
-- 329 of 512 --
EXHIBIT 5
Page 17 of 23
vii. Closing of Arbitration Hearing: The Presiding Arbitrator shall
specifically inquire of all parties whether they have any further proofs to
offer or witnesses to be heard. Upon receiving negative replies or if he or
she is satisfied that the record is complete, the Presiding Arbitrator shall
declare the Arbitration Hearing closed with an appropriate notation made
on the record. Subject to being reopened as provided below, the time
within which the Panel is required to make the award shall commence to
run, in the absence of contrary agreement by the parties, upon the closing
of the Arbitration Hearing.
With respect to complex disputes, the Panel may, in its sole discretion,
defer the closing of the Arbitration Hearing for a period of up to thirty (30)
days after the presentation of proofs in order to permit the parties to
submit post-hearing briefs and argument, as the Panel deems appropriate,
prior to making an award.
For good cause, the Arbitration Hearing may be reopened for up to thirty
(30) days on the Panel's initiative, or upon application of a party, at any
time before the award is made
O. Awards
An Award must be in writing and shall be made promptly by the Panel and, unless
otherwise agreed by the parties or specified by law, no later than thirty (30) days from the
date of closing the Arbitration Hearing. If all parties so request, the Award shall contain
findings of fact and conclusions of law. The Award, and all other rulings and determinations
by the Panel, may be by a majority vote.
Parties shall accept as legal delivery of the Award the placing of the Award or a true
copy thereof in the mail addressed to a party or its representative at its last known address
or personal service of the Award on a party or its representative.
Awards are binding only on the parties to the Arbitration and are not binding on
any non-parties to the Arbitration and may not be used or cited as precedent in any
other proceeding.
Amended as of September 20, 2007
-- 330 of 512 --
EXHIBIT 5
Page 18 of 23
After the expiration of twenty (20) days from initial delivery, the Award (with
corrections, if any) shall be final and binding on the parties, and the parties shall undertake
to carry out the Award without delay.
Proceedings to confirm, modify or vacate an Award shall be conducted in
conformity with and controlled by the Federal Arbitration Act. 9 U.S.C. § 1, et seq.
P. Return of Documents
Within sixty (60) days after the Award and the conclusion of any judicial
proceedings with respect thereto, each party and the Panel shall return any documents
produced by any other party, including all copies thereof. If a party receives a discovery
request in any other proceeding which would require it to produce any documents
produced to it by any other party in a proceeding hereunder, it shall not produce such
documents without first notifying the producing party and giving said party reasonable time
to respond, if appropriate, to the discovery request.
4. Miscellaneous
A. Expedited Procedures
Any party to a Mediation may direct a request for an expedited Mediation Hearing to
the Chairman of the Mediation Committee, to the selected Mediators, and to all other
parties at any time. The Chairman of the Mediation Committee, or at his or her direction,
the then selected Mediators, shall grant any request which is supported by good and
sufficient reasons. If such a request is granted, the Mediation shall be completed within as
short a period as practicable, as determined by the Chairman of the Mediation Committee
or, at his or her direction, the then selected Mediators.
Any party to an Arbitration may direct a request for expedited proceedings to the
Administrator, to the Panel, and to all other parties at any time. The Administrator, or the
Presiding Arbitrator if the Panel has been selected, shall grant any such request which is
supported by good and sufficient reasons. If such a request is granted, the Arbitration shall
be completed within as short a time as practicable, as determined by the Administrator
and/or the Presiding Arbitrator.
Amended as of September 20, 2007
-- 331 of 512 --
EXHIBIT 5
Page 19 of 23
B. Temporary or Preliminary Injunctive Relief
Any party may seek temporary or preliminary injunctive relief with the filing of a
Complaint or at any time thereafter. If such relief is sought prior to the time that an
Arbitration Panel has been selected, then the Administrator shall select a single Arbitrator
who is a lawyer who has no interest in the subject matter of the dispute, and no connection
to any of the parties, to hear and determine the request for temporary or preliminary
injunction. If such relief is sought after the time that an Arbitration Panel has been selected,
then the Arbitration Panel will hear and determine the request. The request for temporary or
preliminary injunctive relief will be determined with reference to the temporary or preliminary
injunction standards set forth in Fed. R. Civ. P. 65.
C. Defaults and Proceedings in the Absence of a Party
Whenever a party fails to comply with the MDR Rules in a manner deemed
material by the Panel, the Panel shall fix a reasonable time for compliance and, if the
party does not comply within said period, the Panel may enter an Order of default or
afford such other relief as it deems appropriate.
Arbitration may proceed in the event of a default or in the absence of any party who, after
due notice, fails to be present or fails to obtain an extension. An Award shall not be made
solely on the default or absence of a party, but the Panel shall require the party who is
present to submit such evidence as the Panel may require for the making of findings,
determinations, conclusions, and Awards.
D. Notice
Each party shall be deemed to have consented that any papers, notices, or
process necessary or proper for the initiation or continuation of a proceeding under these
rules or for any court action in connection therewith may be served on a party by mail
addressed to the party or its representative at its last known address or by personal
service, in or outside the state where the MDR proceeding is to be held.
The Corporate Secretary and the parties may also use facsimile transmission, telex,
telegram, or other written forms of electronic communication to give the notices required by
these rules.
-- 332 of 512 --
EXHIBIT 5
Page 20 of 23
E. Expenses
The expenses of witnesses shall be paid by the party causing or requesting the
appearance of such witnesses. All expenses of the MDR proceeding, including
compensation, required travel and other reasonable expenses of the Panel, and the cost of
any proof produced at the direct request of the Panel, shall be borne equally by the parties
and shall be paid periodically on a timely basis, unless they agree otherwise or unless the
Panel in the Award assesses such expenses, or any part thereof against any party (or
parties). In exceptional cases, the Panel may award reasonable attorneys' fees as an item
of expense, and the Panel shall promptly determine the amount of such fees based on
affidavits or such other proofs as the Panel deems sufficient.
F. Disqualification or Disability of A Panel Member
In the event that any Arbitrator of a Panel with more than one Arbitrator should
become disqualified, resign, die, or refuse or be unable to perform or discharge his or her
duties after the commencement of MDR but prior to the rendition of an Award, and the
parties are unable to agree upon a replacement, the remaining Panel member(s):
i. shall designate a replacement, subject to the right of any party to
challenge such replacement for cause.
ii. shall decide the extent to which previously held hearings shall be
repeated.
If the remaining Panel members consider the proceedings to have progressed to
a stage as to make replacement impracticable, the parties may agree, as an alternative
to the recommencement of the Mandatory Dispute Resolution process, to resolution of
the dispute by the remaining Panel members.
In the event that a single Arbitrator should become disqualified, resign, die, or
refuse or be unable to perform or discharge his or her duties after the commencement of
MDR but prior to the rendition of an Award, and the parties are unable to agree upon a
replacement, the Administrator shall appoint a successor, subject to the right of any
party to challenge such successor for cause, and the successor shall decide the extent
to which previously held proceedings shall be repeated.
-- 333 of 512 --
EXHIBIT 5
Page 21 of 23
G. Extensions of Time
Subject to the provisions of Paragraph 3.H.(viii.), any time limit set forth in these
Rules may be extended upon agreement of the parties and approval of: (1) the Mediator if
the proceeding is then in Mediation; (2) the Administrator if the proceeding is in Arbitration,
but no Arbitration Panel has been selected; or (3) the Arbitration Panel, if the proceeding is
in Arbitration and the Arbitration Panel has been selected.
H. Intervention
The Plans, their Controlled Affiliates, and BCBSA, to the extent subject to MMDR
pursuant to their License Agreements, shall have the right to move to intervene in any
pending Arbitration. A written motion for intervention shall be made to: (1) the
Administrator, if the proceeding is in Arbitration, but no Arbitration Panel has been selected;
or (2) the Arbitration Panel, if the proceeding is in Arbitration and the Arbitration Panel has
been selected. The written motion for intervention shall be delivered to the BCBSA
Corporate Secretary (which shall also constitute service on the BCBSA if it is a respondent)
and to any Plan(s) and/or Controlled Affiliate(s) which are parties to the proceeding. Any
party to the proceeding can submit written objections to the motion to intervene. The
motion for intervention shall be granted upon good cause shown. Intervention also may be
allowed by stipulation of the parties to the Arbitration proceeding. Intervention shall be
allowed upon such terms as the Arbitration Panel decides.
I. BCBSA Assistance in Resolution of Disputes
The resources and personnel of the BCBSA may be requested by any member
Plan at any time to try to resolve disputes with another Plan.
J. Neutral Evaluation
The parties can voluntarily agree at any time to have an independent party render a
neutral evaluation of the parties’ respective positions.
Amended as of September 20, 2007
-- 334 of 512 --
EXHIBIT 5
Page 22 of 23
K. Recovery of Attorney Fees and Expenses
i. Motions to Compel
Nothwithstanding any other provisions of these Rules, any Party subject to the
License Agreements (for purposes of this Section K and all of its sub- sections only
hereinafter referred to collectively and individually as a “Party”) that initiates a court
action or administrative proceeding solely to compel adherence to these Rules shall
not be determined to have violated these Rules by initiating such action or
proceeding.
ii. Recovery of Fees, Expenses and Costs
The Arbitration Panel may, in its sole discretion, award a Party its reasonable
attorneys’ fees, expenses and costs associated with a filing to compel adherence to
these Rules and/or reasonable attorneys’ fees, expenses and costs incurred in
responding to an action filed in violation of these Rules; provided, however, that
neither fees, expenses, nor costs shall be awarded by the Arbitration Panel if the
Party from which the award is sought can demonstrate to the Arbitration panel, in its
sole discretion, that it did not violate these Rules or that it had reasonable grounds
for believing that its action did not violate these Rules.
iii. Requests for Reimbursement
For purposes of this Section K, any Party may request reimbursement of fees,
expenses and/or costs by submitting said request in writing to the Arbitration Panel at
any time before an award is delivered pursuant Paragraph to 3.O above with a copy
to the Party from which reimbursement is sought, explaining why it is entitled to such
reimbursement. The Party from which reimbursement is sought shall have twenty
(20) days to submit a response to such request to the Arbitration Panel with a copy to
the Party seeking reimbursement.
Amended as of September 20, 2007
-- 335 of 512 --
EXHIBIT 5
Page 23 of 23
L. Calculation of Time and Deadlines
In computing any period of time prescribed or allowed under these rules, the day of
the act or event from which the designated period of time begins to run shall not be included.
The last day of the period so computed shall be included, unless it is a Saturday, a Sunday,
or a legal holiday, in which event the period runs until the end of the next day which is not
one of the aforementioned days. When the period of time prescribed is less than six (6) days,
intermediate Saturdays, Sundays and legal holidays shall be excluded in the computation. As
used in this rule, “legal holiday” includes New Year’s Day, Martin Luther King, Jr. Day,
Washington’s Birthday, Memorial Day, Independence Day, Labor Day, Columbus Day,
Veterans Day, Thanksgiving Day, Christmas Day and any other day appointed as a holiday
by the President or the Congress of the United States.
Amended as of September 20, 2007
-- 336 of 512 --
BLUE SHIELD LICENSE AGREEMENT
(Includes revisions, if any, adopted by Member Plans through their September 17, 2020 meeting)
This agreement by and between Blue Cross and Blue Shield Association ("BCBSA") and The Blue Shield Plan,
known as ______________ (the "Plan").
Preamble
WHEREAS, the Plan and/or its predecessor(s) in interest (collectively the "Plan") had the right to use the BLUE
SHIELD and BLUE SHIELD Design service marks (collectively the "Licensed Marks") for health care plans in its service
area, which was essentially local in nature;
WHEREAS, the Plan was desirous of assuring nationwide protection of the Licensed Marks, maintaining uniform
quality controls among Plans, facilitating the provision of cost effective health care services to the public and otherwise
benefiting the public;
WHEREAS, to better attain such ends, the Plan and the predecessor of BCBSA executed the Agreement(s) Relating
to the Collective Service Mark "Blue Shield"; and
WHEREAS, BCBSA and the Plan desire to supercede said Agreement(s) to reflect their current practices and to
assure the continued integrity of the Licensed Marks and of the BLUE SHIELD system;
NOW, THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as
follows:
-- 337 of 512 --
Agreement
1. BCBSA hereby grants to the Plan, upon the terms and conditions of this
License Agreement (“Agreement” or “Primary License Agreement”), the right to use
BLUE SHIELD in its trade and/or corporate name (the "Licensed Name"), and the right
to use the Licensed Marks, in the sale, marketing and administration of health care
plans and related services in the Service Area set forth and defined in paragraph 5
below. As used herein, health care plans and related services shall include acting as a
nonprofit health care plan, a for-profit health care plan, or mutual health insurer
operating on a not-for-profit or for-profit basis, under state law; financing access to
health care services; when working with a bank that holds the relevant license to use
the Licensed Name and Marks, offering: (i) tax-favored savings accounts for medical
expenses and means for accessing such accounts, such as debit cards or checks, that
are provided solely to support access to such tax-favored savings accounts, all
pursuant to such license, or (ii) prepaid rewards cards that are provided for completion
of a wellness program, all pursuant to such license; providing health care management
and administration; administering, but not underwriting, non-health portions of Workers’
Compensation Insurance; delivering health care services, except hospital services (as
defined in the Guidelines to Membership Standards Applicable to Regular Members);
and performing the Eligibility and Enrollment functions of HR administration for all
benefit plans offered by a group account to its members, including benefit plans not
provided by the Plan, provided that the Plan has contracted to provide Health
Coverage under the Licensed Marks to the account (as the terms “Health Coverage”,
“Eligibility” and “Enrollment” are defined in Exhibit 4, Paragraph 2.t.).
2. The Plan may use the Licensed Marks and Name in connection with the
offering of: i) health care plans and related services in the Service Area through
Controlled Affiliates, provided that each such Controlled Affiliate is separately licensed
to use the Licensed Marks and Name under the terms and conditions contained in the
Agreement attached as Exhibit 1 hereto (the "Controlled Affiliate License Agreement");
and ii) insurance coverages offered by life insurers under the applicable law in the
Service Area, other than those which the Plan may offer in its own name, provided
through Controlled Affiliates, provided that each such Controlled Affiliate is separately
licensed to use the Licensed Marks and Name under the terms and conditions
contained in the Agreement attached as Exhibit 1A hereto (the "Controlled Affiliate
License Agreement Applicable to Life Insurance Companies") or the Agreement
attached as Exhibit 1A1 hereto (the “Controlled Affiliate Trademark License Agreement
for Life and Disability Insurance Products”) and further provided that the offering of such
services does not and will not dilute or tarnish the unique value of the Licensed Marks
and Name; and iii) administration and underwriting of Workers’ Compensation
Insurance Controlled Affiliates, provided that each such Controlled Affiliate is separately
licensed to use the Licensed Marks and Name under the terms and conditions
contained in the Agreement attached as Exhibit 1 hereto (the “Controlled Affiliate
License”); and iv) regional Medicare Advantage PPO Products in cooperation with one
or more other Plans through jointly-held Controlled Affiliates, provided that each such
Controlled Affiliate is separately licensed to use the Licensed Marks and Name under
the terms and conditions contained in the Agreement attached as Exhibit 1B hereto (the
“Controlled Affiliate License Agreement Applicable to Regional Medicare Advantage
PPO Products”); and v) regional Medicare Part D Prescription Drug Plan products in
cooperation with one or more other Plans through jointly-held Controlled Affiliates,
provided that each such Controlled Affiliate is separately licensed to use the Licensed
Marks and Name under the terms and conditions contained in the Agreement attached
as Exhibit 1C hereto (the “Controlled Affiliate License Agreement Applicable to Regional
Medicare Part D Prescription Drug Plan Products”). As used herein, a Controlled
Affiliate is defined as an entity organized and operated in such a manner that it is
subject to the bona fide control of a Plan or Plans and, if the entity meets the standards
of Paragraph 2a.B but not Paragraph 2a.A, the entity, its owners, and persons with
Amended as of September 19, 2014
-- 338 of 512 --
authority to select or appoint members or board members, other than a Plan or Plans,
have received written approval of BCBSA. Absent written approval by BCBSA of an
alternative method of control, bona fide control shall have the meaning set forth in
Paragraphs 2a. and 2b.
2a. With respect to the Controlled Affiliate Licenses authorized in clauses
i) through iii) of Paragraph 2, bona fide control shall mean that a Plan (the “Sponsoring
Plan”) authorized to use the Licensed Marks in the Service Area of the Controlled
Affiliate pursuant to this Primary License Agreement with BCBSA must have:
A. The legal authority, directly or indirectly through wholly-owned subsidiaries: (a) to select members of the
Controlled Affiliate's governing body having more than 50% voting control thereof; (b) to exercise control
over the policy and operations of the Controlled Affiliate; (c) to prevent any change in the articles of
incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate with which
the Sponsoring Plan do not concur. In addition, the Sponsoring Plan directly or indirectly through wholly-
owned subsidiaries shall own more than 50% of any for-profit Controlled Affiliate, provided that in
instances where the Sponsoring Plan formed a publicly traded Controlled Affiliate Licensee and such
publicly traded Controlled Affiliate Licensee owns and controls other Controlled Affiliate Licensees, the
Sponsoring Plan directly or indirectly shall own and control more than 50% of any Controlled Affiliate that is
indirectly owned and controlled by the publicly traded Controlled Affiliate Licensee; or
B. The legal authority directly or indirectly through wholly-owned subsidiaries (a) to select members of the
Controlled Affiliate's governing body having not less than 50% voting control thereof; (b) to prevent any
change in the articles of incorporation, bylaws or other establishing or governing documents of the
Controlled Affiliate with which the Sponsoring Plan do not concur; (c) to exercise control over the policy
and operations of the Controlled Affiliate at least equal to that exercised by persons or entities (jointly or
individually) other than the Sponsoring Plan. Notwithstanding anything to the contrary in (a) through (c)
hereof, the Controlled Affiliate’s establishing or governing documents must also require written approval by
the Sponsoring Plan before the Controlled Affiliate can:
1. Change its legal and/or trade name;
2. Change the geographic area in which it operates;
3. Change any of the types of businesses in which it engages;
4. Create, or become liable for by way of guarantee, any indebtedness, other than
indebtedness arising in the ordinary course of business;
5. Sell any assets, except for sales in the ordinary course of business or sales of equipment no
longer useful or being replaced;
6. Make any loans or advances except in the ordinary course of business;
Amended as of March 26, 2015
-2-
-- 339 of 512 --
7. Enter into any arrangement or agreement with any party
directly or indirectly affiliated with any of the owners of the
Controlled Affiliate or persons or entities with the authority to select or appoint members or
board members of the Controlled Affiliate, other than the Sponsoring Plan or other Plans
(excluding owners of stock holdings of under 5% in a publicly traded Controlled Affiliate);
8. Conduct any business other than under the Licensed Marks
and Name;
9. Take any action that the Sponsoring Plan or BCBSA
reasonably believes will adversely affect the Licensed
Marks or Names.
In addition, the Sponsoring Plan directly or indirectly through wholly owned subsidiaries shall own at least
50% of any for-profit Controlled Affiliate, provided that in instances where the Sponsoring Plan formed a
publicly traded Controlled Affiliate Licensee and such publicly traded Controlled Affiliate Licensee owns and
controls other Controlled Affiliate Licensees, the Sponsoring Plan directly or indirectly shall own and control at
least 50% of any Controlled Affiliate that is indirectly owned and controlled by the publicly traded Controlled
Affiliate Licensee; or
C. With respect to a Controlled Affiliate that is 100% controlled by Plans including the Sponsoring Plan
and which offers solely Medicaid, Medicare Advantage PPO, Medicare Advantage HMO and/or Special
Need Plans products and services, the legal authority by the Sponsoring Plan together with such other
Plans (a) to select all members of the Controlled Affiliate’s governing body; (b) to prevent any change
in the articles of incorporation, bylaws, or other establishing or governing documents of the Controlled
Affiliate; (c) to exercise control over the policy and operations of the Controlled Affiliate. In addition, the
Sponsoring Plan and such other Plans shall own 100% of any for-profit Controlled Affiliate, with the
Sponsoring Plan and such other Plans each having an ownership interest. Such 100% control and
ownership by Plans shall be direct or, if indirect, solely through affiliates that are licensed to use marks
owned by BCBSA. Further, the Sponsoring Plan and such other Plans shall execute the “Addendum to
Controlled Affiliate License” attached as Exhibit B-1 to Exhibit 1 attached hereto; or
Amended as of June 20, 2019
-- 340 of 512 --
D. With respect to a Controlled Affiliate that is 100% controlled by a Sponsoring Plan which on a Blue-branded
basis, offers solely a Basic Medicare Part D Prescription Drug product, the legal authority by the
Sponsoring Plan (a) to select all members of the Controlled Affiliate’s governing body; (b) to prevent any
change in the articles of incorporation, bylaws or other establishing or governing documents of the
Controlled Affiliate; (c) to exercise control over the policy and operations of the Controlled Affiliate. In
addition, the Sponsoring Plan shall own 100% of any for-profit Controlled Affiliate. Such 100% control
and ownership by the Plan shall be direct or, if indirect, solely through affiliates that are licensed to use
marks owned by BCBSA. Further, the Sponsoring Plan and Participating Plan as defined on the
Controlled Affiliate License Agreement shall execute the “Addendum to Controlled Affiliate License”
attached as Exhibit B-2 to Exhibit 1 attached hereto.
E. With respect to a Controlled Affiliate that operates as a clinic, the legal authority by the Sponsoring Plan to
exercise control over the policy and operations of the Controlled Affiliate as defined in Exhibit 1,
Standard 1(E) and the Guidelines to Administer Standard 1 (E). In addition, if the clinic is for-profit, the
Sponsoring Plan shall own at least 50% of the Controlled Affiliate and prevent any change in the articles
of incorporation, bylaws or other establishing documents of the Controlled Affiliate with which the
Sponsoring Plan does not concur.
2b. With respect to the Controlled Affiliate License Agreements authorized in
clauses iv) and v) of Paragraph 2, bona fide control shall mean that the Controlled Affiliate is organized and operated in
such a manner that it meets the following requirements:
A. The Controlled Affiliate is owned or controlled by two or more Plans authorized to use the Licensed Marks
pursuant to this License Agreement with BCBSA (for purposes of this subparagraph A. through subparagraph C., the
“Controlling Plans”); and
Amended as of June 20, 2019
-2a-
-- 341 of 512 --
B. Each Controlling Plan is authorized pursuant to this Agreement to use the Licensed Marks in a geographic
area in the Region (as that term is defined in such Controlled Affiliate License Agreements) and every
geographic area in the Region is so licensed to at least one of the Controlling Plans; and
C. The Controlling Plans must have the legal authority directly or indirectly through wholly-owned
subsidiaries (a) to select members of the Controlled Affiliate’s governing body having not less than
100% voting control thereof; (b) to prevent any change in the articles of incorporation, bylaws or other
establishing or governing documents of the Controlled Affiliate with which the Controlling Plans do not
concur; and (c) to exercise control over the policy and operations of the Controlled Affiliate.
Notwithstanding anything to the contrary in (a) through (c) of this subparagraph E., the Controlled
Affiliate’s establishing or governing documents must also require written approval by each of the
Controlling Plans before the Controlled Affiliate can:
1. Change its legal and/or trade names;
2. Change the geographic area in which it operates (except such approval shall not be required
with respect to business of the Controlled Affiliate conducted under the Licensed Marks
within the Service Area of one of the Controlling Plans pursuant to a separate controlled
affiliate license agreement with BCBSA sponsored by such Controlling Plan);
3. Change any of the type(s) of businesses in which it engages (except such approval shall not be
required with respect to business of the Controlled Affiliate conducted under the Licensed
Marks within the Service Area of one of the Controlling Plans pursuant to a separate
controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan);
4. Take any action that any Controlling Plan or BCBSA reasonably believes will adversely affect
the Licensed Marks and Name.
In addition, the Controlling Plans directly or indirectly through wholly- owned
subsidiaries shall own 100% of any for-profit Controlled Affiliate.
Amended as of June 20, 2019
(the next page is 3)
-2b-
-- 342 of 512 --
3. With respect to a Controlled Affiliate that is not licensed to use the
Licensed Marks and Name, the Plan may, in communications that contain the Licensed Marks or Name, indicate its
corporate relationship to the Affiliate and permit such Affiliate to indicate its corporate relationship to the Plan, solely in
the circumstances, style and manner specified by BCBSA from time-to-time in regulations of general application
consistent with the avoidance of confusion or mistake or the dilution or tarnishment of the Licensed Marks and Name.
No rights are hereby created in any Controlled Affiliate to use the Licensed Marks or Name in its own name or
otherwise.
4. The Plan recognizes the importance of a comprehensive national network
of independent BCBSA licensees which are committed to strengthening the Licensed
Marks and Name. The Plan further recognizes that its actions within its Service Area
may affect the value of the Licensed Marks and Name nationwide. The Plan agrees
(a) to maintain in good standing its membership in BCBSA; (b) promptly to pay its dues
to BCBSA, said dues to represent the royalties for this License Agreement; (c)
materially to comply with all applicable laws; (d) to comply with the Membership Standards Applicable to Regular
Members of BCBSA, a current copy of which is attached as Exhibit 2 hereto; and (e) reasonably to permit BCBSA,
upon a written, good faith request and during reasonable business hours, to inspect the Plan's books and records
necessary to ascertain compliance herewith. As to other Plans and third parties, BCBSA shall maintain the
confidentiality of all documents and information furnished by the Plan pursuant hereto, or pursuant to the Membership
Standards, and clearly designated by the Plan as containing proprietary information of the Plan.
5. The rights hereby granted are exclusive to the Plan within the
geographical area(s) served by the Plan on June 30, 1972, and/or as to which the Plan
has been granted a subsequent license, which is hereby defined as the "Service Area,"
except that BCBSA reserves the right to use the Licensed Marks in said Service Area,
and except to the extent that said Service Area may overlap areas served by one or
more other licensed Blue Shield Plans as of said date or subsequent license, as to
which overlapping areas the rights hereby granted are nonexclusive as to such other
Plan or Plans only.
Amended as of June 19, 2014
-3-
-- 343 of 512 --
6. Except as expressly provided by BCBSA with respect to National
Accounts, Government Programs and certain other necessary and collateral uses, the
current rules and regulations governing which are attached as Exhibit 3 and Exhibit 4
hereto, and are contained in other documents referenced herein, or as expressly
provided herein, the Plan may not use the Licensed Marks and Name outside the
Service Area or in connection with other goods and services, nor may the Plan use the
Licensed Marks or Name in a manner which is intended to transfer in the Service Area
the goodwill associated therewith to another mark or name. Nothing herein shall be
construed to prevent the Plan from engaging in lawful activity anywhere under other
marks and names not confusingly similar to the Licensed Marks and Name, provided
that engaging in such activity does and will not dilute or tarnish the unique value of the
Licensed Marks and Name. In addition to any and all remedies available hereunder,
BCBSA may impose monetary fines on the Plan for the Plan’s use of the Licensed
Marks and Names outside the Service Area, and provided that the procedure used in
imposing a fine is consistent with procedures specifically prescribed by BCBSA from
time to time in regulations of general application. In the case of regional Medicare
Advantage PPO and regional Medicare Part D Prescription Drug Plan products offered
by consenting and participating Plans in a region that includes the Service Areas, or
portions thereof, of more than one Plan, such fine may be imposed jointly on the
consenting and participating Plans for use of the Licensed Marks and Name in any
geographic area of the region in which a Plan having exclusive rights to the Licensed
Marks and Name does not consent to and participate in such offering, provided that the
basis for imposition of such fine is consistent with rules specifically prescribed by
BCBSA from time to time in regulations of general application.
7. The Plan agrees that it will display the Licensed Marks and Name only in
such form, style and manner as shall be specifically prescribed by BCBSA from
time-to-time in regulations of general application in order to prevent impairment of the distinctiveness of the Licensed Marks
and Name and the goodwill pertaining thereto.
The Plan shall cause to appear on all materials on or in connection with which the Licensed Marks or Name are used such
legends, markings and notices as BCBSA may reasonably request in order to give appropriate notice of service mark or other
proprietary rights therein or pertaining thereto.
8. BCBSA agrees that: (a) it will not grant any other license effective during
the term of this License Agreement for the use of the Licensed Marks or Name which is
inconsistent with the rights granted to the Plan hereunder; and (b) it will not itself use
the Licensed Marks in derogation of the rights of the Plan or in a manner to deprive the
Plan of the full benefits of this License Agreement, provided that BCBSA shall have the
right to use the Licensed Marks in conjunction with any national offering under the
Federal Employees Health Benefits Program in the manner set forth in Exhibit 4,
Paragraph 4 (including subparagraphs) to this License Agreement. The Plan agrees
that it will not attack the title of BCBSA in and to the Licensed Marks or Name or attack
the validity of the Licensed Marks or of this License Agreement. The Plan further
agrees that all use by it of the Licensed Marks and Name or any similar mark or name
shall inure to the benefit of BCBSA, and the Plan shall cooperate with BCBSA in
effectuating the assignment to BCBSA of any service mark or trademark registrations
of the Licensed Marks or any similar mark or name held by the Plan or a Controlled
Affiliate of the Plan, all or any portion of which registration consists of the Licensed
Marks.
Amended as of November 16, 2006
-3a-
-- 344 of 512 --
9. (a). Should the Plan fail to comply with the provisions of paragraphs 2-4,
6, 7 and/or 12, and not cure such failure within thirty (30) days of receiving written
notice thereof (or commence curing such failure within such thirty day period and
continue diligent efforts to complete the curing of such failure if such curing cannot
reasonably be completed within such thirty day period), BCBSA shall have the right to
issue a notice that the Plan is in a state of noncompliance. Except as to the termination
of a Plan's License Agreement or the merger of two or more Plans, disputes as to
noncompliance, and all other disputes between or among BCBSA, the Plan, other Plans and/or Controlled Affiliates,
shall be submitted promptly to mediation and mandatory dispute resolution pursuant to the rules and regulations of
BCBSA, a current copy of which is attached as Exhibit 5 hereto, and shall be timely presented and resolved. The
mandatory dispute resolution panel shall have authority to issue orders for specific performance and assess monetary
penalties. If a state of noncompliance as aforesaid is undisputed by the Plan or is found to exist by a mandatory dispute
resolution panel and is uncured as provided above, BCBSA shall have the right to seek judicial enforcement of the
License Agreement. Except, however, as provided in paragraphs 9(d)(iii), 15(a)(i)-(viii), and 15(a)(x) below, no Plan's
license to use the Licensed Marks and Name may be finally terminated for any reason without the affirmative vote of
three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans.
(b). Notwithstanding any other provision of this License Agreement, a
Plan's license to use the Licensed Marks and Name may be forthwith terminated by the affirmative vote of three-fourths
of the Plans and three-fourths of the total then current weighted vote of all the Plans at a special meeting expressly
called by BCBSA for the purpose on ten (10) days written notice to the Plan advising of the specific matters at issue
and granting the Plan an opportunity to be heard and to present its response to Member Plans for: (i) failure to comply
with any minimum capital or liquidity requirement under the Membership Standard on Financial Responsibility; or (ii)
impending financial insolvency; or (iii) the pendency of any action instituted against the Plan seeking its dissolution or
liquidation or its assets or seeking appointment of a trustee, interim trustee, receiver or other custodian for any of its
property or business or seeking the declaration or establishment of a trust for any of its property
of business, unless this License Agreement has been earlier terminated
under paragraph 15(a); or (iv) such other reason as is determined in good faith immediately and irreparably to threaten
the integrity and reputation of BCBSA, the Plans and/or the Licensed Marks.
Amended as of March 16, 2006
-4-
-- 345 of 512 --
(c). To the extent not otherwise provided therein, neither: (i) the
Membership Standards Applicable to Regular Members of BCBSA; nor (ii) the rules and regulations governing
Government Programs and certain other uses; nor (iii) the
rules and regulations governing mediation and mandatory dispute resolution, may be amended unless and until each
such amendment is first adopted by the affirmative vote of threefourths of the Plans and of threefourths of the total then
current weighted vote of all the Plans. The rules and regulations governing National Accounts and other national
programs required by the Membership Standards Applicable to Regular Members of BCBSA (Exhibit 2) are contained,
in addition to those set forth in Exhibit 3, in the following documents, as amended from time to time: (1) the Inter-Plan
Programs Policies and Provisions; (2) Inter-Plan Medicare Advantage Program Policies and Provisions. The voting
requirements specified in rules and regulations governing such national programs may not be amended unless and
until each such amendment is first adopted by the affirmative vote of three-fourths of the Plans and of three-fourths of
the total then current weighted vote of all the Plans.
Amended as of November 21, 2014
-4a-
-- 346 of 512 --
(d). The Plan may operate as a for-profit company on the following
conditions:
(i) The Plan shall discharge all responsibilities which it has to
the Association and to other Plans by virtue of this Agreement and the
Plan's membership in BCBSA.
(ii) The Plan shall not use the licensed Marks and Name, or
any derivative thereof, as part of its legal name or any symbol used to
identify the Plan in any securities market. The Plan shall use the
Licensed Marks and Name as part of its trade name within its service
area for the sale, marketing and administration of health care and related
services in the service area.
(iii) The Plan's license to use the Licensed Marks and Name
shall automatically terminate effective: (a) thirty days after the Plan
knows, or there is an SEC filing indicating that, any Institutional Investor,
has become the Beneficial Owner of securities representing 10% or more
of the voting power of the Plan (“Excess Institutional Voter”), unless such
Excess Institutional Voter shall cease to be an Excess Institutional Voter
prior to such automatic termination becoming effective; (b) thirty days
after the Plan knows, or there is an SEC filing indicating that, any
Noninstitutional Investor has become the Beneficial Owner of securities
representing 5% or more of the voting power of the Plan (“Excess
Noninstitutional Voter”) unless such Excess Noninstitutional Voter shall
cease to be an Excess Noninstitutional Voter prior to such automatic
termination becoming effective; (c) thirty days after the Plan knows, or
there is an SEC filing indicating that, any Person has become the
Beneficial Owner of 20% or more of the Plan’s then outstanding common
stock or other equity securities which (either by themselves or in
combination) represent an ownership interest of 20% or more pursuant to
determinations made under paragraph 9(d)(iv) below (“Excess Owner”),
unless such Excess Owner shall cease to be an Excess Owner prior to
such automatic termination becoming effective; (d) ten business days
after individuals who at the time the Plan went public constituted the
Board of Directors of the Plan (together with any new directors whose
election to the Board was approved by a vote of 2/3 of the directors then
still in office who were directors at the time the Plan went public or whose
election or nomination was previously so approved) (the "Continuing
Directors") cease for any reason to constitute a majority of the Board of
Directors; or (e) ten business days after the Plan consolidates with or
merges with or into any person or conveys, assigns, transfers or sells all
or substantially all of its assets to any person other than a merger in
which the Plan is the surviving entity and immediately after which merger,
no person is an Excess Institutional Voter, an Excess Noninstitutional
Voter or an Excess Owner: provided that, if requested by the affected
Plan in a writing received by BCBSA prior to such automatic termination
Amended as of September 17, 1997
-5-
-- 347 of 512 --
becoming effective, the provisions of this paragraph 9(d)(iii) may be
waived, in whole or in part, upon the affirmative vote of a majority of the
disinterested Plans and a majority of the total then current weighted vote
of the disinterested Plans. Any waiver so granted may be conditioned
upon such additional requirements (including but not limited to imposing
new and independent grounds for termination of this License) as shall be
approved by the affirmative vote of a majority of the disinterested Plans
and a majority of the total then current weighted vote of the disinterested
Plans. If a timely waiver request is received, no automatic termination
shall become effective until the later of: (1) the conclusion of the
applicable time period specified in paragraphs 9(d)(iii)(a)-(d) above, or (2)
the conclusion of the first Member Plan meeting after receipt of such a
waiver request.
In the event that the Plan's license to use the Licensed Marks and Name
is terminated pursuant to this Paragraph 9(d)(iii), the license may be reinstated in BCBSA’s sole discretion
if, within 30 days of the date of such termination, the Plan demonstrates that the Person referred to in
clause (a), (b) or (c) of the preceding paragraph is no longer an Excess Institutional Voter, an Excess
Noninstitutional Voter or an Excess Owner.
(iv) The Plan shall not issue any class or series of security other
than (i) shares of common stock having identical terms or options or
derivatives of such common stock, (ii) non-voting, non-convertible debt securities or (iii) such other
securities as the Plan may approve, provided that BCBSA receives notice at least thirty days prior to the
issuance of such securities, including a description of the terms for such securities, and BCBSA shall
have the authority to determine how such other securities will be counted in determining whether any
Person is an Excess Institutional Voter, Excess Noninstitutional Voter or an Excess Owner.
(v) For purposes of paragraph 9(d)(iii), the following definitions shall apply:
(a) "Affiliate" and "Associate" shall have the respective
meanings ascribed to such terms in Rule 12b-2 of the General
Rules and Regulations under the Securities Exchange Act of 1934,
as amended and in effect on November 17, 1993 (the "Exchange
Act").
(b) A Person shall be deemed the "Beneficial Owner" of
and shall be deemed to "beneficially own" any securities:
Amended as of September 17, 1997
-5a-
-- 348 of 512 --
(i) which such Person or any of such
Person's Affiliates or Associates beneficially owns, directly or
indirectly;
(ii) which such Person or any of such
Person's Affiliates or Associates has (A) the right to acquire (whether such right is exercisable immediately or
only after the passage of time) pursuant to any agreement, arrangement or understanding, or upon the exercise of
conversion rights, exchange rights, warrants or options, or otherwise; or (B)
the right to vote pursuant to any agreement, arrangement or understanding; provided, however, that a Person shall not
be deemed the Beneficial Owner of, or to beneficially own, any security if the agreement, arrangement or
understanding to vote such security (1) arises solely from a revocable proxy or consent given to such Person in
response to a public proxy or consent solicitation made pursuant to, and in accordance with, the applicable rules and
regulations promulgated under the Exchange Act and (2) is not also then reportable on Schedule 13D under the
Exchange Act (or any comparable or successor report); or
(iii) which are beneficially owned, directly
or indirectly, by any other Person (or any Affiliate or Associate thereof) with
which such Person (or any of such Person's Affiliates or Associates) has any
agreement, arrangement or understanding (other than customary agreements with and
between underwriters and selling group members with respect to a bona fide public
offering of securities) relating to the acquisition, holding, voting (except to the extent
contemplated by the proviso to (b)(ii)(B) above) or disposing of any securities of the
Plan.
Notwithstanding anything in this definition of Beneficial Ownership to the contrary, the phrase "then outstanding," when
used with reference to a Person's Beneficial Ownership of securities of the Plan, shall mean the number of such
securities then issued and outstanding together with the number of such securities not then actually issued and
outstanding which such Person would be deemed to own beneficially hereunder.
(c) A Person shall be deemed an “Institutional Investor” if (but only if) such Person (i) is an entity or group
identified in the SEC’s Rule 13d-1(b)(1)(ii) as constituted on June 1, 1997, and (ii) every filing made by such Person
with the SEC under Regulation 13D-G (or any successor Regulation) with respect to such Person’s Beneficial
Ownership of Plan securities shall have contained a certification identical to the one required by item 10 of SEC
Schedule 13G as constituted on June 1, 1997.
(d) “Noninstitutional Investor” means any Person who is not an
Institutional Investor.
(e) Person" shall mean any individual, firm, partnership, corporation, trust, association, joint venture or other
entity, and shall include any successor (by merger or otherwise) of such entity. Amended as of September 17, 1997
-5b- (The next page is page 6)
-- 349 of 512 --
10. This License Agreement shall remain in effect: (a) until terminated as
provided herein; or (b) until this and all such other License Agreements are terminated
by the affirmative vote of three-fourths of the Plans and three-fourths of the total then
current weighted vote of all the Plans; (c) until terminated by the Plan upon eighteen
(18) months written notice to BCBSA or upon a shorter notice period approved by
BCBSA in writing at its sole discretion.
11. Except as otherwise provided in paragraph 15 below or by the
affirmative vote of three-fourths of the Plans and three-fourths of the total then current
weighted vote of all the Plans, or unless this and all such other License Agreements
are simultaneously terminated by force of law, the termination of this License
Agreement for any reason whatsoever shall cause the reversion to BCBSA of all rights
in and to the Licensed Marks and Name, and the Plan agrees that it will promptly
discontinue all use of the Licensed Marks and Name, will not use them thereafter, and
will promptly, upon written notice from BCBSA, change its corporate name so as to
eliminate the Licensed Name therefrom.
12. The license hereby granted to Plan to use the Licensed Marks and
Name is and shall be personal to the Plan so licensed and shall not be assignable by
any act of the Plan, directly or indirectly, without the written consent of BCBSA. Said
license shall not be assignable by operation of law, nor shall Plan mortgage or part with
possession or control of this license or any right hereunder, and the Plan shall have no
right to grant any sublicense to use the Licensed Marks and Name.
13. BCBSA shall maintain appropriate service mark registrations of the
Licensed Marks and BCBSA shall take such lawful steps and proceedings as may be
necessary or proper to prevent use of the Licensed Marks by any person who is not
authorized to use the same. Any actions or proceedings undertaken by BCBSA under
the provisions of this paragraph shall be at BCBSA's sole cost and expense. BCBSA
shall have the sole right to determine whether or not any legal action shall be taken on
account of unauthorized use of the Licensed Marks, such right not to be unreasonably
exercised. The Plan shall report any unlawful usage of the Licensed Marks to BCBSA
in writing and agrees, free of charge, to cooperate fully with BCBSA's program of
enforcing and protecting the service mark rights, trade name rights and other rights in
the Licensed Marks.
14. The Plan hereby agrees to save, defend, indemnify and hold BCBSA
And any other Plan(s) harmless from and against all claims, damages, liabilities and
Costs of every kind, nature and description which may arise as a result of the activities
of the Plan or of any hospital, medical group, clinic or other provider of health services
that is owned or controlled directly or indirectly by Plan. BCBSA hereby agrees to
save, defend, indemnify and hold the Plan and any other Plan(s) harmless from and
against all claims, damages, liabilities and costs of every kind, nature and description
which may arise exclusively and directly as a result of the activities of BCBSA.
Amended as of June 21, 2012
-6-
-- 350 of 512 --
15. (a). This Agreement shall automatically terminate upon the occurrence of
any of the following events: (i) a voluntary petition shall be filed by the Plan or by
BCBSA seeking bankruptcy, reorganization, arrangement with creditors or other relief
under the bankruptcy laws of the United States or any other law governing insolvency
or debtor relief, or (ii) an involuntary petition or proceeding shall be filed against the
Plan or BCBSA seeking bankruptcy, reorganization, arrangement with creditors or
other relief under the bankruptcy laws of the United States or any other law governing
insolvency or debtor relief and such petition or proceeding is consented to or
acquiesced in by the Plan or BCBSA or is not dismissed within sixty (60) days of the date upon which the petition or
other document commencing the proceeding is served upon the Plan or BCBSA respectively, or (iii) an order for relief is
entered against the Plan or BCBSA in any case under the bankruptcy laws of the United States, or the Plan or BCBSA
is adjudged bankrupt or insolvent (as that term is defined in the Uniform Commercial Code as enacted in the state of
Illinois) by any court of competent jurisdiction, or (iv) the Plan or BCBSA makes a general assignment of its assets for
the benefit of creditors, or (v) any government or any government official, office, agency, branch, or unit assumes
control of the Plan or delinquency proceedings (voluntary or involuntary) are instituted, or (vi) an action is brought by
the Plan or BCBSA seeking its dissolution or liquidation of its assets or seeking the appointment of a trustee, interim
trustee, receiver or other custodian for any of its property or business, or (vii) an action is instituted by any
governmental entity or officer against the Plan or BCBSA seeking its dissolution or liquidation of its assets or seeking
appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business and such action
is consented to or acquiesced in by the Plan or BCBSA or is not dismissed within one hundred thirty (130) days of the
date upon which the pleading or other document commencing the action is served upon the Plan or BCBSA
respectively, provided that if the action is stayed or its prosecution is enjoined, the one hundred thirty (130) day period
is tolled for the duration of the stay or injunction, and provided further, that the Association’s Board of Directors may toll
or extend the 130 day period at any time prior to its expiration, or (viii) a trustee, interim trustee, receiver or other
custodian for any of the Plan's or BCBSA's property or business is appointed, or the Plan or BCBSA is ordered
dissolved or liquidated, or (ix) the Plan shall fail to pay its dues and shall not cure such failure within thirty (30) days of
receiving written notice thereof, or (x) if, due to regulatory action, the Plan together with any applicable Controlled
Affiliate becomes unable to do business using the Names and Marks in any State or portion thereof included in its
Service Area, provided that: (i) automatic termination shall not occur prior to the exhaustion by any such Plan of its
rights to appeal or challenge such regulatory action; and (ii) in the event the Plan is licensed to do business using the
Names and Marks in multiple States or portions of States, the termination of its License Agreement shall be solely
limited to the State(s) or portions thereof in which the regulatory action applies. By not appealing or challenging such
regulatory action within the time prescribed by law or regulation, and in any event no later than 120 days after such
action is taken, a Plan shall be deemed to have exhausted its rights to appeal or challenge, and automatic termination
shall proceed.
-7-
-- 351 of 512 --
Notwithstanding any other provision of this Agreement, a declaration or a
request for declaration of the existence of a trust over any of the Plan’s or BCBSA’s property or business shall not in
itself be deemed to constitute or seek appointment of a trustee, interim trustee, receiver or other custodian for purposes
of subparagraphs 15(a)(vii) and (viii) of this Agreement.
Amended as of March 26, 2015
-7a-
-- 352 of 512 --
(b). BCBSA, or the Plans (as provided and in addition to the rights
conferred in Paragraph 10(b) above), may terminate this Agreement immediately upon written notice upon the
occurrence of either of the following events: (a) the Plan or BCBSA becomes insolvent (as that term is defined in the
Uniform Commercial Code enacted in the state of Illinois), or (b) any final judgment against the Plan or BCBSA remains
unsatisfied or unbonded of record for a period of sixty (60) days or longer.
(c). If this License Agreement is terminated as to BCBSA for any reason
stated in subparagraphs 15(a) and (b) above, the ownership of the Licensed Marks
shall revert to each of the Plans.
(d). Upon termination of this License Agreement or any Controlled Affiliate
License Agreement of a Larger Controlled Affiliate, as defined in Exhibit 1 to this License Agreement, the following
conditions shall apply, except that, in the event of a partial termination of this Agreement pursuant to Paragraph 15 (a)(x)
(ii) of this Agreement, the notices, national account listing, payment and audit right listed below shall be applicable solely
with respect to the geographic area for which the Plan’s license to use the Licensed Names and Marks is terminated:
(i) The terminated entity shall send a notice through the U.S. mails, with first class postage affixed, to all
individual and group customers, providers, brokers and agents of products or services
sold, marketed, underwritten or administered by the terminated entity or its Controlled
Affiliates under the Licensed Marks and Name. The form and content of the notice shall
be specified by BCBSA and shall, at a minimum, notify the recipient of the termination
of the license, the consequences thereof, and instructions for obtaining alternate
products or services licensed by BCBSA, subject to any conflicting state law and state
regulatory requirements. This notice shall be mailed within 15 days after termination or,
if termination is pursuant to paragraph 10(d) of this Agreement, within 15 days after the
written notice to BCBSA described in paragraph 10(d).
(ii) The terminated entity shall deliver to BCBSA within five days of a request by BCBSA a listing of
national accounts in which the terminated entity is involved (in a Control, Participating or
Servicing capacity), identifying the national account and the terminated entity's role
therein. For those accounts where the terminated entity is the Control Plan, the Plan
must also indicate the Participating and Servicing Plans in the national account
syndicate.
Amended as of June 16, 2005
-8-
-- 353 of 512 --
(iii) Unless the cause of termination is an event stated in paragraph 15(a) or (b) above respecting
BCBSA, the Plan and its Licensed Controlled Affiliates shall be jointly liable for payment
to BCBSA of an amount equal to the Re-Establishment Fee (described below)
multiplied by the number of Licensed Enrollees of the terminated entity and its Licensed
Controlled Affiliates;
provided that if any other Plan is permitted by BCBSA to use marks or names licensed by BCBSA in the
Service Area established by this Agreement, the Re-Establishment Fee shall be
multiplied by a fraction, the numerator of which is the number of Licensed
Enrollees of the terminated entity and its Licensed Controlled Affiliates and the denominator of which is
the total number of Licensed Enrollees in the Service Area. The Re-Establishment Fee
shall be indexed to a base fee of $80. The Re-Establishment Fee through December
31, 2005 shall be $80. The
Re-Establishment Fee for calendar years after December 31, 2005 shall be adjusted on January 1 of
each calendar year up to and including January 1, 2010 and shall be the base fee
multiplied by 100% plus the cumulative percentage increase or decrease in the Plans’
gross administrative expense (standard BCBSA definition) per Licensed Enrollee since
December 31, 2004. The adjustment shall end on January 1, 2011, at which time the
Re-Establishment Fee shall be fixed at the then-current amount and no longer
automatically adjusted. For example, if the Plans’ gross administrative expense per
Licensed Enrollee was $278.60, $285.00 and $290.00 for calendar year end 2004,
2005 and 2006, respectively, the January 1, 2007 Re-Establishment Fee would be
$83.27 (100% of the base fee plus $1.84 for calendar year 2005 and $1.43 for calendar
year 2006). Licensed Enrollee means each and every person and covered dependent
who is enrolled as an individual or member of a group receiving products or services
sold, marketed or administered under marks or names licensed by BCBSA as
determined at the earlier of (a) the end of the last fiscal year of the terminated entity
which ended prior to termination or (b) the fiscal year which ended before any
transactions causing the termination began. Notwithstanding the foregoing, the amount
payable pursuant to this subparagraph (d)(iii) shall be due only
Amended as of June 16, 2005
-8a-
-- 354 of 512 --
to the extent that, in BCBSA's opinion, it does not cause the net worth of the Plan to fall
below 100% of the Health Risk-Based Capital formula or its equivalent under any
successor formula, as set forth in the applicable financial responsibility standards
established by BCBSA (provided such equivalent is approved for purposes of this sub
paragraph by the affirmative vote of three-fourths of the Plans and three-fourths of the
total then current weighted vote of all the Plans), measured as of the date of termination
and adjusted for the value of any transactions not made in the ordinary course of
business. This payment shall not be due in connection with transactions exclusively by
or among Plan or their affiliates, including reorganizations,
combinations or mergers, where the BCBSA Board of Directors determines that the
license termination does not result in a material diminution in the number of Licensed
Enrollees or the extent of their coverage. At least 50% of the Re-Establishment Fee
shall be awarded to the Plan (or Plans) that receive the new license(s) for the service
area(s) at issue; provided, however, that such award shall not become due or payable
until all disputes, if any, regarding the amount of and BCBSA’s right to such Re-
Establishment Fee have been finally resolved; and provided further that the award shall
be based on the final amount actually received by BCBSA. The Board of Directors shall
adopt a resolution which it may amend from time to time that shall govern BCBSA’s use
of its portion of the award. In the event that the terminated entity’s license is reinstated
by BCBSA or is deemed to have remained in effect without interruption by a court of
competent jurisdiction, BCBSA shall reimburse the Plan (and/or its Licensed Controlled
Affiliates, as the case may be) for payments made under this subparagraph only to the
extent that such payments exceed the amounts due to BCBSA pursuant to
subparagraph 15(d)(vi) and any costs associated with reestablishing the Service Area,
including any payments made by BCBSA to a Plan or Plans (or their Licensed
Controlled Affiliates) for purposes of replacing the terminated entity.
(iv) The terminated entity shall comply with all financial settlement procedures set forth in
BCBSA’s License Termination Contingency Plan, as amended from time
to time and shall work diligently and in good faith with
Amended as of June 16, 2005
-8b-
-- 355 of 512 --
BCBSA, any Alternative Control Licensee or Replacement Licensee and any existing
or potential new account for Blue-branded products and services to minimize the
disruption of termination, and honor, to the fullest extent possible, the desire of
accounts to continue to receive or obtain Blue-branded products and services through
a new Licensee (“Transition”). Such diligence and good faith on the part of the
terminated entity shall include, but not be limited to: (a) working cooperatively with
BCBSA to protect the
Names and Marks from potential harm; (b) cooperating with BCBSA’s use of the
Names and Marks in the terminated entity’s former service area during the termination
and Transition; (c) transmitting, upon the request of an existing Blue account or of
BCBSA with
consent and on behalf of an existing Blue account, all member and account-data
relating to the Federal Employee Program to BCBSA, and all member and account
data relating to other programs to an Alternative Control Licensee or Replacement
Licensee; (d) working with BCBSA and the Alternative Control or Replacement
Licensee with respect to potential new Blue accounts headquartered in the terminated
entity’s former service area; (e) continuing to service Blue accounts during the
Transition; (f) continuing to comply with National Programs, Federal Employee
Program and NASCO policies and procedures and all voluntary BCBSA programs,
policies and performance standards, such as Away From Home Care, including being
responsible for payment of all penalties for non-compliance duly levied in conformity
with the License Agreements, Membership Standards, or the Federal Employee
Program agreements, that may arise during the Transition; (g) maintaining and
providing access to its provider networks, as defined by Federal Employee Program
agreements and National Account Program Policies and Provisions, and Inter-Plan
Programs Policies and Provisions, and making those networks and discounts available
to members and providers who participate in National Programs and the Federal
Employee Program during the Transition; (h) maintaining its technical connections and
processing capabilities during the Transition; and (i) working diligently to conclude all
financial settlements and account reconciliations as negotiated in the termination
transition agreement.
Amended as of November 16, 2006
-8c-
-- 356 of 512 --
(v) Notwithstanding any other provision in this Agreement, BCBSA shall have the right,
with the approval of its Board of Directors, to assess additional fines against the
terminated entity during the Transition in the event it fails to maintain and provide
access to provider networks as defined by Federal Employee Program agreements,
National Account Program Policies and Provisions, and Inter-Plans Programs Policies
and
Provisions, and/or pass on applicable discounts. Such
fines shall be in addition to any other assessments,
fees or liquidated damages payable herein, or under existing policies and programs
and shall be imposed to make whole BCBSA and/or the Plans. Terminated entity shall
pay any such fines to BCBSA no later than 30 days after they are approved by the
Board of Directors.
(vi) BCBSA shall have the right to examine and audit and/or hire at terminated entity’s expense a third-
party auditor to examine and audit the books and records of the terminated entity and
its Licensed Controlled Affiliates to verify compliance with the terms and requirements
of this paragraph 15(d).
(vii) Subsequent to termination of this Agreement, the terminated entity and its affiliates, agents, and
employees shall have an ongoing and continuing obligation to protect all BCBSA and
Blue Licensee data that was acquired or accessed during the period this Agreement
was in force, including but not limited to all confidential processes, pricing, provider,
discount and other strategic and competitively sensitive information (“Blue Information”)
from disclosure, and shall not, either alone or with another entity, disclose such Blue
Information or use it in any manner to compete without the express written permission
of BCBSA.
(viii) As to a breach of 15 (d) (i), (ii), (iii), (iv), (vi), or (vii) the parties agree that the obligations are
immediately enforceable in a court of competent jurisdiction. As to a breach of 15 (d) (i),
(ii), (iv), (vi), or (vii) by the Plan, the parties agree there is no adequate remedy at law
and BCBSA is entitled to obtain specific performance.
Amended as of November 16, 2006
-8d-
-- 357 of 512 --
(ix) In the event that the terminated entity’s license is reinstated by BCBSA or is deemed to have
remained in effect without interruption by a court of competent jurisdiction, the Plan and
its Licensed Controlled Affiliates shall be jointly liable for reimbursing BCBSA the
reasonable costs incurred by BCBSA in connection with the termination and the
reinstatement or court action, and any associated legal proceedings, including but not
limited to: outside legal fees, consulting fees, public relations fees, advertising costs,
and costs incurred to develop, lease or establish an interim
provider network. Any amount due to BCBSA under this subparagraph may be waived in whole or in
part by the BCBSA Board of Directors in its sole discretion.
(e). BCBSA shall be entitled to enjoin the Plan or any related party in a
court of competent jurisdiction from entry into any transaction which would result in a
termination of this License Agreement unless the License Agreement has been
terminated pursuant to paragraph 10 (d) of this Agreement upon the required six (6)
month written notice.
(f). BCBSA acknowledges that it is not the owner of assets of the Plan.
Amended as of June 16, 2006
-8e-
-- 358 of 512 --
16. This Agreement supersedes any and all other agreements between the parties
with respect to the subject matter herein, and contains all of the covenants and agreements of the parties as to
the licensing of the Licensed Marks and Name. This Agreement may be amended only by the affirmative vote of
three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans as officially
recorded by the BCBSA Corporate Secretary.
17. If any provision or any part of any provision of this Agreement is judicially declared unlawful, each and every other
provision, or any part of any provision, shall continue in full force and effect notwithstanding such judicial
declaration.
18. No waiver by BCBSA or the Plan of any breach or default in performance on the part of BCBSA or the Plan or any
other licensee of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any
subsequent breach or default in performance of said terms, covenants or conditions.
19a. All notices provided for hereunder shall be in writing and shall be sent in duplicate by regular mail to BCBSA or
the Plan at the address currently published for each by BCBSA and shall be marked respectively to the attention
of the President and, if any, the General Counsel, of BCBSA or the Plan.
19b. Except as provided in paragraphs 9(b), 9(d)(iii), 15(a), and 15(b) above, this
Agreement may be terminated for a breach only upon at least 30 days’ written notice to the Plan advising of the
specific matters at issue and granting the Plan an opportunity to be heard and to present its response to the
Member Plans.
19c. For all provisions of this Agreement referring to voting, the term ‘Plans’ shall mean all entities licensed under the
Blue Cross License Agreement and/or the Blue Shield License Agreement, and in all votes of the Plans under
this Agreement the Plans shall vote together. For weighted votes of the Plans, the Plan shall have a number of
votes equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of
weighted votes (if any) that it holds as a Blue Shield Plan. For all other votes of the Plans, the Plan shall have
one vote. For all questions requiring an affirmative three-fourths weighted vote of the Plans, the requirement
shall be deemed satisfied with a lesser weighted vote unless the greater of: (i) 6/52 or more of the Plans
(rounded to the nearest whole number, with 0.5 or multiples thereof being rounded to the next higher whole number)
fail to cast weighted votes in favor of the question; or (ii) three (3) of the Plans fail to cast weighted votes in favor
of the question. Notwithstanding the foregoing provision, if there are thirty-six (36) Plans, the requirement of an
affirmative three-fourths weighted vote shall be deemed satisfied with a lesser weighted vote unless four (4) or
more Plans fail to cast weighted votes in favor of the question.
Amended as of June 16, 2006
-8f-
(The next page is page 9)
-- 359 of 512 --
20. Nothing herein contained shall be construed to constitute the parties hereto as
partners or joint venturers, or either as the agent of the other, and Plan shall have no right to bind or obligate
BCBSA in any way, nor shall it represent that it has any right to do so. BCBSA shall have no liability to third
parties with respect to any aspect of the business, activities, operations, products, or services of the Plan.
21. This Agreement shall be governed, construed and interpreted in accordance
with the laws of the State of Illinois.
IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed, effective as of the date of
last signature written below.
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By
Title
Date
Plan:
By
Title
Date
-9-
-- 360 of 512 --
EXHIBIT 1
BLUE SHIELD
CONTROLLED AFFILIATE LICENSE AGREEMENT
(Includes revisions adopted by Member Plans through their September 17, 2020 meeting)
This Agreement by and among Blue Cross and Blue Shield Association ("BCBSA") and _______ (“Controlled
Affiliate"), a Controlled Affiliate of the Blue Shield Plan, known as _________ ("Plan" or “Sponsoring Plan”), which is also
a Party signatory hereto.
WHEREAS, BCBSA is the owner of the BLUE SHIELD and BLUE SHIELD Design service marks;
WHEREAS, Plan and Controlled Affiliate desire that the latter be entitled to use the BLUE SHIELD and BLUE SHIELD
Design service marks (collectively the "Licensed Marks") as service marks and be entitled to use the term BLUE
SHIELD in a trade name ("Licensed Name");
NOW THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby
agree as follows:
1. GRANT OF LICENSE
Subject to the terms and conditions of this Agreement, BCBSA hereby grants to Controlled Affiliate the right to use the
Licensed Marks and Name in connection with, and only in connection with: (i) health care plans and related services, as
defined in BCBSA's License Agreement with Plan, and administering the non-health portion of workers’ compensation
insurance, and (ii) underwriting the indemnity portion of workers’ compensation insurance, provided that Controlled
Affiliate’s total premium revenue comprises less than 15 percent of the Sponsoring Plan’s net subscription revenue.
This grant of rights is non-exclusive and is limited to the Service Area served by the Plan. Subject to Paragraph 3A(3) of
this Agreement, Controlled Affiliate may use the Licensed Marks and Name in its legal name on the following conditions:
(i) the legal name must be approved in advance, in writing, by BCBSA; (ii) Controlled Affiliate shall not do business
outside the Service Area under any name or mark; and (iii) Controlled Affiliate shall not use the Licensed Marks and
Name, or any derivative thereof, as part of any name or symbol used to identify itself in any securities market, unless
such Controlled Affiliate is a not-for-profit company which may use the Licensed Marks and Name, or an approved
derivative therefor, to identify itself in debt securities markets. Controlled Affiliate may use the Licensed Marks and
Name in its Trade Name only with the prior, written, consent of BCBSA.
Amended as of March 26, 2015
-1-
-- 361 of 512 --
2. QUALITY CONTROL
A. Controlled Affiliate agrees to use the Licensed Marks and Name only in connection with the licensed services
and further agrees to be bound by the conditions regarding quality control shown in attached Exhibit A as they may be
amended by BCBSA from time-to-time.
B. Controlled Affiliate agrees to comply with all applicable federal, state and local laws.
C. Controlled Affiliate agrees that it will provide on an annual basis (or more often if reasonably required by Plan or
by BCBSA) a report or reports to Plan and BCBSA demonstrating Controlled Affiliate's compliance with the requirements
of this Agreement including but not limited to the quality control provisions of this paragraph and the attached Exhibit A.
D. Controlled Affiliate agrees that Plan and/or BCBSA may, from time-to-time, upon reasonable notice, review and
inspect the manner and method of Controlled Affiliate's rendering of service and use of the Licensed Marks and Name.
E. As used herein, a Controlled Affiliate is defined as an entity organized and operated in such a manner, that the
Sponsoring Plan has:
(1) The legal authority directly or indirectly through wholly-owned subsidiaries:
(a) to select members of the Controlled Affiliate’s governing body having not less than 50% voting control
thereof; and
(b) to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of
the Controlled Affiliate with which the Sponsoring Plan does not concur; and
(c) to exercise control over the policy and operations of the Controlled Affiliate at least equal to that exercised by
persons or entities (jointly or individually) other than the Sponsoring Plan; and
Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate’s establishing or governing
documents must also require written approval by the Sponsoring Plan before the Controlled Affiliate can:
(i) change its legal and/or trade names;
(ii) change the geographic area in which it operates;
(iii) change any of the type(s) of businesses in which it engages;
Amended as of September 19, 2014
-2-
-- 362 of 512 --
(iv) create, or become liable for by way of guarantee, any indebtedness, other than indebtedness arising
in the ordinary course of business;
(v) sell any assets, except for sales in the ordinary course of business or sales of equipment no longer
useful or being replaced;
(vi) make any loans or advances except in the ordinary course of business;
(vii) enter into any arrangement or agreement with any party directly or indirectly affiliated with any of the
owners or persons or entities with the authority to select or appoint members or board members of
the Controlled Affiliate, other than the Sponsoring Plan or other Plans (excluding owners of stock
holdings of under 5% in a publicly traded Controlled Affiliate);
(viii) conduct any business other than under the Licensed Marks and Name;
(ix) take any action that Sponsoring Plan or BCBSA reasonably believes will adversely affect the
Licensed Marks and Name.
In addition, the Sponsoring Plan directly or indirectly through wholly owned subsidiaries shall own at least 50% of any
for-profit Controlled Affiliate, provided that in instances where the Sponsoring Plan formed a publicly traded Controlled
Affiliate Licensee and such publicly traded Controlled Affiliate Licensee owns and controls other Controlled Affiliate
Licensees, the Sponsoring Plan directly or indirectly shall own and control at least 50% of any Controlled Affiliate that is
indirectly owned and controlled by the publicly traded Controlled Affiliate Licensee.
Or
(2) The legal authority directly or indirectly through wholly-owned subsidiaries;
(a) to select members of the Controlled Affiliate’s governing body having more
than 50% voting control thereof and to:
(b) to prevent any change in the articles of incorporation, bylaws or other
establishing or governing documents of the Controlled Affiliate with which the Sponsoring Plan do not
concur; and
c) to exercise control over the policy and operations of the Controlled
Affiliate.
Amended as of March 26, 2015
-3-
-- 363 of 512 --
In addition, the Sponsoring Plan directly or indirectly through wholly-owned subsidiaries shall own more than 50% of any
for-profit Controlled Affiliate, provided that in instances where the Sponsoring Plan formed a publicly traded Controlled
Affiliate Licensee and such publicly traded Controlled Affiliate Licensee owns and controls other Controlled Affiliate
Licensees, the Sponsoring Plan directly or indirectly shall own and control more than 50% of any Controlled Affiliate that
is indirectly owned and controlled by the publicly traded Controlled Affiliate Licensee.
Or
(3) With respect to a Controlled Affiliate that is 100% controlled by Plans including the Sponsoring Plan and which
offers solely Medicaid, Medicare Advantage PPO, Medicare Advantage HMO and/or Special Need Plans products and
services, the Sponsoring Plan has the legal authority together with such other Plans:
(a) to select all members of the Controlled Affiliate’s governing body; and
(b) to prevent any change in the articles of incorporation, bylaws or other
establishing or governing documents of the Controlled Affiliate; and
(c) to exercise control over the policy and operations of the Controlled
Affiliate.
In addition, the Sponsoring Plan and such other Plans shall own 100% of any for-profit Controlled Affiliate, with the
Sponsoring Plan and such other Plans each having an ownership interest. Such control and ownership by Plans must
be direct or, if indirect, solely through affiliates that are licensed to use marks owned by BCBSA. Further, the Sponsoring
Plan and such other Plans shall execute a separate Addendum to Controlled Affiliate License Agreement attached
hereto as Exhibit B-1 for each product noted in Paragraph 2E(3) that is licensed to use the Marks.
Or
(4) With respect to a Controlled Affiliate that is 100% controlled by a Sponsoring Plan which on a Blue-branded basis
offers solely a Basic Medicare Part D Prescription Drug product, the Sponsoring Plan has the legal authority:
(a) to select all members of the Controlled Affiliate’s governing body; and
(b) to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents
of the Controlled Affiliate; and
(c) to exercise control over the policy and operations of the Controlled Affiliate.
Amended June 20, 2019
4
-- 364 of 512 --
In addition, the Sponsoring Plan shall own 100% of any for-profit Controlled Affiliate. Such 100% control and ownership
by Sponsoring Plan must be direct or, if indirect, solely through affiliates that are licensed to use marks owned by
BCBSA, Further, the Participating Plan as defined in Exhibit B-2 and the Sponsoring Plan shall execute the Addendum
to Controlled Affiliate License Agreement attached hereto as Exhibit B-2.
Or
(5) With respect to a Controlled Affiliate that is operating as a clinic, absent an alternative method of control approved
in writing by BCBSA, the Sponsoring Plan shall have bonafide operational control over the Controlled Affiliate as
specified in Exhibit A, Standard 1 (E) and the Guidelines to Administer Standard 1 (E). In addition, if the clinic is for-
profit, the Sponsoring Plan shall own at least 50% of the Controlled Affiliate and prevent any change in the articles of
incorporation, bylaws or other establishing documents of the Controlled Affiliate with which it does not concur.
3. FOR-PROFIT, PUBLICLY TRADED LICENSEES
A. The Controlled Affiliate may operate as a for-profit publicly traded company on the following conditions:
(1) The Controlled Affiliate shall discharge all responsibilities which it has to
the Association and to other Plans by virtue of this Agreement.
(2) The Controlled Affiliate shall provide 90 days advance written notice to
BCBSA prior to the initial filing with the SEC.
(3) The Controlled Affiliate shall not use the Licensed Marks and Name, or
any derivative thereof, as part of its legal name or any symbol used to identify the
Controlled Affiliate in any securities market. The Controlled Affiliate shall use the
Licensed Marks and Name as part of its trade name within its service area for the
sale, marketing and administration of health care and related services in the
service area.
(4) The Controlled Affiliate’s license to use the Licensed Marks and Name
shall automatically terminate effective: (a) thirty days after the Controlled Affiliate
knows, or there is an SEC filing indicating that, any Institutional Investor, has
become the Beneficial Owner of securities representing 10% or more of the
voting power of the Controlled Affiliate (“Excess Institutional Voter”), unless such
Excess Institutional Voter shall cease to be an Excess Institutional Voter prior to
such automatic termination becoming effective; (b) thirty days after the Controlled
Affiliate knows, or there is an SEC filing indicating that, any Noninstitutional
Investor, other than a Plan or Plans or Controlled Affiliate licensee or licensees
has become the Beneficial Owner of securities representing 5% or more of the
voting power of the Controlled Affiliate (“Excess Noninstitutional Voter”) unless
such Excess Noninstitutional Voter shall cease to be an Excess Noninstitutional
Voter prior to such automatic termination becoming effective; (c) thirty days after
Amended as of June 29, 2019
-5-
-- 365 of 512 --
the Controlled Affiliate knows, or there is an SEC filing indicating that, any
Person has become the Beneficial Owner, other than a Plan or Plans or
Controlled Affiliate licensee or licensees, of 20% or more of the Controlled
Affiliate’s then outstanding common stock or other equity securities which (either
by themselves or in combination) represent an ownership interest of 20% or
more pursuant to determinations made under Paragraph 3A(4) below (“Excess
Owner”), unless such Excess Owner shall cease to be an Excess Owner prior to
such automatic termination becoming effective; (d) ten business days after
individuals who at the time the Controlled Affiliate went public constituted the
Board of Directors of the Controlled Affiliate (together with any new directors
whose election to the Board was approved by a vote of 2/3 of the directors then
still in office who were directors at the time the Controlled Affiliate went public or
whose election or nomination was previously so approved) (the “Continuing
Directors”) cease for any reason to constitute a majority of the Board of Directors;
or (e) ten business days after the Controlled Affiliate consolidates with or merges
with or into any person or conveys, assigns, transfers or sells all or substantially
all of its assets to any person other than a merger in which the Sponsoring Plan
is the surviving entity and immediately after which merger, no person is an
Excess Institutional Voter, an Excess Noninstitutional Voter or an Excess Owner:
provided that, if requested by the affected Controlled Affiliate in a writing received
by BCBSA prior to such automatic termination becoming effective, the provision
of this paragraph 3A(4) may be waived, in whole or in part, upon the affirmative
vote of a majority of the disinterested Plans and a majority of the total then
current weighted vote of the disinterested Plans. Any waiver so granted may be
conditioned upon such additional requirements (including but not limited to
imposing new and independent grounds for termination of this License) as shall
be approved by the affirmative vote of a majority of the disinterested Plans and a
majority of the total then current weighted vote of the disinterested Plans. If a
timely waiver request is received, no automatic termination shall become
effective until the later of: (1) the conclusion of the applicable time period
specified in paragraphs 3A(4)(a)-(d) above, or (2) the conclusion of the first
Member Plan meeting after receipt of such a waiver request.
In the event that the Controlled Affiliate’s license, or any other license, to use the Licensed Marks and Name is
terminated pursuant to Paragraph 3A(4), the license may be reinstated in BCBSA’s sole discretion if, within 30
days of the date of such termination, the Controlled Affiliate demonstrates that the Person referred to in clause
(a), (b) or (c) of the preceding paragraph is no longer an Excess Institutional Voter, an Excess Noninstitutional
Voter or an Excess Owner.
(5) The Controlled Affiliate shall not issue any class or series of security other
than (i) shares of common stock having identical terms or options or derivatives
of such common stock, (ii) non-voting, non-convertible debt securities, or (iii)
such other securities as the Controlled Affiliate may approve, provided that
BCBSA receives notice at least thirty days prior to the issuance of such
securities, including a description of the terms for such securities, and BCBSA
shall have the authority to determine how such other securities will be counted in
determining whether any Person is an Excess Institutional Voter, Excess
Noninstitutional Voter or an Excess Owner. Amended as of March 26, 2015
-6-
-- 366 of 512 --
(6) For purposes of paragraph 3(A) above, the following definitions shall
apply:
(i) “Affiliate” and “Associate” shall have the respective meanings ascribed to such terms in Rule 12b-2 of the
General Rules and Regulations under the Securities Exchange Act of 1934, as amended and in effect on
November 17, 1993 (the “Exchange Act”).
(ii) A Person shall be deemed the “Beneficial Owner” of and shall be deemed to “beneficially own” any
securities:
(1) which such Person or any of such Person’s Affiliates or Associates beneficially owns, directly or
indirectly;
(2) which such Person or any of such Person’s Affiliates or Associates has (A) the right to acquire
(whether such right is exercisable immediately or only after the passage of time) pursuant to any agreement,
arrangement or understanding, or upon the exercise of conversion rights, exchange rights, warrants or options, or
otherwise; or (B) the right to vote pursuant to any agreement, arrangement or understanding; provided, however,
that a Person shall not be deemed the Beneficial Owner of, or to beneficially own, any security if the agreement,
arrangement or understanding to vote such security (1) arises
solely from a revocable proxy or consent given to such Person in response to a public proxy or consent
solicitation made pursuant to, and in accordance with, the applicable rules and regulations promulgated under the
Exchange Act and (2) is not also then reportable on Schedule 13D under the Exchange Act (or any comparable
or successor report); or
(3) which are beneficially owned, directly or indirectly, by any other Person (or any Affiliate or Associate
thereof) with which such Person (or any of such Person’s Affiliates or Associates) has any agreement,
arrangement or understanding (other than customary agreements with and between underwriters and selling
group members with respect to a bona fide public offering of securities) relating to the acquisition, holding, voting
(except to the extent contemplated by the proviso to (ii)2(B) above) or disposing of any securities of the
Controlled Affiliate.
Notwithstanding anything in this definition of Beneficial Ownership to the contrary, the phrase “then outstanding”,
when used with reference to a Person’s Beneficial Ownership of securities of the Controlled Affiliate, shall mean
the number of such securities then issued and outstanding together with the number of such securities not then
actually issued and outstanding which such Person would be deemed to own beneficially hereunder.
Amended as of March 26, 2015
-7-
-- 367 of 512 --
(iii) A Person shall be deemed an “Institutional Investor” if (but only if) such Person (i) is an entity or group
identified in the SEC’s Rule 13d-1(b)(1)(ii) as constituted on June 1, 1997, and (ii) every filing made by such Person with
the SEC under Regulation 13D-G (or any successor Regulation) with respect to such Person’s Beneficial Ownership of
Plan securities shall have contained a certification identical to the one required by item 1 of SEC Schedule 13G as
constituted on June 1, 1997.
(iv) “Noninstitutional Investor” means any Person who is not an Institutional Investor.
(v) “Person” shall mean any individual, firm, partnership, corporation, trust, association, joint venture or other
entity, and shall include any successor (by merger or otherwise) of such entity.
4. SERVICE MARK USE
A. Controlled Affiliate recognizes the importance of a comprehensive national network of independent BCBSA
licensees which are committed to strengthening the Licensed Marks and Name. The Controlled Affiliate further
recognizes that its actions within its Service Area may affect the value of the Licensed Marks and Name nationwide.
B. Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks and Name, including
but not limited to use of such symbols or words as BCBSA shall specify to protect the Licensed Marks and Name and
shall comply with such rules (generally applicable to Controlled Affiliates licensed to use the Licensed
Marks and Name) relative to service mark use, as are issued from time-to-time by BCBSA. Controlled Affiliate
recognizes and agrees that all use of the Licensed Marks and Name by Controlled Affiliate shall inure to the benefit of
BCBSA.
C. Controlled Affiliate may not directly or indirectly use the Licensed Marks and Name in a manner that transfers or
is intended to transfer in the Service Area the goodwill associated therewith to another mark or name, nor may
Controlled Affiliate
engage in activity that may dilute or tarnish the unique value of the Licensed Marks and Name.
D. If Controlled Affiliate meets the standards of 2E(1) but not 2E(2) above and any of Controlled Affiliate's
advertising or promotional material is reasonably determined by BCBSA and/or the Plan to be in contravention of rules
and regulations governing the use of the Licensed Marks and Name, Controlled Affiliate shall for ninety (90) days
thereafter obtain prior approval from BCBSA of advertising and promotional efforts using the Licensed Marks and Name,
approval or disapproval thereof to be forthcoming within five (5) business days of receipt of same by BCBSA or its
designee.
In all advertising and promotional efforts, Controlled Affiliate shall observe the Service Area limitations applicable to
Plan.
Amended as of March 26, 2015
-8-
-- 368 of 512 --
E. Notwithstanding any other provision in the Plan’s License Agreement with BCBSA or in this Agreement,
Controlled Affiliate shall use its best efforts to promote and build the value of the Licensed Marks and Name.
5. SUBLICENSING AND ASSIGNMENT
Controlled Affiliate shall not, directly or indirectly, sublicense, transfer, hypothecate, sell, encumber or mortgage, by
operation of law or otherwise, the rights granted hereunder and any such act shall be voidable at the sole option of Plan
or BCBSA. This Agreement and all rights and duties hereunder are personal to Controlled Affiliate.
6. INFRINGEMENT
Controlled Affiliate shall promptly notify Plan and Plan shall promptly notify BCBSA of any suspected acts of
infringement, unfair competition or passing off that
may occur in relation to the Licensed Marks and Name. Controlled Affiliate shall not be entitled to require Plan or
BCBSA to take any actions or institute any proceedings to prevent infringement, unfair competition or passing off by
third parties. Controlled Affiliate agrees to render to Plan and BCBSA, without charge, all reasonable assistance in
connection with any matter pertaining to the protection of the Licensed Marks and Name by BCBSA.
7. LIABILITY INDEMNIFICATION
Controlled Affiliate and Plan hereby agree to save, defend, indemnify and hold BCBSA harmless from and against all
claims, damages, liabilities and costs of every kind, nature and description (except those arising solely as a result of
BCBSA's negligence) that may arise as a result of or related to: (i) Controlled Affiliate's rendering of services under the
Licensed Marks and Name; or (ii) the activities of any hospital, medical group, clinic or other provider of health services
that is owned or controlled directly or indirectly by Plan or Controlled Affiliate.
8. LICENSE TERM
A. Except as otherwise provided herein, the license granted by this Agreement shall remain in effect for a period of
one (1) year and shall be automatically extended for additional one (1) year periods unless terminated pursuant to the
provisions herein.
B. This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further
action by any party or entity in the event that: (i) the Plan ceases to be authorized to use the Licensed Marks and Name;
or (ii) pursuant to Paragraph 15(a)(x) of the Blue Cross License Agreement the Plan ceases to be authorized to use the
Licensed Names and Marks in the geographic area served by the Controlled Affiliate provided, however, that if the
Controlled Affiliate is serving more than one State or portions thereof, the termination of this Agreement shall be
Amended as of March 26, 2015
-9-
-- 369 of 512 --
limited to the State(s) or portions thereof in which the Plan’s license to use the Licensed Marks and Names is
terminated. By not appealing or challenging such regulatory action
within the time prescribed by law or regulation, and in any event no later than 120 days after such action is taken, a Plan
shall be deemed to have exhausted its rights to appeal or challenge, and automatic termination shall
proceed.
C. Notwithstanding any other provision of this Agreement, this license to use the Licensed Marks and Name may
be forthwith terminated by the Plan or the affirmative vote of the majority of the Board of Directors of BCBSA present
and voting at a special meeting expressly called by BCBSA for the purpose on ten (10) days written notice to the Plan
advising of the specific matters at issue and granting the Plan an opportunity to be heard and to present its response to
the Board for: (1) failure to comply with any applicable minimum capital or liquidity requirement under the quality control
standards of this Agreement; or (2) failure to comply with the "Organization and Governance" quality control standard of
this Agreement; or (3) impending financial
insolvency; or (4) for a Smaller Controlled Affiliate (as defined in Exhibit A), failure to comply with any of the applicable
requirements of Standards 2, 3, 4, 5 or 7 of attached Exhibit A; or (5) the pendency of any action instituted against the
Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking appointment of a trustee, interim trustee,
receiver or other custodian for any of its property or business or seeking the declaration or establishment of a trust for
any of its property or business, unless this Controlled Affiliate License Agreement has been earlier terminated under
paragraph
8(E); or (6) failure by a Controlled Affiliate that meets the standards of 2E(1) but not 2E(2) above to obtain BCBSA's
written consent to a change in the identity of any owner, in the extent of ownership, or in the identity of any person or
entity with the authority to select or appoint members or board members, provided that as to publicly traded Controlled
Affiliates this provision shall apply only if the change affects a person or entity that owns at least 5% of the Controlled
Affiliate's stock before or after the change; or (7) such other reason as is determined in good faith immediately and
irreparably to threaten the integrity and reputation of BCBSA, the Plans, any other licensee including Controlled Affiliate
and/or the Licensed Marks and Name.
D. Except as otherwise provided in Paragraphs 8(B), 8(C) or 8(E) herein, should Controlled Affiliate fail to comply
with the provisions of this Agreement and not cure such failure within thirty (30) days of receiving written notice thereof
(or commence a cure within such thirty day period and continue diligent efforts to complete the cure if such curing
cannot reasonably be completed within such thirty day period) BCBSA or the Plan shall have the right to issue a notice
that the Controlled Affiliate is in a state of noncompliance. If a state of noncompliance as aforesaid is undisputed by the
Controlled Affiliate or is found to exist by a mandatory dispute resolution panel and is uncured as provided above,
BCBSA shall have the right to seek judicial enforcement of the Agreement or to issue a notice of termination thereof.
Notwithstanding any other provisions of this Agreement, any disputes as to the termination of this License pursuant to
Paragraphs 8(B), 8(C) or 8(E) of this Agreement shall not be subject to mediation and mandatory dispute resolution. All
other disputes between BCBSA, the Plan and/or Controlled Affiliate shall be submitted promptly to mediation and
mandatory dispute
Amended as of March 26, 2015
-10-
-- 370 of 512 --
resolution. The mandatory dispute resolution panel shall have authority to issue orders for specific performance and
assess monetary penalties. Except, however, as provided
in Paragraphs 8(B) and 8(E) of this Agreement, this license to use the Licensed Marks and Name may not be finally
terminated for any reason without the affirmative vote of a majority of the present and voting members of the Board of
Directors of BCBSA.
E. This Agreement and all of Controlled Affiliate's rights hereunder shall
immediately terminate without any further action by any party or entity in the event that:
(1) Controlled Affiliate shall no longer comply with item 2(E) above;
(2) Appropriate dues, royalties and other payments for Controlled
Affiliate pursuant to paragraph 10 hereof, which are the royalties for this License Agreement, are more than sixty (60)
days in arrears to BCBSA; or
(3) Any of the following events occur: (i) a voluntary petition shall be
filed by Controlled Affiliate seeking bankruptcy, reorganization, arrangement with creditors or other relief under the
bankruptcy laws of the United States or any other law governing insolvency or debtor relief, or (ii) an involuntary petition
or proceeding shall be filed against Controlled Affiliate seeking bankruptcy, reorganization, arrangement with creditors or
other relief under the bankruptcy laws of the United States or any other law governing insolvency or debtor relief and
such petition or proceeding is consented to or acquiesced in by Controlled Affiliate or is not dismissed within sixty (60)
days of
the date upon which the petition or other document commencing the proceeding is served upon the Controlled Affiliate,
or (iii) an order for relief is entered against Controlled Affiliate in any case under the bankruptcy laws of the United
States, or Controlled Affiliate is adjudged bankrupt or insolvent as those terms are defined in the Uniform Commercial
Code as enacted in the State of Illinois by any court of competent jurisdiction, or (iv) Controlled Affiliate makes a general
assignment of its assets for the benefit of creditors, or (v) any government or any government official, office, agency,
branch, or unit assumes control of Controlled Affiliate or delinquency proceedings (voluntary or involuntary) are
instituted, or (vi) an action is brought by Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking
the appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business, or (vii) an
action is instituted by any governmental entity or officer against Controlled Affiliate seeking its dissolution or liquidation
of its assets or seeking the appointment of a trustee, interim trustee, receiver or other custodian for any of its property or
business and such action is consented to or acquiesced in by Controlled Affiliate or is not dismissed within one hundred
thirty (130) days of the date upon which the pleading or other document commencing the action is served upon the
Controlled Affiliate, provided that if the action is stayed or its prosecution is enjoined, the one hundred thirty (130) day
period is tolled for the duration of the stay or injunction, and provided further, that the Association’s Board of Directors
may toll or extend the 130 day period at any time prior to its expiration, or (viii) a trustee, interim trustee, receiver or
other custodian for any of Controlled Affiliate's property or business is appointed or the Controlled Affiliate
is ordered dissolved or liquidated. Notwithstanding any other provision of this Agreement, a declaration or a request for
declaration of the existence of a trust over any of the Controlled Affiliate’s property or business shall not in itself be
deemed to
Amended as of March 26, 2015
-11-
-- 371 of 512 --
constitute or seek appointment of a trustee, interim trustee, receiver or other custodian for purposes of subparagraphs
8(E)(3)(vii) and (viii) of this Agreement.
(4) The for-profit, publicly traded Controlled Affiliate is terminated
pursuant to Paragraph 3A(4) of this Agreement. In which case, the licenses of any controlled Affiliates directly or
indirectly owned by the terminated for profit, publicly traded Controlled Affiliate also shall immediately terminate as
provided for in paragraph 3A(4) of this Agreement
F. Upon termination of this Agreement for cause or otherwise, Controlled Affiliate agrees that it shall
immediately discontinue all use of the Licensed Marks and Name, including any use in its trade name.
G. Upon termination of this Agreement, Controlled Affiliate shall immediately notify all of its customers that it is
no longer a licensee of BCBSA and, if directed by the Association’s Board of Directors, shall provide instruction on how
the customer can contact BCBSA or a designated licensee to obtain further information on securing coverage. The
notification required by this paragraph shall be in writing and in a form approved by BCBSA. The BCBSA shall have the
right to audit the terminated entity's books and records to verify compliance with this paragraph.
H. In the event this Agreement terminates pursuant to 8(b) hereof, or in the event the Controlled Affiliate is a
Larger Controlled Affiliate (as defined in Exhibit A), upon termination of this Agreement, the provisions of Paragraph 8.G.
shall not apply and the following provisions shall apply, except that, in the event of a partial termination of this
Agreement pursuant to Paragraph 8(B)(ii) of this Agreement, the notices, national account listing, payment, and audit
right listed below shall be applicable solely with respect to the geographic area for which the Plan’s license to use the
Licensed Names and Marks is terminated:
(1) The Controlled Affiliate shall send a notice through the U.S. mails,
with first class postage affixed, to all individual and group customers, providers, brokers and agents of products or
services sold, marketed, underwritten or administered by the Controlled Affiliate under the Licensed Marks and Name.
The form and content of the notice shall be specified by BCBSA and shall, at a minimum, notify the recipient of the
termination of the license, the consequences thereof, and instructions for obtaining alternate products or services
licensed by BCBSA, subject to any conflicting state law and state regulatory requirements. This notice shall be mailed
within 15 days after termination.
(2) The Controlled Affiliate shall deliver to BCBSA within five days of a
request by BCBSA a listing of national accounts in which the Controlled Affiliate is involved (in a control, participating or
servicing capacity), identifying the national account and the Controlled Affiliate’s role therein.
Amended as of March 26, 2015
-12-
-- 372 of 512 --
(3) Unless the cause of termination is an event respecting BCBSA
stated in paragraph 15(a) or (b) of the Plan’s license agreement with BCBSA to use the Licensed Marks and Name, the
Controlled Affiliate, the Plan, and any other Licensed Controlled Affiliates of the Plan shall be jointly liable for payment to
BCBSA of an
amount equal to the Re-Establishment Fee (described below) multiplied by the number of Licensed Enrollees of the
Controlled Affiliate; provided that if any other Plan is permitted by BCBSA to use marks or names licensed by BCBSA in
the Service Area established by this Agreement, the Re-Establishment Fee shall be multiplied by a fraction, the
numerator of which is the number of Licensed Enrollees of the Controlled Affiliate, the Plan, and any other Licensed
Controlled Affiliates and the denominator of which is the total number of Licensed Enrollees in the Service Area.
The Re-Establishment Fee shall be indexed to a base fee of $80. The Re-Establishment Fee through December 31,
2005 shall be $80. The Re-Establishment Fee for calendar years after December 31, 2005 shall be adjusted on January
1 of each calendar year up to and including January 1, 2010 and shall be the base fee multiplied by 100% plus the
cumulative percentage increase or decrease in the Plans’ gross administrative expense (standard BCBSA definition) per
Licensed Enrollee since December 31, 2004. The adjustment shall end on January 1, 2011, at which time the Re-
Establishment Fee shall be fixed at the then-current amount and no longer automatically adjusted. For example, if the
Plans’ gross administrative expense per Licensed Enrollee was $278.60, $285.00 and $290.00 for calendar year end
2004, 2005 and 2006, respectively, the January 1, 2007 Re-Establishment Fee would be $83.27 (100% of base fee plus
$1.84 for calendar
year 2005 and $1.43 for calendar year 2006. Licensed Enrollee means each and every person and covered dependent
who is enrolled as an individual or member of a group receiving products or services sold, marketed or administered
under marks or names licensed by BCBSA as determined at the earlier of (i) the end of the last fiscal year of the
terminated entity which ended prior to termination or (ii) the fiscal year which ended before any transactions causing the
termination began. Notwithstanding the foregoing, the amount payable pursuant to this subparagraph H. (3) shall be due
only to the extent that, in BCBSA’s opinion, it does not cause the net worth of the Controlled Affiliate, the Plan or any
other Licensed Controlled Affiliates of the Plan to fall below 100% of the Health Risk-Based Capital formula, or its
equivalent under any successor formula, as set forth in the applicable financial responsibility standards established by
BCBSA (provided such equivalent is approved for purposes of this sub paragraph by the affirmative vote of three-fourths
of the Plans and three-fourths of the total then current weighted vote of all the Plans); measured as of the date of
termination, and adjusted for the value of any transactions not made in the ordinary course of business. This payment
shall not be due in connection with transactions exclusively by or among Plans or their affiliates, including
reorganizations, combinations or mergers, where the BCBSA Board of Directors determines that the license termination
does not result in a material diminution in the number of Licensed Enrollees or the extent of their coverage. At least 50%
of the Re-Establishment Fee shall be awarded to the Plan (or Plans) that receive the new license(s) for the service
area(s) at issue; provided, however, that such award shall not become due or payable until all disputes, if any, regarding
the amount of and BCBSA’s right to such Re-Establishment Fee have been finally resolved; and provided
Amended as of March 26, 2015
-13-
-- 373 of 512 --
further that the award shall be based on the final amount actually received by BCBSA. The Board of Directors shall
adopt a resolution which it may amend from time to time that shall govern BCBSA’s use of its portion of the award. In the
event that the Controlled Affiliate’s license is reinstated by BCBSA or is deemed to have remained in effect without
interruption by a court of competent jurisdiction, BCBSA shall reimburse the Controlled Affiliate (and/or the Plan or its
other Licensed Controlled Affiliates, as the
case may be) for payments made under this subparagraph 8.H.(3) only to the extent that such payments exceed the
amounts due to BCBSA pursuant to paragraph 8.M. and any cost associated with reestablishing the Service Area,
including any payments made by BCBSA to a Plan or Plans (or their Licensed Controlled Affiliates) for purposes of
replacing the Controlled Affiliate.
(4) BCBSA shall have the right to examine and audit and/or hire at
terminated entity’s expense a third party auditor to examine and audit the books and records of the Controlled Affiliate,
the Plan, and any other Licensed Controlled Affiliates of the Plan to verify compliance with this paragraph 8.H.
(5) Subsequent to termination of this Agreement, the terminated entity
and its affiliates, agents, and employees shall have an ongoing and continuing obligation to protect all BCBSA and Blue
Licensee data that was acquired or accessed during the period this Agreement was in force, including but not limited to
all confidential processes, pricing, provider, discount and other strategic and competitively sensitive information (“Blue
Information”) from disclosure, and shall not, either alone or with another entity, disclose such Blue Information or use it
in any manner to compete without the express written permission of BCBSA.
(6) As to a breach of 8.H.(1), (2), (3), (4) or (5) the parties agree that
the obligations are immediately enforceable in a court of competent jurisdiction. As to a breach of 8.H.(1), (2) or (4) by
the Controlled Affiliate, the parties agree there is no adequate remedy at law and BCBSA is entitled to obtain specific
performance.
I. This Agreement shall remain in effect until terminated by the
Controlled Affiliate or the Plan upon not less than eighteen (18) months written notice to the Association or upon a
shorter notice period approved by BCBSA in writing at its sole discretion, or until terminated as otherwise provided
herein. The Plan’s right to terminate without cause upon such notice is unfettered and may be exercised in the Plan’s
sole discretion.
J. In the event the Controlled Affiliate is a Smaller Controlled Affiliate
(as defined in Exhibit A), the Controlled Affiliate agrees to be jointly liable for the amount described in H.3.and M. hereof
upon termination of the BCBSA license agreement of any Larger Controlled Affiliate of the Plan.
K. BCBSA shall be entitled to enjoin the Controlled Affiliate or any related party in a court of competent
jurisdiction from entry into any transaction which would result in a termination of this Agreement unless the Plan’s
license from BCBSA to use the Licensed Marks and Names has been terminated pursuant to 10(d) of the Plan’s license
agreement upon the required 18 months written notice.
Amended as March 26, 2015
-14-
-- 374 of 512 --
L. BCBSA acknowledges that it is not the owner of assets of the
Controlled Affiliate.
M. In the event that the Plan has more than 50 percent voting control of the Controlled Affiliate under Paragraph
2(E)(2) above and is a Larger Controlled Affiliate (as defined in Exhibit A), then the vote called for in Paragraphs 8(C)
and 8(D)
above shall require the affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted
vote of all the Plans.
N. In the event this Agreement terminates and is subsequently
reinstated by BCBSA or is deemed to have remained in effect without interruption by a court of competent jurisdiction,
the Controlled Affiliate, the Plan, and any other Licensed Controlled Affiliates of the Plan shall be jointly liable for
reimbursing BCBSA the reasonable costs incurred by BCBSA in connection with the termination and the reinstatement
or court action, and any associated legal proceedings, including but not limited to: outside legal fees, consulting fees,
public relations fees, advertising costs, and costs incurred to develop, lease or establish an interim provider network.
Any amount due to BCBSA under this subparagraph may be waived in whole or in part by the BCBSA Board of
Directors in its sole discretion.
9. DISPUTE RESOLUTION
The parties agree that any disputes between them or between or among either of them and one or more Plans or
Controlled Affiliates of Plans that use in any manner the Blue Shield and Blue Shield Marks and Name are subject to the
Mediation and Mandatory Dispute Resolution process attached to and made a part of Plan's License from BCBSA to use
the Licensed Marks and Name as Exhibit 5 as amended from time-to-time, which documents are incorporated herein by
reference as though fully set forth herein.
10. LICENSE FEE
Controlled Affiliate will pay to BCBSA a fee for this License determined pursuant to the formula(s) set forth in Exhibit
C.
11. JOINT VENTURE
Nothing contained in the Agreement shall be construed as creating a joint venture, partnership, agency or
employment relationship between Plan and Controlled Affiliate or between either and BCBSA.
12. NOTICES AND CORRESPONDENCE
Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and shall be
addressed in duplicate to the last known address of each other party, marked respectively to the attention of its
President and, if any, its General Counsel.
Amended as of March 26, 2015
-15-
-- 375 of 512 --
13. COMPLETE AGREEMENT
This Agreement contains the complete understandings of the parties in relation to the subject matter hereof. This
Agreement may only be amended by the affirmative vote of three-fourths of the Plans and three-fourths of the total then
current weighted vote of all the Plans as officially recorded by the BCBSA Corporate Secretary.
14. SEVERABILITY
If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such findings shall in no way
affect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition for any
unlawful term or condition so long as the effect of such substitution is to provide the parties with the benefits of this
Agreement.
15. NONWAIVER
No waiver by BCBSA of any breach or default in performance on the part of Controlled Affiliate or any other licensee
of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any subsequent breach or
default in performance of said terms, covenants or conditions.
15A. VOTING
For all provisions of this Agreement referring to voting, the term ‘Plans’ shall mean all entities licensed under the Blue
Cross License Agreement and/or the Blue Shield License Agreement, and in all votes of the Plans under this
Agreement the Plans shall vote together. For weighted votes of the Plans, the Plan shall have a number of votes equal
to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes (if any)
that it holds as a Blue Shield Plan. For all other votes of the Plans, the Plan shall have one vote. For all questions
requiring an affirmative three-fourths weighted vote of the Plans, the requirement shall be deemed satisfied with a
lesser weighted vote unless the greater of: (i) 6/52 or more of the Plans (rounded to the nearest whole number, with 0.5
or multiples thereof being rounded to the next higher whole number) fail to cast weighted votes in favor of the question;
or (ii) three (3) of the Plans fail to cast weighted votes in favor of the question.
Notwithstanding the foregoing provision, if there are thirty-six (36) Plans, the requirement of an affirmative three-fourths
weighted vote shall be deemed satisfied with a lesser weighted vote unless four (4) or more Plans fail to cast weighted
votes in favor of the question.
Amended as of March 26, 2015
-16-
-- 376 of 512 --
THIS PAGE IS INTENTIONALLY BLANK.
-- 377 of 512 --
16. GOVERNING LAW
This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of
Illinois.
17. HEADINGS
The headings inserted in this agreement are for convenience only and shall have no bearing on the interpretation
hereof.
IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed and effective as of the
date of last signature written below.
Controlled Affiliate:
By:
Date:____________________________________
Plan:
By:
Date:____________________________________
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By:______________________________________
Date:____________________________________
Amended as of March 26, 2015
-17-
-- 378 of 512 --
EXHIBIT A
CONTROLLED AFFILIATE LICENSE STANDARDS
September 2020
PREAMBLE
For purposes of definition:
• A "smaller Controlled Affiliate:" (1) comprises less than fifteen percent (15%) of Sponsoring Plan's and its
licensed Controlled Affiliates' total member enrollment (as reported on the BCBSA Quarterly Enrollment
Report, excluding rider and freestanding coverage, and treating an entity seeking licensure as licensed);* or
(2) underwrites the indemnity portion of workers’ compensation insurance and has total premium revenue less
than 15 percent of the Sponsoring Plan’s net subscription revenue.
• A "larger Controlled Affiliate" comprises fifteen percent (15%) or more of Sponsoring Plan's and its licensed
Controlled Affiliates' total member enrollment (as reported on the BCBSA Quarterly Enrollment Report,
excluding rider and freestanding coverage, and treating an entity seeking licensure as licensed.)*
Changes in Controlled Affiliate status:
If any Controlled Affiliate's status changes regarding: its Plan ownership level, its risk acceptance or direct delivery of
medical care, the Controlled Affiliate shall notify BCBSA within thirty (30) days of such occurrence in writing and come
into compliance with the applicable standards within six (6) months.
If a smaller Controlled Affiliate’s health and workers’ compensation administration business reaches or surpasses fifteen
percent (15%) of the total member enrollment of the Sponsoring Plan and licensed Controlled Affiliates, the Controlled
Affiliate shall:
Amended as of September 19, 2014
-18-
-- 379 of 512 --
EXHIBIT A (continued)
1. Within thirty (30) days, notify BCBSA of this fact in writing, including evidence that the Controlled Affiliate meets the
minimum liquidity and capital (BCBSA “Health Risk-Based Capital (HRBC)” as defined by the NAIC and state-
established minimum reserve) requirements of the larger Controlled Affiliate Financial Responsibility standard; and
2. Within six (6) months after reaching or surpassing the fifteen percent (15%) threshold, demonstrate compliance with
all license requirements for a larger Controlled Affiliate.
If a Controlled Affiliate that underwrites the indemnity portion of workers’ compensation insurance receives a change in
rating or proposed change in rating, the Controlled Affiliate shall notify BCBSA within 30 days of notification by the
external rating agency.
*For purposes of this calculation,
The numerator equals:
Applicant Controlled Affiliate's member enrollment, as defined in BCBSA's Quarterly Enrollment Report (excluding rider
and freestanding coverage).
The denominator equals:
Numerator PLUS Sponsoring Plan and all other licensed Controlled Affiliates' member enrollment, as reported in
BCBSA's Quarterly Enrollment Report (excluding rider and freestanding coverage).
Amended as of September 19, 2014
-19-
-- 380 of 512 --
EXHIBIT A (continued)
STANDARDS FOR LICENSED CONTROLLED AFFILIATES
Each licensed controlled affiliate shall be subject to certain standards as determined below:
1. What percent of the licensed controlled affiliate is controlled by the Sponsoring Plan and other Plans?
More than 50% by
Sponsoring Plan
ò
Standard 1A, 4
50% by Sponsoring Plan
ò
Standard 1B, 4
100% Plan Control but
less than 50%
Sponsoring Plan Control
and it offers solely
Medicaid, Medicare
Advantage PPO,
Medicare Advantage
HMO and/or Special
Need Plans products and
services
ò
Standard 1C, 4
100% Sponsoring Plan control
and on a Blue-branded basis,
it only offers Basic Medicare
Part D Prescription Drug Plan
product
ò
Standard 1D, 4
At least 50% by Sponsoring
Plan or operational Control by
Sponsoring Plan and it solely
operates as a Clinic as
defined in Standard 1E.
ò
Standard 1E, 4
IN ADDITION,
2. Is risk being assumed?
Yes No
÷ ò ø ÷ ò
Controlled Affiliate
underwrites any indemnity
portion of workers’
compensation insurance
ò
Standards 7A-7E, 11
Controlled Affiliate
comprises < 15% of total
member enrollment of
Sponsoring Plan and its
licensed affiliates, and
does not underwrite the
indemnity portion of
workers’ compensation
insurance
ò
Standard 2 (Guidelines
1.1,1.2) and Standard
11
Controlled Affiliate
comprises > 15% of total
member enrollment of
Sponsoring Plan and its
licensed affiliates, and
does not underwrite the
indemnity portion of
workers’ compensation
insurance
ò
Standard 6H
Controlled Affiliate
comprises < 15% of total
member enrollment of
Sponsoring Plan and its
licensed affiliates
ò
Standard 2
(Guidelines 1.1,1.3) and
Standard 11
Controlled Affiliate
comprises > 15% of
total member
enrollment of
Sponsoring Plan and
its licensed affiliates
ò
Standard 6H
IN ADDITION,
3. Is medical care being directly provided as a staff model HMO?
Yes
ò
Standard 3A
No
ò
Standard 3B
Amended as of June 20, 2019
-20-
-- 381 of 512 --
EXHIBIT A (continued)
STANDARDS FOR LICENSED CONTROLLED AFFILIATES
Each licensed controlled affiliate shall be subject to certain standards as determined below:
IN ADDITION,
4. Is the licensed controlled affiliate operating as a Clinic, as defined in Standard 1(E)?
Yes
ò
Standard 3C and Standard 2, 1.4 (if organized as a health plan that also operates as a Clinic.
5. If the controlled affiliate has health or workers’ compensation administration business, does such business comprise 15% or more of the total member
enrollment of Plan and its licensed Controlled Affiliates?
Yes No
ò ÷ ÷ ø
Standards 6A-6J Controlled Affiliate
is not a former
primary licensee and is not
subject to Standard 1(C)
ò
Standards 5,8,9B,10,11
Controlled Affiliate is a former
primary licensee
ò
Standards 5,8,9A,10,11
Controlled Affiliate is
not a former primary
licensee and is
subject to Standard
1(C)
ò
Standards 5,8,9B,11
Amended as of June 20, 2019
-21-
-- 382 of 512 --
EXHIBIT A (continued)
Standard 1 - Organization and Governance
1A.) The Standard for more than 50% Plan control is:
A Controlled Affiliate shall be organized and operated in such a manner that a Plan authorized to use the Licensed
Marks in the Service Area of the Controlled Affiliate pursuant to the separate Primary License Agreement with BCBSA
has the legal authority, directly or indirectly through wholly-owned subsidiaries: 1) to select members of the Controlled
Affiliate’s governing body having more than 50% voting control thereof; and 2) to prevent any change in the articles of
incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate with which the Sponsoring
Plan do not concur; and 3) to exercise control over the policy and operations of the Controlled Affiliate. In addition, the
Sponsoring Plan directly or indirectly through wholly-owned subsidiaries shall own more than 50% of any for-profit
Controlled Affiliate.
1B.) The Standard for 50% Plan control is:
A Controlled Affiliate shall be organized and operated in such a manner that a Plan authorized to use the Licensed
Marks in the Service Area of the Controlled Affiliate pursuant to the separate Primary License Agreement with BCBSA
has the legal authority, directly or indirectly through wholly-owned subsidiaries:
1) to select members of the Controlled Affiliate’s governing body having not less than 50% voting control thereof; and
2) to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the
Controlled Affiliate with which the Sponsoring Plan do not concur; and
3) to exercise control over the policy and operations of the Controlled Affiliate at least equal to that exercised by
persons or entities (jointly or individually) other than the Sponsoring Plan.
Amended September 19, 2014
-22-
-- 383 of 512 --
EXHIBIT A (continued)
Notwithstanding anything to the contrary in 1) through 3) hereof, the Controlled Affiliate’s establishing or governing
documents must also require written approval by the Sponsoring Plan before the Controlled Affiliate can:
o change the geographic area in which it operates
o change its legal and/or trade names
o change any of the types of businesses in which it engages
o create, or become liable for by way of guarantee, any indebtedness, other than indebtedness arising in the
ordinary course of business
o sell any assets, except for sales in the ordinary course of business or sales of equipment no longer useful or being
replaced
o make any loans or advances except in the ordinary course of business
o enter into any arrangement or agreement with any party directly or indirectly affiliated with any of the owners or
persons or entities with the authority to select or appoint members or board members of the Controlled
Affiliate, other than the Sponsoring Plan or other Plans (excluding owners of stock holdings of under 5% in
a publicly traded Controlled Affiliate)
o conduct any business other than under the Licensed Marks and Name
o take any action that the Sponsoring Plan or BCBSA reasonably believes will adversely affect the Licensed Marks
and Name.
In addition, the Sponsoring Plan directly or indirectly through wholly-owned subsidiaries shall own at least 50% of any
for-profit Controlled Affiliate.
Amended September 27, 2018
-23-
-- 384 of 512 --
1C.) The Standard for a Controlled Affiliate that offers solely Medicaid, Medicare Advantage PPO, Medicare
Advantage HMO and/or Special Need Plans products and service and has100% Plan control but less than 50%
Sponsoring Plan Control:
A Controlled Affiliate shall be organized and operated in such a manner that (i) it offers solely Medicaid, Medicare
Advantage PPO, Medicare Advantage HMO and/or Special Need Plans products and services; and (ii) a Plan
authorized to use the Licensed Marks in the Service Area of the Controlled Affiliate pursuant to the separate Primary
License Agreement with BCBSA (the “Sponsoring Plan,) has the legal authority together with Other Plans:
1) to select all members of the Controlled Affiliate’s governing body; and
2) to prevent any change in the articles of incorporation, bylaws, or other establishing or governing documents of the
Controlled Affiliate; and
3) to exercise control over the policy and operations of the Controlled Affiliate.
In addition, the Sponsoring Plan and such other Plans shall own 100% of any for-profit Controlled Affiliate, with the
Sponsoring Plan and such other Plans each having an ownership interest. Such 100% control and ownership by Plans
shall be direct or, if indirect, solely through affiliates that are licensed to use marks owned by BCBSA. Further, the
Sponsoring Plan and such other Plans shall execute the Addendum to Controlled Affiliate License.
1D). The Standard for a Controlled Affiliate that on a Blue-branded basis, only offers a Basic Medicare Part D
Prescription Drug product and has 100% Plan control is:
A Controlled Affiliate shall be organized and operated in such a manner that (i) on a Blue-branded basis, it only offers a
Basic Medicare Part D Prescription Drug product; and (ii) the Sponsoring Plan has the legal authority:
1) to select all members of the Controlled Affiliate’s governing body; and
2) to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the
Controlled Affiliate; and
3) to exercise control over the policy and operations of the Controlled Affiliate.
In addition, the Sponsoring Plan shall own 100% of any for-profit Controlled Affiliate. Such 100% control and ownership
by Sponsoring Plan must be direct or, if indirect, solely through affiliates that are licensed to use marks owned by
BCBSA.
Further, the Sponsoring Plan and Participating Plan shall execute the Addendum to Controlled Affiliate License.
-24-
-- 385 of 512 --
1E). The Standard for a Controlled Affiliate that operates as a Clinic and the Sponsoring Plan has control of the Clinic
is:
A Controlled Affiliate shall be organized in such a manner that it operates as a Clinic and Sponsoring Plan exercises
operational control over the Controlled Affiliate.
In addition, if the Clinic is for-profit, the Sponsoring Plan shall own at least 50% of the Controlled Affiliate and prevent
any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled
Affiliate.
Amended June 20, 2019
-25-
-- 386 of 512 --
EXHIBIT A (continued)
Standard 2 - Financial Responsibility
A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its
contractual obligations to its customers. If a risk-assuming Controlled Affiliate ceases operations for any reason, Blue
Cross and/or Blue Cross Plan coverage will be offered to all Controlled Affiliate subscribers without exclusions,
limitations or conditions based on health status. If a nonrisk-assuming Controlled Affiliate ceases operations for any
reason, Sponsoring Plan will provide for services to its customers.
The requirements of the preceding two sentences shall apply to all lines of business unless a line of business is
specially exempted from the requirement(s) by the BCBSA Board of Directors.
Standard 3 - State Licensure/Certification
3A.) The Standard for a Controlled Affiliate that employs, owns or contracts on a substantially exclusive basis for
medical services is:
A Controlled Affiliate shall maintain unimpaired licensure or certification for its medical care providers to operate under
applicable state laws.
3B.) The Standard for a Controlled Affiliate that does not employ, own or contract on a substantially exclusive basis for
medical services is:
A Controlled Affiliate shall maintain unimpaired licensure or certification to operate under applicable state laws.
3C.) The Standard for a Controlled Affiliate that operates as a Clinic as defined in Standard 1(E) is:
A Controlled Affiliate shall maintain appropriate and unimpaired licensure and
certifications.
Standard 4 - Certain Disclosures
A Controlled Affiliate shall make adequate disclosure in contracting with third parties and in disseminating public
statements of 1) the structure of the Blue Cross and Blue Shield System; and 2) the independent nature of every
licensee; and 3) the Controlled Affiliate's financial condition.
Amended as of June 20, 2019
-26-
-- 387 of 512 --
EXHIBIT A (continued)
Standard 5 - Reports and Records for Certain Smaller Controlled Affiliates
For a smaller Controlled Affiliate that does not underwrite the indemnity portion of workers’ compensation insurance, the
Standard is:
A Controlled Affiliate and/or its Sponsoring licensed Plan shall furnish, on a timely and accurate basis, reports and
records relating to these Standards and the License Agreements between BCBSA and Controlled Affiliate.
Standard 6 - Other Standards for Larger Controlled Affiliates
Standards 6(A) - (I) that follow apply to larger Controlled Affiliates.
Standard 6(A): Board of Directors
A Controlled Affiliate Governing Board shall act in the interest of its Corporation in providing cost-effective health care
services to its customers. A Controlled Affiliate shall maintain a governing Board, which shall control the Controlled
Affiliate, composed of a majority of persons other than providers of health care services, who shall be known as public
members. A public member shall not be an employee of or have a financial interest in a health care provider, nor be a
member of a profession which provides health care services.
Standard 6(B): Responsiveness to Customers
A Controlled Affiliate shall be operated in a manner responsive to customer needs and requirements.
Standard 6(C): Participation in National Programs
A Controlled Affiliate shall effectively and efficiently participate in each national program as from time to time may be
adopted by the Member Plans for the purposes of providing portability of membership between the licensees and ease
of claims processing for customers receiving benefits outside of the Controlled Affiliate's Service Area.
Amended as of September 19, 2014
-27-
-- 388 of 512 --
EXHIBIT A (continued)
Standard 6(C): Participation in National Programs (continued)
Such programs are applicable to licensees, and include:
1. BlueCard Program;
2. InterPlan Teleprocessing System (ITS);
3. National Account Programs;
4. Business Associate Agreement for Blue Cross and Blue Shield Licensees, effective April 14, 2003; and
5. Inter-Plan Medicare Advantage Program.
Standard 6(D): Financial Performance Requirements
In addition to requirements under the national programs listed in
Standard 6C: Participation in National Programs, a Controlled Affiliate shall take such action as required to ensure its
financial performance in programs and contracts of an inter-licensee nature or where BCBSA is a party.
Standard 6(E): Cooperation with Plan Performance Response Process
A Controlled Affiliate shall cooperate with BCBSA's Board of Directors and its Brand Enhancement & Protection
Committee in the administration of the Plan Performance Response Process and in addressing Controlled Affiliate
performance problems identified thereunder.
Standard 6(F): Independent Financial Rating
A Controlled Affiliate shall obtain a rating of its financial strength from an independent rating agency approved by
BCBSA's Board of Directors for such purpose.
Standard 6(G): Local and National Best Efforts
Notwithstanding any other provision in the Plan’s License Agreement with BCBSA or in this License Agreement, during
each year, a Controlled Affiliate shall use its best efforts to promote and build the value of the Blue Shield Mark.
Amended as of November 21, 2014
-28-
-- 389 of 512 --
EXHIBIT A (continued)
Standard 6(H): Financial Responsibility
A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its
contractual obligations to its customers.
Standard 6(I): Reports and Records
A Controlled Affiliate shall furnish to BCBSA on a timely and accurate basis reports and records relating to compliance
with these Standards and the License Agreements between BCBSA and Controlled Affiliate. Such reports and records
are the following:
A) BCBSA Controlled Affiliate Licensure Information Request; and
B) Triennial trade name and service mark usage material, including disclosure material; and
C) Changes in the ownership and governance of the Controlled Affiliate, including changes in its charter, articles of
incorporation, or bylaws, changes in a Controlled Affiliate's Board composition, or changes in the identity of
the Controlled Affiliate's Principal Officers, and changes in risk acceptance, contract growth, or direct
delivery of medical care; and
D) Semi-annual “Health Risk-Based Capital (HRBC) Report” as defined by the NAIC, Annual Certified Audit Report,
Insurance Department Examination Report, Annual Statement filed with State Insurance Department (with
all attachments), and
Amended as of November 17, 2011
-29-
-- 390 of 512 --
EXHIBIT A (continued)
Standard 6(J): Control by Unlicensed Entities Prohibited
No Controlled Affiliate shall cause or permit an entity other than a Plan or a Licensed Controlled Affiliate thereof to
obtain control of the Controlled Affiliate or to acquire a substantial portion of its assets related to licensable
services.
Standard 7 - Other Standards for Risk-Assuming Workers’ Compensation Controlled Affiliates
Standards 7(A) - (E) that follow apply to Controlled Affiliates that underwrite the indemnity portion of workers’
compensation insurance.
Standard 7 (A): Financial Responsibility
A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its
contractual obligations to its customers.
Standard 7(B): Reports and Records
A Controlled Affiliate shall furnish, on a timely and accurate basis, reports and records relating to compliance with
these Standards and the License Agreements between BCBSA and the Controlled Affiliate. Such reports and
records are the following:
A. BCBSA Controlled Affiliate Licensure Information Request; and
B. Triennial trade name and service mark usage materials, including disclosure materials; and
C. Annual Certified Audit Report, Annual Statement as filed with the State Insurance Department (with all
attachments), Annual NAIC’s Risk-Based Capital Worksheets for Property and Casualty Insurers; and
D. Quarterly Estimated Risk-Based Capital for Property and Casualty Insurers, Insurance Department
Examination Report; and
Amended as of November 17, 2011
-30-
-- 391 of 512 --
EXHIBIT A (continued)
E. Notification of all changes and proposed changes to independent ratings within 30 days of receipt and
submission of a copy of all rating reports; and
F. Changes in the ownership and governance of the Controlled Affiliate including changes in its charter, articles
of incorporation, or bylaws, changes in a Controlled Affiliate’s Board composition, Plan control, state license
status, operating area, the Controlled Affiliate’s Principal Officers or direct delivery of medical care.
Standard 7(C): Loss Prevention
A Controlled Affiliate shall apply loss prevention protocol to both new and existing business.
Standard 7(D): Claims Administration
A Controlled Affiliate shall maintain an effective claims administration process that includes all the necessary
functions to assure prompt and proper resolution of medical and indemnity claims.
Standard 7(E): Disability and Provider Management
A Controlled Affiliate shall arrange for the provision of appropriate and necessary medical and rehabilitative
services to facilitate early intervention by medical professionals and timely and appropriate return to work.
Amended as of November 16, 2000
-31-
-- 392 of 512 --
EXHIBIT A (continued)
Standard 8 - Cooperation with Controlled Affiliate License Performance Response Process Protocol
A Controlled Affiliate and its Sponsoring Plan shall cooperate with BCBSA’s Board of Directors and its Brand
Enhancement & Protection Committee in the administration of the Controlled Affiliate License Performance
Response Process Protocol (ALPRPP) and in addressing Controlled Affiliate compliance problems identified
thereunder.
Standard 9(A) - Participation in National Programs by Smaller Controlled Affiliates that were former Primary
Licensees
A smaller controlled affiliate that formerly was a Primary Licensee shall effectively and efficiently participate in certain
national programs from time to time as may be adopted by Member Plans for the purposes of providing ease of claims
processing for customers receiving benefits outside of the Controlled Affiliate’s service area and be subject to certain
relevant financial and reporting requirements.
A. National program requirements include:
• BlueCard Program;
• Inter-Plan Teleprocessing System (ITS);
• National Account Programs.
B. Financial Requirements include:
• Standard 6(D): Financial Performance Requirements and Standard 6(H): Financial Responsibility; or
• A financial guarantee covering the Controlled Affiliate’s Inter-Plan Programs obligations in a form, and from
a guarantor, acceptable to BCBSA.
Amended as of November 21, 2014
-32-
-- 393 of 512 --
EXHIBIT A (continued)
Standard 9(A) - Participation in National Programs by Smaller Controlled Affiliates that were former Primary
Licensees
C. Reporting requirements include:
a. The Semi-annual Health Risk-Based Capital (HRBC) Report.
Amended as of June 13, 2002
-33-
-- 394 of 512 --
Exhibit A (continued)
Standard 9(B) - Participation in National Programs by Smaller Controlled Affiliates
A smaller controlled affiliate shall participate in national programs in accordance with BlueCard and other relevant
Policies and Provisions shall effectively and efficiently participate in national programs from time to time as may be
adopted by Member Plans for the purposes of providing ease of claims processing for customers receiving benefits
outside of the controlled affiliate’s service area and be subject to certain relevant financial and reporting requirements.
A. National program requirements include:
• BlueCard Program;
• Inter-Plan Teleprocessing System (ITS);
• National Account Programs.
B. Financial Requirements include:
• Standard 6(D): Financial Performance Requirements and Standard 6(H): Financial Responsibility; or
• A financial guarantee covering the Controlled Affiliate’s Inter-Plan Programs obligations in a form, and from a
guarantor, acceptable to BCBSA.
Amended as of June 20, 2013
-34-
-- 395 of 512 --
EXHIBIT A (continued)
Standard 10 - Participation in Inter-Plan Medicare Advantage Program
A smaller controlled affiliate for which this standard applies pursuant to the Preamble section of Exhibit A of the
Controlled Affiliate License Agreement shall effectively and efficiently participate in certain national programs from
time to time as may be adopted by Member Plans for the purposes of providing ease of claims processing for
customers receiving benefits outside of the controlled affiliate’s service area.
National program requirements include:
A. Inter-Plan Medicare Advantage Program.
Standard 11: Participation in Master Business Associate Agreement by Smaller Controlled Affiliate
Licensees
Effective April 14, 2003, all smaller controlled affiliates shall comply with the terms of the Business
Associate Agreement for Blue Cross and Blue Shield Licensees to the extent they perform the functions of
a business associate or subcontractor to a business associate, as defined by the Business Associate
Agreement.
Amended as of September 19, 2014
-35-
-- 396 of 512 --
EXHIBIT B-1
ADDENDUM TO CONTROLLED AFFILIATE LICENSE TO BE EXECUTED BY CONTROLLED AFFILIATES
LICENSED UNDER CONTROLLED AFFILIATE LICENSE STANDARD 1C.
ADDENDUM TO CONTROLLED AFFILIATE LICENSE
This Addendum is made to that certain Blue Shield Controlled Affiliate License Agreement executed by and among Blue
Cross and Blue Shield Association (“Licensor”), __________________________ (“Controlled Affiliate Licensee”) and
_________________________________________(“Sponsoring Plan”) dated the _____ day of ____________ , _____
(“Agreement”). The parties to this Addendum are Licensor, Controlled Affiliate Licensee, Sponsoring Plan, and the
undersigned other Plans (‘Other Plans”). This Addendum is made and shall be deemed effective as of the date of the
Agreement.
WHEREAS, the Sponsoring Plan asserts that it can serve the Medicaid, Medicare Advantage PPO, Medicare Advantage
HMO and/or Special Need Plans market in its Service Area more efficiently and with less risk through an enterprise
jointly owned and controlled with other Plans than through a wholly owned and Controlled Affiliate Licensee;
WHEREAS, in such circumstance Controlled Affiliate License Standard 1C permits the licensing of a Controlled Affiliate
that is less than 50% owned and controlled by the Sponsoring Plan but which is 100% owned and controlled by Plans
including the Sponsoring Plan, subject to certain conditions;
WHEREAS, one such condition is that the Sponsoring Plan and all such other owning and controlling Plans enter into
this Addendum;
NOW THEREFORE, for good and valuable consideration, including the promises and covenants set forth herein, the
parties agree as follows:
1. This Addendum is limited to [identify product name].
2. The Sponsoring Plan shall participate operationally in Controlled Affiliate’s business that is conducted under the
Licensed Marks. The parties understand that participation may take many forms, one of which should be
providing a network of providers in the Service Area of the Controlled Affiliate for the Medicaid, Medicare
Advantage PPO, Medicare Advantage HMO and/or Special Need Plans services being offered under the
Agreement and being involved in network development and provider engagement functions.
3. Each of the Other Plans agrees that (i) it will cooperate fully with the Sponsoring Plan and BCBSA as needed to
enable Sponsoring Plan and Controlled Affiliate Licensee to meet their obligations to Licensor under the
Agreement and all associated rules and regulations of Licensor, including the Brand Regulations, (ii) it
-36-
-- 397 of 512 --
will not take any action, either individually or jointly with any of the Other Plans, that
would cause Sponsoring Plan or Controlled Affiliate Licensee to violate the
Agreement, and (iii) it will not fail to take any action, either individually or jointly with
any of the Other Plans, where such failure would cause Sponsoring Plan or
Controlled Affiliate Licensee to violate the Agreement.
4. Each of the Other Plans acknowledges that it has reviewed the Agreement and understands that Sponsoring Plan
has the right to terminate the Agreement without cause upon notice as provided in Paragraph 8 of the Agreement,
and that such right is unfettered and may be exercised by Sponsoring Plan in its sole discretion.
WHEREFORE, by signing below the parties agree to be bound to the terms stated herein.
BLUE CROSS BLUE SHIELD ASSOCIATION
By: ________________________________________
[Controlled Affiliate Licensee]
By: ________________________________________
[Sponsoring Plan]
By: ________________________________________
[Other Plan 1]
By: ________________________________________
[Other Plan 2]
By: ________________________________________
Amended as of September 27, 2018
-37-
-- 398 of 512 --
EXHIBIT B-2
ADDENDUM TO CONTROLLED AFFILIATE LICENSE TO BE EXECUTED BY CONTROLLED AFFILIATES
LICENSED UNDER CONTROLLED AFFILIATE LICENSE STANDARD 1D.
ADDENDUM TO CONTROLLED AFFILIATE LICENSE
This Addendum is made to that certain Blue Shield Controlled Affiliate License Agreement executed by and among Blue
Cross and Blue Shield Association (“Licensor”), __________________________ (“Controlled Affiliate Licensee”),
_____________________________________(“Sponsoring Plan”) and ___________________________________
(“Participating Plan”) dated the _____ day of ____________ , _____ (“Agreement”).
WHEREAS, the Participating Plan is defined as the Plan that holds the Primary License with BCBSA to use the Service
Marks in the Service Area where the Controlled Affiliate will use the Service Marks;
WHEREAS, the Participating Plan asserts that it can offer a lower cost Basic Medicare Part D Prescription Drug Plan
product more efficiently in the Participating Plan’s Service Area through the Controlled Affiliate Licensee;
WHEREAS, the Controlled Affiliate shall only use the Service Marks inside of the Participating Plan(s) Service Area
subject to each Participating Plan signing a separate Addendum;
WHEREAS, in such circumstance Controlled Affiliate License Standard 1D permits the licensing of a Controlled Affiliate
that is 100% owned and controlled by a Sponsoring Plan, subject to certain conditions;
WHEREAS, one such condition is that the Sponsoring Plan, Controlled Affiliate and the Participating Plan enter into this
Addendum;
NOW THEREFORE, for good and valuable consideration, including the promises and covenants set forth herein, the
parties agree as follows:
1. The Participating Plan shall participate in Controlled Affiliate’s business that is conducted under the Licensed
Marks. The parties understand that the Participating Plan shall conduct sales support and marketing of the
Controlled Affiliate’s Basic Medicare Part D Prescription Drug Plan product offered in the Participating Plan’s
Service Area. Any other form of participation shall require BCBSA’s written approval.
2. Participating Plan agrees that (i) it will cooperate fully with the Sponsoring Plan and BCBSA as needed to enable
Sponsoring Plan and
38
-- 399 of 512 --
Controlled Affiliate Licensee to meet their obligations to Licensor under the
Agreement and all associated rules and regulations of Licensor, including the Brand Regulations, (ii) it will not
take any action that would cause Sponsoring Plan or Controlled Affiliate Licensee to violate the Agreement, and
(iii) it will not fail to take any action, either individually or jointly with the Sponsoring Plan or Controlled Affiliate
Licensee, where such failure would cause Sponsoring Plan or Controlled Affiliate Licensee to violate the
Agreement.
3. The Controlled Affiliate Licensee shall only use the Licensed Marks authorized by the Participating Plan in
connection with the Basic Medicare Part D Prescription Drug Plan product offered in the Participating Plan’s
Service Area.
4. The Sponsoring Plan and Controlled Affiliate acknowledge that it has reviewed the Agreement and understands
that Participating Plan has the right to terminate this Agreement: (i) immediately upon the expiration or
termination of the Plan Participation Agreement by and between Participating Plan and Controlled Affiliate upon
written notice to the Sponsoring Plan, Controlled Affiliate Licensee and Licensor, or (ii) without cause upon 18
months written notice to the Sponsoring Plan, Controlled Affiliate Licensee and Licensor, and that such right is
unfettered and may be exercised by Participating Plan in its sole discretion. In the event that Participating Plan
and Controlled Affiliate fail to execute the Plan Participation Agreement by ____________(Date), Participating
Plan may terminate this Agreement immediately upon notice to Sponsoring Plan, Controlled Affiliate Licensee
and Licensor.
5. This Agreement and all of Controlled Affiliate Licensee's rights hereunder shall immediately terminate without any
further action by any party or entity in the event that the Sponsoring Plan or Participating Plan ceases to be
authorized to use the Licensed Marks and Name.
WHEREFORE, by signing below the parties agree to be bound to the terms stated herein.
BLUE CROSS BLUE SHIELD ASSOCIATION
By: ________________________________________
[Controlled Affiliate Licensee]
By: ________________________________________
[Sponsoring Plan]
By: ________________________________________
[Participating Plan]
By: ________________________________________ Amended March 17, 2016
39
-- 400 of 512 --
EXHIBIT C
ROYALTY FORMULA FOR SECTION 9 OF THE
CONTROLLED AFFILIATE LICENSE AGREEMENT
Controlled Affiliate will pay BCBSA a fee for this license in accordance with the following formula:
FOR RISK PRODUCTS:
For Controlled Affiliates not underwriting the indemnity portion of workers’ compensation insurance:
An amount equal to its pro rata share of Sponsoring Plan's dues payable to BCBSA computed with the addition of
the Controlled Affiliate's members using the Marks on health care plans and related services as reported on the
Quarterly Enrollment Report with BCBSA. The payment by Sponsoring Plan of its dues to BCBSA, including that
portion described in this paragraph, will satisfy the requirement of this paragraph, and no separate payment will be
necessary.
For Controlled Affiliates underwriting the indemnity portion of workers’ compensation insurance:
An amount equal to 0.35 percent of the gross revenue per annum of Controlled Affiliate arising from products using
the marks; plus, an annual fee of $5,000 per license for a Controlled Affiliate subject to Standard 7.
Amended as of September, 19, 2014
-40-
-- 401 of 512 --
EXHIBIT C (continued)
FOR NONRISK PRODUCTS:
For third-party administrative business, an amount equal to its pro rata share of Sponsoring Plan’s dues payable to
BCBSA computed with the addition of the Controlled Affiliate’s members using the Marks on health care plans and
related services as reported on the Quarterly Enrollment Report with BCBSA. The payment by Sponsoring Plan of
its dues to BCBSA, including that portion described in this paragraph, will satisfy the requirement of this paragraph,
and no separate payment will be necessary.
For non-third party administrative business (e.g., case management, provider networks, etc.), an amount equal to
0.24 percent of the gross revenue per annum of Controlled Affiliate arising from products using the marks; plus:
1) An annual fee of $5,000 per license for a Controlled Affiliate subject to
Standard 6 D.
2) An annual fee of $2,000 per license for all other Controlled Affiliates.
The foregoing shall be reduced by one-half where both a BLUE CROSS® and BLUE SHIELD® License are issued to
the same Controlled Affiliate. In the event that any license period is greater or less than one (1) year, any amounts due
shall be prorated. Royalties under this formula will be calculated, billed and paid in arrears.
Amended as of September 19, 2014
-41-
-- 402 of 512 --
EXHIBIT 1A
CONTROLLED AFFILIATE LICENSE AGREEMENT
APPLICABLE TO LIFE INSURANCE COMPANIES
(Includes revisions adopted by Member Plans through their September 17, 2020 meeting)
This agreement by and among Blue Cross and Blue Shield Association ("BCBSA")
_______________________________("Controlled Affiliate"), a Controlled Affiliate of the Blue Shield Plan(s), known as
_______________________________________("Plan").
WHEREAS, BCBSA is the owner of the BLUE SHIELD and BLUE SHIELD Design service marks;
WHEREAS, the Plan and the Controlled Affiliate desire that the latter be entitled to use the BLUE SHIELD and BLUE
SHIELD Design service marks (collectively the "Licensed Marks") as service marks and be entitled to use the term
BLUE SHIELD in a trade name ("Licensed Name");
NOW, THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby
agree as follows:
1. GRANT OF LICENSE
Subject to the terms and conditions of this Agreement, BCBSA hereby grants to the Controlled Affiliate the exclusive
right to use the licensed Marks and Names in connection with and only in connection with those life insurance and
related services authorized by applicable state law, other than health care plans and related services (as defined in the
Plan's License Agreements with BCBSA) which services are not separately licensed to Controlled Affiliate by BCBSA,
in the Service Area served by the Plan, except that BCBSA reserves the right to use the Licensed Marks and Name in
said Service Area, and except to the extent that said Service Area may overlap the area or areas served by one or
more other licensed Blue Shield Plans as of the date of this License as to which overlapping areas the rights hereby
granted are non-exclusive as to such other Plan or Plans and their respective Licensed Controlled Affiliates only.
Controlled Affiliate cannot use the Licensed Marks or Name outside the Service Area or in its legal or trade name;
provided, however, that if and only for so long as Controlled Affiliate also holds a Blue Shield Affiliate License
Agreement applicable to health care plans and related services, Controlled Affiliate may use the Licensed Marks and
Name in its legal and trade name according to the terms of such license agreement.
Amended as of June 12, 2003
-1-
-- 403 of 512 --
2. QUALITY CONTROL
A. Controlled Affiliate agrees to use the Licensed Marks and Name only in relation to the sale, marketing and
rendering of authorized products and further agrees to be bound by the conditions regarding quality control shown in
Exhibit A as it may be amended by BCBSA from timetotime.
B. Controlled Affiliate agrees that Plan and/or BCBSA may, from timetotime, upon reasonable notice, review and
inspect the manner and method of Controlled Affiliate's rendering of service and use of the Licensed Marks and Name.
C. Controlled Affiliate agrees that it will provide on an annual basis (or more often if reasonably required by Plan
or by BCBSA) a report to Plan and BCBSA demonstrating Controlled Affiliate's compliance with the requirements of this
Agreement including but not limited to the quality control provisions of Exhibit A.
D. As used herein, a Controlled Affiliate is defined as an entity organized and operated in such a manner that it
is subject to the bona fide control of a Plan or Plans. Absent written approval by BCBSA of an alternative method of
control, bona fide control shall mean the legal authority, directly or indirectly through whollyowned subsidiaries: (a) to
select members of the Controlled Affiliate's governing body having not less than 51% voting control thereof; (b) to
exercise operational control with respect to the governance thereof; and (c) to prevent any change in its articles of
incorporation, bylaws or other governing documents deemed inappropriate. In addition, a Plan or Plans shall own at
least 51% of any forprofit Controlled Affiliate. If the Controlled Affiliate is a mutual company, the Plan or its designee(s)
shall have and maintain, in lieu of the requirements of items (a) and (c) above, proxies representing 51% of the votes at
any meeting of the policyholders and shall demonstrate that there is no reason to believe this such proxies shall be
revoked by sufficient policyholders to reduce such percentage below 51%.
3. SERVICE MARK USE
Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks, including but not limited to
use of such symbols or words as BCBSA shall specify to protect the Licensed Marks, and shall comply with such rules
(applicable to all Controlled Affiliates licensed to use the Marks) relative to service mark use, as are issued from
timetotime by BCBSA. If there is any public reference to the affiliation between the Plan and the Controlled Affiliate, all
of the Controlled Affiliate's licensed services in the Service Area of the Plan shall be rendered under the Licensed
Marks. Controlled Affiliate recognizes and agrees that all use of the Licensed Marks by Controlled Affiliate shall inure to
the benefit of BCBSA. -2-
-- 404 of 512 --
4. SUBLICENSING AND ASSIGNMENT
Controlled Affiliate shall not sublicense, transfer, hypothecate, sell, encumber or mortgage, by operation of law or
otherwise, the rights granted hereunder and any such act shall be voidable at the option of Plan or BCBSA. This
Agreement and all rights and duties hereunder are personal to Controlled Affiliate.
5. INFRINGEMENTS
Controlled Affiliate shall promptly notify Plan and BCBSA of any suspected acts of infringement, unfair competition or
passing off which may occur in relation to the Licensed Marks. Controlled Affiliate shall not be entitled to require Plan or
BCBSA to take any actions or institute any proceedings to prevent infringement, unfair competition or passing off by
third parties. Controlled Affiliate agrees to render to Plan and BCBSA, free of charge, all reasonable assistance in
connection with any matter pertaining to the protection of the Licensed Marks by BCBSA.
6. LIABILITY INDEMNIFICATION
Controlled Affiliate hereby agrees to save, defend, indemnify and hold Plan and BCBSA harmless from and against
all claims, damages, liabilities and costs of every kind, nature and description which may arise as a result of Controlled
Affiliate's rendering of health care services under the Licensed Marks.
7. LICENSE TERM
The license granted by this Agreement shall remain in effect for a period of one (1) year and shall be automatically
extended for additional one (1) year periods upon evidence satisfactory to the Plan and BCBSA that Controlled Affiliate
meets the then applicable quality control standards, unless one of the parties hereto notifies the other party of the
termination hereof at least sixty (60) days prior to expiration of any license period.
This Agreement may be terminated by the Plan or by BCBSA for cause at any time provided that Controlled Affiliate
has been given a reasonable opportunity to cure and shall not effect such a cure within thirty (30) days of receiving
written notice of the intent to terminate (or commence a cure within such thirty day period and continue diligent efforts
to complete the cure if such curing cannot reasonably be completed within such thirty day period). By way of example
and not for purposes of limitation, Controlled Affiliate's failure to abide by the quality control provisions of Paragraph 2,
above, shall be considered a proper ground for cancellation of this Agreement.
-3-
-- 405 of 512 --
This Agreement and all of Controlled Affiliate’s rights hereunder shall immediately terminate without any further
action by any party or entity in the event that:
A. Controlled Affiliate shall no longer comply with Standard No. 1 (Organization and Governance) of Exhibit A or,
following an opportunity to cure, with the remaining quality control provisions of Exhibit A, as it may be amended from
time-to-time; or
B. Plan ceases to be authorized to use the Licensed Marks; or
C. Appropriate dues for Controlled Affiliate pursuant to item 8 hereof, which are the royalties for this License
Agreement are more than sixty (60) days in arrears to BCBSA.
Upon termination of this Agreement for cause or otherwise, Controlled Affiliate agrees that it shall immediately
discontinue all use of the Licensed Marks including any use in its trade name.
In the event of any disagreement between Plan and BCBSA as to whether grounds exist for termination or as to any
other term or condition hereof, the decision of BCBSA shall control, subject to provisions for mediation or mandatory
dispute resolution in effect between the parties.
Upon termination of this Agreement, Licensed Controlled Affiliate shall immediately notify all of its customers that it is
no longer a licensee of the Blue Cross and Blue Shield Association and provide instruction on how the customer can
contact the Blue Cross and Blue Shield Association or a designated licensee to obtain further information on securing
coverage. The written notification required by this paragraph shall be in writing and in a form approved by the
Association. The Association shall have the right to audit the terminated entity's books and records to verify compliance
with this paragraph.
8. DUES
Controlled Affiliate will pay to BCBSA a fee for this license in accordance with the following formula:
An annual fee of five thousand dollars ($5,000) per license, plus
.05% of gross revenue per year from branded group products, plus
.5% of gross revenue per year from branded individual products plus
.14% of gross revenue per year from branded individual annuity products.
-4-
-- 406 of 512 --
The foregoing percentages shall be reduced by one-half where both a BLUE
CROSS® and BLUE SHIELD® license are issued to the same entity. In the
event that any License period is greater or less than one (1) year, any
amounts due shall be prorated. Royalties under this formula will be
calculated, billed and paid in arrears.
Plan will promptly and timely transmit to BCBSA all dues owed by Controlled
Affiliate as determined by the above formula and if Plan shall fail to do so,
Controlled Affiliate shall pay such dues directly.
9. JOINT VENTURE
Nothing contained in this Agreement shall be construed as creating a joint venture, partnership, agency or
employment relationship between Plan and Controlled Affiliate or between either and BCBSA.
9A. VOTING
For all provisions of this Agreement referring to voting, the term ‘Plans’ shall mean all entities licensed under the
Blue Cross License Agreement and/or the Blue Shield License Agreement, and in all votes of the Plans under this
Agreement the Plans shall vote together. For weighted votes of the Plans, the Plan shall have a number of votes equal
to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes (if any)
that it holds as a Blue Shield Plan. For all other votes of the Plans, the Plan shall have one vote. For all questions
requiring an affirmative three-fourths weighted vote of the Plans, the requirement shall be deemed satisfied with a
lesser weighted vote unless the greater of: (i) 6/52 or more of the Plans (rounded to the nearest whole number, with
0.5 or multiples thereof being rounded to the next higher whole number) fail to cast weighted votes in favor of the
question; or (ii) three (3) of the Plans fail to cast weighted votes in favor of the question. Notwithstanding the foregoing
provision, if there are thirty-six (36) Plans, the requirement of an affirmative three-fourths weighted vote shall be
deemed satisfied with a lesser weighted vote unless four (4) or more Plans fail to cast weighted votes in favor of the
question.
10. NOTICES AND CORRESPONDENCE
Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and shall be
addressed in duplicate to the last known address of each other party, marked respectively to the attention of its
President and, if any, its General Counsel.
Amended as of November 20, 1997
-5-
-- 407 of 512 --
11. COMPLETE AGREEMENT
This Agreement contains the complete understandings of the parties in relation to the subject matter hereof. This
Agreement may only be amended by a writing executed by all parties.
12. SEVERABILITY
If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such finding shall in no way
effect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition for any
unlawful term or condition so long as the effect of such substitution is to provide the parties with the benefits of this
Agreement.
13. NONWAIVER
No waiver by BCBSA of any breach or default in performance on the part of the Controlled Affiliate or any other
licensee of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any subsequent
breach or default in performance of said terms, covenants or conditions.
14. GOVERNING LAW
This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of
Illinois.
Amended as of June 16, 2005
-6-
-- 408 of 512 --
IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed, effective as of the date of
last signature written below.
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By: _
Date: _
Controlled Affiliate
By: _
Date: _
Plan
By: _
Date: _
-7-
-- 409 of 512 --
EXHIBIT A
CONTROLLED AFFILIATE LICENSE STANDARDS
LIFE INSURANCE COMPANIES
Page 1 of 2
PREAMBLE
The standards for licensing Life Insurance Companies (Life and Health Insurance companies, as defined by state
statute) are established by BCBSA and are subject to change from time-to-time upon the affirmative vote of three-
fourths (3/4) of the Plans and three-fourths (3/4) of the total weighted vote of all Plans. Each Licensed Plan is required
to use a standard controlled affiliate license form provided by BCBSA and to cooperate fully in assuring that the
licensed Life Insurance Company maintains compliance with the license standards.
An organization meeting the following standards shall be eligible for a license to use the Licensed Marks within the
service area of its sponsoring Licensed Plan to the extent and the manner authorized under the Controlled Affiliate
License applicable to Life Insurance Companies and the principal license to the Plan.
Standard 1 - Organization and Governance
The LIC shall be organized and operated in such a manner that it is controlled by a licensed Plan or Plans which have,
directly or indirectly: 1) not less than 51% of the voting control of the LIC; and 2) the legal ability to prevent any change
in the articles of incorporation, bylaws or other establishing or governing documents of the LIC with which it does not
concur; and 3) operational control of the LIC.
If the LIC is a mutual company, the Plan or its designee(s) shall have and maintain, in lieu of the requirements of items
1 and 2 above, proxies representing at least 51% of the votes at any policyholder meeting and shall demonstrate that
there is no reason to believe such proxies shall be revoked by sufficient policyholders to reduce such percentage below
51%.
Standard 2 - State Licensure
The LIC must maintain unimpaired licensure or certificate of authority to operate under applicable state laws as a life
and health insurance company in each state in which the LIC does business.
-1-
-- 410 of 512 --
EXHIBIT A
CONTROLLED AFFILIATE LICENSE STANDARDS
LIFE INSURANCE COMPANIES
Page 2 of 2
Standard 3 - Records and Examination
The LIC and its sponsoring licensed Plan(s) shall maintain and furnish, on a timely and accurate basis, such records
and reports regarding the LIC as may be required in order to establish compliance with the license agreement. The LIC
and its sponsoring licensed Plan(s) shall permit BCBSA to examine the affairs of the LIC and shall agree that BCBSA's
board may submit a written report to the chief executive officer(s) and the board(s) of directors of the sponsoring
Plan(s).
Standard 4 - Mediation
The LIC and its sponsoring Plan(s) shall agree to use the then-current BCBSA mediation and mandatory dispute
resolution processes, in lieu of a legal action between or among another licensed controlled affiliate, a licensed Plan or
BCBSA.
Standard 5 - Financial Responsibility
The LIC shall maintain adequate financial resources to protect its customers and meet its business obligations.
Standard 6 - Cooperation with Affiliate License Performance Response Process Protocol
The LIC and its Sponsoring Plan(s) shall cooperate with BCBSA’s Board of Directors and its Brand Enhancement
& Protection Committee in the administration of the Affiliate License Performance Response Process Protocol
(ALPRPP) and in addressing LIC compliance problems identified thereunder.
-2-
-- 411 of 512 --
Exhibit 1A1
CONTROLLED AFFILIATE
TRADEMARK LICENSE AGREEMENT
FOR LIFE AND DISABILTY INSURANCE PRODUCTS
This Agreement by and among Blue Cross and Blue Shield Association ("BCBSA") and ___________________,
(“Life and Disability Controlled Affiliate”) which is a company offering life and disability insurance products owned and
controlled by __________________, ____________, _____________ ( individually, “Sponsoring Plan” and when
referred to collectively, “Sponsoring Plans”).
Whereas, BCBSA is the owner of the BLUE CROSS and BLUE SHIELD word and design service marks and any
derivatives thereof (“Licensed Marks”);
Whereas, each Sponsoring Plan is licensed separately by BCBSA to use one or more of the Licensed Marks in a
particular Service Area;
Whereas, the Sponsoring Plans and the Life and Disability Controlled Affiliate desire that the latter be entitled to use the
appropriate Licensed Marks in connection with life and disability insurance products in some or all of such Sponsoring
Plans’ Service Areas and in the Service Areas of other Regular Member Plans, as defined in the BCBSA By-laws,
(“Blue Plans”) consistent with the terms of this Agreement.
NOW, THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby
agree as follows:
1. GRANT OF LICENSE
a. Subject to the terms and conditions of this Agreement, BCBSA hereby grants to the Life and Disability
Controlled Affiliate the limited right to use the Licensed Marks in connection with and only in connection with the
following life and disability insurance products authorized by state law: (1) Group: Term Life, Long Term Disability,
Whole Life, Benefit Life, Universal Life; (2) Individual: Term Life, Whole Life, Dependent Life, Spouse Life; (3) Other:
Disability Income, Short Term Disability, Long Term Disability, Income Replacement; and (4) such other life and
disability products approved by BCBSA in writing (“Licensed Products”) in the Service Areas served by the Sponsoring
Plans or in the Service Area or Areas of one or more other licensed Blue Plans, provided that such Blue Plans have
consented to such use as authorized by this Agreement. Life and Disability Controlled Affiliate may not use the
Licensed Marks in its legal or trade name.
-1-
-- 412 of 512 --
b. Notwithstanding that the license granted to Life and Disability Controlled Affiliate is a license to use all of
the Licensed Marks, Life and Disability Controlled Affiliate may only use those of the Licensed Marks in the Service
Area of a Sponsoring Plan or other consenting Blue Plan as described below that such Plan is authorized to use as a
Blue Plan pursuant to its separate license agreements with BCBSA.
c. Life and Disability Controlled Affiliate may use the Licensed Marks in the Service Areas of Sponsoring
Plans or in the Service Area of a Blue Plan that is not a signatory to this Agreement only after such Sponsoring Plan(s)
or non-signatory Blue Plan consents to such use by executing a written consent in substantially the same form as the
Consent Agreement attached as Exhibit B.
d. The following provisions apply with respect to Consent Agreements once such agreements have been
fully and properly executed:
i.All sales, marketing and advertising materials developed by and proposed for use by Life and Disability
Controlled Affiliate in the Service Area of Sponsoring Plan or consenting Blue Plan (hereinafter, such consenting
Sponsoring Plan or consenting Blue Plan collectively referred to “Consenting Plan(s)”) must clearly identify the
Consenting Plan (for example, a statement on such materials that reads “This product is offered with the
cooperation of Blue Cross and/or Blue Shield of [Geography]”);
ii.To the extent the Consenting Plan has separate divisions or other Affiliates that use the Licensed Marks in
distinct geographic areas within its Service Area, consent obtained under this Agreement may be limited to one or
more of such specific geographic areas as specified by the Consenting Plan in its signed Consent Agreement.
For purposes of this entire Agreement, all references to the Service Area of a Sponsoring Plan, Blue Plan or
Consenting Plan may include the entire Service Area or a distinct geographic area within such Service Area as
specified in this Section 1 D (2);
iii.Where BCBSA has licensed two or more Blue Plans to use the same Licensed Marks in the same Service
Area, in addition to the requirements set forth in Section D (1) above, the sales, marketing and advertising
materials referenced in such section above must be communicated to the Consenting Plan’s existing and
prospective accounts through or with the approval of such Consenting Plan, and the personnel of such
Consenting Plan must actively participate in all sales and marketing activities conducted by Life and Disability
Controlled Affiliate in the same Service Area, including participating in meetings (whether in-person or via
telephone, video or internet conference) with both existing and prospective accounts of the Consenting Plan;
-2-
-- 413 of 512 --
iv.Life and Disability Controlled Affiliate shall be entitled to use in a Service Area only those Licensed Marks
that the Consenting Plan has been granted by BCBSA the license to use under its Blue Plan license agreements
(for example, if a Consenting Plan is licensed to use only the Blue Cross Marks in its Service Area, the materials
used by Life and Disability Controlled Affiliate in that Service Area may only contain or reference the Blue Cross
Marks and not the Blue Shield Marks).
v.If a Consent Agreement is terminated, Life and Disability Controlled Affiliate shall, unless BCBSA and the
Consenting Plan agree in their sole discretion to a phase out in writing, immediately (i) cease all use of the
Licensed Marks, including in connection with any and all sales and marketing of the Licensed Products in the
Service Area where consent has been terminated, and (ii) notify its customers that it is no longer a licensee and
provide instruction on how the customer can contact BCBSA or a designated licensee to obtain further
information on securing coverage. The notification required by this paragraph shall be in writing and in form
approved by BCBSA.
2. QUALITY CONTROL
A. Life and Disability Controlled Affiliate agrees to use the
Licensed Marks only in relation to the sale, marketing and administration of the Licensed Products and further agrees to
be bound by the conditions regarding quality control shown in Exhibit A and the Guidelines to Administer the Standards
for Trademark License Agreement for Life and Disability Insurance Products attached thereto.
B. Life and Disability Controlled Affiliate agrees that BCBSA
may, from timetotime, upon reasonable notice, review and inspect the manner and method of Life and Disability
Controlled Affiliate's rendering of service and use of the Licensed Marks.
C. Life and Disability Controlled Affiliate agrees that it will
provide on an annual basis (or more often if reasonably required by BCBSA) a report to BCBSA demonstrating Life and
Disability Controlled Affiliate's compliance with the requirements of this Agreement including but not limited to the
quality control provisions of Exhibit A.
D. As used herein, a Life and Disability Controlled Affiliate is
defined as: An entity organized and operated in such a manner that it is 100% owned and controlled by Sponsoring
Plans. Absent written approval by BCBSA of an alternative method of control, control shall mean the legal authority,
directly or indirectly through wholly-owned subsidiaries: (a) to select members of the Life and Disability Controlled
Affiliate's governing body having not less than 100% voting control thereof; (b) to exercise operational control with
respect to the governance -3-
-- 414 of 512 --
thereof; and (c) to prevent any change in its articles of incorporation, bylaws or other governing documents deemed
inappropriate. In addition, a Sponsoring Plan or Plans shall own at least 100% of any for profit Life and Disability
Controlled Affiliate.
3. SERVICE MARK USE
Life and Disability Controlled Affiliate shall at all times make proper
service mark use of the Licensed Marks and shall ensure all uses of the Licensed Marks comply with the BCBSA Brand
Regulations, as amended by BCBSA from time to time. Life and Disability Controlled Affiliate recognizes and agrees
that all use of the Licensed Marks by Life and Disability Controlled Affiliate shall inure to the benefit of BCBSA.
4. SUBLICENSING AND ASSIGNMENT
The license hereby granted to Life and Disability Controlled Affiliate
to use the Licensed Marks is and shall be personal to Life and Disability Controlled Affiliate and shall not be assignable
by any act of the Life and Disability Controlled Affiliate, directly or indirectly, without the written consent of BCBSA. Said
license shall not be assignable by operation of law, nor shall Life and Disability Controlled Affiliate mortgage or part with
possession or control of this license or any right hereunder, and the Life and Disability Controlled Affiliate shall have no
right to grant any sublicense to use the Licensed Marks.
5. INFRINGEMENTS
Life and Disability Controlled Affiliate shall promptly notify BCBSA of
any suspected acts of infringement, unfair competition or passing off which may occur in relation to the Licensed Marks.
Life and Disability Controlled Affiliate shall not be entitled to require BCBSA to take any actions or institute any
proceedings to prevent infringement, unfair competition or passing off by third parties. Life and Disability Controlled
Affiliate agrees to render to BCBSA, free of charge, all reasonable assistance in connection with any matter pertaining
to the protection of the Licensed Marks by BCBSA. BCBSA shall have sole control of the defense and resolution of any
claim of infringement brought or threatened by others.
6. LIABILITY INDEMNIFICATION
Life and Disability Controlled Affiliate hereby agrees to save, defend,
indemnify and hold BCBSA harmless from and against all claims, damages, liabilities and costs of every kind, nature
and description which may arise as a result of Life and Disability Controlled Affiliate's conduct.
-4-
-- 415 of 512 --
7. LICENSE TERM
A. The license granted by this Agreement shall remain in effect for a
period of one (1) year and shall be automatically extended for additional one (1) year periods, unless either BCBSA or
Life and Disability Controlled Affiliate notifies the other party in writing of the termination hereof at least sixty (60) days
prior to expiration of any license period.
B. This Agreement may be terminated by BCBSA for cause at any
time provided that Life and Disability Controlled Affiliate has been given a reasonable opportunity to cure and shall not
effect such a cure within thirty (30) days of receiving written notice of the intent to terminate (or commence a cure within
such thirty day period and continue diligent efforts to complete the cure if such curing cannot reasonably be completed
within such thirty day period). By way of example and not for purposes of limitation, Life and Disability Controlled
Affiliate's failure to abide by the conditions regarding use of the Licensed Marks set forth in Section 1 of this Agreement
or the quality control provisions of Section 2 (other than with respect to Section 2 D which is subject to immediate
termination as stated in Section 7 C (1) below) shall be considered proper grounds for termination of this Agreement.
C. This Agreement and all of Life and Disability Controlled Affiliate's
rights hereunder shall immediately terminate without any further action by any party or entity in the event that:
(i)Life and Disability Controlled Affiliate shall no longer
comply with Section 2 D (or Standard No. 1 (Organization and Governance) of Exhibit A); or
(ii)Any Sponsoring Plan ceases to be authorized to use the
Licensed Marks; or
(iii)Appropriate fees for Life and Disability Controlled Affiliate
pursuant to Section 8 of this Agreement are more than sixty (60) days in arrears to BCBSA.
Upon termination of this Agreement for cause or otherwise, Life and Disability Controlled Affiliate agrees that it shall
immediately discontinue all use of the Licensed Marks.
In the event of any disagreement between Life and Disability Controlled Affiliate and BCBSA as to whether grounds
exist for termination or as to any other term or condition hereof, the decision of BCBSA shall control, subject to
provisions for mediation or mandatory dispute resolution in effect between the parties.
-5-
-- 416 of 512 --
Upon termination of this Agreement, Licensed Life and Disability Controlled Affiliate shall immediately notify all of its
customers that it is no longer a licensee of BCBSA and provide instruction on how the customer can contact BCBSA or
a designated licensee to obtain further information on securing coverage. The notification required by this paragraph
shall be in writing and in a form approved by BCBSA. BCBSA shall have the right to audit the terminated entity's books
and records to verify compliance with this paragraph.
8. ROYALTIES
Life and Disability Controlled Affiliate will pay to BCBSA a fee for this license in accordance with the
following formula:
◦ An annual fee of five thousand dollars ($5,000) per license, plus
◦ .05% of gross revenue per year from group products sold under the Licensed Marks, plus
◦ .5% of gross revenue per year from individual products sold under the Licensed Marks
In the event that any license period is greater or less than one (1) year, any amounts due shall be prorated. Royalties
under this formula will be calculated, billed and paid in arrears.
Life and Disability Controlled Affiliate will promptly and timely transmit to BCBSA all fees owed by Life and Disability
Controlled Affiliate as determined by the above formula.
9. JOINT VENTURE
Nothing contained in this Agreement shall be construed as creating a joint venture, partnership, agency or
employment relationship between any Sponsoring Plan and Life and Disability Controlled Affiliate or between among
them and/or BCBSA.
10. VOTING
For all provisions of this Agreement referring to voting, the term ‘Plans’ shall mean all entities licensed
under the Blue Cross License Agreement and/or the Blue Shield License Agreement, and in all votes of the Plans
under this Agreement the Plans shall vote together. For weighted votes of the Plans, the Plan shall have a number of
votes equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted
votes (if any) that it holds as a Blue Shield Plan. For all other votes of the Plans, the
-6-
-- 417 of 512 --
Plan shall have one vote. For all questions requiring an affirmative three-fourths weighted vote of the Plans, the
requirement shall be deemed satisfied with a lesser weighted vote unless the greater of: (i) 6/52 or more of the Plans
(rounded to the nearest whole number, with 0.5 or multiples thereof being rounded to the next higher whole number) fail
to cast weighted votes in favor of the question; or (ii) three (3) of the Plans fail to cast weighted votes in favor of the
question. Notwithstanding the foregoing provision, if there are thirty-six (36) Plans, the requirement of an affirmative
three-fourths weighted vote shall be deemed satisfied with a lesser weighted vote unless four (4) or more Plans fail to
cast weighted votes in favor of the question.
11. NOTICES AND CORRESPONDENCE
Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing
and shall be addressed in duplicate to the last known address of each other party, marked respectively to the attention
of its President and, if any, its General Counsel.
12. COMPLETE AGREEMENT
This Agreement contains the complete understandings of the parties in relation to the subject matter
hereof. This Agreement may only be amended by: (a) a writing signed by all parties; or (b) a writing approved by the
affirmative vote of three-fourths of the Blue Plans and three-fourths of the total then current weighted vote of all the
Blue Plans as officially recorded by the BCBSA Corporate Secretary. Upon such adoption by the Blue Plans, this
Agreement and all other Trademark License Agreements for Life and Disability Insurance Products then in effect shall
simultaneously be amended.
13. SEVERABILITY
If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such finding shall
in no way affect the remaining obligations of the parties hereunder and the court may substitute a lawful term or
condition for any unlawful term or condition so long as the effect of such substitution is to provide the parties with the
benefits of this Agreement.
14. NONWAIVER
No waiver by BCBSA of any breach or default in performance on the part of the Life and Disability
Controlled Affiliate or any other licensee of any of the terms, covenants or conditions of this Agreement shall constitute
a waiver of any subsequent breach or default in performance of said terms, covenants or conditions.
15. GOVERNING LAW
This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the
State of Illinois.
-7-
IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed, effective as of the date of
last signature written below.
-- 418 of 512 --
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By: _
Date: _
Life and Disability Controlled Affiliate:
By: _
Date: _
Sponsoring Plan:
By: __ _
Date: _
Name:________________________________________
Sponsoring Plan:
By: __ _
Date: _
Name:________________________________________
[Add other Sponsoring Plans as necessary]
-8-
-- 419 of 512 --
EXHIBIT A
LICENSE STANDARDS APPLICABLE TO TRADEMARK LICENSE
AGREEMENT FOR LIFE AND DISABILITY INSURANCE PRODUCTS
Page 1 of 2
Standard 1 - Organization and Governance
Any Life and Disability Controlled Affiliate licensed under the Trademark License Agreement for Life and Disability
Insurance Products (“licensee”) shall be organized and operated in such a manner that it is an entity organized and
operated in such a manner that it is 100% owned and controlled by Sponsoring Plans. Absent written approval by
BCBSA of an alternative method of control, control shall mean the legal authority, directly or indirectly through wholly-
owned subsidiaries: (a) to select members of the Life and Disability Controlled Affiliate's governing body having not less
than 100% voting control thereof; (b) to exercise operational control with respect to the governance thereof; and (c) to
prevent any change in its articles of incorporation, bylaws or other governing documents deemed inappropriate. In
addition, a Sponsoring Plan or Plans shall own at least 100% of any for profit Life and Disability Controlled Affiliate.
Standard 2 - State Licensure
The licensee must maintain unimpaired licensure or certificate of authority to operate under applicable state laws as a
life company in each state in which the licensee does business.
Standard 3 - Records and Examination
The licensee shall maintain and furnish, on a timely and accurate basis, such records and reports regarding the
licensee as may be required in order to establish compliance with the Agreement. The licensee shall permit BCBSA to
examine the affairs of the licensee and shall agree that BCBSA's board may submit a written report to the chief
executive officer(s) and the board(s) of directors of the Sponsoring Plan(s).
Standard 4 - Mediation
The licensee, its Sponsoring Plan(s) and all consenting Blue Plans shall agree to use the then-current BCBSA
mediation and mandatory dispute resolution processes, in lieu of a legal action between or among another licensed Life
and Disability Controlled Affiliate, a Sponsoring Plan and or consenting Blue Plan or BCBSA.
-1-
-- 420 of 512 --
EXHIBIT A
LICENSE STANDARDS APPLICABLE TO TRADEMARK LICENSE
AGREEMENT FOR LIFE AND DISABILITY INSURANCE PRODUCTS
Page 2 of 2
Standard 5 - Financial Responsibility
The licensee shall maintain adequate financial resources to protect its customers and meet its business obligations.
Standard 6 - Cooperation with BCBSA Governance
The licensee shall cooperate with BCBSA’s Board of Directors and its Brand Enhancement & Protection
Committee in the administration of and in addressing licensee compliance problems that may be identified in
connection with the operation or administration of the Trademark License Agreement for Life and Disability
Insurance Products.
-2-
-- 421 of 512 --
EXHIBIT B
CONSENT AGREEMENT
This Consent Agreement is made and entered into by and among the undersigned Blue Plan, and
____________________ (“Life and Disability Controlled Affiliate”), and the Blue Cross and Blue Shield Association
(“BCBSA”) and shall be deemed effective on ______________________ (“Effective Date”).
Whereas, BCBSA owns the Blue Cross and Blue Shield word and design service marks and any derivative mark thereof
(the “Brands”);
Whereas, the undersigned Blue Plan is licensed to use one or more of the Brands within a specific geographic area
(“Service Area”);
Whereas Life and Disability Controlled Affiliate is licensed by BCBSA to use one or more of the Brands to offer life and
disability insurance products (“Products”) as defined and authorized in the Trademark License Agreement for Life and
Disability Insurance Products (“Life and Disability License Agreement”);
Whereas neither the Blue Plan nor its affiliates offer the Products under any of the Brands in such Blue Plan’s Service
Area or portion thereof where Blue Plan has consented to sale of the Products by Life and Disability Controlled Affiliate;
and
Whereas BCBSA and the undersigned Blue Plan desire to consent to Life and Disability Controlled Affiliate’s use of the
Brands in Blue Plan’s Service Area consistent with the terms of the Life and Disability License Agreement and this
Consent Agreement.
Now, therefore, in consideration of the obligations and conditions stated in this Agreement, Blue Plan, Life and Disability
Controlled Affiliate and BCBSA agree as follows:
1. Life and Disability Controlled Affiliate may market, sell, administer and underwrite the Products in Blue Plan’s
Service Area under the Brands licensed to Blue Plan in such Service Area subject to the terms of this Consent
Agreement, the Life and Disability License Agreement and Blue Plan’s license agreement(s) with BCBSA. Life
and Disability Controlled Affiliate’s rights under the Brands to offer the Products under the Brands are limited
to offering the Products only under the Brand(s) licensed to the consenting Blue Plan.
2. Life and Disability Controlled Affiliate shall work with the undersigned Blue Plan to develop a written sales and
marketing agreement that
identifies the relationship between it and Blue Plan for the sales, marketing and customer service for the
Products. The term of the sales and marketing agreement shall be the same as the term of this Consent
Agreement.
1
-- 422 of 512 --
3. All sales, marketing and advertising materials developed by and proposed for use by Life and Disability
Controlled Affiliate in a consenting Blue Plan’s Service Area must clearly identify the consenting Blue Plan
(for example, a statement on such materials that reads “This product is offered with the cooperation of
Blue Cross and/or Blue Shield of [Geography]”);
4. Life and Disability Controlled Affiliate may use the Brands to sell the Products in the following Service Area
or portion thereof as designated by Blue Plan:
___________________________________________________
5. If two or more Blue Plans to use the same Licensed Marks in the same Service Area, Life and Disability
Controlled Affiliate shall work with the consenting Blue Plan in the following manner: (a) the sales,
marketing and advertising materials must be communicated to the consenting Blue Plan’s existing and
prospective accounts through or with the approval of such Blue Plan, and (b) the personnel of such Blue
Plan must actively participate in all sales and marketing activities conducted by Life and Disability
Controlled Affiliate in the same Service Area, including participating in meetings (whether in-person or via
telephone, video or internet conference) with both existing and prospective accounts of the consenting
Blue Plan;
6. Life and Disability Controlled Affiliate shall be entitled to use in a Service Area only those Licensed Marks
that the consenting Blue Plan has been granted by BCBSA the license to use under its license agreement
(for example, if a consenting Blue Plan is licensed to use only the Blue Cross Marks in its Service Area,
the materials used by Life and Disability Controlled Affiliate in that Service Area may only contain or
reference the Blue Cross Marks and not the Blue Shield Marks).
7. If this Consent Agreement is terminated, Life and Disability Controlled Affiliate shall, unless each BCBSA
and the Blue Plan agree in their sole discretion to a phase out in writing, immediately (i) cease all use of
the Licensed Marks, including in connection with any and all sales and marketing of the Licensed Products
in the Service Area where consent has been terminated, and (ii) notify its customers that it is no longer a
licensee of BCBSA and provide instruction on how the customer can contact BCBSA or a designated
licensee to obtain further information on securing coverage. The notification required by this paragraph
shall be in writing and in form approved by BCBSA.
2
-- 423 of 512 --
8. The term of this Consent Agreement shall be one year from the Effective Date. Unless either Blue Plan or
Life and Disability Controlled Affiliate provides the other party with written notice of its desire not to renew
this Consent Agreement at least 60 days prior to expiration of the term or any extended term or unless
terminated as provided in Paragraph 9 below, this Consent Agreement shall automatically renew for
subsequent one year periods.
9. This Consent Agreement may be terminated as follows:
a. Upon mutual written consent of Life and Disability Controlled Affiliate and Blue Plan;
b. By Blue Plan or Life and Disability Controlled Affiliate upon 60 days advance written notice to the
non-terminating party and BCBSA; or
c. By Blue Plan immediately if Life and Disability Controlled Affiliate does not comply with this Consent
Agreement or the sales protocol agreement.
10. This Consent Agreement shall automatically terminate if Blue Plan’s primary licensee agreement
terminates for any reason or if the Life and Disability License Agreement terminates for any reason.
Agreed and Accepted by:
[Blue Plan]:
By:_____________________
Title:____________________
BLUE CROSS AND BLUE SHIELD ASSOCIATION:
By:________________________
Title:________________________
LIFE AND DISABILITY CONTROLLED AFFILIATE:
By:_______________________
Title:_____________________
3
-- 424 of 512 --
Exhibit 1B
BLUE SHIELD
CONTROLLED AFFILIATE LICENSE AGREEMENT
APPLICABLE TO REGIONAL MEDICARE ADVANTAGE PPO PRODUCTS
(Adopted by Member Plans at their September 17, 2020)
This Agreement by and among Blue Cross and Blue Shield Association ("BCBSA") and _______ (“Controlled
Affiliate"), a Controlled Affiliate of the Blue Cross Plan(s), known as _________ ("Controlling Plans"), each of which is
also a Party signatory hereto.
WHEREAS, BCBSA is the owner of the BLUE SHIELD and BLUE SHIELD Design service marks;
WHEREAS, under the Medicare Modernization Act, companies may apply to and be awarded a contract by the
Centers for Medicare and Medicaid Services (“CMS”) to offer Medicare Advantage PPO products in geographic regions
designated by CMS (hereafter “regional MAPPO products”).
WHEREAS, some of the CMS-designated regions include the Service Areas, or portions thereof, of more than one
Plan.
WHEREAS, the Controlling Plans and Controlled Affiliate desire that the latter be entitled to use the BLUE SHIELD
and BLUE SHIELD Design service marks (collectively the "Licensed Marks") as service marks and be entitled to use the
term BLUE SHIELD in a trade name ("Licensed Name") to offer regional MAPPO products in a region that includes the
Service Areas, or portions thereof, of more than one Controlling Plan;
NOW THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby
agree as follows:
1. GRANT OF LICENSE
Subject to the terms and conditions of this Agreement, BCBSA hereby grants to Controlled Affiliate the right to use the
Licensed Marks and Name in connection with, and only in connection with the sale, marketing and administration of
regional MAPPO products and related services.
This grant of rights is non-exclusive and is limited to the following states: _________________ (the “Region”).
Controlled Affiliate may use the Licensed
-1-
-- 425 of 512 --
Marks and Name in its legal name on the following conditions: (i) the legal name must be approved in advance, in
writing, by BCBSA; (ii) Controlled Affiliate shall not do business outside the Region under any name or mark except
business conducted in the Service Area of a Controlling Plan provided that Controlled Affiliate is separately licensed by
BCBSA to use the Licensed Marks and Name in connection with health care plans and related services in the Service
Area of such Controlling Plan; and (iii) Controlled Affiliate shall not use the Licensed Marks and Name, or any derivative
thereof, as part of any name or symbol used to identify itself in any securities market. Controlled Affiliate may use the
Licensed Marks and Name in its Trade Name only with the prior, written, consent of BCBSA.
2. QUALITY CONTROL
A. Controlled Affiliate agrees to use the Licensed Marks and Name only in connection with the licensed services
and further agrees to be bound by the conditions regarding quality control shown in attached Exhibit A as they may be
amended by BCBSA from time-to-time.
B. Controlled Affiliate agrees to comply with all applicable federal, state and local laws.
C. Controlled Affiliate agrees that it will provide on an annual basis (or more often if reasonably required by the
Controlling Plans or by BCBSA) a report or reports to the Controlling Plans and BCBSA demonstrating Controlled
Affiliate's compliance with the requirements of this Agreement including but not limited to the quality control provisions of
this paragraph and the attached Exhibit A.
D. Controlled Affiliate agrees that the Controlling Plans and/or BCBSA may, from time-to-time, upon reasonable
notice, review and inspect the manner and method of Controlled Affiliate's rendering of service and use of the Licensed
Marks and Name.
E. As used herein, a Controlled Affiliate is defined as an entity organized and operated in such a manner, that it
meets the following requirements:
(1) Controlled Affiliate is owned or controlled by two or more Controlling Plans;
(2) Each Controlling Plan is authorized pursuant to a separate Blue Shield License Agreement to use the Licensed
Marks in a geographic area in the Region and every geographic area in the Region is so licensed to at least one of the
Controlling Plans; and
-2-
-- 426 of 512 --
(3) The Controlling Plans must have the legal authority directly or indirectly through wholly-owned subsidiaries:
(a) to select members of the Controlled Affiliate’s governing body having not less than 100% voting control thereof;
(b) to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of
the Controlled Affiliate with which the Controlling Plans do not concur;
(c) to exercise control over the policy and operations of the Controlled Affiliate; and
Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate’s establishing or governing
documents must also require written approval by each of the Controlling Plans before the Controlled Affiliate can:
(i)change its legal and/or trade names;
(ii) change the geographic area in which it operates (except such approval shall not be required with
respect to business of the Controlled Affiliate conducted under the Licensed Marks within the
Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license
agreement with BCBSA sponsored by such Controlling Plan);
(iii) change any of the type(s) of businesses in which it engages (except such approval shall not be
required with respect to business of the Controlled Affiliate conducted under the Licensed Marks
within the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate
license agreement with BCBSA sponsored by such Controlling Plan);
(iv) take any action that any Controlling Plan or BCBSA reasonably believes will adversely affect the
Licensed Marks and Name.
In addition, the Controlling Plans directly or indirectly through wholly owned subsidiaries shall own 100% of any for-profit
Controlled Affiliate.
-3-
-- 427 of 512 --
3. SERVICE MARK USE
A. Controlled Affiliate recognizes the importance of a comprehensive national network of independent BCBSA
licensees which are committed to strengthening the Licensed Marks and Name. The Controlled Affiliate further
recognizes that its actions within the Region may affect the value of the Licensed Marks and Name nationwide.
B. Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks and Name, including
but not limited to use of such symbols or words as BCBSA shall specify to protect the Licensed Marks and Name and
shall comply with such rules (generally applicable to Controlled Affiliates licensed to use the Licensed Marks and Name)
relative to service mark use, as are issued from time-to-time by BCBSA. Controlled Affiliate recognizes and agrees that
all use of the Licensed Marks and Name by Controlled Affiliate shall inure to the benefit of BCBSA.
C. Controlled Affiliate may not directly or indirectly use the Licensed Marks and Name in a manner that transfers or
is intended to transfer in the Region the goodwill associated therewith to another mark or name, nor may Controlled
Affiliate engage in activity that may dilute or tarnish the unique value of the Licensed Marks and Name.
D. Controlled Affiliate shall use its best efforts to promote and build the value of the Licensed Marks and Name in
connection with the sale, marketing and administration of regional MAPPO products and related services.
4. SUBLICENSING AND ASSIGNMENT
Controlled Affiliate shall not, directly or indirectly, sublicense, transfer, hypothecate, sell, encumber or mortgage, by
operation of law or otherwise, the rights granted hereunder and any such act shall be voidable at the sole option of any
Controlling Plan or BCBSA. This Agreement and all rights and duties hereunder are personal to Controlled Affiliate.
-4-
-- 428 of 512 --
5. INFRINGEMENT
Controlled Affiliate shall promptly notify the Controlling Plans and the Controlling Plans shall promptly notify BCBSA of
any suspected acts of infringement, unfair competition or passing off that may occur in relation to the Licensed Marks
and Name. Controlled Affiliate shall not be entitled to require the Controlling Plans or BCBSA to take any actions or
institute any proceedings to prevent infringement, unfair competition or passing off by third parties. Controlled Affiliate
agrees to render to the Controlling Plans and BCBSA, without charge, all reasonable assistance in connection with any
matter pertaining to the protection of the Licensed Marks and Name by BCBSA.
6. LIABILITY INDEMNIFICATION
Controlled Affiliate and the Controlling Plans hereby agree to save, defend, indemnify and hold BCBSA harmless from
and against all claims, damages, liabilities and costs of every kind, nature and description (except those arising solely as
a result of BCBSA's negligence) that may arise as a result of or related to Controlled Affiliate's rendering of services
under the Licensed Marks and Name.
7. LICENSE TERM
A. Except as otherwise provided herein, the license granted by this Agreement shall remain in effect for a period of
one (1) year and shall be automatically extended for additional one (1) year periods unless terminated pursuant to the
provisions herein.
B. This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further
action by any party or entity in the event that: (i) any one of the Controlling Plans ceases to be authorized to use the
Licensed Marks and Name; or (ii) pursuant to Paragraph 15(a)(x) of the Blue Shield License Agreement any one of the
Controlling Plans ceases to be authorized to use the Licensed Names and Marks in the Region.
C. Notwithstanding any other provision of this Agreement, this license to use the Licensed Marks and Name may
be forthwith terminated by the Controlling Plans or the affirmative vote of the majority of the Board of Directors of
BCBSA present and voting at a special meeting expressly called by BCBSA for the purpose on ten (10) days written
notice to the Controlling Plans advising of the specific matters at issue and granting the Controlling Plans an opportunity
to be heard and to present their response to the Board for: (1) failure to comply with any applicable minimum capital or
liquidity requirement under the quality control standards of this
-5-
-- 429 of 512 --
Agreement; or (2) failure to comply with the "Organization and Governance" quality control standard of this Agreement;
or (3) impending financial insolvency; or (4) failure to comply with any of the applicable requirements of Standards 2, 3,
4, or 5 of attached Exhibit A; or (5) the pendency of any action instituted against the Controlled Affiliate seeking its
dissolution or liquidation of its assets or seeking
appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business or seeking the
declaration or establishment of a trust for any of its property or business, unless this Controlled Affiliate License
Agreement has been earlier terminated under paragraph 7(E); or (6) such other reason as is determined in good faith
immediately and irreparably to threaten the integrity and reputation of BCBSA, the Plans (including the Controlling
Plans), any other licensee including Controlled Affiliate and/or the Licensed Marks and Name.
D. Except as otherwise provided in Paragraphs 7(B), 7(C) or 7(E) herein, should Controlled Affiliate fail to comply
with the provisions of this Agreement and not cure such failure within thirty (30) days of receiving written notice thereof
(or commence a cure within such thirty day period and continue diligent efforts to
complete the cure if such curing cannot reasonably be completed within such thirty day period) BCBSA or the
Controlling Plans shall have the right to issue a notice that the Controlled Affiliate is in a state of noncompliance. If a
state of noncompliance as aforesaid is undisputed by the Controlled Affiliate or is found to exist by a mandatory dispute
resolution panel and is uncured as provided above, BCBSA shall have the right to seek judicial enforcement of the
Agreement or to issue a notice of termination thereof. Notwithstanding any other provisions of this Agreement, any
disputes as to the termination of this License pursuant to Paragraphs 7(B), 7(C) or 7(E) of this Agreement shall not be
subject to mediation and mandatory dispute resolution. All other disputes between or among BCBSA, any of the
Controlling Plans and/or Controlled Affiliate shall be submitted promptly to mediation and mandatory dispute resolution.
The mandatory dispute resolution panel shall have authority to issue orders for specific performance and assess
monetary penalties. Except, however, as provided in Paragraphs 7(B) and 7(E) of this Agreement, this license to use the
Licensed Marks and Name may not be finally terminated for any reason without the affirmative vote of a majority of the
present and voting members of the Board of Directors of BCBSA.
E. This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any
further action by any party or entity in the event that:
(1) Controlled Affiliate shall no longer comply with item 2(E) above;
(2) Appropriate dues, royalties and other payments for Controlled Affiliate pursuant to paragraph 9 hereof,
which are the royalties for this License Agreement, are more than sixty (60) days in arrears to BCBSA; or
-6-
-- 430 of 512 --
(3) Any of the following events occur: (i) a voluntary petition shall be filed by Controlled Affiliate seeking
bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy laws of the United States or
any other law governing insolvency or debtor relief, or (ii) an involuntary petition or proceeding shall be filed against
Controlled Affiliate seeking bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy
laws of the United States or any other law governing insolvency or debtor relief and such petition or
proceeding is consented to or acquiesced in by Controlled Affiliate or is not dismissed within sixty (60) days of the date
upon which the petition or other document commencing the proceeding is served upon the Controlled Affiliate, or (iii) an
order for relief is entered against Controlled Affiliate in any case under the bankruptcy laws of the United States, or
Controlled Affiliate is adjudged bankrupt or insolvent as those terms are defined in the Uniform Commercial Code as
enacted in the State of Illinois by any court of competent jurisdiction, or (iv) Controlled Affiliate makes a general
assignment of its assets for the benefit of creditors, or (v) any government or any government official, office, agency,
branch, or unit assumes control of Controlled Affiliate or delinquency proceedings (voluntary or involuntary) are
instituted, or (vi) an action is brought by Controlled Affiliate seeking its
dissolution or liquidation of its assets or seeking the appointment of a trustee, interim trustee, receiver or other custodian
for any of its property or business, or (vii) an action is instituted by any governmental entity or officer against Controlled
Affiliate seeking its dissolution or liquidation of its assets or seeking the appointment of a trustee, interim trustee,
receiver or other custodian for any of its property or business and such action is consented to or acquiesced in by
Controlled Affiliate or is not dismissed within one hundred thirty (130) days of the date upon which the pleading or other
document commencing the action is served upon the Controlled Affiliate, provided that if the action is stayed or its
prosecution is enjoined, the one hundred thirty (130) day period is tolled for the duration of the stay or injunction, and
provided further, that the Association’s Board of Directors may toll or extend the 130 day period at any time prior to its
expiration, or (viii) a trustee, interim trustee, receiver or other custodian for any of Controlled Affiliate's property or
business is appointed or the Controlled Affiliate is ordered dissolved or liquidated. Notwithstanding any other provision of
this Agreement, a declaration or a request for declaration of the existence of a trust over any of the Controlled Affiliate’s
property or business shall not in itself be deemed to constitute or seek appointment of a trustee, interim trustee, receiver
or other custodian for purposes of subparagraphs 7(E)(3)(vii) and (viii) of this Agreement.
F. Upon termination of this Agreement for cause or otherwise, Controlled Affiliate agrees that it shall immediately
discontinue all use of the Licensed Marks and Name, including any use in its trade name, except to the extent that it
continues to be authorized to use the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to
a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan.
-7-
-- 431 of 512 --
G. Upon termination of this Agreement, Controlled Affiliate shall immediately notify all of its customers to whom
it provides products or services under the Licensed Marks pursuant to this Agreement that it is no longer a licensee of
BCBSA and, if directed by the Association’s Board of Directors, shall provide instruction on how the customer can
contact BCBSA or a designated licensee to obtain further information on securing coverage. The notification required by
this
paragraph shall be in writing and in a form approved by BCBSA. The BCBSA shall
have the right to audit the terminated entity's books and records to verify compliance with this paragraph.
H. In the event this Agreement terminates pursuant to 7(B) hereof, upon termination of this Agreement the
provisions of Paragraph 7(G) shall not apply and the following provisions shall apply, except that, in the event that
Controlled Affiliate is separately licensed by BCBSA to use the Licensed Marks in the Service Area of a Controlling Plan
and termination of this Agreement is due to a partial termination of such Controlling Plan’s license pursuant to
Paragraph 15(a)(x)(ii) of the Blue Shield License Agreement, the notices, national account listing, payment, and audit
right listed below shall be applicable solely with respect to the Region and the geographic area for which the Controlling
Plan’s license to use the Licensed Names and Marks is terminated:
(1) The Controlled Affiliate shall send a notice through the U.S. mails, with first class postage affixed, to all
individual and group customers, providers, brokers and agents of products or services sold, marketed, underwritten or
administered by the Controlled Affiliate under the Licensed Marks and Name. The form and content of the notice shall
be specified by BCBSA and shall, at a minimum, notify the recipient of the termination of the license, the consequences
thereof, and instructions for obtaining alternate products or services licensed by BCBSA. This notice shall be mailed
within 15 days after termination.
(2) The Controlled Affiliate shall deliver to BCBSA within five days of a request by BCBSA a listing of national
accounts in which the Controlled Affiliate is involved (in a control, participating or servicing capacity), identifying the
national account and the Controlled Affiliate’s role therein.
(3) Unless the cause of termination is an event respecting BCBSA stated in paragraph 15(a) or (b) of the Plan’s
license agreement with BCBSA to use the Licensed Marks and Name, the Controlled Affiliate, the Controlling Plans, and
any other Licensed Controlled Affiliates of the Controlling Plans shall be jointly liable for payment to BCBSA of an
amount equal to $25 multiplied by the number of Licensed Enrollees of the Controlled Affiliate; provided that if any Plan
other than a Controlling Plan is permitted by BCBSA to use marks or names licensed by BCBSA in a geographic area in
the Region, the payment for Licensed Enrollees in such geographic area shall be multiplied by a fraction, the numerator
of which is the number of Licensed Enrollees of the Controlled Affiliate, the Controlling Plans, and
-8-
-- 432 of 512 --
any other Licensed Controlled Affiliates of the Controlling Plans in such geographic area and the denominator of which
is the total number of Licensed Enrollees in such geographic area. Licensed Enrollee means each and every person and
covered dependent who is enrolled as an individual or member of a group receiving products or services sold, marketed
or administered under marks or names licensed by BCBSA as determined at the earlier of (i) the end of the last fiscal
year of the terminated entity which ended prior to termination or (ii) the fiscal year which ended before any transactions
causing the termination began. Notwithstanding the
foregoing, the amount payable pursuant to this subparagraph H. (3) shall be due only to the extent that, in BCBSA’s
opinion, it does not cause the net worth of the Controlled Affiliate, the Controlling Plans or any other Licensed Controlled
Affiliates of the Controlling Plans to fall below 100% of the Health Risk-Based Capital formula, or its equivalent under
any successor formula, as set forth in the applicable financial responsibility standards established by BCBSA (provided
such equivalent is approved for purposes of this subparagraph by the affirmative vote of three-fourths of the Plans and
three-fourths of the total then current weighted vote of all the Plans); measured as of the date of termination, and
adjusted for the value of any transactions not made in the ordinary course of business. This payment shall not be due in
connection with transactions exclusively by or among Plans (including the Controlling Plans) or their affiliates, including
reorganizations, combinations or mergers, where the BCBSA Board of Directors determines that the license
termination does not result in a material diminution in the number of Licensed Enrollees or the extent of their coverage.
In the event that the Controlled Affiliate’s license is reinstated by BCBSA or is deemed to have remained in effect
without interruption by a court of competent jurisdiction, BCBSA shall reimburse the Controlled Affiliate (and/or the
Controlling Plans or their other Licensed Controlled Affiliates, as the case may be) for payments made under this
subparagraph 7.H.(3) only to the extent that such payments exceed the amounts due to BCBSA pursuant to paragraph
7.K. and any costs associated with reestablishing the terminated Controlling Plan’s Service Area or the Region,
including any payments made by BCBSA to a Plan or Plans (including the other Controlling Plans), or their Licensed
Controlled Affiliates, for purposes of replacing the Controlled Affiliate.
(4) BCBSA shall have the right to audit the books and records of the Controlled Affiliate, the Controlling Plans, and
any other Licensed Controlled Affiliates of the Controlling Plans to verify compliance with this paragraph 7.H.
(5) As to a breach of 7.H.(1), (2), (3) or (4), the parties agree that the obligations are immediately enforceable in a
court of competent jurisdiction. As to a breach of 7.H.(1), (2) or (4) by the Controlled Affiliate, the parties agree there is
no adequate remedy at law and BCBSA is entitled to obtain specific performance.
-9-
-- 433 of 512 --
I. BCBSA shall be entitled to enjoin the Controlled Affiliate or any related party in a court of competent
jurisdiction from entry into any transaction which would result in a termination of this Agreement unless a Controlling
Plan’s license from BCBSA to use the Licensed Marks and Names has been terminated pursuant to 10(d) of such
Controlling Plan’s license agreement upon the required 6 month written notice.
J. BCBSA acknowledges that it is not the owner of assets of the Controlled Affiliate.
K. In the event this Agreement terminates and is subsequently reinstated by BCBSA or is deemed to have remained
in effect without interruption by a court of competent jurisdiction, the Controlled Affiliate, the Controlling Plans, and any
other
Licensed Controlled Affiliates of the Controlling Plans shall be jointly liable for reimbursing BCBSA the reasonable costs
incurred by BCBSA in connection with the termination and the reinstatement or court action, and any associated legal
proceedings, including but not limited to: outside legal fees, consulting fees, public relations fees, advertising costs, and
costs incurred to develop, lease or establish an interim provider network. Any amount due to BCBSA under this
subparagraph may be waived in whole or in part by the BCBSA Board of Directors in its sole discretion.
8. DISPUTE RESOLUTION
The parties agree that any disputes between or among them or between or among any of them and one or more
Plans or Controlled Affiliates of Plans that use in any manner the Blue Shield and Blue Shield Marks and Name are
subject to the
Mediation and Mandatory Dispute Resolution process attached to and made a part of each Controlling Plan’s License
from BCBSA to use the Licensed Marks and Name as Exhibit 5 as amended from time-to-time, which documents are
incorporated herein by reference as though fully set forth herein.
9. LICENSE FEE
Controlled Affiliate will pay to BCBSA a fee for this License determined pursuant to the formula(s) set forth in Exhibit
B.
10. JOINT VENTURE
Nothing contained in this Agreement shall be construed as creating a joint venture, partnership, agency or
employment relationship between the Controlling Plans and Controlled Affiliate or between either and BCBSA.
11. NOTICES AND CORRESPONDENCE
Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and shall be
addressed in duplicate to the last
-10-
-- 434 of 512 --
known address of each other party, marked respectively to the attention of its President and, if any, its General Counsel.
12. COMPLETE AGREEMENT
This Agreement contains the complete understandings of the parties in relation to the subject matter hereof. This
Agreement may only be amended by the affirmative vote of three-fourths of the Plans and three-fourths of the total then
current weighted vote of all the Plans as officially recorded by the BCBSA Corporate Secretary.
13. SEVERABILITY
If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such findings shall in no way
affect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition for any
unlawful term or condition so long as the effect of such substitution is to provide the parties with the benefits of this
Agreement.
14. NONWAIVER
No waiver by BCBSA of any breach or default in performance on the part of Controlled Affiliate or any other licensee
of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any subsequent breach or
default in performance of said terms, covenants or conditions.
14A. VOTING
For all provisions of this Agreement referring to voting, the term ‘Plans’ shall mean all entities licensed under the Blue
Cross License Agreement and/or the Blue Shield License Agreement, and in all votes of the Plans under this
Agreement the Plans shall vote together. For weighted votes of the Plans, the Plan shall have a number of votes equal
to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes (if any)
that it holds as a Blue Shield Plan. For all other votes of the Plans, the Plan shall have one vote. For all
questions requiring an affirmative three-fourths weighted vote of the Plans, the requirement shall be deemed satisfied
with a lesser weighted vote unless the greater of: (i) 6/52 or more of the Plans (rounded to the nearest whole number,
with
0.5 or multiples thereof being rounded to the next higher whole number) fail to cast weighted votes in favor of the
question; or (ii) three (3) of the Plans fail to cast weighted votes in favor of the question. Notwithstanding the foregoing
provision, if there are thirty-six (36) Plans, the requirement of an affirmative three-fourths weighted vote shall be
deemed satisfied with a lesser weighted vote unless four (4) or more Plans fail to cast weighted votes in favor of the
question.
-11-
-- 435 of 512 --
15. GOVERNING LAW
This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of
Illinois.
16. HEADINGS
The headings inserted in this agreement are for convenience only and shall have no bearing on the interpretation
hereof.
-12-
-- 436 of 512 --
IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed and effective as of the date
of last signature written below.
Controlled Affiliate:
By:________________________________________
Date:______________________________________
Controlling Plan:
By: ________________________________________
Date:_______________________________________
Controlling Plan:
By: ________________________________________
Date:_______________________________________
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By:________________________________________
Date:______________________________________
13
-- 437 of 512 --
EXHIBIT A
CONTROLLED AFFILIATE LICENSE STANDARDS
APPLICABLE TO REGIONAL MEDICARE
ADVANTAGE PPO PRODUCTS
September 2020
PREAMBLE
The standards for licensing Controlled Affiliates for Medicare Advantage PPO Products are established by BCBSA and
are subject to change from time-to-time upon the affirmative vote of three-fourths (3/4) of the Plans and three-fourths
(3/4) of the total weighted vote. Each Controlling Plan is required to use a standard Controlled Affiliate license form
provided by BCBSA and to cooperate fully in assuring that the licensed Controlled Affiliate maintains compliance with
the license standards.
Standard 1 - Organization and Governance
A Controlled Affiliate is defined as an entity organized and operated in such a manner, that it meets the following
requirements:
(1) Controlled Affiliate is owned or controlled by two or more Controlling Plans;
(2) Each Controlling Plan is authorized pursuant to a separate Blue Shield License Agreement to use the Licensed
Marks in a geographic area in the Region and every geographic area in the Region is so licensed to at least one of the
Controlling Plans; and
(3) The Controlling Plans must have the legal authority directly or indirectly through wholly-owned subsidiaries:
(a) to select members of the Controlled Affiliate’s governing body having not less than 100% voting control
thereof;
(b) prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of
the Controlled Affiliate with which the Controlling Plans do not concur;
(c) exercise control over the policy and operations of the Controlled Affiliate; and
-1-
-- 438 of 512 --
EXHIBIT A (continued)
Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate’s establishing or governing
documents must also require written approval by each of the Controlling Plans before the Controlled Affiliate can:
(i) change its legal and/or trade names;
(ii) change the geographic area in which it operates (except
such approval shall not be required with respect to
business of the Controlled Affiliate conducted under the Licensed Marks within the Service
Area of one of the Controlling Plans pursuant to a separate controlled affiliate license
agreement with BCBSA sponsored by such Controlling Plan);
(iii) change any of the type(s) of businesses in which it
engages (except such approval shall not be required with respect to business of the
Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the
Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA
sponsored by such Controlling Plan);
(iv) take any action that any Controlling Plan or BCBSA
reasonably believes will adversely affect the Licensed Marks and Name.
In addition, the Controlling Plans directly or indirectly through wholly-owned subsidiaries shall own 100% of any for-profit
Controlled Affiliate.
Standard 2 - Financial Responsibility
A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its
contractual obligations to its customers.
Standard 3 - State Licensure/Certification
A Controlled Affiliate shall maintain appropriate and unimpaired licensure and certifications.
-2-
-- 439 of 512 --
EXHIBIT A (continued)
Standard 4 - Certain Disclosures
A Controlled Affiliate shall make adequate disclosure in contracting with third parties and in disseminating public
statements of:
a. the structure of the Blue Cross and Blue Shield System; and
b. the independent nature of every licensee.
Standard 5 - Reports and Records for Controlled Affiliates
A Controlled Affiliate and/or its Controlling Plans shall furnish, on a timely and accurate basis, reports and records
relating to these Standards and the License Agreements between BCBSA and Controlled Affiliate.
Standard 6 - Best Efforts
During each year, a Controlled Affiliate shall use its best efforts to promote and build the value of the Blue Shield Marks.
Standard 7 - Participation in Certain National Programs
A Controlled Affiliate shall effectively and efficiently participate in certain national programs from time to time as may be
adopted by Member Plans for the purposes of providing ease of claims processing for customers receiving benefits
outside of the Controlled Affiliate’s service area.
National program requirements include:
a. Inter-Plan Teleprocessing System (ITS); and
b. Inter-Plan Medicare Advantage Program.
Standard 8 - Participation in Master Business Associate Agreement
Controlled Affiliates shall comply with the terms of the Business Associate Agreement for Blue Cross and Blue Shield
Licensees to the extent they perform the functions of a business associate or subcontractor to a business associate, as
defined by the Business Associate Agreement.
Amended as of November 15, 2007
-3-
-- 440 of 512 --
EXHIBIT B
ROYALTY FORMULA FOR SECTION 9 OF THE
CONTROLLED AFFILIATE LICENSE AGREEMENTS
APPLICABLE TO REGIONAL MEDICARE ADVANTAGE PPO PRODUCTS
Controlled Affiliate will pay BCBSA a fee for this license in accordance with the following formula:
An amount equal to its pro rata share of each Controlling Plan dues payable to BCBSA computed with the addition
of the Controlled Affiliate's members using the Marks on regional MAPPO products and related services as
reported on the Quarterly Enrollment Report with BCBSA. The payment by each Controlling Plan of its dues to
BCBSA, including that portion described in this paragraph, will satisfy the requirement of this paragraph, and no
separate payment will be necessary.
Amended as of June 14, 2007
-4-
-- 441 of 512 --
Exhibit 1C
BLUE SHIELD
CONTROLLED AFFILIATE LICENSE AGREEMENT
APPLICABLE TO REGIONAL MEDICARE PART D PRESCRIPTION DRUG PLAN PRODUCTS
(Adopted by Member Plans at their September 17, 2020 meeting)
This Agreement by and among Blue Cross and Blue Shield Association ("BCBSA") and _______ (“Controlled
Affiliate"), a Controlled Affiliate of the Blue Cross Plan(s), known as _________ ("Controlling Plans"), each of which is
also a Party signatory hereto.
WHEREAS, BCBSA is the owner of the BLUE SHIELD and BLUE SHIELD Design service marks;
WHEREAS, under the Medicare Modernization Act, companies may apply to and be awarded a contract by the
Centers for Medicare and Medicaid Services (“CMS”) to offer Medicare Part D Prescription Drug Plan products in
geographic regions designated by CMS (hereafter “regional PDP products”).
WHEREAS, some of the CMS-designated regions include the Service Areas, or portions thereof, of more than one
Plan.
WHEREAS, the Controlling Plans and Controlled Affiliate desire that the latter be entitled to use the BLUE SHIELD
and BLUE SHIELD Design service marks (collectively the "Licensed Marks") as service marks and be entitled to use the
term BLUE SHIELD in a trade name ("Licensed Name") to offer regional PDP products in a region that includes the
Service Areas, or portions thereof, of more than one Controlling Plan;
NOW THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby
agree as follows:
1. GRANT OF LICENSE
Subject to the terms and conditions of this Agreement, BCBSA hereby grants to Controlled Affiliate the right to use the
Licensed Marks and Name in connection with, and only in connection with the sale, marketing and administration of
regional PDP products and related services.
This grant of rights is non-exclusive and is limited to the following states: _________________ (the “Region”).
Controlled Affiliate may use the Licensed
-1-
-- 442 of 512 --
Marks and Name in its legal name on the following conditions: (i) the legal name must be approved in advance, in
writing, by BCBSA; (ii) Controlled Affiliate shall not do business outside the Region under any name or mark except
business conducted in the Service Area of a Controlling Plan provided that Controlled Affiliate is separately licensed by
BCBSA to use the Licensed Marks and Name in connection with health care plans and related services in the Service
Area of such Controlling Plan; and (iii) Controlled Affiliate shall not use the Licensed Marks and Name, or any derivative
thereof, as part of any name or symbol used to identify itself in any securities market. Controlled Affiliate may use the
Licensed Marks and Name in its Trade Name only with the prior, written, consent of BCBSA.
2. QUALITY CONTROL
A. Controlled Affiliate agrees to use the Licensed Marks and Name only in connection with the licensed services
and further agrees to be bound by the conditions regarding quality control shown in attached Exhibit A as they may be
amended by BCBSA from time-to-time.
B. Controlled Affiliate agrees to comply with all applicable federal, state and local laws.
C. Controlled Affiliate agrees that it will provide on an annual basis (or more often if reasonably required by the
Controlling Plans or by BCBSA) a report or reports to the Controlling Plans and BCBSA demonstrating Controlled
Affiliate's compliance with the requirements of this Agreement including but not limited to the quality control provisions of
this paragraph and the attached Exhibit A.
D. Controlled Affiliate agrees that the Controlling Plans and/or BCBSA may, from time-to-time, upon reasonable
notice, review and inspect the manner and method of Controlled Affiliate's rendering of service and use of the Licensed
Marks and Name.
E. As used herein, a Controlled Affiliate is defined as an entity organized and operated in such a manner, that it
meets the following requirements:
(1) Controlled Affiliate is owned or controlled by two or more Controlling Plans;
(2) Each Controlling Plan is authorized pursuant to a separate Blue Shield License Agreement to use the Licensed
Marks in a geographic area in the Region and every geographic area in the Region is so licensed to at least one of the
Controlling Plans; and
-2-
-- 443 of 512 --
(3) The Controlling Plans must have the legal authority directly or
indirectly through wholly-owned subsidiaries:
(a) to select members of the Controlled Affiliate’s governing body having not less than 100% voting control
thereof;
(b) to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of
the Controlled Affiliate with which the Controlling Plans do not concur;
(c) to exercise control over the policy and operations of the
Controlled Affiliate; and
Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate’s establishing or governing
documents must also require written approval by each of the Controlling Plans before the Controlled Affiliate can:
(i) change its legal and/or trade names;
(ii) change the geographic area in which it operates (except such approval shall not be required
with respect to business of the Controlled Affiliate conducted under the Licensed Marks
within the Service Area of one of the Controlling Plans pursuant to a separate controlled
affiliate license agreement with BCBSA sponsored by such Controlling Plan);
(iii) change any of the type(s) of businesses in which it
engages (except such approval shall not be required with respect to business of the
Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the
Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA
sponsored by such Controlling Plan);
(iv) take any action that any Controlling Plan or BCBSA reasonably believes will adversely affect
the Licensed Marks and Name.
In addition, the Controlling Plans directly or indirectly through wholly owned subsidiaries shall own 100% of any for-profit
Controlled Affiliate.
-3-
-- 444 of 512 --
3. SERVICE MARK USE
A. Controlled Affiliate recognizes the importance of a comprehensive national network of independent BCBSA
licensees which are committed to strengthening the Licensed Marks and Name. The Controlled Affiliate further
recognizes that its actions within the Region may affect the value of the Licensed Marks and Name nationwide.
B. Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks and Name, including
but not limited to use of such symbols or words as BCBSA shall specify to protect the Licensed Marks and Name and
shall comply with such rules (generally applicable to Controlled Affiliates licensed to use the Licensed Marks and Name)
relative to service mark use, as are issued from time-to-time by BCBSA. Controlled Affiliate recognizes and agrees that
all use of the Licensed Marks and Name by Controlled Affiliate shall inure to the benefit of BCBSA.
C. Controlled Affiliate may not directly or indirectly use the Licensed Marks and Name in a manner that transfers or
is intended to transfer in the Region the goodwill associated therewith to another mark or name, nor may Controlled
Affiliate engage in activity that may dilute or tarnish the unique value of the Licensed Marks and Name.
D. Controlled Affiliate shall use its best efforts to promote and build the value of the Licensed Marks and Name in
connection with the sale, marketing and administration of regional PDP products and related services.
4. SUBLICENSING AND ASSIGNMENT
Controlled Affiliate shall not, directly or indirectly, sublicense, transfer, hypothecate, sell, encumber or mortgage, by
operation of law or otherwise, the rights granted hereunder and any such act shall be voidable at the sole option of any
Controlling Plan or BCBSA. This Agreement and all rights and duties hereunder are personal to Controlled Affiliate.
5. INFRINGEMENT
Controlled Affiliate shall promptly notify the Controlling Plans and the Controlling Plans shall promptly notify BCBSA of
any suspected acts of infringement, unfair competition or passing off that may occur in relation to the Licensed Marks
and Name. Controlled Affiliate shall not be entitled to require the Controlling Plans or BCBSA to take any actions or
institute any proceedings to prevent infringement, unfair competition or passing off by third parties. Controlled Affiliate
agrees to render to the Controlling Plans and BCBSA, without charge, all reasonable assistance in connection with any
matter pertaining to the protection of the Licensed Marks and Name by BCBSA.
-4-
-- 445 of 512 --
6. LIABILITY INDEMNIFICATION
Controlled Affiliate and the Controlling Plans hereby agree to save, defend, indemnify and hold BCBSA harmless from
and against all claims, damages, liabilities and costs of every kind, nature and description (except those arising solely as
a result of BCBSA's negligence) that may arise as a result of or related to Controlled Affiliate's rendering of services
under the Licensed Marks and Name.
7. LICENSE TERM
A. Except as otherwise provided herein, the license granted by this Agreement shall remain in effect for a period of
one (1) year and shall be automatically extended for additional one (1) year periods unless terminated pursuant to the
provisions herein.
B. This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further
action by any party or entity in the event that: (i) any one of the Controlling Plans ceases to be authorized to use the
Licensed Marks and Name; or (ii) pursuant to Paragraph 15(a)(x) of the Blue Shield License Agreement any one of the
Controlling Plans ceases to be authorized to use the Licensed Names and Marks in the Region.
C. Notwithstanding any other provision of this Agreement, this license to use the Licensed Marks and Name may
be forthwith terminated by the Controlling Plans or the affirmative vote of the majority of the Board of Directors of
BCBSA present and voting at a special meeting expressly called by BCBSA for the purpose on ten (10) days written
notice to the Controlling Plans advising of the specific matters at issue and granting the Controlling Plans an opportunity
to be heard and to present their response to the Board for: (1) failure to comply with any applicable minimum capital or
liquidity requirement under the quality control standards of this
Agreement; or (2) failure to comply with the "Organization and Governance" quality control standard of this Agreement;
or (3) impending financial insolvency; or (4) failure to comply with any of the applicable requirements of Standards 2, 3,
4, or 5 of attached Exhibit A; or (5) the pendency of any action instituted against the Controlled Affiliate seeking its
dissolution or liquidation of its assets or seeking appointment of a trustee, interim trustee, receiver or other custodian for
any of its property or business or seeking the declaration or establishment of a trust for any of its property or business,
unless this Controlled Affiliate License Agreement has been earlier terminated under paragraph 7(E); or (6) such other
reason as is determined in good faith immediately and irreparably to threaten the integrity and reputation of BCBSA, the
Plans (including the Controlling Plans), any other licensee including Controlled Affiliate and/or the Licensed Marks and
Name.
D. Except as otherwise provided in Paragraphs 7(B), 7(C) or 7(E) herein, should Controlled Affiliate fail to comply
with the provisions of this Agreement and not cure such failure within thirty (30) days of receiving written notice thereof
(or commence a cure within such thirty day period and continue diligent efforts to
-5-
-- 446 of 512 --
complete the cure if such curing cannot reasonably be completed within such thirty day period) BCBSA or the
Controlling Plans shall have the right to issue a notice that the Controlled Affiliate is in a state of noncompliance. If a
state of noncompliance as aforesaid is undisputed by the Controlled Affiliate or is found to exist by a mandatory dispute
resolution panel and is uncured as provided above, BCBSA shall have the right to seek judicial enforcement of the
Agreement or to issue a notice of termination thereof. Notwithstanding any other provisions of this Agreement, any
disputes as to the termination of this License pursuant to Paragraphs 7(B), 7(C) or 7(E) of this Agreement shall not be
subject to mediation and mandatory dispute resolution. All other disputes between or among BCBSA, any of the
Controlling Plans and/or Controlled Affiliate shall be submitted promptly to mediation and mandatory dispute resolution.
The mandatory dispute resolution panel shall have authority to issue orders for specific performance and assess
monetary penalties. Except, however, as provided in Paragraphs 7(B) and 7(E) of this Agreement, this license to use the
Licensed Marks and Name may not be finally terminated for any reason without the affirmative vote of a majority of the
present and voting members of the Board of Directors of BCBSA.
E. This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further
action by any party or entity in the event that:
(1) Controlled Affiliate shall no longer comply with item 2(E) above;
(2) Appropriate dues, royalties and other payments for Controlled Affiliate pursuant to paragraph 9 hereof, which are
the royalties for this License Agreement, are more than sixty (60) days in arrears to BCBSA; or
(3) Any of the following events occur: (i) a voluntary petition shall be filed by Controlled Affiliate seeking
bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy laws of the United States or
any other law governing insolvency or debtor relief, or (ii) an involuntary petition or proceeding shall be filed against
Controlled Affiliate seeking bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy
laws of the United States or any other law governing insolvency or debtor relief and such petition or proceeding is
consented to or acquiesced in by Controlled Affiliate or is not dismissed within sixty (60) days of the date upon which the
petition or other document commencing the proceeding is served upon the Controlled Affiliate, or (iii) an order for relief is
entered against Controlled Affiliate in any case under the bankruptcy laws of the United States, or Controlled Affiliate is
adjudged bankrupt or insolvent as those terms are defined in the Uniform Commercial Code as enacted in the State of
Illinois by any court of competent jurisdiction, or (iv) Controlled Affiliate makes a general assignment of its assets for the
benefit of creditors, or (v) any government or any government official, office, agency, branch, or unit assumes control of
Controlled Affiliate or delinquency proceedings (voluntary or involuntary) are instituted, or (vi) an action is brought by
Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking the appointment of a trustee, interim
-6-
-- 447 of 512 --
trustee, receiver or other custodian for any of its property or business, or (vii) an action is instituted by any governmental
entity or officer against Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking the appointment
of a trustee, interim trustee, receiver or other custodian for any of its property or business and such action is consented
to or acquiesced in by Controlled Affiliate or is not dismissed within one hundred thirty (130) days of the date upon which
the pleading or other document commencing the action is served upon the Controlled Affiliate, provided that if the action
is stayed or its prosecution is enjoined, the one hundred thirty (130) day period is tolled for the duration of the stay or
injunction, and provided further, that the Association’s Board of Directors may toll or extend the 130 day period at any
time prior to its expiration, or (viii) a trustee, interim trustee, receiver or other custodian for any of Controlled Affiliate's
property or business is appointed or the Controlled Affiliate is ordered dissolved or liquidated. Notwithstanding any other
provision of this Agreement, a declaration or a request for declaration of the existence of a trust over any of the
Controlled Affiliate’s property or business shall not in itself be deemed to constitute or seek appointment of a trustee,
interim trustee, receiver or other custodian for purposes of subparagraphs 7(E)(3)(vii) and (viii) of this Agreement.
F. Upon termination of this Agreement for cause or otherwise, Controlled Affiliate agrees that it shall immediately
discontinue all use of the Licensed Marks and Name, including any use in its trade name, except to the extent that it
continues to be authorized to use the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to
a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan.
G. Upon termination of this Agreement, Controlled Affiliate shall immediately notify all of its customers to whom
it provides products or services under the Licensed Marks pursuant to this Agreement that it is no longer a licensee of
BCBSA and, if directed by the Association’s Board of Directors, shall provide instruction on how the customer can
contact BCBSA or a designated licensee to obtain further information on securing coverage. The notification required by
this paragraph shall be in writing and in a form approved by BCBSA. The BCBSA shall
have the right to audit the terminated entity's books and records to verify compliance with this paragraph.
H. In the event this Agreement terminates pursuant to 7(B) hereof, upon termination of this Agreement the
provisions of Paragraph 7(G) shall not apply and the following provisions shall apply, except that, in the event that
Controlled Affiliate is separately licensed by BCBSA to use the Licensed Marks in the Service Area of a Controlling Plan
and termination of this Agreement is due to a partial termination of such Controlling Plan’s license pursuant to
Paragraph 15(a)(x)(ii) of the Blue Shield License Agreement, the notices, national account listing, payment, and audit
right listed below shall be applicable solely with respect to the Region and the geographic area for which the Controlling
Plan’s license to use the Licensed Names and Marks is terminated:
-7-
-- 448 of 512 --
(1) The Controlled Affiliate shall send a notice through the U.S. mails, with first class postage affixed, to all individual
and group customers, providers, brokers and agents of products or services sold, marketed, underwritten or
administered by the Controlled Affiliate under the Licensed Marks and Name. The form and content of the notice shall
be specified by BCBSA and shall, at a minimum, notify the recipient of the termination of the license, the consequences
thereof, and instructions for obtaining alternate products or services licensed by BCBSA. This notice shall be mailed
within 15 days after termination.
(2) The Controlled Affiliate shall deliver to BCBSA within five days of a request by BCBSA a listing of national
accounts in which the Controlled Affiliate is involved (in a control, participating or servicing capacity), identifying the
national account and the Controlled Affiliate’s role therein.
(3) Unless the cause of termination is an event respecting BCBSA stated in paragraph 15(a) or (b) of the Plan’s
license agreement with BCBSA to use the Licensed Marks and Name, the Controlled Affiliate, the Controlling Plans, and
any other Licensed Controlled Affiliates of the Controlling Plans shall be jointly liable for payment to BCBSA of an
amount equal to $25 multiplied by the number of Licensed Enrollees of the Controlled Affiliate; provided that if any Plan
other than a Controlling Plan is permitted by BCBSA to use marks or names licensed by BCBSA in a geographic area in
the Region, the payment for Licensed Enrollees in such geographic area shall be multiplied by a fraction, the numerator
of which is the number of Licensed Enrollees of the Controlled Affiliate, the Controlling Plans, and any other Licensed
Controlled Affiliates of the Controlling Plans in such geographic area and the denominator of which is the total number of
Licensed Enrollees in such geographic area. Licensed Enrollee means each and every person and covered dependent
who is enrolled as an individual or member of a group receiving products or services sold, marketed or administered
under marks or names licensed by BCBSA as determined at the earlier of (i) the end of the last fiscal year of the
terminated entity which ended prior to termination or (ii) the fiscal year which ended before any transactions causing the
termination began. Notwithstanding the foregoing, the amount payable pursuant to this subparagraph H. (3) shall be due
only to the extent that, in BCBSA’s opinion, it does not cause the net worth of the Controlled Affiliate, the Controlling
Plans or any other Licensed Controlled Affiliates of the Controlling Plans to fall below 100% of the Health Risk-Based
Capital formula, or its equivalent under any successor formula, as set forth in the applicable financial responsibility
standards established by BCBSA (provided such equivalent is approved for purposes of this subparagraph by the
affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all the Plans);
measured as of the date of termination, and adjusted for the value of any transactions not made in the ordinary course
of business. This payment shall not be due in connection with transactions exclusively by or among Plans (including the
Controlling Plans) or their affiliates, including reorganizations, combinations or mergers, where the BCBSA Board of
Directors determines that the license
-8-
-- 449 of 512 --
termination does not result in a material diminution in the number of Licensed Enrollees or the extent of their coverage.
In the event that the Controlled Affiliate’s
license is reinstated by BCBSA or is deemed to have remained in effect without interruption by a court of competent
jurisdiction, BCBSA shall reimburse the Controlled Affiliate (and/or the Controlling Plans or their other Licensed
Controlled Affiliates, as the case may be) for payments made under this subparagraph 7.H.(3) only to the extent that
such payments exceed the amounts due to BCBSA pursuant to paragraph 7.K. and any costs associated with
reestablishing the terminated Controlling Plan’s Service Area or the Region, including any payments made by BCBSA to
a Plan or Plans (including the other Controlling Plans), or their Licensed Controlled Affiliates, for purposes of replacing
the Controlled Affiliate.
(4) BCBSA shall have the right to audit the books and records of the Controlled Affiliate, the Controlling Plans, and
any other Licensed Controlled Affiliates of the Controlling Plans to verify compliance with this paragraph 7.H.
(5) As to a breach of 7.H.(1), (2), (3) or (4), the parties agree that the obligations are immediately enforceable in a
court of competent jurisdiction. As to a breach of 7.H.(1), (2) or (4) by the Controlled Affiliate, the parties agree there is
no adequate remedy at law and BCBSA is entitled to obtain specific performance.
I. BCBSA shall be entitled to enjoin the Controlled Affiliate or any related party in a court of competent
jurisdiction from entry into any transaction which would result in a termination of this Agreement unless a Controlling
Plan’s license from BCBSA to use the Licensed Marks and Names has been terminated pursuant to 10(d) of such
Controlling Plan’s license agreement upon the required 6 month written notice.
J. BCBSA acknowledges that it is not the owner of assets of the Controlled Affiliate.
K. In the event this Agreement terminates and is subsequently reinstated by BCBSA or is deemed to have remained
in effect without interruption by a court of competent jurisdiction, the Controlled Affiliate, the Controlling Plans, and any
other Licensed Controlled Affiliates of the Controlling Plans shall be jointly liable for reimbursing BCBSA the reasonable
costs incurred by BCBSA in connection with the termination and the reinstatement or court action, and any associated
legal proceedings, including but not limited to: outside legal fees, consulting fees, public relations fees, advertising costs,
and costs incurred to develop, lease or establish an interim provider network. Any amount due to BCBSA under this
subparagraph may be waived in whole or in part by the BCBSA Board of Directors in its sole discretion.
-9-
-- 450 of 512 --
8. DISPUTE RESOLUTION
The parties agree that any disputes between or among them or between or among any of them and one or more
Plans or Controlled Affiliates of Plans that use in any manner the Blue Shield and Blue Shield Marks and Name are
subject to the Mediation and Mandatory Dispute Resolution process attached to and made a part of each Controlling
Plan’s License from BCBSA to use the Licensed Marks and Name as Exhibit 5 as amended from time-to-time, which
documents are incorporated herein by reference as though fully set forth herein.
9. LICENSE FEE
Controlled Affiliate will pay to BCBSA a fee for this License determined pursuant to the formula(s) set forth in Exhibit
B.
10. JOINT VENTURE
Nothing contained in this Agreement shall be construed as creating a joint venture, partnership, agency or
employment relationship between the Controlling Plans and Controlled Affiliate or between either and BCBSA.
11. NOTICES AND CORRESPONDENCE
Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and shall be
addressed in duplicate to the last known address of each other party, marked respectively to the attention of its
President and, if any, its General Counsel.
12. COMPLETE AGREEMENT
This Agreement contains the complete understandings of the parties in relation to the subject matter hereof. This
Agreement may only be amended by the affirmative vote of three-fourths of the Plans and three-fourths of the total then
current weighted vote of all the Plans as officially recorded by the BCBSA Corporate Secretary.
-10-
-- 451 of 512 --
13. SEVERABILITY
If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such findings shall in no way
affect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition for any
unlawful term or condition so long as the effect of such substitution is to provide the parties with the benefits of this
Agreement.
14. NONWAIVER
No waiver by BCBSA of any breach or default in performance on the part of Controlled Affiliate or any other licensee
of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any subsequent breach or
default in performance of said terms, covenants or conditions.
14A. VOTING
For all provisions of this Agreement referring to voting, the term ‘Plans’ shall mean all entities licensed under the Blue
Cross License Agreement and/or the Blue Shield License Agreement, and in all votes of the Plans under this
Agreement the Plans shall vote together. For weighted votes of the Plans, the Plan shall have a number of votes equal
to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes (if any)
that it holds as a Blue Shield Plan. For all other votes of the Plans, the Plan shall have one vote. For all questions
requiring an affirmative three-fourths weighted vote of the Plans, the
requirement shall be deemed satisfied with a lesser weighted vote unless the greater of: (i) 6/52 or more of the Plans
(rounded to the nearest whole number, with
0.5 or multiples thereof being rounded to the next higher whole number) fail to cast weighted votes in favor of the
question; or (ii) three (3) of the Plans fail to cast weighted votes in favor of the question. Notwithstanding the foregoing
provision, if there are thirty-six (36) Plans, the requirement of an affirmative three-fourths weighted vote shall be
deemed satisfied with a lesser weighted vote unless four (4) or more Plans fail to cast weighted votes in favor of the
question.
15. GOVERNING LAW
This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of
Illinois.
16. HEADINGS
The headings inserted in this agreement are for convenience only and shall have no bearing on the interpretation
hereof.
-11-
-- 452 of 512 --
IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed and effective as of the date
of last signature written below.
Controlled Affiliate:
By:________________________________________
Date:______________________________________
Controlling Plan:
By: ________________________________________
Date:_______________________________________
Controlling Plan:
By: ________________________________________
Date:_______________________________________
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By:________________________________________
Date:______________________________________
-12-
-- 453 of 512 --
EXHIBIT A
CONTROLLED AFFILIATE LICENSE STANDARDS
APPLICABLE TO REGIONAL MEDICARE
PART D PRESCRIPTION DRUG PLAN PRODUCTS
September 2020
PREAMBLE
The standards for licensing Controlled Affiliates for Medicare Part D Prescription Drug Plan Products are established by
BCBSA and are subject to change from time-to-time upon the affirmative vote of three-fourths (3/4) of the Plans and
three-fourths (3/4) of the total weighted vote. Each Controlling Plan is required to use a standard Controlled Affiliate
license form provided by BCBSA and to cooperate fully in assuring that the licensed Controlled Affiliate maintains
compliance with the license standards.
Standard 1 - Organization and Governance
A Controlled Affiliate is defined as an entity organized and operated in such a manner, that it meets the following
requirements:
(1) Controlled Affiliate is owned or controlled by two or more Controlling Plans;
(2) Each Controlling Plan is authorized pursuant to a separate Blue Shield License Agreement to use the Licensed
Marks in a geographic area in the Region and every geographic area in the Region is so licensed to at least one of the
Controlling Plans; and
(3) The Controlling Plans must have the legal authority directly or indirectly through wholly-owned subsidiaries:
(a) to select members of the Controlled Affiliate’s governing body having not less than 100% voting control
thereof;
(b) prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of
the Controlled Affiliate with which the Controlling Plans do not concur;
(c) exercise control over the policy and operations of the Controlled Affiliate; and
-13-
-- 454 of 512 --
EXHIBIT A (continued)
Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate’s establishing or governing
documents must also require written approval by each of the Controlling Plans before the Controlled Affiliate can:
(i) change its legal and/or trade names;
(ii) change the geographic area in which it operates (except
such approval shall not be required with respect to business of the Controlled Affiliate
conducted under the Licensed Marks within the Service Area of one of the Controlling Plans
pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such
Controlling Plan);
(iii) change any of the type(s) of businesses in which it
engages (except such approval shall not be required with respect to business of the
Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the
Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA
sponsored by such Controlling Plan);
(iv) take any action that any Controlling Plan or BCBSA
reasonably believes will adversely affect the Licensed Marks and Name.
In addition, the Controlling Plans directly or indirectly through wholly-owned subsidiaries shall own 100% of any for-profit
Controlled Affiliate.
Standard 2 - Financial Responsibility
A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its
contractual obligations to its customers.
Standard 3 - State Licensure/Certification
A Controlled Affiliate shall maintain appropriate and unimpaired licensure and certifications.
-14-
-- 455 of 512 --
EXHIBIT A (continued)
Standard 4 - Certain Disclosures
A Controlled Affiliate shall make adequate disclosure in contracting with third parties and in disseminating public
statements of:
a. the structure of the Blue Cross and Blue Shield System; and
b. the independent nature of every licensee.
Standard 5 - Reports and Records for Controlled Affiliates
A Controlled Affiliate and/or its Controlling Plans shall furnish, on a timely and accurate basis, reports and records
relating to these Standards and the License Agreements between BCBSA and Controlled Affiliate.
Standard 6 - Best Efforts
During each year, a Controlled Affiliate shall use its best efforts to promote and build the value of the Blue Shield Marks.
Standard 7 - Participation in Master Business Associate Agreement
Controlled Affiliates shall comply with the terms of the Business Associate Agreement for Blue Cross and Blue Shield
Licensees to the extent they perform the functions of a business associate or subcontractor to a business associate, as
defined by the Business Associate Agreement.
-15-
-- 456 of 512 --
EXHIBIT B
ROYALTY FORMULA FOR SECTION 9 OF THE
CONTROLLED AFFILIATE LICENSE AGREEMENTS
APPLICABLE TO REGIONAL MEDICARE PART D PRESCRIPTION DRUG PLAN PRODUCTS
Controlled Affiliate will pay BCBSA a fee for this license in accordance with the following formula:
An amount equal to its pro rata share of each Controlling Plan dues payable to BCBSA computed with the addition
of the Controlled Affiliate's members using the Marks on regional PDP products and related services as reported
on the Quarterly Enrollment Report with BCBSA. The payment by each Controlling Plan of its dues to BCBSA,
including that portion described in this paragraph, will satisfy the requirement of this paragraph, and no separate
payment will be necessary.
Amended as of June 14, 2007
-16-
-- 457 of 512 --
EXHIBIT 2
Membership Standards
Page 1 of 5
Preamble
The Membership Standards apply to all organizations seeking to become or to continue as Regular Members of the
Blue Cross and Blue Shield Association. Any organization seeking to become a Regular Member must be found to be
in substantial compliance with all Membership Standards at the time membership is granted and the organization must
be found to be in substantial compliance with all Membership Standards for a period of two (2) years preceding the date
of its application. If Membership is sought by an entity which controls or is controlled by one or more Plans, such
compliance shall be determined on the basis of compliance by such Plan or Plans.
The Regular Member Plans shall have authority to interpret these Standards.
A Regular Member Plan that operates as a “Shell Holding Company” is defined as an entity that assumes no
underwriting risk and has less than 1% of the consolidated enterprise assets (excludes investments in subsidiaries) and
less than 5% of the consolidated enterprise net general and administrative expenses.
A Regular Member Plan that operates as a “Hybrid Holding Company” is defined as an entity that assumes no
underwriting risk and has either more than 1% of the consolidated enterprise assets (excludes investments in
subsidiaries) or more than 5% of the consolidated enterprise net general and administrative expenses.
Standard 1: A Plan shall maintain a governing Board, which shall control the Plan and ensure that the Plan follows
appropriate practices of corporate governance. A Plan's Board shall not be controlled by any special
interest group, shall make an annual determination that a majority of its directors are independent,
and shall act in the best interest of its Corporation and its customers. The Board shall be composed
of a majority of persons other than providers of health care services, who shall be known as public
members. A public member shall not be an employee of or have a financial interest in a health care
provider, nor be a member of a profession which provides health care services.
Amended as of March 15, 2007
-- 458 of 512 --
EXHIBIT 2
Membership Standards
Page 2 of 5
Standard 2: A Plan shall furnish to the Association on a timely and accurate basis reports and records relating to
compliance with these Standards and the License Agreements between the Association and the
Plans. Such reports and records are the following:
A. BCBSA Membership Information Request;
B. Triennial trade name and service mark usage material, including disclosure material under Standard 7;
C. Changes in the governance of the Plan, including changes in a Plan's Charter, Articles of
Incorporation, or Bylaws, changes in a Plan's Board composition, or changes in the identity of
the Plan's Principal Officers;
D. Quarterly Financial Report, Semi-annual “Health Risk-Based Capital (HRBC) Report” as defined by the NAIC,
Annual Budget, Annual Certified Audit Report, Insurance Department Examination Report,
Annual Statement filed with State Insurance Department (with all attachments), Plan, Subsidiary
and Affiliate Report; and
• Plans that are a Shell Holding Company as defined in the Preamble hereto are required to
furnish only a calendar year-end “Health Risk-Based Capital (HRBC) Report” as defined by
the NAIC.
Amended as of November 17,2011
-- 459 of 512 --
EXHIBIT 2
Membership Standards
Page 3 of 5
E. Quarterly Enrollment Report, Quarterly Member Touchpoint Measures Index (MTM) through
12/31/2011, and Semi-annual MTM Index starting 1/1/2012 and thereafter.
• For purposes of MTM reporting only, a Plan shall file a separate MTM report for each
Geographic Market.
Standard 3: A Plan shall be operated in a manner that provides reasonable financial assurance that it can fulfill its
contractual obligations to its customers.
Standard 4: A Plan shall be operated in a manner responsive to customer needs and requirements.
Standard 5: A Plan shall effectively and efficiently participate in each national program as from time to time may be
adopted by the Member Plans for the purposes of providing portability of membership between
the Plans and ease of claims processing for customers receiving benefits outside of the Plan's
Service Area.
Such programs are applicable to Blue Cross and Blue Shield Plans, and include:
A. Inter-Plan Teleprocessing System (ITS);
B. BlueCard Program;
C. National Account Programs;
D. Business Associate Agreement for Blue Cross and Blue Shield Licensees, effective April 14, 2003; and
E. Inter-Plan Medicare Advantage Program.
Amended as of November 21, 2014
-- 460 of 512 --
EXHIBIT 2
Membership Standards
Page 4 of 5
Standard 6: In addition to requirements under the national programs listed in Standard 5: Participation in National
Programs, a Plan shall take such action as required to ensure its financial performance in
programs and contracts of an inter-Plan nature or where the Association is a party.
Standard 7: A Plan shall make adequate disclosure in contracting with third parties and in disseminating public
statements of (i) the structure of the Blue Cross and Blue Shield System, (ii) the independent
nature of every Plan, and (iii) the Plan's financial condition.
Standard 8: A Plan shall cooperate with the Association's Board of Directors and its Brand Enhancement & Protection
Committee in the administration of the Plan Performance Response Process and in addressing
Plan performance problems identified thereunder.
Standard 9: A Plan shall obtain a rating of its financial strength from an independent rating agency approved by the
Association's Board of Directors for such purpose.
Standard 10: Notwithstanding any other provision in this License Agreement, during each year, a Plan and its
Controlled Affiliate(s) engaged in providing licensable services (excluding Life Insurance and
Charitable Foundation Services) shall use their best efforts to promote and build the value of the
Blue Shield Marks.
Standard 11: Neither a Plan nor any Larger Controlled Affiliate shall cause or permit an entity other than a Plan or a
Licensed Controlled Affiliate thereof to obtain control of the Plan or Larger Controlled Affiliate or to
acquire a substantial portion of its assets related to licensable services.
Amended as of June 16, 2005
-- 461 of 512 --
EXHIBIT 2
Membership Standards
Page 5 of 5
Standard 12: No provider network, or portion thereof, shall be rented or otherwise made available to a National
Competitor if the Licensed Marks or Names are used in any way with such network.
A provider network may be rented or otherwise made available, provided there is no use of the Licensed Marks
or Names with respect to the network being rented.
Standard 13: Each Plan shall operate in a manner to reasonably: 1) protect the security and confidentiality of
Personally Identifiable Information (PII) and Protected Health Information (PHI); 2) protect the
Brands from reputational damage; and 3) cooperate with BCBSA and other Plans if a data
security incident or data breach occurs.
Amended as of June 18, 2015
-- 462 of 512 --
EXHIBIT 3
GUIDELINES WITH RESPECT TO USE OF
LICENSED NAME AND MARKS IN CONNECTION WITH NATIONAL ACCOUNTS
Page 1 of 3
1. The strength of the Blue Cross/Blue Shield National Accounts mechanism, and the continued provision of cost
effective, quality health care benefits to National Accounts, are predicated on locally managed provider networks
coordinated on a national scale in a manner consistent with effective service to National Account customers and
consistent with the preservation of the integrity of the Blue Cross/Blue Shield system and the Licensed Marks. These
guidelines shall be interpreted in keeping with such ends.
2. A National Account is an entity with employee and/or retiree locations in more than one Plan's Service Area.
Unless otherwise agreed, a National Account is deemed located in the Service Area in which the corporate
headquarters of the National Account is located. A local plant, office or division headquarters of an entity may be
deemed a separate National Account when that local plant, office or division headquarters 1) has employee locations in
more than one Service Area, and 2) has independent health benefit decision-making authority for the employees
working at such local plant, office or division headquarters and for employees working at other locations outside the
Service Area. In such a case, the local plant, office or division headquarters is a National Account that is deemed
located in the Service Area in which such local plant, office or division headquarters is located. The Control Plan of a
National Account is the Plan in whose Service Area the National Account is located. A participating ("Par") Plan is a
Plan in whose Service Area the National Account has employee and/or retiree locations, but in which the National
Account is not located. In the event that a National Account parent company consolidates health benefit-decision
making for itself and its wholly-owned subsidiary companies, the parent company and the subsidiary companies shall
be considered one National Account. The Control Plan for such a National Account shall be the Plan in whose Service
Area the parent company headquarters is located.
3. The National Account Guidelines enunciated herein below shall be applicable only with respect to the business of
new National Accounts acquired after January 1, 1991.
4. Control Plans shall utilize National Account identification cards complying with then currently effective BCBSA
graphic standards in connection with all National Accounts business to facilitate administration thereof, to minimize
subscriber and provider confusion, and to reflect a commitment to cooperation among Plans.
Amended as of June 12, 2003
-- 463 of 512 --
Exhibit 3
Page 2 of 3
5. Disputes among Plans and/or BCBSA as to the interpretation or implementation of these Guidelines or as to other
National Accounts issues shall be submitted to mediation and mandatory dispute resolution as provided in the License
Agreement. For two years from the effective date of the License Agreement, however, such disputes shall be subject to
mediation only, with the results of such mediation to be collected and reported in order to establish more definitive
operating parameters for National Accounts business and to serve as ground rules for future binding dispute resolution.
6. The Control Plan may use the BlueCard Program (as defined by IPPC) to deliver benefits to employees and non-
Medicare eligible retirees in a Participating Plan’s service area if an alternative arrangement with the Participating Plan
cannot be negotiated. The Participating Plan’s minimum servicing requirement for those employees and non-Medicare
retirees in its service area is to deliver benefits using the BlueCard Program. Account delivery is subject to the policies,
provisions and procedures of the BlueCard Program.
7. For provider payments in a Participating Plan’s area (on non-BlueCard claims), payment to the provider may be
made by the Participating Plan or the Control Plan at the Participating Plan's option. If the Participating Plan elects to
pay the provider, it may not withhold payment of a claim verified by the Control Plan or its designated processor, and
payment must be in conformity with service criteria established by the Board of Directors of BCBSA (or an authorized
committee thereof) to assure prompt payment, good service and minimum confusion with providers and subscribers.
The Control Plan, at the Participating Plan's request, will also assure that measures are taken to protect the
confidentiality of the data pertaining to provider reimbursement levels and profiles.
Amended as of June 14, 1996
-- 464 of 512 --
Exhibit 3
Page 3 of 3
8. The Control Plan, in its financial agreements with a National Account, is expected to reasonably reflect the
aggregate amount of differentials passed along to the Control Plan by all Participating Plans in a National Account.
9. Other than in contracting with health care providers or soliciting such contracts in areas contiguous to a Plan's
Service Area in order to serve its subscribers or those of its licensed Controlled Affiliate residing or working in its
Service Area, a Control Plan may not use the Licensed Marks and/or Name, as a tag line or otherwise, to negotiate
directly with providers outside its Service Area.
Amended as of March 13, 2003
-- 465 of 512 --
Exhibit 4
GOVERNMENT PROGRAMS AND CERTAIN OTHER USES
Page 1 of 14
1. A Plan and its licensed Controlled Affiliate may use the Licensed Marks and Name in bidding on and executing a
contract to serve a Government Program, and in thereafter communicating with the Government concerning the
Program. With respect, however, to such contracts entered into after the 1st day of January, 1991, the Licensed Marks
and Name will not be used in communications or transactions with beneficiaries or providers in the Government
Program located outside a Plan's Service Area, unless the Plan can demonstrate to the satisfaction of BCBSA's
governing body that such a restriction on use of the Licensed Marks and Name will jeopardize its ability to procure the
contract for the Government Program. As to both existing and future contracts for Government Programs, Plans will
discontinue use of the Licensed Marks and Name as to beneficiaries and Providers outside their Service Area as
expeditiously as circumstances reasonably permit. Effective January 1, 1995, except as provided in the first sentence
above, all use by a Plan of the Licensed Marks and Name in Government Programs outside of the Plan's Service Area
shall be discontinued. Incidental communications outside a Plan's Service Area with resident or former resident
beneficiaries of the Plan, and other categories of necessary incidental communications approved by BCBSA, are not
prohibited. For purposes of this Paragraph 1, the term “Government Programs” shall mean Medicare Part A, Medicare
Part B and other non-risk government programs.
2. In connection with activity otherwise in furtherance of the License Agreement, a Plan and its Controlled Affiliates
that are licensed to use the Licensed Marks and Name in its Service Area pursuant to the Controlled Affiliate
License Agreements authorized in clauses a) through c) of Paragraph 2 of the Plan’s License Agreement with
BCBSA may use the Licensed Marks and Name outside the Plan’s Service Area in the following circumstances
which are deemed legitimate and necessary and not likely to cause consumer confusion:
2.1 Common Business Communications
a. sending letterhead, envelopes, and similar items solely for administrative purposes (e.g., not for purposes of
marketing, advertising, promoting, selling or soliciting the sale of health care plans and related services);
b. distributing business cards other than in marketing and selling;
c. advertising in publications or electronic media solely to persons for employment;
Amended as of June 19, 2014
-- 466 of 512 --
EXHIBIT 4
Page 2 of 14
2.2 Marketing Spillover
a. advertising in print, electronic or other media which serve, as a substantial market, the Service Area of the Plan
or licensed Controlled Affiliate, provided that no Plan or Controlled Affiliate may advertise outside its
Service Area on the national broadcast and cable networks and that advertisements in national print
media are limited to the smallest regional edition encompassing the Service Area;
b. advertising by direct mail where the addressee's zip code plus 4 includes, at least in part, the Plan's Service
Area or that of a licensed Controlled Affiliate;
2.3 Provider Contracting
a. contracting with health care providers or soliciting such contracts in areas contiguous to the Plan's Service Area
in order to serve its subscribers or those of such licensed Controlled Affiliates residing or working in its
service area;
b. issuing a small sign containing the legal name or trade name of the Plan or such licensed Controlled Affiliates
for display by a provider to identify the latter as a participating provider of the Plan or Controlled Affiliate;
c. negotiating case-specific reimbursement rates with a provider that does not have a contract applicable to a
specific member’s services rendered or to be rendered with the Licensee (or any of the Licensees in the
case of overlapping Service Areas) in whose Service Area the health care provider is located, so long as
(1) the Licensee engaging in the negotiations complies with all applicable Inter-Plan Programs Policies and
Provisions and Brand Regulations related to case-specific rate negotiations, and
(2) the Licensee (or all Licensees in the case of overlapping Service Areas) in whose Service Area the health care
provider is located provides consent before negotiations commence.
Amended as of January 22, 2019
-- 467 of 512 --
EXHIBIT 4
Page 3 of 14
d. contracting with a pharmacy management organization (“Pharmacy Intermediary”) to gain access to a
national or regional pharmacy network to provide self-administered prescription drugs to deliver a
pharmacy benefit for all of the Plan’s or licensed Controlled Affiliate’s members nationwide, provided,
however, that the Pharmacy Intermediary may not use the Licensed Marks or Name in contracting with
the pharmacy providers in such network;
Amended as of January 22, 2019
-- 468 of 512 --
EXHIBIT 4
Page 4 of 14
e. contracting with the corporate owner of a national or regional retail pharmacy chain to gain access to the
pharmacies in the chain to provide self-administered prescription drugs to deliver a pharmacy benefit for
all of the Plan’s or licensed Controlled Affiliate’s members nationwide, provided that (1) the Plan and the
Controlled Affiliate may
not contract directly with pharmacists or pharmacy stores outside the Plan’s Service Area, and (2) neither
the Plan’s or the Controlled Affiliate’s name nor the Licensed Marks or Name may be posted or otherwise
displayed at or by any pharmacy store outside the Plan’s Service Area;
f. contracting with a dental management organization (“Dental Intermediary”) to gain access to a national or
regional dental network to deliver a routine dental benefit for all of the Plan’s or licensed Controlled
Affiliate’s members nationwide, provided, however, that the Dental Intermediary may not use the Licensed
Marks or Name in contracting with the dental providers in such network;
g. contracting with a vision management organization (“Vision Intermediary”) to gain access to a national or
regional vision network to deliver a routine vision benefit for all of the Plan’s or licensed Controlled
Affiliate’s members nationwide, provided, however, that the Vision Intermediary may not use the Licensed
Marks or Name in contracting with the vision providers in such network;
h. contracting with an independent clinical laboratory for analysis and clinical assessment of specimens that
are collected within the Plan’s Service Area;
i. contracting with a durable medical equipment or home medical equipment company for durable medical
equipment and supplies and home medical equipment and supplies that are shipped to a location within
the Plan’s Service Area;
j. contracting with a specialty pharmaceutical company for non-routine biological therapeutics that are
ordered by a health care professional located within the Plan’s Service Area;
k. contracting with a company that operates provider sites in the Plan’s Service Area, provided that the
contract is solely for services rendered at a site (e.g., hospital, mobile van) that is within the Plan’s Service
Area;
-- 469 of 512 --
EXHIBIT 4
Page 5 of 14
l. contracting with a company that makes health care professionals available in the Plan’s Service Area
(e.g., traveling home health nurse), provided that the contract is solely for services rendered by health
care professionals who are located within the Plan’s Service Area.
m. Permitting Control/Home Plans’ ability to resolve members’ service issues requiring outreach to out-of-
area providers as set forth in the Inter-Plan Programs and Inter-Plan Medicare Advantage Program
Policies.
2.4 Services to National Accounts
a. in conjunction with contracting with a National Account as Control Licensee or Alternate Control Licensee (as
those terms are defined in the Inter-Plan Programs Policies and Provisions (“IP Policies”)) to offer Blue-
branded Health Coverage to the National Account, offering Blue-branded Health and Wellness Programs
to all members of the National Account, including members who have not enrolled in the Blue-branded
Health Coverage (“non-Blue Health Coverage members”), provided that:
(i) the Plan and/or Licensed Controlled Affiliate has no contact or interaction with providers outside of
the Plan’s Service Area, except as specifically provided in the IP Policies and in 2.4(b); and
(ii) if in accordance with IP Policies another Licensee is soliciting or servicing under the Brands a local
plant, office or division of the account that is outside of the Plan’s Service Area, the Plan and/or
licensed Controlled Affiliate may not offer Blue-branded Health and Wellness Programs to any
employees working at such local plant, office or division without the consent of such other Licensee;
and
(iii) if the Plan and/or licensed Controlled Affiliate provides an information card to the non-Blue Health
Coverage members, the card may not display the Symbols in the masthead, must contain a
prominent disclosure conveying that it is not a health insurance card, and otherwise must be
designed so that it is dissimilar to a Blue member identification card.
Amended as of September 17, 2020
-- 470 of 512 --
EXHIBIT 4
Page 6 of 14
2.4 Services to National Accounts (continued)
For purposes of this subparagraph a, the following definitions apply:
“Health and Wellness Program” shall mean a program that includes at least one of the following
elements or a related element:
– Health Risk Assessment and/or Preventive Screenings
– Exercise and Fitness Programs
– Health and Wellness Events (e.g., attendance at a health fair, a 5K walk)
– Nutrition and Weight Management
– Health Education (e.g., smoking cessation classes)
– Prenatal and Parenting Education
– Disease or Chronic Condition Management
The above listing is intended to represent examples of the types of programs that may be offered, and
other programs, including those offered through different media such as the internet or telephonically, may
also be deemed Health and Wellness programs.
“Health Coverage” shall mean providing or administering medical, surgical, hospital, major medical, or
catastrophic coverage, or any HMO, PPO, POS or other managed care plan for the foregoing services.
b. as part of a Health and Wellness Program that is otherwise compliant with Brand Regulation 4.11.4(a),
contracting with a health and wellness organization to gain access to providers to deliver a discrete health
and wellness event (“Event”) held at a National Account’s worksite outside of the Licensee’s Service Area,
provided that:
(i) the services delivered at the Event are limited to fingerstick screenings for cholesterol and glucose,
seasonal flu immunizations, blood pressure measurements, body mass index measurements, and other
routine screenings, immunizations and measurements; and
(ii) neither such services nor their costs are applied as claims against any benefit plan; and
(iii) the Event is presented during one or more limited periods during a benefit year and is available to all
employees at the worksite.
Amended as of March 26, 2015
-- 471 of 512 --
EXHIBIT 4
Page 7 of 14
c. in conjunction with contracting with a National Account as Control Licensee or Alternate Control Licensee to
offer Blue-branded Health Coverage to the National Account, performing the Eligibility and Enrollment
functions of HR administration for all benefit plans offered by the National Account to its members,
including benefit plans that are not underwritten or administered by the Plan, provided that:
(i) in performing such functions, the Plan and/or licensed Controlled Affiliate does not use the Brands in
any communications with health care providers outside of the Plan’s Service Area, and otherwise
limits its use of the Brands outside of the Service Area to communications with the account’s
members, the other benefit plan providers with which the account has contracted and other
reasonably necessary communications to perform such functions; and
(ii) if in accordance with IP Policies another Licensee is soliciting or servicing under the Brands a local
plant, office or division of the account that is outside of the Plan’s Service Area, the Plan and/or
licensed Controlled Affiliate may not perform Eligibility and Enrollment functions for employees
working at such local plant, office or division without the consent of such other Licensee;
d. in conjunction with contracting with a National Account as Control Licensee or Alternate Control Licensee to
perform or investigate fraud, waste and abuse investigation activities for a non-participating provider in a
Par/Host Plan’s service area, as long as the Control/Home Plan is given permission to do so by the
Par/Host Plan and specific conditions are met in accordance with Inter-Plan Programs and Inter-Plan
Medicare Advantage Program policies.
For purposes of this subparagraph b, the following definitions apply:
“Health Coverage” has the meaning set forth in subparagraph 2.4.a.
Amended as of September 27, 2018
-- 472 of 512 --
EXHIBIT 4
Page 8 of 14
“Eligibility” means services that manage the account’s eligibility data and determine or process
determinations relating to eligibility for benefit plans offered by the account to its employees, including such
services as:
• monitoring and auditing data to ensure that only entitled individuals are enrolled in each such
benefit plan;
• review of eligibility documentation (e.g. marriage licenses, birth certificates, student status
verification letters, employment records);
• identification of key member segments such as over-age dependents, part-time employees,
employees reaching certain milestones (e.g. Medicare-eligible, retirees);
• termination of coverage for those individuals found to be ineligible for coverage under a
benefit plan, and, if applicable, generation of a COBRA event; and
• management of “hour-banking” for union environments in which union members can bank
hours to remain eligible for benefits.
“Enrollment” means services that enroll eligible individuals and their spouses/dependents or terminate or
change their enrollment in the account’s benefit plans on an ongoing basis and during open enrollment
periods, including such services as:
• the coordination of each step in open enrollment process from project planning and system
set-up to the generation of confirmation statements;
• ongoing enrollment support for new hires and changes due to life events and work status
adjustments;
• evidence of insurability (EOI) administration for life and disability coverage;
• transmission of eligibility/enrollment information to the account’s benefit plan providers;
• review and reconciliation of error reports received from the account’s benefit plan providers;
and
• transmission of information to the account’s payroll
system (e.g., benefit deductions, employee demographic data).
Amended as of March 26, 2015
-- 473 of 512 --
EXHIBIT 4
Page 9 of 14
2.5 Knowledge Sharing
a. submitting scholarly articles authored or co-authored by the Plan or Controlled Affiliate or its respective
employees for publication in peer-reviewed journals;
b. permitting an internal representative of the Licensee (e.g., officer, employee) to speak or present at a
conference or symposium outside of the Licensee’s Service Area regarding either (i) healthcare financing,
administration, delivery or policy, or (ii) topics within the representative’s functional discipline or expertise
at the Licensee, for which the event sponsor will issue communications to promote, administer, and/or
recap the event that will identify the Licensee’s representative as a participant. The communications
outside of the Licensee’s Service Area that mention the Licensee’s representative shall be limited to
materials and digital media provided to attendees, on-site signage, advertising in relevant trade
publications, direct mail and email to attendees and prospective attendees, and the sponsor’s website,
Participation in any conference or symposium outside of the Licensee’s Service Area may not be for the
purpose of marketing or selling products or services.
If the Licensee’s representative wishes to use the Brands in any manner, including use in his/her title, when
participating as a speaker or presenter outside of the Licensee’s Service Area about a topic that is not
related to healthcare financing, administration, delivery, or policy, or to topics within the representative’s
functional discipline or expertise at the Licensee, the Licensee must notify BCBSA and receive prior
approval from BCBSA before participating.
Amended as of March 26, 2015
-- 474 of 512 --
EXHIBIT 4
Page 10 of 14
2.6 Other Uses
a. entering into a license agreement between and among BCBSA, the Plan and a debit card issuer located
outside the Plan’s Service Area, and entering into a corresponding operating agreement or agreements, in
order to offer a debit card bearing the Licensed Marks and Name to eligible persons as defined by the
aforementioned license agreement;
b. appearing in communications issued by an independent third party to recognize outstanding performance of
the Plan or Controlled Affiliate or a member of the Plan’s or Controlled Affiliate’s senior management as
part of an established program of the third party for which the Plan has provided information to be
considered for the recognition, provided that such use complies with regulations of general application
specifically prescribed by BCBSA from time to time;
c. to identify itself as being a joint sponsor of an event, program or activity along with other Plans or such Plans’
licensed Controlled Affiliates, provided that such use complies with regulations of general application
specifically prescribed by BCBSA from time to time;
d. hosting meetings or events (collectively, “events”) in Washington, D.C. or a Plan’s State Capitol related to
policy and business issues in the Licensee’s Service Area, or hosting events in conjunction with the
assemblies or conventions of national political parties. Such events may not involve marketing or selling
products or services. Use of the Brands outside the Licensee’s Service Area in connection with such
events shall be limited to materials and digital media provided to attendees and prospective attendees and
onsite signage. For any such events in Washington, D.C. that are open to attendees other than
government officials or their staffs, or are briefings open to all Congressional staff, or are otherwise likely to
receive media coverage, the Licensee is required to provide advance notice to BCBSA. For events hosted
outside of Washington, D.C. in conjunction with the assemblies or conventions of national political parties,
the Licensee is required to provide advance notice to BCGSA and to the local Plan(s);
Amended as of March 26, 2015
-- 475 of 512 --
EXHIBIT 4
Page 11 of 14
e. permitting an affiliate that is not licensed to use the Licensed Marks to identify its corporate relationship
with the Plan, provided that such use complies with regulations of general application specifically
prescribed by BCBSA from time to time.
3. In connection with activity otherwise in furtherance of the License Agreement, a Controlled Affiliate that is licensed
to use the Licensed Marks and Name pursuant to a Controlled Affiliate License Agreement authorized in clauses d) or
e) of Paragraph 2 of the Plan’s License Agreement with BCBSA may use the Licensed Marks and Name outside the
Region (as that term is defined in such respective Controlled Affiliate License Agreements) in the following
circumstances which are deemed legitimate and necessary and not likely to cause consumer confusion:
a. sending letterhead, envelopes, and similar items solely for administrative purposes (e.g., not for purposes of
marketing, advertising, promoting, selling or soliciting the sale of health care plans and related services);
b. distributing business cards other than in marketing and selling;
c. contracting with health care providers or soliciting such contracts in areas contiguous to the Region in order to
serve its subscribers residing in the Region, provided that the Controlled Affiliate may not use the names
of any of its Controlling Plans in connection with such contracting unless the provider is located in a
geographic area that is also contiguous to such Controlling Plan’s Service Area;
d. issuing a small sign containing the legal name or trade name of the Controlled Affiliate for display by a provider
to identify the latter as a participating provider of the Controlled Affiliate, provided that the Controlled
Affiliate may not use the names of any of its Controlling Plans on such signs unless the provider is located
in a geographic area that is also contiguous to such Controlling Plan’s Service Area;
e. advertising in publications or electronic media solely to persons for employment;
Amended as of March 26, 2015
-- 476 of 512 --
EXHIBIT 4
Page 12 of 14
f. advertising in print, electronic or other media which serve, as a substantial market, the Region, provided that
the Controlled Affiliate may not advertise outside its Region on the national broadcast and cable networks
and that advertisements in national print media are limited to the smallest regional edition encompassing
the Region, and provided further that any such advertising by the Controlled Affiliate may not reference
the name of any of its Controlling Plans unless the respective Controlling Plan is authorized under
paragraph 2 of this Exhibit 4 to advertise in such media;
g. advertising by direct mail where the addressee's zip code plus 4 includes, at least in part, the Region,
provided that such advertising by the Controlled Affiliate may not reference the name of any of its
Controlling Plans unless the respective Controlling Plan is authorized under paragraph 2 of this Exhibit 4
to send direct mail to such zip code plus 4.
h. [Intentionally left blank, pending review by the Inter-Plan Programs Committee of the applicability of the case
management rule to such Controlled Affiliates.]
i. contracting with a pharmacy management organization (“Pharmacy Intermediary”) to gain access to a national or
regional pharmacy network to provide self-administered prescription drugs to deliver a pharmacy benefit
for the Controlled Affiliate’s regional Medicare Advantage PPO or regional Medicare Part D Prescription
Drug members enrolled under the Licensed Marks pursuant to such respective Controlled Affiliate License
Agreements, provided, however, that the Pharmacy Intermediary may not use the Licensed Marks or
Name in contracting with the pharmacy providers in such network;
j. contracting with the corporate owner of a national or regional retail pharmacy chain to gain access to the
pharmacies in the chain to provide self-administered prescription drugs to deliver a pharmacy benefit to
the Controlled Affiliate’s regional Medicare Advantage PPO
or regional Medicare Part D Prescription Drug members enrolled under the Licensed Marks pursuant to such
respective
-- 477 of 512 --
EXHIBIT 4
Page 13 of 14
Controlled Affiliate License Agreements, provided that (1) the Controlled Affiliate may not contract directly
with pharmacists or pharmacy stores outside the Region, and (2) neither the Controlled Affiliate’s name
nor the Licensed Marks or Name may be posted or otherwise displayed at or by any pharmacy store
outside the Region;
k. contracting with a dental management organization (“Dental Intermediary”) to gain access to a national or
regional dental network to deliver a routine dental benefit for the Controlled Affiliate’s regional Medicare
Advantage PPO members enrolled under the Licensed Marks pursuant to such Controlled Affiliate
License Agreement, provided, however, that the Dental Intermediary may not use the Licensed Marks or
Name in contracting with the dental providers in such network;
l. contracting with a vision management organization (“Vision Intermediary”) to gain access to a national or
regional vision network to deliver a routine vision benefit for the Controlled Affiliate’s regional Medicare
Advantage members enrolled under the Licensed Marks pursuant to such Controlled Affiliate License
Agreement, provided, however, that the Vision Intermediary may not use the Licensed Marks or Name in
contracting with the vision providers in such network;
m. contracting with an independent clinical laboratory for analysis and clinical assessment of specimens that are
collected within the Controlled Affiliate’s Region;
n. contracting with a durable medical equipment or home medical equipment company for durable medical
equipment and supplies and home medical equipment and supplies that are shipped to a location within
the Controlled Affiliate’s Region;
o. contracting with a specialty pharmaceutical company for non-routine biological therapeutics that are ordered by
a health care professional located within the Region;
p. contracting with a company that operates provider sites in the Region, provided that the contract is solely for
services rendered at a site (e.g., hospital, mobile van) that is within the Region;
EXHIBIT 4
-- 478 of 512 --
Page 14 of 14
q. contracting with a company that makes health care professionals available in the Region (e.g., traveling home
health nurse), provided that the contract is solely for services rendered by health care professionals who
are located within the Region.
4. BCBSA shall retain the right to use the Licensed Marks in conjunction with the Federal Employee Program and
with any other national offering made to federal employees pursuant to the Federal Employees Health Benefits
Program (FEHBP), including the right to license such use to its vendors, but only in the following manner.
a. the Licensed Marks may only be used by BCBSA with the term “Federal Employee Program”, “Federal”,
“FEP”, or similar language identifying the program as a benefit program for federal employees;
b. the Licensed Marks may not be used by BCBSA with the name(s) of a specific Plan or Plans and;
c. any use by BCBSA in conjunction with a new national FEHBP program proposed after the enactment of
this amendment will require the approval of the BCBSA Board of Directors.
5. Where required by applicable state or local law or regulation, a Plan or its licensed Controlled Affiliate may
submit documents that contain the Brands to, and file forms that contain the Brands with, state or local regulators in a
state not included in its Service Area, provided that it gives reasonable advance notice to the local Plan of its intent to
submit such documents or file such forms. Notwithstanding, in no event may a Plan or its licensed Controlled Affiliate
use the Brands to register, or to obtain or maintain a license, a certificate of authority, or an equivalent document
authorizing it to act as a risk-bearing entity or third party administrator in a state not included in its Service Area. If the
local Plan advises BCBSA that it believes its License Agreement has been or would be violated by any submission or
filing, BCBSA shall determine whether such submission or filing is required by state or local law or regulation and
violates the License Agreement, subject to the Plan’s or licensed Controlled Affiliate’s rights to obtain an independent
review of such determination under Paragraph 9(a) and Exhibit 5 of its License Agreement or Paragraph 8 of the
Controlled Affiliate License. For purposes of this paragraph, “local Plan” is defined as each Plan whose Service Area
includes all or part of the state in which the foregoing applicable state or local law or regulation has been enacted.
Amended as of March 26, 2015
-- 479 of 512 --
EXHIBIT 5
Page 1 of 23
MEDIATION AND MANDATORY DISPUTE RESOLUTION (MMDR) RULES
The Blue Cross and Blue Shield Plans ("Plans") and the Blue Cross Blue Shield Association ("BCBSA") recognize
and acknowledge that the Blue Cross and Blue Shield system is a unique nonprofit and for-profit system offering cost
effective health care financing and services. The Plans and BCBSA desire to utilize Mediation and Mandatory Dispute
Resolution (“MMDR”) to avoid expensive and time-consuming litigation that may otherwise occur in the federal and state
judicial systems. Even MMDR should be viewed, however, as methods of last resort, all other procedures for dispute
resolution having failed. Except as otherwise provided in the License Agreements, the Plans, their Controlled Affiliates
and BCBSA agree to submit all disputes to MMDR pursuant to these Rules and in lieu of litigation.
1. Initiation of Proceedings
A. Pre-MMDR Efforts
Before filing a Complaint to invoke the MMDR process, the CEO of a complaining party, or his/her designated
representative, shall undertake good faith efforts with the other side(s) to try to resolve any dispute.
B. Complaint
To commence a proceeding, the complaining party (or parties) shall provide by certified mail, return receipt requested,
a written Complaint to the BCBSA Corporate Secretary (which shall also constitute service on BCBSA if it is a
respondent) and to any Plan(s) and/or Controlled Affiliate(s) named therein. The Complaint shall contain:
i. identification of the complaining party (or parties) requesting the proceeding;
ii. identification of the respondent(s);
iii. identification of any other persons or entities who are interested in a resolution of the dispute;
iv. a full statement describing the nature of the dispute;
v. identification of all of the issues that are being submitted for resolution;
Amended as of November 21, 1996
-- 480 of 512 --
EXHIBIT 5
Page 2 of 23
vi. the remedy sought;
vii. a statement as to whether the complaining party (or parties) elect(s) first to pursue Mediation;
viii.any request, if applicable, that the matter be handled on an expedited basis and the reasons therefor;
and
ix. a statement signed by the CEO of the complaining party affirming that the CEO has undertaken efforts,
or has directed efforts to be undertaken, to resolve the dispute before resorting to the MMDR process.
The complaining party (or parties) shall file and serve with the Complaint copies of all documents which the party (or
parties) intend(s) to offer at the Arbitration Hearing and a statement identifying the witnesses the party (or parties)
intend(s) to present at the Hearing, along with a summary of each witness' expected testimony.
C. Answer
Within twenty (20) days after receipt of the Complaint, each respondent shall serve on BCBSA and on the
complaining party (or parties):
i. a full Answer to the aforesaid Complaint;
ii. a statement of any Counterclaims against the complaining party (or parties), providing with respect
thereto the information specified in Paragraph 1.B., above;
iii. a statement as to whether the respondent elects to first pursue Mediation; and
iv. any request, if applicable, that the matter be handled on an expedited basis and the reasons therefor.
The respondent(s) shall file and serve with the Answer or by the date of the Initial Conference set forth in Paragraph
3.C., below, copies of all documents which the respondent(s) intend(s) to offer at the Arbitration Hearing and a
statement identifying the witnesses the party (or parties) intend(s) to present at the Hearing, along with a summary of
each witness' expected testimony.
Amended as of September 20, 2007
-- 481 of 512 --
EXHIBIT 5
Page 3 of 23
D. Reply To Counterclaim
Within ten (10) days after receipt of any Counterclaim, the complaining party (or parties) shall serve on BCBSA and
on the responding party (or parties) a Reply to the Counterclaim. Such Reply must provide the same information
required by Paragraph 1.C., above.
2. Mediation
To facilitate the mediation of disputes between or among BCBSA, the Plans and/or their Controlled Affiliates, the
BCBSA Board has provided for Mediation under these Rules. Mediation may be pursued in lieu of or in an effort to
obviate the Mandatory Dispute Resolution process, and all parties are strongly urged, but not required, to exhaust the
mediation procedure provided for herein. In the event any party refuses to proceed with Mediation, the parties shall
proceed immediately to Mandatory Dispute Resolution, as provided in Section 3.
A. Selection of Mediators
If all parties agree to pursue Mediation, they shall promptly attempt to agree upon: (i) the number of mediators
desired, not to exceed three mediators; and (ii) the selection of experienced mediator(s) from an independent entity to
mediate all disputes set forth in the Complaint and Answer (and Counterclaim and Reply, if any). In the event the parties
are unable to agree upon the selection or number of mediators, both within five (5) days of the service of the Answer or
Reply to Counterclaim, whichever is later, the BCBSA Corporate Secretary shall immediately refer the matter to a
nationally recognized professional ADR organization (such as CPR or JAMS) for mediation by a single mediator to be
selected by the ADR organization.
B. Binding Decision
Before the Mediation Hearing described below, the BCBSA Corporate Secretary shall contact the parties to determine
whether they wish to be bound by any recommendation of the selected mediator(s) for resolution of the disputes. If all
wish to be bound, the Corporate Secretary will send appropriate documentation to them for their signatures before the
Mediation Hearing begins.
Amended as of September 20, 2007
-- 482 of 512 --
EXHIBIT 5
Page 4 of 23
C. Mediation Procedure
The Mediator(s) shall apply the mediation procedures and processes provided for herein (not the rules of the ADR
organization with which they are affiliated) and shall promptly advise the parties of a scheduled Mediation Hearing date.
Unless a party requests an expedited procedure, or unless all parties to the proceeding agree to one or more extensions
of time, the Mediation Hearing set forth below shall be completed within forty (40) days of BCBSA's receipt of the
Complaint. The selected mediator(s), unless the parties otherwise agree, shall adhere to the following procedure:
i. Each party must be represented by its CEO or other representative who has been delegated full
authority to resolve the dispute. However, parties may send additional representatives as they see fit.
ii. Each party will be given one-half hour to present its case, beginning with the complaining party (or
parties), followed by the other party or parties. The parties are free to structure their presentations as
they see fit, using oral statements or direct examination of witnesses. However, neither cross-
examination nor questioning of opposing representatives will be permitted. At the close of each
presentation, the selected mediator(s) will be given an opportunity to ask questions of the presenters
and witnesses. All parties must be present throughout the Mediation Hearing. The selected mediator(s)
may extend the time allowed for each party's presentation at the Mediation Hearing. The selected
mediator(s) may meet in executive session, outside the presence of the parties, or may meet with the
parties separately, to discuss the controversy.
iii. After the close of the presentations, the parties will attempt to negotiate a settlement of the dispute. If
the parties desire, the selected mediators, or any one or more of the selected mediator(s), will sit in on
the negotiations.
Amended as of September 20, 2007
-- 483 of 512 --
EXHIBIT 5
Page 5 of 23
iv. After the close of the presentations, the selected mediator(s) may meet privately to agree upon a
recommendation for resolution of the dispute which would be submitted to the parties for their
consideration and approval. If the parties have previously agreed to be bound by the results of this
procedure, this recommendation shall be binding upon the parties.
v. The purpose of the Mediation Hearing is to assist the parties to settle their grievances short of
mandatory dispute resolution. As a result, the Mediation Hearing has been designed to be as informal
as possible. Rules of evidence shall not apply. There will be no transcript of the proceedings, and no
party may make a tape recording of the Mediation Hearing.
vi. In order to facilitate a free and open discussion, the Mediation proceeding shall remain confidential. A
"Stipulation to Confidentiality" which prohibits future use of settlement offers, all position papers or other
statements furnished to the selected mediator(s), and decisions or recommendations in any Mediation
proceeding shall be executed by each party.
vii. Upon request of the selected mediator(s), or one of the parties, BCBSA staff may also submit
documentation at any time during the proceedings.
D. Notice of Termination of Mediation
If the Mediation cannot be completed within the prescribed or agreed time period due to the lack of cooperation of any
party, as determined by the selected mediator(s), or if the Mediation does not result in a final resolution of all disputes at
the Mediation Hearing or within ten (10) days after the Mediation Hearing, any party or any one of the selected
mediator(s) shall so notify the BCBSA Corporate Secretary, who shall promptly issue a Notice of Termination of
Mediation to all parties, to the selected mediator(s), and to the MDR Administrator. Such notice shall serve to bring the
Mediation to an end and to initiate Mandatory Dispute Resolution. Upon agreement of all parties and the mediator(s), the
Mediation process may continue at the same time the MDR process is invoked. In such case, the Notice of Termination
of Mediation described above serves to initiate the MDR proceeding, but does not terminate mediation proceedings,
which may proceed simultaneous with the MDR proceeding.
Amended as of September 20, 2007
-- 484 of 512 --
EXHIBIT 5
Page 6 of 23
3. Mandatory Dispute Resolution (MDR)
If any party elects not to first pursue Mediation, or if a Notice of Termination of Mediation is issued as set forth in
Paragraph 2.D., above, then the unresolved disputes set forth in any Complaint and Answer (and Counterclaim and
Reply, if any) shall be subject to mandatory binding arbitration (herein referred to as “MDR”).
A. MDR Administrator
The Administrator for purposes of Mandatory Arbitration shall be an independent nationally recognized entity such as
CPR or JAMS, specializing in alternative dispute resolution. In the event the parties pursued Mediation with CPR, JAMS
or a similar organization, that organization also shall serve as the MDR Administrator, unless all parties notify the
BCBSA Corporate Secretary in writing within two (2) days of receiving the Notice of Termination of Mediation that they
wish to pursue MDR with another nationally recognized organization serving as MDR Administrator.
In the event the parties (i) did not pursue Mediation, (ii) pursued mediation with a Mediator not affiliated with an ADR
organization that offers a panel of arbitrators, or (iii) all parties that pursued Mediation notified the BCBSA Corporate
Secretary that they wish to have an MDR Administrator that is different from the organization with which their mediator
was affiliated, they shall promptly attempt to agree on a nationally recognized ADR entity that supplies a panel of
arbitrators. If they reach such agreement within five (5) days of the Notice of Termination of Mediation or receipt of the
Answer or Reply to Counterclaim (whichever is later), the parties shall promptly inform the BCBSA Corporate Secretary
of their agreed upon ADR organization. In the event the parties are unable to reach agreement on an MDR Administrator
within that timeframe, the BCBSA Corporate Secretary shall immediately refer the matter to CPR, JAMS or a similar
organization for MDR.
Any person who served as a Mediator shall not serve as an arbitrator for the same or similar dispute for purposes of
MDR.
B. Rules for MDR
The rules controlling all aspects of MDR shall be exclusively those provided for herein. The rules promulgated or
otherwise used by the MDR Administrator organization shall not apply.
Amended as of September 20, 2007
-- 485 of 512 --
EXHIBIT 5
Page 7 of 23
C. Initial Conference
Within seven (7) days after a Notice of Termination has issued, or the matter has otherwise been referred to an MDR
Administrator, or within five (5) days after the time for filing and serving the Answer or Reply to any Counterclaim
(whichever is later) if the parties elect first not to mediate, the parties shall confer with the Administrator to discuss
selecting a dispute resolution panel ("the Panel"). This conference (the “Initial Conference”) may be by telephone. The
parties are encouraged to agree to the composition of the Panel and to present that agreement to the Administrator at
the Initial Conference. If the parties do not agree on the composition of the Panel by the time of the Initial Conference, or
by any extension thereof agreed to by all parties and the Administrator, then the Panel Selection Process set forth in
subparagraph D, below, shall be followed.
D. Panel Selection Process
The Administrator shall designate, prior to the Initial Conference, at least seven potential arbitrators. Each party shall
be permitted to strike any designee for cause and the Administrator shall determine the sufficiency thereof in its sole
discretion. The Administrator will designate a replacement for any designee so stricken. Each party shall then be
permitted one peremptory strike from the list of designees. The Administrator shall set the dates for exercising all strikes,
which shall be set to encourage the prompt selection of arbitrators.
After the parties exercise any designee strikes for cause and their peremptory strike against any designee of their
choice, the parties shall each rank the remaining panel members in order of preference and provide the Administrator,
without serving on any other party, their ranked list. The Administrator shall not disclose any party’s ranked list to
members of the panel or to other parties.
From the remaining designees, and after considering opportunities to maximize, so far as possible, the collectively
stated arbitrator preferences provided by the parties on their ranked lists, the Administrator shall select a three member
Panel. The Panel Selection Process shall be completed no later than ten (10) days after the Initial Conference.
Each Arbitrator shall be compensated at his or her normal hourly rate or, in the absence of an established rate, at
a reasonable hourly rate to be promptly fixed by the Administrator for all time spent in connection with the proceedings
and shall be reimbursed for any travel and other reasonable expenses.
Amended as of September 20, 2007
-- 486 of 512 --
EXHIBIT 5
Page 8 of 23
E. Duties Of The Arbitrators
The Panel shall promptly designate a Presiding Arbitrator for the purposes reflected below, but shall retain the power
to review and modify any ruling or other action of said Presiding Arbitrator. Each Arbitrator shall be an independent
Arbitrator, shall be governed by the Code of Ethics for Arbitrators in Commercial Disputes, and shall at or prior to the
commencement of any Arbitration Hearing take an oath to that effect. Each Arbitrator shall promptly disclose in writing to
the Panel and to the parties any circumstances, whenever arising, that might cause doubt as to such Arbitrator's
compliance, or ability to comply, with said Code of Ethics, and, absent resignation by such Arbitrator, the remaining
Arbitrators shall determine in their sole discretion whether the circumstances so disclosed constitute grounds for
disqualification and for replacement. With respect to such circumstances arising or coming to the attention of a party
after an Arbitrator's selection, a party may likewise request the Arbitrator's resignation or a determination as to
disqualification by the remaining Arbitrators. With respect to a sole Arbitrator, the determination as to disqualification
shall be made by the Administrator.
There shall be no ex parte communication between the parties or their counsel and any member of the Panel.
F. Panel's Jurisdiction And Authority
The Panel's jurisdiction and authority shall extend to all disputes between or among the Plans, their Controlled
Affiliates, and/or BCBSA, except for those disputes excepted from these MMDR procedures as set forth in the License
Agreements.
With the exception of punitive or treble damages, the Panel shall have full authority to award the relief it deems
appropriate to resolve the parties' disputes, including monetary awards and injunctions, mandatory or prohibitory. The
Panel has no authority to award punitive or treble damages except that the Panel may allocate or assess responsibility
for punitive or treble damages assessed by another tribunal. Subject to the above limitations, the Panel may, by way of
example, but not of limitation:
Amended as of September 20, 2007
-- 487 of 512 --
EXHIBIT 5
Page 9 of 23
i. interpret or construe the meaning of any terms, phrase or provision in any license between BCBSA and
a Plan or a Controlled Affiliate relating to the use of the BLUE CROSS® or BLUE SHIELD® service
marks.
ii. determine whether BCBSA, a Plan or a Controlled Affiliate has violated the terms or conditions of any
license between the BCBSA and a Plan or a Controlled Affiliate relating to the use of the BLUE
CROSS® or BLUE SHIELD® service marks.
iii. decide challenges as to its own jurisdiction.
iv. issue such orders for interim relief as it deems appropriate pending Hearing and Award in any
Arbitration.
It is understood that the Panel is expected to resolve issues based on governing principles of law, preserving to the
maximum extent legally possible the continued integrity of the Licensed Marks and the BLUE CROSS/BLUE SHIELD
system. The Panel shall apply federal law to all issues which, if asserted in the United States District Court, would give
rise to federal question jurisdiction, 28 U.S.C. § 1331. The Panel shall apply Illinois law to all issues involving
interpretation, performance or construction of any License Agreement or Controlled Affiliate License Agreement unless
the agreement otherwise provides. As to other issues, the Panel shall choose the applicable law based on conflicts of
law principles of the State of Illinois.
G. Administrative Conference
Within five (5) days of the Panel being selected, the Presiding Arbitrator shall confer with the parties and the other
members of the Panel and shall schedule, in writing, a conference in which the parties and the Panel shall participate
(the “Administrative Conference”). The Administrative Conference shall take place no later than fifteen (15) days after
the Panel is selected. At the Administrative Conference the parties and the Panel shall discuss the scheduling of the
Arbitration Hearing and any other matter appropriate to be considered, including but not limited to: any written discovery
in the form of requests for production of documents or requests to admit facts; the identity of any witness whose
deposition a party may desire and a showing of exceptional good cause for the taking
Amended as of September 20, 2007
-- 488 of 512 --
EXHIBIT 5
Page 10 of 23
of any such deposition; the desirability of bifurcation or other separation of the issues; the need for and the type of
record of conferences and hearings, including the need for transcripts; the need for expert witnesses and how expert
testimony should be presented; the appropriateness of motions to dismiss and/or for full or partial summary judgment;
consideration of stipulations; the desirability of presenting any direct testimony in writing; and the necessity for any on-
site inspection by the Panel. If the parties agree, the Administrative Conference may be by telephone.
H. Discovery
i. Requests for Production of Documents: All requests for the production of documents must be
served no later than five (5) days after the date of the Initial Conference. Within twenty (20) days after
receipt of a request for production of documents, a party shall (a) serve responses and objections to
the request, (b) produce all responsive, non-privileged documents to the requesting party, and (c) to the
extent any responsive documents are withheld on the grounds of attorney-client privilege or work
product, produce a log identifying such documents in the manner specified in Fed. R. Civ. P. 26(b)(5).
If, after reviewing a privilege log, the requesting party believes attorney-client privilege or work product
protection was improperly claimed by the producing party with respect to any document, the requesting
party may ask the Presiding Arbitrator to conduct an in-camera inspection of the same. With respect to
documentary and other discovery produced in any MDR proceeding by BCBSA, the fact that a party’s
CEO or other senior officers may serve on the BCBSA Board of Directors, BCBSA Board Committees
or other BCBSA work groups, task forces and the like, shall not be a basis for defeating an otherwise
valid claim of attorney-client privilege or work product protection over such documentary or other
discovery materials by BCBSA.
ii. Requests for Admissions: Requests for Admissions may be served up to twenty-one (21) days prior
to the discovery cut-off set by the Presiding Arbitrator. A party served with Requests For Admissions
must respond within twenty (20) days of receipt of said request. The good faith use of and response to
Requests for Admissions is encouraged, and the Panel shall have full discretion, with reference to the
Federal Rules of Civil Procedure, in awarding appropriate sanctions with respect to abuse of the
procedure.
Amended as of September 20, 2007
-- 489 of 512 --
EXHIBIT 5
Page 11 of 23
iii. Depositions: As a general rule, the parties will not be permitted to take party or non-party deposition
testimony for discovery purposes. The Presiding Arbitrator, in his or her sole discretion, shall have the
authority to permit a party to take such deposition testimony upon a showing of exceptional good
cause. The parties will be permitted to take de bene esse deposition testimony to the fullest extent
permitted by law of any witness who cannot be compelled to testify at the Arbitration Hearing. No
deposition, for discovery purposes or otherwise, shall exceed three (3) hours, excluding objections and
colloquy of counsel. Depositions may be recorded in any manner recognized by the Federal Rules of
Civil Procedure and the parties shall specify in each notice of deposition or request for permission to
take deposition testimony the manner in which such deposition shall be recorded.
iv. Expert witness(es): If a party intends to present the testimony of an expert witness during the oral
hearing, it shall provide all other parties with a written statement setting forth the information required to
be provided by Fed. R. Civ. P. 26(a)(2)(B) ten (10) days prior to the discovery cut-off set by the
Presiding Arbitrator. If a party intends to present the testimony of a rebuttal expert witness during the
Arbitration Hearing, it shall provide all other parties with a written statement setting forth the information
required to be provided by Fed. R. Civ. P. 26(a)(2)(B) within twenty (20) days after the date on which
the written statement of the expert witness whose testimony is to be rebutted was produced.
v. Discovery cut-off: The Presiding Arbitrator shall determine the date on which the discovery period will
end, but the discovery period shall not exceed thirty (30) days from the date of the Administrative
Conference without the agreement of all parties.
Amended as of September 20, 2007
As used in these Rules, "de bene esse deposition" means a deposition that is not taken for discovery purposes, but is taken for the purpose of
reading part or all of the deposition transcript into the record at the Arbitration Hearing, to the extent permitted by the Panel, because the witness
cannot be compelled to testify at the Arbitration Hearing or has exercised a right provided under these Rules to provide deposition testimony in lieu
of testimony at the Arbitration Hearing.
1
1
-- 490 of 512 --
EXHIBIT 5
Page 12 of 23
vi. Additional discovery: Any additional discovery will be at the discretion of the Presiding Arbitrator.
vii. Discovery Disputes: Any discovery disputes shall be raised by motion to the Presiding Arbitrator, who
is authorized to resolve all such disputes, and whose resolution will be binding on the parties unless
modified by the Arbitration Panel. Prior to raising any discovery dispute with the Presiding Arbitrator,
the parties shall meet and confer, telephonically or in person, in an attempt to resolve or narrow the
dispute. If a party refuses to comply with a decision resolving a discovery dispute, the Panel, in keeping
with Fed. R. Civ. P. 37, may refuse to allow that party to support or oppose designated claims or
defenses, prohibit that party from introducing designated matters into evidence or, in extreme cases,
decide an issue submitted for resolution adversely to that party.
viii.Extensions: The time for responding to discovery requests may be extended by the Presiding
Arbitrator for good and sufficient cause shown. Any request for such an extension shall be made in
writing.
I. Panel Suggested Settlement/Mediation
At any point during the proceedings, the Panel at the request of any party or on its own initiative, may suggest that the
parties explore settlement and that they do so at or before the conclusion of the Arbitration Hearing, and the Panel shall
give such assistance in settlement negotiations as the parties may request and the Panel may deem appropriate.
Alternatively, the Panel may direct the parties to endeavor to mediate their disputes as provided above, or to explore a
mini-trial proceeding, or to have an independent party render a neutral evaluation of the parties’ respective positions.
The Panel shall enter such sanctions as it deems appropriate with respect to any party failing to pursue in good faith
such Mediation or other alternate dispute resolution methods.
Amended as of September 20, 2007
-- 491 of 512 --
EXHIBIT 5
Page 13 of 23
J. Subpoenas on Third Parties
Pursuant to, and consistent with, the Federal Arbitration Act, 9 U.S.C. § 9 et seq., and subject to Paragraph 3.G(iii)
above, a party may request the issuance of a subpoena on any third party, including but not limited to any third party
Blue Plan or any officer, employee or director of a third party Blue Plan, to compel deposition testimony or the
production of documents, and, if good and sufficient cause is shown, the Panel shall issue such a subpoena.
K. Arbitration Hearing
An Arbitration Hearing will be held within thirty (30) days after the Administrative Conference if no discovery is taken,
or within thirty (30) days after the close of discovery, unless all parties and the Panel agree to extend the Arbitration
Hearing date, or unless the parties agree in writing to waive the Arbitration Hearing. The parties may mutually agree on
the location of the Arbitration Hearing. If the parties fail to agree, the Arbitration Hearing shall be held in Chicago, Illinois,
or at such other location determined by the Presiding Arbitrator to be most convenient to the participants. The Panel will
determine the date(s) and time(s) of the Arbitration Hearing(s) after consultation with all parties and shall provide
reasonable notice thereof to all parties or their representatives.
L. Arbitration Hearing Memoranda
Twenty (20) days prior to the Arbitration Hearing, each party shall submit to the other party (or parties) and to the
Panel an Arbitration Hearing Memorandum which sets forth the applicable law and any argument as to any relevant
issue. The Arbitration Hearing Memorandum will supplement, and not repeat, the allegations, information and
documents contained in or with the Complaint, Answer, Counterclaim and Reply, if any. Ten (10) days prior to the
Arbitration Hearing, each party shall submit to each other party a list of all expert and fact witnesses (but not including
rebuttal fact witness) that such party intends to have testify at the Arbitration Hearing and a brief summary of the
testimony each such witness is expected to give. In addition, no later than five (5) days prior to the Arbitration, each
party may submit to each other party and to the Panel a Response Arbitration Hearing Memorandum which sets forth
any response to another party's Arbitration Hearing Memorandum.
Amended as of September 20, 2007
-- 492 of 512 --
EXHIBIT 5
Page 14 of 23
M. Notice For Testimony
Ten (10) days prior to the Arbitration Hearing, any party may serve a Notice on any other party (or parties) requesting
the attendance at the Arbitration Hearing of any officer, employee or director of the other party (or parties) for the
purpose of providing noncumulative testimony. If a party fails to produce one of its officers, employees or directors
whose noncumulative testimony during the Arbitration Hearing is reasonably requested by an adverse party, the Panel
may refuse to allow that party to support or oppose designated claims or defenses, prohibit that party from introducing
designated matters into evidence or, in extreme cases, decide an issue submitted for mandatory dispute resolution
adversely to that party; provided, however, that a party may refuse to produce a director to testify if, within two (2) days
of receiving a notice requesting the attendance of such director at the Arbitration Hearing, the party agrees to make the
director available for a de bene esse deposition at a mutually convenient time at any location within fifty (50) miles of the
director’s primary residence chosen by the party requesting the director’s testimony. This Rule may not be used for the
purpose of burdening or harassing any party, and the Presiding Arbitrator may impose such orders as are appropriate so
as to prevent or remedy any such burden or harassment.
Pursuant to, and consistent with, the Federal Arbitration Act, 9 U.S.C. § 9 et seq., twenty (20) days or more prior
to the Arbitration Hearing, a party may request the issuance of a subpoena on any third party, including but not limited to
any third party Blue Plan, BCBSA or any officer, employee or director of a third party Blue Plan or BCBSA for the
purpose of providing noncumulative testimony at the Arbitration Hearing, and, if good and sufficient cause is shown, the
Panel shall issue such a subpoena; provided however, that a director of a third party Blue Plan or BCBSA may refuse to
testify if, within two (2) days of receiving a subpoena requesting the attendance of such director at the Arbitration
Hearing, the director agrees to make him/herself available for a de bene esse deposition at a mutually convenient time
at any location within fifty (50) miles of the director’s primary residence chosen by the party requesting the director’s
testimony. Each Blue Plan agrees to waive, on its own behalf and on behalf of its directors and officers, any objection it
otherwise might have to any such subpoena based on service, venue or extraterritoriality.
Amended as of September 20, 2007
-- 493 of 512 --
EXHIBIT 5
Page 15 of 23
N. Arbitration Hearing Procedures
i. Attendance at Arbitration Hearing: Any person having a direct interest in the proceeding is entitled to
attend the Arbitration Hearing. The Presiding Arbitrator shall otherwise have the power to require the
exclusion of any witness, other than a party or other essential person, during the testimony of any other
witness. It shall be discretionary with the Presiding Arbitrator to determine the propriety of the
attendance of any other person.
ii. Confidentiality: The Panel and all parties shall maintain the privacy of the Arbitration Proceeding. The
parties and the Panel shall treat the Arbitration Hearing and any discovery or other proceedings or
events related thereto, including any award resulting therefrom, as confidential except as otherwise
necessary in connection with a judicial challenge to or enforcement of an award or unless otherwise
required by law.
iii. Stenographic Record: Any party, or if the parties do not object, the Panel, may request that a
stenographic or other record be made of any Arbitration Hearing or portion thereof. The costs of the
recording and/or of preparing the transcript shall be borne by the requesting party and by any party who
receives a copy thereof. If the Panel requests a recording and/or a transcript, the costs thereof shall be
borne equally by the parties.
iv. Oaths: The Panel may require witnesses to testify under oath or affirmation administered by any duly
qualified person and, if requested by any party, shall do so.
v. Order of Arbitration Hearing: An Arbitration Hearing shall be opened by the recording of the date,
time, and place of the Arbitration Hearing, and the presence of the Panel, the parties, and their
representatives, if any. The Panel may, at the beginning of the Arbitration Hearing, ask for statements
clarifying the issues involved.
Amended as of September 20, 2007
-- 494 of 512 --
EXHIBIT 5
Page 16 of 23
Unless otherwise agreed, the complaining party (or parties) shall then present evidence to support their
claim(s). The respondent(s) shall then present evidence supporting their defenses and Counterclaims,
if any. The complaining party (or parties) shall then present evidence supporting defenses to the
Counterclaims, if any, and rebuttal.
Witnesses for each party shall submit to questions by adverse parties and/or the Panel.
The Panel has the discretion to vary these procedures, but shall afford a full and equal opportunity to all
parties for the presentation of any material and relevant evidence.
vi. Evidence: The parties may offer such evidence as is relevant and material to the dispute and shall
produce such evidence as the Panel may deem necessary to an understanding and resolution of the
dispute. Unless good cause is shown, as determined by the Panel or agreed to by all other parties, no
party shall be permitted to offer evidence at the Arbitration Hearing which was not disclosed prior to the
Arbitration Hearing by that party. The Panel may receive and consider the evidence of witnesses by
affidavit upon such terms as the Panel deems appropriate.
The Panel shall be the judge of the relevance and materiality of the evidence offered, and conformity to
legal rules of evidence, other than enforcement of the attorney-client privilege and the work product
protection, shall not be necessary. The Federal Rules of Evidence shall be considered by the Panel in
conducting the Arbitration Hearing but those rules shall not be controlling. All evidence shall be taken in
the presence of the Panel and all of the parties, except where any party is in default or has waived the
right to be present.
Settlement offers by any party in connection with Mediation or MDR proceedings, decisions or
recommendations of the selected mediators, and a party's position papers or statements furnished to
the selected mediators shall not be admissible evidence or considered by the Panel without the
consent of all parties.
-- 495 of 512 --
EXHIBIT 5
Page 17 of 23
vii. Closing of Arbitration Hearing: The Presiding Arbitrator shall specifically inquire of all parties whether
they have any further proofs to offer or witnesses to be heard. Upon receiving negative replies or if he
or she is satisfied that the record is complete, the Presiding Arbitrator shall declare the Arbitration
Hearing closed with an appropriate notation made on the record. Subject to being reopened as
provided below, the time within which the Panel is required to make the award shall commence to run,
in the absence of contrary agreement by the parties, upon the closing of the Arbitration Hearing.
With respect to complex disputes, the Panel may, in its sole discretion, defer the closing of the
Arbitration Hearing for a period of up to thirty (30) days after the presentation of proofs in order to
permit the parties to submit post-hearing briefs and argument, as the Panel deems appropriate, prior to
making an award.
For good cause, the Arbitration Hearing may be reopened for up to thirty (30) days on the Panel's
initiative, or upon application of a party, at any time before the award is made
O. Awards
An Award must be in writing and shall be made promptly by the Panel and, unless otherwise agreed by the parties or
specified by law, no later than thirty (30) days from the date of closing the Arbitration Hearing. If all parties so request,
the Award shall contain findings of fact and conclusions of law. The Award, and all other rulings and determinations by
the Panel, may be by a majority vote.
Parties shall accept as legal delivery of the Award the placing of the Award or a true copy thereof in the mail
addressed to a party or its representative at its last known address or personal service of the Award on a party or its
representative.
Awards are binding only on the parties to the Arbitration and are not binding on any non-parties to the Arbitration and
may not be used or cited as precedent in any other proceeding.
Amended as of September 20, 2007
-- 496 of 512 --
EXHIBIT 5
Page 18 of 23
After the expiration of twenty (20) days from initial delivery, the Award (with corrections, if any) shall be final and
binding on the parties, and the parties shall undertake to carry out the Award without delay.
Proceedings to confirm, modify or vacate an Award shall be conducted in conformity with and controlled by the
Federal Arbitration Act. 9 U.S.C. § 1, et seq.
P. Return of Documents
Within sixty (60) days after the Award and the conclusion of any judicial proceedings with respect thereto, each party
and the Panel shall return any documents produced by any other party, including all copies thereof. If a party receives a
discovery request in any other proceeding which would require it to produce any documents produced to it by any other
party in a proceeding hereunder, it shall not produce such documents without first notifying the producing party and
giving said party reasonable time to respond, if appropriate, to the discovery request.
4. Miscellaneous
A. Expedited Procedures
Any party to a Mediation may direct a request for an expedited Mediation Hearing to the Chairman of the Mediation
Committee, to the selected Mediators, and to all other parties at any time. The Chairman of the Mediation Committee, or
at his or her direction, the then selected Mediators, shall grant any request which is supported by good and sufficient
reasons. If such a request is granted, the Mediation shall be completed within as short a period as practicable, as
determined by the Chairman of the Mediation Committee or, at his or her direction, the then selected Mediators.
Any party to an Arbitration may direct a request for expedited proceedings to the Administrator, to the Panel, and to all
other parties at any time. The Administrator, or the Presiding Arbitrator if the Panel has been selected, shall grant any
such request which is supported by good and sufficient reasons. If such a request is granted, the Arbitration shall be
completed within as short a time as practicable, as determined by the Administrator and/or the Presiding Arbitrator.
Amended as of September 20, 2007
-- 497 of 512 --
EXHIBIT 5
Page 19 of 23
B. Temporary or Preliminary Injunctive Relief
Any party may seek temporary or preliminary injunctive relief with the filing of a Complaint or at any time thereafter. If
such relief is sought prior to the time that an Arbitration Panel has been selected, then the Administrator shall select a
single Arbitrator who is a lawyer who has no interest in the subject matter of the dispute, and no connection to any of the
parties, to hear and determine the request for temporary or preliminary injunction. If such relief is sought after the time
that an Arbitration Panel has been selected, then the Arbitration Panel will hear and determine the request. The request
for temporary or preliminary injunctive relief will be determined with reference to the temporary or preliminary injunction
standards set forth in Fed. R. Civ. P. 65.
C. Defaults and Proceedings in the Absence of a Party
Whenever a party fails to comply with the MDR Rules in a manner deemed material by the Panel, the Panel shall fix a
reasonable time for compliance and, if the party does not comply within said period, the Panel may enter an Order of
default or afford such other relief as it deems appropriate. Arbitration may proceed in the event of a default or in the
absence of any party who, after due notice, fails to be present or fails to obtain an extension. An Award shall not be
made solely on the default or absence of a party, but the Panel shall require the party who is present to submit such
evidence as the Panel may require for the making of findings, determinations, conclusions, and Awards.
D. Notice
Each party shall be deemed to have consented that any papers, notices, or process necessary or proper for the
initiation or continuation of a proceeding under these rules or for any court action in connection therewith may be served
on a party by mail addressed to the party or its representative at its last known address or by personal service, in or
outside the state where the MDR proceeding is to be held.
The Corporate Secretary and the parties may also use facsimile transmission, telex, telegram, or other written forms
of electronic communication to give the notices required by these rules.
-- 498 of 512 --
EXHIBIT 5
Page 20 of 23
E. Expenses
The expenses of witnesses shall be paid by the party causing or requesting the appearance of such witnesses. All
expenses of the MDR proceeding, including compensation, required travel and other reasonable expenses of the Panel,
and the cost of any proof produced at the direct request of the Panel, shall be borne equally by the parties and shall be
paid periodically on a timely basis, unless they agree otherwise or unless the Panel in the Award assesses such
expenses, or any part thereof against any party (or parties). In exceptional cases, the Panel may award reasonable
attorneys' fees as an item of expense, and the Panel shall promptly determine the amount of such fees based on
affidavits or such other proofs as the Panel deems sufficient.
F. Disqualification or Disability of A Panel Member
In the event that any Arbitrator of a Panel with more than one Arbitrator should become disqualified, resign, die, or
refuse or be unable to perform or discharge his or her duties after the commencement of MDR but prior to the rendition
of an Award, and the parties are unable to agree upon a replacement, the remaining Panel member(s):
i. shall designate a replacement, subject to the right of any party to challenge such replacement for
cause.
ii. shall decide the extent to which previously held hearings shall be repeated.
If the remaining Panel members consider the proceedings to have progressed to a stage as to make replacement
impracticable, the parties may agree, as an alternative to the recommencement of the Mandatory Dispute Resolution
process, to resolution of the dispute by the remaining Panel members.
In the event that a single Arbitrator should become disqualified, resign, die, or refuse or be unable to perform or
discharge his or her duties after the commencement of MDR but prior to the rendition of an Award, and the parties are
unable to agree upon a replacement, the Administrator shall appoint a successor, subject to the right of any party to
challenge such successor for cause, and the successor shall decide the extent to which previously held proceedings
shall be repeated.
-- 499 of 512 --
EXHIBIT 5
Page 21 of 23
G. Extensions of Time
Subject to the provisions of Paragraph 3.H.(viii), any time limit set forth in these Rules may be extended upon
agreement of the parties and approval of: (1) the Mediator if the proceeding is then in Mediation; (2) the Administrator if
the proceeding is in Arbitration, but no Arbitration Panel has been selected; or (3) the Arbitration Panel, if the proceeding
is in Arbitration and the Arbitration Panel has been selected.
H. Intervention
The Plans, their Controlled Affiliates, and BCBSA, to the extent subject to MMDR pursuant to their License
Agreements, shall have the right to move to intervene in any pending Arbitration. A written motion for intervention shall
be made to: (1) the Administrator, if the proceeding is in Arbitration, but no Arbitration Panel has been selected; or (2)
the Arbitration Panel, if the proceeding is in Arbitration and the Arbitration Panel has been selected. The written motion
for intervention shall be delivered to the BCBSA Corporate Secretary (which shall also constitute service on the BCBSA
if it is a respondent) and to any Plan(s) and/or Controlled Affiliate(s) which are parties to the proceeding. Any party to the
proceeding can submit written objections to the motion to intervene. The motion for intervention shall be granted upon
good cause shown. Intervention also may be allowed by stipulation of the parties to the Arbitration proceeding.
Intervention shall be allowed upon such terms as the Arbitration Panel decides.
I. BCBSA Assistance In Resolution of Disputes
The resources and personnel of the BCBSA may be requested by any member Plan at any time to try to resolve
disputes with another Plan.
J. Neutral Evaluation
The parties can voluntarily agree at any time to have an independent party render a neutral evaluation of the
parties’ respective positions.
Amended as of September 20, 2007
-- 500 of 512 --
EXHIBIT 5
Page 22 of 23
K. Recovery of Attorney Fees and Expenses
i. Motions to Compel
Nothwithstanding any other provisions of these Rules, any Party subject to the License Agreements (for purposes
of this Section K and all of its sub-sections only hereinafter referred to collectively and individually as a “Party”)
that initiates a court action or administrative proceeding solely to compel adherence to these Rules shall not be
determined to have violated these Rules by initiating such action or proceeding.
ii Recovery of Fees, Expenses and Costs
The Arbitration Panel may, in its sole discretion, award a Party its reasonable attorneys’ fees, expenses and costs
associated with a filing to compel adherence to these Rules and/or reasonable attorneys’ fees, expenses and
costs incurred in responding to an action filed in violation of these Rules; provided, however, that neither fees,
expenses, nor costs shall be awarded by the Arbitration Panel if the Party from which the award is sought can
demonstrate to the Arbitration panel, in its sole discretion, that it did not violate these Rules or that it had
reasonable grounds for believing that its action did not violate these Rules.
iii Requests for Reimbursement
For purposes of this Section K, any Party may request reimbursement of fees, expenses and/or costs by
submitting said request in writing to the Arbitration Panel at any time before an award is delivered pursuant to
Paragraph 3.O above, with a copy to the Party from which reimbursement is sought, explaining why it is entitled
to such reimbursement. The Party from which reimbursement is sought shall have twenty (20) days to submit a
response to such request to the Arbitration Panel with a copy to the Party seeking reimbursement.
Amended as of September 20, 2007
-- 501 of 512 --
EXHIBIT 5
Page 23 of 23
L. Calculation of Time and Deadlines
In computing any period of time prescribed or allowed under these rules, the day of the act or event from which the
designated period of time begins to run shall not be included. The last day of the period so computed shall be included,
unless it is a Saturday, a Sunday, or a legal holiday, in which event the period runs until the end of the next day which is
not one of the aforementioned days. When the period of time prescribed is less than six (6) days, intermediate
Saturdays, Sundays and legal holidays shall be excluded in the computation. As used in this rule, “legal holiday”
includes New Year’s Day, Martin Luther King, Jr. Day, Washington’s Birthday, Memorial Day, Independence Day, Labor
Day, Columbus Day, Veterans Day, Thanksgiving Day, Christmas Day and any other day appointed as a holiday by the
President or the Congress of the United States.
Amended as of September 20, 2007
-- 502 of 512 --
Exhibit 21
SUBSIDIARIES OF THE COMPANY
Legal Name Domestic Jurisdiction Doing Business As
Alliance Care Management, LLC Delaware
American Imaging Management, Inc. Illinois AIM Specialty Health
America's 1st Choice of South Carolina, Inc. South Carolina
America's Health Management Services, Inc. South Carolina
AMERIGROUP Community Care of New Mexico, Inc. New Mexico
AMERIGROUP Corporation Delaware AMERIGROUP CORPORATION; AGP Corporation;
AMGP; AMGP Corporation; AMGP Missouri
Amerigroup Delaware, Inc. Delaware
Amerigroup District of Columbia, Inc. District of Columbia
Amerigroup Insurance Company Texas
Amerigroup Iowa, Inc. Iowa
Amerigroup IPA of New York, LLC New York
Amerigroup Kansas, Inc. Kansas
AMERIGROUP Maryland, Inc. Maryland AMERIGROUP Community Care
Amerigroup Mississippi, Inc. Mississippi
AMERIGROUP New Jersey, Inc. New Jersey AMERIGROUP Community Care
AMERIGROUP Ohio, Inc. Ohio AMERIGROUP Community Care
Amerigroup Oklahoma Inc. Oklahoma
Amerigroup Partnership Plan, LLC Illinois
Amerigroup Pennsylvania, Inc. Pennsylvania
AMERIGROUP Tennessee, Inc. Tennessee AMERIGROUP Community Care
AMERIGROUP Texas, Inc. Texas AMERIGROUP Community Care
AMERIGROUP Washington, Inc. Washington
AMGP Georgia Managed Care Company, Inc. Georgia AMERIGROUP; AMERIGROUP Community Care;
AMERIGROUP Georgia; AMGP Georgia
AMH Health Plans of Maine, Inc. Maine
AMH Health, LLC Maine
Anthem Blue Cross Life and Health Insurance Company California
Anthem Financial, Inc. Delaware
Anthem Health Plans of Kentucky, Inc. Kentucky Anthem Blue Cross and Blue Shield
Anthem Health Plans of Maine, Inc. Maine Anthem Blue Cross and Blue Shield; Associated
Hospital Service
Anthem Health Plans of New Hampshire, Inc. New Hampshire Anthem Blue Cross and Blue Shield
Anthem Health Plans of Virginia, Inc. Virginia Anthem Blue Cross and Blue Shield
Anthem Health Plans, Inc. Connecticut Anthem Blue Cross and Blue Shield
Anthem Holding Corp. Indiana Anthem Properties, Inc.
Anthem Innovation Israel, Ltd. Israel
Anthem Insurance Companies, Inc. Indiana
Anthem Blue Cross and Blue Shield; Blue Cross and
Blue Shield of Indiana; Empire Blue Cross-Retiree
Solutions; Empire Blue Cross Blue Shield-Retiree
Solutions; Anthem BC Health Insurance Company;
Anthem Kentucky Managed Care Plan, Inc. Kentucky Anthem Blue Cross and Blue Shield Medicaid
Anthem Life & Disability Insurance Company New York
Anthem Life Insurance Company Indiana
Anthem Partnership Holding Company, LLC Indiana
-- 503 of 512 --
Exhibit 21
Anthem Services Company, LLC Indiana
Anthem Southeast, Inc. Indiana
Anthem UM Services, Inc. Indiana
Anthem Workers' Compensation, LLC Indiana
Applied Pathways LLC Illinois
Arcus Enterprises, Inc. Delaware
Aspire Health, Inc. Delaware
Associated Group, Inc. Indiana
ATH Holding Company, LLC Indiana
Beacon CBHM LLC Delaware
Beacon Health Financing LLC Delaware
Beacon Health Holdings LLC Delaware
Beacon Health Options Care Services, Inc. Delaware
Beacon Health Options Holdco, Inc. Delaware
Beacon Health Options of California, Inc. California
Beacon Health Options of Ohio, Inc. Ohio
Beacon Health Options of Pennsylvania, Inc. Pennsylvania
Beacon Health Options, Inc. Virginia
Beacon Health Strategies LLC Massachusetts
Beacon Health Vista Parent, Inc. Delaware
Beacon Plan Funding, LLC Delaware
BHS IPA, LLC New York
Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. Georgia Anthem Blue Cross and Blue Shield
Blue Cross Blue Shield of Wisconsin Wisconsin Anthem Blue Cross and Blue Shield
Blue Cross of California California Anthem Blue Cross
Blue Cross of California Partnership Plan, Inc. California Anthem Blue Cross Partnership Plan
BVO Holdings, LLC Delaware
CareMarket, Inc. Indiana Sydney Care
CareMore Health Plan California
CareMore Health Plan of Arizona, Inc. Arizona
CareMore Health Plan of Nevada Nevada
CareMore Health Plan of Texas, Inc. Texas
CareMore Health System California
CareMore, LLC Indiana
CCHA, LLC Colorado Colorado Community Health Alliance
Cerulean Companies, Inc. Georgia
CHCS IPA, Inc. New York
Claim Management Services, Inc. Wisconsin Anthem Blue Cross and Blue Shield
Community Care Health Plan of Louisiana, Inc. Louisiana Healthy Blue
Community Care Health Plan of Nebraska, Inc. Nebraska WellCare of Nebraska; Healthy Blue
Community Care Health Plan of Nevada, Inc. Nevada Anthem Blue Cross and Blue Shield Healthcare
Solutions; AMERIGROUP Community Care
Community Insurance Company Ohio Anthem Blue Cross and Blue Shield;
Compcare Health Services Insurance Corporation Wisconsin Anthem Blue Cross and Blue Shield;
Crossroads Acquisition Corp. Delaware
DBG Holdings, Inc. Indiana
DeCare Analytics, LLC Minnesota
DeCare Dental Health International, LLC Minnesota
DeCare Dental Insurance Ireland, Ltd. Ireland
-- 504 of 512 --
Exhibit 21
DeCare Dental Networks, LLC Minnesota
DeCare Dental, LLC Minnesota
DeCare Operations Ireland, Limited Ireland
Delivery Network, LLC Florida
Designated Agent Company, Inc. Kentucky
EasyScripts Cutler Bay, LLC Florida
EasyScripts Hialeah, LLC Florida
EasyScripts Westchester, LLC Florida
EasyScripts, LLC Florida
EHC Benefits Agency, Inc. New York
Empire HealthChoice Assurance, Inc. New York Empire Blue Cross; Empire Blue Cross Blue Shield
Empire HealthChoice HMO, Inc. New York Empire Blue Cross HMO; Empire Blue Cross Blue
Shield HMO
Federal Government Solutions, LLC Wisconsin
FHC Health Systems, Inc. Virginia
Florida Health Partners, Inc. Florida
Freedom Health, Inc. Florida
Golden West Health Plan, Inc. California
GR Health Solutions, LLC Pennsylvania
Greater Georgia Life Insurance Company Georgia Anthem Life
Group Retiree Health Solutions, Inc. Pennsylvania
Health Core, Inc. Delaware
Health Management Corporation Virginia LiveHealth Online; HMC of Virginia; Health
Management of Virginia, Inc.
Health Ventures Partner, L.L.C. Illinois
HealthKeepers, Inc. Virginia
HealthLink HMO, Inc. Missouri HealthLink HMO
HealthLink Insurance Company Illinois
HealthLink, Inc. Illinois
HealthPlus HP, LLC New York Empire BlueCross BlueShield HealthPlus; Empire
BlueCross HealthPlus
HealthSun Health Plans, Inc. Florida
HealthSun Physicians Network I, LLC Florida
HealthSun Physicians Network, LLC Florida
Healthy Alliance Life Insurance Company Missouri Anthem Blue Cross and Blue Shield
HEP AP Holdings, Inc. Delaware
Highland Acquisition Holdings, LLC Delaware
Highland Intermediate Holdings, LLC Delaware
Highland Investor Holdings, LLC Delaware
HMO Colorado, Inc. Colorado HMO Colorado; HMO Nevada
HMO Missouri, Inc. Missouri Amerigroup Missouri; Anthem Blue Cross and Blue
Shield
IEC Group Holdings, Inc. Idaho
IEC Group, Inc. Idaho AmeriBen
Imaging Management Holdings, LLC Delaware
IngenioRx, Inc. Indiana Ingenio, Inc.; IngenioRx Administrators
Legato Health Technologies, LLP India
Legato Health Technologies Philippines, Inc. Philippines
Legato Holdings I, Inc. Indiana Legato Health Technologies
Legato Holdings II, LLC Indiana
-- 505 of 512 --
Exhibit 21
Living Complete Technologies, Inc. Maryland TAI Software, Inc.
Massachusetts Behavioral Health Partnership, LLP Massachusetts
Matthew Thornton Health Plan, Inc. New Hampshire
Meridian Resource Company, LLC Wisconsin
Missouri Care, Incorporated Missouri Healthy Blue; Missouri Care; Missouri Care Health
Plan
Momentum Health Partners, LLC North Carolina
Nash Holding Company, LLC Delaware
National Government Services, Inc. Indiana NGS of Indiana
New England Research Institutes, Inc. Massachusetts Summit Community Care
NGS Federal, LLC Indiana
North Florida Behavioral Health Partners, Inc. Florida
Optimum Healthcare, Inc. Florida
OPTIONS Health Care, Inc. Delaware
Park Square Holdings, Inc. California
Park Square I, Inc. California
Park Square II, Inc. California
Pasteur Medical Bird Road, LLC Florida
Pasteur Medical Center, LLC Delaware
Pasteur Medical Cutler Bay, LLC Florida
Pasteur Medical Group, LLC Florida
Pasteur Medical Hialeah Gardens, LLC Florida
Pasteur Medical Kendall, LLC Florida
Pasteur Medical Management, LLC Florida
Pasteur Medical Miami Gardens, LLC Florida
Pasteur Medical North Miami Beach, LLC Florida
Pasteur Medical Partners, LLC Florida
Resolution Health, Inc. Delaware Delaware Resolution Health, Inc.
RightCHOICE Managed Care, Inc. Delaware
RightCHOICE Benefit Administrators; Anthem Blue
Cross and Blue Shield;
Rocky Mountain Hospital and Medical Service, Inc. Colorado
Anthem Blue Cross and Blue Shield; Anthem Blue
Cross Blue Shield
SellCore, Inc. Delaware SellCore Insurance Services, Inc.
Simply Healthcare Plans, Inc. Florida Clear Health Alliance; Better Health; Amerigroup
Florida
Southeast Services, Inc. Virginia
State Sponsored Services, Inc. Indiana
Amerigroup GBD Disease Management Program;
Anthem GBD Disease Management Program;
Amerigroup GBD Behavioral Health; Anthem GBD
Behavioral Health
The Anthem Companies of California, Inc. California
The Anthem Companies, Inc. Indiana
TrustSolutions, LLC Wisconsin
UNICARE Health Plan of West Virginia, Inc. West Virginia
UNICARE Illinois Services, Inc. Illinois
UniCare Life & Health Insurance Company Indiana UNICARE Adjuster
UNICARE National Services, Inc. Delaware
UniCare Specialty Services, Inc. Delaware
Value Health Reinsurance, Inc. Arizona
ValueOptions Federal Services, Inc. Virginia
ValueOptions of Kansas, Inc. Kansas
-- 506 of 512 --
Exhibit 21
ValueOptions of New Jersey, Inc. New Jersey
ValueOptions of Texas, Inc. Texas
Valus, Inc. Indiana DBG, Inc.
Wellmax Health Medical Centers, LLC Florida
Wellmax Health Physicians Network, LLC Florida
WellPoint Acquisition, LLC Indiana
WellPoint California Services, Inc. Delaware
WellPoint Dental Services, Inc. Delaware
WellPoint Health Solutions, Inc. Indiana
WellPoint Holding Corp. Delaware
WellPoint Information Technology Services, Inc. California
WellPoint Insurance Services, Inc. Hawaii
WellPoint Military Care Corporation Indiana
Wisconsin Collaborative Insurance Company Wisconsin
WPMI, LLC Delaware
Zip Drug Inc. Delaware
-- 507 of 512 --
Exhibit 23
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
• Form S-8 No. 333-84906 and Form S-8 No. 333-129334 pertaining to the Anthem 401(k) Plan;
• Form S-8 No. 333-156099 pertaining to the Anthem, Inc. Employee Stock Purchase Plan;
• Form S-8 No. 333-159830 pertaining to the Anthem Incentive Compensation Plan;
• Form S-8 No. 333-218190 pertaining to the 2017 Anthem Incentive Compensation Plan; and
• Form S-3 No. 333-249877 pertaining to the Anthem, Inc. registration of senior debt securities, subordinated debt securities, preferred stock, common
stock, depositary shares, warrants, rights, stock purchase contracts and stock purchase units
of our reports dated February 18, 2021, with respect to the consolidated financial statements and financial statement schedule listed in the Index at Item 15(c) of
Anthem, Inc., and the effectiveness of internal control over financial reporting of Anthem, Inc., included in its Annual Report (Form 10-K) for the year ended
December 31, 2020.
/S/ ERNST & YOUNG LLP
Indianapolis, Indiana
February 18, 2021
1
-- 508 of 512 --
Exhibit 31.1
CERTIFICATION PURSUANT TO
RULE 13a-14(a) AND RULE 15d-14(a) OF THE EXCHANGE ACT RULES,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Gail K. Boudreaux, certify that:
1. I have reviewed this report on Form 10-K of Anthem, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over
financial reporting.
Date: February 18, 2021 /s/ GAIL K. BOUDREAUX
President and Chief Executive Officer
-- 509 of 512 --
Exhibit 31.2
CERTIFICATION PURSUANT TO
RULE 13a-14(a) AND RULE 15d-14(a) OF THE EXCHANGE ACT RULES,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, John E. Gallina, certify that:
1. I have reviewed this report on Form 10-K of Anthem, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over
financial reporting.
Date: February 18, 2021 /s/ JOHN E. GALLINA
Executive Vice President and
Chief Financial Officer
-- 510 of 512 --
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Anthem, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2020 as filed with the Securities and
Exchange Commission on the date hereof (the “Report”), I, Gail K. Boudreaux, President and Chief Executive Officer of the Company, certify, pursuant to 18
U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ GAIL K. BOUDREAUX
Gail K. Boudreaux
President and Chief Executive Officer
February 18, 2021
-- 511 of 512 --
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Anthem, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2020 as filed with the Securities and
Exchange Commission on the date hereof (the “Report”), I, John E. Gallina, Executive Vice President and Chief Financial Officer of the Company, certify,
pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ JOHN E. GALLINA
John E. Gallina
Executive Vice President and Chief Financial Officer
February 18, 2021
-- 512 of 512 --